<SEC-DOCUMENT>0001493152-25-009703.txt : 20250310
<SEC-HEADER>0001493152-25-009703.hdr.sgml : 20250310
<ACCEPTANCE-DATETIME>20250310162054
ACCESSION NUMBER:		0001493152-25-009703
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		76
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250310
DATE AS OF CHANGE:		20250310

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Ensysce Biosciences, Inc.
		CENTRAL INDEX KEY:			0001716947
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				822755287
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38306
		FILM NUMBER:		25724003

	BUSINESS ADDRESS:	
		STREET 1:		7946 IVANHOE AVENUE
		STREET 2:		SUITE 201
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
		BUSINESS PHONE:		(858) 263-4196

	MAIL ADDRESS:	
		STREET 1:		7946 IVANHOE AVENUE
		STREET 2:		SUITE 201
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Leisure Acquisition Corp.
		DATE OF NAME CHANGE:	20170913
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10-k.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ENSC="http://ensysce.com/20241231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2024%2D(with%2DECD%2Dand%2DCYD) -->
<!-- Field: Set; Name: xdx; ID: xdx_037_ENSC_ensysce.com_20241231 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20240101_20241231 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DEntityCentralIndexKey_0001716947 -->
<!-- Field: Set; Name: xdx; ID: xdx_076_XDX_form10%2Dk.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_Segment_0_Segment -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000004" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000005" name="dei:EntityCentralIndexKey">0001716947</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2024-12-31" id="xdx2ixbrl0148" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2023-12-31" id="xdx2ixbrl0149" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31" id="xdx2ixbrl0154" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31" id="xdx2ixbrl0155" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENSC:LossOnConversionsAndChangeInFairValueOfConvertibleNotes" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0231" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0285" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0286" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0287" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0288" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0289" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENSC:StockIssuedDuringPeriodValueCommitmentFee" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0293" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENSC:StockIssuedDuringPeriodValueCommitmentFee" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0295" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0303" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0304" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0311" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0312" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0317" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0319" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0320" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0323" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENSC:TransactionCostsAssociatedWithPublicOffering" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0329" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENSC:TransactionCostsAssociatedWithPublicOffering" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0331" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENSC:TransactionCostsAssociatedWithPublicOffering" contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0332" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENSC:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0337" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENSC:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0339" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENSC:StockIssuedDuringPeriodValueReverseStockSplits" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0343" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENSC:StockIssuedDuringPeriodValueReverseStockSplits" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0344" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENSC:StockIssuedDuringPeriodValueReverseStockSplits" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0345" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENSC:StockIssuedDuringPeriodValueReverseStockSplits" contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0346" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENSC:StockIssuedDuringPeriodValueReverseStockSplits" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0347" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0351" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0354" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0355" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0357" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0358" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0379" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0380" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0381" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0382" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0383" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0389" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0390" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENSC:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0405" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENSC:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0406" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENSC:IssuanceOfCommonStockUponWarrantInducements" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0413" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENSC:IssuanceOfCommonStockUponWarrantInducements" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0414" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENSC:TransactionCostsAssociatedWithPublicOfferingAndWarrantInducements" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0419" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENSC:TransactionCostsAssociatedWithPublicOfferingAndWarrantInducements" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0421" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENSC:TransactionCostsAssociatedWithPublicOfferingAndWarrantInducements" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0422" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0425" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0427" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0428" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENSC:StockIssuedDuringPeriodValueReverseStockSplits" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0431" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENSC:StockIssuedDuringPeriodValueReverseStockSplits" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0432" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENSC:StockIssuedDuringPeriodValueReverseStockSplits" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0433" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENSC:StockIssuedDuringPeriodValueReverseStockSplits" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0434" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENSC:StockIssuedDuringPeriodValueReverseStockSplits" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0435" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0439" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0442" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0443" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0445" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0446" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENSC:LossOnConversionsAndChangeInFairValueOfConvertibleNotes" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0482" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProvisionForLoanLeaseAndOtherLosses" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0491" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0516" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENSC:ProceedsFromWarrantInducementNetOfIssuanceCosts" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0519" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENSC:TransactionCostsFromPublicOfferings" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0521" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENSC:TransactionCostAssociatedWithWarrantInducement" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0525" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0527" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENSC:IncrementalFairValueOfWarrantInducement1" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0558" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENSC:IncrementalFairValueOfWarrantInducement2" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0561" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENSC:OriginalDebtDiscountFromConvertibleNotes" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0566" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENSC:DebtDiscountFromWarrantsIssuance" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0569" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENSC:IssuanceCostFromConvertibleNotes" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0572" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENSC:SettlementOfCommitmentFeeInShares" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0578" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl0639" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0640" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl0644" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0645" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl0649" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0650" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl0654" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0655" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="AsOf2024-12-31_custom_FinancedInsuranceMember" id="xdx2ixbrl0770" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="AsOf2023-12-31_custom_FinancedInsuranceMember" id="xdx2ixbrl0792" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2023-12-31" id="xdx2ixbrl1097" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1099" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1101" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1103" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1105" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1107" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1109" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1111" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1113" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENSC:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1115" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2024-12-31" id="xdx2ixbrl1123" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2024-12-31" id="xdx2ixbrl1129" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" contextRef="AsOf2024-12-31" id="xdx2ixbrl1137" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENSC:IncomeTaxReconciliationExpiringAttributes" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1208" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1219" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1220" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2024-12-31" id="xdx2ixbrl1245" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2023-12-31" id="xdx2ixbrl1246" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="AsOf2024-12-31" id="xdx2ixbrl1248" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="AsOf2023-12-31" id="xdx2ixbrl1249" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="AsOf2024-12-31" id="xdx2ixbrl1251" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="AsOf2023-12-31" id="xdx2ixbrl1252" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2024-12-31" id="xdx2ixbrl1254" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2023-12-31" id="xdx2ixbrl1255" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1289" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="ensc-20241231.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2024-01-01to2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_CommonStock0.0001ParValuePerShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENSC:CommonStock0.0001ParValuePerShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_WarrantsToPurchaseOneShareOfCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENSC:WarrantsToPurchaseOneShareOfCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-07">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_EBIRIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ENSC:EBIRIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_EBIRIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ENSC:EBIRIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_KeyPersonnelMember_custom_EBIRIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ENSC:KeyPersonnelMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ENSC:EBIRIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_UnrelatedPartyMember_custom_EBIRIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ENSC:UnrelatedPartyMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ENSC:EBIRIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-03-012023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-12-012024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-12-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember_custom_CustomerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ENSC:CustomerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember_custom_CustomerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ENSC:CustomerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_LiabilityClassifiedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ENSC:LiabilityClassifiedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_LiabilityClassifiedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ENSC:LiabilityClassifiedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_LiabilityClassifiedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ENSC:LiabilityClassifiedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_MPARMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ENSC:MPARMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_MPARMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ENSC:MPARMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_TAAPOUDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ENSC:TAAPOUDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_TAAPOUDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ENSC:TAAPOUDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_ConvertibleDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_ConvertibleDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TwoThousandTwentyThreeNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ENSC:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_TwoThousandTwentyThreeNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ENSC:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_FinancedInsuranceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ENSC:FinancedInsuranceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_FinancedInsuranceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ENSC:FinancedInsuranceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_TwoThousandTwentyThreeNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ENSC:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_TwoThousandTwentyThreeNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ENSC:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-222023-10-23_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENSC:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-22</xbrli:startDate>
        <xbrli:endDate>2023-10-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-222023-10-23_custom_SecuritiesPurchaseAgreementMember_custom_TwoThousandTwentyThreeNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENSC:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ENSC:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-22</xbrli:startDate>
        <xbrli:endDate>2023-10-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-25_custom_FirstClosingSecuritiesPurchaseAgreementMember_custom_TwoThousandTwentyThreeNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENSC:FirstClosingSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ENSC:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-242023-10-25_custom_FirstClosingSecuritiesPurchaseAgreementMember_custom_TwoThousandTwentyThreeNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENSC:FirstClosingSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ENSC:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-24</xbrli:startDate>
        <xbrli:endDate>2023-10-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-11-29_custom_SecondClosingSecuritiesPurchaseAgreementMember_custom_TwoThousandTwentyThreeNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENSC:SecondClosingSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ENSC:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-11-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-11-292023-11-29_custom_SecondClosingSecuritiesPurchaseAgreementMember_custom_TwoThousandTwentyThreeNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENSC:SecondClosingSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ENSC:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-11-29</xbrli:startDate>
        <xbrli:endDate>2023-11-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-23_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENSC:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_TwoThousandTwentyThreeNotesMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ENSC:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENSC:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-012024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-272024-11-27">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-27</xbrli:startDate>
        <xbrli:endDate>2024-11-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-27">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-182024-10-18">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-18</xbrli:startDate>
        <xbrli:endDate>2024-10-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-012024-08-31_custom_RegisteredDirectOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENSC:RegisteredDirectOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-01</xbrli:startDate>
        <xbrli:endDate>2024-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-31_custom_RegisteredDirectOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENSC:RegisteredDirectOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-012024-08-31_custom_PrefundedWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENSC:PrefundedWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-01</xbrli:startDate>
        <xbrli:endDate>2024-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-31_custom_PrefundedWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENSC:PrefundedWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-29_custom_SeriesAandBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENSC:SeriesAandBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-11-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-012024-02-29">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-01</xbrli:startDate>
        <xbrli:endDate>2024-02-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-012024-08-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-01</xbrli:startDate>
        <xbrli:endDate>2024-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-29_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-29_custom_SeriesAWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENSC:SeriesAWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-29_custom_SeriesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENSC:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-012024-02-29_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-01</xbrli:startDate>
        <xbrli:endDate>2024-02-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-29">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-112023-05-12">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-11</xbrli:startDate>
        <xbrli:endDate>2023-05-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-12">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-12_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-12_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-12_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012023-02-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2023-02-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-02-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-02-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-062023-02-06">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-06</xbrli:startDate>
        <xbrli:endDate>2023-02-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_WarrantOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ENSC:WarrantOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_WarrantOneMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ENSC:WarrantOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_WarrantOneMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ENSC:WarrantOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_WarrantOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ENSC:WarrantOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_WarrantTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ENSC:WarrantTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_WarrantTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ENSC:WarrantTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_WarrantThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ENSC:WarrantThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_WarrantThreeMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ENSC:WarrantThreeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_WarrantThreeMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ENSC:WarrantThreeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_WarrantThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ENSC:WarrantThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_WarrantFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ENSC:WarrantFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_WarrantFourMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ENSC:WarrantFourMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_WarrantFourMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ENSC:WarrantFourMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_WarrantFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ENSC:WarrantFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-29_custom_InstitutionalInvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENSC:InstitutionalInvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-29_custom_InvestorWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENSC:InvestorWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-29_custom_PlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENSC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-29_custom_PlacementAgentWarrantsMember11635781">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENSC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_InvestorWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENSC:InvestorWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-12_us-gaap_WarrantMember_custom_PlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENSC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-12_custom_SeriesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENSC:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-12_custom_SeriesAWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENSC:SeriesAWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-12_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-31_us-gaap_WarrantMember_custom_PlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENSC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-25_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-11-28_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-11-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_PublicWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENSC:PublicWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_Notes2021And2022Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENSC:Notes2021And2022Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-29_custom_Notes2021And2022Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENSC:Notes2021And2022Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-29_custom_TwoThousandTwentyOneOmnibusIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ENSC:TwoThousandTwentyOneOmnibusIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_BoardOfMembersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ENSC:BoardOfMembersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember_custom_StockOptionAvailableForFutureGrantUnder2021OmnibusIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ENSC:StockOptionAvailableForFutureGrantUnder2021OmnibusIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_WarrantOutstandingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENSC:WarrantOutstandingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CaliforniaFranchiseTaxBoardMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-012017-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CaliforniaFranchiseTaxBoardMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_DomesticCountryMember_us-gaap_ResearchMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_StateAndLocalJurisdictionMember_us-gaap_ResearchMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENSC:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-252024-04-25_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-25</xbrli:startDate>
        <xbrli:endDate>2024-04-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-01-31_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-01-31_us-gaap_SubsequentEventMember_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001716947</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Segment">
      <xbrli:measure>ENSC:Segment</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="Fact000971" toRefs="Footnote001002"/>
  <ix:relationship fromRefs="Fact000973" toRefs="Footnote001002"/>
  <ix:relationship fromRefs="Fact000975" toRefs="Footnote001002"/>
  <ix:relationship fromRefs="Fact000977" toRefs="Footnote001002"/>
  <ix:relationship fromRefs="Fact000989" toRefs="Footnote001002"/>
  <ix:relationship fromRefs="Fact000997" toRefs="Footnote001002"/>
  <ix:relationship fromRefs="Fact000979" toRefs="Footnote001017"/>
  <ix:relationship fromRefs="Fact000981" toRefs="Footnote001017"/>
  <ix:relationship fromRefs="Fact000983" toRefs="Footnote001017"/>
  <ix:relationship fromRefs="Fact000985" toRefs="Footnote001032"/>
  <ix:relationship fromRefs="Fact000987" toRefs="Footnote001032"/>
  <ix:relationship fromRefs="Fact000991" toRefs="Footnote001032"/>
  <ix:relationship fromRefs="Fact000995" toRefs="Footnote001032"/>
  <ix:relationship fromRefs="Fact000993" toRefs="Footnote001055"/>
  <ix:relationship fromRefs="Fact000999" toRefs="Footnote001055"/>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>WASHINGTON,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>Form
<span id="xdx_905_edei--DocumentType_c20240101__20241231_zLFDlUdNZV1c"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000012" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--DocumentAnnualReport_c20240101__20241231_zeIWh7yBr91k"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000013" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ANNUAL
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the fiscal year ended: <span id="xdx_90F_edei--DocumentPeriodEndDate_c20240101__20241231_z1cdUFTRor3l"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:datemonthdayyearen" id="Fact000014" name="dei:DocumentPeriodEndDate"><span id="xdx_90E_edei--CurrentFiscalYearEndDate_c20240101__20241231_zO414aZJJPV1"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:datemonthdayen" id="Fact000015" name="dei:CurrentFiscalYearEndDate">December 31</ix:nonNumeric></span>, <span id="xdx_902_edei--DocumentFiscalYearFocus_c20240101__20241231_zcnZq75Voexd"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000016" name="dei:DocumentFiscalYearFocus">2024</ix:nonNumeric></span></ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OR
</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--DocumentTransitionReport_c20240101__20241231_zpmXyevKEQu7"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000017" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRANSITION
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to</b></span> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
File Number <span id="xdx_905_edei--EntityFileNumber_c20240101__20241231_zg7aF4nWJ6i9"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000018" name="dei:EntityFileNumber">001-38306</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_90E_edei--EntityRegistrantName_c20240101__20241231_zUoJPigIimdb"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000019" name="dei:EntityRegistrantName">ENSYSCE
BIOSCIENCES, INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_901_edei--EntityIncorporationStateCountryCode_c20240101__20241231_zb2wQEItjko2"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:stateprovnameen" id="Fact000020" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--EntityTaxIdentificationNumber_c20240101__20241231_zeO1H6mqCDY2"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000021" name="dei:EntityTaxIdentificationNumber">82-2755287</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
                                            or other jurisdiction</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
    incorporation or organization)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
                                            Employer</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    No.)</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_907_edei--EntityAddressAddressLine1_c20240101__20241231_zIlVo7QHAIuf"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000022" name="dei:EntityAddressAddressLine1">7946
                                            Ivanhoe Avenue</ix:nonNumeric></span></b>, <b><span id="xdx_90B_edei--EntityAddressAddressLine2_c20240101__20241231_zIdIHngcg9Dj"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000023" name="dei:EntityAddressAddressLine2">Suite 201</ix:nonNumeric></span></b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_907_edei--EntityAddressCityOrTown_c20240101__20241231_zYRzmxZ9tFsb"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000024" name="dei:EntityAddressCityOrTown">La
    Jolla</ix:nonNumeric></span></b>, <b><span id="xdx_901_edei--EntityAddressStateOrProvince_c20240101__20241231_zEJtF1Su7f0b"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:stateprovnameen" id="Fact000025" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span></b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_901_edei--EntityAddressPostalZipCode_c20240101__20241231_zknCzHCcSgJ8"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000026" name="dei:EntityAddressPostalZipCode">92037</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of principal executive offices)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_edei--CityAreaCode_c20240101__20241231_zc7UjO4lBj84"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000027" name="dei:CityAreaCode">(858)</ix:nonNumeric></span>
    <span id="xdx_90F_edei--LocalPhoneNumber_c20240101__20241231_zXojg73HebPa"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000028" name="dei:LocalPhoneNumber">263-4196</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&#8217;s
    telephone number, including area code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITIES
REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT</b>:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 39%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 39%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--Security12bTitle_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--CommonStock0.0001ParValuePerShareMember_zFofw4haM423"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_CommonStock0.0001ParValuePerShareMember" id="Fact000029" name="dei:Security12bTitle">Common
    Stock, $0.0001 par value per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--TradingSymbol_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--CommonStock0.0001ParValuePerShareMember_zmsKHvwyuzN8"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_CommonStock0.0001ParValuePerShareMember" id="Fact000030" name="dei:TradingSymbol">ENSC</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    <span id="xdx_905_edei--SecurityExchangeName_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--CommonStock0.0001ParValuePerShareMember_zfgt4ECNmhsh"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_CommonStock0.0001ParValuePerShareMember" format="ixt-sec:exchnameen" id="Fact000031" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--Security12bTitle_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseOneShareOfCommonStockMember_zcqp88wvxwra"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_WarrantsToPurchaseOneShareOfCommonStockMember" id="Fact000032" name="dei:Security12bTitle">Warrants,
    to purchase one share of Common Stock</ix:nonNumeric></span> </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--TradingSymbol_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseOneShareOfCommonStockMember_zkca4UBXBvI2"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_WarrantsToPurchaseOneShareOfCommonStockMember" id="Fact000033" name="dei:TradingSymbol">ENSCW</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OTC
    Pink Open Market</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITIES
REGISTERED PURSUANT TO SECTION 12(g) OF THE ACT: NONE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; <span id="xdx_90A_edei--EntityWellKnownSeasonedIssuer_c20240101__20241231_z7oDRhJvAanf"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000034" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act. Yes &#9744; <span id="xdx_90E_edei--EntityVoluntaryFilers_c20240101__20241231_zTPiXnIrB9T"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000035" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. <span id="xdx_904_edei--EntityCurrentReportingStatus_c20240101__20241231_zyK2lcg91QJj"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000036" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). <span id="xdx_906_edei--EntityInteractiveDataCurrent_c20240101__20241231_zwhDwlBCxec6"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000037" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company,
or an emerging growth company. See definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller
reporting company&#8221;, and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer &#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 55%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer &#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--EntityFilerCategory_c20240101__20241231_zmWcwa5D8AGb"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:entityfilercategoryen" id="Fact000038" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span> &#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company <span id="xdx_90B_edei--EntitySmallBusiness_c20240101__20241231_zf7R08HW5ih1"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000039" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company <span id="xdx_902_edei--EntityEmergingGrowthCompany_c20240101__20241231_z22P7SSuKQ99"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000040" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to section 13(a) of the Exchange Act &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. <span id="xdx_90E_edei--IcfrAuditorAttestationFlag_c20240101__20241231_zUQcPJuDVF47"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000041" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements. <span id="xdx_90A_edei--DocumentFinStmtErrorCorrectionFlag_c20240101__20241231_zn8WbT8kowcd"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000042" name="dei:DocumentFinStmtErrorCorrectionFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; No <span id="xdx_907_edei--EntityShellCompany_dbF_c20240101__20241231_zfJK7DrODIy8"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000043" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate market value of the common stock held by non-affiliates of the registrant on June 28, 2024, the last business day of the registrant&#8217;s
most recently completed second fiscal quarter, was $<span id="xdx_90F_edei--EntityPublicFloat_iI_pn5n6_c20240628_zPKvCrWoaNqh"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2024-06-28" id="Fact000044" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.0</ix:nonFraction></span> million. The aggregate market value was computed by reference to the closing
price of the common stock on such date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant
had <span id="xdx_90C_edei--EntityCommonStockSharesOutstanding_iI_c20250307_zR1lwfkvcBG8"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2025-03-07" id="Fact000045" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,405,134</ix:nonFraction></span> shares of common stock outstanding as of March 7, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DOCUMENTS
INCORPORATED BY REFERENCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--DocumentsIncorporatedByReferenceTextBlock_c20240101__20241231_zK1ZoGav7QNg"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000046" name="dei:DocumentsIncorporatedByReferenceTextBlock">None</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENSYSCE
BIOSCIENCES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDEX</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Jo_001">Risk
    Factor Summary</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Jo_002">Glossary</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Jo_003">Cautionary
    Note Regarding Forward-Looking Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Jo_004">PART
    I</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Jo_005">Item
    1. Business</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Jo_006">Item
    1A. Risk Factors</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Jo_007">Item
    1B. Unresolved Staff Comments</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Jo_008">Item
    1C. Cybersecurity</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Jo_009">Item
    2. Properties</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Jo_010">Item
    3. Legal Proceedings</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Jo_011">Item
    4. Mine Safety Disclosures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Jo_012">PART
    II</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Jo_013">Item
    5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Jo_014">Item
    7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Aa_001">Item 7A. Quantitative and Qualitative Disclosures About Market Risk</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">79</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Aa_002">Item 8. Financial Statements and Supplementary Data</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">79</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Aa_003">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">79</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Aa_004">Item 9A. Controls and Procedures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">79</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Aa_005">Item 9B. Other Information</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">80</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Aa_006">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">80</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Aa_007">PART III</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">81</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Aa_008">Item 10. Directors, Executive Officers and Corporate Governance</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">81</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Aa_009">Item 11. Executive Compensation</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">86</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Aa_010">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">91</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_007">Item 13. Certain Relationships and Related Transactions, and Director Independence</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">92</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_008">Item 14. Principal Accounting Fees and Services</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">94</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_009">PART IV</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">95</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_010">Item 15. Exhibits and Financial Statement Schedules</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">95</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#aj_001">Item 16. Form 10-K Summary</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#aj_002">SIGNATURES</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Jo_001"></span>Risk
Factor Summary</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below
is a summary of material factors that make an investment in our securities speculative or risky. Importantly, this summary does not address
all of the risks and uncertainties that we face. Additional discussion of the risks and uncertainties in this summary, as well as other
risks and uncertainties that we face, can be found under the section titled &#8220;<i>Risk Factors</i>&#8221; of this Annual Report on
Form 10-K. This summary is qualified in its entirety by that more complete discussion of such risks and uncertainties. If we are unable
to adequately address these and other risks we face, our business, results of operations, financial condition and prospects may be harmed.
You should consider carefully the risks and uncertainties described under the section titled &#8220;<i>Risk Factors</i>&#8221; as part
of your evaluation of an investment in our securities:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are a clinical-stage pharmaceutical company with a limited operating history. We have incurred significant financial losses since
    our inception and anticipate that we will continue to incur significant financial losses for the foreseeable future.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    must obtain regulatory approval and fulfill numerous other requirements to be successful.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    require substantial additional funding.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    depend heavily on the success of PF614 and PF614-MPAR product candidates, which are currently in clinical trials, and which may not
    be successful.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we fail to discover, develop and commercialize other product candidates, we may be unable to grow our business.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we do not achieve our projected development and commercialization goals within the timeframes we expect, the development and commercialization
    of our product candidates may be delayed.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitive
    products may reduce or eliminate potential commercial opportunity for our product candidates.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    business could be harmed if we lose the services of our key personnel or if we are unable to hire additional highly qualified employees.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    employees or others on which our business depends may engage in misconduct or other improper activities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government
    grant awards may not be available to us in the future.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    currently rely on, and expect to rely on in the future, third parties to conduct our clinical trials.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    expect to be completely dependent on third parties to manufacture our product candidates.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    regulatory approval processes are lengthy, time-consuming, and inherently unpredictable.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
    authorities may disagree with our regulatory plan for our product candidates.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may incur unexpected costs or experience delays in completing, or ultimately be unable to complete, the preclinical and clinical
    studies necessary.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
    if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming,
    and uncertain.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may encounter difficulties enrolling patients in our clinical trials.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fast
    track designation by the FDA for PF614, for management of moderate to severe chronic pain when a continuous, around-the-clock analgesic
    is needed for an extended period of time, may not lead to a faster development or regulatory review or approval process and does
    not assure FDA approval.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    the FDA does not conclude that certain of our product candidates satisfy the requirements for the Section 505(b)(2) regulatory approval
    pathway, or if such requirements are not as we expect, the approval pathway will likely take significantly longer, cost significantly
    more and entail significantly greater complications and risks than anticipated, and in either case may not be successful.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    in methods of product candidate manufacturing or formulation may result in additional costs or delay.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval,
    limit the commercial profile of an approved label, or result in significant negative consequences following regulatory approval,
    if obtained.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
    if any of our product candidates receives regulatory approval, we may fail to achieve the degree of market acceptance necessary for
    commercial success.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are subject to potential product liability lawsuits against us or any of our future collaborators.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oxycodone
    is a Schedule II controlled substance under the federal CSA, and we must comply with the CSA or its state equivalents.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we are unable to obtain and maintain patent protection for our products candidates, or if the scope of the patent protection obtained
    is not sufficiently broad, our competitors could develop and commercialize product candidates that are similar or identical to our
    product candidates.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may face litigation from third parties claiming that our products or business infringe, misappropriate, or otherwise violate their
    intellectual property rights, or seeking to challenge the validity of our patents.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may become involved in lawsuits to protect or enforce our patents or other intellectual property.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    expiration or loss of patent protection may adversely affect our future revenues and operating earnings.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may not be able to obtain protection under the Hatch-Waxman Amendments by extending the patent term.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may not be able to protect our intellectual property rights throughout the world.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may be subject to claims that we infringed, misappropriated or otherwise violated the intellectual property of a third party, or
    claiming ownership of what we regard as our own intellectual property.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    intellectual property agreements with third parties may be subject to disagreements.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intellectual
    property rights do not necessarily address all potential threats to our business.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyber-attacks
    or other failures in our telecommunications or information technology systems, or those of third parties could result in information
    theft, data corruption and significant disruption of our business.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Raising
    additional capital in the public or private equity markets at prices per share below the current market price of our common stock
    could cause dilution to our stockholders, adversely affect the market price of our common stock, restrict our operations or require
    us to relinquish rights to our technologies or product candidates.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    internal controls over financial reporting currently do not meet all of the standards contemplated by Section 404 of Sarbanes-Oxley
    Act.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq
    may delist our common stock and/or our Public Warrants may not continue to trade on the OTC Pink Open Market.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Jo_002"></span>GLOSSARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 24%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Definitions:</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 74%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2013
    Framework</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    reporting criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated
    Framework (2013)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021
    Notes</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    senior secured convertible promissory notes in the aggregate original principal amount of $15.9 million, sold in two closings on
    September 24, 2021 and November 5, 2021, respectively, pursuant to the Securities Purchase Agreement entered into on September 24,
    2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021
    Omnibus Incentive Plan</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ensysce
    Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022
    Notes</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    senior secured convertible promissory notes in the aggregate original principal amount of $8.5 million, sold in two closings on June
    30, 2022 and August 8, 2022, respectively, pursuant to the Securities Purchase Agreement entered into on June 30, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023
    Notes</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    senior secured convertible promissory notes in the aggregate original principal amount of $1.8 million, sold in two closings on October
    25, 2023 and November 28, 2023, respectively, pursuant to the Securities Purchase Agreement entered into on October 23, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022
    December Offering</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company&#8217;s December 2022 registered direct offering of common stock (including pre-funded warrants in lieu thereof). The Offering
    closed on December 9, 2022 for aggregate consideration of $4.1 million</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023
    February Offering </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company&#8217;s February 2023 registered direct offering of common stock and private placement warrants for aggregate consideration
    of $3.0 million</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023
    May Offering</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company&#8217;s May 2023 registered direct offering of common stock (including pre-funded warrants in lieu thereof) for aggregate
    consideration of $7.0 million</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024
    February Warrant Inducement</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company&#8217;s February 2024 transaction including the cash exercise of certain existing warrants at a reduced price and the issuance
    of new warrants</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024
    August Warrant Inducement</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company&#8217;s August 2024 transaction including the cash exercise of certain existing warrants at a reduced price and the issuance
    of new warrants</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024
    August Offering </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company&#8217;s August 2024 registered direct offering of common stock, issuance of private placement warrants and the cash exercise
    of certain existing warrants at a reduced price and the issuance of new warrants. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ADFs</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abuse
    deterrent formulations</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ADHD</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention
    deficit hyperactivity disorder</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ANDA</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abbreviated
    New Drug Application</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>API</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Active
    pharmaceutical ingredient</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AUC</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Area
    under the concentration time curve </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>August
    Inducement Letter</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inducement
    offer letter entered into with certain holders of existing warrants to purchase 480,234 shares of the Company&#8217;s common stock
    (issued in February of 2024) to reduce the exercise price from $15.90 per share to $7.05 per share. The Company also agreed to amend
    certain existing warrants to purchase up to an aggregate of 133,334 shares of common stock that were previously issued in November
    2023 and had an exercise price of $23.51 per share such that the amended warrants have a reduced exercise price of $7.05 per share.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board
    of directors of Ensysce, or a committee thereof, as applicable</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business
    Combination</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    definitive merger agreement among LACQ, Merger Sub and Former Ensysce, dated January 31, 2021, providing for, among other things,
    and subject to terms and conditions therein, the business combination between LACQ and Former Ensysce pursuant to the merger of Merger
    Sub with and into Former Ensysce, with Former Ensysce continuing as the surviving entity and as a wholly-owned subsidiary of LACQ
    </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CARA</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
    Addiction and Recovery Act </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CDC</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Center
    for Disease Control</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CDER</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Center
    for Drug Evaluation and Research</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>cGMP</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    Good Manufacturing Practice</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cmax</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maximum
    plasma concentration </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CMC</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chemistry,
    manufacturing, and controls</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CMOs</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract
    manufacturing organizations </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CNS</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Central
    nervous system</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Company</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ensysce
    Biosciences, Inc. and its consolidated subsidiaries</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>COVID-19</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Novel
    coronavirus disease</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Covistat</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    subsidiary renamed EBIR, Inc.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CROs</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract
    research organizations</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CSA</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controlled
    Substances Act</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CSOS</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controlled
    Substance Ordering System</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DEA</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States Drug Enforcement Agency</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DSCSA</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 74%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    II of the Federal Drug Quality and Security Act of 2013, known as the Drug Supply Chain Security Act</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EB</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ensysce
    Biosciences, Inc. prior to its merger with Signature Acquisition Corp. pursuant to the EB-ST Agreement.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EBIR</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previously
    known as Covistat, Inc., EBIR, Inc. is a clinical stage pharmaceutical company that is developing a compound utilized in the Company&#8217;s
    overdose protection program for the treatment of COVID-19 and 79.2%-owned subsidiary of the Company</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EB-ST
    Agreement </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement
    and Plan of Merger, dated as of December 28, 2015, by and among Signature, SAQ, and EB </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EMA</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European
    Medicines Agency</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ensysce</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ensysce
    Biosciences Inc. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EPO</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European
    Patent Office</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ETASU</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Elements
    to assure a products safe use</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exchange
    Act </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
    Exchange Act of 1934, as amended</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FDA</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States Food and Drug Administration</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FDC
    Act </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal
    Food, Drug and Cosmetic Act, as amended</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Former
    Ensysce</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ensysce
    Biosciences, Inc., a Delaware corporation, prior to the consummation of the merger with and into Merger Sub</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>February
    Inducement Letter</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inducement
    offer letter entered into with certain holders of existing warrants to purchase 240,120 shares of the Company&#8217;s common stock
    (issued on May 12, 2023) to reduce the exercise price from $54.60 per share to $19.65 per share.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GAAP
    </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally
    Accepted Accounting Principles in the United States of America</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GCP</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Good
    Clinical Practices</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GMP</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Good
    Manufacturing Practices</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Hatch-Waxman
    Act or Hatch-Waxman Amendments</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug
    Price Competition and Patent Term Restoration Act of 1984</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>HHS</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States Department of Health and Human Services </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IMPDs</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investigational
    Medicinal Product Dossiers</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IND</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investigational
    New Drug</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Investor
    Notes</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    2021 Notes, 2022 Notes and 2023 Notes, collectively.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IRB</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Institutional
    Review Board</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JOBS
    Act </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jumpstart
    Our Business Startups Act of 2012</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LACQ</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leisure
    Acquisition Corp., a Delaware Corporation</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LACQ
    Warrants</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    that relate to the Business Combination or were issued prior to it and are exercisable for 1,467 shares of our common stock at a
    weighted average exercise price of $40,888.50 per share</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MAD</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Multi-Ascending
    Dose</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Merger
    </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    merger of Merger Sub with and into Former Ensysce, with Former Ensysce continuing as the surviving entity and a wholly owned subsidiary
    of LACQ, which changed its name to Ensysce Biosciences, Inc. following consummation of the Merger.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Merger
    Agreement </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement
    and Plan of Merger, dated as of January 31, 2021, by and among LACQ, Merger Sub and Former Ensysce, providing for, among other things,
    and subject to the terms and conditions therein, a business combination between Former Ensysce and LACQ pursuant to the proposed
    merger of Merger Sub with and into Former Ensysce, with Former Ensysce surviving the transaction as a wholly-owned subsidiary of
    LACQ, which changed its name to Ensysce Biosciences, Inc. following consummation of the Merger</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Merger
    Sub</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EB
    Merger Sub, Inc., a Delaware corporation, a wholly-owned subsidiary of LACQ prior to the consummation of the Merger</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MPAR
    Grant</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 74%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development grant related to the development of its MPAR<sup>&#174;</sup> overdose prevention technology awarded to the Company
    by NIH through NIDA in September 2018</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nasdaq</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Nasdaq Stock Market LLC</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NCE</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    Chemical Entity</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NDA</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    Drug Application</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NEO</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Named
    Executive Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NIDA</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">National
    Institute of Drug Abuse</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NIH</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">National
    Institutes of Health</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NME</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    molecular entity </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Orange
    Book</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA&#8217;s
    publication Approved Drug Products with Therapeutic Equivalence Evaluations</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OUD
    Grant</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development grant related to the development of its TAAP/MPAR<sup>&#174;</sup> abuse deterrent technology for Opioid Use Disorder
    awarded to the Company by NIH/NIDA in September 2019</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PCT</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
    Cooperation Treaty</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PDMA</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
    Prescription Drug Marketing Act </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PK</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmacokinetics</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Prior
    Warrants</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    issued pursuant to the Securities Purchase Agreement. The Prior Warrants issued in (i) 2021 are exercisable for an aggregate of 302
    shares of our common stock at an exercise price of $54.60 per share and in (ii) 2022 are exercisable for an aggregate of 2,594 shares
    of our common stock at an exercise price of $54.60 per share </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PTA</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
    Term Adjustment</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PTE</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
    Term Extension</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Public
    Warrants</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    redeemable warrants issued by us and sold as part of the units in the LACQ IPO (whether they were purchased in the LACQ IPO or thereafter
    in the open market). The Public Warrants are exercisable for an aggregate of approximately 2,778 shares of our common stock at an
    exercise price of $41,400.00 per share</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>R&amp;D</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and Development </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registered
    Direct Offering</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    2024 registered direct offering of common stock (236,880 shares), private placement warrants (to purchase up to 473,760 shares) and
    the cash exercise of certain existing warrants (480,234 warrant shares) at a reduced price and the issuance of new warrants (to purchase
    up to 1,440701 shares).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recro</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recro
    Gainesville LLC </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recro
    Agreement </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing
    Agreement, dated September 19, 2019, by and between Recro Gainesville LLC and the Company </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REMS</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
    evaluation and mitigation strategy</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Resale
    Registration Statement</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ensysce&#8217;s
    Resale Registration Statement filed on August 9, 2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SARS-CoV-2
    </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severe
    acute respiratory syndrome coronavirus 2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SAQ</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature
    Acquisition Corp., a wholly-owned subsidiary of Signature</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SEC</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
    Securities and Exchange Commission</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
    Act </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
    Act of 1933, as amended</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
    Purchase Agreement</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Securities Purchase Agreement, dated as of September 24, 2021, June 30, 2022, October 23, 2023, or August 28, 2024 as the context
    dictates, by and between Ensysce and the institutional investors party thereto</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature
    </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature
    Therapeutics Inc.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SPA</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    Securities Purchase Agreement, dated as of September 24, 2021, June 30, 2022, October 23, 2023, or August 28, 2024 as the context
    dictates, by and between Ensysce and the institutional investors party thereto</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUPPORT
    Act </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Substance
    Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TAAP</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trypsin
    Activated Abuse Protection</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TEAEs</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treatment-emergent
    adverse events</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>USPTO</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States Patent and Trademark Office</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Jo_003"></span>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report on Form 10-K includes statements that express our opinions, expectations, beliefs, plans, objectives, assumptions, or projections
regarding future events or future results and therefore are, or may be deemed to be, &#8220;<i>forward-looking statements</i>.&#8221;
These forward-looking statements can generally be identified by the use of forward-looking terminology, including the terms &#8220;<i>believes</i>,&#8221;
&#8220;<i>estimates</i>,&#8221; &#8220;<i>anticipates</i>,&#8221; &#8220;<i>expects</i>,&#8221; &#8220;<i>seeks</i>,&#8221; &#8220;<i>projects</i>,&#8221;
&#8220;<i>intends</i>,&#8221; &#8220;<i>plans</i>,&#8221; &#8220;<i>may</i>,&#8221; &#8220;<i>will</i>,&#8221; or &#8220;<i>should</i>&#8221;
or, in each case, their negative or other variations or comparable terminology. These forward-looking statements include all matters
that are not historical facts. They appear in a number of places throughout this Annual Report on Form 10-K and include statements regarding
our intentions, beliefs or current expectations concerning, among other things, results of operations, financial condition, liquidity,
prospects, growth, strategies and the markets in which we operate. Such forward-looking statements are based on available current market
material and management&#8217;s expectations, beliefs and forecasts concerning future events impacting our company. Factors that may
impact such forward-looking statements include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    estimates regarding expenses, revenue, capital requirements and timing and availability of and the need for additional financing
    will almost certainly not match actual amounts and timing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to continue as a going concern for the next twelve months;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    risk that our lead product candidate PF614 and PF614-MPAR may not be successful in limiting or impeding abuse, overdose, or misuse
    or providing additional safety upon commercialization;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reliance
    by us on third-party contract research organizations, or CROs, for our research and development activities and clinical trials</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    need for substantial additional funding to complete the development and commercialization of our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    risk that our clinical trials may fail to replicate positive results from earlier preclinical studies or clinical trials conducted
    by us or third parties;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    risk that the potential product candidates that we develop may not progress through clinical development or receive required regulatory
    approvals within expected timelines or at all;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    risk that clinical trials may not confirm any safety, potency, or other product characteristics described or assumed in this Annual
    Report on Form 10-K;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    risk that we will be unable to successfully market or gain market acceptance of our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    risk that our product candidates may not be beneficial to patients or successfully commercialized;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    risk that we have overestimated the size of the target market, patients&#8217; willingness to try new therapies, and the willingness
    of physicians to prescribe these therapies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">effects
    of competition;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    risk that third parties on which we depend for laboratory, clinical development, manufacturing, and other critical services will
    fail to perform satisfactorily;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    risk that our business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the
    effects of health epidemics</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    risk that we will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or
    will infringe the intellectual property protection of others;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    loss of key members of our management team;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in our regulatory environment;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability to attract and retain key scientific, medical, commercial, or management personnel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in our industry;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to remediate any material weaknesses or establish and maintain effective internal controls over financial reporting;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    risk that our common stock will be delisted from Nasdaq;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    risk that we may not be able to regain or maintain compliance with applicable listing standards of Nasdaq;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    litigation associated with the Business Combination Transactions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    factors disclosed in this Annual Report on Form 10-K; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    factors beyond our control.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
forward-looking statements contained in this Annual Report on Form 10-K are based on our current expectations and beliefs concerning
future developments and their potential effects on our company. There can be no assurance that future developments affecting us will
be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond
our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied
by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the
heading &#8220;<i>Risk Factors</i>&#8221;. Should one or more of these risks or uncertainties materialize, or should any of the assumptions
prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We will not undertake
any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise,
except as may be required under applicable securities laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>References
in this Annual Report on Form 10-K to &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; the &#8220;Company&#8221; or &#8220;Ensysce&#8221;
generally refer to Ensysce and its consolidated subsidiaries.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Jo_004"></span>PART
I</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Jo_005"></span>Item
1. Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were originally incorporated in the State of Delaware in April 2003 as PharmacoFore, Inc. and, in January 2012, we changed our name from
PharmacoFore, Inc. to Signature Therapeutics Inc. (&#8220;<i>Signature</i>&#8221;). In December 2015, Signature merged with and into
Ensysce Biosciences, Inc. (&#8220;<i>Former Ensysce</i>&#8221;). In June 2021, Former Ensysce merged with and into Leisure Acquisition
Corporation (&#8220;<i>LACQ</i>&#8221;). As part of the transaction, LACQ changed its name to &#8220;Ensysce Biosciences, Inc.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
mailing address of our principal executive office is 7946 Ivanhoe Avenue, Suite 201, La Jolla, California 92037. Our corporate telephone
number is (858) 263-4196. Our website address is www.ensysce.com. Information contained on our website, or connected thereto, does not
constitute part of, and is not incorporated by reference into, this Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Channels
for Disclosure of Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investors,
the media, and others should note that we announce material information to the public through filings with the SEC, the investor relations
page on our website, blog posts on our website, press releases, public conference calls, webcasts, and our twitter feed (@EnsysceBio).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information disclosed by the foregoing channels could be deemed to be material information. As such, we encourage investors, the media,
and others to follow the channels listed above and to review the information disclosed through such channels.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
updates to the list of disclosure channels through which we will announce information will be posted on the investor relations page on
our website.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business
Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical stage pharmaceutical company seeking to develop innovative solutions for severe pain relief while reducing the potential
for opioid misuse, abuse, and overdose.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently developing product candidates designed to improve the safety of prescription drugs. Our primary focus has been on opioid
pain products and opioid use disorder products. Prescription opioid abuse presents major burdens to society, resulting in significant
costs, illnesses, and deaths, many of which we believe could be prevented through the use of our proprietary technologies. We believe
the intertwined issues of (1) the widespread abuse of prescription opioids and (2) the resultant reluctance of many prescribers to write
prescriptions for opioid analgesics have resulted in the persistent under-treatment of patients with moderate-to-severe pain. Our platforms
utilize a novel molecular delivery technology designed to deter prescription opioid abuse at the molecular level.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current development pipeline includes two new drug platforms - an abuse-resistant opioid prodrug technology &#8211; the&#8239;Trypsin
Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology - the Multi-Pill Abuse Resistant,
or the MPAR&#174; platform. The TAAP platform is designed to seek to improve the care of patients with severe pain while reducing the
human and economic costs associated with prescription opioid drug abuse. The MPAR&#174; platform when combined with our TAAP prodrugs
is designed not only to seek to prevent abuse of prescription drugs but also to reduce overdose occurrences. Each prodrug is intended
to be able to be combined with our MPAR&#174; technology for overdose protection.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
technology under the TAAP platform when applied to opioid drugs is designed to release clinically effective opioid drugs only when exposed
to specific physiological conditions (i.e., when the drug is ingested and exposed to the digestive enzyme trypsin). Our lead product
candidate, PF614, is a TAAP oxycodone prodrug that is a biologically inactive compound which can be metabolized in the body to produce
a drug with demonstrable features aimed at resisting both oral and non-oral modes of prescription drug abuse. This approach differs from
current formulation-based strategies such as OxyContin OP which uses Intac&#174; Technology (crush-resistant polymers) and Extampza&#174;ER
which uses DETERx&#8482; (insoluble fatty acid salts in polymers), in a number of ways. First, the TAAP technology seeks to remove the
ability of a user to abuse PF614 intravenously or intranasally based on preclinical studies that show PF614 does not readily convert
into oxycodone in the blood stream and trypsin is not present in the nasal passage, and, accordingly, PF614 would not convert to oxycodone
in the nose. Furthermore, the chemically modified and abuse-resistance TAAP opioid drug is unaffected by simple physical manipulations
designed to extract abusable amounts of opioid, such as through kitchen chemistry. Our portfolio of TAAP product candidates is based
on a differentiated understanding of chemical reactivity and metabolism, as well as the key pillars of our unique approach which focuses
on: (1) enzyme mediated metabolic activation localized in the gastrointestinal track; (2) rearrangement chemistry to achieve pharmacokinetic
release of active drug products; and (3) preclinical and clinical data that set forth the metabolic and chemical activation profile for
each of our clinical candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utilizing
this approach, we filed an Investigational New Drug application, or IND (116794), and commenced a Phase 1 clinical trial for PF614, which
was completed in February 2018. The clinical data from the Phase 1 trial demonstrated that oxycodone released from PF614 as chemically-designed,
and that it was absorbed following oral administration of the TAAP PF614, resulting in blood levels that matched the same release profile
as the extended release oxycodone product, OxyContin OP. A second multi-ascending dose study with a bioequivalent arm was completed in
July 2022 and a nasal human abuse potential (HAP) study was completed in October 2022. A second oral HAP study was completed in March
2023. A study to evaluate efficacy was completed in December 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
MPAR<sup>&#174;</sup> technology is designed to limit the bioavailability of active opioid following co-ingestion of multiple doses, whether
inadvertent or intentional, through a combination of a TAAP prodrug with nafamostat. Nafamostat is a small molecule that clinical studies
have shown to have a steep dose response curve and to be a highly potent trypsin inhibitor. When combined with our TAAP prodrugs, our
MPAR<sup>&#174;</sup> technology is designed not to affect metabolism and the release of the active pharmaceutical ingredient. However,
if the MPAR<sup>&#174; </sup>combination product is taken in larger quantities than intended, the excess nafamostat is designed to inhibit
trypsin, thereby preventing metabolic activation and averting a drug overdose. We believe the potential benefits to society of an opioid
that resists both oral and parenteral abuse are considerable. A Phase 1 study to explore the combination of PF614 and nafamostat, PF614-MPAR-101
was initiated in December of 2021, and early data from the study reported in May 2022 demonstrated the combination product showed overdose
protection, with a reduction in the release of oxycodone over that of PF614 delivered alone. A second part of this trial to confirm overdose
protection from PF614-MPAR 25 mg was completed in 2023 and data reported in May 2023. PF614-MPAR was granted Breakthrough Therapy designation
by the FDA in January 2024. A second study, PF614-MPAR-102, designed to evaluate the overdose protection across a range of dosages, initiated
enrollment of subjects in December 2024 and is continuing enrollment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
pipeline has been developed over the course of 15 years of research and investment and includes three clinical-stage product candidates.
While our principal focus and lead product candidates are geared towards combating abuse and overdose of opioid drugs, we have, over
the years of research and development, discovered and recognized qualities and unique features of certain product candidates that may
be useful in addressing other treatments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>PF614
</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PF614
is our lead TAAP prodrug candidate under development for the treatment of acute or chronic pain. PF614 is a delayed release TAAP prodrug
designed to release oxycodone under certain specific physiological circumstances when taken orally. PF164 was evaluated for safety and
pharmacokinetic release of oxycodone in a Phase 1 single ascending dose clinical trial in 64 healthy subjects. The trial showed that
PF614 was well tolerated with no serious adverse events. The study also showed pharmacokinetics had a maximum blood concentration of
oxycodone at 4 to 6 hours after swallowing PF614, demonstrating its delayed release profile. A second Phase 1b multi-ascending dose study
(MAD) was initiated in 2021 to evaluate PF614 delivered to healthy subjects twice daily for 4.5 days. This study evaluated both safety
and PK, with a second part to evaluate the bioequivalence (BE) of PF614 versus OxyContin. Final data from this trial was reported in
July 2022. The MAD study demonstrated both the safety of PF614 showing it was well tolerated at doses up to 200 mg, which was comparable
to 80 mg of OxyContin both delivered twice daily. The BE study arm followed the successful completion of the multi-ascending twice-daily
dosing study of PF614 and compared the release of oxycodone from PF614 versus OxyContin&#174; administered to subjects in both fasted
and fed states. It was concluded that 100 mg PF614 was bioequivalent to 40 mg OxyContin under both fasted and fed conditions. This data
is critical to understand future prescribing criteria for PF614 as an agent bioequivalent to OxyContin and therefore may be developed
through the 505(b)(2) regulatory path as defined by the FDA. The intranasal (IN) and oral human abuse potential of PF614 was assessed
in two different studies. In study 1, PF614-103, we evaluated the abuse potential of PF614 100 mg relative to crushed oxycodone immediate-release
(IR) tablets 40 mg (equivalent opioid doses) and placebo following intranasal administration. In study 2, PF614-104, we evaluated the
oral abuse potential of intact PF614 at 3 different dose levels 50, 100 and 200 mg to IR oxycodone 40 mg and placebo. The purpose of
this study is to assess the PK and human oral abuse potential of PF614. An efficacy study, PF614-201 was conducted to evaluate 50 and
100 mg PF614 in 16 healthy male subjects for the time of onset of pain relief and the ability of PF614 to relieve pain. The data will
be used to design our Phase 3 clinical trials. We believe PF614 has the potential to provide a safer alternative to the abuse deterrent
formulated opioid products that are currently commercially available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>PF614-MPAR</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PF614-MPAR,
a combination product of PF614 and nafamostat has been designed to limit abuse potential by providing resistance to use through injection
or inhalation and to provide overdose protection against excessive oral ingestion. Our IND application (150966) for PF614-MPAR received
FDA allowance on April 27, 2021 following the release of a Full Clinical Hold from January 8, 2021. We addressed deficiencies from the
initial IND submission, amended the protocol and submitted a response to the clinical hold letter on March 29, 2021. We initiated a Phase
1 clinical trial, PF614-MPAR-101, to evaluate safety and PK in healthy subjects in December 2021. Initial data from this trial was reported
in May of 2022. The PF614-MPAR-101 overdose protection study examined PF614 administered orally alone or in combination with the trypsin
inhibitor nafamostat (MPAR<sup>&#174;</sup>) to healthy volunteers. The initial data demonstrated the overdose protection of our MPAR<sup>&#174;
</sup>combination product, with reduced release of oxycodone from PF614 in a simulated overdose situation. It also demonstrated the PF614
in the systemic circulation (simulated injection) did not convert to oxycodone. We completed the clinical portion and reported data from
Part A of this study in December 2022. Part B of the study to test the overdose protection of the selected PF614-MPAR 25 mg formulation
by administering an escalating number of dose units to a group of healthy subjects completed enrollment in March 2023. The PK data from
Part B successfully showed that PF614-MPAR<sup>&#174;</sup> 25 mg administered at a prescribed dose of one or two dose units (capsules)
provided oxycodone in an equivalent manner to PF614 without MPAR<sup>&#174;</sup>. However, the simultaneous administration of 3 dose
units or greater of PF614-MPAR 25 mg, resulted in reduced oxycodone in the circulation, as compared to the unprotected PF614. There was
a highly significant difference between the oxycodone blood levels following delivery of PF614 200 mg versus 8 dose units of PF614-MPAR
25 mg (200 mg PF614 total) demonstrating the overdose protection produced by the MPAR<sup>&#174;</sup> technology. This was reported in
May of 2023. PF614-MPAR was granted Breakthrough Therapy designation by the FDA in January 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MPAR
is being tested clinically in partnership with Quotient Sciences, using its integrated Translational Pharmaceutics&#174; platform to search
for a PF614-MPAR formulation that allows conversion into oxycodone within the prescribed dose range but reduces conversion to oxycodone
at higher than prescribed dose levels in an overdose scenario.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market
Opportunity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Drug
Abuse and Drug Overdose</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opioid
pain medications are essential for improving the care and outcomes of a majority of Americans who live with chronic pain. In 2023, 34.9%
of adults had chronic pain, with 8.5% of those having high impact chronic pain. Millions of adults suffered from pain every day for the
preceding three months and almost 40 million adults experience severe levels of pain, which is linked to worse health status. High impact
chronic pain is characterized by extended periods of suffering which impair life quality to a severe degree. Prescription opioids drugs,
such as morphine, hydromorphone, hydrocodone, and oxycodone, have a long history of use for the management of severe and chronic pain.
Prescriptions for opioid medications in 2023 totaled almost 140 million, with $3.8 billion in market size in the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
CDC recently provided recommendations for clinicians who provide pain care, defining acute pain (duration less than 1 month), subacute
pain (duration of 1&#8211;3 months), or chronic pain (duration of 3 months or more), not including sickle cell disease related pain management,
cancer pain treatment, palliative care, and end-of life care<i>. </i>These guidelines are based on the indications, acute and chronic
pain, that we intend to explore for our TAAP and MPAR&#174; opioid products including PF614.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opioids
are offered in a variety of dosages including immediate-release tablets (or capsules), extended-release tablets (or capsules), patches,
and other dose forms. Oxycodone is one of the most effective pain killers available today. This drug helps the patient to overcome pain
and focus on his or her work. Opioids have a risk of dependence and, when used improperly, a common side effect of high doses of opioids
like oxycodone can be euphoria, or a &#8220;high.&#8221; As a result of these side effects, opioids have become amongst the most misused
or abused prescription drugs in the United States. Opioid abuse was declared a public-health emergency in 2017 when more than 91 people
died each day from opioid-related overdoses. In 2021, the total number of opioid-related deaths rose to 109,600, whereas in 2022 that
number had declined to 81,806.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
large increase in overall overdose deaths is now driven by use of synthetic opioids, in particular fentanyl, as prescription opioids
have become harder to obtain. Prescription opioid-involved death rates from 2019 to 2022 were relatively flat at 14,319 to 14,716, respectively,
showing that attention to the problem had yielded a beneficial effect. However, 6.1 million Americans over the age of 12 were reported
to be suffering from opioid use disorder (&#8220;<i>OUD</i>&#8221;) in 2024. Based on information from the CDC, the most common drugs
involved in prescription opioid overdose deaths include Methadone, Oxycodone (such as OxyContin&#174;), and Hydrocodone (such as Vicodin&#174;).
The CDC indicates that improving opioid prescribing, treatment of opioid use disorder, and prevention of opioid use disorder would help
to improve the opioid crisis. Misuse or abuse of opioids is often done in one of the following manners:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#9679;</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Oral
    Excessive Tablet Abuse</i>. Generally recognized as the most prevalent route of administration by abusers, an abuser orally ingests
    more tablets (or capsules) than is recommended for pain relief.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#9679;</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Nasal
    snorting</i>. Crushed tablets are insufflated for absorption of the drug through the nasal tissues.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#9679;</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Injection</i>.
    The opioid is physically or chemically removed from the dosage and injected into the vein using a syringe.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Oral
    Manipulated Tablet Abuse</i>. Extended-release tablets or patches are crushed, chewed, or otherwise physically or chemically manipulated
    to defeat an extended-release mechanism and provide an immediate-release of the opioid for oral ingestion.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Poly-pharmacy</i>.
    Opioids are sometimes used in conjunction with alcohol, methamphetamine, benzodiazepines or other drugs to enhance the euphoria.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Overdose</i>.
    Users may accidentally introduce excessive quantities of drugs in their systems or combine drugs that may heighten the chance of
    adverse effects of drugs. Some patients may over-ingest drugs accidentally or with the express intent of suicide.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Chronic
    or prolonged use.</i> Chronic or prolonged use of opioids resulting in dependence is another form of misuse or abuse.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amphetamines
like Adderall are manufactured in pill form and are intended for oral ingestion. As of late 2022, seventy-five percent of Adderall prescriptions
are prescribed to the 10.5 million adults, age 22 or older, that are diagnosed with attention deficit hyperactivity disorder, or ADHD.
The number of prescriptions have fallen in 2023 and 2024 due to shortages of the medication. ADHD is the most common neurodevelopment
disorder in children. Five million adults misuse stimulant medication annually, by using alternative consumption methods to achieve a
more intense high faster; snorting or injecting are most-common methods of abuse. Both of these methods involve crushing pills.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that having prescription drug products available that have a reduced potential for abuse by crushing and injecting, snorting,
and chewing could provide an even greater reduction of prescription opioid related deaths in the abuse of opioids or amphetamines.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Technology Platform Solution</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">TAAP
Prescription Drugs</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
technology under the TAAP platform utilizes a novel technology designed to deter prescription drug abuse at the molecular level. The
molecular delivery system is designed to release clinically effective drugs only when exposed to specific physiological conditions (i.e.,
when the drug is&#8239;ingested and exposed to the digestive enzyme trypsin). Our TAAP prodrugs delivery system demonstrates a number
of features aimed at resisting both oral and non-oral modes of abuse. This platform&#8217;s approach differs from current formulation-based
strategies (abuse deterrent formulations, or ADFs) in a number of ways. First, the abuse-resistance provided by TAAP is designed to be
unaffected by simple physical manipulations (e.g., crushing and extraction and/or chewing of the dose form provided to patients). We
believe the potential benefits to society of applying TAAP to opioids and amphetamines providing medication that resists both oral and
parenteral abuse are considerable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">MPAR&#174;
Prescription Drugs</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MPAR<sup>&#174;
</sup>combination therapy, involves co-formulating TAAP prodrugs with a trypsin inhibitor, nafamostat, which, when administered at prescribed
dose levels, are intended to have no effect on the conversion of the prodrug to the active ingredient thus allowing normal drug plasma
exposure levels. However, if the drug were taken in greater than prescribed quantities, the trypsin inhibitor would also be present at
higher levels, inhibiting the first step in the activation process, preventing the conversion of the prodrug to the active ingredient
thus limiting the potential to an overdose from the medication.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Development Programs</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently developing product candidates designed to improve the safety and performance of prescription drugs. Our primary focus has
been on opioid pain products and opioid use disorder products. Each prodrug is intended to be able to be combined with our MPAR&#174;
technology for overdose protection. Additionally, nafamostat, which is an ingredient in our overdose protection combination products,
may be developed for infection and pulmonary lung diseases. Besides our clinical candidates, we have a product portfolio of other TAAP
and MPAR<sup>&#174;</sup> opioids and amphetamines that could potentially be developed to build on this pipeline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clinical
agents</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">PF614</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PF614
is a chemically modified, extended-release oxycodone-derivative which releases clinically effective oxycodone only when exposed trypsin
in the gut (i.e., when the drug is ingested). This approach differs from formulation-based strategies which are currently commercially
available, in a number of ways. First, the abuse-resistance provided by PF614 is retained even when dissolved in water and is designed
to be unaffected by simple physical manipulations (e.g., extraction, chewing, and/or crushing). It also limits the bioavailability of
active medication following co-ingestion of multiple doses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
ingestion, the release of oxycodone from PF614 proceeds via a two-step process comprised of (1) trypsin activation in the small intestine
and (2) a subsequent intramolecular cyclization release reaction. This reaction releases oxycodone with concomitant formation of a cyclic
urea metabolite. The time-course of oxycodone release from PF614 is a function of the kinetics of (i) the trypsin hydrolysis and (ii)
the cyclization-release reaction. In the Phase 1 study of PF614, the time to maximal blood concentration of oxycodone (T<sub>max</sub>)
was five to six hours for the release of oxycodone and this time cannot be modified by crushing, chewing, or physically manipulating
the drug product. Oxycodone safety, metabolism, and pharmacokinetics have been well studied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>PF614-101
Phase 1 Clinical Trial</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PF614
(IND 116796) has been evaluated in a Phase 1 clinical study for safety and pharmacokinetics of oxycodone release in 64 healthy subjects
in seven different closing cohorts from November 2016 to January 2018. This study was conducted for us by PRA Health Sciences &#8211;
Early Development Services Lenexa, Kansas, principal investigator, Daniel Dickerson, M.D., Ph.D. to evaluate the safety and pharmacokinetics
of PF614, as well as the pharmacokinetics of oxycodone at doses sufficient to characterize the extent to which plasma oxycodone is produced
and maintained following oral ingestion of PF614 and was compared to the oxycodone released from extended release oxycodone from OxyContin
OP. Subjects were randomized to receive a single dose of PF614 (dose of 15, 25, 50, 100, and 200 mg with 6 subjects per dosing group)
or OxyContin OP (dose of 10, 20, 50, and 80 mg with 2 subjects per dosing group). New subjects were recruited for each cohort. Cohort
1 compared subjects receiving PF614 and OxyContin OP with and without naltrexone blockade. Naltrexone is an opioid blocker to prevent
opioids from attaching to the opioid receptors, preventing the effect of the opioid medication such as pain relief, feeling of euphoria
or respiratory depression. The single ascending dose study also compared the release of oxycodone from PF614 under both fasted and fed
conditions at the highest dose of PF614 evaluated, 200 mg. The pharmacokinetics of the prodrug fragments was also evaluated. In addition,
this study instructed as to the &#8220;conversion efficiency&#8221; of the PF614 prodrug to oxycodone, with respect to OxyContin.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pharmacokinetic
Analyses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shape of the plasma concentration versus time curve of oxycodone was similar following administration of OxyContin OP (oxycodone extended
release) and PF614. The efficiency of conversion for PF614 to oxycodone was determined to be approximately 86%. A PF614 dose of 50 mg
yields oxycodone exposure comparable to a 20.01 mg dose of OxyContin, indicating a potency ratio of 0.40. This data has allowed us to
match doses of PF614 to those of commercially available OxyContin OP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Safety</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
total of 64 subjects were included in this study, of which 23 (35.9%) experienced 47 treatment-emergent adverse events, or TEAEs. The
majority of TEAEs were either gastrointestinal disorders or nervous system disorders with no deaths, serious adverse events, or severe
TEAEs. Additionally, there were no discontinuations due to study drug-related adverse events. Over half of TEAEs were study drug related,
but they were mostly mild in severity. The three TEAEs that were moderate in severity were nephrolithiasis, or kidney stones, nausea,
and vomiting, with the nausea and vomiting being study drug related. Comparing safety data across cohorts, the data indicated that dose,
naltrexone, and fed/fasted state had no clinically relevant effect on the safety profile of PF614. PF614 was generally well tolerated
at doses up to 200 mg in healthy subjects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>PF614-102
Phase 1b Clinical Trial</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Phase 1b study was conducted by ICON (formerly PRA Health Sciences) with Dr. M Johnston as Principal investigator. This was a 2-part
study comprised of a MAD study (Part A) and a comparative bioavailability/bioequivalence and food effect study (Part B) in healthy subjects.
Part A treated a total of 24 subjects and utilized a randomized, open-label, MAD design with up to 3 separate dose groups of 8 subjects
per group. Within each dose group, subjects were randomized to receive either PF614 (n=6) or OxyContin (n=2). Subjects received repeated
BID doses, planned to be administered every 12 hours (q12h) over a 5-day period, for a total of 9 doses. PF614 doses were 50 mg, 100
mg, and 200 mg, which were expected to be approximately equivalent to the 20 mg, 40 mg, and 80 mg OxyContin doses, for Dose Groups 1,
2, and 3, respectively. Serial PK sampling was performed for the first day/first dose (Day 1) and for the last day/last dose (Day 5).
Only trough PK samples were taken within 30 minutes prior to the morning dose on Days 2, 3, and 4. Safety assessments, including regular
assessments of adverse events (AEs), vital signs (pulse rate, blood pressure, respiratory rate, and oxygen saturation [SpO<sub>2</sub>]),
clinical laboratory tests, 12-lead electrocardiograms (ECGs), and cardiac telemetry were monitored throughout the study. Subjects were
monitored for hypotension, hypopnea, apnea, and oxygen desaturation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Part
B treated a total of 60 subjects and utilized an open-label, single-dose, randomized, 4-way crossover design. Subjects were randomized
to receive each of the following single oral doses of study drugs in a Williams design crossover manner (1 at each treatment period):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Treatment A: 100 mg PF614, administered under fasted conditions (hereafter referred to as 100 mg PF614, fasted)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Treatment B: 100 mg PF614, administered under fed conditions (high-fat breakfast) (hereafter referred to as 100 mg PF614, fed)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Treatment C: 40 mg OxyContin, administered under fasted conditions (hereafter referred to as 40 mg OxyContin, fasted)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Treatment D: 40 mg OxyContin, administered under fed conditions (high-fat breakfast) (hereafter referred to as 40 mg OxyContin, fed)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
treatment was separated by a washout interval of 5 days. Serial PK sampling was performed after each study drug administration up to
120 hours post dose. Safety including regular assessments of AEs, vital signs (pulse rate, blood pressure, respiratory rate, and SpO<sub>2
</sub>), clinical laboratory tests, and 12-lead ECGs were monitored. Subjects were monitored for hypotension, hypopnea, apnea, and oxygen
desaturation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pharmacokinetics</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Part
A: The shape of the plasma concentration versus time curve of oxycodone was similar following administration of PF614 and OxyContin (oxycodone
extended release). Oxycodone plasma exposure (T<sub>max</sub>, C<sub>max,ss</sub> and AUC<sub>tau</sub>) were assessed and PF614 showed
similar trends as OxyContin following administration of multiple oral BID doses. Due to the small sample number for OxyContin some PK
parameters could not be calculated. Trough concentrations of oxycodone were generally similar from Day 2 through Day 4, suggesting that
subjects achieved steady state after repeated oral BID dosing of PF614 and OxyContin at all dose levels.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Part
B: A total of 57 subjects were included in the PK analyses. The data for C<sub>max</sub>, AUC<sub>0-t</sub>, and AUC<sub>0-inf</sub>
of oxycodone post 100 mg PF614 versus 40 mg OxyContin dosing under fasted and fed conditions were completely contained within the standard
bioequivalence limits of 80% to 125%. Therefore, it was concluded that 100 mg PF614 was bioequivalent to 40 mg OxyContin under both fasted
and fed conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Safety</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PF614
was generally safe and well-tolerated following oral administration of 50 mg, 100 mg, or 200 mg PF614 BID for 5 days. There was no apparent
difference in the safety profile of single oral doses of 100 mg PF614 when administered in the fasted or fed state or between PF614 and
OxyContin when administered in the fasted and fed state. PF614 was generally safe and well-tolerated following single and multiple oral
doses under naltrexone blockade.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>PF614-103
Intranasal Human Abuse Potential Clinical Trial</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PF614-103
was a randomized, double-blind, placebo- and active-controlled, 3-way crossover study to evaluate the abuse potential and pharmacokinetics
of intranasally administered PF614, relative to crushed oxycodone IR tablets and placebo, in non-dependent recreational opioid users
conducted by Lotus Clinical Trials LLC through Ohio Clinical Trials, Inc with Principal investigator, Dr. G. Apseloff.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
study consisted of 4 phases: Screening, Qualification, Treatment, and Follow-up. Subjects were randomized to receive PF614 100mg or crushed
oxycodone 40 mg intranasally. The primary objective of the study was to evaluate the abuse potential of PF614 relative to crushed oxycodone
immediate-release (IR) tablets and placebo following intranasal administration in non-dependent recreational opioid users (n=26), with
the primary pharmacodynamic endpoint being the maximum effect (E<sub>max</sub>) for Drug Liking (&#8220;<i>at this moment</i>&#8221;)
measured up to 24 hours after dosing using a visual analogue scale (VAS). The secondary objectives of the study were to evaluate the
pharmacokinetic profile of PF614 relative to crushed oxycodone IR tablets following intranasal administration, to evaluate the safety
of PF614 following intranasal administration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the study, PF614 powder produced a statistically significant lower peak &#8220;drug liking&#8221; (Emax) when compared with intranasal
crushed IR oxycodone (p = 0.0133) using the full modified completer population in a 3-period crossover of PF614 vs. crushed oxycodone
and placebo. Furthermore, in a first period analysis of initial impressions of each drug, a statistically significant difference was
noted between PF614 (n=8) and crushed IR oxycodone (n=10) (p = 0.0175), even with this smaller cohort of subjects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statistically
significant differences in peak effects (Emax) between PF614 and crushed IR oxycodone intranasal were also demonstrated for the secondary
endpoint of &#8220;take drug again,&#8221; also using a first period analysis (p &lt; 0.0001).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
intranasal HAP study was designed to test if known recreational drug users &#8220;<i>liked</i>&#8221; the product and is critical for
labeling claims for new drugs in this class. The primary measure in this study, &#8220;<i>drug liking</i>,&#8221; is recommended by the
FDA in their Guidance on &#8220;Assessment of Abuse Potential of Drugs.&#8221; This measure is known to correlate with a drug&#8217;s
potential for abuse. The results demonstrated that inhaled powdered PF614 had significantly lower drug liking than inhaled crushed IR
oxycodone.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>PF614-104
Oral Human Abuse Potential Clinical Trial</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PF614-104
was a randomized, double-blind, placebo- and active-controlled, 5-way crossover study to evaluate the abuse potential and pharmacokinetics
of orally administered PF614, relative to oxycodone IR tablets and placebo, in non-dependent recreational opioid users conducted by DVCR,
Kansas.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
study consisted of 4 phases: Screening, Qualification, Treatment, and Follow-up. Subjects were randomized to receive PF614 50, 100 and
200 mg, oxycodone 40 mg or placebo orally. The primary objective of the study was to evaluate the abuse potential of PF614 relative to
oxycodone immediate-release (IR) tablets and placebo following oral administration in non-dependent recreational opioid users (n=28),
with the primary pharmacodynamic endpoint being the maximum effect (E<sub>max</sub>) for Drug Liking (&#8220;<i>at this moment</i>&#8221;)
and &#8220;Take Drug Again&#8221; Emax (Secondary endpoint) measured up to 24 hours after dosing using a visual analogue scale (VAS).
The secondary objectives of the study were to evaluate the pharmacokinetic profile of PF614 relative to oxycodone IR tablets and to evaluate
the safety of PF614.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PF614
produced statistically lower effects than oxycodone, the lowest dose p&lt;0.0001, and statistically significant overall &#8220;Drug Liking&#8221;
at both the low and the mid doses p&lt;0.0001 and p=0.0025, respectively. PF614 took a significantly lower median time to reach Emax
for &#8220;Drug Liking&#8221; than oxycodone at all three dose levels, which is highly important for reducing drug abuse. Similar findings
were noted with a second endpoint &#8220;Take Drug Again&#8221;. The secondary endpoint was met at both the low and mid dose of PF614
with highly significant values of p&lt;0.001 and p=0.0038, respectively, and was numerically lower than comparator even at double the
dose, demonstrating that recreational users would be less motivated to abuse PF614 compared to immediate release oxycodone.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2022, we received written guidance from the FDA that an acute pain indication may be appropriate for PF614. The FDA guidance,
while not binding, states that our proposed clinical development approach of conducting at least two adequate and well-controlled clinical
trials in two different pain models comparing PF614 to a placebo and to another immediate release (IR) opioid, such as IR oxycodone,
appears reasonable to support a new drug application for PF614 for an acute pain indication. The FDA guidance also provides additional
guidance with respect to the non-clinical studies and clinical trials planned by us. The clinical development pathway of PF614 for an
acute pain indication may reduce the development timeline and be more cost-effective than initially pursuing a chronic pain indication
for PF614.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>PF614-201
Time of Onset clinical study</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PF614-201
was a randomized, double-blind, placebo-controlled study of PF614 50 and 100 mg to evaluate the onset of analgesia following administration
of a single oral dose of PF614 in healthy male subjects in an experimental pain model (cold pressor test [CPT]). This study was initiated
in September of 2023 and enrolled 16 subjects. The Treatment Phase consisted of 2 treatment periods; PF614 50 mg or 100 mg versus placebo.
The CPT, pharmacodynamic (PD), and safety assessments were conducted prior to dosing and for six hours after each study drug administration.
This study was the first to successfully demonstrate the efficacy of PF614. Data was reported December 2023, stating the time-of-onset
of pain relief from both doses of PF614 was identified, and PF614 did decrease the intensity of pain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Next
Steps</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
End of Phase 2 regulatory meeting was held on January 30, 2024. The meeting clarified the non-clinical and clinical Phase 3 study plans
for the further development of PF614 which are expected to initiate in mid-2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">PF614-MPAR</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
initiated a Phase 1 study that is evaluating PF614-MPAR in study entitled &#8220;A Single Dose, 2 Part Study to Evaluate the Pharmacokinetics
of Oxycodone and PF614, when PF614 Solution is Co-Administered with nafamostat, as an Immediate Release Solution and/or Extended Release
(ER) Capsule Formulations in Healthy Subjects:&#8221; We are clinically testing MPAR<sup>&#174;</sup> in partnership with Quotient Sciences,
using its integrated Translational Pharmaceutics<sup>&#174;</sup> platform to search for a PF614-MPAR formulation that allows conversion
into oxycodone within the prescribed dose range but reduces conversion to oxycodone at higher than prescribed dose levels in an overdose
scenario.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>PF614-MPAR-101
Phase 1 Clinical Trial</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary objectives of the Phase 1 study are to assess the pharmacokinetics of oxycodone, when PF614 solution is administered alone and
with nafamostat as an immediate release solution and/or extended-release capsule prototypes. The study is designed to aid in the selection
of the optimal nafamostat formulation and dose to combine with PF614 in order to provide oxycodone when a prescribed dose is taken yet
attenuate the maximum plasma concentration (C<sub>max</sub>) and the area under the concentration time curve (AUC) of oxycodone when
more than the prescribed PF614-MPAR dose is taken. Initial data was reported in May 2022 that demonstrated nafamostat administer in combination
with PF614 in a simulated overdose situation reduced the release of oxycodone from PF614 as designed. We completed the clinical portion
of Part A of this study in December 2022, with the identification of an optimal drug product formulation. A second, Part B was initiated
in January 2023 to test the overdose protection of the selected formulation by administering an escalating number of dose units to a
group of healthy subjects. Enrollment was completed in March 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Part
B was a dose escalation study of PF614 25 mg alone, or increasing dose units of PF614-MPAR 25 mg (PF614 25 mg with 1 mg formulated nafamostat),
and enrolled 6 to 8 healthy subjects in each cohort. PF614-MPAR 25 mg was delivered at 1, 2, 3, 5, and 8 doses simultaneously, with safety
and PK endpoints. The plasma PK of oxycodone released from PF614 or PF614-MPAR was measured and compared to prior data where PF614 was
delivered up to 200 mg alone. Additionally, the PK of parent PF614 and metabolic fragments were measured.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
results of the study successfully demonstrated that up to 2 dose units of PF614-MPAR delivered oxycodone at the same level as was derived
from PF614 without MPAR<sup>&#174;</sup>. At 3 units of PF614-MPAR the amount of oxycodone delivered was reduced compared to a 75 mg dose
of PF614. At 8 dose units there was a significant decrease (p&lt;0.00333) in the maximal oxycodone plasma concentration (Cmax) as compared
to that delivered from unprotected PF614 200 mg. In addition, delivering 2 doses of PF614-MPAR sequentially, 12 hours apart did not affect
the release of oxycodone from the 2nd dose. Data from this study was reported in May 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PF614-MPAR
was granted Breakthrough Therapy designation by the FDA in January 2024. A Type D meeting request to discuss the non-clinical program
for PF614-MPAR was submitted in 2023 and responses to questions were received in February 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>PF614-MPAR-102
Phase 1b Clinical Trial</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary objectives of the Phase 1b study are to assess the pharmacokinetics of oxycodone when PF614 is administered alone and with formulated
nafamostat, evaluate a food effect, and explore PF614-MPAR delivered in a multi-ascending dose study. The study initiated in December
2024 and will continue through 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
life sciences industry is characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary
products. We expect to face competition from a number of sources, including pharmaceutical and biotechnology companies, generic drug
companies, drug delivery companies, and academic and research institutions. Most of these existing and potential competitors have significantly
greater financial and other resources than we do.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
key competitive factors that are expected to affect the development and commercial success of our product candidates include safety and
tolerability, the ability of our product candidates to limit human abuse potential, bioavailability and therapeutic efficacy of our product
candidates, market indications and convenience of dosing and distribution. PF614 will also face competition from commercially available
generic and branded extended-release and long-acting opioid drugs other than oxycodone, including, but not limited to, fentanyl, hydromorphone,
oxymorphone, and methadone, as well as opioids that are currently in clinical development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that obtaining an abuse-deterrent label through the FDA for our prodrugs would provide us with a significant competitive advantage.
There are only four commercially available (in the United States) opioid drugs for chronic pain relief that have an abuse-deterrent label.
These drugs are MorphaBond&#8482; ER, marketed by Daiichi Sankyo, OxyContin<sup>&#174;</sup> ER and Hysingla<sup>&#174;</sup> ER, both
of which are marketed by Purdue Pharma, LP, and Collegium Pharmaceutical, Inc.&#8217;s XTampza<sup>&#174;</sup>ER. However, obtaining
an abuse-deterrent label involves a lengthy and complicated process with no certainty of success. We believe abuse-deterrent opioids
represent a therapeutic option to maximize pain relief in patients for whom opioid analgesia is indicated, while reducing the risks of
abuse and diversion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
number of other companies including, but not limited to, Pfizer Inc., Daiichi Sankyo, Endo Health Solutions, Nektar Therapeutics, Teva
Pharmaceutical, Inc., Egalet Ltd., KemPharm Inc., Elysium Therapeutics Inc., and Acura Pharmaceutical, have either extended-release or
abuse-deterrent products in various stages of development. Other companies offer products indicated for chronic, severe, long-term pain
with various delivery technologies, but these products do not have abuse-deterrent claims on their labels. Vertex has recently announced
the approval of a non-opioid pain product, suzetrigine, that inhibits NaV1.8. The clinical data provided to date has indicated that suzetrigine
did not provide superior pain relief compared to the opioid control arm of the Phase 3 study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not believe there are other companies developing products that have an overdose mechanism similar to our MPAR<sup>&#174;</sup> technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends in part on our ability to obtain and maintain proprietary protection for product candidates and any of our
future product candidates, novel discoveries, product development technologies, and know-how; to operate without infringing on the proprietary
rights of others; and to prevent others from infringing our proprietary rights. Our policy is to seek to protect our proprietary position
by, among other methods, filing or in-licensing United States and foreign patents and patent applications related to our proprietary
technology, inventions, and improvements that are important to the development and implementation of our business. We also rely on trademarks,
trade secrets, know-how, continuing technological innovation, and potential in-licensing opportunities to develop and maintain our proprietary
position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, EBIR entered into a Technology Transfer Agreement with Mucokinetica to acquire its intellectual property and all assets
associated with the inhaled nafamostat program. Specifically, EBIR acquired Patent EP2124926B1 and all data and assets associated with
the development and expansion of the inhaled nafamostat program. These assets included COVID-19 and cystic fibrosis drug targets in development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration for this intellectual property, Mucokinetica received a 1% equity ownership in EBIR, and its founders, Roderick Hall and
Peter Cole, entered into Consulting Agreements with EBIR. The Consulting Agreements were subsequently terminated by Messrs. Hall and
Cole.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patents
and Patent Applications</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
own numerous patents and applications in the United States and significant commercial markets, such as Europe, China, and Japan, relating
to our product candidates currently in development, as well as other product candidates that may be developed in the future. These patents
and applications are projected to expire between 2028 and 2042, subject to any patent term adjustment or extension that might be available
in a particular jurisdiction. A table of the key patent families and their natural or projected expiry dates is presented below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Countries
    of Filings*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    or Projected Expiry Date</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>TAAP
    and MPAR Patents and Applications for Opioids</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions
    Comprising Enzyme-Cleavable Ketone-Modified Opioid Prodrugs and Optional Inhibitors Thereof</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.,
    Australia, Brazil, Canada, China, Europe, Hong Kong, Israel, India, Japan, Mexico, Russia</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2030</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions
    Comprising Enzyme-Cleavable Opioid Prodrugs and Inhibitors Thereof</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2030</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions
    Comprising Enzyme-Cleavable Oxycodone Prodrugs</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.,
    Australia, Brazil, Canada, China, Europe, Hong Kong, Israel, India, Japan, Russia</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2032</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions
    Comprising Enzyme-Cleavable Prodrugs and Controlled Release Nafamostat and Methods of Use Thereof</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.,
    PCT, Taiwan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2042</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Active
    Agent Prodrugs with Heterocyclic Linkers</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.,
    Australia, Brazil, Canada, China, Europe, Hong Kong, Israel, India, Japan, Russia</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2032</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enzyme-Cleavable
    Methadone Prodrugs and Methods of Use Thereof</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.,
    PCT, Europe, Brazil, China, Japan, Korea, Canada, Mexico, Australia, India, Israel</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2042</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Nafamostat
    Patents and Applications</span></i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods
    of Treating Coronavirus Infections and COVID-19</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.,
    Canada, Europe</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2041</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oral
    formulations of Nafamostat</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.,
    PCT, Taiwan, Europe, Brazil, China, Japan, Korea, Canada, Mexico, Australia, India, Israel</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2042</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods
    of Treating Respiratory Diseases with Mucostasis</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Germany,
    France, Italy, United Kingdom</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2028</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>TAAP
    and MPAR Patents and Applications for Amphetamines</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions
    Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.,
    Europe</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2031</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions
    Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.,
    Europe, Hong Kong</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2040</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*&#8221;<i>Europe</i>&#8221;
refers to patent applications filed in, and patents issued by, the European Patent Office (&#8220;<i>EPO</i>&#8221;), which can provide
the basis for rights in multiple countries that are members of the European Patent Convention.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we seek broad coverage under our existing patent applications, there is always a risk that an alteration to the products or processes
may provide sufficient basis for a competitor to avoid infringing our patent claims. In addition, patents, if granted, expire and we
cannot provide any assurance that any patents will be issued from our pending or any future applications or that any potentially issued
patents will adequately protect our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individual
patents extend for varying periods depending on the date of filing of the patent application or the date of patent issuance and the legal
term of patents in the countries in which they are obtained. Generally, patents issued for regularly filed applications in the United
States are granted a term of 20 years from the earliest effective non-provisional filing date. In addition, in certain instances, a patent
term can be extended to recapture a period due to delay by the United States Patent and Trademark Office (&#8220;<i>USPTO</i>&#8221;)
in issuing the patent as well as a portion of the term effectively lost as a result of the FDA regulatory review period. However, as
to the FDA component, the restoration period cannot be longer than five years and the total patent term including the restoration period
must not exceed fourteen years following FDA approval. The duration of foreign patents varies in accordance with provisions of applicable
local law, but typically is also 20 years from the earliest effective non-provisional filing date. However, the actual protection afforded
by a patent varies on a product-by-product basis, from country to country, and depends upon many factors, including the type of patent,
the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country,
and the validity and enforceability of the patent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success will also depend in part on not infringing upon the proprietary rights of third parties. It is uncertain whether the
issuance of any third-party patent would require us to alter our development or commercial strategies for our products or processes,
or to obtain licenses or cease certain activities. Our breach of any license agreements or failure to obtain a license to proprietary
rights that we may require to develop or commercialize our future products may have an adverse impact on us. If third parties prepare
and file patent applications in the United States that also claim technology to which we have rights, we may have to participate in interference
or derivation proceedings in the USPTO to determine priority of invention. For more information, please see &#8220;<i>Risk Factors&#8212;Risks
Related to Our Intellectual Property</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>TAAP
and MPAR&#174; Patents and Applications for Opioids</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are the owner of patent families that include several granted U.S. patents, as well as granted patents and pending patent applications
in numerous foreign jurisdictions, including Australia, Brazil, Canada, China, Europe, India, Japan, and Russia, relating to chemically
modified opioids, such as oxycodone, methadone, and hydromorphone, covalently linked using specific linkers to a gastrointestinal enzyme-cleavable
moiety and pharmaceutical compositions containing these modified opioids, pharmaceutical compositions containing these modified opioids
and a gastrointestinal enzyme inhibitor, and methods of using the same to treat pain. Three of these patent families are directed to
ketone containing opioids and cover PF614 and PF614-MPAR and certain methadone TAAP product candidates that are still in the discovery
phase. These three families contain issued patents in the United States and certain foreign jurisdictions, including Australia, Brazil,
Canada, China, Europe, India, Japan, and Russia and expire between 2030 and 2032, subject to any applicable patent term extension that
might be available in a jurisdiction. We also own pending United States, Patent Cooperation Treaty (PCT), and Taiwan applications directed
to oral formulations of PF614-MPAR, which if pursued and issued would expire in 2042, subject to any potential patent term adjustment
or extension that may be available in a jurisdiction. We also own one patent family that includes granted patents in the United States,
as well as granted patents and pending patent applications in numerous foreign jurisdictions, including Australia, Brazil, Canada, China,
Europe, India, Japan, and Russia, relating to chemically modified ketone-containing agents, such as oxycodone, methadone, and hydromorphone,
covalently linked using specific linkers to a gastrointestinal enzyme-cleavable moiety, pharmaceutical compositions containing these
modified ketone-containing agents, pharmaceutical compositions containing these modified ketone-containing agents and a gastrointestinal
enzyme inhibitor, and methods of using the same to treat pain, would cover certain methadone TAAP product candidates that are still in
discovery phase and expire in 2032. While we own these patent families, we have not updated records in the various patent offices to
reflect our ownership of these patent families. Failure to update such ownership may result in an innocent purchaser potentially acquiring
rights in such patents that are adverse to our interests. Furthermore, as noted above, we have not obtained assignments for certain patent
applications relating to abuse-resistant amphetamines.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that one patent covering PF614 will be eligible for up to five years of patent term extension in the United States and intend
to pursue such extension. In addition to patent exclusivity until at least 2032, under the provisions of the Hatch-Waxman Act, upon any
approval in the United States, we believe that PF614 will be eligible for five-year New Chemical Entity, or NCE, regulatory exclusivity,
during which time no 505(b)(2) New Drug Application, or NDA, or Abbreviated New Drug Application, or ANDA, can be approved that contains
the same active moiety as the chemical entity in the PF614 NDA. In addition, if an ANDA or 505(b)(2) applicant were to file its application
referencing the NDA for PF614 before expiration of our formulation patent and the applicant asserted that the patent is invalid or would
not be infringed, it may be subject to additional waiting periods prior to the FDA&#8217;s approval (including a statutory thirty-month
stay, starting at the end of the five-year NCE regulatory exclusivity period, if we sue for infringement, or a shorter period if the
patent expires of there are certain settlements or judicial decisions in the patent litigation) and may ultimately be required to wait
until the natural expiration of our compositions patents if the patents are found to be valid and infringed by the challenging applicant.
For more information please see &#8220;&#8212;<i>Patents and Patent Applications.&#8221;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nafamostat
Patents Applications</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
own pending applications in the U.S., Canada and Europe directed to the use of orally administered nafamostat and extended-release formulations
of nafamostat. Some of the claims are directed to the use of oral nafamostat for the treatment of infections caused by coronaviruses,
including COVID-19, and pending United States, PCT, and Taiwan patent applications directed to oral formulations of nafamostat. We intend
to pursue these applications in the United States and other significant commercial markets and any patents that may be issued would expire
in 2041 and 2042, respectively, subject to any applicable patent term adjustment or extension in a particular jurisdiction. Additionally,
we acquired one European patent from Mucokinetica Ltd. that is directed to the use of certain compounds, including nafamostat, for the
manufacture of a medicament for the treatment of respiratory diseases with mucostasis or poor mucus clearance. This patent was validated
in Germany, France, Italy, and the United Kingdom and expires in 2028, subject to any applicable patent term extension that might be
available in Europe Union or United Kingdom. Currently, we do not have any issued patent or pending application directed to methods of
treating infections caused by coronaviruses, including COVID-19, with inhaled nafamostat, but intend to file pending applications upon
development of a suitable inhalation formulation of nafamostat. We believe that one patent covering nafamostat will be eligible for up
to five years of patent term extension in the United States and Europe and intend to pursue such extension. In addition to patent exclusivity,
under the provisions of the Hatch-Waxman Act, upon any approval in the United States, we believe that nafamostat will be eligible for
five-year NCE regulatory exclusivity, during which time no 505(b)(2) NDA or ANDA can be approved that contains the same active moiety
as the chemical entity in the nafamostat NDA. In addition, if an ANDA or 505(b)(2) applicant were to file its application referencing
the NDA for nafamostat before expiration of our use patent and the applicant asserted that the patent is invalid or would not be infringed,
it may be subject to additional waiting periods prior to the FDA&#8217;s approval (including a statutory thirty-month stay, starting
at the end of the five-year NCE regulatory exclusivity period, if we sue for infringement, or a shorter period if the patent expires
of there are certain settlements or judicial decisions in the patent litigation) and may ultimately be required to wait until the natural
expiration of our compositions patents if the patents are found to be valid and infringed by the challenging applicant. For more information
please see &#8220;&#8212;<i>Patent and Patent Applications</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>TAAP
and MPAR&#174; Patents and Applications for Amphetamines</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are the owner of one patent family that includes pending applications in the United States and numerous European foreign jurisdictions
relating to chemically modified amphetamines covalently linked to a gastrointestinal enzyme-cleavable moiety, pharmaceutical compositions
containing the modified amphetamines, pharmaceutical compositions containing the modified amphetamines and a gastrointestinal enzyme
inhibitor and methods of using the same to treat a subject. While we own this patent family, we have not updated the records in the various
patent offices to reflect our ownership of this patent family. Failure to update such ownership may result in an innocent purchaser potentially
acquiring rights in such patents that are adverse to our interests. In addition, we own pending United States and European patent applications
directed to pharmaceutical compositions containing chemically modified amphetamines covalently linked to a gastrointestinal enzyme-cleavable
moiety and a trypsin inhibitor and methods of using the same to treat a subject. We have not obtained assignments from all of the inventors
of these applications to date, which could negatively impact our ability to pursue or enforce this application. If issued, these patent
applications would expire between 2031 and 2040, subject to any applicable patent term adjustment or extension that might be available
in a jurisdiction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Trademarks
and Trade Secrets</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to pursue trademark registrations in the United States and other significant commercial markets for our product candidates as
they progress through clinical development. We received registration of our trademark for MPAR on May 16, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
we rely upon trade secrets, know-how, continuing technological innovation, and potential in-licensing opportunities to develop and maintain
our competitive position. We seek to protect our proprietary information, in part, using confidentiality and invention assignment agreements
with our commercial partners, collaborators, employees, and consultants. These agreements are designed to protect our proprietary information
and, in the case of the invention assignment agreements, to grant us ownership of technologies that are developed through a relationship
with an employee or a third party. These agreements may be breached, and we may not have adequate remedies for any breach. In addition,
our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our commercial partners,
collaborators, employees, and consultants use intellectual property owned by others in their work for us, disputes may arise as to the
rights in related or resulting know-how and inventions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Manufacturing
and Supply</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently own or operate manufacturing facilities for the production of clinical or commercial quantities of our product candidates.
Our drug substance and drug products are manufactured for us by CMOs, to our specifications. Any manufacturing problem or the loss of
a CMO could be disruptive to our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
lead product candidate, PF614, is a small molecule opioid prodrug. As such, it is a controlled substance, regulated by the Drug Enforcement
Administration (&#8220;<i>DEA</i>&#8221;) and state-controlled substance authorities. Our CMOs will be required to be registered with
DEA and will be responsible for obtaining adequate quota to manufacture and otherwise handle controlled substances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently engage third parties to provide clinical supplies of PF614 and nafamostat. We also currently engage a CMO to provide drug product
manufacture of PF614, PF614-MPAR and nafamostat. We currently have sufficient supplies of PF614 and nafamostat on hand for our current
clinical trial needs. Any reliance on suppliers may involve several risks, including a potential inability to obtain critical materials
and reduced control over production costs, delivery schedules, reliability, and quality.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Government
Grants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have received funding under federal grant award programs through governmental agencies, such as the NIH and NIDA. For the year ended
December 31, 2024, we received federal grant funding totaling $5.2 million consisting of $3.1 million from NIH related to the Phase 1
clinical trial for PF614-MPAR and $2.1 million from NIDA for preclinical development of our opioid use disorder-MPAR<sup>&#174;</sup>
technology. Current remaining funding under the PF614-MPAR grant totaled $1.6 million as of December 31, 2024, covering the period through
May 2025. The PF614-MPAR grant includes a remaining $9.0 million of approved funding through May 2027. We may apply for additional grant
funding from these or similar governmental agencies in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Government
Regulation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, pharmaceutical products are subject to extensive regulation by the FDA, and those pharmaceutical products that are
controlled substance are also subject to extensive regulation by the DEA. The Federal Food, Drug, and Cosmetic Act (the &#8220;<i>FDC
Act</i>&#8221;), the Controlled Substances Act (&#8220;<i>CSA</i>&#8221;), and other federal, state, and local statutes and regulations,
govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and
marketing, distribution, prescribing, dispensing, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical
products. Pharmaceutical products used for the prevention, treatment, or cure of a disease or condition of a human being are subject
to regulation under the FDC Act. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative
or judicial sanctions, such as clinical hold, FDA refusal to approve pending NDAs, revocation of licensing authority, warning or untitled
letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties,
and criminal prosecution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
FDA Drug Approval Process</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
approval is required before any new drug can be marketed. A new drug is one not generally recognized by experts qualified by scientific
training and experience, as safe and effective for its intended use. The process of drug development is complex and lengthy. The activities
undertaken before a new pharmaceutical product may be marketed in the United States generally include, but are not limited to, preclinical
studies; submission to the FDA of an IND, which must become active before human clinical trials may commence; adequate and well-controlled
human clinical trials to establish the safety and efficacy of the product; submission to the FDA of an NDA; filing of the NDA by FDA;
satisfactory completion of an FDA pre-approval inspection of the clinical trial sites and manufacturing facility or facilities at which
both the active ingredients and finished drug product are produced to assess compliance with, among other things, patient informed consent
requirements, the clinical trial protocols, current Good Clinical Practices, or GCP, and GMPs; and FDA review and approval of the NDA
prior to any commercial sale and distribution of the product in the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical
studies include laboratory evaluation of product chemistry and formulation, and in some cases, animal studies and other studies to preliminarily
assess the potential safety and efficacy of the product candidate. The results of preclinical studies together with manufacturing information,
analytical data, and detailed information including protocols for proposed human clinical trials are then submitted to the FDA as a part
of an IND. An IND must become effective, and approval must be obtained from an Institutional Review Board (&#8220;<i>IRB</i>&#8221;)
prior to the commencement of human clinical trials. The IND becomes effective 30 days following its receipt by the FDA unless the FDA
objects to, or otherwise raises concerns or questions and imposes a clinical hold. We, the FDA, or the IRB may suspend or terminate a
clinical trial at any time after it has commenced due to safety or efficacy concerns or for commercial reasons. In the event the FDA
imposes a clinical hold, the IND sponsor must address any outstanding FDA concerns or questions to the satisfaction of the FDA before
clinical trials can proceed or resume.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human
clinical trials are typically conducted in three sequential phases that may sometimes overlap or be combined:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
Phase 1, the initial introduction of the drug into patients, the product is tested to assess safety, dosage tolerance, metabolism, pharmacokinetics,
pharmacological actions, side effects associated with drug exposure, and to obtain early evidence of a treatment effect if possible.
Phase 2 usually involves trials in a limited patient population to determine the effectiveness of the drug for a particular indication,
determine optimal dose and regimen, and to identify common adverse effects and safety risks. If a compound demonstrates evidence of effectiveness
and an acceptable safety profile in Phase 2 evaluations, Phase 3 trials are undertaken to obtain additional information about clinical
effects and confirm efficacy and safety in a larger number of patients, typically at geographically dispersed clinical trial sites, to
permit the FDA to evaluate the overall benefit-risk relationship of the drug and to provide adequate information for the labeling of
the product. In most cases, the FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate the safety and efficacy
of the drug. In rare instances, a single Phase 3 trial may be sufficient when either (1) the trial is a large, multicenter trial demonstrating
internal consistency and a statistically very persuasive finding of a clinically meaningful effect on mortality, irreversible morbidity,
or prevention of a disease with a potentially serious outcome and confirmation of the result in a second trial would be practically or
ethically impossible or (2) the single trial is supported by other confirmatory evidence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the manufacturer of an investigational drug in a Phase 2 or Phase 3 clinical trial for a serious or life-threatening disease
is required to make available, such as by posting on its website, its policy on evaluating and responding to requests for expanded access
to such investigational drug.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
completion of the required clinical testing, an NDA is prepared and submitted to the FDA. FDA approval of the NDA is required before
marketing and distribution of the product may begin in the United States. The NDA must include the results of all preclinical, clinical,
and other testing and a compilation of data relating to the product&#8217;s pharmacology, chemistry, manufacture, and controls. The cost
of preparing and submitting an NDA is substantial. The submission of most NDAs is additionally subject to a substantial application user
fee, currently exceeding $3.1 million for Fiscal Year 2022. Under an approved NDA, the applicant is also subject to an annual program
fee, currently exceeding $330,000. These fees typically increase annually. Under limited circumstances, an applicant may be exempt from
or seek a waiver of the application fee requirement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA has 60 days from its receipt of an NDA to determine whether the application will be filed based on the FDA&#8217;s determination
that it is adequately organized and sufficiently complete to permit substantive review. Once the submission is filed, the FDA begins
an in-depth review. The FDA has agreed to certain performance goals to complete the review of NDAs. For a standard review, the goal for
review of a new molecular entity (&#8220;<i>NME</i>&#8221;) is ten months from the date the FDA files the NDA, while the goal for review
of a non-NME is ten months from the date of receipt of the NDA. For an NDA that has received a priority review designation from the FDA,
the goal for review of an NME is six months from the date the FDA files the NDA, while the goal for review of a non-NME is six months
from the date of receipt of the NDA. An NDA can receive a priority review designation when the FDA determines the drug has the potential
to treat a serious or life-threatening condition and, if approved, would be a significant improvement in safety or effectiveness compared
to available therapies. The review process for both standard and priority reviews may be extended by the FDA for three or more additional
months to consider certain late-submitted information, or information intended to clarify information already provided in the NDA submission.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may also refer applications for novel drug products, as well as drug products that present difficult questions of safety or efficacy,
to be reviewed by an advisory committee&#8212;typically a panel that includes clinicians, statisticians, and other experts&#8212;for
review, evaluation, and a recommendation as to whether the NDA should be approved. The FDA is not bound by the recommendation of an advisory
committee, but generally follows such recommendations. Before approving an NDA, the FDA will typically inspect one or more clinical sites
to assure compliance with GCP. Additionally, the FDA will inspect the facility or the facilities at which the drug product is manufactured.
The FDA will not approve the product unless compliance with cGMP is satisfactory and the NDA contains data that provide substantial evidence
that the drug is safe and effective in the claimed indication.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
the FDA evaluates the NDA and completes any clinical and manufacturing site inspections, it issues either an approval letter or a complete
response letter. A complete response letter generally outlines the deficiencies in the NDA submission and may require substantial additional
testing, or information, in order for the FDA to reconsider the application for approval. If, or when, those deficiencies have been addressed
to the FDA&#8217;s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing
such resubmissions in two or six months depending on the type of information included. An approval letter authorizes commercial marketing
and distribution of the drug with specific prescribing information for specific indications. As a condition of NDA approval, the FDA
may require a risk evaluation and mitigation strategy (&#8220;<i>REMS</i>&#8221;) to help ensure that the benefits of the drug outweigh
the potential risks to patients. A REMS can include medication guides, communication plans for healthcare professionals, and elements
to assure a products safe use (&#8220;<i>ETASU</i>&#8221;). An ETASU REMS can include, but is not limited to, special training or certification
for prescribing or dispensing the product, dispensing the product only under certain circumstances, special monitoring, and the use of
patient-specific registries. The requirement for a REMS can materially affect the potential market and profitability of the product.
Moreover, the FDA may require substantial post-approval testing and surveillance to monitor the product&#8217;s safety or efficacy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
approval, the FDA evaluates the results from in vitro manipulation and extraction, pharmacokinetics, and clinical human abuse potential
studies to determine whether the accumulated evidence is sufficient to warrant claims of abuse deterrence. Post-marketing studies may
also be required to determine whether the marketing of a product with abuse-deterrent properties results in meaningful reductions in
abuse, misuse, and related adverse clinical outcomes, including addiction, overdose, and death in the post-approval setting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problems are identified following
initial marketing. Changes to some of the conditions established in an approved NDA, including changes in indications, product labeling,
manufacturing processes, or facilities, require submission and FDA approval of a new NDA, or supplement to an approved NDA, before the
change can be implemented. An NDA supplement for a new indication typically requires clinical data similar to that in the original application,
and the FDA uses the same procedures and actions in reviewing NDA supplements as it does in reviewing original NDAs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Section
505(b)(2) NDAs</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
alternative to the NDA pathway described above is an NDA submitted under Section 505(b)(2) of the FDC Act, which enables the applicant
to rely, in part, on the FDA&#8217;s prior findings in approving a similar product or published literature in support of its application.
Section 505(b)(2) NDAs often provide an alternate path to FDA approval for modified formulations, new routes of administration, or new
uses of previously approved products. Section 505(b)(2) permits the submission of an NDA where at least some of the information required
for approval comes from studies not conducted by, or for, the applicant and for which the applicant has not obtained a right of reference.
If the Section 505(b)(2) applicant can establish that reliance on the FDA&#8217;s prior findings of safety or effectiveness is scientifically
appropriate, it may eliminate the need to conduct certain preclinical or clinical studies of the new product. The FDA may also require
companies to perform additional studies or measurements to support the change from the approved product. The FDA may then approve the
new product candidate for all, or some, of the indications for which the referenced product has been approved, as well as for any new
indication sought by the Section 505(b)(2) applicant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fast
Track Designation and Priority Review</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
is required to facilitate the development, and expedite the review, of drugs that are intended for the treatment of a serious or life-threatening
disease or condition for which there is no effective treatment and which demonstrate the potential to address unmet medical needs for
the condition. Fast Track designation may be granted for products that are intended to treat a serious or life-threatening disease or
condition for which there is no effective treatment and preclinical or clinical data demonstrate the potential to address unmet medical
needs for the condition. Fast Track designation applies to both the product and the specific indication for which it is being studied.
Any product submitted to FDA for marketing, including under a Fast Track designation, may be eligible for other types of FDA programs
intended to expedite development and review, such as priority review.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Priority
review may be granted for products that are intended to treat a serious or life-threatening condition and, if approved, would provide
a significant improvement in safety and effectiveness compared to available therapies. FDA will attempt to direct additional resources
to the evaluation of an application designated for priority review to facilitate the review.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Breakthrough
Therapy Designation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
Breakthrough Therapy designation is designed to expedite the development and review of drugs that are intended to treat a serious condition
where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapies. The primary
intent of Breakthrough Therapy designation is to develop evidence needed to support approval as efficiently as possible. The designation
provides all the features of Fast Track designation including accelerated approval and priority review along with intensive guidance
involving FDA senior managers on an efficient drug development program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Disclosure
of Clinical Trial Information</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sponsors
of clinical trials of FDA-regulated products, including drugs, are required to register and disclose certain clinical trial information
on the website www.clinicaltrials.gov. Information related to the product, patient population, phase of investigation, trial sites and
investigators, and other aspects of a clinical trial are then made public as part of the registration. Sponsors are also obligated to
disclose the results of their clinical trials after completion. Disclosure of the results of clinical trials can be delayed in certain
circumstances for up to two years after the date of completion of the trial. Competitors may use this publicly available information
to gain knowledge regarding the progress of clinical development programs as well as clinical trial design.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
Hatch-Waxman Amendments</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments, a portion of a product&#8217;s
U.S. patent term that was lost during clinical development and regulatory review by the FDA may be restored. The Hatch-Waxman Amendments
also provide a process for listing patents pertaining to approved products in the FDA&#8217;s Approved Drug Products with Therapeutic
Equivalence Evaluations (commonly known as the &#8220;<i>Orange Book</i>&#8221;) and for a competitor seeking approval of an application
that references a product with listed patents to make certifications pertaining to such patents. In addition, the Hatch-Waxman Amendments
provide for a statutory protection, known as non-patent exclusivity, against the FDA&#8217;s acceptance or approval of certain competitor
applications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Patent
Term Extension</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
Term Extension (&#8220;<i>PTE</i>&#8221;) in the United States can compensate for lost patent grant time during product development and
the regulatory review process for a patent that covers a new product or its use. This PTE period is generally one-half the time between
the effective date of an IND (falling after issuance of the patent) and the submission date of an NDA, plus the time between the submission
date of an NDA and the approval of that application, provided the sponsor acted with diligence. PTEs that can be obtained are for up
to five years beyond the expiration of the patent or fourteen years from the date of product approval, whichever is earlier. Only one
patent applicable to an approved drug may be extended and the extension must be applied for prior to expiration of the patent. The USPTO,
in consultation with the FDA, reviews and approves the application for any patent term extension or restoration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries
in which we file, the patent term is 20 years from the earliest date of filing a nonprovisional patent application related to the patent.
A U.S. patent also may be accorded patent term adjustment, or PTA, under certain circumstances to compensate for delays in obtaining
the patent from the USPTO. In some instances, such a PTA may result in a U.S. patent term extending beyond 20 years from the earliest
date of filing a non-provisional patent application related to the U.S. patent. In addition, in the United States, the term of a U.S.
patent that covers an FDA-approved drug may also be eligible for a patent term extension, or PTE, which permits patent term restoration
as compensation for the patent term lost during the FDA regulatory review process. The Hatch-Waxman Act permits a PTE of up to five years
beyond the expiration of the patent. The length of the PTE is related to the length of time the drug is under regulatory review. PTE
cannot extend the remaining term of a patent beyond a total of fourteen years from the date of product approval and only one patent applicable
to an approved drug may be extended. Similar provisions are available in Europe and certain other jurisdictions to extend the term of
a patent that covers an approved drug. In the future, if and when our products receive FDA approval, we expect to apply for PTEs on patents
covering products eligible for PTE. We plan to seek PTEs for any of our issued patents in any jurisdiction where these are available;
however, there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with our assessment
of whether such extensions should be granted, and if granted, the length of such extensions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also believe that (1) PF614 and nafamostat will be eligible for a five-year NCE regulatory exclusivity, and (2) PF614-MPAR will be eligible
for a three-year clinical investigation, or CI, regulatory exclusivity, under the Hatch-Waxman Act, during which time no ANDA can be
approved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Hatch-Waxman Act, patents covering the product such as patents claiming the approved composition of matter, approved methods of use,
approved formulations, and approved dosing and administration shall be listed in the Orange Book, which identifies drug products approved
by FDA under the FDC Act. Applicable regulatory exclusivities, such as the five-year NCE exclusivity and the three-year CI exclusivity,
are also listed in the Orange Book. If an ANDA or 505(b)(2) applicant were to file its application before expiration of all patents listed
in the Orange Book, it must certify whether it will either honor or challenge all the patents listed in the Orange Book. If an Orange
Book listed patent is challenged and we sue the ANDA or 505(b)(2) applicant for infringement, a statutory 30-month stay of approval,
started at the end of the NCE exclusivity period, will be put in place that will prohibit the FDA from finally approving the ANDA or
505(b)(2) application until the 30-months have expired or after a court has held in favor of the ANDA or 505(b)(2) applicant. The 30-month
stay begins at the end of the five-year NCE exclusivity period. If the Orange Book listed patent(s) is ultimately held valid and infringed,
the ANDA or 505(b)(2) applicant will not be finally approved until the Orange Book listed patent(s) expires. If a pediatric study is
requested by the FDA in a Pediatric Written Request, or PWR, and we complete the pediatric study according to the terms of the PWR, all
unexpired Orange Book listed exclusivities (patent or regulatory) will be extended by six months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Similar
provisions are available in Europe, Japan, and certain other jurisdictions to extend the exclusivity of a patent that covers an approved
drug. In Europe, we believe PF614 and nafamostat will be eligible for 10 years of regulatory exclusivity from European Marketing Application,
or EMA, approval. In Japan, we believe PF614 will be eligible for eight years of regulatory exclusivity from a Japanese new drug application,
or J-NDA, approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Orange
Book Listing</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
seeking approval for a drug through an NDA, applicants are required to list with the FDA each patent with claims covering the applicant&#8217;s
product or method of using the product. Upon approval of a drug, each of the patents identified in the application for the drug are then
published in the FDA&#8217;s Orange Book. Drugs listed in the Orange Book can, in turn, be cited by potential generic competitors in
support of approval of an ANDA. An ANDA provides for marketing of a drug product that has the same active ingredients in the same strengths
and dosage form as the listed drug and has been shown to be bioequivalent to the listed drug. Other than the requirement for bioequivalence
testing, ANDA applicants are not required to conduct, or submit results of, preclinical or clinical tests to prove the safety or effectiveness
of their drug product. Drugs approved in this way are commonly referred to as &#8220;<i>generic equivalents</i>&#8221; to the listed
drug and can often be substituted by pharmacists under prescriptions written for the original listed drug.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ANDA applicant is required to certify to the FDA concerning any patents listed for the approved product in the FDA&#8217;s Orange Book.
Specifically, the applicant must certify that: (i) the required patent information has not been filed; (ii) the listed patent has expired;
(iii) the listed patent has not expired but will expire on a particular date and approval is sought after patent expiration; or (iv)
the listed patent is invalid or will not be infringed by the new product. The ANDA applicant may also elect to submit a Section VIII
statement certifying that its proposed ANDA labeling does not contain (or carves out) any language regarding the patented method-of-use
rather than certify to a listed method-of-use patent. If the applicant does not challenge the listed patents, the ANDA application will
not be approved until all the listed patents claiming the referenced product have expired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
certification that the new product will not infringe the already approved product&#8217;s listed patents, or that such patents are invalid,
is called a Paragraph IV certification. If the ANDA applicant has provided a Paragraph IV certification to the FDA, the applicant must
also send notice of the Paragraph IV certification to the NDA and patent holders once the ANDA has been filed with and accepted by the
FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification.
The filing of a patent infringement lawsuit within 45 days of the receipt of a Paragraph IV certification automatically prevents the
FDA from approving the ANDA until the earlier of 30 months, expiration of the patent, settlement of the lawsuit, or a decision in the
infringement case that is favorable to the ANDA applicant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
applicant submitting an NDA under Section 505(b)(2) of the FDC Act, which permits the filing of an NDA where at least some of the information
required for approval comes from studies not conducted by, or for, the applicant and for which the applicant has not obtained a right
of reference, is required to certify to the FDA regarding any patents listed in the Orange Book for the approved product it references
to the same extent that an ANDA applicant would.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Market
Exclusivity</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
exclusivity provisions under the FDC Act also can delay the submission or the approval of certain applications. The FDC Act provides
a five-year period of non-patent marketing exclusivity within the United States to the first applicant to gain approval of an NDA for
a new chemical entity (&#8220;<i>NCE</i>&#8221;). A drug is entitled to NCE exclusivity if it contains a drug substance with no active
moiety of which has been previously approved by the FDA. During the exclusivity period, the FDA may not accept for review an ANDA or
a 505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right
of reference to all the data required for approval. However, an application may be submitted after four years if it contains a Paragraph
IV certification. For a drug that has been previously approved by the FDA, the FDC Act also provides three years of marketing exclusivity
for an NDA, 505(b)(2) NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that
were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, for
new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the new conditions of use and does
not prohibit the FDA from approving ANDAs for drugs for the original conditions of use, such as the originally approved indication. Five-year
and three-year exclusivity will not delay the submission or approval of a full NDA; however, an applicant submitting a full NDA would
be required to conduct or obtain a right of reference to all of the non-clinical studies and adequate and well-controlled clinical trials
necessary to demonstrate safety and effectiveness.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Post-Marketing
Requirements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
approval of a new product, a pharmaceutical company and the approved product are subject to continuing regulation by the FDA, including,
among other things, monitoring and recordkeeping activities, reporting to the applicable regulatory authorities of adverse experiences
with the product, providing the regulatory authorities with updated safety and efficacy information, product sampling and distribution
requirements, and complying with promotion and advertising requirements, which include, among others, standards for direct-to-consumer
advertising, restrictions on promoting drugs for uses or in patient populations that are not described in the drug&#8217;s approved labeling
(known as &#8220;<i>off-label use</i>&#8221;), limitations on industry-sponsored scientific and educational activities and requirements
for promotional activities involving the internet. Although physicians may prescribe legally available drugs for off-label uses, manufacturers
may not market or promote such off-label uses. Modifications or enhancements to the product or its labeling or changes of the site of
manufacture are often subject to the approval of the FDA and other regulators, who may or may not grant approval or may include in a
lengthy review process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prescription
drug advertising is subject to federal, state, and foreign regulations. In the United States, the FDA regulates prescription drug promotion,
including direct-to-consumer advertising. Prescription drug promotional materials must be submitted to the FDA in conjunction with their
first use. Any distribution of prescription drug products and pharmaceutical samples must comply with the U.S. Prescription Drug Marketing
Act (&#8220;<i>PDMA</i>&#8221;), a part of the FDC Act. In addition, Title II of the Federal Drug Quality and Security Act of 2013, known
as the Drug Supply Chain Security Act or the DSCSA, has imposed new &#8220;<i>track and trace</i>&#8221; requirements on the distribution
of prescription drug products by manufacturers, distributors, and other entities in the drug supply chain. These requirements are being
phased in over a ten-year period. Unless the products were packaged prior to November 27, 2018, the DSCSA requires product identifiers
(i.e., serialization) on prescription drug products in order to establish an electronic interoperable prescription product system to
identify and trace certain prescription drugs distributed in the United States. The DSCSA replaced the prior drug &#8220;<i>pedigree</i>&#8221;
requirements under the PDMA and preempts existing state drug pedigree laws and regulations. The DSCSA also establishes requirements for
the licensing of wholesale distributors and third-party logistic providers. These licensing requirements preempt states from imposing
licensing requirements that are inconsistent with, less stringent than, directly related to, or otherwise encompassed by standards established
by FDA pursuant to the DSCSA. Until FDA promulgates regulations to address the DSCSA&#8217;s new national licensing standard, current
state licensing requirements typically remain in effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, once a product is approved, its manufacture is subject to comprehensive and continuing regulation by the FDA. The
FDA regulations require that products be manufactured in specific facilities and in accordance with cGMP. cGMP regulations require among
other things, quality control and quality assurance as well as the corresponding maintenance of records and documentation and the obligation
to investigate and correct any deviations from cGMP. Drug manufacturers and other entities involved in the manufacture and distribution
of approved drugs are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced
inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to
expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. These regulations also impose
certain organizational, procedural, and documentation requirements with respect to manufacturing and quality assurance activities. NDA
holders using contract manufacturers, laboratories, or packagers are responsible for the selection and monitoring of qualified firms,
and, in certain circumstances, qualified suppliers to these firms. These firms and, where applicable, their suppliers are subject to
inspections by the FDA at any time, and the discovery of violative conditions, including failure to conform to cGMP, could result in
enforcement actions that interrupt the operation of any such product or may result in restrictions on a product, manufacturer, or holder
of an approved NDA, including, among other things, recall or withdrawal of the product from the market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
CSA and DEA Regulation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
products are regulated as &#8220;<i>controlled substances</i>&#8221; as defined under the CSA and regulations promulgated by DEA. The
law and regulations establish registration, security, recordkeeping, reporting, storage, distribution, importation, exportation, and
other requirements administered by DEA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controlled
substances are classified into five schedules: Schedule I, II, III, IV, or V, depending on the abuse potential. Schedule I substances
by definition have no established medicinal use and may not be marketed or sold in the United States. A pharmaceutical product may be
listed as Schedule II, III, IV, or V, with Schedule II substances considered to present the highest risk of abuse and Schedule V substances
the lowest relative risk of abuse among such substances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PF614
will be classified as a Schedule II controlled substance under the CSA and regulations because it contains oxycodone which is already
regulated as a Schedule II controlled substance. Consequently, the manufacturing, shipping, storing, selling, prescribing, and dispensing
of our products is subject to a high degree of regulation. Schedule II drugs are subject to the strictest requirements for registration,
security, recordkeeping, and reporting. Facilities must maintain complete and accurate inventories and records of all controlled substances
received, manufactured, stored, and distributed. These facilities must comply with strict security requirements to prevent diversion
of drugs in their possession. Also, distribution and dispensing of these drugs are highly regulated. For example, all Schedule II drug
prescriptions must be signed by a physician, presented to a pharmacist and generally limited to a 30-day supply, and may not be refilled,
that is, a new prescription is required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
registration is required for any facility that manufactures, distributes, imports, or exports any controlled substance. Also, practitioners
and pharmacies are required to register every three years. The registration is specific to the location, activity, and controlled substance
schedule. For example, separate registrations are needed for import and manufacturing, and each registration will specify which schedules
of controlled substances the facility is authorized to handle. Our contract manufacturers must be registered with DEA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the CSA establishes an annual quota system that limits the manufacturing of API and dosage forms in the United States of Schedule
I and II controlled substances. First, the DEA establishes an annual aggregate quota for how much active opioid ingredients, such as
oxycodone and tapentadol, may be produced in total in the United States based on the DEA&#8217;s estimate of the quantity needed to meet
legitimate scientific and medicinal needs. The limited aggregate number of opioids that the DEA allows to be produced in the United States
each year is allocated among individual companies, who must submit applications annually to the DEA for individual production quotas.
Also, dosage form manufacturers must also request a procurement quota to acquire opioid API to manufacture dosage forms for distribution.
We and our contract manufacturers must receive an annual quota from the DEA in order to produce or procure any Schedule I or Schedule
II substance, including oxycodone base for use in manufacturing PF614. The DEA may adjust aggregate production quotas and individual
production and procurement quotas from time to time during the year. DEA has substantial discretion in whether or not to make such adjustments.
Our contract manufacturers must apply for and obtain the necessary quotas on an annual basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2017, the DEA reduced the amount of almost every Schedule II opiate and opioid medication that may be manufactured in the United
States in calendar year 2018 by 20%. In October 2018, the SUPPORT Act was enacted, which included amendments to the CSA to require that
appropriate quota reductions be made after estimating potential for diversion. DEA announced that the estimate is based on rates of overdose
deaths and abuse, the overall public health impact related to specific controlled substances and may include other factors as appropriate.
For 2019, the DEA proposed decreased manufacturing quotas for the six most frequently misused opioids, including oxycodone, by an average
of 10% as compared to the 2018 quotas. In October 2019, consistent with the SUPPORT Act, DEA proposed additional regulations to amend
the manner in which the agency grants quotas to manufacturers. The proposed regulations will establish use-specific quotas, including
commercial sales, product development, transfer, replacement, and packaging. To decrease the risk of diversion and increase accountability,
inventory allowances will be reduced, and procurement quota certifications will be required. The DEA proposed further decreasing manufacturing
quotas in 2020 for five of the six opioids (fentanyl, hydrocodone, hydromorphone, oxycodone, and oxymorphone), by an average of 28%.
For 2021, the DEA decreased the aggregate quota for oxycodone by about 13% and for hydrocodone by about 10% from the final established
2020 quotas. Because PF614 is regulated as a Schedule II controlled substance, it is subject to the DEA&#8217;s aggregate, individual
production, and procurement quota scheme.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordering
and distribution of any Schedule I or II controlled substance are also subject to special ordering requirements under either the electronic
Controlled Substance Ordering System (&#8220;<i>CSOS</i>&#8221;) or use of DEA Form 222s. Information regarding specific transactions
are reported to DEA, and cumulative reports of such transactions are required monthly/quarterly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
DEA also requires drug manufacturers to design and implement a system that identifies and reports suspicious orders of controlled substances.
Such orders include those of unusual size, those that deviate substantially from a normal pattern, and those of unusual frequency. Manufacturers
must refuse to complete any sale and report to DEA any orders for which it is unable to resolve any potential &#8220;<i>red flags</i>.&#8221;
A compliant suspicious order monitoring system includes well-defined due diligence, &#8220;<i>know your customer</i>&#8221; process as
well as systems to identify and monitor ordering and sales of controlled substances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
enforce these requirements, the DEA conducts periodic inspections of registered establishments that handle controlled substances. Failure
to maintain compliance with applicable requirements, especially security and recordkeeping and as manifested in loss or diversion or
inability to account for all controlled substances, can result in administrative, civil, or criminal enforcement action that could have
a material adverse effect on our business, results of operations, and financial condition. The DEA may seek civil penalties, refuse to
renew necessary registrations, or initiate administrative proceedings to revoke those registrations. The DEA may also reduce or deny
quota to manufacturing facilities based on non-compliance with these requirements. In certain circumstances, violations could result
in criminal proceedings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individual
states also independently regulate controlled substances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Legislative
and Regulatory Initiatives for Opioids</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
response to widespread prescription opioid abuse, the United States government and a number of state legislatures have enacted legislation
and regulations intended to fight the opioid epidemic. The number and scope of legislative and regulatory actions, particularly in the
last three years, emphasize the severity of the opioid epidemic and its impact on our society. The FDA has stated that addressing prescription
drug abuse is a priority and has reaffirmed that the development of abuse-deterrent opioids is a key part of that strategy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recent
actions to address the opioid abuse epidemic include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
    guidance: In April 2015, the FDA adopted final guidance regarding studies and clinical trials that should be conducted to demonstrate
    that a given formulation has abuse-deterrent properties, how those studies and clinical trials will be evaluated, and what product
    labeling claims may be approved based on the results of those studies and clinical trials. The guidance describes four categories
    of abuse-deterrence studies and clinical trials: Categories 1, 2, and 3 consist of pre-marketing studies and clinical trials designed
    to evaluate a product candidate&#8217;s potentially abuse-deterrent properties under controlled conditions, while Category 4, post-marketing
    clinical trials and studies, assesses the real-world impact of abuse-deterrent formulations. The final guidance also provides examples
    of product label claims that may be made based on the results of the corresponding studies and clinical trials.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
    Opioids Action Plan: In February 2016, the FDA released an action plan to address the opioid abuse epidemic and reassess the FDA&#8217;s
    approach to opioid medications. The FDA&#8217;s plan is part of a broader initiative led by the U.S. Department of Health and Human
    Services (&#8220;<i>HHS</i>&#8221;), to address opioid-related overdose, death, and dependence.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CDC
    Prescribing Guidelines: In November 2022, the CDC released a new Guideline for Prescribing Opioids for Pain to update their 2016
    Guidelines. The new guidance includes recommendations for managing acute (duration of &lt;1 month), subacute (duration of 1&#8211;3
    months), and chronic (duration of &gt;3 months) pain. The guideline addresses the following four areas: 1) determining whether or
    not to initiate opioids for pain, 2) selecting opioids and determining opioid dosages, 3) deciding duration of initial opioid prescription
    and conducting follow-up, and 4) assessing risk and addressing potential harms of opioid use. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
    Drug Safety Communication: In April 2023, the FDA issued a communication that in the ongoing effort to address the nation&#8217;s
    opioid crisis, it was making several updates to the prescribing information of opioid pain medicines to provide additional guidance
    on their use. The changes include label updates addressing addiction, abuse and misuse as well as life-threatening respiratory depression,
    accidental ingestion, risks from concomitant use with other CNS depressants, neonatal withdrawal and opioid analgesic risk evaluation
    and mitigation strategy.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enhanced
    Warnings and Safety Labeling: In March 2016, the FDA announced required enhanced warnings for immediate-release opioid pain medications
    related to risks of misuse, abuse, addiction, overdose, and death. Subsequently, there have been several class-wide labeling changes,
    including the addition of boxed warnings relating to serious risks of using certain opioids medications along with benzodiazepines
    and other central nervous system depressants, including alcohol (Decembers 2016); and additional information relating to the new
    class-wide REMS (Septembers 2018).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enactment
    of the Comprehensive Addiction and Recovery Act (&#8220;<i>CARA</i>&#8221;): In 2016, the CARA was enacted to address the national
    epidemics of prescription opioid abuse and heroin use. Consistent with the initiatives of HHS, this legislation sought to, among
    other things, expand the availability of naloxone for law enforcement and other first responders; form an interagency task force
    to develop best practices for pain management with opioid medications; and provide resources to improve state monitoring of controlled
    substances, including opioids. In 2018, CARA 2.0 was introduced as follow-up legislation to limit initial prescriptions for opioids
    to 3 days, while exempting initial prescriptions for chronic care, cancer care, hospice or end of life care, and palliative care.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enactment
    of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (&#8220;<i>SUPPORT
    Act</i>&#8221;): In November 2018, the SUPPORT Act was enacted as a comprehensive legislative response to the continuing opioid epidemic.
    It includes a number of measures directed towards regulation and improvement of treatment for substance use-disorder and increased
    coverage by CMS of medically assisted treatment options. In addition, the SUPPORT Act requires HHS to report to Congress on existing
    barriers to access to abuse-deterrent opioid formulations by Medicare Part C and D beneficiaries. It also includes a number of requirements
    directed at reducing the potential for oversupply of opioids to reduce the potential for misuse and diversion.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Properties</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal executive office is located at 7946 Ivanhoe Ave., Suite 201 in La Jolla, California, where we lease a total of 850 square feet
of office space that we use for our administrative activities. All development activities are undertaken at contract research organizations.
The lease expires in October 2025. We believe that our current arrangements will be sufficient to meet our needs for the foreseeable
future, and that, should it be needed, suitable space will be available to accommodate our administrative activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Human
Capital Resources (Employees)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have seven full-time employees, one part-time employee and one consultant. Of these, five have a Ph.D. From time to time, we also retain
independent contractors to support our organization. None of our employees are represented by a labor union or covered by collective
bargaining agreements, and we believe our relationship with our employees is good.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Jo_006"></span>Item
1A. Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Business, Financial Condition and Capital Requirements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>There
is substantial doubt about our ability to continue as a going concern.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not have revenue generating activities and is dependent on additional financing to fund operations. These conditions raise
substantial doubt about the Company&#8217;s ability to continue as a going concern. While we believe that we will be able to raise the
capital we need to continue our operations, there can be no assurances that we will be successful in these efforts or will be able to
resolve our liquidity issues or eliminate our operating losses. If we are unable to obtain sufficient funding, we would need to significantly
reduce our operating plans and curtail some or all of our product development activities. Accordingly, our business, prospects, financial
condition and results of operations will be materially and adversely affected, and we may be unable to continue as a going concern. If
we seek additional financing to fund our business activities in the future and there remains substantial doubt about our ability to continue
as a going concern, investors or other financing sources may be unwilling to provide additional funding on commercially reasonable terms
or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are a clinical-stage pharmaceutical company with a limited operating history. We have incurred significant financial losses since our
inception and anticipate that we will continue to incur significant financial losses for the foreseeable future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage pharmaceutical company with a limited operating history. We have not yet demonstrated an ability to generate revenues,
obtain regulatory approvals, engage in clinical development beyond Phase 1 trials, manufacture any product on a commercial scale or arrange
for a third party to do so on our behalf or enter into licensing arrangements to commercialize a product, or conduct sales and marketing
activities necessary for successful product commercialization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no products approved for commercial sale and we have not generated any revenue from product sales to date, nor do we expect to generate
any significant revenue from product sales for the next few years. We will continue to incur significant research and development and
other expenses related to our product development, preclinical and clinical activities and ongoing operations. As a result, we are not
profitable and have incurred losses in each period since our inception. Net losses and negative cash flows have had, and will continue
to have, an adverse effect on our stockholders&#8217; equity and working capital. Net losses and negative cash flows have had, and will
continue to have, an adverse effect on our stockholders&#8217; equity and working capital. We expect to continue to incur significant
losses for the foreseeable future as we continue our research and development of, and seek regulatory approvals for, our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we continue to suffer losses as we have since inception, investors may not receive any return on their investment and may lose their
entire investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, as a public company, we incur significant additional legal, accounting and other expenses that we did not incur as a private
company as we:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">meet
    the requirements and demands of being a public company;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expand
    our operational, financial and management systems and increase personnel to support our operations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire
    additional clinical, quality control, medical, scientific and other technical personnel to support our clinical operations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">advance
    our clinical-stage product candidate PF614 through clinical development;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">advance
    our preclinical stage product candidates into clinical development;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
    regulatory approvals for any product candidates that successfully complete clinical trials;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">undertake
    any pre-commercialization activities to establish sales, marketing and distribution capabilities for any product candidates for which
    we may receive regulatory approval in regions where we choose to commercialize our products on our own or jointly with third parties;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain,
    expand and protect our intellectual property portfolio; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
    milestone, royalty or other payments due under any future in-license or collaboration agreements.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical
product development entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail
to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval, secure market access and reimbursement and
become commercially viable. Therefore, any investment in us would be highly speculative. Our prospects are subject to the costs, uncertainties,
delays and difficulties frequently encountered by companies in clinical development, especially clinical-stage pharmaceutical companies
such as ours. Any predictions you make about our future success or viability may not be as accurate as they would otherwise be if we
had a longer operating history or a history of successfully developing and commercializing pharmaceutical products. We will likely encounter
unforeseen expenses, difficulties, complications, delays and other known or unknown factors in achieving our business objectives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
our expenses could increase beyond our expectations if we are required by the United States Food and Drug Administration, or FDA, or
other regulatory authorities to perform clinical trials in addition to those that we currently expect to conduct, or if there are any
delays in establishing appropriate manufacturing arrangements for or in completing our clinical trials or the development of any of our
product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
ability to generate revenue from any of our potential products is subject to our ability to obtain regulatory approval and fulfill numerous
other requirements and we may never be successful in generating revenues or becoming profitable.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to become and remain profitable depends on our ability to generate revenue or execute other business development arrangements.
We do not expect to generate significant revenue, if any, unless and until we are able to obtain regulatory approval for, and successfully
commercialize the product candidates we are developing or may develop. Successful commercialization, to the extent it occurs, will require
achievement of many key milestones, including demonstrating safety and efficacy in clinical trials, obtaining regulatory approval for
these product candidates, manufacturing, marketing and selling, or entering into other agreements to commercialize, those products for
which we may obtain regulatory approval, satisfying any post-marketing requirements and obtaining reimbursement for our products from
private insurance or government payors. Because of the uncertainties and risks associated with these activities, we cannot accurately
and precisely predict the timing and amount, if any, of revenues, the extent of any further losses or when we might achieve profitability.
We may never succeed in these activities and, even if we do, we may never generate revenues that are sufficient enough for us to achieve
profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual
basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
failure to become and remain profitable may depress the market price of our common stock and could impair our ability to raise capital,
expand our business, diversify our product offerings or continue our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
require substantial additional funding. If we are unable raise capital when needed, we could be forced to delay, reduce or terminate
our product discovery and development programs or commercialization efforts.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical stage pharmaceutical company that will need to raise additional capital to continue to operate as a going concern. Our
quarterly operating results are likely to show continued losses in the future. Our operations have consumed substantial amounts of cash
since inception. We expect to continue to spend substantial amounts to continue the clinical and preclinical development of our product
candidates, including our planned Phase 2 program for nafamostat and planned clinical trials for PF614 and PF614-MPAR. We will need to
raise additional capital to complete our currently planned clinical trials and any future clinical trials. Other unanticipated costs
may arise during our development efforts. If we can obtain marketing approval for product candidates that we develop, we would require
significant additional amounts of funding to launch and commercialize such product candidates. We cannot reasonably estimate the actual
amounts necessary to successfully complete the development and commercialization of any product candidate we develop and we will require
substantial additional funding to complete the development and commercialization of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future need for additional funding depends on many factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, progress, results and costs of researching and developing our current product candidates, as well as other additional product
    candidates we may develop and pursue in the future, including the costs related to preclinical and clinical development of the product;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing of, and the costs involved in, obtaining marketing approvals for our product candidates and any other additional product candidates
    we may develop and pursue in the future;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of future product candidates that we may pursue and their development requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject
    to receipt of regulatory approval, the costs of commercialization activities for our product candidates, to the extent such costs
    are not the responsibility of any future collaborators, including the costs and timing of establishing product sales, marketing,
    distribution and manufacturing capabilities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject
    to receipt of regulatory approval, the amount of revenue, if any, received from commercial sales of our product candidates or any
    other additional product candidates we may develop and pursue in the future;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent to which we in-license or acquire rights to other products, product candidates or technologies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to establish collaboration arrangements for the development of our product candidates on favorable terms, if at all;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">dependent
    on financing, our headcount growth and associated costs as we expand our research and development and establishes a commercial infrastructure;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights, including
    enforcing and defending intellectual property related claims; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of operating as a public company.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
change in the outcome of any of these or other factors with respect to the development of any of our product candidates could significantly
change the costs and timing associated with the development of that product candidate, and many of these factors are outside of our control.
Identifying potential product candidates and conducting preclinical studies and clinical trials is a time-consuming, expensive and uncertain
process that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory and marketing
approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Accordingly,
we will need to continue to rely on additional financing to achieve our business objectives. We cannot be certain that additional funding
will be available on acceptable terms, or at all. Please see the risk factors under &#8220;<i>Risks Related to the Ownership of Common
Stock and Financial Reporting</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements
into the second quarter of 2025, while advancing our main product candidates such as, PF614 and PF614-MPAR and nafamostat through their
respective next phases of clinical development. Our estimate may prove to be wrong, and we could use our available capital resources,
if any, sooner than we currently expect. Further, changing circumstances, some of which may be beyond our control, could cause us to
consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned. To the
extent this occurs, it could impose significant dilution on our stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds
for our current or future operating plans. Attempting to secure additional financing may divert our management from our day-to-day activities,
which may adversely affect our ability to develop our product candidates. Our failure to raise capital as and when needed or on acceptable
terms would have a negative impact on our financial condition and our ability to pursue our business strategy, and we may have to delay,
reduce the scope of, suspend or eliminate one or more of our platforms, programs, planned clinical trials or future commercialization
efforts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business is highly dependent on the success of our product candidates. If we are unable to successfully complete clinical development,
obtain regulatory approval for or commercialize one or more of our product candidates, or if we experience delays in doing so, our business
will be materially harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future success and ability to generate significant revenue from our product candidates, which we do not expect will occur for several
years, is dependent on our ability to successfully develop, obtain regulatory approval for and commercialize one or more of our product
candidates. A Phase 1b study of PF614 was completed mid-year 2022. Two Human Abuse Potential clinical studies were completed in 2023.
An efficacy Phase 2 study of PF614 was completed in December 2023. A Phase 1 trial for PF614-MPAR was completed in May 2023 and a Phase
1b trial for PF614-MPAR was initiated in December 2024. A Phase 1 safety study of nafamostat was completed in 2020. All of our other
product candidates are in earlier stages of development and will require substantial additional investment for manufacturing, preclinical
testing, clinical development, regulatory review and approval in one or more jurisdictions. If any of our product candidates encounter
safety or efficacy problems, development delays or regulatory issues or other problems, our development plans and business would be materially
harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not have the financial resources to continue development of our product candidates. Even if clinical trials are completed, we may
experience other issues that may delay or prevent regulatory approval of, or our ability to commercialize, our product candidates, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
    to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that our product candidates are safe and
    effective;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">insufficiency
    of our financial and other resources to complete the necessary clinical trials and preclinical studies;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">negative
    or inconclusive results from our clinical trials, preclinical studies or the clinical trials of others for product candidates that
    are similar to ours, leading to a decision or requirement to conduct additional clinical trials or preclinical studies or abandon
    a program;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product-related
    adverse events experienced by subjects in our clinical trials, including unexpected toxicity results, or by individuals using drugs
    or therapeutic biologics similar to our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in submitting an Investigational New Drug application, or IND, or comparable foreign applications or delays or failure in obtaining
    the necessary approvals from regulators to commence a clinical trial or a suspension or termination, or hold, of a clinical trial
    once commenced;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">conditions
    imposed by the FDA, the European Medicines Agency, or EMA, or comparable foreign regulatory authorities regarding the scope or design
    of our clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">poor
    effectiveness of our product candidates during clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">better
    than expected performance of control arms, such as placebo groups, which could lead to negative or inconclusive results from our
    clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in enrolling subjects in clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">high
    drop-out rates of subjects from clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inadequate
    supply or quality of product candidates or other materials necessary for the conduct of our clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">greater
    than anticipated clinical trial or manufacturing costs;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unfavorable
    FDA, EMA or comparable regulatory authority inspection and review of a clinical trial site;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    of our third-party contractors or investigators to comply with regulatory requirements or the clinical trial protocol or otherwise
    meet their contractual obligations in a timely manner, or at all;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unfavorable
    FDA, EMA or comparable regulatory authority inspection and review of manufacturing facilities or inability of those facilities to
    maintain a compliance status acceptable to the FDA, EMA or comparable regulatory authorities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight around
    clinical testing generally or with respect to our therapies in particular; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">varying
    interpretations of data by the FDA, EMA and comparable foreign regulatory authorities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product candidates will require additional, time-consuming development efforts prior to commercial sale, including preclinical studies,
clinical trials and approval by the FDA and applicable foreign regulatory authorities. All product candidates are prone to the risks
of failure that are inherent in pharmaceutical product development, including the possibility that such product candidate will not be
shown to be sufficiently safe and effective for approval by regulatory authorities. In addition, we cannot assure stockholders that any
such products that are approved will be manufactured or produced economically, successfully commercialized or widely accepted in the
marketplace or be more effective than other commercially available alternatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
depend heavily on the success of our lead product candidate PF614, which is currently in clinical trials. Our clinical trials of PF614
may not be successful. If we are unable to commercialize PF614 or experience significant delays in doing so, our business will be materially
harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have invested a significant portion of our efforts and financial resources in the research and development of our lead product candidate,
PF614 and we expect to continue to do so. Our ability to generate revenues from the sale of abuse-deterrent opioid products, which may
not occur at a significant level for several years, will depend heavily on the successful development, regulatory approval and eventual
commercialization of PF614.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot commercialize product candidates in the United States without first obtaining regulatory approval for the product from the FDA;
similarly, we cannot commercialize product candidates outside of the United States without obtaining regulatory approval from similar
regulatory authorities outside of the United States. Even if PF614 or another product candidate were to successfully obtain approval
from the FDA and non-U.S. regulatory authorities, any approval might contain significant limitations related to use restrictions for
specified age groups, warnings, precautions or contraindications, or may be subject to burdensome post-approval study or risk management
requirements. If we are unable to obtain regulatory approval for PF614 in one or more jurisdictions, or any approval contains significant
limitations, we may not be able to obtain sufficient funding or generate sufficient revenue to continue the development, marketing and/or
commercialization of PF614 or any other product candidate that we may discover, in-license, develop or acquire in the future. Furthermore,
even if we obtain regulatory approval for PF614, we will still need to develop a commercial organization, or collaborate with third parties
for the commercialization of PF614, establish commercially viable pricing and obtain approval for adequate reimbursement from third-party
and government payors. If we or our commercialization collaborators are unable to successfully commercialize PF614, we may not be able
to generate sufficient revenues to continue our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Due
to the significant resources required for the development of our product pipeline, and depending on our ability to access capital, we
must prioritize the development of certain product candidates over others. Moreover, we may fail to expend our limited resources on product
candidates or indications that may have been more profitable or for which there is a greater likelihood of success.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have three clinical-stage product candidates as well as certain other product candidates that are at various stages of preclinical
development. We seek to maintain a process of prioritization and resource allocation to maintain an optimal balance between aggressively
pursuing our more advanced clinical-stage product candidates, such as PF614 and PF614-MPAR, and ensuring the development of additional
potential product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the significant resources required for the development of our product candidates, we must focus on specific diseases and disease pathways
and decide which product candidates to pursue and advance and the amount of resources to allocate to each. Our decisions concerning the
allocation of research, development, collaboration, management and financial resources toward particular product candidates or therapeutic
areas may not lead to the development of any viable commercial products and may divert resources away from better opportunities. If we
make incorrect determinations regarding the viability or market potential of any of our product candidates or misinterpret trends in
the pharmaceutical industry, in particular for opioid abuse and drug overdose, our business, financial condition, and results of operations
could be materially adversely affected. As a result, we may (i) fail to capitalize on viable commercial products or profitable market
opportunities, (ii) be required to forego or delay pursuit of opportunities with other product candidates or other diseases and disease
pathways that may later prove to have greater commercial potential than those we choose to pursue, or (iii) relinquish valuable rights
to such product candidates through collaboration, licensing, or other royalty arrangements in cases in which it would have been advantageous
for us to invest additional resources to retain sole development and commercialization rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
PF614 and PF614-MPAR product candidates may not be successful in limiting or impeding abuse, overdose or misuse or providing additional
safety upon commercialization.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are committing a substantial majority of our resources to the development of products utilizing our TAAP and MPAR<sup>&#174;</sup>. There
can be no assurance that our products will perform as tested and limit or impede the actual abuse, overdose or misuse of such products
or provide other benefits in commercial settings. Moreover, there can be no assurance that if our products are approved by the FDA, the
post-approval epidemiological studies required by the FDA as a condition of any such approvals of the products will show a reduction
in the consequences of abuse and misuse by patients for whom the applicable product is prescribed. The failure of our products to limit
or impede actual abuse, overdose or misuse or provide other safety benefits in practice will have a material adverse impact on market
acceptance for such products and on our financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we do not achieve our projected development and commercialization goals within the timeframes we expect, the development and commercialization
of our product candidates may be delayed, and our business and results of operations may be harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
planning purposes, we seek to estimate the timing of the accomplishment of various scientific, clinical, regulatory and other product
development objectives. These milestones may include our expectations regarding the commencement or completion of scientific studies
and clinical trials, the submission of regulatory filings, or commercialization objectives. From time to time, we may publicly announce
the expected timing of some of these milestones, such as the completion of an ongoing clinical trial, the initiation of other clinical
programs, receipt of marketing approval or a commercial launch of a product. The potential achievement of many of these milestones may
be outside of our control. Each of these milestones is based on a variety of assumptions which, if not realized as expected, may cause
the timing of such potential achievement of the respective milestones to vary considerably from our estimates, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    available capital resources or capital constraints we experience;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    rate of progress, costs and results of our clinical trials and research and development activities, including the extent of scheduling
    conflicts with participating clinicians and collaborators;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to identify and enroll patients who meet clinical trial eligibility criteria;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    receipt of approvals by the FDA and other regulatory authorities and the timing thereof;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
    outcomes;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    actions, decisions or rules issued by regulators;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to access sufficient, reliable and affordable supplies of materials used in the manufacture of our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    efforts of our collaborators with respect to the commercialization of our product candidates; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    securing of, costs related to, and timing issues associated with, product manufacturing as well as sales and marketing activities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to achieve any announced milestones in the timeframes we expect, the development and commercialization of our product candidates
may be delayed, and our business and results of operations may be harmed and it could negatively impact our share price performance.
Please see &#8220;<i>Business</i>&#8221; for more information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Competitive
products may reduce or eliminate commercial opportunity for our product candidates, if approved. If our competitors develop technologies
or product candidates more rapidly than we do, or their technologies or product candidates are more effective or safer than any such
technologies or product candidate of ours, our ability to develop and successfully commercialize our own technologies or product candidates
may be adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical and commercial landscapes for the solution of opioid abuse and drug overdose are highly competitive and subject to rapid and
significant technological change. We face competition with respect to our indications for our product candidates and will face competition
with respect to any other product candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies,
specialty pharmaceutical companies and biotechnology companies worldwide. There are several large pharmaceutical and biotechnology companies
that currently market and sell drugs or are pursuing the development of product candidates for the treatment of the indications that
we are pursuing. These companies include, but are not limited to, Purdue Pharma, LP, Collegium Pharmaceutical, Inc. and Vertex Pharmaceuticals
Incorporated. Potential competitors include companies developing novel non-opioid pain drug candidates such as pharmaceutical companies
and academic institutions, government agencies and other public and private research organizations that conduct research, seek patent
protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that a significant number of product candidates are currently under development for the same indications that we are currently
pursuing, and some or all may become commercially available in the future for the treatment of conditions for which we are trying or
may try to develop product candidates. Our potential competitors include large pharmaceutical and biotechnology companies, specialty
pharmaceutical and generic drug companies, academic institutions, government agencies and research institutions. See the section entitled
&#8220;<i>Business &#8212; Competition</i>&#8221; for examples of the competition that our product candidates face.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
competitors may have significantly greater financial resources, established presence in the market, expertise in research and development,
manufacturing, preclinical and clinical testing, obtaining regulatory approvals and reimbursement and marketing approved products than
us. Accordingly, our competitors may be more successful than we may be in obtaining regulatory approval for therapies and achieving widespread
market acceptance. Our competitors&#8217; products may be more effective, or more effectively marketed and sold, than any product candidate
we may commercialize and may render our therapies obsolete or non-competitive before we can recover development and commercialization
expenses. If any of our product candidates, including PF614, is approved, these product candidates could compete with a range of therapeutic
treatments that are in development. In addition, our competitors may succeed in developing, acquiring or licensing technologies and products
that are more effective or less costly than PF614, our other product candidates or any other product candidates that we may develop,
which could render our product candidates obsolete and noncompetitive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we obtain approval for any of our product candidates, we may face competition based on many different factors, including the efficacy,
safety and tolerability of our products, the ease with which our products can be administered, the timing and scope of regulatory approvals
for these products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent
position. Existing and future competing products could present superior treatment alternatives, including being more effective, safer,
less expensive or marketed and sold more effectively than any products we may develop.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitive
products may make any products we develop obsolete or noncompetitive before we are able to recover the expense of developing and commercializing
our product candidates. Such competitors could also recruit our employees, which could negatively impact our level of expertise and our
ability to execute our business plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our competitors may obtain patent protection, regulatory exclusivities or FDA approval and commercialize products more rapidly
than we do, if we are successful at all, which may impact future approvals or sales of any of our product candidates that receive regulatory
approval. If the FDA approves the commercial sale of PF614 or any other product candidate, we will also be competing with respect to
marketing capabilities and manufacturing efficiency. We expect any such competition among products will be based on product efficacy
and safety, the timing and scope of regulatory approvals, availability of supply, marketing and sales capabilities, product price, reimbursement
coverage by government and private third-party payors, regulatory exclusivities and patent position. Our profitability and financial
position will suffer if our product candidates receive regulatory approval but cannot compete effectively in the marketplace.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mergers
and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller
number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through
collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified
scientific and management personnel and establishing clinical trial sites, as well as in acquiring technologies complementary to, or
necessary for, our programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business could be harmed if we lose the services of our key personnel or if we are unable to hire additional highly qualified employees.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business depends upon our ability to attract and retain highly qualified personnel, including managerial, sales and technical personnel.
We compete for key personnel with other companies, healthcare institutions, academic institutions, government entities and other organizations.
Our ability to maintain and expand our business may be impaired if we are unable to retain our current key personnel or hire or retain
other qualified personnel in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently only have seven full-time employees, one part-time employee and one consultant and we expect to add additional employees. Our
future success also depends on our ability to identify, attract, hire or engage, retain and motivate other well-qualified managerial,
technical, clinical and regulatory personnel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competition
for such individuals, particularly in the United States, is intense, and we may not be able to hire sufficient personnel to support our
efforts. There can be no assurance that such professionals will be available in the market, or that we will be able to retain existing
professionals or to meet or to continue to meet their compensation requirements. Furthermore, our cost base with respect to such compensation,
which may include equity compensation, may increase significantly, which could have a material adverse effect on our financial results,
including the potential for additional dilution to our stockholders. Failure to establish and maintain an effective management team and
work force could adversely affect our ability to operate, grow and manage our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
employees, independent contractors, principal investigators, consultants, commercial collaborators, service providers and other vendors
may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could
have an adverse effect on our results of operations. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to the risk that we and our CROs&#8217; employees and contractors, including principal investigators, consultants, commercial
collaborators, service providers and other vendors may engage in fraudulent or other illegal activity. Misconduct by these parties could
include intentional, reckless and/or negligent conduct or other unauthorized activities that violate the laws and regulations of the
FDA and other similar regulatory bodies, including those laws that require the reporting of true, complete and accurate information to
such regulatory bodies; manufacturing standards; federal and state healthcare fraud and abuse and health regulatory laws and other similar
foreign fraudulent misconduct laws; or laws that require the true, complete and accurate reporting of financial information or data.
Activities subject to these laws also involve the improper use or misrepresentation of information obtained during clinical trials, which
could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter third-party
misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged
risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance
with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting
our rights, those actions could have a significant impact on our business and financial results, including the imposition of significant
civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and
other federal healthcare programs, reputational harm, diminished profits and future earnings, and curtailment of our operations, any
of which could adversely affect our ability to operate our business and our results of operations</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Some
of our programs are partially supported by government grant awards, which may not be available to us in the future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have received funding under grant award programs funded by governmental agencies, such as the NIH and NIDA. To fund a portion of our
future research and development programs, we may apply for additional grant funding from these or similar governmental agencies in the
future. However, funding by these, and other, governmental agencies may be significantly reduced or eliminated in the future for several
reasons. For example, some programs are subject to a yearly appropriations process in Congress. In addition, we may not receive full
funding under current or future grants because of budgeting constraints of the agency administering the program or unsatisfactory progress
on the study being funded. Therefore, we cannot provide any assurance that we will receive any future grant funding from any government
agencies, or, if received, we will receive the full amount of the particular grant award. Any such reductions could delay the development
of our product candidates and the introduction of new products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Dependence on Third-Party Providers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
currently rely on, and expect to rely on in the future, third parties to conduct our clinical trials, and those third parties may not
perform satisfactorily, including failing to meet deadlines for completing such trials, failing to satisfy legal or regulatory requirements
or terminating the relationship.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently rely on, and expect to rely on in the future, third-party CROs to conduct research and development activities and our clinical
trials for our product candidates. Agreements with these CROs might terminate for a variety of reasons, including for their failure to
perform. Entry into alternative arrangements, if necessary, could significantly delay our product development activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
reliance on these CROs for research and development activities and clinical trials will reduce our control over these activities but
will not relieve us of any of our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials
is conducted in accordance with the general investigational plan and protocols in the applicable IND. Moreover, the FDA requires compliance
with standards, commonly referred to as good clinical practices, or GCPs, for conducting, recording and reporting the results of clinical
trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial
participants are protected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
these CROs do not successfully carry out their contractual duties, meet expected deadlines or conduct the clinical trials in accordance
with regulatory requirements or our stated protocols, it could adversely affect the development of our product candidates and it could
result in us not being able to obtain, or being delayed in obtaining, marketing approvals for our product candidates and it could adversely
affect our efforts to successfully commercialize our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
expect to be completely dependent on third parties to manufacture our product candidates, and our commercialization of our product candidates
could be halted, delayed or made less profitable if those third parties fail to maintain a compliance status acceptable to the FDA or
comparable foreign regulatory authorities, fail to provide to us with sufficient quantities of our product candidates or fail to do so
at acceptable quality levels or prices.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently have, nor do we plan to acquire, the capability or infrastructure to manufacture the ingredients in our product candidates
for use in our clinical trials or for commercial product, if any. We have entered into an agreement with Purisys LLC (&#8220;Purisys&#8221;)
for production of PF614 drug substance and a Manufacturing Agreement (the &#8220;Recro Agreement&#8221;) with Recro Gainesville LLC (&#8220;Recro&#8221;)
now known as Societal CDMO, (&#8220;Societal&#8221;) for the production of PF614 capsules and other materials and services with respect
to our clinical studies. In addition, we do not have the capability to encapsulate any of our product candidates as a finished product
for commercial distribution. As a result, we expect to be obligated to rely on contract manufacturers, like Societal, if and when any
of our product candidates are approved for commercialization. In the event that Societal is unable to perform its obligations under the
Recro Agreement, we may be unable to replace the Recro Agreement on terms as favorable to us. We have not entered into an agreement with
any contract manufacturers for commercial supply and may not be able to engage a contract manufacturer for commercial supply of any of
our product candidates on favorable terms to us, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
processes used by our contract manufacturers to manufacture our product candidates must be approved by the FDA or comparable foreign
regulatory authorities and the facilities at which the product candidates are manufactured must maintain a compliance status acceptable
to the FDA and foreign regulatory authorities. FDA and foreign regulatory authorities will conduct inspections after we submit a new
drug application, or NDA, to the FDA or its equivalent to other relevant regulatory authorities. We will not control the manufacturing
process of, and will be completely dependent on, its contract manufacturing partners for compliance with cGMPs for manufacture of both
active drug substances and finished products. These cGMP regulations cover all aspects of the manufacturing, testing, quality control
and record keeping relating to our product candidates. If our contract manufacturers, including Societal, do not successfully manufacture
material that conforms to our specifications and the strict regulatory requirements of the FDA or others, our product candidates may
not be approved. If these facilities do not maintain a compliance status acceptable to the FDA, Drug Enforcement Agency, or DEA, or comparable
regulatory authorities, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop,
obtain regulatory approval for or market our product candidates, if approved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
contract manufacturers, including Purisys and Societal, will be subject to ongoing periodic unannounced inspections by the FDA, DEA and
corresponding state and foreign agencies for compliance with cGMPs, security, recordkeeping and similar regulatory requirements. Although
we will not have control over our contract manufacturers&#8217; compliance with these regulations and standards, we are nonetheless responsible
for assuring such compliance. Failure by any of our contract manufacturers to comply with applicable regulations could result in sanctions
being imposed on us, including fines, injunctions, civil penalties, failure to grant approval to market any of our product candidates,
delays, suspensions or withdrawals of approvals, operating restrictions and criminal prosecutions, any of which could significantly and
adversely affect our business and results of operations. Failure by our contract manufacturers to comply with or maintain any of these
standards could adversely affect our ability to develop, obtain regulatory approval for or market any of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If,
for any reason, these third parties, including Societal, are unable or unwilling to perform, we may not be able to terminate our agreements
with them, and we may not be able to locate alternative manufacturers or formulators or enter into favorable agreements with them and
we cannot be certain that any such third parties will have the manufacturing capacity to meet future requirements. If these manufacturers
or any alternate manufacturer of finished drug product experiences any significant difficulties in its respective manufacturing processes
for our ingredients or finished products or should cease doing business with us, we could experience significant interruptions in the
supply of any of our product candidates or may not be able to create a supply of our product candidates at all. Our inability to coordinate
the efforts of our third-party manufacturing partners, or the lack of capacity available at our third-party manufacturing partners, could
impair our ability to supply any of our product candidates at required levels. Because of the significant regulatory requirements that
we would need to satisfy in order to qualify a new bulk or finished product manufacturer, if we face these or other difficulties with
our current manufacturing partners, we could experience significant interruptions in the supply of any of our product candidates if we
decide to transfer the manufacture of any of our product candidates to one or more alternative manufacturers in an effort to deal with
the difficulties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
manufacturing problem or the loss of a contract manufacturer, including Societal, could be disruptive to our operations and delay development
of our investigational products. Additionally, we rely on third parties to supply the raw materials needed to manufacture our potential
products. Any reliance on suppliers may involve several risks, including a potential inability to obtain critical materials and reduced
control over production costs, delivery schedules, reliability and quality. Any unanticipated disruption to a future contract manufacturer
caused by problems at suppliers could delay shipment of any of our investigational products and, if approved, product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot guarantee that our future manufacturing and supply partners will be able to reduce the costs of commercial scale manufacturing
of any of our product candidates over time. If the commercial-scale manufacturing costs of any of our product candidates are higher than
expected, these costs may significantly impact our operating results. In order to reduce costs, we may need to develop and implement
process improvements. However, in order to do so, we will need, from time to time, to notify or make submissions with regulatory authorities,
and the improvements may be subject to approval by such regulatory authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot be sure that we will receive these necessary approvals or that these approvals will be granted in a timely fashion. We also cannot
guarantee that we will be able to enhance and optimize output in our commercial manufacturing process. If we cannot enhance and optimize
output, we may not be able to reduce our costs over time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Factors
that may inhibit our efforts to commercialize our product candidates on our own include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    inability to recruit and retain effective sales and marketing personnel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inability of sales personnel to obtain access to or persuade physicians to prescribe any future products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies
    with more extensive product lines; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen
    costs and expenses associated with creating an independent sales and marketing organization.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to our existing and future product candidates, we may choose to collaborate with third parties that have direct sales forces
and established distribution systems to serve as an alternative to our own sales force and distribution systems. Our future product revenue
may be lower than if we directly marketed or sold our product candidates, if approved. In addition, any revenue we receive will depend
in whole or in part upon the efforts of these third parties, which may not be successful and are generally not within our control. If
we are not successful in commercializing any approved products, our future product revenue will suffer, and we may incur significant
additional losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will
not be successful in commercializing our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Product Development, Regulatory Approval, Manufacturing and Commercialization</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming and inherently unpredictable,
and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not permitted to commercialize, market, promote or sell any product candidate in the United States without obtaining regulatory approval
from the FDA. Foreign regulatory authorities, such as the EMA, impose similar requirements. The time required to obtain approval by the
FDA and comparable foreign authorities is inherently unpredictable, but typically takes many years following the commencement of clinical
trials and depends upon numerous factors, including substantial discretion of the regulatory authorities. In addition, approval policies,
regulations, or the type and amount of clinical data necessary to gain approval may change during a product candidate&#8217;s clinical
development and may vary among jurisdictions. To date, we have not submitted an NDA to the FDA or similar drug approval submissions to
comparable foreign regulatory authorities for our most advanced product candidate, PF614, or any other product candidate. We must complete
additional preclinical studies and clinical trials to demonstrate the safety and efficacy of our product candidates in humans before
we will be able to obtain these approvals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
testing is expensive, difficult to design and implement, can take many years to complete and is inherently uncertain as to outcome. We
cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. The clinical development
of our initial and potential additional product candidates is susceptible to the risk of failure inherent at any stage of development,
including failure to demonstrate efficacy in a clinical trial or across a broad population of patients, the occurrence of adverse events
that are severe or medically or commercially unacceptable, failure to comply with protocols or applicable regulatory requirements, and
determination by the FDA or any comparable foreign regulatory authority that a product candidate may not continue development or is not
approvable. It is possible that even if any of our product candidates has a beneficial effect, that effect will not be detected during
clinical evaluation because of one or more of a variety of factors, including the size, duration, design, measurements, conduct or analysis
of our clinical trials. Conversely, because of the same factors, our clinical trials may indicate an apparent positive effect of such
product candidate that is greater than the actual positive effect, if any. Similarly, in our clinical trials, we may fail to detect toxicity
of, or intolerability caused by, such product candidate, or mistakenly believe that our product candidates are toxic or not well tolerated
when that is not in fact the case. Serious adverse events, or SAEs, or other adverse effects, as well as tolerability issues, could hinder
or prevent market acceptance of the product candidate at issue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current and future product candidates could fail to receive regulatory approval for many reasons, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable foreign regulatory authorities may disagree as to the design or implementation of our clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate
    is safe and effective for our proposed indication;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory
    authorities for approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from clinical trials or preclinical
    studies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA to the FDA
    or other submission or to obtain regulatory approval in the United States, the European Union or elsewhere;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable foreign regulatory authorities may find deficiencies with the manufacturing processes of third-party manufacturers
    with which we contract for clinical and commercial supplies; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering
    our clinical data insufficient for approval.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
lengthy approval process as well as the unpredictability of clinical trial results may result in us failing to obtain regulatory approval
to market any product candidate we develop, which would substantially harm our business, results of operations and prospects. The FDA
and other comparable foreign authorities have substantial discretion in the approval process and determining when or whether regulatory
approval will be granted for any product candidate that we develop. Even if we believe the data collected from future clinical trials
of our product candidates are promising, such data may not be sufficient to support approval by the FDA or any other regulatory authority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited
indications than we request, may not approve the price we intend to charge for our products, may grant approval contingent on the performance
of costly post-marketing clinical trials, or may approve a product candidate with labeling that does not include the claims necessary
or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the
commercial prospects for our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may recommend scheduling with respect to any of our current or future product candidates. In such event, prior to a product launch,
the DEA will need to determine the controlled substance schedule of the product, considering the recommendation of the FDA. The timing
of the scheduling process is uncertain and may delay our ability to market any product candidate that we successfully developed and approved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 43; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
our clinical trials fail to replicate positive results from earlier preclinical studies or clinical trials conducted by us or third parties,
we may be unable to successfully develop, obtain regulatory approval for, or commercialize our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
results observed from preclinical studies or early-stage clinical trials of our product candidates may not necessarily be predictive
of the results of later-stage clinical trials that we conduct. Similarly, positive results from such preclinical studies or early-stage
clinical trials may not be replicated in our subsequent preclinical studies or clinical trials. For example, preclinical studies showed
that PF614 does not readily convert into oxycodone in the blood stream following direct injection, and the Phase 1 trial we have conducted
with TAAP prodrug PF614 (&#8220;<i>prodrug</i>&#8221;: a medication or compound that, after administration, is metabolized, i.e., converted
within the body into a pharmacologically active drug), demonstrated that, after oral administration, the corresponding opioid was measured
in the subjects&#8217; blood. Furthermore, our product candidates may not be able to demonstrate similar activity or adverse event profiles
as other product candidates that we believe may have similar profiles.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
can be no assurance that any of our clinical trials will ultimately be successful or support further clinical development of any of our
product candidates. There is a high failure rate for drugs proceeding through clinical trials. Many companies in the pharmaceutical and
biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in early-stage
development, and we cannot be certain that we will not face similar setbacks. These setbacks have been caused by, among other things,
preclinical findings made while clinical trials were underway or safety or efficacy observations made in preclinical studies and clinical
trials, including previously unreported adverse events.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
preclinical and clinical data are often susceptible to varying interpretations and analyses and many companies that believed their product
candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain FDA, EMA or comparable foreign
regulatory authority approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
FDA, EMA or comparable foreign regulatory authorities may disagree with our regulatory plan for our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hold INDs for PF614 and nafamostat and completed a Phase 1 trial for each product candidate. We have completed multiple human abuse potential
and efficacy studies for PF614. We have applied for and received fast track designation for PF614. However, fast track designation does
not guarantee a faster development or regulatory review or approval process and does not assure FDA approval. We have received feedback
from the FDA on requirements to achieve abuse deterrent labeling claims for PF614. We have also received an IND for PF614-MPAR and have
completed an initial Phase 1 study. We have been granted Breakthrough Therapy designation by the FDA for PF614-MPAR. For all INDs that
we hold we have received feedback on required pre-clinical, manufacturing and clinical studies that will be required for an NDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
clinical trial results may not support approval of our product candidates. The general approach for FDA approval of a new drug is dispositive
data from two or more well-controlled Phase 3 clinical trials of the product candidate in the relevant patient population. Phase 3 clinical
trials typically involve a large number of patients, have significant costs, and take years to complete. In addition, there is no assurance
that the endpoints and trial designs that we intend to use for our planned clinical trials, including those that we have developed based
on feedback from regulatory agencies or those that have been used for the approval of similar drugs, will be acceptable for future approvals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Interim
topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become
available and are subject to audit and verification procedures that could result in material changes in the final data.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may publish interim topline or preliminary data from our clinical trials. Interim data from clinical trials that we
may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues
and more patient data become available. Preliminary or topline data also remain subject to audit and verification procedures that may
result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary
data should be viewed with caution until the final data is available. Adverse differences between preliminary or interim data and final
data could significantly harm our reputation and business prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 44; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and
uncertain and may prevent us from obtaining approvals for the commercialization of our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
product candidate we develop and the activities associated with such development and commercialization, including our design, testing,
manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, and distribution, are subject
to comprehensive regulation by the FDA and other regulatory authorities in the United States and by comparable authorities in other countries.
Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate in a given jurisdiction.
We have not received approval to market any product candidates from regulatory authorities in any jurisdiction and it is possible that
none of the product candidates we are developing or may seek to develop in the future will ever obtain regulatory approval. Ensysce has
no experience in submitting and supporting the applications necessary to gain marketing approvals and we expect to rely on third-party
CROs or regulatory consultants to assist us in this process. Securing regulatory approval requires the submission of extensive preclinical
and clinical data and supporting information to the various regulatory authorities for each therapeutic indication to establish the product
candidate&#8217;s safety and efficacy. Securing regulatory approval also requires the submission of information about the product manufacturing
process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Any product candidates we develop may not
be effective, may be only moderately effective, or may prove to have undesirable or unintended side effects, toxicities or other characteristics
that may preclude us from obtaining marketing approval or prevent or limit commercial use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process of obtaining marketing approvals, both in the United States and abroad, is expensive, may take many years if additional clinical
trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type,
complexity, and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes
in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may
cause delays in the approval or rejection of an application. The FDA and comparable authorities in other countries have substantial discretion
in the approval process and may refuse to accept any application or may decide that our data is insufficient for approval and requires
additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical
testing could delay, limit, or prevent marketing approval of a product candidate. Any marketing approval that we may ultimately obtain
could be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable. For
example, during the product approval process, the FDA will determine whether a REMS plan is necessary to assure the safe use of the product.
All opioid analgesic products currently on the market in the United States are subject to a REMS. A REMS may be required to include various
elements, such as a medication guide or patient package insert, a communication plan to educate health care providers of the risks, limitations
on who may prescribe or dispense the drug or other measures that the FDA deems necessary to assure the safe use of the drug. In addition,
the REMS plan must include a timetable to assess the strategy at eighteen months, three years and seven years after approval. We may
be required to develop a REMS for the product, or participate in a REMS with other manufacturers, or to develop a similar strategy as
required by a regulatory authority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if approved, our contract manufacturers will need to obtain quota from DEA to manufacture sufficient quantities and maintain inventories
of product to be commercially distributed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we experience delays in obtaining manufacturing approval or if we fail to obtain manufacturing approval of any product candidates we
may develop, the commercial prospects for those product candidates may be harmed, and our ability to generate revenues will be materially
impaired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 45; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may incur unexpected costs or experience delays in completing, or ultimately be unable to complete, the preclinical and clinical studies
necessary for development and commercialization of our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
obtain the requisite regulatory approvals to commercialize any of our product candidates, we must demonstrate through extensive preclinical
studies and clinical trials that our product candidates are safe and effective in humans. We may experience delays in completing our
clinical trials or preclinical studies and initiating or completing additional clinical trials or preclinical studies, including as a
result of regulators not allowing or delay in allowing clinical trials to proceed under an IND, or not approving or delaying approval
for any clinical trial grant or similar approval that we need to initiate a clinical trial. We may also experience numerous unforeseen
events during our clinical trials that could delay or prevent our ability to receive marketing approval or commercialize the product
candidates we develop, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulators,
    or institutional review boards, or IRBs, or other reviewing bodies may not authorize us or our investigators to commence a clinical
    trial, or to conduct or continue a clinical trial at a prospective or specific trial site;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may not reach agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to
    extensive negotiation and may vary significantly among different CROs and trial sites;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may experience challenges or delays in recruiting principal investigators or study sites to lead our clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of subjects or patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment
    in these clinical trials may be insufficient or slower than we anticipate, and the number of clinical trials being conducted at any
    given time may be high and result in fewer available patients for any given clinical trial, or patients may drop out of these clinical
    trials at a higher rate than we anticipate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    third-party contractors, including those manufacturing our product candidates or conducting clinical trials on our behalf, may fail
    to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may have to amend clinical trial protocols submitted to regulatory authorities or conduct additional studies to reflect changes in
    regulatory requirements or guidance, which we may be required to resubmit to an IRB and regulatory authorities for re-examination;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulators
    or other reviewing bodies may find deficiencies with or subsequently find fault with the manufacturing processes or facilities of
    third-party manufacturers with which we enter into agreement for clinical and commercial supplies, or the supply or quality of any
    product candidate or other materials necessary to conduct clinical trials of our product candidates may be insufficient, inadequate
    or not available at an acceptable cost, or we may experience interruptions in supply; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential for approval policies or regulations of the FDA or the applicable foreign regulatory agencies to significantly change in
    a manner rendering our clinical data insufficient for approval.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulators
or IRBs of the institutions in which clinical trials are being conducted may suspend, limit or terminate a clinical trial, or data monitoring
committees may recommend that we suspend or terminate a clinical trial, due to a number of factors, including failure to conduct the
clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial
site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold (such as the clinical hold placed on PF614-MPAR
in January 2021), safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental
regulations or administrative actions, or lack of adequate funding to continue the clinical trial. Negative or inconclusive results from
our clinical trials or preclinical studies could mandate repeated or additional clinical trials and, to the extent we choose to conduct
clinical trials in other indications, could result in changes to or delays in clinical trials of our product candidates in such other
indications. We do not know whether any clinical trials that we conduct will demonstrate adequate efficacy and safety to result in regulatory
approval to market our product candidates for the indications that we are pursuing. If later-stage clinical trials do not produce favorable
results, our ability to obtain regulatory approval for our product candidates will be adversely impacted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 46; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
failure to successfully initiate and complete clinical trials and to demonstrate the efficacy and safety necessary to obtain regulatory
approval to market our product candidates would significantly harm its business. The development costs of our product candidates will
also increase if we experience delays in testing or regulatory approvals and we may be required to obtain additional funds to complete
clinical trials. We cannot assure stockholders that our clinical trials will begin as planned or be completed on schedule, if at all,
or that we will not need to restructure or otherwise modify our trials after they have begun. Significant clinical trial delays could
also shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors
to bring products to market before we do and impair our ability to successfully commercialize our product candidates, which may harm
our business and results of operations. In addition, many of the factors that cause, or lead to, delays of clinical trials may ultimately
lead to the denial of regulatory approval of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise
adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
timely completion of clinical trials in accordance with our protocols depends on, among other things, our ability to enroll a sufficient
number of patients who remain in the study until its conclusion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may experience difficulties in patient enrollment in our clinical trials for a variety of factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    patient eligibility criteria defined in the protocol;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    size of the patient population required for analysis of the trial&#8217;s primary endpoints;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    proximity of patients to study sites;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    design of the trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competing
    clinical trials and clinicians&#8217; and patients&#8217; perceptions as to the potential advantages and risks of the product candidate
    being studied in relation to other available therapies, including any new drugs that may be approved for the indications that we
    are investigating;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain and maintain patient consents; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    risk that patients enrolled in clinical trials will drop out of the trials before completion.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our clinical trials may compete with other clinical trials for product candidates that are in the same therapeutic areas as
our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who
might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number
of qualified clinical investigators is limited, we may conduct some of our clinical trials at the same clinical trial sites that some
of our competitors use, which will reduce the number of patients who are available for our clinical trials in such clinical trial site.
Furthermore, if significant adverse events or other side effects are observed in any of our clinical trials, we may have difficulty recruiting
patients to our trials and patients may drop out of our trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
inability to enroll enough patients for our clinical trials would result in significant delays or might require us to abandon one or
more clinical trials or our development efforts altogether. Delays in patient enrollment may result in increased costs, negatively affect
the timing or outcome of the planned clinical trials, delay the product candidate development and approval process and jeopardize our
ability to seek and obtain the regulatory approval required to commence product sales and generate revenue, which could cause our value
to decline and limit our ability to obtain additional financing if needed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 47; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fast
Track designation by the FDA for PF614 for chronic pain may not lead to a faster development or regulatory review or approval process
and does not assure FDA approval.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have obtained Fast Track designation for PF614 for management of moderate to severe chronic pain when a continuous, around-the-clock
analgesic is needed for an extended period. We believe that Fast Track designation will enable us to facilitate the development and expedite
the review of PF614. Fast Track designation does not ensure that PF614 will receive marketing approval or that approval will be granted
within any timeframe. As a result, we may not experience a faster development process, review or approval compared to conventional FDA
procedures. In addition, the FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data
from our clinical development program. Fast Track designation does not guarantee that an NDA will obtain priority review designation.
If any of these events occur, it could require us to conduct more extensive clinical trials and go through more extensive FDA reviews,
which could substantially increase expenses and delay the time for commercializing our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
the FDA does not conclude that certain of our product candidates satisfy the requirements for the Section 505(b)(2) regulatory approval
pathway, or if the requirements for such product candidates under Section 505(b)(2) are not as we expect, the approval pathway for those
product candidates will likely take significantly longer, cost significantly more and entail significantly greater complications and
risks than anticipated, and in either case may not be successful.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may seek FDA approval through the Section 505(b)(2) regulatory pathway for our product candidate PF614. Section 505(b)(2) of the Federal
Food, Drug and Cosmetic Act, or FDC Act, permits the submission of an NDA where at least some of the information required for approval
comes from studies that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference.
Section 505(b)(2), if applicable to us under the FDC Act, would allow an NDA we submit to FDA to rely in part on data in the public domain
or on the FDA&#8217;s prior conclusions regarding the safety and effectiveness of an approved product, or listed drug, which could expedite
the development program for our product candidates by potentially decreasing the amount of data that we would need to generate in order
to obtain FDA approval. If the FDA does not agree that the 505(b)(2) regulatory pathway is appropriate or scientifically justified for
PF614, we may need to conduct additional preclinical and clinical trials, provide additional data and information, and meet additional
standards for regulatory approval. For example, the FDA may not agree that we have provided a scientific bridge, through comparative
bioavailability data, to demonstrate that reliance on the prior findings of safety or efficacy for a listed drug is justified. If this
were to occur, the time and financial resources required to obtain FDA approval for this product candidate, and complications and risks
associated with this product candidate, would likely substantially increase. We could need to obtain additional funding, which could
result in significant dilution to the ownership interests of our then existing stockholders to the extent we issue equity securities
or convertible debt. We cannot assure you that we would be able to obtain such additional financing on terms acceptable to us, if at
all. Moreover, the inability to pursue the Section 505(b)(2) regulatory pathway may result in new competitive products reaching the market
more quickly than our product candidates, which would likely materially adversely impact of our competitive position and prospects. Even
if we are allowed to pursue the Section 505(b)(2) regulatory pathway, we cannot assure our stockholders that our product candidates will
receive the requisite approvals for commercialization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, notwithstanding the approval of a number of products by the FDA under Section 505(b)(2) over the last few years, certain brand-name
pharmaceutical companies and others have objected to the FDA&#8217;s interpretation of Section 505(b)(2). If the FDA&#8217;s interpretation
of Section 505(b)(2) is successfully challenged, the FDA may change its 505(b)(2) policies and practices, which could delay or even prevent
the FDA from approving any NDA that we submit under Section 505(b)(2). The pharmaceutical industry is highly competitive, and Section
505(b)(2) NDAs are subject to special requirements designed to protect the patent rights of sponsors of previously approved drugs that
are referenced in a Section 505(b)(2) NDA. These requirements may give rise to patent litigation and mandatory delays in approval of
our NDAs for up to 30 months or longer depending on the outcome of any litigation. It is not uncommon for a manufacturer of an approved
product to file a citizen petition with the FDA seeking to delay approval of, or impose additional approval requirements for, pending
competing products. If successful, such petitions can significantly delay, or even prevent, the approval of the new product. Even if
the FDA ultimately denies such a petition, the FDA may substantially delay approval while it considers and responds to the petition.
In addition, even if we are able to utilize the Section 505(b)(2) regulatory pathway, there is no guarantee this would ultimately lead
to accelerated product development or earlier approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 48; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
even if our product candidates are approved under Section 505(b)(2), the approval may be subject to limitations on the indicated uses
for which the products may be marketed or to other conditions of approval, or may contain requirements for costly post-marketing testing
and surveillance to monitor the safety or efficacy of the products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we submit a 505(b)(2) application that references a third-party product, we may be subject to a patent infringement suit and the approval
of our product may be delayed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we submit a 505(b)(2) application that relies in whole or in FDA&#8217;s findings for a listed drug, we will be required to certify to
the FDA that either: (1) there is no patent information listed in the FDA&#8217;s publication Approved Drug Products with Therapeutic
Equivalence Evaluations, which we refer to as the Orange Book, with respect to the listed drug; (2) the patents listed in the Orange
Book have expired; (3) the listed patents have not expired, but will expire on a particular date and approval is sought after patent
expiration; or (4) the listed patents are invalid or will not be infringed by the manufacture, use or sale of our product. A certification
that our new drug will not infringe the Orange Book-listed patents for the applicable listed drug, or that such patents are invalid,
is called a paragraph IV certification. If we submit a paragraph IV certification to the FDA, a notice of the paragraph IV certification
must also be sent to the NDA holder once our 505(b)(2) application is filed by the FDA. The third party may then initiate a lawsuit to
defend the patents identified in the notice. The filing of a patent infringement lawsuit within 45 days of receipt of the notice automatically
prevents the FDA from approving our 505(b)(2) application until the earliest of 30 months or the date on which the patent expires, the
lawsuit is settled, or the court reaches a decision in the infringement lawsuit in our favor. If the third party does not file a patent
infringement lawsuit within the required 45-day period, our 505(b)(2) application will not be subject to the 30-month stay of FDA approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in methods of product candidate manufacturing or formulation may result in additional costs or delay.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
product candidates proceed through preclinical studies to late-stage clinical trials towards potential approval and commercialization,
it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way
in an effort to optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives. Any
of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other
future clinical trials conducted with the materials manufactured using altered processes. Such changes may also require additional testing,
FDA notification or FDA approval. This could delay or prevent completion of clinical trials, require conducting bridging clinical trials
or repeating one or more clinical trials, increase clinical trial costs, delay or prevent approval of our product candidates and jeopardize
our ability to commence sales and generate revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval,
limit the commercial profile of an approved label, or result in significant negative consequences following regulatory approval, if obtained.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Undesirable
side effects caused by any of our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials
and could result in restrictive warnings or contraindication or the delay or denial of regulatory approval by the FDA or comparable foreign
regulatory authorities. In our planned and future clinical trials of our product candidates, we may observe a less favorable safety and
tolerability profile than was observed in earlier-stage testing of these candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Undesirable
side effects have been observed in our product candidates to date. For example, in clinical trials of PF614, opioid side effects were
observed. Many compounds that initially showed promise in clinical or earlier-stage testing are later found to cause undesirable or unexpected
side effects that prevented further development of the compound. Results of future clinical trials of our product candidates could reveal
a high and unacceptable severity and prevalence of side effects or unexpected characteristics, despite a favorable tolerability profile
observed in earlier-stage testing. If unacceptable side effects arise in the development of our product candidates, we, the FDA or comparable
foreign regulatory authorities, the IRBs, or independent ethics committees at the institutions in which its trials are conducted, could
suspend, limit or terminate our clinical trials, or the independent safety monitoring committee could recommend that we suspend, limit
or terminate our trials, or the FDA or comparable foreign regulatory authorities could order us to cease clinical trials or deny approval
of our product candidates for any or all targeted indications. Treatment-emergent side effects that are deemed to be drug-related could
delay recruitment of clinical trial subjects or may cause subjects that enroll in our clinical trials to discontinue participation in
our clinical trials. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We
may need to train medical personnel using our product candidates to understand the side effect profiles for our clinical trials and upon
any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of
our product candidates could result in harm to patients that are administered our product candidates. Any of these occurrences may adversely
affect our business, financial condition and prospects significantly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 49; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
clinical trials of our product candidates are conducted in carefully defined sets of patients who have agreed to enter into clinical
trials. Consequently, it is possible that our clinical trials may indicate an apparent positive effect of a product candidate that is
greater than the actual positive effect, if any, or alternatively fail to identify undesirable side effects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>FDA&#8217;s
evolving standards for the approval of opioid products may delay or prevent approval of our product candidates. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
has identified addressing misuse and abuse of opioid drugs as one of its highest priorities. As part of its plan, the agency has established
new standards for the development of prescription opioids with abuse-deterrent formulations and has published two sets of guidance. Since
the publication of the second guidance in November 2017, FDA has not approved any new abuse&#8211;deterrent opioid drugs. If we are unable
to meet FDA&#8217;s new and evolving standards for approving opioid products, we will not be able to market our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Product
liability lawsuits against us or any of our future collaborators could divert our resources and attention, cause us to incur substantial
liabilities and limit commercialization of our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing,
marketing and use of pharmaceutical products. Currently, we have no products that have been approved for commercial sale; however, the
use of our product candidates by us and any collaborators in clinical trials, and the sale of these product candidates, if approved,
in the future, may expose us to liability claims. We face an inherent risk of product liability lawsuits related to the use of our product
candidates in patients and will face an even greater risk if product candidates are approved by regulatory authorities and introduced
commercially. Product liability claims may be brought against us by participants enrolled in our clinical trials, patients, health care
providers, pharmaceutical companies, our collaborators or others using, administering or selling any of our future approved products.
If we cannot successfully defend ourselves against any such claims, we may incur substantial liabilities or be required to limit commercialization
of our product candidates. Regardless of the merits or eventual outcome, liability claims may result in:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">decreased
    demand for any of our future approved products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injury
    to our reputation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal
    of clinical trial participants;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">termination
    of clinical trial sites or entire trial programs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    litigation costs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial
    monetary awards to, or costly settlements with, patients or other claimants;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    recalls or a change in the indications for which they may be used;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss
    of revenue;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">diversion
    of management and scientific resources from our business operations; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inability to commercialize our product candidates.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
the clinical trial process is designed to identify and assess potential side effects, clinical development does not always fully characterize
the safety and efficacy profile of a new medicine, and it is always possible that a drug, even after regulatory approval, may exhibit
unforeseen side effects. If our product candidates were to cause adverse side effects during clinical trials or after approval, we may
be exposed to substantial liabilities. Physicians and patients may not comply with any warnings that identify known potential adverse
effects and patients who should not use our product candidates. If any of our product candidates are approved for commercial sale, we
will be highly dependent upon consumer perceptions of us and the safety and quality of our products. We could be adversely affected if
we are subject to negative publicity associated with illness or other adverse effects resulting from patients&#8217; use or misuse of
our products or any similar products distributed by other companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 50; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we maintain product liability insurance coverage consistent with industry norms, including clinical trial liability, this insurance may
not fully cover potential liabilities that we may incur. The cost of any product liability litigation or other proceeding, even if resolved
in our favor, could be substantial. We will need to increase our insurance coverage if we commercialize any product that receives regulatory
approval. In addition, insurance coverage is becoming increasingly expensive. If we are unable to maintain sufficient insurance coverage
at an acceptable cost or to otherwise protect against potential product liability claims, it could prevent or inhibit the development
and commercial production and sale of our product candidates, which could harm our business, financial condition, results of operations
and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Oxycodone
is a Schedule II controlled substance under the federal CSA, and any failure to comply with the CSA or its state equivalents would have
a negative impact on our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oxycodone,
the ingredient in PF614, is classified as a Schedule II controlled substance under the Controlled Substances Act, or CSA and regulations
promulgated by the DEA. The law and regulations classify substances as Schedule I, II, III, IV or V controlled substances, with Schedule
I controlled substances considered to present the highest risk of substance abuse and Schedule V controlled substances the lowest risk.
Scheduled controlled substances are subject to DEA regulations relating to supply, procurement, manufacturing, storage, shipment, sale,
use, distribution and physician prescription procedures. For example, Schedule II controlled substances are subject to various restrictions,
including, but not limited to, mandatory written prescriptions and the prohibition of refills. In addition to federal scheduling, oxycodone
is subject to state-controlled substance laws and regulations, and in some cases, with additional requirements than those imposed by
federal law and regulations. Though state controlled substances laws often mirror federal law, because the states are separate jurisdictions,
they may schedule products separately.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entities
must register annually with the DEA to manufacture, distribute, dispense, import, export and conduct research using controlled substances.
In addition, the DEA requires entities handling controlled substances to maintain complete and accurate records and file reports, including
reports related to thefts or losses of any controlled substances, and to obtain authorization to destroy any controlled substances. Registered
entities also must follow specific labeling and packaging requirements. Facilities must maintain appropriate security measures to control
against diversion of controlled substances. Security requirements vary by controlled substance schedule with the most stringent requirements
applying to Schedule I and Schedule II controlled substances. Required security measures include background checks on employees and physical
control of inventory through measures such as vaults and inventory reconciliations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
CMOs, who manufacture and distribute PF614 are required to be registered with DEA and relevant state authorities and comply with all
security, recordkeeping and reporting requirements. Manufacturers and distributors are subject to routine inspections and audits by the
DEA related to compliance with security, recordkeeping and reporting requirements. Failure to maintain the required registrations or
to comply and follow these requirements can lead to significant civil and/or criminal penalties and possibly even lead to a revocation
of a DEA registration to manufacture or distribute such products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Manufacturing
of oxycodone is subject to annual quotas that limit the amount of API and dosage forms that can be produced in any given year; the failure
of our CMOs to obtain the necessary manufacturing and/or procurement quota would have a negative impact on our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
CSA and DEA regulations establish an annual aggregate production quota for Schedule I and II controlled substances, including oxycodone
and other narcotic drugs. In addition, each manufacturer of active pharmaceutical ingredient, or API or dosage forms must obtain an individual
manufacturing or production quota that limits the amount of product that a company can produce and/or distribute each year. The DEA allocates
manufacturing quota issued to companies so as to not exceed the aggregate quota established for a given year. Moreover, companies must
demonstrate the need for procurement quota based on expected demand and sales of the controlled substance the DEA requires the submission
of substantial evidence of expected legitimate medical and scientific need for the drug product before assigning its aggregate production
quotas, or manufacturing and procurement quotas to manufacturers. The DEA has decreased the aggregate quota for certain narcotic drugs,
including oxycodone from 2015 to 2024. Also, in October 2018, Congress passed the SUPPORT Act, updated in 2019, which requires the DEA
to consider potential diversion in establishing quotas for narcotic drugs which could lead to continued decreases in quota available
to API manufacturers and dosage form manufacturers of these substances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 51; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
future years, we may need greater amounts of controlled substances that are subject to the DEA&#8217;s quota system to sustain our development
program. We may also need significantly greater amounts to implement our commercialization plans if the FDA approves our proposed formulations.
If any of our manufacturers of API or dosage forms are unable to obtain the necessary annual quota to meet the research and development
or commercial demand for PF614, our business would be negatively impacted. Any delay or refusal by the DEA in establishing a quota, a
reduction in quota, or a failure to increase quota over time could delay or stop the clinical development or commercial sale of some
of our products or product candidates. This could have a material adverse effect on our business, results of operations, financial condition
and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to our Intellectual Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to obtain and maintain patent protection for our products candidates, or if the scope of the patent protection obtained
is not sufficiently broad, our competitors could develop and commercialize product candidates that are similar or identical to our product
candidates, and our ability to successfully commercialize our product candidates may be adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success will depend, in part, on our ability to obtain and maintain patent protection in the United States and other countries
with significant commercial markets with respect to our product candidates. We seek to protect our proprietary position by filing patent
applications in the United States and abroad related to our product candidates that are important to our business, as appropriate. We
cannot be certain that patents will be issued or granted with respect to applications that are currently pending or that we may apply
for in the future with respect to one or more of our product candidates, or that issued or granted patents will not later be found to
be invalid and/or unenforceable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent
applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our
research and development output before it is too late to obtain patent protection. Although we may enter into non-disclosure and confidentiality
agreements with parties who have access to patentable aspects of our research and development output, such as our employees, distribution
partners, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before
a patent application is filed, thereby jeopardizing our ability to seek patent protection.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent position of pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent
years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent
rights are highly uncertain. Our pending and future patent applications may not result in patents being issued, and even if issued, the
patents may not meaningfully protect our product candidates, effectively prevent competitors and third parties from commercializing competitive
products or otherwise provide us with any competitive advantage. Even if the patent applications that we own or licenses issue as patents,
they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise
provide us with any competitive advantage. For product candidates for which we do not hold or do not obtain composition of matter patents,
competitors who obtain the requisite regulatory approval can offer products with the same composition as our product candidate so long
as the competitors do not infringe any method patents that we may hold. Method patents protect the product when used or sold for the
specified method. However, this type of patent protection can be more difficult to enforce and does not limit a competitor from making
and marketing a product that is identical to our product candidate that is either labeled or marketed for an indication that is outside
of the patented method, or for which there is a substantial use in commerce outside the patented method. Our competitors or other third
parties may be able to circumvent our patents by developing similar or alternative products in a non-infringing manner.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
in either the patent laws, implementing regulations or interpretation of the patent laws in the United States and other countries may
also diminish the value of our patents or narrow the scope of our patent protection. The laws of foreign countries may not protect our
rights to the same extent as the laws of the United States, and many companies have encountered significant difficulties in protecting
and defending such rights in foreign jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 52; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot be certain that our patents and patent rights will be effective in protecting our product candidates and technologies. Failure
to protect such assets may have a material adverse effect on our business, operations, financial condition and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may face litigation from third parties claiming that our products or business infringe, misappropriate, or otherwise violate their intellectual
property rights, or seeking to challenge the validity of our patents.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future success is also dependent in part on the strength of our intellectual property, trade secrets and know-how, which have been developed
from years of research and development, and on our ability, and the ability of our future collaborators, to develop, manufacture, market
and sell our product candidates, if approved, and use our proprietary technologies without alleged or actual infringement, misappropriation
or other violation of the patents and other intellectual property rights of third parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be exposed to, or be threatened with, adversarial proceedings or additional future litigation by third parties regarding intellectual
property rights with respect to our current and any future product candidates and technology, including interference or derivation proceedings,
post grant review and <i>inter partes</i> review before the United States Patent and Trademark Office, or USPTO, or similar adversarial
proceedings or litigation in other jurisdictions seeking to challenge the validity of our intellectual property rights, claiming that
we have misappropriated the trade secrets of others, or claiming that our technologies, products or activities infringe the intellectual
property rights of others.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been many lawsuits and other proceedings involving patent and other intellectual property rights in the biotechnology and pharmaceutical
industries, including patent infringement lawsuits, interferences, oppositions, post grant review, <i>inter partes</i> review and reexamination
proceedings before the USPTO, and corresponding foreign patent offices. Numerous United States and foreign issued patents and pending
patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. As the biotechnology
and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims
of infringement of the intellectual property rights of third parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are aware of patents owned by third parties, including potential competitors, that are directed to compositions comprising a chemically
modified opioid, such as oxycodone, which decreases the potential of the opioid to be abused or cause overdose and related methods of
use. Third parties, including potential competitors, may assert infringement claims against us based on existing patents or patents that
may be granted in the future including, perhaps, the aforementioned patents, regardless of their merit. There is a risk that third parties
may choose to engage in litigation with us to enforce or to otherwise assert their patent rights against us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we believe such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable
and infringed, and the holders of any such patents may be able to block our ability to commercialize such product candidate unless we
obtain a license under the applicable patents, or until such patents expire or are finally determined to be invalid or unenforceable.
Similarly, if any third-party patents were held by a court of competent jurisdiction to cover aspects of our compositions, formulations,
or methods of treatment, prevention or use, the holders of any such patents may be able to block our ability to develop and commercialize
the applicable product candidate unless we obtain a license or until such patent expires or is finally determined to be invalid or unenforceable.
In either case, such a license may not be available on commercially reasonable terms, or at all. Even if we were able to obtain a license,
it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. Some claimants may have substantially
greater resources than we do and may be able to sustain the costs of complex intellectual property litigation to a greater degree and
for longer periods of time than we could. In addition, patent holding companies that focus solely on extracting royalties and settlements
by enforcing patent rights may target us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or to enable the commercialization
of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In such
an event, we would be unable to further practice our technologies or develop and commercialize any of our product candidates at issue,
which could harm our business and financial condition significantly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 53; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parties
making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop
and commercialize one or more of our product candidates, if approved. Defense of these claims, regardless of their merit, would involve
substantial litigation expense and would be a substantial diversion of management and employee time and resources from our business.
Third parties making such claims may have the ability to dedicate substantially greater resources to these legal actions than us or our
licensors or collaborators can. In the event of a successful claim of infringement, misappropriation or other violation against us, we
may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign
our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary
expenditure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
litigation and other proceedings may also absorb significant management time. The cost to us of any patent litigation or other proceeding,
even if resolved in our favor, could be substantial. During the course of any patent or other intellectual property litigation or other
proceeding, there could be public announcements of the results of hearings, rulings on motions, and other interim proceedings or developments
and if securities analysts or investors regard these announcements as negative, the perceived value of our product candidates or intellectual
property could be diminished. Accordingly, the market price of our common stock may decline. Uncertainties resulting from the initiation
and continuation of patent litigation or other proceedings could have a material adverse effect on our business, ability to compete in
the marketplace, financial condition, results of operations and growth prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming
and unsuccessful.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitors
may infringe, misappropriate or otherwise violate our patents, trademarks, copyrights or other intellectual property, or those of our
licensors. To counter infringement, misappropriation, unauthorized use or other violations, we may be required to file legal claims,
which can be expensive and time consuming and divert the time and attention of our management and scientific personnel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
can be no assurances that we will be successful with respect to any litigation matters which may arise in the ordinary course of our
business. Such a failure may have a material impact on our business, results of operations and financial condition in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be able to prevent, alone or with any future licensors, infringement, misappropriation or other violations of our intellectual
property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. Any claims we
assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents.
In addition, in a patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable,
in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk
that, even if the validity of such patents is upheld, the court will construe the patent&#8217;s claims narrowly or decide that we do
not have the right to stop the other party from using the invention at issue on the grounds that our patents do not cover the invention.
An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties
or other competitors and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive
products. Any of these occurrences could adversely affect our competitive business position, business prospects and financial condition.
Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable,
or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we
could ultimately be forced to cease use of such trademarks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
any infringement, misappropriation or other intellectual property litigation, any award of monetary damages we receive may not be commercially
valuable. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there
is a risk that some of our confidential information could be compromised by disclosure during litigation. Moreover, there can be no assurance
that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years
before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the
attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 54; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
expiration or loss of patent protection may adversely affect our future revenues and operating earnings.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on patent, trademark, trade secret and other intellectual property protection in the discovery, development, manufacturing and sale
of our product candidates. In particular, patent protection is important in the development and eventual commercialization of our product
candidates. Patents covering our product candidates normally provide market exclusivity, which is important in order to improve the probability
that our product candidates are able to become profitable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
of our patents relating to PF614 will expire in 2030. In addition, certain of our patents relating to the use of nafamostat for treating
respiratory diseases will expire in 2028. While we are seeking additional patent coverage which may protect the technology underlying
these patents, there can be no assurances that such additional patent protection will be granted, or if granted, that these patents will
not be infringed upon or otherwise held enforceable. Even if we are successful in obtaining a patent, patents have a limited lifespan.
In the United States, the natural expiration of a utility patent is generally 20 years after it is filed. Various extensions may be available;
however, the life of a patent, and the protection it affords, is limited. Without patent protection of our product candidates, we may
be open to competition from generic versions of such methods and compositions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we do not obtain protection under the Hatch-Waxman Amendments by extending the patent term, our business may be harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success will largely depend on our ability to obtain and maintain patent and other intellectual property in the United States
and other countries with respect to our product candidates. Given the amount of time required for the development, testing and regulatory
review of new product candidates, patents protecting our product candidates might expire before or shortly after such candidates begin
to be commercialized. We expect to seek extensions of patent terms in the United States and, if available, in other countries where we
are prosecuting patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depending
upon the timing, duration and specifics of FDA marketing approval of our product candidates, one or more of our United States patents
may be eligible for limited patent term extension, or PTE, under the Drug Price Competition and Patent Term Restoration Act of 1984,
referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years beyond the
normal expiration of the patent as compensation for patent term lost during development and the FDA regulatory review process, which
is limited to the approved indication (and potentially additional indications approved during the period of extension) covered by the
patent. This extension is limited to only one patent that covers the approved product, the approved use of the product, or a method of
manufacturing the product. If we are unable to extend the expiration date of our existing patents or obtain new patents with longer expiry
dates, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical
and preclinical data to obtain approval of competing products following our patent expiration and launch their product earlier than might
otherwise be the case.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to protect our intellectual property rights throughout the world, which could negatively impact our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing,
prosecuting and defending patents covering our product candidates in all countries throughout the world would be prohibitively expensive,
and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States.
In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws
in the United States. Further, licensing partners may not prosecute patents in certain jurisdictions in which we may obtain commercial
rights, thereby precluding the possibility of later obtaining patent protection in these countries. Consequently, we may not be able
to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products
made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions
where we have not obtained patent protection to develop our own products and may also export infringing products to territories where
we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our product
candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 55; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The
legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets
and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for
us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings
to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts
and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our
patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits
that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce
our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual
property that we develop or license. Furthermore, while we intend to protect our intellectual property rights in our expected significant
markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market
our product candidates. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate, which
may have an adverse effect on our ability to successfully commercialize our product candidates in all of our expected significant foreign
markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the requirements for patentability may differ in certain countries, particularly developing countries. For example, unlike other countries,
China has a heightened requirement for patentability, and specifically requires a detailed description of medical uses of a claimed drug.
In India, unlike the United States, there is no link between regulatory approval of a drug and our patent status. Furthermore, generic
or biosimilar drug manufacturers or other competitors may challenge the scope, validity or enforceability of us or our licensors&#8217;
patents, requiring us or our licensees or any future licensors to engage in complex, lengthy and costly litigation or other proceedings.
In addition, certain countries in Europe and developing countries, including China and India, have compulsory licensing laws under which
a patent owner may be compelled to grant licenses to third parties. In those countries, We and our licensees or any future licensors
may have limited remedies if patents are infringed or if we or our licensees or any future licensors are compelled to grant a license
to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly,
we and our licensees&#8217; or any future licensors&#8217; efforts to enforce intellectual property rights around the world may be inadequate
to obtain a significant commercial advantage from the intellectual property that we own or license.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them
or that our trade secrets will be misappropriated or disclosed and if we are unable to protect the confidentiality of our trade secrets,
the value of our technology could be materially adversely affected and our business would be harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to seeking patents for some of our technology and products, we also rely on trade secrets, including unpatented know-how, technology
and other proprietary information, in seeking to develop and maintain a competitive position. Because we expect to rely on third parties
to manufacture our product candidates and we expect to collaborate with third parties on the development of our product candidates, we
must, at times, share trade secrets with them. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality
agreements with parties who have access to them, such as our employees, consultants, independent contractors, advisors, corporate collaborators,
outside scientific collaborators, contract manufacturers, suppliers and other third parties. We also enter into confidentiality and invention
or patent assignment agreements with employees and certain consultants. We also seek to preserve the integrity and confidentiality of
our data, trade secrets and know-how by maintaining physical security of our premises and physical and electronic security of our information
technology systems. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to
protect our proprietary technologies will be effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our inception, we have sought to contract with manufacturers to supply commercial quantities of pharmaceutical formulations and products.
As a result, we have disclosed, under confidentiality agreements, various aspects of our technology with potential manufacturers and
suppliers. We believe that these disclosures, while necessary for our business, may have resulted and may result in the attempt by potential
manufacturers and suppliers to improperly assert ownership claims to our technology in an attempt to gain an advantage in negotiating
manufacturing and supplier rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot guarantee that our trade secrets and other proprietary and confidential information will not be disclosed or that competitors
will not otherwise gain access to our trade secrets. Any party with whom we have executed such an agreement may breach that agreement
and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches.
Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and
the outcome is unpredictable. In addition, some courts both within and outside the United States may be less willing or unwilling to
protect trade secrets. Further, if any of our trade secrets were to be lawfully obtained or independently developed by a competitor,
we would have no right to prevent such third party, or those to whom they communicate such technology or information, from using that
technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor,
our business and competitive position could be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 56; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
secrets and know-how can be difficult to protect as trade secrets and know-how will over time be disseminated within the industry through
independent development, the publication of journal articles, and the movement of personnel skilled in the art from company to company
or academic to industry scientific positions. If we fail to prevent material disclosure of the know-how, trade secrets and other intellectual
property related to our technologies to third parties, we will not be able to establish or maintain a competitive advantage in our market,
which could materially adversely affect our business, results of operations and financial condition. Even if we are able to adequately
protect our trade secrets and proprietary information, our trade secrets could otherwise become known or could be independently discovered
by our competitors. For example, we are aware that certain of our former employees founded Elysium Therapeutics, which appears to be
developing orally administered abuse deterrent opioids. Additionally, competitors could purchase our products and attempt to replicate
some or all of the competitive advantages we derive from our development efforts, design around our protected technology or develop their
own competitive technologies that fall outside of our intellectual property rights. If any of our trade secrets were to be lawfully obtained
or independently developed by a competitor, in the absence of patent protection, we would have no right to prevent them, or those to
whom they communicate, from using that technology or information to compete with us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be able to prevent misappropriation of our intellectual property, trade secrets or confidential information, particularly in
countries where the laws may not protect those rights as fully as in the United States. Furthermore, because of the substantial amount
of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information
could be compromised by disclosure during this type of litigation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Intellectual
property rights do not necessarily address all potential threats to our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
granted, patents may remain open to opposition, interference, re-examination, post-grant review, inter partes review, nullification or
derivation action in court or before patent offices or similar proceedings for a given period after allowance or grant, during which
time third parties can raise objections against such grant. In the course of such proceedings, which may continue for a protracted period
of time, the patent owner may be compelled to limit the scope of the allowed or granted claims thus attacked or may lose the allowed
or granted claims altogether. In addition, the degree of future protection afforded by our intellectual property rights is uncertain
because even granted intellectual property rights have limitations and may not adequately protect our business. The following examples
are illustrative:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">others
    may be able to make formulations that are similar to our product candidates or other formulations but that are not covered by the
    claims of our patent rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    patents of third parties may have an adverse effect on our business;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    or any future strategic partners might not have been the first to conceive or reduce to practice the inventions covered by the issued
    patent or pending patent application that we own;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    or any future strategic partners might not have been the first to file patent applications covering certain of our inventions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">others
    may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual
    property rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">it
    is possible that our pending patent applications will not lead to issued patents;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issued
    patents that we may own or that we exclusively license in the future may not provide us with any competitive advantage, or may be
    held invalid or unenforceable, as a result of legal challenges by our competitors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    competitors might conduct research and development activities in countries where we do not have patent rights and then use the information
    learned from such activities to develop competitive products for sale in our major commercial markets;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">third
    parties performing manufacturing or testing for us using our product candidates or technologies could use the intellectual property
    of others without obtaining a proper license;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may not develop additional proprietary technologies that are patentable; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    patents of others may have an adverse effect on our business.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Should
any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and
prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
validity, scope and enforceability of any patents listed in the Orange Book that cover our product candidates can be challenged by third
parties.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
one of our product candidates is approved by the FDA, one or more third parties may challenge the current patents, or patents that may
issue in the future, within our portfolio which could result in the invalidation of, or render unenforceable, some or all of the relevant
patent claims or a finding of non-infringement. For example, if a third party submits an application under Section 505(b)(2) or an abbreviated
new drug application, or ANDA, for a generic drug containing any of our product candidates, and relies in whole or in part on studies
conducted by or for us, the third party will be required to certify to the FDA that either: (1) there is no patent information listed
in the Orange Book with respect to our NDA for the applicable approved drug candidate; (2) the patents listed in the Orange Book have
expired; (3) the listed patents have not expired, but will expire on a particular date and approval is sought after patent expiration;
or (4) the listed patents are invalid or will not be infringed by the manufacture, use or sale of the third party&#8217;s generic drug.
A certification that the new drug will not infringe the Orange Book-listed patents for the applicable approved drug candidate, or that
such patents are invalid, is called a paragraph IV certification. If the third party submits a paragraph IV certification to the FDA,
a notice of the paragraph IV certification must also be sent to us once the third party&#8217;s ANDA is accepted for filing by the FDA.
We may then initiate a lawsuit to defend the patents identified in the notice. The filing of a patent infringement lawsuit within 45
days of receipt of the notice automatically prevents the FDA from approving the third party&#8217;s ANDA until the earliest of 30 months
or the date on which the patent expires, the lawsuit is settled, or the court reaches a decision in the infringement lawsuit in favor
of the third party. If we do not file a patent infringement lawsuit within the required 45-day period, the third party&#8217;s ANDA will
not be subject to the 30-month stay of FDA approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 57; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
a third party may challenge the current patents, or patents that may be issued in the future, within our portfolio which could result
in the invalidation of some or all the patents that might otherwise be eligible for listing in the Orange Book for one of our products.
If a third party successfully challenges all of the patents that might otherwise be eligible for listing in the Orange Book for one of
our products, we will not be entitled to the 30-month stay of FDA approval upon the filing of an ANDA for a generic drug containing any
of our product candidates, and relies in whole or in part on studies conducted by or for us. Litigation or other proceedings to enforce
or defend intellectual property rights are often very complex in nature, may be very expensive and time-consuming, may divert our management&#8217;s
attention from our core business, and may result in unfavorable results that could limit our ability to prevent third parties from competing
with our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cyber-attacks
or other failures in our telecommunications or information technology systems, or those of our collaborators, CROs, third-party logistics
providers, distributors or other contractors or consultants, could result in information theft, data corruption and significant disruption
of our business operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We,
our collaborators, CROs, third-party logistics providers, distributors and other contractors and consultants utilize information technology,
or IT, systems and networks to process, transmit and store electronic information in connection with our business activities. As use
of digital technologies has increased, cyber incidents, including third parties gaining access to employee accounts using stolen or inferred
credentials, computer malware, viruses, spamming, phishing attacks or other means, and deliberate attacks and attempts to gain unauthorized
access to computer systems and networks, have increased in frequency and sophistication. These threats pose a risk to the security of
us, our collaborators&#8217;, CROs&#8217;, third-party logistics providers&#8217;, distributors&#8217; and other contractors&#8217; and
consultants&#8217; systems and networks, and the confidentiality, availability and integrity of our data. There can be no assurance that
we will be successful in preventing cyber-attacks or successfully mitigating their effects. Similarly, there can be no assurance that
our collaborators, CROs, third-party logistics providers, distributors and other contractors and consultants will be successful in protecting
our clinical and other data that is stored on their systems. Like other companies, we have on occasion experienced, and will continue
to experience, threats to our data and systems, including malicious codes and viruses, phishing, business email compromise attacks or
other cyber-attacks. Any cyber-attack, data breach or destruction or loss of data could result in a violation of applicable United States
and international privacy, data protection and other laws and subject us to litigation and governmental investigations and proceedings
by federal, state and local regulatory entities in the United States and by international regulatory entities, resulting in exposure
to material civil and/or criminal liability. Further, our general liability insurance and corporate risk program may not cover all potential
claims to which we are exposed and may not be adequate to indemnify us for all liability that may be imposed, which could have a material
adverse effect on our business and prospects. For example, the loss of clinical trial data from completed or ongoing clinical trials
for any of our product candidates could result in delays in our development and regulatory approval efforts and significantly increase
our costs to recover or reproduce the data. In addition, we may suffer reputational harm or face litigation or adverse regulatory action
as a result of cyber-attacks or other data security breaches and may incur significant additional expense to implement further data protection
measures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to the Ownership of Common Stock and Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Raising
additional capital has caused, and may in the future cause, dilution to our stockholders, adversely affect the market price of our common
stock, restrict our operations or require us to relinquish rights to our technologies or product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
expenses have increased in connection with our planned operations. Unless and until we can generate a substantial amount of revenue from
our product candidates, we expect to finance our future cash needs through public or private equity offerings, debt financings, collaborations,
licensing arrangements or other sources, or any combination of the foregoing. In addition, we may seek additional capital due to favorable
market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 58; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that we raise additional capital through the sale of common stock, convertible securities or other equity securities as we
have done in the past, our stockholders&#8217; ownership interest has been, and may in the future be, diluted. In addition, debt financing,
if available, may result in fixed payment obligations and may involve agreements that include restrictive covenants that limit our ability
to take specific actions, such as incurring additional debt, making capital expenditures, creating liens, redeeming stock or declaring
dividends, that could adversely impact our ability to conduct our business. In addition, securing financing could require a substantial
amount of time and attention from our management and may divert a disproportionate amount of their attention away from day-to-day activities,
which may adversely affect our management&#8217;s ability to oversee the development of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we may sell securities in the public or private equity markets if and when conditions are favorable, or at prices per share
below the current market price of our common stock, even if we do not have an immediate need for additional capital at that time. Sales
of substantial amounts of shares of our common stock, or the perception that such sales could occur, could adversely affect the prevailing
market price of our shares and our ability to raise capital. We may issue additional shares of common stock in future financing transactions
or as incentive compensation for our executive management and other key personnel, consultants and advisors. Moreover, sales of substantial
amounts of shares in the public market, or the perception that such sales could occur, may adversely affect the prevailing market price
of our common stock and make it more difficult for us to raise additional capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt
financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability
to take specific actions, such as incurring additional debt, making acquisitions, engaging in acquisition, merger or collaboration transactions,
selling or licensing our assets, making capital expenditures, redeeming our stock, making certain investments, declaring dividends or
encumbering our assets to secure future indebtedness. Such restrictions could adversely impact our ability to conduct our operations
and execute our business plan. The Investor Notes contain such restrictions including a pledge of substantially all of our tangible and
intangible assets, including our intellectual property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we raise additional funds through upfront payments or milestone payments pursuant to strategic collaborations, strategic alliances or
marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or
intellectual property, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable
to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit,
reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates
that we would otherwise prefer to develop and market ourselves.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are a smaller reporting company within the meaning of the Securities Act, and if we take advantage of certain exemptions from disclosure
requirements available to &#8220;smaller reporting companies,&#8221; this could make our securities less attractive to investors and
may make it more difficult to compare our performance with other public companies.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a &#8220;<i>smaller reporting company</i>&#8221; as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take
advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements.
We will remain a smaller reporting company until the last day of the fiscal year in which (i) the market value of our common stock held
by non-affiliates is greater than or equal to $250 million as of the end of that fiscal year&#8217;s second fiscal quarter, and (ii)
our annual revenues are greater than or equal to $100 million during the last completed fiscal year and the market value of our common
stock held by non-affiliates exceeds $700 million as of the end of that fiscal year&#8217;s second fiscal quarter. To the extent we take
advantage of such reduced disclosure obligations, it may also make comparison of our financial statements with other public companies
difficult or impossible.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 59; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
internal controls over financial reporting may not meet all of the standards contemplated by Section 404 of Sarbanes-Oxley Act, and failure
to maintain effective internal controls over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act could impair
our ability to produce timely and accurate financial statements or comply with applicable regulations and have a material adverse effect
on our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management has significant requirements for enhanced financial reporting and internal controls as a public company. The process of designing
and implementing effective internal controls is a continuous effort that will require us to anticipate and react to changes in our business
and the economic and regulatory environments and to expend significant resources to maintain a system of internal controls that is adequate
to satisfy our reporting obligations as a public company. If we are unable to maintain appropriate internal financial reporting controls
and procedures, it could cause us to fail to meet our reporting obligations on a timely basis or result in material misstatements in
our consolidated financial statements, which could harm our operating results. In addition, we are required, pursuant to Section 404
of the Sarbanes-Oxley Act, to furnish a report by management on, among other things, the effectiveness of our internal controls over
financial reporting. This assessment needs to include disclosure of any material weaknesses identified by our management in our internal
control over financial reporting. The rules governing the standards that must be met for our management to assess our internal control
over financial reporting are complex and require significant documentation, testing, and possible remediation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Matters
impacting our internal controls may cause us to be unable to report our financial information on a timely basis and thereby subject us
to adverse regulatory consequences, including sanctions by the SEC, or violations of applicable stock exchange listing rules, which may
result in a breach of the covenants under existing or future financing arrangements. There also could be a negative reaction in the financial
markets due to a loss of investor confidence in us and the reliability of our financial statements. This could materially adversely affect
us and lead to a decline in the market price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
amount of our future losses is uncertain and our quarterly and annual operating results may fluctuate significantly or fall below the
expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
quarterly and annual operating results may fluctuate significantly in the future due to a variety of factors, many of which are outside
of our control and may be difficult to predict, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing and success or failure of clinical trials for our product candidates or competing product candidates, or any other change
    in the competitive landscape of our industry,</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to successfully recruit and retain subjects for clinical trials, and any delays caused by difficulties in such efforts;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    risk/benefit profile, cost and reimbursement policies with respect to our product candidates, if approved, and existing and potential
    future therapeutics that compete with our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain marketing approval for our product candidates and the timing and scope of any such approvals we may receive;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing and cost of, and level of investment in, research and development activities relating to our product candidates, which may
    change from time to time;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of manufacturing our product candidates, which may vary depending on the quantity of production and the terms of our agreements
    with manufacturers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to attract, hire and retain qualified personnel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenditures
    that we will or may incur to develop additional product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    level of demand for our product candidates should they receive approval, which may vary significantly;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    changing and volatile U.S. and global economic environments; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">future
    accounting pronouncements or changes in our accounting policies.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 60; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results.
As a result, comparing our operating results on a period-to-period basis may not be meaningful. This variability and unpredictability
could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our operating
results or revenue fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the
forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially.
Such a stock price decline could occur even when we have met any previously publicly stated guidance we may provide, if any.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants
for shares of our common stock, if exercised, will increase the number of shares eligible for future resale in the public market and
result in dilution to our stockholders. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have issued a significant amount of warrants to purchase shares of our common stock in connection with various financing transactions.
To the extent these warrants are exercised, additional shares of our common stock will be issued, which will result in dilution to the
holders of shares of our common stock and increase the number of shares of common stock eligible for resale in the public market. Sales
of substantial numbers of such shares of common stock in the public market or the fact that such warrants may be exercised could adversely
affect the market price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
issuance of additional capital stock in connection with financings, acquisitions, investments and our 2021 Omnibus Incentive Plan will
dilute all other stockholders. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to issue additional capital stock in the future that will result in dilution to all other stockholders. We have granted equity
awards to employees, directors, and consultants under our 2021 Omnibus Incentive Plan and plan to do so in the future. We may also raise
capital through equity financings in the future. As part of our business strategy, we may acquire or make investments in complementary
companies, products, or technologies and issue equity securities to pay for any such acquisition or investment. Any such issuances of
additional capital stock may cause stockholders to experience significant dilution of their ownership interests and the per share value
of our common stock to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to maintain compliance with the listing standards of Nasdaq, our common stock could be delisted and may become subject
to &#8220;penny stock&#8221; rules, which could have a material adverse effect on the liquidity of our common stock, the ability of investors
to sell their shares and our ability to raise funding.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 14, 2024, we received notice from Nasdaq stating that we had demonstrated compliance with the $2.5 million stockholders&#8217;
equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) as of September 30, 2024. On December 20, 2024, we received notice from
Nasdaq that we had regained compliance with the bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). There can be no assurance
that we will be able to maintain compliance with such Nasdaq Listing Rules and our common stock could be delisted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
de-listing of our common stock on Nasdaq could have a material adverse effect on us, including on our ability to raise capital through
alternative financing sources on terms acceptable to us, or at all, and may result in the potential loss of confidence by investors,
suppliers, customers and employees and fewer business development opportunities. Upon any delisting, our common stock could become subject
to the regulations of the SEC relating to the market for penny stocks. Penny stocks are securities with a price of less than $5.00 per
share unless (i) the securities are traded on a &#8220;recognized&#8221; national exchange or (ii) the issuer has net tangible assets
less than $2,000,000 (if the issuer has been in continuous operation for at least three years) or $5,000,000 (if in continuous operation
for less than three years), or with average annual revenues of less than $6,000,000 for the last three years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
procedures applicable to penny stocks requires a broker-dealer to (i) obtain from the investor information concerning his financial situation,
investment experience and investment objectives; (ii) reasonably determine, based on that information, that transactions in penny stocks
are suitable for the investor and that the investor has sufficient knowledge and experience as to be reasonably capable of evaluating
the risks of penny stock transactions; (iii) provide the investor with a written statement setting forth the basis on which the broker-dealer
made the determination in (ii) above; and (iv) receive a signed and dated copy of such statement from the investor, confirming that it
accurately reflects the investor&#8217;s financial situation, investment experience and investment objectives. The regulations applicable
to penny stocks may severely affect the market liquidity for our common stock and could limit the ability of stockholders to sell their
common stock in the secondary market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 61; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Jo_007"></span>Item
1B. Unresolved Staff Comments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Jo_008"></span>Item
1C. Cybersecurity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risk
Management and Strategy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_985_ecyd--CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_iB_c20240101__20241231_gBFCRMPITB-QSD_zrJ4t4LmRmt6" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" continuedAt="ConU000072-01" escape="true" id="Fact000072" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20240101__20241231_zUKS2abTeTnl" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000073" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock">We
have developed and implemented cybersecurity risk management <span id="xdx_90E_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_zHF0Co8bNU5i" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000074" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag">processes</ix:nonNumeric></span> intended to protect the confidentiality, integrity and availability
of our critical systems and information.</ix:nonNumeric></span></span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C09_gBFCRMPITB-QSD_zsgHQMstrId5"><ix:continuation continuedAt="ConU000072-02" id="ConU000072-01">Our
cybersecurity risk management program includes:</ix:continuation></span></span></p>

<div id="xdx_C00_gBFCRMPITB-QSD_z6xjululqQJ5"><ix:continuation continuedAt="ConU000072-03" id="ConU000072-02"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:continuation></div><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_C01_gBFCRMPITB-QSD_zXzyyOd3IIdd"><ix:continuation continuedAt="ConU000072-04" id="ConU000072-03"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></ix:continuation></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span id="xdx_C06_gBFCRMPITB-QSD_zXeq3V56thp5"><ix:continuation continuedAt="ConU000072-05" id="ConU000072-04"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></ix:continuation></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_C0F_gBFCRMPITB-QSD_zNk1nulOvbHb"><ix:continuation continuedAt="ConU000072-06" id="ConU000072-05"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">physical,
    technological and administrative controls intended to support our cybersecurity and data governance framework, including protections
    designed to protect the confidentiality, integrity and availability of our key information systems;</span></ix:continuation></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_C06_gBFCRMPITB-QSD_zqcOwhfmJBMk"><ix:continuation continuedAt="ConU000072-07" id="ConU000072-06"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></ix:continuation></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_C05_gBFCRMPITB-QSD_zTmSWUz17bzd"><ix:continuation continuedAt="ConU000072-08" id="ConU000072-07"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></ix:continuation></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_C00_gBFCRMPITB-QSD_zyI3XlGnrdYf"><ix:continuation continuedAt="ConU000072-09" id="ConU000072-08"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></ix:continuation></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_C02_gBFCRMPITB-QSD_z1r8qYFjI8Tf"><ix:continuation continuedAt="ConU000072-10" id="ConU000072-09"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></ix:continuation></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_C0F_gBFCRMPITB-QSD_zJm1V5hjaM76"><ix:continuation continuedAt="ConU000072-11" id="ConU000072-10"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></ix:continuation></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_C04_gBFCRMPITB-QSD_z1jKQhsiCn0g"><ix:continuation continuedAt="ConU000072-12" id="ConU000072-11"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">risk
    assessments designed to help identify material cybersecurity risks to our critical systems and information;</span></ix:continuation></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_C0A_gBFCRMPITB-QSD_zBFV0EGw5HHk"><ix:continuation continuedAt="ConU000072-13" id="ConU000072-12"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></ix:continuation></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_C03_gBFCRMPITB-QSD_z8OAcBOKMZuk"><ix:continuation continuedAt="ConU000072-14" id="ConU000072-13"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></ix:continuation></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_C0A_gBFCRMPITB-QSD_zAMeuhKSS0c"><ix:continuation continuedAt="ConU000072-15" id="ConU000072-14"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></ix:continuation></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_C00_gBFCRMPITB-QSD_zWQHppVQsHob"><ix:continuation continuedAt="ConU000072-16" id="ConU000072-15"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></ix:continuation></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_C0F_gBFCRMPITB-QSD_zLDoKBCUxfe4"><ix:continuation continuedAt="ConU000072-17" id="ConU000072-16"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></ix:continuation></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_C06_gBFCRMPITB-QSD_zwcJ4EubvNa7"><ix:continuation continuedAt="ConU000072-18" id="ConU000072-17"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">designated
    team members are responsible for managing our cybersecurity risk assessment processes, our security controls, and our response to
    cybersecurity incidents; and</span></ix:continuation></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_C05_gBFCRMPITB-QSD_zPZEbwFggPn7"><ix:continuation continuedAt="ConU000072-19" id="ConU000072-18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></ix:continuation></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_C00_gBFCRMPITB-QSD_zvmaQVunnAF1"><ix:continuation continuedAt="ConU000072-20" id="ConU000072-19"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></ix:continuation></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_C07_gBFCRMPITB-QSD_zBHQZaaGRJG6"><ix:continuation continuedAt="ConU000072-21" id="ConU000072-20"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></ix:continuation></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_C07_gBFCRMPITB-QSD_zSIN4BYk2GU"><ix:continuation continuedAt="ConU000072-22" id="ConU000072-21"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></ix:continuation></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_C07_gBFCRMPITB-QSD_zknBwOYRlBn8"><ix:continuation continuedAt="ConU000072-23" id="ConU000072-22"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></ix:continuation></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C09_gBFCRMPITB-QSD_zr7OuYltEiS6"><ix:continuation continuedAt="ConU000072-24" id="ConU000072-23"><span id="xdx_900_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240101__20241231_zcYWaDPcQxKl" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000075" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag">the
    use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of our security controls.</ix:nonNumeric></span></ix:continuation></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C09_gBFCRMPITB-QSD_zDSM0TBjHpjc"><ix:continuation continuedAt="ConU000072-25" id="ConU000072-24"><span id="xdx_903_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_c20240101__20241231_zVdSnzIvXkNe" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000076" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock">We
have <span id="xdx_90B_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20240101__20241231_zfiiJoTFjLdl" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000077" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">no</ix:nonNumeric></span>t identified risks from known cybersecurity threats that have materially affected or are reasonably likely to materially affect
us, including our operations, business strategy, results of operations, or financial condition</ix:nonNumeric></span>. See Item 1A. &#8220;Risk Factors &#8211;
</ix:continuation></span><i><span id="xdx_C0F_gBFCRMPITB-QSD_z5X4zMXdPdtb"><ix:continuation id="ConU000072-25">Cyber-attacks or other failures in our telecommunications or information technology systems, or those of our collaborators, CROs,
third-party logistics providers, distributors or other contractors or consultants, could result in information theft, data corruption
and significant disruption of our business operations.&#8221;</ix:continuation></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Governance</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_980_ecyd--CybersecurityRiskBoardOfDirectorsOversightTextBlock_c20240101__20241231_gBFCRBODOTB-DXZW_zyvoTFXRdyM6" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" continuedAt="ConU000080-01" escape="true" id="Fact000080" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board considers cybersecurity risk as part of its risk oversight function. <span id="xdx_904_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_c20240101__20241231_zoYYvSunh82i" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000081" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">The <span id="xdx_905_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_dbT_c20240101__20241231_zqU5TW3cZ1Y8" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000082" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">Audit Committee</ix:nonNumeric></span> oversees our cybersecurity and other information
technology risks and management&#8217;s implementation of our cybersecurity risk management program</ix:nonNumeric></span>. <span id="xdx_907_ecyd--CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_c20240101__20241231_zELxueJrRiN1" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000083" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">The Audit Committee receives periodic
reports from management on our cybersecurity risks. In addition, <span id="xdx_90E_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_dbT_c20240101__20241231_zGUxsf9VJjVe" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000084" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">management</ix:nonNumeric></span> updates the Board and the Audit Committee, as necessary,
regarding any material cybersecurity incidents, as well as any incidents with lesser impact potential.</ix:nonNumeric></span></span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C0D_gBFCRBODOTB-DXZW_zwHipcCVCbbi"><ix:continuation continuedAt="ConU000080-02" id="ConU000080-01"><span id="xdx_90B_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240101__20241231_zdeUgQwC1NF9" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000085" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">Our
management team, including our Chief Financial Officer, is responsible for assessing and managing our material risks from cybersecurity
threats.</ix:nonNumeric></span> Our Chief Financial Officer has primary responsibility for our overall cybersecurity risk management program. Our Chief Financial
Officer has experience supervising and managing company information technology departments.</ix:continuation></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C0B_gBFCRBODOTB-DXZW_zuQdHufMRrw5"><ix:continuation id="ConU000080-02">Our
management team supervises efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means,
which may include briefings from external security personnel; threat intelligence and other information obtained from governmental, public
or private sources; and alerts and reports produced by security tools deployed in the information technology environment.</ix:continuation></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Jo_009"></span>Item
2. Properties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal executive office is located at 7946 Ivanhoe Ave., Suite 201 in La Jolla, California, where we lease a total of 850 square feet
of office space that we use for our administrative activities. All development activities are undertaken at contract research organizations.
The lease expires in October 2025. We believe that our current arrangements will be sufficient to meet our needs for the foreseeable
future, and that, should it be needed, suitable space will be available to accommodate our administrative activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 62; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Jo_010"></span>Item
3. Legal Proceedings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we could become involved in disputes and various litigation matters that arise in the normal course of business. These
may include disputes and lawsuits related to intellectual property, licensing, contract law and employee relations matters. Periodically,
we review the status of significant matters, if any exist, and assess the potential financial exposure. If the potential loss from any
claim or legal claim is considered probable and the amount can be estimated, we accrue a liability for the estimated loss. Legal proceedings
are subject to uncertainties, and the outcomes are difficult to predict. Because of such uncertainties, accruals are based on the best
information available at the time. As additional information becomes available, we reassess the potential liability related to pending
claims and litigation. As of the date hereof, we are not a party to any material legal proceeding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Jo_011"></span>Item
4. Mine Safety Disclosures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Jo_012"></span>PART
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Jo_013"></span>Item
5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Market
Price and Ticker Symbol</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is currently listed on the Nasdaq Stock Market under the symbol &#8220;ENSC.&#8221; Our Public Warrants are currently listed
on the OTC Pink Open Market under the symbol &#8220;ENSCW.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
closing price of our common stock and Public Warrants on March 7, 2025, was $5.02 and $0.176, respectively. Over-the-counter market quotations
on the OTC Pink Open Market reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not necessarily represent
actual transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Holders</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 7, 2025, there were approximately 73 holders of record of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such
numbers do not include beneficial owners holding our securities through nominee names.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Dividends</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not paid any cash dividends on our common stock to date. We may retain future earnings, if any, for future operations, expansion
and debt repayment and has no current plans to pay cash dividends for the foreseeable future. Any decision to declare and pay dividends
in the future will be made at the discretion of the Board and will depend on, among other things, our results of operations, financial
condition, cash requirements, contractual restrictions and other factors that the Board may deem relevant. In addition, our ability to
pay dividends may be limited by covenants of any existing and future outstanding indebtedness we or our subsidiaries incur. We do not
anticipate declaring any cash dividends to holders of our common stock in the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 63; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
Authorized for Issuance under Equity Compensation Plans</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides information as of December 31, 2024, with respect to securities that may be issued under our equity compensation
plans:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Plan Category</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br/> Securities to be<br/>
    Issued upon<br/> Exercise of<br/> Outstanding<br/> Options,<br/> Warrants and<br/> Rights</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise Price<br/>
    of Outstanding<br/> Options,<br/> Warrants and<br/> Rights</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br/> Securities<br/> Remaining<br/>
    Available for<br/> Future Issuance<br/> Under Equity<br/> Compensation<br/> Plans<br/> (Excluding<br/> Securities<br/> Reflected in the<br/>
    First Column)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Equity compensation plans approved by security holders</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">38,785</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">501.65</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">10,596</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Equity compensation plans not approved by security holders</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,785</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">501.65</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,596</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Recent
Sales of Unregistered Securities and Use of Proceeds</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of unregistered securities during 2024 have been disclosed in 10-Q Report for the quarter ending September 30 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Purchases
of Equity Securities by the Issuer and Affiliated Purchasers </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 64; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Jo_014"></span>Item
7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ensysce
is a clinical stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the fear of and the
potential for opioid misuse, abuse and overdose. Our lead product candidate, PF614, is an extended release TAAP prodrug of oxycodone.
TAAP modification of prescription drugs removed the ability to crush, chew or manipulate and inject to achieve the effect of the medication
more quickly than by swallowing. MPAR<sup>&#174;</sup> adds a layer of overdose protection to each TAAP product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our inception in 2003, we devoted substantially all of our efforts and financial resources to organizing and staffing our company, business
planning, raising capital, discovering product candidates and securing related intellectual property rights and conducting research and
development activities for our product candidates. We do not have any products approved for sale and we have not generated any revenue
from product sales. We may never be able to develop or commercialize a marketable product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
lead product candidate, PF614, is in Phase 3 clinical development, PF614-MPAR is in Phase 1b clinical development and nafamostat is proceeding
towards Phase 1 clinical development. Our other product candidates and our research initiatives are in preclinical or earlier stages
of development. Our ability to generate revenue from product sales sufficient to achieve profitability will depend heavily on the successful
development and eventual commercialization of one or more of our product candidates. We have not yet successfully completed any pivotal
clinical trials, nor have we obtained any regulatory approvals, manufactured a commercial-scale drug, or conducted sales and marketing
activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred significant operating losses since inception and we expect to continue to incur net losses for the foreseeable future.
We expect that our expenses and capital requirements will increase substantially in connection with our ongoing development activities,
particularly if and as we:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue
    preclinical studies and continues existing and initiates new clinical trials for PF614, PF614-MPAR and nafamostat, our lead product
    candidates being tested for chronic pain and infectious disease;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">advance
    the development of our product candidate pipeline of other product candidates, including through business development efforts to
    invest in or in-license other technologies or product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain,
    expand and protect our intellectual property portfolio;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire
    additional clinical, quality control, medical, scientific and other technical personnel to support our clinical operations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
    regulatory approval for any product candidates that successfully complete clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">undertake
    any pre-commercialization activities to establish sales, marketing and distribution capabilities for any product candidates for which
    we may receive regulatory approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expand
    our infrastructure and facilities to accommodate our growing employee base; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">add
    operational, financial and management information systems and personnel, including personnel to support our research and development
    programs, any future commercialization efforts and our transition to operating as a public company.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred and expect to continue to incur additional costs associated with operating as a public company, including significant legal,
accounting, insurance, investor relations and other expenses. We may never become profitable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 65; Options: NewSection; Value: 65 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
require substantial additional funding to support our continuing operations and pursue our growth strategy. Until we can generate significant
revenue from product sales, if ever, we expect to finance our operations through a combination of private and public equity offerings,
debt financings or other capital sources, which may include collaborations with other companies or other strategic transactions. To the
extent that we raise additional capital through the sale of private or public equity or convertible debt securities, existing ownership
interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights
of our equity holders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt
financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take
specific actions, such as incurring additional debt, issuing additional equity, making acquisitions or capital expenditures or declaring
dividends. If we raise additional funds through collaborations or other strategic transactions with third parties, we may have to relinquish
valuable rights to our technologies, future revenue streams, research programs or drug candidates, or grant licenses on terms that may
not be favorable to us. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on
favorable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly
delay, scale back or discontinue the development and commercialization of one or more of our product candidates or delay our pursuit
of potential in-licenses or acquisitions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased
expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not
become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, we may be unable to
continue our operations at planned levels and be forced to reduce or terminate our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have generated limited revenues and have incurred significant operating losses since our inception and expect to continue to incur operating
losses for the foreseeable future. These factors raise substantial doubt about our ability to continue as a going concern. Our future
viability is dependent on our ability to raise additional capital to finance our operations. Without raising additional capital through
a future offering, we believe that current cash on hand is sufficient to fund operations into the second quarter of 2025. We based this
estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. See &#8220;&#8212;
<i>Liquidity and Capital Resources</i>.&#8221; Our future viability beyond the twelve months is dependent on our ability to raise additional
capital to finance our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to incur substantial expenses in the foreseeable future for the development and potential commercialization of our product candidates
and ongoing internal research and development programs. At this time, we cannot reasonably estimate the nature, timing or aggregate amount
of costs for our development, potential commercialization, and internal research and development programs. However, in order to complete
our current and future preclinical studies and clinical trials, and to complete the process of obtaining regulatory approval for our
product candidates, as well as to build the sales, marketing and distribution infrastructure that we believe will be necessary to commercialize
our product candidates, if approved, we may require substantial additional funding in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 66; Value: 65 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2024
Registered Direct Offering and 2024 August Warrant Inducement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2024, we entered into a definitive Securities Purchase Agreement with certain institutional investors, pursuant to which we agreed
to issue and sell in a registered direct offering, (i) an aggregate of 166,054 shares of our common stock, par value $0.0001 per share
at an offering price of $7.05 per share, (ii) pre-funded warrants to purchase up to 70,827 shares of Common Stock, at a price per pre-funded
warrant equal to $7.0485, the price per share less $0.0001, for gross proceeds of approximately $1.7 million before the deduction of
placement agent fees and offering expenses. The pre-funded warrants were subsequently exercised in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also entered into an inducement agreement with certain warrant holders for the exercise of certain outstanding warrants to purchase up
to an aggregate of 480,234 shares of our common stock originally issued in February 2024, having an exercise price of $15.90 per share,
at a reduced exercise price of $7.05 per share, for gross proceeds of approximately $3.4 million before the deduction of placement agent
fees and offering expenses. We also agreed to amend certain existing warrants to purchase up to an aggregate of 133,334 shares of common
stock that were previously issued in November 2023 and have an exercise price of $23.5125 per share such that the amended warrants will
have a reduced exercise price of $7.05 per share effective upon the closing of the offering and will be exercisable from the date on
which stockholder approval is received with respect to the issuance of the shares of common stock issuable upon exercise of such warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
a concurrent private placement, pursuant to the terms of the inducement agreement and Securities Purchase Agreement, we also agreed to
issue and sell unregistered warrants to purchase up to 1,863,706 shares of common stock. The warrants have an exercise price of $7.05
per share and are exercisable from the date on which stockholder approval is received with respect to the issuance of the shares of common
stock issuable upon exercise of the warrants. One half of the warrants will expire eighteen months after they are exercisable and the
other half will expire five years after they are exercisable. The warrants contain customary anti-dilution adjustments to the exercise
price, including for share splits, share dividends, rights offering and pro rata distributions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
agreed to pay the placement agent a cash fee equal to 7% of the aggregate gross proceeds of the offerings or $354,000. We also agreed
to pay the placement agent $100,950 for expenses. We also issued to the placement agent warrants to purchase up to 50,200 shares of common
stock. These warrants have an exercise price equal to $8.8125 per share and are exercisable for five years from the commencement of sales
in the Offerings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2024
February Warrant Inducement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2024, we entered into an Inducement Letter with certain holders of existing warrants to purchase up to an aggregate of 240,120
shares of our common stock issued to the holders in connection with the 2023 May Offering. Pursuant to the Inducement Letter, the holders
agreed to exercise for cash their existing warrants to purchase an aggregate of 240,120 shares of Common Stock at a reduced exercise
price of $19.65 per share in consideration of our agreement to issue new unregistered Series A Warrants to purchase up to 240,120 shares
of Common Stock and new unregistered Series B Warrants to purchase up to 240,120 shares of Common Stock. The Series A Warrants have an
exercise price of $15.90 per share and have a term equal to eighteen months from the date of issuance. The Series B Warrants have an
exercise price of $15.90 per share and will expire on May 12, 2028. The gross proceeds to us from the exercise of the warrants were approximately
$4.7 million, prior to deducting placement agent fees and estimated offering expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the execution of the Inducement Letter, we entered into a waiver related to the 2023 Notes&#8217; SPA it had entered
into as of October 23, 2023. The SPA contained restrictions on our ability to undertake certain transactions, which included entering
into the Inducement Letter. The Waiver permitted us to enter into the Inducement Letter but required repayment of the remaining $0.5
million of investor held notes issued under the SPA with a premium of $0.5 million following closing of the inducement transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
utilized an exclusive placement agent for the 2024 Warrant Inducement and incurred approximately $0.3 million in legal fees and other
closing costs. Additionally, we issued to the placement agent as compensation unregistered warrants to purchase up to 16,811 shares of
Common Stock, equal to 7.0% of the aggregate number of shares of Common Stock (or warrants) placed in the transaction. The placement
agent warrants expire on May 12, 2028, and have an exercise price of $24.5625 per share of Common Stock (equal to 125% of the reduced
exercise price per Existing Warrant).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2023
Notes</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 23, 2023, we entered into a Securities Purchase Agreement (the &#8220;SPA&#8221;) for an aggregate financing of $1.7 million
with investors, including $0.2 million with a board member. At the first closing under the SPA, which occurred on October 25, 2023, we
issued to the investors (i) senior secured convertible promissory notes in the aggregate principal amount of $612,000 for an aggregate
purchase price of $566,667 and (ii) warrants to purchase 83,714 shares of our common stock in the aggregate. At the second closing under
the SPA, which occurred on November 28, 2023, we issued to the investors referenced above, (i) additional notes in the aggregate principal
amount of $1,224,000 for an aggregate purchase price of $1,133,333 and (i) additional warrants to purchase 167,427 shares of the common
stock in the aggregate. The notes matured on April 25, 2024 and May 28, 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
combined notes are subject to an original issue discount of 8%, have a term of six months from their respective date of issuance and
accrue interest at the rate of 6.0% per annum. The notes are convertible into common stock, at a per share conversion price equal to
$23.51. Beginning ninety days following issuance of the notes at the first closing and second closing, respectively, we are obligated
to redeem monthly one third of the original principal amount under the applicable note, plus accrued but unpaid interest, liquidated
damages and any other amounts then owing to the holder of such note. We are required to pay the redemption amount in cash with a premium
of 10% or, at the election of the investor at any time, some or all of the principal amount and interest may be paid by conversion of
shares under the note into common stock based on a conversion price equal to $23.51. Conversions and repayments of principal and interest
on the notes in January and February 2024 totaled $1.7 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrants have an exercise price of $23.51 and are exercisable for five years following issuance on each of the first and second closing
dates under the SPA. Warrants for 88,261 shares of common stock were exercised in January 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 67; Value: 65 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2023
May Offering</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 12, 2023, we completed a public offering of an aggregate of 120,059 shares of its common stock at par value $0.0001 per share (including
pre-funded warrants in lieu thereof), Series A-1 warrants to purchase up to 120,059 shares of common stock and Series A-2 warrants to
purchase up to 120,059 shares of common stock, at a combined public offering price of $58.31 per share (or pre-funded warrant in lieu
thereof) and accompanying warrants. The Series A-1 warrants have an exercise price of $54.60 per share, are exercisable immediately upon
issuance and expire five years from the date of issuance, and the Series A-2 warrants have an exercise price of $54.60 per share, are
exercisable immediately upon issuance and expire eighteen months from the date of issuance. <span style="background-color: white">A holder
of a warrant issued in the offering will not have the right to exercise any portion of its warrants if the holder, together with its
affiliates, would beneficially own in excess of 4.99% (or 9.99% at the election of the holder prior to the date of issuance) of the number
of shares of Common Stock outstanding immediately after giving effect to such exercise; provided, however, that upon 61 days&#8217; prior
notice us, the holder may increase or decrease the beneficial ownership limitation, provided that in no event shall the beneficial ownership
limitation exceed 9.99%.</span> Gross proceeds from this offering are approximately $7.0 million before the deduction of placement agent
fees and related costs of $0.7 million. The Series A-1 and Series A-2 warrants were repriced to $19.65 per share and exercised in February
2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.C.
Wainwright &amp; Co. acted as the exclusive placement agent for the offering. We also registered warrants issued to the placement agent
to purchase 8,404 shares of common stock at a per share exercise price of $72.882, which is 125% of the price of the shares in the offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the offering, we amended certain existing warrants to purchase up to an aggregate of 14,006 shares of our common stock
that were previously issued in September 2021 through December 2022 to purchasers in the offering at exercise prices ranging from $252.00
to $2,808.00 per share, such that the amended warrants have a reduced exercise price of $54.60 per share, at an additional offering price
of $1.875 per amended warrant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2023
February Offering</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 2, 2023, we entered into a definitive Securities Purchase Agreement with certain institutional investors , pursuant to which
we agreed to issue and sell in a registered direct offering, priced &#8220;at-the-market&#8221; under the rules of The Nasdaq Stock Market,
an aggregate of 19,842 shares of our common stock, par value $0.0001 per share, at an offering price of $151.2 per share, for gross proceeds
of approximately $3.0 million before the deduction of placement agent fees and related costs of $0.3 million. The closing of the Offering
occurred on February 6, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
a concurrent private placement, we issued to the institutional investors, for each share of common stock purchased in the offering, a
common warrant to purchase one share of common stock. The common warrants are exercisable immediately upon issuance and terminate five
and one-half years following issuance. The common warrants have an exercise price of $128.70 per share and are exercisable to purchase
an aggregate of up to 19,842 shares of Common Stock and expire on August 7, 2028. A holder of a common warrant will not have the right
to exercise any portion of its warrants if the holder, together with its affiliates, would beneficially own in excess of 4.99% (or 9.99%
at the election of the holder prior to the date of issuance) of the number of shares of common stock outstanding immediately after giving
effect to such exercise; provided, however, that upon 61 days&#8217; prior notice to us, the holder may increase or decrease the beneficial
ownership limitation, provided that in no event shall the beneficial ownership limitation exceed 9.99%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.C.
Wainwright &amp; Co. acted as the exclusive placement agent (the &#8220;<i>Placement Agent</i>&#8221;) for the offering. We issued placement
agent warrants to purchase up to 1,389 shares of common stock to the Placement Agent (including its designees). These warrants have an
exercise price equal to $189.00 per share and are exercisable for five years from the commencement of sales in the offering. The common
warrants and placement agent warrants and the shares of our common stock issuable upon the exercise of the common warrants and placement
agent warrants are not being registered under the Securities Act of 1933, as amended, are not being offered pursuant to the Registration
Statement, and are being offered pursuant to the exemption provided in Section 4(a)(2) under the Securities Act of 1933 and Rule 506(b).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the Securities Purchase Agreement, we agreed not to issue, enter into any agreement to issue or announce the issuance or proposed issuance
of any shares of common stock or any securities convertible into or exercisable or exchangeable for Common Stock for a period of 30 days
following the closing of the offering. Our officers and directors agreed, subject to limited exceptions, for a period of 90 days after
the closing of the offering, to not offer, sell, contract to sell, hypothecate, pledge or otherwise dispose of, directly or indirectly,
or establish or increase a put equivalent position or liquidate or decrease a call equivalent position within the meaning of Section
16 of the Securities Exchange Act of 1934, as amended, with respect to, any shares of common stock or securities convertible, exchangeable
or exercisable into, shares of common stock beneficially owned, held or thereafter acquired by them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 68; Value: 65 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2022
December Offering</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 7, 2022, we entered into an underwriting agreement with Lake Street Capital Management, LLC (the &#8220;<i>Underwriter</i>&#8221;),
pursuant to which we agreed to issue and sell (i) 12,667 shares of our common stock, par value $0.0001 per share, (ii) pre-funded warrants
to purchase 3,445 shares of common stock and (iii) warrants to purchase 32,223 shares of common stock to the Underwriter in a public
offering. In addition, we granted the Underwriter the option, for 45 days from the closing of the offering, to purchase up to 1,900 additional
shares of common stock and common warrants to purchase up to an additional 4,834 shares of common stock. The Underwriter agreed to purchase
our shares pursuant to at a price of $234.30 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
lieu of a purchase of common stock that would otherwise result in an investor&#8217;s beneficial ownership exceeding 4.99% (or, at the
election of the investor, 9.99%) of the outstanding common stock, a pre-funded warrant was offered, each of which enables the investor
to purchase one share of common stock at an exercise price of $0.0001. Each pre-funded warrant was exercisable upon issuance and will
expire when exercised in full (all pre-funded warrants were exercised immediately upon issuance). Each pre-funded warrant was sold with
a common warrant to purchase two shares of common stock. The public purchase price of one share of common stock and accompanying common
warrant to purchase two shares of Common Stock is $252.00 and the combined purchase price of one pre-funded warrant and accompanying
common warrant to purchase two shares of common stock is $252.00.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
common warrant is exercisable immediately at an exercise price of $252.00 per share and will expire five years following the date of
issuance. The offering closed on December 9, 2022 and we received aggregate gross proceeds of approximately $4.1 million from the Offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2022
Notes</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2022, we entered into an $8.0 million convertible financing agreement with institutional investors. The agreement provided for
two closings, each for notes payable of $4.24 million (resulting in gross cash proceeds of $4.0 million). Funds were received for the
first closing on July 1, 2022 and for the second closing on August 9, 2022. The remaining amount of principal and interest on the 2022
Notes was repaid in the first quarter of 2023. We were obligated under the 2022 Notes to pay additional cash as true-up payments for
interest or redemption amounts that we paid in shares of common stock that were valued below $361.05 or the lower conversion price of
$135.15 in effect between January 12, 2023 and May 12, 2023. The true-up payments compensate the holder for the difference between the
value of a share and the conversion price in effect at the time of redemption, multiplied by the number of shares paid. The true-up payments
totaling $0.6 million were paid on May 12, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with each of the first and second closings of the 2022 Notes we also issued warrants to purchase 2,594 shares of our common
stock. The warrants have a current exercise price of $54.60 and are exercisable for five years following issuance of the 2022 Notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Components
of Our Operating Results</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenue</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have generated limited revenue since our inception and we do not expect to generate any revenue from the sale of products in the near
future, if at all. If our development efforts are successful and we commercialize our products, or if we enter into collaboration or
license agreements with third parties, we may generate revenue in the future from product sales, as well as upfront, milestone and royalty
payments from such collaboration or license agreements, or a combination thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have received funding under federal grants from the National Institutes of Health (&#8220;NIH&#8221;) through the National Institute
on Drug Abuse (&#8220;NIDA&#8221;). In September 2018 and August 2024, we were awarded a research and development grant related to the
development of our MPAR&#174; overdose prevention technology (the &#8220;MPAR Grant&#8221;). In September 2019, we were awarded a second
research and development grant related to the development of our TAAP/MPAR&#174; abuse deterrent technology for Opioid Use Disorder (&#8220;OUD&#8221;)
(the &#8220;OUD Grant&#8221;). Grant funds are awarded annually through a Notice of Award which contains certain terms and conditions
including, but not limited to, complying with the grant program legislation, regulation and policy requirements, complying with conditions
on expenditures of funds with respect to other applicable statutory requirements such as the federal appropriations acts, periodic reporting
requirements, and budget requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 69; Value: 65 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Operating
Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses consist primarily of costs incurred for research activities, including drug discovery efforts and the development
of our product candidates. We expense research and development costs as incurred, which include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses
    incurred to conduct the necessary preclinical studies and clinical trials required to obtain regulatory approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses
    incurred under agreements with CROs that are primarily engaged in the oversight and conduct of our drug discovery efforts and preclinical
    studies, clinical trials and CMOs that are primarily engaged to provide preclinical and clinical drug substance and product for our
    research and development programs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    costs related to acquiring and manufacturing materials in connection with our drug discovery efforts and preclinical studies and
    clinical trial materials, including manufacturing validation batches, as well as investigative sites and consultants that conduct
    our clinical trials, preclinical studies and other scientific development services;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">payments
    made in cash or equity securities under third-party licensing, acquisition and option agreements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">employee-related
    expenses, including salaries and benefits, travel and stock-based compensation expense for employees engaged in research and development
    functions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    related to compliance with regulatory requirements; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">allocated
    facilities-related costs, depreciation and other expenses, which include rent and utilities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognize external development costs as incurred. Any advance payments that we make for goods or services to be received in the future
for use in research and development activities are recorded as prepaid expenses. Such amounts are expensed as the related goods are delivered
or the related services are performed, or until it is no longer expected that the goods will be delivered or the services rendered. We
estimate and accrue for the value of goods and services received from CROs and other third parties each reporting period based on an
evaluation of the progress to completion of specific tasks using information provided to us by our service providers. This process involves
reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf
and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or
otherwise notified of actual costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not track our research and development expenses on a program-by-program basis. Our direct external research and development expenses
consist primarily of external costs, such as fees paid to outside consultants, CROs, CMOs and research laboratories in connection with
our preclinical development, process development, manufacturing and clinical development activities. We do not allocate employee costs,
costs associated with our discovery efforts, laboratory supplies, and facilities, including depreciation or other indirect costs, to
specific programs because these costs are deployed across multiple programs and, as such, are not separately classified. We use internal
resources primarily to conduct our research and development as well as to manage our preclinical development, process development, manufacturing
and clinical development activities. These employees work across multiple programs and, therefore, we do not track our costs by program
and cannot state precisely the total costs incurred for each of our clinical and preclinical programs on a project-by-project basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 70; Value: 65 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development activities are central to our business model. Product candidates in later stages of clinical development generally have
higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage
clinical trials. As a result, we expect that our research and development expenses will remain elevated as we continue our existing,
and commence additional, planned clinical trials for PF614, PF614-MPAR&#174; and nafamostat, as well as conduct other preclinical and
clinical development, including submitting regulatory filings for our other product candidates, subject to our ability to obtain financing.
We also expect our related personnel costs to increase and, as a result, we expect our research and development expenses, including costs
associated with stock-based compensation, to remain elevated. In addition, we may incur additional expenses related to milestone and
royalty payments payable to third parties with whom we may enter into license, acquisition and option agreements to acquire the rights
to future product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the preclinical
and clinical development of any of our product candidates or when, if ever, material net cash inflows may commence from any of our product
candidates. The successful development and commercialization of our product candidates are highly uncertain. This uncertainty is due
to the numerous risks and uncertainties associated with product development and commercialization, including the uncertainty of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, progress, outcome and costs of our preclinical development activities, clinical trials and other research and development
    activities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    an appropriate safety and efficacy profile with investigational new drug (&#8220;<i>IND</i>&#8221;) enabling studies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successful
    patient enrollment in and the initiation and completion of clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing, receipt and terms of any marketing approvals from applicable regulatory authorities including the FDA and non-U.S. regulators;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent of any required post-marketing approval commitments to applicable regulatory authorities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    clinical and commercial manufacturing capabilities or making arrangements with third-party manufacturers in order to ensure that
    we or our third-party manufacturers are able to make product successfully;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">development
    and timely delivery of clinical-grade and commercial-grade drug formulations that can be used in our clinical trials and for commercial
    launch;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining,
    maintaining, defending and enforcing patent claims and other intellectual property rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    and changing government regulation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">launching
    commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining
    a continued acceptable safety profile of our product candidates following approval, if any, of our product candidates.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
changes in the outcome of any of these variables with respect to the development of our product candidates in preclinical and clinical
development could mean a significant change in the costs and timing associated with the development of these product candidates. For
example, if the FDA or another regulatory authority were to delay our planned start of clinical trials or require us to conduct clinical
trials or other testing beyond those that we currently expect or if we experience significant delays in enrollment in any of our planned
clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development
of that product candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 71; Value: 65 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of employee-related expenses, including salaries and related benefits, travel and stock-based
compensation for personnel in executive, business development, finance, human resources, legal, information technology, and administrative
functions. General and administrative expenses also include direct and allocated facility-related costs as well as insurance costs and
professional fees for legal, patent, consulting, investor and public relations, accounting and audit services. We expense general and
administrative costs as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support the continued
development of our product candidates, subject to our ability to obtain financing. We also anticipate that we will continue to incur
significant accounting, audit, legal, regulatory, compliance and director and officer insurance costs as well as investor and public
relations expenses. Additionally, if and when we believe a regulatory approval of a product candidate appears likely, we anticipate an
increase in payroll and other employee-related expenses as a result of our preparation for commercial operations, especially as it relates
to the sales and marketing of that product candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Income (Expense)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Change
in fair value of convertible notes</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2022 Notes were accounted for under ASC 480 &#8211; <i>Distinguishing Liabilities from Equity, </i>due to share settlement features contained
within the notes. We used a discounted cash flow model and a Monte Carlo simulation to estimate the fair value of the notes, both of
which rely on unobservable Level 3 inputs. Changes in the fair value of the notes are recognized through earnings for each reporting
period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<!-- Field: Page; Sequence: 72; Value: 65 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Change
in fair value of liability classified warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
use a Black-Scholes option pricing model to estimate the fair value of the warrants. Changes in the fair value of the warrants are recognized
through earnings for each reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Interest
Expense</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
expense consists of interest accrued on our financed directors&#8217; and officers&#8217; insurance, and interest from the 2023 Notes
based on the stated interest rate. In addition, the 2023 Notes reflects amortization of the debt discount from the original issuance
and a discount associated with the warrant issuances and amortization of the associated debt issuance costs that are all recorded as
interest expense. Interest expense related to the 2022 Notes was included in the estimate of fair value of the convertible notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Provision
for Income Taxes</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not recorded any significant amounts related to income tax expense, we have not recognized any reserves related to uncertain tax
positions, nor have we recorded any income tax benefits for the majority of our net losses we have incurred to date or for our research
and development tax credits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities
for the expected future tax consequences of events that have been included in the financial statements or our tax returns. Deferred tax
assets and liabilities are determined based on difference between the financial statement carrying amounts and tax bases of existing
assets and liabilities and for loss and credit carryforwards, which are measured using the enacted tax rates and laws in effect in the
years in which the differences are expected to reverse. The realization of our deferred tax assets is dependent upon the generation of
future taxable income, the amount and timing of which are uncertain. Valuation allowances are provided, if, based upon the weight of
available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of December 31, 2024
and 2023, we continue to maintain a full valuation allowance against all of our deferred tax assets based on our evaluation of all available
evidence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning
in 2022, the Tax Cuts and Jobs Act, or the Tax Act, eliminated the option to deduct research and development expenditures currently and
requires taxpayers to capitalize and amortize them over five or fifteen years pursuant to Internal Revenue Code Section 174. This has
not impacted our effective tax rate or our cash tax payable in 2024; however, if the requirement to capitalize Section 174 expenditures
is not modified, it may also impact our effective tax rate and our cash tax liability in future years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
file income tax returns in the United States federal tax jurisdiction and state jurisdictions and may become subject to income tax audit
and adjustments by related tax authorities. Our tax return period for United States federal income taxes for the tax years since 2021
remain open to examination under the statute of limitations by the Internal Revenue Service and state jurisdictions. We record reserves
for potential tax payments to various tax authorities related to uncertain tax positions, if any. The nature of uncertain tax positions
is subject to significant judgment by management and subject to change, which may be substantial. These reserves are based on a determination
of whether and how much a tax benefit taken by us in our tax filings or whether our position is more likely than not to be realized following
the resolution of any potential contingencies related to the tax benefit. We develop our assessment of uncertain tax positions, and the
associated cumulative probabilities, using internal expertise and assistance from third-party experts. As additional information becomes
available, estimates are revised and refined. Differences between estimates and final settlement may occur resulting in additional tax
expense. Potential interest and penalties associated with such uncertain tax positions is recorded as a component of our provision for
income taxes. To date, no amounts are being presented as an uncertain tax position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<!-- Field: Page; Sequence: 73; Value: 65 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our results of operations for the years ended December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Results
of Operations</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Comparison
of the Years ended December 31, 2024 and 2023</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    Ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Change</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Federal
    grants</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,210,031</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,230,520</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,979,511</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating
    expenses:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research
    and development</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,219,437</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,587,473</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(368,036</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">General
    and administrative</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,720,728</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,361,234</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(640,506</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Total
    operating expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,940,165</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,948,707</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,008,542</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Loss
    from operations</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(6,730,134</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(10,718,187</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,988,053</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other
    income (expense):</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Loss
    on conversions and change in fair value of convertible notes</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">146,479</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(146,479</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Change
    in fair value of liability classified warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">16,292</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">283,958</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(267,666</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Interest
    expense</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,290,444</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(353,945</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(936,499</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Other
    income and expense, net</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,277</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,420</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,857</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Total
    other income (expenses), net</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,256,875</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">91,912</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,348,787</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(7,987,009</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(10,626,275</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,639,266</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    loss attributable to noncontrolling interests</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(74</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(13,201</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,127</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Deemed
    dividend related to warrants down round provision</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">290</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,937</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(12,647</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net
    loss attributable to common stockholders</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(7,987,225</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(10,626,011</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,638,786</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Federal
Grants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
from federal grants totaled $5.2 million for the year ended December 31, 2024, compared to $2.2 million for the year ended December 31,
2023, respectively. The $3.0 million difference is due to the timing of research activities eligible for funding, with increased activities
under the OUD grant following the selection of a lead drug candidate in June 2024 and funding under the newly awarded MPAR grant which
began in September 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses were $7.2 million for the year ended December 31, 2024, compared to $7.6 million for the year ended December
31, 2023, respectively, representing a decrease of $0.4 million. The decrease was primarily the result of reduced external research and
development costs related to clinical and pre-clinical programs for PF614 and PF614-MPAR, with decreased clinical trial activity for
both programs in the 2024 period. We do not currently track expenses on a program-by-program basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses were $4.7 million for the year ended December 31, 2024, compared to $5.4 million for the year ended December
31, 2023 respectively, representing a decrease of $0.6 million. The decrease was primarily a result of reduced stock-based compensation
expenses. We expect future general and administrative expenses to approximate current levels.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 74; Value: 65 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Income and Expense</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
income and expense for the year ended December 31, 2024, consisted primarily of interest expense associated with the amortization of
the original issue discount and the debt issuance costs for the 2023 Notes and represented a net change in other income and expense of
$1.3 million compared to the year ended December 31, 2023. The comparative period for 2023 consisted primarily of changes in fair value
associated with the 2022 Notes and the liability-classified warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sources
of Liquidity and Capital</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, we had $3.5 million of cash and cash equivalents. Since inception, we have generated limited revenues and have
incurred significant operating losses and negative cash flows from our operations, and we anticipate that we will continue to incur losses
for at least the foreseeable future. We have not yet commercialized any of our product candidates and we do not expect to generate revenue
from sales of any product candidates for several years, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have funded our operations to date primarily with proceeds from the sale of common equity, funding under federal research grants and
borrowings under convertible promissory notes. To fund future operations, we will need to raise additional capital. The amount and timing
of future funding requirements will depend on many factors, including the timing and results of our ongoing research and development
efforts and related general and administrative support. We anticipate that we will fund our operations through public or private equity
or debt financings or other sources, such as potential collaboration agreements. We cannot make assurances that anticipated additional
financing will be available to us on favorable terms, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
remaining cash funding under the MPAR federal research grant totaled $10.6 million at December 31, 2024 and is expected to be utilized
by May 31, 2027. Pursuant to the terms and conditions, we are required to submit progress reports to NIDA on an annual basis and a final
research performance progress report within 120 days of the performance period end date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going
Concern</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have generated limited revenues and have incurred significant operating losses since our inception. We expect to continue to incur significant
expenses and operating losses for the foreseeable future. Without capital raised through financing transactions, existing cash resources
are sufficient to allow us to fund current planned operations into the second quarter of 2025, which raises substantial doubt about our
ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
additional information on risks associated with our substantial capital requirements, please read the section titled &#8220;<i>Risk Factors</i>&#8221;
included elsewhere in this Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 75; Value: 65 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
Flows for the years ended December 31, 2024 and 2023</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our cash flows for each of the periods presented:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ended December&#160;&#160;31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    cash used in operating activities</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7,502,700</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10,779,982</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    cash provided by financing activities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,881,173</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,755,884</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    increase (decrease) in cash and cash equivalents</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,378,473</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,024,098</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Operating
Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2024 and 2023, we used cash in operating activities of $7.5 million and $10.8 million, respectively. The
decrease primarily resulted from additional revenue cash inflow from grant funding and a reduction in research and development activities
in 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Financing
Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, net cash provided by financing activities was $9.9 million, primarily consisting of net proceeds from
the August 2024 public offering $1.7 million, warrant exercises and warrant inducements of $9.1 million, net of transaction costs, less
repayment of convertible notes of $0.5 million and financed insurance premiums of $0.4 million. During the year ended December 31, 2023,
net cash provided by financing activities was $8.8 million, primarily consisting of net proceeds from 2023 February and 2023 May offerings
of $8.7 million and net proceeds from 2023 Notes of $1.6 million, less the repayment of financed insurance premiums of $0.5 million and
cash payment of 2022 Notes of $1.0 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Funding
Requirements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
primary use of cash is to fund operating expenses, primarily related to our research and development activities. Cash used to fund operating
expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable, accrued
expenses and prepaid expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect our expenses, excluding non-cash expenses to recognize the fair value of warrants and convertible notes, to remain elevated in
connection with our ongoing activities, particularly as we advance the preclinical activities and clinical trials of our product candidates.
In addition, upon the completion of the Merger, we have incurred, and will continue to incur, additional costs associated with operating
as a public company, including significant legal, accounting, insurance, investor relations and other expenses. The timing and amount
of our operating expenditures will depend largely on our ability to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">advance
    preclinical development of our early-stage programs and clinical trials of our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacture,
    or have manufactured on our behalf, our preclinical and clinical drug material and develop processes for late state and commercial
    manufacturing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
    regulatory approvals for any product candidates that successfully complete clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
    a sales, marketing, medical affairs and distribution infrastructure to commercialize any product candidates for which we may obtain
    marketing approval and intend to commercialize on our own;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire
    additional clinical, quality control and scientific personnel;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<!-- Field: Page; Sequence: 76; Value: 65 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expand
    our operational, financial and management systems and increase personnel, including personnel to support our clinical development,
    manufacturing and commercialization efforts and our operations as a public company;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain,
    maintain, expand and protect our intellectual property portfolio;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manage
    the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights,
    including enforcing and defending intellectual property related claims; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manage
    the costs of operating as a public company.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Commitments</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commitments as of December 31, 2024 included an estimated $12.0 million related to open purchase orders and contractual obligations that
occurred in the ordinary course of business, including commitments with contract research organizations for multi-year pre-clinical and
clinical research studies. Although open purchase orders are considered enforceable and legally binding, the terms generally allow us
the option to cancel, reschedule, and adjust requirements based on our business needs prior to the delivery of goods or the performance
of services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Working
Capital</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the numerous risks and uncertainties associated with research, development and commercialization of biologic product candidates, we
are unable to estimate the exact amount of our working capital requirements. Our future funding requirements will depend on and could
increase significantly as a result of many factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, progress, results and costs of researching and developing our product candidates, and conducting preclinical and clinical
    trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs, timing and outcome of regulatory review of our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs, timing and ability to manufacture our product candidates to supply our clinical and preclinical development efforts and our
    clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of future activities, including product sales, medical affairs, marketing, manufacturing and distribution, for any of our product
    candidates for which we receive marketing approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of manufacturing commercial-grade product and necessary inventory to support commercial launch;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability to receive additional non-dilutive funding, including grants from organizations and foundations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    revenue, if any, received from commercial sale of our products, should any of our product candidates receive marketing approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of preparing, filing and prosecuting patent applications, obtaining, maintaining, expanding and enforcing our intellectual
    property rights and defending intellectual property-related claims;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to establish and maintain collaborations on favorable terms, if at all; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent to which we acquire or in-license other product candidates and technologies.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.25in"></p>

<!-- Field: Page; Sequence: 77; Value: 65 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies and Significant Judgments and Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
consolidated financial statements are prepared in accordance with GAAP. The preparation of our consolidated financial statements and
related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses.
We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under
the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that
are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ
from these estimates under different assumptions or conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
our significant accounting policies are described in more detail in Note 3 to our audited consolidated financial statements, we believe
that the following accounting policy is the most critical to the judgments and estimates used in the preparation of our consolidated
financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Accrued
Research and Development Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development
expenses. This process involves reviewing open contracts and purchase orders, communicating with our applicable personnel to identify
services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the
service when it has not yet been invoiced or otherwise notified of actual costs. Many of our service providers invoice us in arrears
for services performed, on a pre-determined schedule or when contractual milestones are met; however, some require advance payments.
We make estimates of our accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances
known to us at that time. We periodically confirm the accuracy of the estimates with the service providers and adjust if necessary. Examples
of estimated accrued research and development expenses include fees paid to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">vendors,
    including research laboratories, in connection with preclinical development activities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CROs
    and investigative sites in connection with preclinical studies and clinical trials; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CMOs
    in connection with drug substance and drug product formulation of preclinical studies and clinical trial materials.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
base our expenses related to preclinical studies and clinical trials on our estimates of the services received and efforts expended pursuant
to quotes and contracts with multiple research institutions and CROs that supply, conduct and manage preclinical studies and clinical
trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result
in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and
result in a prepayment of the expense. Payments under some of these contracts depend on factors such as the successful enrollment of
patients and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which services will
be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level
of effort varies from the estimate, we adjust the accrual or the prepaid expense accordingly. Although we do not expect our estimates
to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative
to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any
period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Off-Balance
Sheet Arrangements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have during the periods presented, and do not currently have, any off-balance sheet arrangements, as defined in the rules and
regulations of the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 78; Value: 65 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recently
Issued Accounting Pronouncements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations
is disclosed in Note 3 to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Smaller
Reporting Company Status</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a &#8220;smaller reporting company&#8221; as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage
of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We
will remain a smaller reporting company until the last day of the fiscal year in which (i) the market value of our common stock held
by non-affiliates exceeds $250 million as of the prior June 30, or (ii) our annual revenues exceeded $100 million during such completed
fiscal year and the market value of our common stock held by non-affiliates exceeds $700 million as of the prior June 30.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Aa_001"></span>Item
7A. Quantitative and Qualitative Disclosure About Market Risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to market risk in the ordinary course of our business. These risks primarily relate to changes in interest rates and inflation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Interest
Rate Risk</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
cash and cash equivalents as of December 31, 2024, consisted of cash and a money market fund account. Because of the short-term nature
of our money market fund, a sudden change in market interest rates would not be expected to have a material impact on our financial position
or results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Inflation
Risk</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not believe that inflation and changing prices had a significant impact on our results of operations for any periods presented herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Aa_002"></span>Item
8. Financial Statements and Supplementary Data</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements required by this Item are included in Item 15 of this report and are presented beginning on page F-1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Aa_003"></span>Item
9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Aa_004"></span>Item
9A. Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Evaluation
of Disclosure Controls and Procedures</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports that we file or submit
under the Securities Exchange Act of 1934 as amended (the &#8220;Exchange Act&#8221;) is recorded, processed, summarized and reported
within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to our
management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required
disclosure. Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness
of our disclosure controls and procedures (as defined in Exchange Act Rule 13a&#8211;15(e) and 15d-15(e)) as of December 31, 2024. Based
on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company&#8217;s disclosure controls and
procedures were effective as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 79; Value: 65 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Management&#8217;s
Annual Report on Internal Control over Financial Reporting</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management is responsible for establishing and maintaining adequate internal control over our financial reporting. Internal control over
financial reporting is defined in Rule 13a-15(f) under the Exchange Act as a process designed by, or under the supervision of, the company&#8217;s
executive and financial officers and effected by the company&#8217;s board of directors, management and other personnel, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes and includes
those policies and procedures that (a) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect
the transactions and dispositions of the assets of the company; (b) provide reasonable assurance that transactions are recorded as necessary
to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures
of the company are being made only in accordance with authorizations of management and directors of the company; and (c) provide reasonable
assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company&#8217;s assets that
could have a material effect on the financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements, errors, or fraud. Also,
projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because
of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, our management assessed the effectiveness of our internal control over financial reporting using the criteria set
forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework (2013)
(the &#8220;2013 Framework&#8221;). In adopting the 2013 Framework, management assessed the applicability of the principles within each
component of internal control and determined whether they have been adequately addressed within the current system of internal control
and adequately documented. Based on this assessment, management, under the supervision and with the participation of our Chief Executive
Officer and Chief Financial Officer, concluded that, as of December 31, 2024, our internal control over financial reporting was effective
based on these criteria.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm regarding internal
control over financial reporting. As a smaller reporting company, we were not required to have, nor have we, engaged our independent
registered public accounting firm to perform an audit of internal control over financial reporting pursuant to SEC rules that permit
us to provide only management&#8217;s report in this Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Changes
in Internal Control Over Financial Reporting</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the
Exchange Act) during the quarter ended December 31, 2024 that have materially affected, or are reasonably likely to materially affect,
our internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Aa_005"></span>Item
9B. Other Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Aa_006"></span>Item
9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 80; Value: 65 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Aa_007"></span>PART
III</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Aa_008"></span>Item
10. Executive Officers and Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following persons are our executive officers and directors:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age*</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Executive
    Officers</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 38%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lynn
    Kirkpatrick, Ph.D.**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President,
    Chief Executive Officer and Class III Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Geoffrey
    Birkett</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Commercial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Humphrey</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer, Secretary and Treasurer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey
    Millard, Ph.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Operating Officer (consultant)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Linda
    Pestano, Ph.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Development Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">William
    Schmidt, Ph.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Medical Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Directors**</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Andrew
    Benton, J.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class
    I Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">William
    Chang</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class
    I Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bob
    Gower, Ph.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">87</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class
    II Director and Chairman of the Board</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adam
    S. Levin, M.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class
    III Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve
    R. Martin</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class
    III Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lee
    Rauch</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class
    I Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Curtis
    Rosebraugh, M.D., MPH</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class
    II Director</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*Ages
presented as of December 31, 2024</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**
Information about Dr. Kirkpatrick is set forth under &#8220;Executive Officers&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Information
about our Executive Officers and Directors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Executive
Officers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Lynn
Kirkpatrick, Ph.D. </i></b>has served as our Chief Executive Officer since January 2009. Dr. Kirkpatrick has spent over 30 years in drug
discovery and development, has initiated the clinical development of four novel drug candidates and now strives to bring highly novel
and safe pain therapies to commercialization. She received a Doctor of Philosophy (&#8220;<i>Ph.D.</i>&#8221;) degree in Medicinal and
Biomedicinal Chemistry at the University of Saskatchewan, completed a Post-Doctoral Fellowship at the Yale University School of Medicine,
and became a tenured full professor in the Department of Chemistry at the University of Regina. She co-founded ProlX Pharmaceuticals,
Corp. (&#8220;<i>ProlX</i>&#8221;) an oncology discovery company, becoming Chief Executive Officer and successfully bringing three small
molecules from discovery into clinical development, two of these her own discoveries from academia. ProlX was acquired by Biomira Inc.,
and Dr. Kirkpatrick became the Chief Scientific Officer of the merged company to focus on the development of oncology products and vaccines.
In 2009, she co-founded PHusis Therapeutics, developing targeted small molecule precision medicines for oncology. At the same time, she
became our Chief Executive Officer. Dr. Kirkpatrick has published extensively in the area of targeted drug discovery, abuse deterrent
pain products and holds numerous patents for novel drugs and modalities. We believe Dr. Kirkpatrick is qualified to serve on our Board
because of her extensive executive experience in our industry and her service as our Chief Executive Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Geoffrey
Birkett </i></b>has served as our Chief Commercial Officer since October 2018. He has over 30 years of experience in the Pharmaceutical
and Biotechnology area. He started his career as a biochemist at the Royal Victoria Infirmary in Newcastle-upon-Tyne, England. He then
moved into the pharmaceutical industry, where he focused on pain/addiction and neuroscience throughout his career. He has developed and
launched several groundbreaking therapies, including Nicorette (POM) and (OTC), Lexapro and several other psychiatry agents with Lundbeck.
Mr. Birkett assisted on the launch of Prozac and Humatrope (human growth hormone) with Eli Lilly. He assisted in moving Seroquel from
Phase 2 to global market leader with multi-billion dollar sales and he also participated in the launch of Zomig for migraines, which
became a European market leader. He worked for most of his pharmaceutical career at AstraZeneca plc in both the United Kingdom and the
United States, where he held many roles including overseeing the global oncology division. When the AstraZeneca merger took place, Mr.
Birkett ran the merger process outside the United States across all markets, and ran a corporate change program to streamline research
and development involving 67,000 staff. Since leaving AstraZeneca, Mr. Birkett has held multiple roles in biotech companies as senior
officer or as a consultant. He is co-founder of a novel drug delivery company and has consulted for IPSOS, a large global research and
consulting firm. He also served as president for North America/Canada of INDIVIOR, a large company producing addiction treatment drugs.
Mr. Birkett joined us in 2018 and is focused on building a world class commercial team. Mr. Birkett attended Henley Business College
in London and INSEAD Business School in France where he studied general management and global leadership.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 81; Value: 65 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>David
Humphrey </i></b>has served as our Chief Financial Officer since February 2021. Prior to joining the Company, Mr. Humphrey was most recently
Chief Financial Officer of Senomyx, Inc. (&#8220;Senomyx&#8221;), a publicly held biotechnology company focused on taste science. In
his previous employment, he guided public company financial reporting, including Forms 10-K, 10-Q, 8-K, S-3, S-8, proxy statements and
SOX internal controls compliance, and acted as primary liaison with the audit committee and external auditors. Mr. Humphrey advised Senomyx&#8217;s
board of directors, as part of core executive management team, in a $75 million acquisition by Firmenich SA, a private Swiss multinational
flavor and fragrance company. Previously, he held finance and accounting leadership positions and consulted at numerous life sciences
companies, including ActivX Biosciences, Aurora Biosciences and Gensia. Mr. Humphrey started his career as an accountant at Price Waterhouse.
He holds a Bachelor of Science with Honors in Accountancy from the University of Illinois at Urbana-Champaign and is a Certified Public
Accountant (inactive) in California.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Jeffrey
Millard, Ph.D. </i></b>has served as our Chief Operating Officer since January 2019. Dr. Millard has both academic and industrial experience
in chemistry and pharmaceutical sciences covering all aspects of chemistry, manufacturing, and controls, or CMC. He has been involved
in both start-up biotech as well as small and mid-sized public biopharmaceutical companies. Dr. Millard has been directly responsible
for research and development activities and writing of more than seven IND submissions and Investigational Medicinal Product Dossiers,
or IMPDs. He has directed the CMC efforts from discovery and in-licensing through commercial launch activities. His experience covers
the application programming interface, or API, lifecycle (from synthetic route scouting, process chemistry, analytical chemistry development
and validation, cGMP production and release of API, to QbD and process validation), and drug product development through manufacture.
Dr. Millard received a Bachelor of Arts from Rice University and a Ph.D. in Pharmaceutical Sciences from the University of Arizona.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Linda
Pestano, Ph.D.</i></b> joined Ensysce in October 2021, as Chief Development Officer. Dr. Pestano has worked throughout her career to
guide the development of novel therapeutics to improve patient outcomes and quality of life. She has 20 years of experience developing
vaccines, drugs and novel biologics for a diverse range of indications. She has been instrumental in guiding new therapies, including
small molecules, nucleic acids, and biologicals through development into clinical trials. Dr. Pestano&#8217;s expertise spans lead development,
pre-clinical and translational studies, and interacting with multiple regulatory agencies. Dr. Pestano received her PhD from Tufts University
and undertook a Post-Doctoral Fellowship with Dana Farber Cancer Institute at the Harvard Medical School in Boston.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>William
K. Schmidt, Ph.D</i></b>., has served as our Chief Medical Officer since January 2016. He is also the Head of NorthStar Consulting, the
Parliamentarian and a former president of the Eastern Pain Association, the largest regional affiliate of the American Pain Society.
He has over 25 years of pharmaceutical industry experience with a special emphasis on the discovery and development of novel analgesic
and narcotic antagonist drugs. He was previously Vice President of Clinical Development for CrystalGenomics (Seoul, South Korea) and
its United States subsidiary, CG Pharmaceuticals (Emeryville, CA); Senior Vice President of Development at Limerick BioPharma; Vice President,
Clinical Research, for Renovis, Inc.; and Vice President, Scientific Affairs and acting Vice President, Clinical Research and Development,
at Adolor Corporation. At Adolor Corporation, Dr. Schmidt was a key member of the team leading to the clinical development, NDA filing,
and FDA approval of Entereg&#174; (alvimopan), a peripherally acting opioid antagonist. Currently Dr. Schmidt serves as an expert on pain
medicine pharmaceutical development with pharmaceutical and biotech companies throughout North America, Europe, Asia, Latin America,
and Australia. Dr. Schmidt received a Bachelor of Arts degree from the University of California Berkeley and his Ph.D. from the University
of California-San Francisco.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Andrew
Benton, J.D.</i></b> has served as a member of our Board since December 2, 2019. Mr. Benton was the President, Chief Executive Officer
and Trustee of Pepperdine University from June 2000 to July 2019. Mr. Benton was the former chairman of both the American Council of
Education, the major coordinating body for all of the nation&#8217;s higher education institutions, and the National Association of Independent
Colleges and Universities. Mr. Benton is also past chair of the Association of Independent California Colleges and Universities and a
member of the American Bar Association, the Council for Higher Education Accreditation, the President&#8217;s Cabinet of the West Coast
Conference, the Association of Presidents of Independent Colleges and Universities, and the Los Angeles World Affairs Council. Mr. Benton
holds an undergraduate degree in American studies from Oklahoma Christian University and a J.D. from Oklahoma University. We believe
that Mr. Benton&#8217;s experience governing academic and other institutions qualifies him to serve on our Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 82; Value: 65 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>William
Chang</i></b> serves as Chief Executive Officer of Westlake Realty Group and Chairman of Westlake International Group where he has worked
for more than 40 years. Mr. Chang is an investor in the San Francisco Giants of Major League Baseball. Mr. Chang was the former Chairman
of U.S. Rugby Football Union. He also served on the Board of the Asia Foundation and San Francisco Port and Social Services Commissions.
Mr. Chang holds a Bachelor&#8217;s degree in Economics from Harvard University. We believe that Mr. Chang&#8217;s extensive business
experience and expertise in corporate governance qualifies him to serve on our Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Bob
Gower, Ph.D.</i></b> has served as our Chairman since 2008. Dr. Gower was Chief Executive Officer of Lyondell Petrochemical from 1985
through his retirement at the end of 1996. In 1997, he acquired businesses from Howell Corporation that became Specified Fuels and Chemicals.
Dr. Gower sold Specified in 2000 and, with Dr. Richard Smalley, founded Carbon Nanotechnologies, Inc. (&#8220;<i>CNI</i>&#8221;) that
same year to develop production capabilities and applications for single wall carbon nanotubes. CNI was acquired by Unidym in 2007. Dr.
Gower founded Ensysce in 2008. He has served on the Board of Directors of several public companies, including Kirby Corporation, OmNova
and Keystone. He also has been and continues to be involved with several not-for-profit organizations and has especially focused on Communities
In Schools Houston, a leading dropout prevention and mental health program, and on Southern Illinois University with focus on the chemistry
department. Dr. Gower received his B.S. from SIU and his Ph.D. from the University of Minnesota. We believe that Mr. Gower&#8217;s previous
board and industry experience qualifies him to serve on our Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Adam
S. Levin, MD</i></b> joined the Board in June 2021 and is the Vice Chair of Clinical Operations for the Department of Orthopaedic Surgery
at Johns Hopkins University, where he has been on faculty since 2014. He is an Associate Professor of Orthopaedic Surgery and Associate
Professor of Oncology, researching treatments related to musculoskeletal oncology, while also maintaining an active clinical practice.
Dr. Levin holds the Virginia M. Percy and William Algernon Percy Chair in Orthopaedic Surgery at Johns Hopkins University. He serves
in additional leadership roles related to billing, coding, and practice management for the Musculoskeletal Tumor Society, the American
Academy of Orthopaedic Surgeons, and the American Medical Association. Prior to joining Johns Hopkins University, Dr. Levin was an Assistant
Professor of Orthopaedic Surgery at the Zucker School of Medicine at Hofstra University in New York between 2012 and 2014. From 2010
to 2012, he was a fellow of musculoskeletal oncology and Clinical Instructor at Memorial Sloan-Kettering Cancer Center, following his
residency training at the North Shore/LIJ Health System (now Northwell Health) from 2005 to 2010. He has been a member of leadership
fellows programs through the North Shore/LIJ Physician High Potential Program, the American Academy of Orthopaedic Surgeons, and the
American Orthopaedic Association. Dr. Levin has also continued to serve as Associate Editor for CME for the Journal of Bone and Joint
Surgery since 2016, and is on the Steering Committee for the Musculoskeletal Tumor Registry. Dr. Levin served as a subject-matter consultant
to our predecessor, LACQ, during their initial review of our preclinical and Phase I clinical trial results. Dr. Levin holds a B.S. in
Biology with a concentration in Animal Physiology from Cornell University, an M.D. from New York Medical College, and is currently studying
at the Johns Hopkins University Carey School of Business for an M.B.A. with a specialization in Healthcare Management, Innovation, and
Technology. We believe that Dr. Levin is qualified to serve as a member of our Board based on his academic and practice experience and
his detailed knowledge of value-based care, acute and chronic pain management, novel drug design, and health care operations and management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Steve
R. Martin</i></b> has served as a member of our Board since August 2020. Mr. Martin was formerly Senior Vice President and Chief Financial
Officer of Armata Pharmaceuticals, Inc., a clinical development stage biotechnology company listed on the New York Stock Exchange, from
January 2016 until his retirement from the position in June 2022. Previously, Mr. Martin served as Senior Vice President and Chief Financial
Officer of Applied Proteomics, Inc., a molecular diagnostics company, from December 2014 to August 2015. From June 2011 to December 2014,
Mr. Martin served as Senior Vice President and Chief Financial Officer of Apricus Biosciences, Inc. (&#8220;Apricus&#8221;), a publicly
traded pharmaceutical company, and served as the Interim Chief Executive Officer of Apricus from November 2012 through March 2013. From
2008 to January 2011, Mr. Martin served as Senior Vice President and Chief Financial Officer of BakBone Software (&#8220;BakBone&#8221;),
a publicly traded software company. During his final 10 months with BakBone until the company&#8217;s acquisition in January 2011, Mr.
Martin also served as BakBone&#8217;s Interim Chief Executive Officer. From 2005 to 2007, Mr. Martin served as Chief Financial Officer
of Stratagene Corporation, a publicly traded research products and clinical diagnostics company. Mr. Martin&#8217;s previous experience
also includes serving as Controller with Gen-Probe Incorporated, a publicly traded molecular diagnostics company, as well as 10 years
with Deloitte &amp; Touche LLP, a public accounting firm. Mr. Martin holds a Bachelor of Science in Accounting from San Diego State University
and is a certified public accountant (inactive). We believe that Mr. Martin&#8217;s expertise in biopharmaceutical industry and accounting
expertise qualifies him to serve on our Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 83; Value: 65 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Lee
Rauch</i></b> has served on our Board since February 2022. She is an experienced Chief Executive Officer and Strategy Advisor, has served
both public and private companies. During her near 40-year career, Ms. Rauch successfully built companies ranging in focus from pre-clinical
research to advanced clinical development, took the lead in mergers and acquisitions and used her experience to secure financing for
public and private biotech companies. Among her many leadership roles, Ms. Rauch, was notably a founding member of McKinsey &amp; Co.&#8217;s
International Pharmaceutical Practice and the Executive Chairman of Springboard Enterprises Health Innovation Hub. Most recently, Ms.
Rauch, served as President and CEO of Viridian Therapeutics, Inc. Ms. Rauch received a B.S. in Chemistry from Arizona State University
and an M.B.A. in Finance from the University of Chicago. We believe that Ms. Rauch&#8217;s biopharmaceutical industry experience and
expertise qualifies her to serve on our Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Curtis
Rosebraugh, M.D., MPH</i></b> has served on our Board since 2021. He is a member of Griebel and Rosebraugh Consulting LLC since May 2018,
where he is a regulatory consultant for small molecule and biological drug development. Prior to forming a consulting firm, he was employed
by the Food and Drug Administration since 2000, holding the position of Director of the Office of Drug Evaluation II (&#8220;ODE II&#8221;)
within the Center for Drug Evaluation and Research (&#8220;<i>CDER</i>&#8221;) from 2007 until his retirement in 2018, with supervisory
responsibility for the evaluation of all drug products within 3 divisions: the Division of Pulmonary, Allergy and Rheumatology Products,
the Division of Metabolism and Endocrinology Products and the Division of Anesthesia, Analgesia, and Addiction Products. In this position,
he has overseen the development and approval of over 50 new drugs, was responsible for the planning of over 100 advisory committee meetings,
led ODE II through several controversial safety issues and has received many honors and awards. Dr. Rosebraugh has been involved in the
development of abuse deterrent opioid formulations and has also been involved in the development of the biosimilar program as well as
many other CDER initiatives. Dr. Rosebraugh received his undergraduate degree in pharmacy in 1981, his Medical Degree in 1986 and completed
a residency in Internal Medicine in 1989, all at the University of Kansas. He completed a Masters of Public Health at Johns Hopkins School
of Public Health in 1999 and a Clinical Pharmacology Fellowship at Georgetown University in 2000. We believe that Dr. Rosebraugh&#8217;s
regulatory experience in the biopharmaceutical industry qualifies him to serve on our Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Role
of Board in Risk Oversight</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board has extensive involvement in the oversight of risk management related to us and our business and accomplishes this oversight through
the regular reporting to the Board by the audit committee. The audit committee represents the Board by periodically reviewing our accounting,
reporting and financial practices, including the integrity of our financial statements, the surveillance of administrative and financial
controls and our compliance with legal and regulatory requirements. Through its regular meetings with management, including the finance,
legal, internal audit and information technology functions, the audit committee reviews and discuss all significant areas of our business
and summarize for the Board all areas of risk and the appropriate mitigating factors. In addition, our Board receives periodic detailed
operating performance reviews from management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Composition
of the Board</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business and affairs are managed under the direction of the Board. Our Board consists of eight directors, which are divided into three
classes (Class I, II and III) with Class I and III each consisting of three directors and Class II consisting of two directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
Committees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
standing committees of our Board consist of an audit committee, a compensation committee and a nominating and corporate governance committee.
Our Board may from time to time establish other committees. Each of the committees reports to the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
president and chief executive officer and other executive officers regularly report to the non-executive directors and the audit, the
compensation and the nominating and corporate governance committees to ensure effective and efficient oversight of our activities and
to assist in proper risk management and the ongoing evaluation of management controls.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 84; Value: 65 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Audit
Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have an audit committee consisting of Steve R. Martin, who serves as the chairperson, Bob Gower and Andrew Benton. Each member of the
audit committee qualifies as an independent director under the Nasdaq corporate governance standards and the independence requirements
of Rule 10A-3 of the Exchange Act. Our Board has determined that Steve R. Martin qualifies as an &#8220;<i>audit committee financial
expert</i>&#8221; as such term is defined in Item 407(d)(5) of Regulation S-K and possesses financial sophistication, as defined under
the rules of Nasdaq.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purpose of the audit committee is to prepare the audit committee report required by the SEC to be included in our proxy statement and
to assist our Board in overseeing and monitoring (1) the quality and integrity of our financial statements, (2) our compliance with legal
and regulatory requirements, (3) our independent registered public accounting firm&#8217;s qualifications and independence, (4) the performance
of our internal audit function and (5) the performance of our independent registered public accounting firm.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board adopted a written charter for the audit committee, which is available on our website.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Compensation
Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a compensation committee consisting of Adam Levin, who serves as the chairperson, Bob Gower, William Chang, and Lee Rauch.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purpose of the compensation committee is to assist our Board in discharging its responsibilities relating to (1) setting our compensation
program and compensation of our executive officers and directors, (2) monitoring our incentive and equity-based compensation plans and
(3) preparing the compensation committee report, if required to be included in our proxy statement under the rules and regulations of
the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board adopted a written charter for the compensation committee, which is available on our website.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nominating
and Corporate Governance Committee</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a nominating and corporate governance committee, consisting of Lee Rauch, who serves as chairperson, Bob Gower, Steve R. Martin
and Curtis Rosebraugh. The purpose of our nominating and corporate governance committee is to assist our Board in discharging its responsibilities
relating to (1) identifying individuals qualified to become new Board members, consistent with criteria approved by the Board, (2) reviewing
the qualifications of incumbent directors to determine whether to recommend them for re-election and selecting, or recommending that
the Board select, the director nominees for the next annual meeting of stockholders, (3) identifying Board members qualified to fill
vacancies on any Board committee and recommending that the Board appoint the identified member or members to the applicable committee,
(4) reviewing and recommending to the Board corporate governance principles applicable to us, (5) overseeing the evaluation of the Board
and management and (6) handling such other matters that are specifically delegated to the committee by the Board from time to time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board adopted a written charter for the nominating and corporate governance committee, which is available on our website.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Delinquent
Section 16(a) Reports</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
to report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Code
of Business Conduct</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
adopted a code of business conduct that applies to all our directors, officers and employees, including our principal executive officer,
principal financial officer and principal accounting officer, which is available on our website. Our code of business conduct is a &#8220;code
of ethics,&#8221; as defined in Item 406(b) of Regulation S-K. We will make any legally required disclosures regarding amendments to,
or waivers of, provisions of our code of ethics on our website.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 85; Value: 65 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Aa_009"></span>Item
11. Executive &amp; Director Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
section discusses the material components of the executive compensation program for our named executive officers. Our named executive
officers, consisting of our principal executive officer and the next two most highly compensated executive officers, for the year ended
December 31, 2024, were:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lynn
    Kirkpatrick, Ph.D., Chief Executive Officer;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Humphrey, Chief Financial Officer; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Geoff
    Birkett, Chief Commercial Officer.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
discussion may contain forward-looking statements that are based on our current plans, considerations, expectations and determinations
regarding future compensation programs. Actual compensation programs that we adopt in the future may differ materially from the currently
planned programs summarized in this discussion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
Compensation Table</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information concerning the compensation earned by our NEOs in respect of our fiscal years ended December 31,
2024 and December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Name
    and Principal<br/> Position</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Salary<br/>
    ($)</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Bonus
    ($)</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock
    and Option<br/> Awards ($)<sup>(1)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Non-Equity<br/>
    Incentive<br/> Plan<br/> Compensation ($)</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>All
    Other<br/> Compensation ($)<sup>(2)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total
    ($)</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%; font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dr. Lynn Kirkpatrick,
    PhD. <br/> Chief Executive Officer</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">432,042</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,350</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">442,392</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">404,875</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">93,800</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,900</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">508,575</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dave
                                    Humphrey</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 26.25pt; text-indent: -26.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Chief
                                            Financial Officer</i></span></p></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">360,917</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,350</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">371,267</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">338,250</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">93,800</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,900</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">441,950</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Geoff Birkett <br/> Chief
    Commercial Officer</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">333,625</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,009</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">343,634</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">312,625</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">70,350</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,379</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">392,354</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    accordance with SEC rules, this column reflects the aggregate grant date fair value of the restricted stock awards and stock option
    awards granted. This amount has been computed in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;), Accounting
    Standards Codification (&#8220;ASC&#8221;) Topic 718. This amount does not reflect the actual economic value that will be realized
    by a named executive officer upon the vesting of the stock awards or stock options, the exercise of the stock options, or the sale
    of the common stock underlying such awards.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts
    shown represent 401(k) matching contributions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Narrative
Disclosure to Summary Compensation Table</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Elements
of Compensation in 2024</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation of our NEOs generally consists of base salary, annual cash bonus opportunities and long-term incentive compensation in the
form of equity awards, as described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Base
Salary</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
base salary payable to each NEO is intended to provide a fixed component of compensation reflecting the executive&#8217;s skill set,
experience, role, responsibilities, and contributions. Base salaries were initially set at the time each NEO commenced employment with
us, are reviewed annually and may be increased based on the individual performance of the NEO, company performance, any change in the
executive&#8217;s position within our business, the scope of the executive&#8217;s responsibilities and any changes thereto. Effective
March 1, 2024, the NEO&#8217;s annual base salary rates were $435,500 for Dr. Kirkpatrick, $363,800 for Mr. Humphrey and $336,300 for
Mr. Birkett. A five percent (5%) cost of living increase was approved for executive officers, effective March 1, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 86; Value: 65 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Annual
Performance-Based Bonuses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of our NEOs&#8217; performance-based cash bonus opportunity is expressed as a percentage of base salary that can be achieved at a target
level by meeting predetermined Company performance objectives established by the Board or the Compensation Committee. The annual bonus
for Dr. Kirkpatrick is targeted at 50% of her base salary, and Mr. Humphrey and Mr. Birkett&#8217;s annual bonuses are targeted at 30%
of their respective base salary. There are no amounts accrued for bonuses as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Long-Term
Equity Incentives</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2021, the Company maintained the Ensysce Biosciences, Inc. 2021 Omnibus Incentive Plan to provide equity-based incentive awards, designed
to align our interests and the interests of our stockholders with those of our employees and consultants, including our NEOs. On January
26, 2022, our stockholders approved the 2021 Amended and Restated Plan. All grants effectuated under predecessor equity plans were converted
to grants outstanding under the 2021 Amended and Restated Plan. In February 2024, the 2021 Amended and Restated Plan was amended to increase
the number of awards that may be granted from 41,139 to 51,626.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employment
Agreements with our NEOs</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dr.
Lynn Kirkpatrick, Ph.D.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2021, we entered into an employment offer letter with Dr. Kirkpatrick. The offer letter provides for Dr. Kirkpatrick&#8217;s
at-will employment as our Chief Executive Officer and sets forth her annual base salary of $380,000. Additionally, the letter provides
for her initial target annual bonus opportunity of up to 50% of base salary. The offer letter also indicates that Dr. Kirkpatrick is
eligible to be granted certain stock awards under our equity incentive plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Kirkpatrick&#8217;s offer letter provides for severance benefits upon a termination of her employment by the Company without &#8220;<i>cause</i>&#8221;,
or upon her resignation for &#8220;<i>good reason</i>&#8221;, in an amount equal to twelve (12) months of her then current base salary
(ignoring any decrease in base salary that forms the basis for good reason); provided, however, that the payment of such benefits is
subject to Dr. Kirkpatrick&#8217;s continued compliance with her obligations under her &#8220;<i>At-Will, Confidential Information and
Assignment of Inventions Agreement</i>&#8221; and her execution of a general release of claims. Additionally, if such termination without
cause or for good reason occurs within the one (1) month prior to, or during the twelve (12) month period immediately following a change
in control, then all outstanding equity awards subject to time-based vesting will become fully vested on the later of Dr. Kirkpatrick&#8217;s
termination date and the change in control. Cause and good reason are as defined in Dr. Kirkpatrick&#8217;s offer letter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dave
Humphrey</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2021, we entered into an employment offer letter with Mr. Humphrey. The offer letter provided for Mr. Humphrey&#8217;s at-will
employment as our Chief Financial Officer at an initial annual base salary of $320,000. Additionally, the letter provided for his initial
target annual bonus opportunity of up to 30% of base salary. The offer letter also indicates that Mr. Humphrey is eligible to be granted
certain stock awards under our equity incentive plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Humphrey&#8217;s offer letter provides for severance benefits upon a termination of his employment by the Company without &#8220;<i>cause</i>&#8221;,
or upon his resignation for &#8220;<i>good reason</i>&#8221;, in an amount equal to six (6) months of his then current base salary (ignoring
any decrease in base salary that forms the basis for good reason); provided, however, that the payment of such benefits is subject to
Mr. Humphrey&#8217;s continued compliance with his obligations under his &#8220;<i>Confidential Information and Assignment Agreement</i>&#8221;
and his execution of a general release of claims. Additionally, if such termination without cause or for good reason occurs within the
one (1) month prior to, or during the twelve (12) month period immediately following a change in control, then all outstanding equity
awards subject to time-based vesting will become fully vested on the later of Mr. Humphrey&#8217;s termination date and the change in
control. Cause and good reason are as defined in Mr. Humphrey&#8217;s offer letter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Geoff
Birkett</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2021, we entered into an employment offer letter with Mr. Birkett. The offer letter provides for Mr. Birkett&#8217;s at-will employment
as our Chief Commercial Officer and sets forth his annual base salary of $300,000. Additionally, the letter provides for his initial
target annual bonus opportunity of up to 30% of base salary. The offer letter also indicates that Mr. Birkett is eligible to be granted
certain stock awards under our equity incentive plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Birkett&#8217;s offer letter provides for severance benefits upon a termination of his employment by the Company without &#8220;cause&#8221;,
or upon his resignation for &#8220;good reason&#8221;, in an amount equal to three (3) months of his then current base salary (ignoring
any decrease in base salary that forms the basis for good reason); provided, however, that the payment of such benefits is subject to
Mr. Birkett&#8217;s continued compliance with his obligations under his &#8220;<i>Confidential Information and Assignment Agreement</i>&#8221;
and his execution of a general release of claims. Additionally, if such termination without cause or for good reason occurs within the
one (1) month prior to, or the twelve (12) month period immediately following a change in control, then all outstanding equity awards
subject to time-based vesting will become fully vested on the later of Mr. Birkett&#8217;s termination date and the change in control.
Cause and good reason are as defined in the offer letter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 87; Value: 65 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>At-Will,
Confidential Information and Assignment of Inventions Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with each respective offer letter, Dr. Kirkpatrick, Mr. Birkett and Mr. Humphrey entered into an &#8220;At-Will, Confidential
Information and Assignment of Inventions Agreement&#8221; (the &#8220;Confidentiality Agreement&#8221;). The Confidentiality Agreements
include customary prohibitions against solicitation of our customers and employees, both during employment and for two (2) years following
any cessation of employment. The Confidentiality Agreements also include standard provisions relating to the Company&#8217;s intellectual
property rights and prohibit the executive from disclosing confidential information. The Confidentiality Agreements are incorporated
by reference into the offer letters and payment of any severance benefits under each executive&#8217;s offer letter is conditioned on
continued compliance with his or her Confidentiality Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
Benefits</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently provide welfare benefits that are available to all of our employees, including our NEOs, including health, dental, vision and
group life insurance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
January 1, 2022, we put into place the Ensysce Biosciences, Inc. 401(k) Plan&#8221; (the &#8220;<i>401(k) Plan</i>&#8221;). The 401(k)
Plan provides eligible employees with an opportunity to save for retirement on a tax-advantaged basis and under which we are permitted
to make safe harbor employer contributions. Employees&#8217; pre-tax contributions are allocated to each participant&#8217;s individual
account and are then invested in selected investment alternatives according to the participants&#8217; directions. The 401(k) Plan is
intended to be qualified under Section 401(a) of the Code, with the related trust intended to be tax exempt under Section 501(a) of the
Code. Under the 401(k) Plan, we make employer contributions to all employees &#8211; regardless of an employee&#8217;s contributions
(or lack thereof) &#8211; in an amount equal to 3% of the employee&#8217;s eligible compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not maintain any defined benefit pension plans or nonqualified deferred compensation plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
Equity Awards at Fiscal Year-End</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides information regarding outstanding equity awards held by our NEOs as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Option
    Awards</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Stock
    Awards</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Name</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Grant
    Date</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of Securities Underlying Unexercised Options Exercisable (#)</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of Securities Underlying Unexercised Options Unexercisable (#)</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Option
    Exercise Price ($)</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Option
    Expiration Date</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of Shares of Stock That Have Not Vested (#)</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Market
    Value of Shares of Stock That Have Not Vested ($)</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 6%; font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dr. Lynn Kirkpatrick,
    PhD.</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left; width: 10%"><span style="font-family: Times New Roman, Times, Serif">1/15/2016</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">74</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 10%; text-align: right">&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,484.00</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1/15/2026</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 10%; text-align: right">&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 10%; text-align: right">&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">1/4/2017</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">128</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,588.00</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1/4/2027</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2/5/2018</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">228</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,048.00</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2/5/2028</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">3/1/2019</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">183</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,324.00</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2/28/2029</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">3/15/2019</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,324.00</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3/14/2029</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2/17/2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">39</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">17</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,040.00</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2/17/2032</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">10/25/2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,667</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">17.70</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10/25/2033</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dave Humphrey</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2/4/2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">73</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,268.00</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2/4/2032</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2/17/2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">16</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,040.00</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2/17/2032</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">10/25/2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,667</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">17.70</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10/25/2033</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Geoff Birkett</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">10/1/2018</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,324.00</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">9/30/2028</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">3/1/2019</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">92</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,324.00</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2/28/2029</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2/17/2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">9</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,040.00</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2/17/2032</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">10/25/2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,001</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">17.70</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10/25/2033</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 88; Value: 65 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pay
Versus Performance</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2022, the SEC adopted additional disclosure requirements regarding the relationship between a registrant&#8217;s executive compensation
and its financial performance. SEC rules in Item 402(v) of Regulation S-K require certain adjustments be made to the Summary Compensation
Table totals to determine Compensation Actually Paid as reported in the Pay Versus Performance Table. Compensation Actually Paid does
not necessarily represent cash and/or equity value earned by or paid to the applicable named executive officer without restriction, but
rather is a valuation calculated under applicable SEC rules. For further information concerning our executive compensation program and
our pay-for-performance philosophy, refer to the preceding compensation discussion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth specified executive compensation and financial performance measures for our two most recently completed fiscal
years, as required under transitional guidance for Smaller Reporting Companies provided by the SEC. We have not paid dividends and do
not sponsor any pension arrangements; thus, no adjustments are made for these items.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
    Compensation Table Total for PEO <sup>(1)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation
    Actually Paid to PEO <sup>(2)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average
    Summary Compensation Table Total for Non-PEO NEOs <sup>(3)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average
    Compensation Actually Paid to Non-PEO NEOs <sup>(4)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value
    of Initial Fixed $100 Investment Based on Total Shareholder Return <sup>(5)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Net
    Income (Loss)</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 16%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">442,392</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">442,392</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">357,451</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">357,451</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.01</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">($</span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,987,225</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">508,575</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">507,187</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">417,152</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">416,177</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.09</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">($</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,626,011</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">622,609</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">152,787</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">573,787</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">372,469</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.80</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">($</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">25,085,496</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    all fiscal years presented, the principal executive officer (&#8220;PEO&#8221;) was our Chief Executive Officer, Dr. Lynn Kirkpatrick.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    amounts disclosed reflect the following adjustments to the amounts reported in the Summary Compensation Table for the PEO:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Less:
    Grant Date Value of Equity Awards</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Fair
    Value as of Year End of Awards Granted in the Year and Outstanding and Unvested as of Year End</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Change
    in Fair Value of Awards Granted in Prior Years and Outstanding and Unvested as of Year End</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Fair
    Value as of Vesting Date of Awards Granted and Vested in the Year</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Change
    in Fair Value of Awards Granted in Prior Years that Vested in the Year</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Less:
    Fair Value as of Prior Year End of Awards Forfeited in the Year</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total
    Adjustments</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 9%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(93,800</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(809</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">93,800</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(579</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,388</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(214,914</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,574</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(256,482</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(469,822</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    all fiscal years presented, the Non-PEO NEOs were Dave Humphrey and Geoff Birkett.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    amounts disclosed reflect the following adjustments to the amounts reported in the Summary Compensation Table for the Non-PEO NEOs:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Less:
    Grant Date Value of Equity Awards</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Fair
    Value as of Year End of Awards Granted in the Year and Outstanding and Unvested as of Year End</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Change
    in Fair Value of Awards Granted in Prior Years and Outstanding and Unvested as of Year End</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Fair
    Value as of Vesting Date of Awards Granted and Vested in the Year</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Change
    in Fair Value of Awards Granted in Prior Years that Vested in the Year</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Less:
    Fair Value as of Prior Year End of Awards Forfeited in the Year</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total
    Adjustments</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 9%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(82,075</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(362</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">82,075</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(613</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(975</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(246,113</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">997</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">43,798</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(201,318</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Shareholder Return is calculated as the sum of (i) the cumulative amount of dividends for the measurement period, assuming reinvestment
    of all dividends, if any, <span style="text-decoration: underline">plus </span>(ii) the cumulative increase or decrease in the price of our common stock each respective year,
    <span style="text-decoration: underline">divided by</span> the price of our common stock at the beginning of the measurement period.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<!-- Field: Page; Sequence: 89; Value: 65 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Relationship
Between Compensation Actually Paid and Company Total Shareholder Return (&#8220;TSR&#8221;)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><img src="form10-k_001.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Relationship
Between Compensation Actually Paid and Net Income (Loss)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_002.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides summary information concerning compensation paid or accrued by us to or on behalf of our non-employee directors
for services rendered to us as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Name</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Fees
    Earned or Paid in Cash ($)</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option
                                            Awards</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total<br/>
    ($)</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Bob Gower</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">25,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">25,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif">William Chang</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Andrew Benton</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Steve Martin</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Adam Levin</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Lee Rauch</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Curt Rosebraugh</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 90; Value: 65 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Aa_010"></span>Item
12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information with respect to the beneficial ownership of shares of our common stock by (i) each director, (ii)
each named executive officer, (iii) all directors and executive officers as a group, and (iv) each person who we know beneficially owns
more than 5% of our common stock as of March 7, 2025, unless otherwise indicated below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
ownership is determined in accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities to
persons who possess sole or shared voting power or investment power with respect to those securities and include shares of common stock
issuable upon the exercise of stock options that are immediately exercisable or exercisable within 60 days after March 7, 2025 but excludes
unvested stock options. Except as otherwise indicated, all of the shares reflected in the table are shares of common stock and all persons
listed below have sole voting and investment power with respect to the shares beneficially owned by them, subject to applicable community
property laws. The information is not necessarily indicative of beneficial ownership for any other purpose.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
computing the number of shares of common stock beneficially owned by a person and the percentage ownership of that person, we deemed
outstanding shares of common stock subject to options or warrants held by that person that are currently exercisable or exercisable within
60 days of March 7, 2025. We did not deem these shares outstanding, however, for the purpose of computing the percentage ownership of
any other person.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Percentage
ownership calculations for beneficial ownership for each person or entity are based on 1,405,134 shares outstanding as of March 7, 2025.
Except as otherwise indicated in the table below, addresses of named beneficial owners are in care of Ensysce Biosciences, Inc., 7946
Ivanhoe Avenue, Suite 201, La Jolla, California 92037. All share amounts have been adjusted for prior reverse stock splits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Beneficial
Ownership Table</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Name and Address
    of Beneficial Owners</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Percentage</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Officers and Directors</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dr. Lynn Kirkpatrick (1)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,433</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Geoff Birkett (2)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,110</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">David Humphrey (3)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,776</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Linda Pestano (4)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,049</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Andrew Benton (5)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,365</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">William Chang (6)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">733</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Bob Gower (7)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">41,655</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2.9</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Adam Levin (8)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,345</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Steve R. Martin (9)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,364</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Lee Rauch (10)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,345</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Curtis Rosebraugh (11)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,345</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">All directors and named executive officers
    as a group (eleven individuals)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">73,520</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5.0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Greater than 5% Holders</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Perceptive Advisors LLC (12)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">86,666</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.2</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates
    less than 1%.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    7,326 shares subject to options.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of shares subject to options.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    6,762 shares subject to options.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of shares subject to options.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    30 shares subject to options.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    11 shares subject to options, 209 shares owned directly by Mr. Chang and his wife and 513 shares owned through trusts in which Mr.
    Chang has sole or shared voting and dispositive power. The business address for Mr. Chang is 520 El Camino Real, 9th Floor, San Mateo,
    CA 94402.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    13 shares subject to options, 8,126 shares held directly and 33,516 shares that may be acquired through the exercise of (i) warrants
    acquired in connection with the October 2023 Securities Purchase Agreement and (ii) warrants acquired in 2022. The business address
    for Mr. Gower is 101 Westcott, Unit 303, Houston, Texas 77007.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of shares subject to options.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of shares subject to options.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of shares subject to options.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of shares subject to options.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on a Schedule 13G/A filed with the SEC on February 14, 2025, by Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences
    Master Fund, Ltd., which lists the business address for all parties as 51 Astor Place, 10<sup>th</sup> Floor, New York, NY 10003.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<!-- Field: Page; Sequence: 91; Value: 65 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_007"></span>Item
13. Certain Relationships and Related Transactions and Director Independence</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than the agreements and arrangements described under the section entitled &#8220;<i>Executive &amp; Director Compensation</i>&#8221;
and the transactions described below, since January 1, 2024, there has not been and there is not currently proposed, any transaction
or series of similar transactions to which (i) we were, or will be, a participant; (ii) the amount involved exceeded, or will exceed,
$120,000 or 1% of the average of our total assets at December 31, 2023 and 2024; and (iii) in which any director, executive officer,
holder of 5% or more of any class of our capital stock or any member of the immediate family of, or entities affiliated with, any of
the foregoing persons, had, or will have, a direct or indirect material interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Convertible
Notes</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the 2023 Notes offering, Bob Gower, our Chairman, purchased an aggregate principal amount of Investor Notes of $216,000 for a purchase
price of $200,000 and Investor Warrants that may be exercised for an aggregate of 29,547 shares of common stock. The per share conversion
price of the Investor Notes and the per share exercise price of the Investor Warrants is $23.51.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Related
Party Transaction Policy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board previously adopted a written related person transaction policy that sets forth the following policies and procedures for the review
and approval or ratification of related person transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
&#8220;<i>Immediate Family Member</i>&#8221; means a child, stepchild, parent, stepparent, spouse, sibling, mother-in-law, father-in-law,
son-in-law, daughter-in-law, brother-in-law, sister-in-law, or any person sharing the household (other than a tenant or employee).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
&#8220;<i>Related Party</i>&#8221; means any (a) person who is or was (since the beginning of the last fiscal year for which we have
filed a Form 10-K and proxy statement, even if they do not presently serve in that role) an executive officer, director or nominee for
election as a director of the Company, (b) greater than 5% beneficial owner of the Company&#8217;s outstanding common stock, or (c) Immediate
Family Member of any of the foregoing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
&#8220;<i>Related Person Transaction</i>&#8221; is any Transaction involving the Company in which a Related Party has or will have a
direct or indirect material interest, as determined by the Audit Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
&#8220;<i>Transaction</i>&#8221; means any financial transaction, arrangement or relationship or any series of similar transactions,
arrangements or relationships, including indebtedness and guarantees of indebtedness and transactions involving employment and similar
relationships.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 92 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the policy, the following types of Transactions are deemed not to create or involve a material interest on the part of the Related Party,
nor will they require approval or ratification, under the policy:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions
    involving the purchase or sale of products or services in the ordinary course of business, not exceeding $50,000 or, if the Company
    is a &#8220;<i>smaller reporting company</i>&#8221; as defined under the Securities Act, if less, one percent of the average of the
    Company&#8217;s total assets as of December 31st for the last two completed fiscal years.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions
    in which the Related Party&#8217;s interest derives solely from his or her service as a director of another corporation or organization
    that is a party to the Transaction.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions
    in which the Related Party&#8217;s interest derives solely from his or her ownership of less than 5% of the equity interest in another
    person (other than a general partnership interest) which is a party to the Transaction.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions
    in which the Related Party&#8217;s interest derives solely from his or her ownership of a class of equity securities of the Company
    and all holders of that class of equity securities received the same benefit on a pro rata basis (e.g., dividends).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions
    in which the Related Party&#8217;s interest derives solely from his or her service as a director, trustee or officer (or similar
    position) of a not-for-profit organization or charity that receives donations from the Company, which donations are made pursuant
    to the Company&#8217;s matching program, as a result of contributions by employees, that is available on the same terms to all employees
    of the Company.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
    arrangements of any executive officer, other than an individual who is an Immediate Family Member of a Related Party, if such arrangements
    have been approved or recommended to the Board for approval by the Compensation Committee.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    compensation arrangements, if such arrangements have been approved by the Board or the Compensation Committee of the Board.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions
    with a Related Party in which the rates or charges involved in the Transaction are determined by competitive bids, or the Transaction
    involves the rendering of services as a common or contract carrier, or public utility, at rates or charges fixed in conformity with
    law or governmental authority.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indemnity
    payments made to directors and executive officers in accordance with the Company&#8217;s then existing certificate of incorporation,
    bylaws and applicable laws.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions
    with a Related Party involving services as a bank depositary of funds, transfer agent, registrar, trustee under a trust indenture
    or similar services.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to its Audit Committee charter, the Audit Committee has the responsibility to review, approve or ratify any Related Person Transactions.
During 2024, no director or officer <span id="xdx_90A_eecd--Rule10b51ArrAdoptedFlag_dbF_c20240101__20241231_z0YPKPmBG3ue" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_900_eecd--NonRule10b51ArrAdoptedFlag_dbF_c20240101__20241231_z8nTEK7TdWIj" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000086" name="ecd:Rule10b51ArrAdoptedFlag"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000087" name="ecd:NonRule10b51ArrAdoptedFlag">adopted</ix:nonNumeric></ix:nonNumeric></span></span> or <span id="xdx_902_eecd--Rule10b51ArrTrmntdFlag_dbF_c20240101__20241231_zi0ocKJEYxT" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_902_eecd--NonRule10b51ArrTrmntdFlag_dbF_c20240101__20241231_z71Ge3ddm2qk" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000088" name="ecd:Rule10b51ArrTrmntdFlag"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000089" name="ecd:NonRule10b51ArrTrmntdFlag">terminated</ix:nonNumeric></ix:nonNumeric></span></span> any contract, instruction or written plan for the purchase or sale of our securities
as either a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2; Value: 92 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Independence</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq
listing rules require that a majority of the board of directors of a company listed on Nasdaq be composed of &#8220;<i>independent directors</i>,&#8221;
which is defined generally as a person other than an officer or employee of the company or its subsidiaries or any other individual having
a relationship that, in the opinion of the company&#8217;s board of directors, would interfere with the director&#8217;s exercise of
independent judgment in carrying out the responsibilities of a director. Based on information provided by each director concerning his
or her background, employment and affiliations, including family relationships, the Board determined that each of Bob Gower, William
Chang, Andrew Benton, Steve R. Martin, Adam S. Levin, Lee Rauch and Curtis Rosebraugh is an independent director under the Nasdaq listing
rules and Rule 10A-3 of the Exchange Act. In making these determinations, the Board considered the current and prior relationships that
each non-employee director has and will have with us and all other facts and circumstances that the Board deems relevant in determining
independence, including the beneficial ownership of our common stock by each non- employee director (and related entities) and the transactions
involving them described in the section entitled &#8220;<i>Certain Relationships and Related Party Transactions.&#8221;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_008"></span>Item
14. Principal Accountant Fees and Services</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 10, 2023, the Audit Committee of our Board appointed Moss Adams LLP (&#8220;<i>Moss Adams</i>&#8221;) as our independent registered
public accounting firm to audit our consolidated financial statements beginning with the fiscal year ending December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the aggregate fees incurred for our independent registered accounting firm for the fiscal years ended December
31, 2024 and 2023. These fees are categorized as audit fees, audit-related fees, tax fees, and all other fees. The nature of the services
provided in each category is described below the table.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Audit Fees</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">409,625</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">472,850</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Audit-Related Fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">76,125</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tax Fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">All Other Fees</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">440,125</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">548,975</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Audit
fees</i>. Consist of fees incurred for professional services rendered for the audit of the consolidated financial statements and review
of the quarterly interim consolidated financial statements. These fees also include the review of registration statements and the delivery
of consents in connection with registration statements. The amount for fiscal year 2023 includes $89,250 for the audit of the year ended
December 31, 2022, completed in conjunction with the audit of the year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Audit-related
fees</i>. Consist of fees incurred for professional services rendered for the compliance audit in accordance with the audit requirements
of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for
Federal Awards related to funding under federal government grants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Tax
fees</i>. There were no fees billed for tax fees for the fiscal years ended December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>All
other fees</i>. There were no fees billed for professional services rendered for other compliance purposes for the fiscal years ended
December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
audit-related and other non-audit services were pre-approved by the Audit Committee, which concluded that the provision of such services
was compatible with the maintenance of the respective firm&#8217;s independence in the conduct of its auditing functions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Value: 92 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_009"></span>PART
IV</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_010"></span>Item
15. Exhibits and Financial Statement Schedules.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENSYSCE
BIOSCIENCES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_001">Report of Independent Registered Public Accounting Firm</a> (PCAOB No. <span id="xdx_900_edei--AuditorFirmId_c20240101__20241231_zS6FlRlPXAz7"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000090" name="dei:AuditorFirmId">659</ix:nonNumeric></span>)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.75in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_002">Consolidated Balance Sheets as of December 31, 2024 and 2023</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_003">Consolidated Statements of Operations for the years ended December 31, 2024 and 2023</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_004">Consolidated Statements of Changes in Stockholders&#8217; Equity (Deficit) for the years ended December 31, 2024 and 2023</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_005">Consolidated Statements of Cash Flows for the years ended December 31, 2024 and 2023</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_006">Notes to the Consolidated Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6
    to F-21</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 92 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="ar_001"></span>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Shareholders and the Board of Directors of</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ensysce
Biosciences Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Opinion
on the Financial Statements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of Ensysce Biosciences Inc. (the &#8220;Company&#8221;) as of December 31,
2024 and 2023, the related consolidated statements of operations and comprehensive income (loss), stockholders&#8217; equity (deficit),
and cash flows for the years then ended, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;).
In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of
the Company as of December 31, 2024 and 2023, and the consolidated results of its operations and its cash flows for the years then ended,
in conformity with accounting principles generally accepted in the United States of America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going
Concern Uncertainty</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note
2 to the financial statements, the Company has incurred recurring losses from operations and has an accumulated deficit that raise substantial
doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note
2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basis
for Opinion</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion
on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public
Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance
with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.
The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part
of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing
an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether
due to error or fraud, and performing procedures to respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles
used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.
We believe that our audits provide a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Critical
Audit Matters</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Critical
audit matters are matters arising from the current period audit of the consolidated financial statements that were communicated or required
to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements
and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
<span id="xdx_907_edei--AuditorName_c20240101__20241231_zJcOmoAeMBh8"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000091" name="dei:AuditorName">Moss Adams LLP</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--AuditorLocation_c20240101__20241231_znV4tI14BP4b"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000092" name="dei:AuditorLocation">San
Diego, California</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
10, 2025</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Options: NewSection -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_002"></span>Ensysce
Biosciences, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Balance Sheets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_304_111_zYdwfkfE1gba" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49D_20241231_zKdPJjaExNH8" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_490_20231231_zENpThzROyKb" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsAbstract_iB_zh9BiMbb8e3h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsCurrentAbstract_i01B_zLl1MrPPUfOh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCzFhH_maACz69m_zEjkFZnZ4PYj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31" id="Fact000100" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,502,077</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31" id="Fact000101" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,123,604</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--UnbilledReceivablesCurrent_i02I_maACz69m_zRwowR2VpOU" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Unbilled receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:UnbilledReceivablesCurrent" contextRef="AsOf2024-12-31" id="Fact000103" format="ixt:numdotdecimal" decimals="0" unitRef="USD">124,115</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:UnbilledReceivablesCurrent" contextRef="AsOf2023-12-31" id="Fact000104" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97,561</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maACz69m_z1J0IToYT8x7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Prepaid expenses and other current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000106" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,718,490</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000107" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,067,703</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AssetsCurrent_i01TI_mtACz69m_maAzsD2_zxRcUZxFNT97" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000109" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,344,682</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000110" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,288,868</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OtherAssetsNoncurrent_i01I_maAzsD2_znvbccnpWTBi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2024-12-31" id="Fact000112" format="ixt:numdotdecimal" decimals="0" unitRef="USD">252,550</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2023-12-31" id="Fact000113" format="ixt:numdotdecimal" decimals="0" unitRef="USD">419,217</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--Assets_iTI_mtAzsD2_zPXcowCdYFHj" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31" id="Fact000115" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,597,232</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31" id="Fact000116" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,708,085</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zdMUu98K6uhe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Liabilities and stockholders&#8217; equity (deficit)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LiabilitiesCurrentAbstract_i01B_zzescSznj7Rk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AccountsPayableCurrent_i02I_maLCzPc4_zM7xNhNMO4Hh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-12-31" id="Fact000124" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,357,079</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-12-31" id="Fact000125" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,936,007</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OtherAccruedLiabilitiesCurrent_i02I_maLCzPc4_zl1ufkiMaJY7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses and other liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000127" format="ixt:numdotdecimal" decimals="0" unitRef="USD">548,458</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000128" format="ixt:numdotdecimal" decimals="0" unitRef="USD">542,260</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NotesPayableCurrent_i02I_maLCzPc4_zMuQBq1gkp0j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Notes payable and accrued interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2024-12-31" id="Fact000130" format="ixt:numdotdecimal" decimals="0" unitRef="USD">301,660</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2023-12-31" id="Fact000131" format="ixt:numdotdecimal" decimals="0" unitRef="USD">854,697</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesCurrent_i01TI_mtLCzPc4_maLzXEm_zEvi31XezHXa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000133" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,207,197</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000134" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,332,964</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LiabilitiesNoncurrentAbstract_i01B_zdZqomIeZhH3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Long-term liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherLiabilitiesNoncurrent_i02I_maLNzK7O_zcqTLSs7dJj9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Other long-term liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="AsOf2024-12-31" id="Fact000139" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,096</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="AsOf2023-12-31" id="Fact000140" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,388</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesNoncurrent_i02TI_mtLNzK7O_maLzXEm_z7nlhKcOMmf2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Total long-term liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2024-12-31" id="Fact000142" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,096</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2023-12-31" id="Fact000143" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,388</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--Liabilities_i01TI_mtLzXEm_maLASEzoWv_zw5GLnA5gG33" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Total liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-12-31" id="Fact000145" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,217,293</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-12-31" id="Fact000146" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,359,352</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CommitmentsAndContingencies_i01I_maLASEzoWv_zPnz7H8WDvHc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Commitments and contingencies (Note 6)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0148">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0149">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--StockholdersEquityAbstract_i01B_zT4NgnB1Wvo3" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Stockholders&#8217; equity (deficit)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PreferredStockValue_i02I_maSEzmDA_zgYK0ywoprBh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Preferred stock, $<span id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20241231_z46a0qqfh78k" title="Preferred stock, par value"><span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20231231_z525HP8CUIG" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000157" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000159" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value, <span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20241231_zLV2GUbeMyA7" title="Preferred stock, shares authorized"><span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231_zhWHTaNzsPB7" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000161" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000163" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized, <span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_do_c20241231_zKW8HSUMqz5j" title="Preferred stock, shares issued"><span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20241231_zL0oQuiodR93" title="Preferred stock, shares outstanding"><span id="xdx_906_eus-gaap--PreferredStockSharesIssued_iI_do_c20231231_z5UgjS5mXKnd" title="Preferred stock, shares issued"><span id="xdx_90F_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20231231_z2KjsFox5HG5" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000165" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000167" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact000169" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000171" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and outstanding at December 31, 2024 and December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0154">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0155">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CommonStockValue_i02I_maSEzmDA_zOrHrUtKwLTg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Common stock, $<span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20241231_zkUTjcBchQh9" title="Common stock, par value"><span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231231_z8zy88mLHplj" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000176" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000178" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value, <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_c20241231_zl7c9IDsstu5" title="Common stock, shares authorized"><span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_c20231231_zBKsgHsEZmrj" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000180" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000182" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized at December 31, 2024 and December 31, 2023; <span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_c20241231_zi5SJTVsyqDl" title="Common stock, shares issued"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000184" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,355,779</ix:nonFraction></span> and <span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_c20231231_zPMQUTE2Gnzf" title="Common stock, shares issued"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact000186" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">209,745</ix:nonFraction></span> shares issued at December 31, 2024 and December 31, 2023, respectively; <span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_c20241231_zgok4ehmIXB" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000188" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,355,773</ix:nonFraction></span> and <span id="xdx_906_eus-gaap--CommonStockSharesOutstanding_iI_c20231231_zgqRl8KqeYR9" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000190" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">209,739</ix:nonFraction></span> shares outstanding at December 31, 2024 and December 31, 2023, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-12-31" id="Fact000173" format="ixt:numdotdecimal" decimals="0" unitRef="USD">136</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31" id="Fact000174" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AdditionalPaidInCapital_i02I_maSEzmDA_zFC0jGfQ7Nhl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-12-31" id="Fact000192" format="ixt:numdotdecimal" decimals="0" unitRef="USD">133,252,585</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-12-31" id="Fact000193" format="ixt:numdotdecimal" decimals="0" unitRef="USD">121,234,195</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maSEzmDA_z0fKT8CI0Qic" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Accumulated deficit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-12-31" id="Fact000195" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">129,544,299</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" id="Fact000196" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">121,557,074</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--StockholdersEquity_i02TI_pp0p0_mtSEzmDA_maSEIPAzn60_zGsOuZMsxb6a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Ensysce Biosciences, Inc. stockholders&#8217; equity (deficit)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000198" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,708,422</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000199" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">322,858</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--MinorityInterest_i02I_pp0p0_maSEIPAzn60_zgHQisIUl2P6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Noncontrolling interests in stockholders&#8217; deficit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2024-12-31" id="Fact000201" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">328,483</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2023-12-31" id="Fact000202" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">328,409</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_i02TI_pp0p0_mtSEIPAzn60_maLASEzoWv_zA88c8vo7Xcg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Total stockholders&#8217; equity (deficit)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31" id="Fact000204" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,379,939</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31" id="Fact000205" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">651,267</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pp0p0_mtLASEzoWv_zJp0ZVIN1n5b" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders&#8217; equity (deficit)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000207" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,597,232</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000208" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,708,085</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_003"></span>Ensysce
Biosciences, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Statements of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30D_113_zhrXkA9VUgG4" summary="xdx: Statement - Consolidated Statements of Operations" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_493_20240101__20241231_ztBL4FjNZ0d9" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_496_20230101__20231231_zLf78JOSnku5" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maCzhoK_maOILzeoD_zkLvI9fizbCc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font-weight: bold; text-align: left">Federal grants</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-01to2024-12-31" id="Fact000210" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,210,031</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31" id="Fact000211" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,230,520</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingExpensesAbstract_iB_zCOu4y05aRwi" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzZir_maOEzRNC_zJ2nf8BCdRNh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000216" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,219,437</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31" id="Fact000217" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,587,473</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--GeneralAndAdministrativeExpense_i01_maCzZir_maOEzRNC_zTNwyeTbmagl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000219" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,720,728</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31" id="Fact000220" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,361,234</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingExpenses_iT_mtOEzRNC_msOILzeoD_zLImeZGQjOP4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-01to2024-12-31" id="Fact000222" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,940,165</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-01-012023-12-31" id="Fact000223" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,948,707</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingIncomeLoss_iT_mtOILzeoD_maPLzb29_z4Xmtofodvfd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000225" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,730,134</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000226" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,718,187</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OtherNonoperatingIncomeExpenseAbstract_iB_zMYnDEBvJQR3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other income (expense):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--LossOnConversionsAndChangeInFairValueOfConvertibleNotes_i01N_di_msNIEzFTC_zSqzdEXtfQyb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Loss on conversions and change in fair value of convertible notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0231">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENSC:LossOnConversionsAndChangeInFairValueOfConvertibleNotes" contextRef="From2023-01-012023-12-31" id="Fact000232" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">146,479</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--ChangeInFairValueOfLiabilityClassifiedWarrants_i01_maNIEzFTC_zbvorAfWNzoe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of liability classified warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENSC:ChangeInFairValueOfLiabilityClassifiedWarrants" contextRef="From2024-01-01to2024-12-31" id="Fact000234" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,292</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENSC:ChangeInFairValueOfLiabilityClassifiedWarrants" contextRef="From2023-01-012023-12-31" id="Fact000235" format="ixt:numdotdecimal" decimals="0" unitRef="USD">283,958</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--InterestExpenseNonoperating_i01N_di_msNIEzFTC_z7h8Ove7tf8b" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Interest expense, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2024-01-01to2024-12-31" id="Fact000237" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,290,444</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2023-01-012023-12-31" id="Fact000238" format="ixt:numdotdecimal" decimals="0" unitRef="USD">353,945</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--OtherNonoperatingIncomeExpense_i01_pp0p0_maNIEzFTC_zyCqEVmlpijg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Other income and expense, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000240" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">17,277</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-01-012023-12-31" id="Fact000241" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,420</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NonoperatingIncomeExpense_iT_mtNIEzFTC_maPLzb29_zxVnuOfA1lrg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Total other income (expense), net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000243" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,256,875</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-01-012023-12-31" id="Fact000244" format="ixt:numdotdecimal" decimals="0" unitRef="USD">91,912</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ProfitLoss_iT_mtPLzb29_maNILATz2z6_zGsI5ajbPti2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000246" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,987,009</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-012023-12-31" id="Fact000247" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,626,275</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_msNILATz2z6_zBwSvAv5owbd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Net loss attributable to noncontrolling interests</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2024-01-01to2024-12-31" id="Fact000249" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">74</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2023-01-012023-12-31" id="Fact000250" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,201</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount_msNILATz2z6_ziKLuEA7opB8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Deemed dividend related to warrants down round provision</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount" contextRef="From2024-01-01to2024-12-31" id="Fact000252" format="ixt:numdotdecimal" decimals="0" unitRef="USD">290</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount" contextRef="From2023-01-012023-12-31" id="Fact000253" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,937</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iT_mtNILATz2z6_zmAziwlP2dHe" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss attributable to common stockholders</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2024-01-01to2024-12-31" id="Fact000255" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,987,225</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-01-012023-12-31" id="Fact000256" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,626,011</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--EarningsPerShareAbstract_iB_zCb7D4uZXYZ" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net loss per basic and diluted share:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net loss per share attributable to common stockholders, basic and diluted</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--EarningsPerShareBasic_c20240101__20241231_zIWYYQAOC7C" title="Net income (loss) per share attributable to common stockholders, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_907_eus-gaap--EarningsPerShareDiluted_c20240101__20241231_zeE2gpT1Xb1b" title="Net income (loss) per share attributable to common stockholders, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-01to2024-12-31" id="Fact000261" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-01to2024-12-31" id="Fact000263" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">11.45</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--EarningsPerShareBasic_c20230101__20231231_zVvbCn8iLYFk" title="Net loss per share attributable to common stockholders, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_900_eus-gaap--EarningsPerShareDiluted_c20230101__20231231_zFTuXUysJ4Z1" title="Net loss per share attributable to common stockholders, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-12-31" id="Fact000265" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-12-31" id="Fact000267" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">70.40</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted average common shares outstanding, basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231_z14IduC6Bdh3" title="Weighted average common shares outstanding, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20241231_zkJIMfvDxlMl" title="Weighted average common shares outstanding, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-01to2024-12-31" id="Fact000269" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-01to2024-12-31" id="Fact000271" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">697,686</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_zRcanG9rRCRg" title="Weighted average common shares outstanding, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_zbx8plg8d198" title="Weighted average common shares outstanding, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-12-31" id="Fact000273" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-12-31" id="Fact000275" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,937</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 7 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_004"></span>Ensysce
Biosciences, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Statements of Changes in Stockholders&#8217; Equity (Deficit)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin: 0"></p>

<p style="margin: 0"></p>

<table cellpadding="0" cellspacing="0" id="xdx_305_114_zJgYKcOfvjUg" summary="xdx: Statement - Consolidated Statements of Changes in Stockholders' Equity (Deficit)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B1_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zAjm7vm8XRz6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zeYLpgDCSszk" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zn972pS1D3c9" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deficit</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--NoncontrollingInterestMember_zpBx1TBXvsKe" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">interests</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B3_zYBt40lDke7b" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stockholders&#8217; Equity (Deficit)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Additional</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Paid-In</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Noncontrolling</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">interests</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_431_c20230101__20231231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zLuezyD3HqUl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 22%; font-weight: bold">Balance on December 31, 2022</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFZxbMAvlirc" title="Balance, shares" style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000283" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">35,650</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000277" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000278" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107,216,615</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000279" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">110,931,063</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000280" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">315,208</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31" id="Fact000281" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,029,652</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_zajKEWVGHj4d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Settlement of restricted stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkkzQboaId6j" title="Settlement of restricted stock units, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000291" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,064</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0285">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0286">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0287">-</span></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0288">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0289">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--StockIssuedDuringPeriodValueCommitmentFee_zmtDYK1f0GN2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Settlement of commitment fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--StockIssuedDuringPeriodSharesCommitmentFee_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgqYRE2IX71l" title="Settlement of commitment fee, shares" style="text-align: right"><ix:nonFraction name="ENSC:StockIssuedDuringPeriodSharesCommitmentFee" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000299" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,964</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0293">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENSC:StockIssuedDuringPeriodValueCommitmentFee" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000294" format="ixt:numdotdecimal" decimals="0" unitRef="USD">400,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0295">-</span></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENSC:StockIssuedDuringPeriodValueCommitmentFee" contextRef="From2023-01-012023-12-31" id="Fact000297" format="ixt:numdotdecimal" decimals="0" unitRef="USD">400,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_z85OkNgr2QCh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Conversion of convertible notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBacbEstZQAf" title="Conversions of convertible notes, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000307" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">27,240</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000301" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000302" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,056,889</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0303">-</span></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0304">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31" id="Fact000305" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,056,892</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zttUYF894vEi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Public offering</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z53XtJbUydql" title="Public offering, net, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000315" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">92,109</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000309" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000310" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,049,995</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0311">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0312">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31" id="Fact000313" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,050,004</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zq9JD3fnByra" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0317">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000318" format="ixt:numdotdecimal" decimals="0" unitRef="USD">879,160</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0319">-</span></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0320">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31" id="Fact000321" format="ixt:numdotdecimal" decimals="0" unitRef="USD">879,160</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_zdFvT4PdM9nd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of warrants - debt discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0323">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000324" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,066,483</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31" id="Fact000327" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,066,483</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--TransactionCostsAssociatedWithPublicOffering_zVe3fZRxc5nl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Transaction costs associated with public offering</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0329">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENSC:TransactionCostsAssociatedWithPublicOffering" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000330" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">447,879</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0331">-</span></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0332">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENSC:TransactionCostsAssociatedWithPublicOffering" contextRef="From2023-01-012023-12-31" id="Fact000333" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">447,879</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_ecustom--StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants_zianfiDsXaE9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of common stock upon exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkT5ddqBr2pk" title="Issuance of common stock upon exercise of warrants, shares" style="text-align: right"><ix:nonFraction name="ENSC:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000341" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">47,792</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENSC:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000335" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENSC:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000336" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0337">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0339">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--StockIssuedDuringPeriodValueReverseStockSplits_zYaljy79zr6h" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Reverse split fractional shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6dfJYUmIaO4" title="Reverse split fractional shares, shares" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000349" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">80</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0343">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0344">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0345">-</span></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0346">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0347">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_zICwZdxLTzb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deemed dividend related to warrants down round provision</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0351">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000352" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,937</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="Fact000353" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,937</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0354">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0355">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ProfitLoss_zOcujScWZAn4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0357">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0358">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="Fact000359" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,613,074</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000360" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,201</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-012023-12-31" id="Fact000361" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,626,275</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_435_c20240101__20241231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zMYUc8COwhH1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance on December 31, 2023</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zreH3EW06F7l" title="Balance, shares" style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000369" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">209,739</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000363" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000364" format="ixt:numdotdecimal" decimals="0" unitRef="USD">121,234,195</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000365" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">121,557,074</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000366" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">328,409</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31" id="Fact000367" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">651,267</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_43C_c20240101__20241231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zOSo0B5OA9qg" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z34SJM7LtSSk" title="Balance, shares" style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000377" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">209,739</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000371" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000372" format="ixt:numdotdecimal" decimals="0" unitRef="USD">121,234,195</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000373" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">121,557,074</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000374" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">328,409</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31" id="Fact000375" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">651,267</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr id="xdx_409_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_zR0zqTOggEy6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Settlement of restricted stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjc2HkFLhz38" title="Settlement of restricted stock units, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000385" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0379">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0380">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0381">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0382">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0383">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zWWGHIylfjTa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Conversion of convertible notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zycG7JG62TOl" title="Conversions of convertible notes, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000393" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">49,702</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000387" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000388" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,168,595</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0389">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0390">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-01to2024-12-31" id="Fact000391" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,168,600</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zuNJJmtTvUS1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Public offering</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNEkXLNdjevh" title="Public offering, net, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000401" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">236,880</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000395" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000396" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,669,977</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-01to2024-12-31" id="Fact000399" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,670,001</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants_zlaha3oELwJl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of common stock upon exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQSm1pySj9Yd" title="Issuance of common stock upon exercise of warrants, shares" style="text-align: right"><ix:nonFraction name="ENSC:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000409" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">139,028</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENSC:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000403" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENSC:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000404" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,433,066</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0405">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0406">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENSC:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants" contextRef="From2024-01-01to2024-12-31" id="Fact000407" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,433,080</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--IssuanceOfCommonStockUponWarrantInducements_zHMkofYfhU8b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issuance of common stock upon warrant inducements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--IssuanceOfCommonStockUponWarrantInducementsShares_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZbdSkzYdWTl" title="Issuance of common stock upon warrant inducements , shares" style="text-align: right"><ix:nonFraction name="ENSC:IssuanceOfCommonStockUponWarrantInducementsShares" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000417" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">720,357</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENSC:IssuanceOfCommonStockUponWarrantInducements" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000411" format="ixt:numdotdecimal" decimals="0" unitRef="USD">72</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENSC:IssuanceOfCommonStockUponWarrantInducements" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000412" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,103,870</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0413">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0414">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENSC:IssuanceOfCommonStockUponWarrantInducements" contextRef="From2024-01-01to2024-12-31" id="Fact000415" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,103,942</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--TransactionCostsAssociatedWithPublicOfferingAndWarrantInducements_zHPtonsiLSk2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Transaction costs associated with public offering and warrant inducements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0419">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENSC:TransactionCostsAssociatedWithPublicOfferingAndWarrantInducements" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000420" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,468,131</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0421">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0422">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENSC:TransactionCostsAssociatedWithPublicOfferingAndWarrantInducements" contextRef="From2024-01-01to2024-12-31" id="Fact000423" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,468,131</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ztjYhTlDQCF8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0425">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000426" format="ixt:numdotdecimal" decimals="0" unitRef="USD">110,723</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0427">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0428">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-01to2024-12-31" id="Fact000429" format="ixt:numdotdecimal" decimals="0" unitRef="USD">110,723</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--StockIssuedDuringPeriodValueReverseStockSplits_zWcS5Xkb3IBg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Reverse split fractional shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjcgrfiHCnR7" title="Reverse split fractional shares, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000437" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">62</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0431">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0432">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0433">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0434">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0435">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_z8GMCnXJiEL7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deemed dividend related to warrants down round provision</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0439">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000440" format="ixt:numdotdecimal" decimals="0" unitRef="USD">290</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="Fact000441" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">290</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0442">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0443">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ProfitLoss_zo0Oa2e1C0Zj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0445">-</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0446">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="Fact000447" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,986,935</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000448" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">74</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000449" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,987,009</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_432_c20240101__20241231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_z3jMto5J4uH4" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 1pt">Balance on December 31, 2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iE_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxCQ2jrTLAl2" title="Balance, shares" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000457" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,355,773</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000451" format="ixt:numdotdecimal" decimals="0" unitRef="USD">136</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000452" format="ixt:numdotdecimal" decimals="0" unitRef="USD">133,252,585</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000453" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">129,544,299</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000454" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">328,483</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31" id="Fact000455" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,379,939</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_430_c20240101__20241231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_zki5kH9dCA0f" style="display: none; vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--SharesOutstanding_iE_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjfjESi1q706" title="Balance, shares" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000465" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,355,773</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000459" format="ixt:numdotdecimal" decimals="0" unitRef="USD">136</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000460" format="ixt:numdotdecimal" decimals="0" unitRef="USD">133,252,585</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000461" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">129,544,299</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000462" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">328,483</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31" id="Fact000463" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,379,939</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 8 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_005"></span>Ensysce
Biosciences, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Statements of Cash Flow</b>s</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30D_112_zIK53doXPMU8" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_499_20240101__20241231_zM7DqB23hqc3" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_494_20230101__20231231_zquZGUW0aoZf" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_z044TuwQxrx6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash flows from operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ProfitLoss_i01_maCzfUO_zBvM18SKzKyf" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000470" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,987,009</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-012023-12-31" id="Fact000471" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,626,275</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zQQ2hF7W5ITg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInInterestPayableNet_i02_maCzfUO_zbTuPHzinvD8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accrued interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInterestPayableNet" contextRef="From2024-01-01to2024-12-31" id="Fact000476" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,927</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInterestPayableNet" contextRef="From2023-01-012023-12-31" id="Fact000477" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,648</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_i02_maCzfUO_zJH3qRiSCb0h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Amortization of orginal issue discount and debt issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="From2024-01-01to2024-12-31" id="Fact000479" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,197,200</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="From2023-01-012023-12-31" id="Fact000480" format="ixt:numdotdecimal" decimals="0" unitRef="USD">326,151</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--LossOnConversionsAndChangeInFairValueOfConvertibleNotes_i02_maCzfUO_zOojyJPNaHFe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Loss on conversions and change in fair value of convertible notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0482">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENSC:LossOnConversionsAndChangeInFairValueOfConvertibleNotes" contextRef="From2023-01-012023-12-31" id="Fact000483" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">146,479</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--ChangeInFairValueOfLiabilityClassifiedWarrants_i02N_di_msCzfUO_zeiW1T1kA2Rk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of liability classified warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENSC:ChangeInFairValueOfLiabilityClassifiedWarrants" contextRef="From2024-01-01to2024-12-31" id="Fact000485" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,292</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENSC:ChangeInFairValueOfLiabilityClassifiedWarrants" contextRef="From2023-01-012023-12-31" id="Fact000486" format="ixt:numdotdecimal" decimals="0" unitRef="USD">283,958</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--ShareBasedCompensation_i02_maCzfUO_zIx9VMvFxrh2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-01to2024-12-31" id="Fact000488" format="ixt:numdotdecimal" decimals="0" unitRef="USD">110,723</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31" id="Fact000489" format="ixt:numdotdecimal" decimals="0" unitRef="USD">879,160</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ProvisionForLoanLeaseAndOtherLosses_i02_maCzfUO_zyPbIcf5Rg6d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0491">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProvisionForLoanLeaseAndOtherLosses" contextRef="From2023-01-012023-12-31" id="Fact000492" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">150</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_ecustom--IncreaseDecreaseInUnbilledReceivable_i02N_di_msCzfUO_z2fyJVHuAFhf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Unbilled receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENSC:IncreaseDecreaseInUnbilledReceivable" contextRef="From2024-01-01to2024-12-31" id="Fact000494" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,554</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENSC:IncreaseDecreaseInUnbilledReceivable" contextRef="From2023-01-012023-12-31" id="Fact000495" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">179,260</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInPrepaidExpensesOther_i02N_di_msCzfUO_zAuGcGKoPekj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Prepaid expenses and other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" contextRef="From2024-01-01to2024-12-31" id="Fact000497" format="ixt:numdotdecimal" decimals="0" unitRef="USD">251,965</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" contextRef="From2023-01-012023-12-31" id="Fact000498" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,392,181</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInAccountsPayable_i02_maCzfUO_zayqldRhdiJf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2024-01-01to2024-12-31" id="Fact000500" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">578,928</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2023-01-012023-12-31" id="Fact000501" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,234,287</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--IncreaseDecreaseInOtherAccruedLiabilities_i02_maCzfUO_zWgo1naDGYzh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Accrued expenses and other liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" contextRef="From2024-01-01to2024-12-31" id="Fact000503" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,198</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" contextRef="From2023-01-012023-12-31" id="Fact000504" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,284,233</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtCzfUO_maCzeYJ_z16Aqm6O4V42" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net cash used in operating activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000506" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,502,700</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-012023-12-31" id="Fact000507" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,779,982</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zACb0eBkE2Jg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash flows from financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_i01_maCzHLj_zYkp4EULaq3f" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Proceeds from public offerings, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2024-01-01to2024-12-31" id="Fact000512" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,670,001</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2023-01-012023-12-31" id="Fact000513" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,050,004</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ProceedsFromWarrantExercises_i01_maCzHLj_zK4G6DAWgcHa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from warrant exercises</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2024-01-01to2024-12-31" id="Fact000515" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,433,080</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0516">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--ProceedsFromWarrantInducementNetOfIssuanceCosts_i01_maCzHLj_zo8FOPFfQya6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Proceeds from warrant inducement, net of issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENSC:ProceedsFromWarrantInducementNetOfIssuanceCosts" contextRef="From2024-01-01to2024-12-31" id="Fact000518" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,103,942</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0519">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--TransactionCostsFromPublicOfferings_i01N_di_msCzHLj_zvVfmZdHgjo9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Transaction costs from public offerings</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0521">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENSC:TransactionCostsFromPublicOfferings" contextRef="From2023-01-012023-12-31" id="Fact000522" format="ixt:numdotdecimal" decimals="0" unitRef="USD">447,879</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_ecustom--TransactionCostAssociatedWithWarrantInducement_i01N_di_msCzHLj_zj0CeGqWVDl9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Transaction costs associated with public offering and warrant inducements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENSC:TransactionCostAssociatedWithWarrantInducement" contextRef="From2024-01-01to2024-12-31" id="Fact000524" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,468,131</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0525">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ProceedsFromConvertibleDebt_i01_maCzHLj_z0tNIpyFAYY6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from issuance of convertible notes, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0527">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2023-01-012023-12-31" id="Fact000528" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,605,635</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--RepaymentsOfConvertibleDebt_i01N_di_msCzHLj_z8hKfOeax8e2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Repayment of convertible notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfConvertibleDebt" contextRef="From2024-01-01to2024-12-31" id="Fact000530" format="ixt:numdotdecimal" decimals="0" unitRef="USD">485,190</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfConvertibleDebt" contextRef="From2023-01-012023-12-31" id="Fact000531" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,208</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_ecustom--RepaymentInsurancePremiums_i01N_di_msCzHLj_zbDHkcib442b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Repayment of financed insurance premiums</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ENSC:RepaymentInsurancePremiums" contextRef="From2024-01-01to2024-12-31" id="Fact000533" format="ixt:numdotdecimal" decimals="0" unitRef="USD">372,529</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ENSC:RepaymentInsurancePremiums" contextRef="From2023-01-012023-12-31" id="Fact000534" format="ixt:numdotdecimal" decimals="0" unitRef="USD">451,668</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtCzHLj_maCzeYJ_zWK7VxBeHQZ1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net cash provided by financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000536" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,881,173</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-012023-12-31" id="Fact000537" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,755,884</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCzeYJ_zMfPArLRqM4b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Increase (decrease) in cash and cash equivalents</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2024-01-01to2024-12-31" id="Fact000539" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,378,473</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-01-012023-12-31" id="Fact000540" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,024,098</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_znW1hcAkV857" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Cash and cash equivalents beginning of period</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact000542" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,123,604</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" id="Fact000543" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,147,702</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_zvk6XhP4qfk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2024-12-31" id="Fact000545" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,502,077</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact000546" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,123,604</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--SupplementalCashFlowInformationAbstract_iB_z9jYe4Vx008k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Supplemental cash flow information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxesPaidNet_i01_zD3vuJ01cX7h" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Income tax payments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2024-01-01to2024-12-31" id="Fact000551" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,200</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2023-01-012023-12-31" id="Fact000552" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,200</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB_zYvbkfOO8Od9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Supplemental disclosure of non-cash investing and financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--IncrementalFairValueOfWarrantInducement1_i01_z7SzbXQhJIA1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Incremental fair value of August 2024 Warrant Inducement</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ENSC:IncrementalFairValueOfWarrantInducement1" contextRef="From2024-01-01to2024-12-31" id="Fact000557" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,210,616</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0558">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--IncrementalFairValueOfWarrantInducement2_i01_ziFYzn3AiYc4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Incremental fair value of February 2024 Warrant Inducement</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ENSC:IncrementalFairValueOfWarrantInducement2" contextRef="From2024-01-01to2024-12-31" id="Fact000560" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,167,372</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0561">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--ConversionsOfConvertibleNotesIntoCommonStock_i01_zVVj6afeVmu4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Conversion of convertible notes into common stock</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ENSC:ConversionsOfConvertibleNotesIntoCommonStock" contextRef="From2024-01-01to2024-12-31" id="Fact000563" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,168,600</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ENSC:ConversionsOfConvertibleNotesIntoCommonStock" contextRef="From2023-01-012023-12-31" id="Fact000564" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,056,892</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--OriginalDebtDiscountFromConvertibleNotes_i01_pp0p0_zvVvdTxYu5z1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Original debt discount from convertible notes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0566">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ENSC:OriginalDebtDiscountFromConvertibleNotes" contextRef="From2023-01-012023-12-31" id="Fact000567" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">136,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--DebtDiscountFromWarrantsIssuance_i01_zVTZMQXdjJl2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Debt discount from warrants issuance</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0569">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ENSC:DebtDiscountFromWarrantsIssuance" contextRef="From2023-01-012023-12-31" id="Fact000570" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,066,483</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--IssuanceCostFromConvertibleNotes_i01_zWDYu8AtLDA4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Issuance cost from convertible notes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0572">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ENSC:IssuanceCostFromConvertibleNotes" contextRef="From2023-01-012023-12-31" id="Fact000573" format="ixt:numdotdecimal" decimals="0" unitRef="USD">226,503</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--FinancedInsurancePremiums_i01_z3cmMO8NyH24" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Financed insurance premiums</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ENSC:FinancedInsurancePremiums" contextRef="From2024-01-01to2024-12-31" id="Fact000575" format="ixt:numdotdecimal" decimals="0" unitRef="USD">232,155</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ENSC:FinancedInsurancePremiums" contextRef="From2023-01-012023-12-31" id="Fact000576" format="ixt:numdotdecimal" decimals="0" unitRef="USD">445,737</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--SettlementOfCommitmentFeeInShares_i01_z2rEXJneeKV" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Settlement of commitment fee in shares</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0578">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ENSC:SettlementOfCommitmentFeeInShares" contextRef="From2023-01-012023-12-31" id="Fact000579" format="ixt:numdotdecimal" decimals="0" unitRef="USD">400,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--DeemedDividendRelatedToWarrantsDownRoundProvision_i01_zjtM6BXbRqta" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Deemed dividend related to warrants down round provision</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ENSC:DeemedDividendRelatedToWarrantsDownRoundProvision" contextRef="From2024-01-01to2024-12-31" id="Fact000581" format="ixt:numdotdecimal" decimals="0" unitRef="USD">290</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ENSC:DeemedDividendRelatedToWarrantsDownRoundProvision" contextRef="From2023-01-012023-12-31" id="Fact000582" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,937</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 9 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_006"></span>Ensysce
Biosciences, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to the Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000584" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock"><p id="xdx_80D_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zdVDDbnm08oh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1 &#8211; <span id="xdx_82A_z1F2juPiW7ai">ORGANIZATION AND PRINCIPAL ACTIVITIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ensysce
Biosciences, Inc. (&#8220;Ensysce&#8221;), along with its <span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EBIRIncMember_zGfKa5m4dwXc" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2024-12-31_custom_EBIRIncMember" id="Fact000586" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">79.2</ix:nonFraction></span>%-owned subsidiary, EBIR, Inc. (&#8220;EBIR&#8221;, formerly known as Covistat,
Inc.) and its wholly-owned subsidiaries EBI Operating, Inc. and EBI OpCo, Inc. (collectively, the &#8220;Company&#8221;), is a clinical-stage
biotech company using its proprietary technology platforms to develop safer prescription drugs. The primary focus of the Company is its
program developing abuse and overdose resistant pain technology with a clinical stage program being the abuse resistant, TAAP (Trypsin
Activated Abuse Protection) opioid product candidate, PF614. In addition, the Company is developing its MPAR&#174; (Multi-Pill Abuse Resistant)
technology for overdose protection which will be applied to the PF614 program. The Company is also applying its TAAP and MPAR&#174; technology
to a methadone prodrug for use in the treatment of Opioid Use Disorder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2020, the Company commenced an initiative to develop a therapeutic for the treatment of certain coronavirus infections through the formation
of a separate entity, EBIR, a Delaware corporation. Pursuant to the articles of incorporation, EBIR was authorized to issue <span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20201231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EBIRIncMember_zHhfUxzBMnxf" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2020-12-31_custom_EBIRIncMember" id="Fact000588" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span>
shares of common stock, $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20201231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EBIRIncMember_z20W3jsIvVhi" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2020-12-31_custom_EBIRIncMember" id="Fact000590" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> par value per share, and <span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20201231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EBIRIncMember_zfEbD7IYdRQ7" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2020-12-31_custom_EBIRIncMember" id="Fact000592" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span> shares of preferred stock, $<span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pp3d_c20201231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EBIRIncMember_zO5JsYwZgeO6" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2020-12-31_custom_EBIRIncMember" id="Fact000594" format="ixt:numdotdecimal" decimals="3" unitRef="USDPShares">0.001</ix:nonFraction></span> par value per share. Ensysce is a <span id="xdx_901_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EBIRIncMember_zkuWFW9jSI79" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2024-12-31_custom_EBIRIncMember" id="Fact000596" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">79.2</ix:nonFraction></span>%
stockholder in EBIR, with <span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20241231__srt--TitleOfIndividualAxis__custom--KeyPersonnelMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EBIRIncMember_zd9VSnMZrrCj" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2024-12-31_custom_KeyPersonnelMember_custom_EBIRIncMember" id="Fact000598" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">19.8</ix:nonFraction></span>% and <span id="xdx_901_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20241231__srt--TitleOfIndividualAxis__custom--UnrelatedPartyMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EBIRIncMember_zBPTRgK0rZAg" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2024-12-31_custom_UnrelatedPartyMember_custom_EBIRIncMember" id="Fact000600" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.0</ix:nonFraction></span>% of the shares held by certain key personnel of the Company and an unrelated party, respectively.
The non-Ensysce owned shares and the activity are reflected on the financial statements as noncontrolling interests.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000602" name="us-gaap:BasisOfAccounting"><p id="xdx_803_eus-gaap--BasisOfAccounting_zTa9y2uZumCd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 - <span id="xdx_82F_z2pKzmMjd7Xk">BASIS OF PRESENTATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States
of America (&#8220;GAAP&#8221;) and pursuant to the rules and regulations of the United States Securities Exchange Commission (&#8220;SEC&#8221;).
The consolidated financial statements include the accounts of Ensysce Biosciences, Inc. and its subsidiaries. All intercompany balances
and transactions have been eliminated in the consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reverse
Stock Split</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2023, the Company completed a <span id="xdx_90F_eus-gaap--StockholdersEquityReverseStockSplit_c20230301__20230331_zTRBRKzcP2F2" title="Reverse stock split"><ix:nonNumeric contextRef="From2023-03-012023-03-31" id="Fact000604" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-12</ix:nonNumeric></span> reverse split of its outstanding common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2024, the Company completed a <span id="xdx_900_eus-gaap--StockholdersEquityReverseStockSplit_c20241201__20241231_zoFw0d9CiXJ4" title="Reverse stock split"><ix:nonNumeric contextRef="From2024-12-012024-12-31" id="Fact000606" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-15</ix:nonNumeric></span> reverse split of its outstanding common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
references in these consolidated financial statements to shares and per share amounts in all periods have been retrospectively restated
to reflect the effects of both reverse splits noted above. The number of authorized shares and the par value of the shares did not change
as a result of the reverse stock splits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going
Concern</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates,
among other things, the realization of assets and satisfaction of liabilities in the normal course of business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not generated any product revenue. There is no assurance that profitable operations will ever be achieved, and, if achieved,
would be sustained on a continuing basis. Product development activities, clinical and pre-clinical testing, and commercialization of
the Company&#8217;s product candidates are necessary to develop the Company&#8217;s products and will require significant additional
financing. There can be no assurance the Company will be able to obtain such funds. These matters, among others, raise substantial doubt
about the Company&#8217;s ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the Company believes in the viability of its strategy to ultimately realize revenues and in its ability to raise additional funds, management
cannot be certain that additional funding will be available on acceptable terms, or at all. The Company&#8217;s ability to continue as
a going concern is dependent upon its ability to obtain adequate financing and achieve profitable operations. As a result, these plans
do not alleviate substantial doubt about the Company&#8217;s ability to continue as a going concern for a period of 12 months following
the date these consolidated financial statements were issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as
a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 10 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2in; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ensysce
Biosciences, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to the Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000608" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_802_eus-gaap--SignificantAccountingPoliciesTextBlock_zJcd5sazGsg9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3 - <span id="xdx_82C_zF7s4AJ9g82f">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000610" name="us-gaap:UseOfEstimates"><p id="xdx_84C_eus-gaap--UseOfEstimates_zveVvBY9DfX5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zxqeiaUXWuV2">Use
of Estimates and Assumptions</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preparation
of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the
amounts reported in the consolidated financial statements and disclosed in the accompanying notes. Actual results may differ from those
estimates and such differences may be material to the consolidated financial statements. The more significant estimates and assumptions
by management include, but are not limited to, the expense recognition for certain accrued research and development services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000612" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_840_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z5Hk2uib2D14" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zygQMHvUosyg">Cash
and Cash Equivalents</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of the consolidated balance sheets and consolidated statements of cash flows, the Company considers all highly liquid instruments
with maturity of three months or less at the time of issuance to be cash equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000614" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_zo3lGgLiIgy9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 11pt; text-align: justify; text-indent: -11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zB4hMW0F5Oqf">Concentrations
of Credit Risk and Off-Balance Sheet Risk</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents are financial instruments that are potentially subject to concentrations of credit risk. The Company&#8217;s cash
and cash equivalents are deposited in accounts at large financial institutions and amounts currently exceed federally insured limits.
The Company has no financial instruments with off-balance sheet risk of loss. Additionally, the Company had a concentration in accounts
payable, as <span id="xdx_909_eus-gaap--ConcentrationRiskBenchmarkDescription_c20240101__20241231_zmw5YXQYZ8Hi" title="Concentration of risk, description"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000616" name="us-gaap:ConcentrationRiskBenchmarkDescription">three and two research and development vendors made up greater than 10% individually, and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerMember_zEZI17ZmWnC8" title="Concentration of risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-01-012024-12-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember_custom_CustomerMember" id="Fact000618" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">74</ix:nonFraction></span>% and <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerMember_zs976MComFLb" title="Concentration of risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember_custom_CustomerMember" id="Fact000620" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">38</ix:nonFraction></span>% in aggregate</ix:nonNumeric></span>, of the
outstanding accounts payable balance as of December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000622" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_848_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zwleZMKpskh6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zaBuj1PHHCUh">Segments</span></i></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 11pt; text-align: justify; text-indent: -11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates and manages its business as <span id="xdx_901_eus-gaap--NumberOfReportableSegments_dc_uSegment_c20240101__20241231_zYDclMDTWv76" title="Number of reportable segments"><span id="xdx_904_eus-gaap--NumberOfOperatingSegments_dc_uSegment_c20240101__20241231_zSrs0LpfcAm6" title="Number of operating segments"><ix:nonFraction name="us-gaap:NumberOfReportableSegments" contextRef="From2024-01-01to2024-12-31" id="Fact000624" format="ixt-sec:numwordsen" decimals="INF" unitRef="Segment"><ix:nonFraction name="us-gaap:NumberOfOperatingSegments" contextRef="From2024-01-01to2024-12-31" id="Fact000626" format="ixt-sec:numwordsen" decimals="INF" unitRef="Segment">one</ix:nonFraction></ix:nonFraction></span></span> reportable and operating segment. Operating segments are defined as components of an
enterprise where separate financial information is evaluated regularly by the chief operating decision maker (CODM) in deciding how to
allocate resources and assess performance. The Company&#8217;s CODM is the Chief Executive Officer, who reviews consolidated financial
information on a company-wide basis for purposes of allocating resources and assessing financial performance and does not regularly review
expenses or financial results on a more granular level.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000628" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zfuggtEVtZz8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zS2zZSGaYFt5">Property
and Equipment</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are fully depreciated as such there is <span id="xdx_902_eus-gaap--Depreciation_do_c20240101__20241231_zW34HL8zFf9k" title="Depreciation"><span id="xdx_904_eus-gaap--Depreciation_do_c20230101__20231231_z93sEe2bE0od" title="Depreciation"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-01-01to2024-12-31" id="Fact000630" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-012023-12-31" id="Fact000632" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> depreciation expense recognized in the years ended December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000634" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_84C_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zgdfIF1FSFS" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.15in; text-align: justify; text-indent: -0.15in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_z2J6dQFu7Vl3">Fair
Value Measurement</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
820, <i>Fair Value Measurements</i>, (&#8220;ASC 820&#8221;) provides guidance on the development and disclosure of fair value measurements.
Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset
or paid to transfer a liability in an orderly transaction between willing market participants at the measurement date. As such, fair
value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset
or a liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ensysce
Biosciences, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to the Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted
    prices in active markets for identical assets or liabilities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs
    other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable
    inputs which are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies,
    or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at
which to classify them for each reporting period. This determination requires significant judgments to be made by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024 and 2023, the recorded values of cash and cash equivalents, prepaid expenses, accounts payable, and accrued expenses
and other liabilities approximate their fair values due to the short-term nature of these items.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company issued liability classified warrants in connection with the issuance of the 2021 Notes and 2022 Notes. The warrants were liability
classified due to certain cash settlement features and included in &#8220;Other long-term liabilities&#8221; on the consolidated balance
sheets. The Company uses a Black Scholes model to estimate the fair value of the warrants. Changes in the fair value of the warrants
are recognized in other income (expense) for each reporting period. Refer to Note 8 for additional details of the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000636" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zqcg3Cg06c27" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables present assets and liabilities measured and recorded at fair value on the Company&#8217;s consolidated balance sheet
as of December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zTJxTK8lOqqa" style="display: none">SCHEDULE
OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_492_20241231_zbJyGlmmJLo3" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_494_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zoWIcGw7gQAd" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zVPzC8Y445B4" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z19LhJzyVOAf" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pp0p0_zSNe1jUc3jbb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left; padding-bottom: 1pt">Liability classified warrants</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31" id="Fact000638" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,096</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0639">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0640">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact000641" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,096</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_z8S9YHvRoyU7" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2024-12-31" id="Fact000643" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,096</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0644">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0645">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact000646" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,096</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20231231_zIgq62KQtgkl" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_492_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zOVXH1TTIcnf" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zWv1Jl7p1Noe" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_496_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zIhTClXTKzl7" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pp0p0_zPGmgVRe3Otf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left; padding-bottom: 1pt">Liability classified warrants</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31" id="Fact000648" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">26,388</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0649">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0650">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact000651" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">26,388</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_z5k42qIGqpu4" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2023-12-31" id="Fact000653" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">26,388</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0654">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0655">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact000656" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">26,388</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_z6ZttRgJPGj8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 12 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ensysce
Biosciences, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to the Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000658" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"><p id="xdx_89A_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zErV5LTICKG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the change in fair value of the Company&#8217;s Level 3 liabilities for the year ended December 31, 2024 (no
level 3 assets as of the year ended December 31, 2024):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_z5EbIprVn8Ke" style="display: none">SCHEDULE
OF CHANGE IN FAIR VALUE OF COMPANY&#8217;S LEVEL 3</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Liability classified warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Fair value, December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pp0p0_c20240101__20241231__us-gaap--FairValueByLiabilityClassAxis__custom--LiabilityClassifiedWarrantsMember_zV4N38CxRu87" title="Beginning balance" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2023-12-31_custom_LiabilityClassifiedWarrantsMember" id="Fact000660" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">26,388</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_pp0p0_c20240101__20241231__us-gaap--FairValueByLiabilityClassAxis__custom--LiabilityClassifiedWarrantsMember_zKkx2wpiMFZb" title="Change in fair value" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" contextRef="From2024-01-012024-12-31_custom_LiabilityClassifiedWarrantsMember" id="Fact000662" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">16,292</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Fair value, December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pp0p0_c20240101__20241231__us-gaap--FairValueByLiabilityClassAxis__custom--LiabilityClassifiedWarrantsMember_zLQych732CG3" title="Ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2024-12-31_custom_LiabilityClassifiedWarrantsMember" id="Fact000664" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,096</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zWYSi7SyxWI1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Federal
Grants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2019, the NIH/NIDA awarded the Company a second research and development grant related to the development of its TAAP/MPAR
abuse deterrent technology for Opioid Use Disorder (the &#8220;OUD Grant&#8221;). The total approved budget was approximately $<span id="xdx_90D_eus-gaap--GrantsReceivable_iI_pn5n6_c20190930_zncQAFem5bdf" title="Grants receivable"><ix:nonFraction name="us-gaap:GrantsReceivable" contextRef="AsOf2019-09-30" id="Fact000666" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.4</ix:nonFraction></span> million,
and the grant period ended August 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2018, the National Institutes of Health (&#8220;NIH&#8221;) through the National Institute on Drug Abuse (&#8220;NIDA&#8221;)
awarded the Company a research and development grant related to the development of its MPAR<sup>&#174;</sup> overdose prevention technology
(the &#8220;MPAR Grant&#8221;). The initial grant was extended several times and cumulative funding under this grant of approximately
$<span id="xdx_90B_eus-gaap--GrantsReceivable_iI_pn5n6_c20231231_zRI4sbUT3RDh" title="Grants receivable"><ix:nonFraction name="us-gaap:GrantsReceivable" contextRef="AsOf2023-12-31" id="Fact000668" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">10.7</ix:nonFraction></span> million was completed in December 2023. A new multi-year MPAR Grant was awarded by NIH through NIDA in August 2024, providing total
funding of $<span id="xdx_902_eus-gaap--GrantsReceivable_iI_pn6n6_c20240831_zI3h2GAO9uSi" title="Grants receivable"><ix:nonFraction name="us-gaap:GrantsReceivable" contextRef="AsOf2024-08-31" id="Fact000670" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">14</ix:nonFraction></span> million through May 2027. As December 31, 2024, the remaining cash funding under the grant is $<span id="xdx_90D_eus-gaap--GrantsReceivable_iI_pn5n6_c20241231_zYzjz6bhtdqk" title="Grants receivable"><ix:nonFraction name="us-gaap:GrantsReceivable" contextRef="AsOf2024-12-31" id="Fact000672" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.6</ix:nonFraction></span> million, covering the
period through May 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes revenue when costs related to the grants are incurred and assessed as reimbursable. The Company believes this policy
is consistent with the overarching premise in Accounting Standards Codification Topic 606, <i>Revenue from Contracts with </i>Customers
(&#8220;ASC 606&#8221;), applied by analogy, to ensure that it recognizes revenues to reflect the transfer of promised goods or services
to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services,
even though there is no &#8220;exchange&#8221; as defined in ASC 606. The Company believes the recognition of revenue as costs are incurred
and reimbursable amounts become due is analogous to the concept of transfer of control of a service over time under ASC 606.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000674" name="ENSC:ScheduleOfRevenueRecognitionUnderGrantsTableTextBlock"><p id="xdx_898_ecustom--ScheduleOfRevenueRecognitionUnderGrantsTableTextBlock_zvfS50tgNAKh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
revenue recognized under the MPAR Grant and OUD Grant was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zICynLUDum6k" style="display: none">SCHEDULE
OF REVENUE RECOGNITION UNDER GRANTS</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20240101__20241231_zQTKndyhkRdl" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20230101__20231231_zOdYbHvG8Kqa" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_hsrt--ProductOrServiceAxis__custom--MPARMember_zflyx04Dq5Cg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">MPAR</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2024-01-012024-12-31_custom_MPARMember" id="Fact000676" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,086,464</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2023-01-012023-12-31_custom_MPARMember" id="Fact000677" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,293,238</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_hsrt--ProductOrServiceAxis__custom--TAAPOUDMember_zl7OjoxNxWKk" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">TAAP/OUD</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2024-01-012024-12-31_custom_TAAPOUDMember" id="Fact000679" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,123,567</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2023-01-012023-12-31_custom_TAAPOUDMember" id="Fact000680" format="ixt:numdotdecimal" decimals="0" unitRef="USD">937,282</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_zIJOxmHgytAa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2024-01-01to2024-12-31" id="Fact000682" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,210,031</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2023-01-012023-12-31" id="Fact000683" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,230,520</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zrt76Hy71T1h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts
requested or eligible to be requested through the NIH payment management system, but for which cash has not been received, are presented
as an unbilled receivable on the Company&#8217;s consolidated balance sheet. As all amounts are expected to be remitted timely, no valuation
allowances are recorded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 13 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ensysce
Biosciences, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to the Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000685" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_843_eus-gaap--ResearchAndDevelopmentExpensePolicy_zPwxZtQDdRsd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span><span><span id="xdx_864_zuSnCCjjiYI4">Research
and Development Costs</span></span></span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s research and development expenses consist primarily of third-party research and development expenses, consulting expenses,
preclinical and clinical studies, and any allocable direct overhead, including facilities and depreciation costs, as well as salaries,
payroll taxes, and employee benefits for those individuals directly involved in ongoing research and development efforts. Research and
development expenses are charged to expense as incurred. Payments made prior to the receipt of goods or services to be used in research
and development are capitalized until the goods or services are received.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000687" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock"><p id="xdx_84A_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zvJ1IjIA6APg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zcuFmWgXI5g4">General
and Administrative Expenses</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of personnel costs associated with the Company&#8217;s executive, finance, human resources,
compliance, and other administrative personnel, as well as accounting and legal professional services fees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000689" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_848_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zucMljGhmxLj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zWpvL49RS8d6">Stock-based
Compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expenses stock-based compensation over the requisite service period based on the estimated grant-date fair value of the awards
using a graded amortization approach. The Company accounts for forfeitures as they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company estimates the fair value of stock option grants using the Black-Scholes option pricing model. The assumptions used in calculating
the fair value of stock-based awards represent management&#8217;s best estimates and involve inherent uncertainties and the application
of management&#8217;s judgment. Stock-based compensation costs are recorded in research and development and general and administrative
expenses in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time-to-time equity classified awards may be modified. On the modification date, the Company estimates the fair value of the awards immediately
before and immediately after modification. The incremental increase in fair value is recognized as expense immediately to the extent
the underlying equity awards are vested and on a straight-line basis over the same remaining amortization schedule as the unvested underlying
equity awards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000691" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_z5abU6pNVae4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_z9agJgAiu3sl">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
taxes are recorded in accordance with ASC 740, <i>Income Taxes</i> (&#8220;ASC 740&#8221;), which provides for deferred taxes using an
asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of
events that have been included in the consolidated financial statements or tax returns. Deferred tax assets and liabilities are determined
based on the difference between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates
in effect for the year in which the differences are expected to reverse. Valuation allowances are provided if, based upon the weight
of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company
recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination
by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical
merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and
penalties accrued related to unrecognized tax benefits as income tax expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 14 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ensysce
Biosciences, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to the Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000693" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zpbniCRCshqg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zA7mwy9Prx82">Earnings
per Share</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
basic earnings per share is calculated by dividing the Company&#8217;s net income or loss attributable to common stockholders by the
weighted average number of common shares outstanding during the period. The diluted earnings per share is calculated by dividing the
Company&#8217;s net earnings attributable to common stockholders by the diluted weighted average number of common shares outstanding
during the period, determined using the treasury stock method and the average stock price during the period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000695" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ztFHVlIk9OWh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following weighted average shares have been excluded from the calculations of diluted weighted average common shares outstanding because
they would have been anti-dilutive (the Company has utilized the principal balance outstanding and the end of period conversion price
for the Convertible Notes for the purposes of the weighted average share calculation below):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zZtpZSMxpsv6" style="display: none">SCHEDULE
OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20240101__20241231_zA7NsW5MKaOk" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_497_20230101__20231231_zqx6boqTHPy5" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zfqHftzvbIn6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000697" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">38,734</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000698" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,784</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zXL6kro0wmf2" style="vertical-align: bottom; background-color: White">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember" id="Fact000700" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">551,287</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="Fact000701" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">253,208</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zwgsLK7HnB17" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Convertible Notes</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_ConvertibleDebtSecuritiesMember" id="Fact000703" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,187</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_ConvertibleDebtSecuritiesMember" id="Fact000704" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">78,086</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zqIJ72JozqZj" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-01to2024-12-31" id="Fact000706" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">599,208</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31" id="Fact000707" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">340,078</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_ze8nSfeAfvJ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000709" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zIzPEraSHQZ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zsxBNeZKd276">Recently
Issued Accounting Pronouncements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the FASB issued ASU 2023-07, &#8220;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&#8221;,
which sets forth improvements to the current segment disclosure requirements in accordance with Topic 280 &#8220;Segment Reporting,&#8221;
including clarifying that entities with a single reportable segment are subject to both new and existing segment reporting requirements.
ASU 2023-07 will be effective retrospectively for fiscal years beginning after December 15, 2023, and interim periods beginning after
December 15, 2024. The Company adopted the standard with an effective date of January 1, 2024 and the adoption did not have a significant
impact on the consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued ASU No. 2023-09, &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&#8221; ASU 2023-09
requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as information on income
taxes paid. ASU 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted.
The Company is currently evaluating the impact of this guidance on its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU 2024-03, Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement Expenses (&#8220;ASU 2024-03&#8221;), which requires disclosure about the types
of costs and expenses included in certain expense captions presented on the income statement. The new disclosure requirements are effective
for the Company&#8217;s annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with
early adoption permitted. The Company is currently evaluating the impact of this pronouncement on our related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU 2024-04, &#8220;Debt &#8211; Debt with Conversion and other Options (Subtopic 470-20) &#8220;, which
set forth to improve the relevance and consistency in the application of induced conversion guidance in Subtopic 470-20, Debt&#8212;
Debt with Conversion and Other Options such as clarifying the requirements for determining whether certain settlements of convertible
debt instruments should be accounted for as an induced conversion. ASU 2024-04 is effective for all entities after December 15, 2025,
with early adoption permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.</span></p>

</ix:nonNumeric><p id="xdx_85E_zryUSNiPk6R6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>


<ix:exclude><!-- Field: Page; Sequence: 15 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ensysce
Biosciences, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to the Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000711" name="us-gaap:OtherCurrentAssetsTextBlock"><p id="xdx_808_eus-gaap--OtherCurrentAssetsTextBlock_ziQn7hWltTf9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4 &#8211; <span id="xdx_82E_zeFWHpBN5mVb">PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000713" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"><p id="xdx_890_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zhZWYehENRfl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses and other current assets consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zTOmKgfzXjV4" style="display: none">SCHEDULE
OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_497_20241231_zsJ6JB7ZzWE8" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_497_20231231_zOg38WjypbNl" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_ecustom--PrepaidResearchAndDevelopment_iI_pp0p0_maOPECzDNl_zX69uge2qLT5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Prepaid research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="ENSC:PrepaidResearchAndDevelopment" contextRef="AsOf2024-12-31" id="Fact000715" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,342,461</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="ENSC:PrepaidResearchAndDevelopment" contextRef="AsOf2023-12-31" id="Fact000716" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">535,474</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PrepaidInsurance_iI_pp0p0_maOPECzDNl_z3i4vqRGFku3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2024-12-31" id="Fact000718" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">315,306</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2023-12-31" id="Fact000719" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">441,871</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0p0_maOPECzDNl_zMlmPQ5H6G54" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2024-12-31" id="Fact000721" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">42,723</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2023-12-31" id="Fact000722" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">72,358</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherAssetsCurrent_iI_pp0p0_maOPECzDNl_zEOzzEPap5c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Other current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000724" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000725" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PrepaidExpenseCurrent_iTI_pp0p0_mtOPECzDNl_zJP3hFCAOgRf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2024-12-31" id="Fact000727" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,718,490</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2023-12-31" id="Fact000728" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,067,703</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A8_z3lPfhNaewUg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000730" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"><p id="xdx_803_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zcxvTJ4bKsV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5 &#8211; <span id="xdx_82B_zrybOIUkKSZ7">ACCRUED EXPENSES AND OTHER LIABILITIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000732" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zyYzX8ee1iMg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses and other liabilities consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_z2VFAiYHpf8d" style="display: none">SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20241231_z6UyDzuT5hZk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20231231_znNSDBaLHgx5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_ecustom--AccruedResearchAndDevelopment_iI_maALAOLzFDV_zzYz7el2CYQ6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Accrued research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="ENSC:AccruedResearchAndDevelopment" contextRef="AsOf2024-12-31" id="Fact000734" format="ixt:numdotdecimal" decimals="0" unitRef="USD">324,521</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="ENSC:AccruedResearchAndDevelopment" contextRef="AsOf2023-12-31" id="Fact000735" format="ixt:numdotdecimal" decimals="0" unitRef="USD">329,228</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AccruedProfessionalFeesCurrentAndNoncurrent_iI_maALAOLzFDV_zKpDrbEp3Pu4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent" contextRef="AsOf2024-12-31" id="Fact000737" format="ixt:numdotdecimal" decimals="0" unitRef="USD">88,995</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent" contextRef="AsOf2023-12-31" id="Fact000738" format="ixt:numdotdecimal" decimals="0" unitRef="USD">110,202</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherAccruedLiabilitiesCurrentAndNoncurrent_iI_maALAOLzFDV_znsy9GWYpIvc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other accrued liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2024-12-31" id="Fact000740" format="ixt:numdotdecimal" decimals="0" unitRef="USD">134,942</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2023-12-31" id="Fact000741" format="ixt:numdotdecimal" decimals="0" unitRef="USD">102,830</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iTI_mtALAOLzFDV_z799HnM7bElk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total accrued expenses and other liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2024-12-31" id="Fact000743" format="ixt:numdotdecimal" decimals="0" unitRef="USD">548,458</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2023-12-31" id="Fact000744" format="ixt:numdotdecimal" decimals="0" unitRef="USD">542,260</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zRQSHJP66Pq1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_8A1_zoP5PQLzdP51" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000746" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_804_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zh3ulZPAYho4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6 - <span id="xdx_82B_zHeM1V6AEDC3">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Purchase
Commitments</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the Company&#8217;s commitments included an estimated $<span id="xdx_903_eus-gaap--ContractualObligation_iI_pn5n6_c20241231_z1LgkISEQIgg" title="Contractual obligation"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2024-12-31" id="Fact000748" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">12.0</ix:nonFraction></span> million related to the Company&#8217;s open purchase
orders and contractual obligations that occurred in the ordinary course of business, including commitments with contract research organizations
for multi-year pre-clinical and clinical research studies. Although open purchase orders are considered enforceable and legally binding,
the terms generally allow the Company the option to cancel, reschedule, and adjust its requirements based on its business needs prior
to the delivery of goods or the performance of services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Litigation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024 and 2023, there were no pending legal proceedings against the Company that are expected to have a material adverse
effect on cash flows, financial condition or results of operations. From time to time, the Company could become involved in disputes
and various litigation matters that arise in the normal course of business. These may include disputes and lawsuits related to intellectual
property, licensing, contract law and employee relations matters. Periodically, the Company reviews the status of significant matters,
if any exist, and assesses its potential financial exposure. If the potential loss from any claim or legal claim is considered probable
and the amount can be estimated, the Company accrues a liability for the estimated loss. Legal proceedings are subject to uncertainties,
and the outcomes are difficult to predict. Because of such uncertainties, accruals are based on the best information available at the
time. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p>

<ix:exclude><!-- Field: Page; Sequence: 16 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ensysce
Biosciences, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to the Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Lease</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s current lease agreement (as amended) has a term that extends through October 31, 2025, with no option to renew. As of
December 31, 2024, the future lease payments totaled $<span id="xdx_901_eus-gaap--OperatingLeasePayments_c20240101__20241231_zGXcYyDsqZOc" title="Future lease payments"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2024-01-01to2024-12-31" id="Fact000750" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,545</ix:nonFraction></span>. The Company recognized total rent expense of $<span id="xdx_90E_eus-gaap--PaymentsForRent_c20240101__20241231_zaHvxCpJFsFh" title="Rent expense"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2024-01-01to2024-12-31" id="Fact000752" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,217</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--PaymentsForRent_c20230101__20231231_z6crpAeTybtj" title="Rent expense"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2023-01-012023-12-31" id="Fact000754" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,747</ix:nonFraction></span> in the
year ended December 31, 2024, and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000756" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_80F_eus-gaap--DebtDisclosureTextBlock_ztHWQcqbfxh3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7 - <span id="xdx_82B_zg5VubIMHgea">NOTES PAYABLE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000758" name="us-gaap:ScheduleOfDebtTableTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfDebtTableTextBlock_zRdvCmgkuhr1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a summary of the Company&#8217;s outstanding debt as of December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_zxqkAlQYmA68" style="display: none">SCHEDULE OF DEBT</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Principal balance</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accrued interest</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net debt balance</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%">2023 Notes</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zU60fbBhchl5" title="Principal balance" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreeNotesMember" id="Fact000760" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">216,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zQwwIJ88fsjb" title="Accrued interest" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreeNotesMember" id="Fact000762" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,368</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_pp0p0_di_c20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zvNzNBWlPKJd" title="Unamortized Debt Discount &amp; Issuance Costs" style="width: 2%">&#160;<span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="AsOf2023-12-31_custom_TwoThousandTwentyThreeNotesMember" id="Fact000764" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,197,200</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--NotesPayable_iI_pp0p0_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zYbjz8oyRlw3" title="Net debt balance" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreeNotesMember" id="Fact000766" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">230,368</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Financed insurance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20241231__us-gaap--DebtInstrumentAxis__custom--FinancedInsuranceMember_zi1MOHF1prN" title="Principal balance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-12-31_custom_FinancedInsuranceMember" id="Fact000768" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">71,292</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20241231__us-gaap--DebtInstrumentAxis__custom--FinancedInsuranceMember_zX7cjlkEPmle" title="Accrued interest" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0770">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--NotesPayable_iI_pp0p0_c20241231__us-gaap--DebtInstrumentAxis__custom--FinancedInsuranceMember_zjfPcpqvL9g2" title="Net debt balance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2024-12-31_custom_FinancedInsuranceMember" id="Fact000772" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">71,292</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20241231_zN6dblsf1W9" title="Principal balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-12-31" id="Fact000774" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">287,292</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20241231_zbT8QYGR1xKj" title="Accrued interest" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="AsOf2024-12-31" id="Fact000776" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,368</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--NotesPayable_iI_pp0p0_c20241231_zKyk7jAmrqDe" title="Net debt balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2024-12-31" id="Fact000778" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">301,660</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a summary of the Company&#8217;s outstanding debt as of December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>balance</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accrued</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>interest</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unamortized Debt</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Discount &amp; Issuance Costs</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net debt</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>balance</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">2023 Notes</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_z6ApS99mzxnd" title="Principal balance" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-12-31_custom_TwoThousandTwentyThreeNotesMember" id="Fact000780" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,836,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zuQoFuAWg6S2" title="Accrued interest" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="AsOf2023-12-31_custom_TwoThousandTwentyThreeNotesMember" id="Fact000782" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">13,078</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_pp0p0_di_c20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zpsKqhY4hFsa" title="Unamortized Debt Discount &amp; Issuance Costs" style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="AsOf2023-12-31_custom_TwoThousandTwentyThreeNotesMember" id="Fact000784" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,197,200</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--NotesPayable_iI_pp0p0_c20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zgo6IaYfBrL5" title="Net debt balance" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2023-12-31_custom_TwoThousandTwentyThreeNotesMember" id="Fact000786" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">651,878</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Financed insurance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20231231__us-gaap--DebtInstrumentAxis__custom--FinancedInsuranceMember_zZYBHGxwKeM3" title="Principal balance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-12-31_custom_FinancedInsuranceMember" id="Fact000788" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">197,249</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20231231__us-gaap--DebtInstrumentAxis__custom--FinancedInsuranceMember_zOneN2YGSs8l" title="Accrued interest" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="AsOf2023-12-31_custom_FinancedInsuranceMember" id="Fact000790" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,570</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_pp0p0_di_c20231231__us-gaap--DebtInstrumentAxis__custom--FinancedInsuranceMember_z3EUfu8HSr32" title="Unamortized Debt Discount &amp; Issuance Costs" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0792">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--NotesPayable_iI_pp0p0_c20231231__us-gaap--DebtInstrumentAxis__custom--FinancedInsuranceMember_zkf50oewR1ta" title="Net debt balance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2023-12-31_custom_FinancedInsuranceMember" id="Fact000794" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">202,819</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20231231_z1UV83Pl5Crf" title="Principal balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-12-31" id="Fact000796" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,033,249</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20231231_zRKee8TWZVyd" title="Accrued interest" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="AsOf2023-12-31" id="Fact000798" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,648</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_pp0p0_di_c20231231_zdnuLAFZdHMc" title="Unamortized Debt Discount &amp; Issuance Costs" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="AsOf2023-12-31" id="Fact000800" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,197,200</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--NotesPayable_iI_pp0p0_c20231231_zXNq56k5z4id" title="Net debt balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2023-12-31" id="Fact000802" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">854,697</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zan8qF5u4ao1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Interest
expense</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
interest expense recognized for financed insurance was $<span id="xdx_902_eus-gaap--InterestExpenseDebt_c20240101__20241231_zdv0ZCGKFl0l" title="Interest expense"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2024-01-01to2024-12-31" id="Fact000804" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,848</ix:nonFraction></span> and $<span id="xdx_90F_eus-gaap--InterestExpenseDebt_c20230101__20231231_zAxb6hqFheed" title="Interest expense"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2023-01-012023-12-31" id="Fact000806" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,716</ix:nonFraction></span> for the year ended December 31, 2024 and 2023, respectively.
Interest expense recognized for the 2023 Notes was $<span id="xdx_903_eus-gaap--InterestExpense_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zazvpgU2aZg8" title="Interest expense"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyThreeNotesMember" id="Fact000808" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,281,597</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--InterestExpense_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zETvqSJ1YjP7" title="Interest expense"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-01-012023-12-31_custom_TwoThousandTwentyThreeNotesMember" id="Fact000810" format="ixt:numdotdecimal" decimals="0" unitRef="USD">339,230</ix:nonFraction></span> for the year-ended December 31, 2024 and 2023, respectively,
which consists of amortization of the debt discount and debt issuance costs and accrued interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 17 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ensysce
Biosciences, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to the Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2023
Notes</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 23, 2023, the Company entered into a Securities Purchase Agreement (&#8220;SPA&#8221;) for an aggregate financing of $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfDebt_pn5n6_c20231022__20231023__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zp7p0hxFUQ73" title="Debt financing amount"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2023-10-222023-10-23_custom_SecuritiesPurchaseAgreementMember" id="Fact000812" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.8</ix:nonFraction></span> million
with investors, including $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfDebt_pn5n6_c20231022__20231023__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zr1xVxeaqvL2" title="Debt financing amount"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2023-10-222023-10-23_custom_SecuritiesPurchaseAgreementMember_custom_TwoThousandTwentyThreeNotesMember" id="Fact000814" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million with a board member. At the first closing under the SPA, which occurred on October 25, 2023, the
Company issued to the investors (i) senior secured convertible promissory notes in the aggregate principal amount of $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20231025__us-gaap--TypeOfArrangementAxis__custom--FirstClosingSecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zbbfr8W7tcdl" title="Aggregate principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-10-25_custom_FirstClosingSecuritiesPurchaseAgreementMember_custom_TwoThousandTwentyThreeNotesMember" id="Fact000816" format="ixt:numdotdecimal" decimals="0" unitRef="USD">612,000</ix:nonFraction></span> for an
aggregate purchase price of $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfDebt_c20231024__20231025__us-gaap--TypeOfArrangementAxis__custom--FirstClosingSecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zVTuPS6WcGU" title="Aggregate purchase price"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2023-10-242023-10-25_custom_FirstClosingSecuritiesPurchaseAgreementMember_custom_TwoThousandTwentyThreeNotesMember" id="Fact000818" format="ixt:numdotdecimal" decimals="0" unitRef="USD">566,667</ix:nonFraction></span> and (ii) warrants to purchase <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231025__us-gaap--TypeOfArrangementAxis__custom--FirstClosingSecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_z0Hg2M4kvoJ3" title="Warrants to purchase common shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-10-25_custom_FirstClosingSecuritiesPurchaseAgreementMember_custom_TwoThousandTwentyThreeNotesMember" id="Fact000820" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">83,714</ix:nonFraction></span> shares of the Company&#8217;s common stock, par value $<span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231025__us-gaap--TypeOfArrangementAxis__custom--FirstClosingSecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zZNmyPVzSY92" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-10-25_custom_FirstClosingSecuritiesPurchaseAgreementMember_custom_TwoThousandTwentyThreeNotesMember" id="Fact000822" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span>
per share in the aggregate. At the second closing under the SPA, which occurred on November 29, 2023, the Company issued to the investors
referenced above, (i) additional notes in the aggregate principal amount of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20231129__us-gaap--TypeOfArrangementAxis__custom--SecondClosingSecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zXh6GJVNDM2e" title="Aggregate principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-11-29_custom_SecondClosingSecuritiesPurchaseAgreementMember_custom_TwoThousandTwentyThreeNotesMember" id="Fact000824" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,224,000</ix:nonFraction></span> for an aggregate purchase price of $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfDebt_c20231129__20231129__us-gaap--TypeOfArrangementAxis__custom--SecondClosingSecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_znDCO1BygGmg" title="Aggregate purchase price"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2023-11-292023-11-29_custom_SecondClosingSecuritiesPurchaseAgreementMember_custom_TwoThousandTwentyThreeNotesMember" id="Fact000826" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,133,333</ix:nonFraction></span>
and (i) additional warrants to purchase <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231129__us-gaap--TypeOfArrangementAxis__custom--SecondClosingSecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zMtyK4wa4mMg" title="Warrants to purchase common shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-11-29_custom_SecondClosingSecuritiesPurchaseAgreementMember_custom_TwoThousandTwentyThreeNotesMember" id="Fact000828" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">167,427</ix:nonFraction></span> shares of the common stock in the aggregate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reflected the outstanding principal amount, the remaining unamortized discount (both original issue discount and the relative
fair value discount associated with the warrants discussed below) and the remaining debt issuance costs as a net amount on the face of
the balance sheet. The amortization of the original debt discount (approximately $<span id="xdx_903_eus-gaap--AmortizationOfDebtDiscountPremium_pn5n6_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zZrOI3gczxp" title="Amortization of debt discount premium"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyThreeNotesMember" id="Fact000830" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million) and issuance costs (approximately $<span id="xdx_901_eus-gaap--AmortizationOfFinancingCosts_pn5n6_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_znoBURwnBXp" title="Amortization of financing costs"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2023-01-012023-12-31_custom_TwoThousandTwentyThreeNotesMember" id="Fact000832" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.3</ix:nonFraction></span>
million) were recorded as interest expense within the consolidated statements of operations. As of December 31, 2024, the original debt
discount and issuance costs were fully amortized to interest expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrants have an exercise price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231023__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zGQi6NF1g2of" title="Warrant, exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-10-23_custom_SecuritiesPurchaseAgreementMember" id="Fact000834" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">23.5125</ix:nonFraction></span>, the same as the conversion price, and are exercisable for five years following the issuance
date. The warrants were equity classified as they are indexed to the Company&#8217;s stock and only settleable in shares. The warrants
were initially measured at fair value using a Black-Scholes valuation model and were allocated along with the 2023 Notes using the relative
fair value method. The initial fair value of $<span id="xdx_904_eus-gaap--PaymentsOfDebtIssuanceCosts_pn5n6_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkykbIhTvnla" title="Payments of debt issuance costs"><ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyThreeNotesMember_us-gaap_WarrantMember" id="Fact000836" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.1</ix:nonFraction></span> million allocated to the warrants was considered a debt discount and was amortized
to interest expense over the remaining term of the notes. As of December 31, 2024, the discount associated with the warrants was fully
amortized to interest expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2024, the Company converted <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20240101__20241231_z2O30PcjZcU9" title="Conversion of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2024-01-01to2024-12-31" id="Fact000838" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">49,702</ix:nonFraction></span> shares of common stock with a conversion value of $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_pn5n6_c20240101__20241231_zle77cfFJId3" title="Conversion of shares value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-01to2024-12-31" id="Fact000840" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.2</ix:nonFraction></span> million related to the 2023 Notes. In addition,
in connection with the SPA, the Company incurred a $<span id="xdx_90D_ecustom--ProceedsFromWarrantInducementNetOfIssuanceCosts_pn5n6_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zXFvSxJxpLnj" title="Transaction cost"><ix:nonFraction name="ENSC:ProceedsFromWarrantInducementNetOfIssuanceCosts" contextRef="From2024-01-012024-12-31_custom_SecuritiesPurchaseAgreementMember" id="Fact000842" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.0</ix:nonFraction></span> million waiver fee as a result of the 2024 February Warrant Inducement (see Note
8) to pay down $<span id="xdx_904_ecustom--IssuanceOfCommonStockValueUponWarrantInducementNetOfIssuanceCosts_pn5n6_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zN8scmQ2jArc" title="Warrant inducement cost"><ix:nonFraction name="ENSC:IssuanceOfCommonStockValueUponWarrantInducementNetOfIssuanceCosts" contextRef="From2024-01-012024-12-31_custom_SecuritiesPurchaseAgreementMember" id="Fact000844" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span> million of the 2023 Notes and incurred $<span id="xdx_90D_ecustom--TransactionCostsAssociatedWithWarrantInducement_pn5n6_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zZEY9dScflk5" title="Transaction cost"><ix:nonFraction name="ENSC:TransactionCostsAssociatedWithWarrantInducement" contextRef="From2024-01-012024-12-31_custom_SecuritiesPurchaseAgreementMember" id="Fact000846" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span> million in transaction costs recorded as such in the consolidated statement
of stockholders&#8217; equity. As of December 31, 2024, the remaining amount of the 2023 Notes relates to senior secured convertible
promissory notes held by a Company board member (see Note 11).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Financed
Insurance Premiums</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2024, the Company renewed and financed its directors&#8217; and officers&#8217; liability insurance in the amount of $<span id="xdx_902_ecustom--FinancedInsurancePremiums_pn5n6_c20240601__20240630_zA0fv0x4kAt1" title="Financed insurance premiums"><ix:nonFraction name="ENSC:FinancedInsurancePremiums" contextRef="From2024-06-012024-06-30" id="Fact000848" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million.
Monthly payments are scheduled from July 2024 through March 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000850" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_809_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zWTGyPa8IOd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8 - <span><span id="xdx_82F_zYuABdEVbHF3">STOCKHOLDERS&#8217; EQUITY</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s current Certificate of Incorporation authorizes <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_c20241231_zrV2WUXLqlIf" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000852" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000,000</ix:nonFraction></span> shares of common stock and <span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_c20241231_zteT8gZgWyJ4" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000854" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500,000</ix:nonFraction></span> shares of preferred
stock, both with par value equal to $<span id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20241231_z9tCfdW3PySl" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000856" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span>. As of December 31, 2024, and December 31, 2023, there were <span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_do_c20241231_zGmajhTfvq3j" title="Preferred stock, shares issued"><span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20241231_z9Zb7qDoIgAa" title="Preferred stock, shares outstanding"><span id="xdx_904_eus-gaap--PreferredStockSharesIssued_iI_do_c20231231_zIDwjrdIbxD" title="Preferred stock, shares issued"><span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20231231_zBCrP6cNUYKd" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000858" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000860" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact000862" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000864" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares of preferred stock
issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ensysce
Biosciences, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to the Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reverse
Stock Split</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 27, 2024, the Company filed an amendment to the Company&#8217;s Third Amended and Restated Certificate of Incorporation (as
amended to date, the &#8220;Certificate of Incorporation&#8221;), with the Secretary of State of the State of Delaware to effect a one-for-fifteen
(<span id="xdx_906_eus-gaap--StockholdersEquityReverseStockSplit_c20241127__20241127_z5RC4Vt5IaK" title="Reverse stock split"><ix:nonNumeric contextRef="From2024-11-272024-11-27" id="Fact000866" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-15</ix:nonNumeric></span>) reverse stock split (the &#8220;Reverse Stock Split&#8221;) of our common stock, par value $<span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20241127_zuinUQtztzPh" title="Common stock par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-11-27" id="Fact000868" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> (the &#8220;Common Stock&#8221;).
The Reverse Stock Split was effective as of 12:01 am on December 6, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described in detail in our definitive proxy statement filed with the SEC on October 18, 2024, the Board authorized a <span id="xdx_90B_eus-gaap--StockholdersEquityReverseStockSplit_c20241018__20241018_z8x7qnNMc7Bg" title="Reverse stock split"><ix:nonNumeric contextRef="From2024-10-182024-10-18" id="Fact000870" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-15</ix:nonNumeric></span> reverse
stock split ratio and directed the implementation of the Reverse Stock Split. As a result of the Reverse Stock Split, at the Effective
Time, every fifteen (15) shares of our pre-Reverse Stock Split Common Stock will be combined and reclassified into one (1) share of our
Common Stock. The post-Reverse Stock Split Common Stock began trading on December 6, 2024, with a new CUSIP number of 293602504. The
Reverse Stock Split does not affect any stockholder&#8217;s ownership percentage of the Common Stock and does not change our authorized
number of shares, alter the par value of the Common Stock or modify any voting rights or other terms of the Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise prices, and the number of shares of Common Stock issuable upon exercise of the Company&#8217;s warrants automatically adjusted,
in accordance with their terms, in proportion to the Reverse Stock Split ratio, and proportionate adjustments were also made to the per
share exercise price and/or the number of shares issuable upon the exercise or vesting of all stock options and restricted stock unit
awards issued by the Company and outstanding immediately prior to the effective time of the Reverse Stock Split, which resulted in a
proportionate decrease in the number of shares of Common Stock reserved for issuance upon exercise or vesting of such stock options and
restricted stock unit awards, and a proportionate increase in the exercise price of all such stock options and restricted stock unit
awards. Concurrently, the number of shares reserved for issuance under the Company&#8217;s Amended and Restated 2021 Omnibus Incentive
Plan immediately prior to the effective time of the Reverse Stock Split were reduced proportionately.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
fractional shares were issued in connection with the Reverse Stock Split. In lieu of the issuance of fractional shares, the Company
rounded up any fractional shares resulting from the Reverse Stock Split to the nearest whole share. Fractional shares will be rounded
up at the participant (per broker) level, with such rounding adjustment subject to each broker&#8217;s particular processes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2024
Registered Direct Offering and 2024 August Warrant Inducement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2024, the Company entered into a definitive Securities Purchase Agreement with certain institutional investors, pursuant to which
the Company agreed to issue and sell in a registered direct offering, (i) an aggregate of <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240801__20240831__us-gaap--StatementEquityComponentsAxis__custom--RegisteredDirectOfferingMember_zMDPs6ZH6uFk" title="Purchase of shares through securities purchase agreement"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-08-012024-08-31_custom_RegisteredDirectOfferingMember" id="Fact000872" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">166,054</ix:nonFraction></span> shares of common stock, par value $<span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240831__us-gaap--StatementEquityComponentsAxis__custom--RegisteredDirectOfferingMember_zHrnkP27SJxk" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-08-31_custom_RegisteredDirectOfferingMember" id="Fact000874" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span>
per share at an offering price of $<span id="xdx_90F_eus-gaap--SharePrice_iI_c20240831__us-gaap--StatementEquityComponentsAxis__custom--RegisteredDirectOfferingMember_zHxXYICrGoab" title="Common stock, share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-08-31_custom_RegisteredDirectOfferingMember" id="Fact000876" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.05</ix:nonFraction></span> per share, (ii) pre-funded warrants to purchase up to <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240801__20240831__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zyXM4NFckifa" title="Purchase of shares through securities purchase agreement"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-08-012024-08-31_custom_PrefundedWarrantMember" id="Fact000878" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">70,827</ix:nonFraction></span> shares of common stock, at a price
per pre-funded warrant equal to $<span id="xdx_90A_eus-gaap--SharePrice_iI_c20240831__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_z0CawEybjKc" title="Common stock , share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-08-31_custom_PrefundedWarrantMember" id="Fact000880" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.0485</ix:nonFraction></span>, the price per share less $<span id="xdx_908_ecustom--AgentFeesAndOfferingExpensesPerShare_iI_c20240831__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zjvbuUdhoHZf" title="Agent fees and offering expenses , per share"><ix:nonFraction name="ENSC:AgentFeesAndOfferingExpensesPerShare" contextRef="AsOf2024-08-31_custom_PrefundedWarrantMember" id="Fact000882" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0015</ix:nonFraction></span>, for gross proceeds of approximately $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn4n6_c20240801__20240831__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zYP4YjzkYVr3" title="Common stock, gross proceeds"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-08-012024-08-31_custom_PrefundedWarrantMember" id="Fact000884" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">1.67</ix:nonFraction></span> million before the
deduction of placement agent fees and offering expenses. The pre-funded warrants were subsequently exercised in full and were not outstanding
as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also entered into the August Inducement Letter with certain warrant holders for the exercise of certain outstanding warrants
to purchase up to an aggregate of <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240229__us-gaap--StatementEquityComponentsAxis__custom--SeriesAandBWarrantsMember_zWgE0XnKYRJg" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-02-29_custom_SeriesAandBWarrantsMember" id="Fact000886" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">480,234</ix:nonFraction></span> shares of common stock of the Company originally issued in February 2024, having an exercise
price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240229__us-gaap--StatementEquityComponentsAxis__custom--SeriesAandBWarrantsMember_zlFMkjGmzJ7j" title="Warrant, exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-02-29_custom_SeriesAandBWarrantsMember" id="Fact000888" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">15.90</ix:nonFraction></span> per share, at a reduced exercise price of $<span id="xdx_905_eus-gaap--SharePrice_iI_pid_c20240229__us-gaap--StatementEquityComponentsAxis__custom--SeriesAandBWarrantsMember_zP21DxvwHphf" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-02-29_custom_SeriesAandBWarrantsMember" id="Fact000890" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.05</ix:nonFraction></span> per share. The Company also agreed to amend certain existing warrants
to purchase up to an aggregate of <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231130_zR66BDEGu974" title="Warrants to purchase common shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-11-30" id="Fact000892" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">133,334</ix:nonFraction> </span>shares of common stock that were previously issued in November 2023 and have an exercise price
of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231130_zzncqRn5F0J" title="Warrant, exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-11-30" id="Fact000894" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">23.51</ix:nonFraction></span> per share such that the amended warrants will have a reduced exercise price of $<span id="xdx_900_eus-gaap--SharePrice_iI_pid_c20231130_z5UmzlHe2fW4" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-11-30" id="Fact000896" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.05</ix:nonFraction></span> per share effective upon the closing of
the offering and will be exercisable from the date on which stockholder approval is received with respect to the issuance of the shares
of common stock issuable upon exercise of such warrants. As the existing November 2023 and February 2024 warrants and their related newly
issued warrants upon inducement were equity classified before and after the exchange, and as the exchange is directly attributable to
an equity offering, the Company recognized the effect of the modification of approximately $<span id="xdx_90C_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20240201__20240229_zGgjQRCV2e0l" title="Stock issuance costs"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2024-02-012024-02-29" id="Fact000898" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">10.2</ix:nonFraction></span> million as an equity issuance cost.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
a concurrent private placement, pursuant to the terms of the August Inducement Letter and Securities Purchase Agreement, the Company
utilized an exclusive placement agent for the 2024 Registered Direct Offering and 2024 August Warrant Inducement and incurred approximately
$<span id="xdx_90C_eus-gaap--LegalFees_pn5n6_c20240801__20240831_zd571bwMMWvg" title="Legal fees"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2024-08-012024-08-31" id="Fact000900" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.6</ix:nonFraction></span> million in legal fees and other closing costs. Additionally, <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240801__20240831_zyLPZZZ75MEc" title="Warrants issue, description"><ix:nonNumeric contextRef="From2024-08-012024-08-31" id="Fact000902" name="us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees">the Company issued to the placement agent as compensation unregistered
warrants to purchase up to <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20240831_zjVKmcCjhfUk" title="Warrants to purchase common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2024-08-31" id="Fact000904" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,200</ix:nonFraction></span> shares of Common Stock.</ix:nonNumeric></span> The placement agent warrants expire on <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_pid_dd_c20240831__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjj8096w4L91" title="Warrant maturity date"><ix:nonNumeric contextRef="AsOf2024-08-31_us-gaap_WarrantMember" format="ixt:datemonthdayyearen" id="Fact000906" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">August 28, 2029</ix:nonNumeric></span>, and have an exercise
price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240831__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zj8c3RQbGKf2" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-08-31_us-gaap_WarrantMember" id="Fact000908" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.81</ix:nonFraction></span> per share of Common Stock. The warrants will become exercisable upon stockholder approval and contain customary anti-dilution
adjustments to the exercise price, including for share splits, share dividends, rights offering and pro rata distributions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 1; Options: NewSection; Value: 15 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ensysce
Biosciences, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to the Consolidated Financial Statements</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2024
February Warrant Inducement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2024, the Company executed an Inducement Letter with certain holders of existing warrants to purchase up to an aggregate of
<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240229__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZ2nDbej97D4" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-02-29_us-gaap_WarrantMember" id="Fact000910" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">240,120</ix:nonFraction></span> shares of the Company&#8217;s common stock issued to the holders in connection with the 2023 May Offering. Pursuant to the Inducement
Letter, the holders agreed to exercise for cash their existing warrants to purchase an aggregate of <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240229__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNcS7ZaG4JA1" title="Warrants to purchase common shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-02-29_us-gaap_WarrantMember" id="Fact000912" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">240,120</ix:nonFraction></span> shares of Common Stock at
a reduced exercise price of $<span id="xdx_909_eus-gaap--SharePrice_iI_pid_c20240229__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znmKsujBCeXe" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-02-29_us-gaap_WarrantMember" id="Fact000914" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">15.90</ix:nonFraction></span> per share in consideration of the Company&#8217;s agreement to issue new unregistered Series A Warrants
(the &#8220;Series A Warrants&#8221;) to purchase up to <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240229__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsMember_zfVCqlxIhNC2" title="Warrants to purchase common shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-02-29_custom_SeriesAWarrantsMember" id="Fact000916" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">240,120</ix:nonFraction></span> shares of Common Stock and new unregistered Series B Warrants (the &#8220;Series
B Warrants&#8221;) to purchase up to<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240229__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zNScdBfwMU24" title="Warrants to purchase common shares"> <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-02-29_custom_SeriesBWarrantsMember" id="Fact000918" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">240,120</ix:nonFraction></span> shares of Common Stock (collectively, the &#8220;New Warrant Shares&#8221;). The Series
A Warrants have an exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240229__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsMember_z5xM6DN4cmSi" title="Warrant, exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-02-29_custom_SeriesAWarrantsMember" id="Fact000920" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">15.90</ix:nonFraction></span> per share and have a term equal to eighteen months from the date of issuance. The Series
B Warrants have an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240229__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_z6FS3gStJm67" title="Warrant, exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-02-29_custom_SeriesBWarrantsMember" id="Fact000922" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">15.90</ix:nonFraction></span> per share and will expire on <span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20240229__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zDHWRkDV8KVk" title="Warrants expiration date"><ix:nonNumeric contextRef="AsOf2024-02-29_custom_SeriesBWarrantsMember" format="ixt:datemonthdayyearen" id="Fact000924" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">May 12, 2028</ix:nonNumeric></span>. The gross proceeds to the Company from the exercise
of the warrants were approximately $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20240201__20240229__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWptwzDrXoY3" title="Proceeds from warrants"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2024-02-012024-02-29_us-gaap_WarrantMember" id="Fact000926" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.7</ix:nonFraction></span> million, prior to deducting placement agent fees and estimated offering expenses. As the existing
warrants and the new warrants were equity classified before and after the exchange, and as the exchange is directly attributable to an
equity offering, the Company recognized the effect of the modification of approximately $<span id="xdx_90A_eus-gaap--EquityClassifiedWrittenCallOptionModificationEquityIssuanceIncreaseDecreaseInEquityAmount_pn5n6_c20240201__20240229__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOGbxXSrtFIl" title="Equity issuance costs"><ix:nonFraction name="us-gaap:EquityClassifiedWrittenCallOptionModificationEquityIssuanceIncreaseDecreaseInEquityAmount" contextRef="From2024-02-012024-02-29_us-gaap_WarrantMember" id="Fact000928" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.2</ix:nonFraction></span> million as an equity issuance cost.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the execution of the Inducement Letter, the Company executed a waiver related to the 2023 Notes&#8217; SPA it had entered
into as of October 23, 2023. The SPA contained restrictions on the Company&#8217;s ability to undertake certain transactions, which included
the execution of the Inducement Letter. The Waiver permitted the Company to execute the Inducement Letter but required repayment of the
certain investor held notes issued under the SPA with a premium following closing of the transaction contemplated thereby. Refer to Note
7 for the details of the waiver fee and the application of the amounts to the outstanding notes and as a transaction cost of the warrant
inducement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilized an exclusive placement agent for the 2024 Warrant Inducement and incurred approximately $<span id="xdx_90C_eus-gaap--LegalFees_pn5n6_c20240201__20240229_zF9uCIklDMN6" title="Legal fees"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2024-02-012024-02-29" id="Fact000930" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.3</ix:nonFraction></span> million in legal fees and
other closing costs. Additionally, <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_pid_c20240201__20240229_zkuKtZJCrPBb" title="Warrants issue, description"><ix:nonNumeric contextRef="From2024-02-012024-02-29" id="Fact000932" name="us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees">the Company issued to the placement agent as compensation unregistered warrants to purchase up to
<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20240229_zw1WmjWwJFs3" title="Warrants to purchase common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2024-02-29" id="Fact000934" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,811</ix:nonFraction></span> shares of Common Stock, equal to 7.0% of the aggregate number of shares of Common Stock (or warrants) placed in the transaction</ix:nonNumeric></span>.
The placement agent warrants expire on <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_pid_dd_c20240229__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIAt1ngothKd" title="Warrant maturity date"><ix:nonNumeric contextRef="AsOf2024-02-29_us-gaap_WarrantMember" format="ixt:datemonthdayyearen" id="Fact000936" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">May 12, 2028</ix:nonNumeric></span>, and have an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240229__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zN0yS4UPZuLa" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-02-29_us-gaap_WarrantMember" id="Fact000938" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">24.56</ix:nonFraction></span> per share of Common Stock (equal to 125% of
the reduced exercise price per Existing Warrant). The closing of the offering occurred on February 14, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2023
May Offering</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 12, 2023, the Company completed a public offering of an aggregate of <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230511__20230512_z8VEGjvliRzd" title="Sale of stock number of shares issued in transaction"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2023-05-112023-05-12" id="Fact000940" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">120,059</ix:nonFraction> </span>shares of its common stock at par value $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230512_zieH72sCICV7" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-05-12" id="Fact000942" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per
share (including pre-funded warrants in lieu thereof) at a combined offering price of $<span id="xdx_909_ecustom--CombinedOfferingPricePerShare_iI_c20230512_z37pZwZ8kCLe" title="Combined offering price"><ix:nonFraction name="ENSC:CombinedOfferingPricePerShare" contextRef="AsOf2023-05-12" id="Fact000944" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">58.305</ix:nonFraction></span> per share, gross proceeds from this offering
were approximately $<span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_pn5n6_c20230511__20230512_zik9BFAOJlL4"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" contextRef="From2023-05-112023-05-12" id="Fact000945" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">7.0</ix:nonFraction></span> million before the deduction of placement agent fees and related costs of $<span id="xdx_903_eus-gaap--OtherExpenses_pn5n6_c20230511__20230512_zNJCPdjLS3n7" title="Related costs"><ix:nonFraction name="us-gaap:OtherExpenses" contextRef="From2023-05-112023-05-12" id="Fact000947" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.7</ix:nonFraction></span> million. The warrants issued in
connection with the 2023 May Offering are described further below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the offering, the Company also agreed to amend certain existing warrants to purchase up to an aggregate of <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230512_zXDbBddXDXHe" title="Warrants to purchase common shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-05-12" id="Fact000949" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,006</ix:nonFraction></span> shares
of the Company&#8217;s common stock that were previously issued in September 2021 through December 2022 to purchasers in the offering
at exercise prices ranging from $<span id="xdx_907_eus-gaap--SharePrice_iI_pid_c20230512__srt--RangeAxis__srt--MinimumMember_zdTzae4jkZ96" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-05-12_srt_MinimumMember" id="Fact000951" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">252.00</ix:nonFraction></span> to $<span id="xdx_901_eus-gaap--SharePrice_iI_pid_c20230512__srt--RangeAxis__srt--MaximumMember_zOgxnFntbxSa" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-05-12_srt_MaximumMember" id="Fact000953" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2,808.00</ix:nonFraction></span> per share, such that effective upon the closing of the offering, the amended warrants
had a reduced exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230512_zFd35NDbQAV5" title="Warrant, exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-05-12" id="Fact000955" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">54.60</ix:nonFraction></span> per share at an additional offering price of $<span id="xdx_903_ecustom--OfferingPricePerShare_iI_c20230512__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMr1snJEmzC5" title="Combined offering price"><ix:nonFraction name="ENSC:OfferingPricePerShare" contextRef="AsOf2023-05-12_us-gaap_WarrantMember" id="Fact000957" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.875</ix:nonFraction></span> per amended warrant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2023
February Offering</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 2, 2023, the Company agreed to issue and sell in a registered direct offering an aggregate of <span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230201__20230202_zGegmGchM5E8" title="Sale of stock number of shares issued in transaction"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2023-02-012023-02-02" id="Fact000959" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">19,842</ix:nonFraction></span> shares of common stock
of the Company, par value $<span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230202_zU2eQ6W6QRv4" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-02-02" id="Fact000961" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share, at an offering price of $<span id="xdx_902_ecustom--CombinedOfferingPricePerShare_iI_c20230202_zksNFHUNxmv8" title="Combined offering price"><ix:nonFraction name="ENSC:CombinedOfferingPricePerShare" contextRef="AsOf2023-02-02" id="Fact000963" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">151.20</ix:nonFraction></span> per share, for gross proceeds of approximately $<span id="xdx_907_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_pn5n6_c20230206__20230206_zTcbsblTicn7" title="Sale of stock, consideration received per transaction"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" contextRef="From2023-02-062023-02-06" id="Fact000965" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.0</ix:nonFraction></span> million
before the deduction of placement agent fees and related costs of $<span id="xdx_90B_eus-gaap--OtherExpenses_pn5n6_c20230206__20230206_z2Yg7VM3pJFd" title="Related costs"><ix:nonFraction name="us-gaap:OtherExpenses" contextRef="From2023-02-062023-02-06" id="Fact000967" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.3</ix:nonFraction></span> million. The closing occurred on February 6, 2023. The warrants
issued in connection with the 2023 February Offering are described further below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 2; Value: 15 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ensysce
Biosciences, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to the Consolidated Financial Statements</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000969" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_89C_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zHn5nlaenwRe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a summary of outstanding warrants to purchase shares of common stock as of December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zXazZfoKgjmh" style="display: none">SCHEDULE
OF OUTSTANDING WARRANT</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Reference</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares
    Underlying Outstanding Warrants</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise
    Price</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Description</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Classification</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(a)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantOneMember_fYSk___z5mcVPdfxjK6" title="Outstanding warrant"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2024-12-31_custom_WarrantOneMember" id="Fact000971" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,913,906</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantOneMember__srt--RangeAxis__srt--MinimumMember_fYSk___z1fzs5eKzkL6" title="Exercise price"><ix:nonFraction name="ENSC:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice" contextRef="AsOf2024-12-31_custom_WarrantOneMember_srt_MinimumMember" id="Fact000973" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.05</ix:nonFraction></span>
                                            - $<span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantOneMember__srt--RangeAxis__srt--MaximumMember_fYSk___zYSSfkKFHT16" title="Exercise price"><ix:nonFraction name="ENSC:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice" contextRef="AsOf2024-12-31_custom_WarrantOneMember_srt_MaximumMember" id="Fact000975" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.8125</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_ecustom--WarrantDescription_c20240101__20241231__us-gaap--AwardTypeAxis__custom--WarrantOneMember_fYSk___zBi4QCTIPhtb" title="Warrant description"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_WarrantOneMember" id="Fact000977" name="ENSC:WarrantDescription">August 2024 Warrants</ix:nonNumeric></span></span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Equity</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">(b)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantTwoMember_fYik___zuqMtLVpfG7d" title="Outstanding warrant"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2024-12-31_custom_WarrantTwoMember" id="Fact000979" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,811</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantTwoMember_fYik___zDDK2IHj4vDc" title="Exercise price"><ix:nonFraction name="ENSC:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice" contextRef="AsOf2024-12-31_custom_WarrantTwoMember" id="Fact000981" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">24.56</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_ecustom--WarrantDescription_c20240101__20241231__us-gaap--AwardTypeAxis__custom--WarrantTwoMember_fYik___zILx7s0ngawa" title="Warrant description"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_WarrantTwoMember" id="Fact000983" name="ENSC:WarrantDescription">February 2024 Warrants</ix:nonNumeric></span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Equity</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">(c)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantThreeMember_fYyk___zseDhakt9JB6" title="Outstanding warrant"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2024-12-31_custom_WarrantThreeMember" id="Fact000985" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">162,881</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantThreeMember__srt--RangeAxis__srt--MinimumMember_fYyk___z0db45Uz6Jfd" title="Exercise price"><ix:nonFraction name="ENSC:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice" contextRef="AsOf2024-12-31_custom_WarrantThreeMember_srt_MinimumMember" id="Fact000987" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.05</ix:nonFraction></span>
                                       - $<span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantThreeMember__srt--RangeAxis__srt--MaximumMember_fYSk___z9VbRgENyBca" title="Exercise price"><ix:nonFraction name="ENSC:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice" contextRef="AsOf2024-12-31_custom_WarrantThreeMember_srt_MaximumMember" id="Fact000989" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">23.51</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_ecustom--WarrantDescription_c20240101__20241231__us-gaap--AwardTypeAxis__custom--WarrantThreeMember_fYyk___zh7PO0s0NUXl" title="Warrant description"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_WarrantThreeMember" id="Fact000991" name="ENSC:WarrantDescription">2023 Notes Warrants</ix:nonNumeric></span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Equity</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">(d)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantFourMember_fZCk___zx1bn6tK0Puj" title="Outstanding warrant"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2024-12-31_custom_WarrantFourMember" id="Fact000993" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">73,474</ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantFourMember__srt--RangeAxis__srt--MinimumMember_fYyk___z70BJWkvuapc" title="Exercise price"><ix:nonFraction name="ENSC:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice" contextRef="AsOf2024-12-31_custom_WarrantFourMember_srt_MinimumMember" id="Fact000995" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">54.56</ix:nonFraction></span>
                                       - $<span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantFourMember__srt--RangeAxis__srt--MaximumMember_fYSk___zECjXJ627D37" title="Exercise price"><ix:nonFraction name="ENSC:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice" contextRef="AsOf2024-12-31_custom_WarrantFourMember_srt_MaximumMember" id="Fact000997" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">41,400</ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_ecustom--WarrantDescription_c20240101__20241231__us-gaap--AwardTypeAxis__custom--WarrantFourMember_fZCk___zWCcFWYok1tj" title="Warrant description"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_WarrantFourMember" id="Fact000999" name="ENSC:WarrantDescription">Other Warrants</ix:nonNumeric></span></span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Equity &amp; Liability</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJTzDJCL87mj" title="Outstanding warrant"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2024-12-31_us-gaap_WarrantMember" id="Fact001001" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,167,072</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0B_zHttwTJw466l" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1F_zzEUMgyiqUNc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001002" xml:lang="en-US">On
    August 29, 2024, in connection with the 2024 Registered Direct Offering and 2024 August Warrant Inducement<b><i>,</i></b> the Company
    issued equity classified warrants to purchase <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240829__us-gaap--ClassOfWarrantOrRightAxis__custom--InstitutionalInvestorMember_zNG3PCMr6ec2" title="Warrants issued" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-08-29_custom_InstitutionalInvestorMember" id="Fact001004" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,964,658</ix:nonFraction></span> shares to certain institutional investors and the placement agent. The warrants
    were issued in connection with the 2024 Registered Direct Offering and the 2024 August Warrant Inducement. The <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240829__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantsMember_zCcwEySoITL6" title="Warrants issued" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-08-29_custom_InvestorWarrantsMember" id="Fact001006" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,914,466</ix:nonFraction></span> investor
    warrants have an exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240829__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantsMember_zKC9jmetdTd9" title="Warrant exercise price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-08-29_custom_InvestorWarrantsMember" id="Fact001008" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.05</ix:nonFraction> </span>per share and are exercisable from the date on which stockholder approval is received. One
    half of the warrants will expire eighteen months after they are exercisable, and the other half will expire five years after they
    are exercisable. The <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240829__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zXGowZWvK2tl" title="Warrants issued" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-08-29_custom_PlacementAgentWarrantsMember" id="Fact001010" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,200</ix:nonFraction></span> placement agent warrants have an exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240829__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zxoN3w5rZkN7" title="Warrant exercise price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-08-29_custom_PlacementAgentWarrantsMember" id="Fact001012" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.8125</ix:nonFraction></span> per share, are exercisable upon stockholder
    approval and expire <span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20240829__us-gaap--StatementClassOfStockAxis__custom--PlacementAgentWarrantsMember_zcyag8G0Zdfk" title="Warrant expiration date" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonNumeric contextRef="AsOf2024-08-29_custom_PlacementAgentWarrantsMember11635781" format="ixt:datemonthdayyearen" id="Fact001014" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">August 28, 2029</ix:nonNumeric></span>. In December 2024, <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantsMember_zuUEfDSwdiP2" title="Investor warrants exercised" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_InvestorWarrantsMember" id="Fact001016" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,760</ix:nonFraction></span> investor warrants were exercised.</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F09_z7hCESe76193" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_F1E_zn22odATDlzh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001017" xml:lang="en-US">On
                                            February 12, 2024, the Company issued <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240212__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__custom--PlacementAgentWarrantsMember_zDxa1qEyCZYj" title="Warrants issued" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-02-12_us-gaap_WarrantMember_custom_PlacementAgentWarrantsMember" id="Fact001019" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">497,042</ix:nonFraction></span> equity classified warrants (Series A Warrants,
                                            Series B Warrants and placement agent warrants) in connection with the Inducement Letter
                                            for the 2024 February warrant inducement and related warrant restructuring. The Series A
                                            and Series B Warrants were immediately exercisable with an exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240212__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zR9dfSKJaEJ6" title="Warrants, exercise price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-02-12_custom_SeriesBWarrantsMember" id="Fact001021" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">15.90</ix:nonFraction></span> per share
                                            and expire on <span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20240212__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsMember_zZOTCaPZu5Pi" title="Warrant expiration date" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonNumeric contextRef="AsOf2024-02-12_custom_SeriesAWarrantsMember" format="ixt:datemonthdayyearen" id="Fact001023" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">August 14, 2025</ix:nonNumeric></span> and <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20240212__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zaaTSgBzpBSd" title="Warrant expiration date" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonNumeric contextRef="AsOf2024-02-12_custom_SeriesBWarrantsMember" format="ixt:datemonthdayyearen" id="Fact001025" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">May 12, 2028</ix:nonNumeric></span>, respectively. The placement agent warrants
                                            were immediately exercisable with an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240212__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCmYK51xOsxl" title="Warrant exercise price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-02-12_us-gaap_WarrantMember" id="Fact001027" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">24.56</ix:nonFraction></span> per share and expire on <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20240212__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zHgYiFEHje1l" title="Warrant expiration date" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonNumeric contextRef="AsOf2024-02-12_custom_SeriesBWarrantsMember" format="ixt:datemonthdayyearen" id="Fact001029" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">May
                                            12, 2028</ix:nonNumeric></span>. In connection with the 2024 August Warrant Inducement, <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240831__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__custom--PlacementAgentWarrantsMember_zaRXUZi5a449" title="Warrants issued" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-08-31_us-gaap_WarrantMember_custom_PlacementAgentWarrantsMember" id="Fact001031" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">480,234</ix:nonFraction></span> warrants were exercised.
                                            As of December 31, 2024, the placement agents remain outstanding.</ix:footnote></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F03_zsyzqHHpCIGb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_F15_zRUWJm7e3Vlj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001032" xml:lang="en-US">On
                                            October 25, 2023, and November 28, 2023, the Company issued warrants to purchase <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231025__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z10EZER6bSc1" title="Warrants issued" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-10-25_us-gaap_WarrantMember" id="Fact001034" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">83,714</ix:nonFraction></span> shares
                                            and <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231128__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zM5GcBQqU1Vd" title="Warrants issued" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-11-28_us-gaap_WarrantMember" id="Fact001036" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">167,427</ix:nonFraction></span> shares, respectively. The warrants were immediately exercisable with an exercise
                                            price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pp4d_c20231025__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGVJ31xafQXb" title="Warrants, exercise price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pp4d_c20231128__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLgwkQtyqAdc" title="Warrants, exercise price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-10-25_us-gaap_WarrantMember" id="Fact001038" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-11-28_us-gaap_WarrantMember" id="Fact001040" format="ixt:numdotdecimal" decimals="4" unitRef="USDPShares">23.51</ix:nonFraction></ix:nonFraction></span></span> per share and expire on <span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20231025__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKB6m7xuUk91" title="Warrant expiration date" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonNumeric contextRef="AsOf2023-10-25_us-gaap_WarrantMember" format="ixt:datemonthdayyearen" id="Fact001042" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">October 25, 2028</ix:nonNumeric></span>, and <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20231128__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztlLffHDnze5" title="Warrant expiration date" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonNumeric contextRef="AsOf2023-11-28_us-gaap_WarrantMember" format="ixt:datemonthdayyearen" id="Fact001044" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">November 28, 2028</ix:nonNumeric></span>, respectively.
                                            In January 2024, a holder of the warrants exercised <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240131__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zonkSPUuw3Eb" title="Warrants exercisable" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-01-31_us-gaap_WarrantMember" id="Fact001046" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">88,261</ix:nonFraction></span> warrants at an exercise price
                                            of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240131__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuaKVnF1utl" title="Warrant, exercise price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-01-31_us-gaap_WarrantMember" id="Fact001048" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">23.51</ix:nonFraction></span> per share. In August 2024, an inducement letter was issued to a holder of <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240831_zAsZNrYfFeFc" title="Warrants to purchase common shares" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-08-31" id="Fact001050" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">133,334</ix:nonFraction></span>
                                            warrants to reduce the exercise price from $<span id="xdx_90E_eus-gaap--SharePrice_iI_pid_c20240830_zwEOqsMWCRwj" title="Share price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-08-30" id="Fact001052" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">23.51</ix:nonFraction></span> to $<span id="xdx_90E_eus-gaap--SharePrice_iI_pid_c20240831_z1RxZeUk6qOa" title="Share price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-08-31" id="Fact001054" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.05</ix:nonFraction></span> per share.</ix:footnote></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F08_zrT6I50Hspde" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F11_zMnLjdxbjTVh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001055" xml:lang="en-US">At
    various dates from the Closing of the Business Combination through September 30, 2023, the Company assumed or issued a total of <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230930_ze0v1hh7LLhh" title="Warrants issued" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-09-30" id="Fact001057" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">73,474</ix:nonFraction></span>
    warrants to provide holders the right to purchase common stock at exercise prices ranging from $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__srt--RangeAxis__srt--MinimumMember_zVIcsZe1mFXd" title="Warrant exercise price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-09-30_srt_MinimumMember" id="Fact001059" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">54.60</ix:nonFraction></span> - $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__srt--RangeAxis__srt--MaximumMember_zVdRSVUA0kk" title="Warrant exercise price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-09-30_srt_MaximumMember" id="Fact001061" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">41,400</ix:nonFraction></span> per share. A total
    of <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230930__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantMember_zTdEAKVUFAk2" title="Class of warrant or right, outstanding" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-09-30_custom_PublicWarrantMember" id="Fact001063" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,778</ix:nonFraction></span> of the outstanding warrants are public warrants which trade on the OTC Pink Open Market under the ticker symbol ENSCW. A
    total of <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230930__us-gaap--StatementEquityComponentsAxis__custom--Notes2021And2022Member_zypGz5J7nhb9" title="Class of warrant or right, outstanding" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-09-30_custom_Notes2021And2022Member" id="Fact001065" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,901</ix:nonFraction></span> outstanding warrants (issued in connection with the 2021 and 2022 Notes) are liability-classified due to certain cash
    settlement features embedded within the warrant agreements. The remaining warrants are equity classified. The warrants expire beginning
    <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230929__us-gaap--StatementEquityComponentsAxis__custom--Notes2021And2022Member_zscjcC1ZwVac" title="Warrant expiration date" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonNumeric contextRef="AsOf2023-09-29_custom_Notes2021And2022Member" format="ixt:datemonthdayyearen" id="Fact001067" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">June 30, 2026</ix:nonNumeric></span>, through <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230930__us-gaap--StatementEquityComponentsAxis__custom--Notes2021And2022Member_zUzYNP45Z9a9" title="Warrant expiration date" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonNumeric contextRef="AsOf2023-09-30_custom_Notes2021And2022Member" format="ixt:datemonthdayyearen" id="Fact001069" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">August 7, 2028</ix:nonNumeric></span></ix:footnote></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A5_zvPN3HK5znT4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001071" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_80E_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zvNMD7NB2Dmb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9 - <span id="xdx_822_zJh5UIxtsbC9">STOCK-BASED COMPENSATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Business Combination, the Company assumed the 2021 Omnibus Incentive Plan. In February 2024, the Company&#8217;s
Board approved an annual increase of <span id="xdx_902_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20240229__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneOmnibusIncentivePlanMember_ze0sw0iTkTxl" title="Common stock, capital shares reserved for future issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2024-02-29_custom_TwoThousandTwentyOneOmnibusIncentivePlanMember" id="Fact001073" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,487</ix:nonFraction></span> shares available for future grant under the 2021 Omnibus Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognized within general and administrative expense stock-based compensation expense of $<span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zuVm0gTmtYFi" title="Share based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001075" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,494</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zc2UqTqsQkW" title="Share based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001077" format="ixt:numdotdecimal" decimals="0" unitRef="USD">627,406</ix:nonFraction></span> for the year ended
December 31, 2024 and 2023, respectively. During the year ended December 31, 2024 and 2023, the company recognized within research and
development expense stock-based compensation expense of $<span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zrSly4VU8tt" title="Share based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact001079" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,229</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zEbEtzMALUtb" title="Share based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact001081" format="ixt:numdotdecimal" decimals="0" unitRef="USD">251,754</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 3; Value: 15 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ensysce
Biosciences, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to the Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Option
Activity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, the Company did not grant any stock options. During the year ended December 31, 2023, the Company granted
stock options to purchase an aggregate of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__srt--TitleOfIndividualAxis__custom--BoardOfMembersMember_zMmuRotliVLb" title="Number of restricted stock granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-01-012023-12-31_custom_BoardOfMembersMember" id="Fact001083" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">37,000</ix:nonFraction></span> shares of common stock to employees and members of the board of directors. The options
vested immediately and have an exercise price of between $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20231231__srt--RangeAxis__srt--MinimumMember_zX4whuzhOu2k" title="Weighted average exercise price, vested or expected to vest"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_srt_MinimumMember" id="Fact001085" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">16.95</ix:nonFraction></span> and $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20231231__srt--RangeAxis__srt--MaximumMember_zyfJUHchePHj" title="Weighted average exercise price, vested or expected to vest"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_srt_MaximumMember" id="Fact001087" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">17.70</ix:nonFraction></span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001089" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zSoo4paadGYi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s stock option activity during the year ended December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zumGmWQcnou3" style="display: none">SCHEDULE OF STOCK OPTION ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    average</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise
    price</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Remaining
    contractual life</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Intrinsic
    value</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%"><span style="font-family: Times New Roman, Times, Serif">Outstanding at December 31, 2023</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231_z3l9JqbA6p3a" title="Option outstanding, beginning balance" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31" id="Fact001091" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">38,785</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231_zezRuMLV5NA6" title="Weighted average exercise price. beginning balance" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31" id="Fact001093" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">501.65</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zooWRqc7cmp7" title="Weighted average remaining contractual term"><ix:nonNumeric contextRef="From2023-01-012023-12-31" format="ixt-sec:duryear" id="Fact001095" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">9.57</ix:nonNumeric></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240101__20241231_zgzhArCAcr8d" title="Aggregate intrinsic value, beginning balance" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1097">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231_zMNI7fHiKiXj" title="Option outstanding, granted" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1099">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zoQqZkWNioJh" title="Weighted average exercise price, granted" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1101">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_pp0p0_c20240101__20241231_zov7cyppPoQ7" title="Aggregate intrinsic value, granted" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1103">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20240101__20241231_z8u3AK8QefA2" title="Option outstanding, exercised" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1105">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20241231_zVjKu15zBDKa" title="Weighted average exercise price, exercised" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1107">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20240101__20241231_zSDXyiP2r521" title="Aggregate intrinsic value, exercised" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1109">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Expired / Forfeited</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20240101__20241231_z2Afjhn6Et57" title="Option outstanding, expired or forfeited" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1111">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zMqLUqBFLRQb" title="Weighted average exercise price, expired or forfeited" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1113">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue_pp0p0_c20240101__20241231_z6V4kuznpLqc" title="Aggregate intrinsic value, expired or forfeited" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1115">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding at December 31, 2024</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20241231_zgDwmLoCOs0k" title="Option outstanding, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31" id="Fact001117" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">38,785</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231_zPlDVN10Yp31" title="Weighted average exercise price, ending balance" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31" id="Fact001119" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">501.65</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_zziDb8xbESG8" title="Weighted average remaining contractual term"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:duryear" id="Fact001121" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.58</ix:nonNumeric></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20240101__20241231_zQG69ztPbRae" title="Aggregate intrinsic value, ending balance" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1123">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Exercisable at December 31, 2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20241231_z9qExBSCGcyl" title="Option, exercisable" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-12-31" id="Fact001125" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">38,734</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20240101__20241231_zBKI5C4aWqI4" title="Weighted average exercise price, exercisable" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-12-31" id="Fact001127" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">493.54</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20240101__20241231_zf9zZYpnXOea" title="Aggregate intrinsic value, Exercisable" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1129">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Vested and expected to vest</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20241231_zPw9sME9h5L4" title="Option vested or expected to vest" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="AsOf2024-12-31" id="Fact001131" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">38,785</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20241231_zEU3q1Ptdym9" title="Weighted average exercise price, vested or expected to vest" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-12-31" id="Fact001133" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">501.65</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_zxz8jWI1HIDf" title="Weighted average remaining contractual term, exercisable"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:duryear" id="Fact001135" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">8.58</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_pp0p0_c20241231_z68lzkM2M505" title="Aggregate intrinsic value, vested or expected to vest" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1137">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zC6ulsxu0Td6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Option
Valuation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001139" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zYYRmefYhdH8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of each stock option granted has been determined using the Black-Scholes option-pricing model. The material assumptions used
in the Black-Scholes model in estimating the fair value of the options granted for the periods presented were as follows (no stock options
were granted during the year ended December 31, 2024):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_z2oPX5VQwyVd" style="display: none">SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Exercise price</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231231__srt--RangeAxis__srt--MinimumMember_zZcUquZc0jL4" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2023-12-31_srt_MinimumMember" id="Fact001141" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">16.95</ix:nonFraction></span>
                                       - <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231231__srt--RangeAxis__srt--MaximumMember_zHEjPXhcWan8" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2023-12-31_srt_MaximumMember" id="Fact001143" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">17.70</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected stock price volatility</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20230101__20231231_ziENiitsN581" title="Expected stock price volatility, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="From2023-01-012023-12-31" id="Fact001145" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">106.77</ix:nonFraction></span>%
                                            - <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20230101__20231231_zJFMwOgQg5Ae" title="Expected stock price volatility, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="From2023-01-012023-12-31" id="Fact001147" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">106.82</ix:nonFraction></span>%</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected term (years)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zk4OslyzUpj4" title="Expected term (years)"><ix:nonNumeric contextRef="From2023-01-012023-12-31" format="ixt-sec:duryear" id="Fact001149" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.00</ix:nonNumeric></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free interest rate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20230101__20231231_zGpGxcLgkT16" title="Risk-free interest rate, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2023-01-012023-12-31" id="Fact001151" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.62</ix:nonFraction></span>%
                                            - <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20230101__20231231_z9sv64O57Lxc" title="Risk-free interest rate, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2023-01-012023-12-31" id="Fact001153" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.89</ix:nonFraction></span>%</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected dividend yield</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231_ztwCi9YKlaLl" title="Expected dividend rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2023-01-012023-12-31" id="Fact001155" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zfoTvSLUuMk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
    stock-price volatility. </i>The expected volatility is derived from the historical volatilities of comparable publicly traded companies
    within the Company&#8217;s industry that the Company considers comparable to the Company&#8217;s business over a period approximately
    equal to the expected term. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
    term.</i> The expected term represents the period that the stock-based awards are expected to be outstanding. The Company&#8217;s
    historical share option exercise experience does not provide a reasonable basis upon which to estimate an expected term due to a
    lack of sufficient data. Therefore, the Company estimates the expected term for employees by using the simplified method provided
    by the Securities and Exchange Commission. The simplified method calculates the expected term as the average of the time-to-vesting
    and the contractual life of the options. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risk-free
    interest rate. </i>The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon
    U.S. Treasury notes with maturities approximately equal to the expected term.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
    dividend yield. </i>The expected dividend is assumed to be zero as the Company has never paid dividends and has no current plans
    to pay any dividends on the Company&#8217;s common stock.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 4; Value: 15 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ensysce
Biosciences, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to the Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted-average grant date fair value of options granted during the year ended December 31, 2023 was $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231_zE9zS42j7ZM7" title="Weighted-average fair value per share , grant"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31" id="Fact001157" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.98</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the Company had an aggregate of $<span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20241231_z82Eu9qbx6T8" title="Unrecognized stock based compensation"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2024-12-31" id="Fact001159" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,860</ix:nonFraction></span> of unrecognized share-based compensation cost, which is expected to be
recognized over the weighted average period of <span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardWeightedAveragePeriodExpectedToBeRecognized_dtY_c20240101__20241231_z1erjG8Kif41" title="Weighted average period"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:duryear" id="Fact001161" name="ENSC:SharebasedCompensationArrangementBySharebasedPaymentAwardWeightedAveragePeriodExpectedToBeRecognized">0.75</ix:nonNumeric></span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Shares
Reserved for Future Issuance</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001163" name="ENSC:ScheduleOfCommonStockFutureIssuanceTableTextBlock"><p id="xdx_899_ecustom--ScheduleOfCommonStockFutureIssuanceTableTextBlock_zuUtL05IOrE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following shares of common stock are reserved for future issuance:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_z3b6beliuu5l" style="display: none">SCHEDULE OF COMMON STOCK FUTURE ISSUANCE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Awards outstanding under the 2021
    Omnibus Incentive Plan</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOvxi2CvahC4" title="Common Stock, capital shares reserved for future issuance" style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001165" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">38,785</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Awards available for future grant under 2021
    Omnibus Incentive Plan</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--StockOptionAvailableForFutureGrantUnder2021OmnibusIncentivePlanMember_zM6typmi2vlf" title="Common Stock, capital shares reserved for future issuance" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember_custom_StockOptionAvailableForFutureGrantUnder2021OmnibusIncentivePlanMember" id="Fact001167" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,596</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Warrants outstanding</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantOutstandingMember_zVYWMclqlRwj" title="Common Stock, capital shares reserved for future issuance" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2024-12-31_custom_WarrantOutstandingMember" id="Fact001169" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,167,072</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total shares of common
    stock reserved for future issuance</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20241231_zjzknOyBbv54" title="Total shares of common stock reserved for future issuance" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2024-12-31" id="Fact001171" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,216,453</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zRAHVVu5xSPg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001173" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_800_eus-gaap--IncomeTaxDisclosureTextBlock_zv5PBNLwc2L7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10 - <span id="xdx_825_zNk4j5t7Q4Gg">INCOME TAXES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001175" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"><p id="xdx_89C_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zZTnJWwXv5j5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
before provision for income taxes consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zNaBR3oaIq67" style="display: none">SCHEDULE OF INCOME TAXES BENEFIT</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    ending December 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">United States</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pp0p0_c20240101__20241231__srt--StatementGeographicalAxis__country--US_z59Nsq1xf00f" title="Loss before provision for income taxes" style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2024-01-012024-12-31_country_US" id="Fact001177" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">7,987,009</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pp0p0_c20230101__20231231__srt--StatementGeographicalAxis__country--US_zNmX9uvzzBW4" title="Loss before provision for income taxes" style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-01-012023-12-31_country_US" id="Fact001179" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">10,626,275</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_z932wY5APsOg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001181" name="ENSC:ScheduleOfFederalAndStateIncomeTaxProvisionBenefitTableTextBlock"><p id="xdx_899_ecustom--ScheduleOfFederalAndStateIncomeTaxProvisionBenefitTableTextBlock_z1fo87DK9eY" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal and state income tax provision (benefit), included in general and administrative expenses in the Consolidated Statement of Operations,
is summarized as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zjSbCT2gWjT1" style="display: none">SCHEDULE OF FEDERAL AND STATE INCOME TAX PROVISION (BENEFIT)</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    ending December 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current state provision</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pp0p0_c20240101__20241231_zBH57HOWOXO6" title="Current state provision" style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="Fact001183" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,300</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pp0p0_c20230101__20231231_zN4vWxoXWq42" title="Current state provision" style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="Fact001185" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,200</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zGfgfCcNbDnj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 5; Value: 15 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ensysce
Biosciences, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to the Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001187" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zWMZoPdyyyf3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
effective tax rate of the Company&#8217;s provision (benefit) for income taxes differs from the federal statutory rate as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zugETMXcPwmj" style="display: none">SCHEDULE OF FEDERAL INCOME TAX RATE RECONCILIATION</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_493_20240101__20241231_zZ614y3olEhe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_491_20230101__20231231_zDgddKBZFF6k" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    ending December 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzZ0P_zhlP8LGZwU57" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Income (benefit) taxes at statutory
    rates</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2024-01-01to2024-12-31" id="Fact001189" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,677,271</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2023-01-012023-12-31" id="Fact001190" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,231,518</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzZ0P_z0qboDzTYj1a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">State income tax, net of federal benefit</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2024-01-01to2024-12-31" id="Fact001192" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">62,342</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2023-01-012023-12-31" id="Fact001193" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">77,243</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_maITEBzZ0P_zAyOgibPmStc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Warrants and convertible debt</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" contextRef="From2024-01-01to2024-12-31" id="Fact001195" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,421</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" contextRef="From2023-01-012023-12-31" id="Fact001196" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">90,392</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_maITEBzZ0P_zp0RWO7SZeX5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Nondeductible executive compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" contextRef="From2024-01-01to2024-12-31" id="Fact001198" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,325</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" contextRef="From2023-01-012023-12-31" id="Fact001199" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,107</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_maITEBzZ0P_z4mBefHk9VP8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock based compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="From2024-01-01to2024-12-31" id="Fact001201" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,633</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="From2023-01-012023-12-31" id="Fact001202" format="ixt:numdotdecimal" decimals="0" unitRef="USD">580,823</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_di_msITEBzZ0P_zwGgLNGQpVgh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development tax credits</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="From2024-01-01to2024-12-31" id="Fact001204" format="ixt:numdotdecimal" decimals="0" unitRef="USD">428,675</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="From2023-01-012023-12-31" id="Fact001205" format="ixt:numdotdecimal" decimals="0" unitRef="USD">629,239</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_407_ecustom--IncomeTaxReconciliationExpiringAttributes_maITEBzZ0P_zXztURcte3Jg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expiring attributes</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="ENSC:IncomeTaxReconciliationExpiringAttributes" contextRef="From2024-01-01to2024-12-31" id="Fact001207" format="ixt:numdotdecimal" decimals="0" unitRef="USD">183,912</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1208">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationTaxContingencies_maITEBzZ0P_zvXAllxY2oM1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Change in tax rates</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxContingencies" contextRef="From2024-01-01to2024-12-31" id="Fact001210" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">296</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxContingencies" contextRef="From2023-01-012023-12-31" id="Fact001211" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,848</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzZ0P_zMAGBoN4Jbbl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="From2024-01-01to2024-12-31" id="Fact001213" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,282</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="From2023-01-012023-12-31" id="Fact001214" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,162</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzZ0P_zOU4xy55K7f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Change in valuation allowance</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2024-01-01to2024-12-31" id="Fact001216" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,936,853</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2023-01-012023-12-31" id="Fact001217" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,372,148</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzZ0P_ziFgkx0EaDB8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1219">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1220">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zyNViFpVYzKl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income taxes reflect the net tax effects of (a) temporary differences between the carrying amounts of assets and liabilities for financial
reporting purposes and the amounts used for income tax purposes, and (b) operating losses and tax credit carryforwards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001222" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zLqQhhHqop98" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s deferred tax assets were comprised of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zxXcPdtKig97" style="display: none">SCHEDULE OF DEFERRED TAX ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_490_20241231_zzn5Gwrmdoj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_491_20231231_z2Obiskxomuh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As
    of December 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred tax assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTAGz96z_zv1N7PxqF0E7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net operating
    loss tax carryforwards</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2024-12-31" id="Fact001224" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">29,728,009</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-12-31" id="Fact001225" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">28,485,164</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_iI_pp0p0_maDTAGz96z_zaldXCXze6s8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Tax credits</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="AsOf2024-12-31" id="Fact001227" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,212,263</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="AsOf2023-12-31" id="Fact001228" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,793,138</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pp0p0_maDTAGz96z_ze4nAv8EZuk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Capitalized research costs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2024-12-31" id="Fact001230" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,655,425</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2023-12-31" id="Fact001231" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,368,767</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0_maDTAGz96z_z6tTMzyXUgmb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2024-12-31" id="Fact001233" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">729,318</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2023-12-31" id="Fact001234" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">746,444</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsOther_iI_pp0p0_maDTAGz96z_zImKrQrVvbN7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2024-12-31" id="Fact001236" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">36,630</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2023-12-31" id="Fact001237" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">31,279</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsGross_iTI_pp0p0_mtDTAGz96z_maDTANzp9G_zZuSG6xTp9N9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross deferred tax assets</span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2024-12-31" id="Fact001239" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">40,361,645</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2023-12-31" id="Fact001240" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">38,424,792</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTANzp9G_zX63HUeRvA79" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Valuation allowance</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-12-31" id="Fact001242" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">40,361,645</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-12-31" id="Fact001243" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">38,424,792</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsNet_iTI_pp0p0_mtDTANzp9G_maDTALNzQQ7_z0mX2Ur829ag" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total deferred tax assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1245">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1246">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred tax liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxLiabilitiesOther_iNI_pp0p0_di_maDTLzuel_zC1227LKsT65" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1248">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1249">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxLiabilities_iNTI_di_mtDTLzuel_msDTALNzQQ7_zFdEMqEMnLz6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Total
    deferred tax liabilities</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1251">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1252">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pp0p0_mtDTALNzQQ7_zVNxT8wB5ZJ3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net deferred tax assets</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1254">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1255">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zWY9G2P2h109" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the Company had federal and California net operating loss (NOL) carryforwards of $<span id="xdx_90A_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zYEOYpWWdzFa" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-12-31_us-gaap_DomesticCountryMember" id="Fact001257" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">116.4</ix:nonFraction></span> million and $<span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--CaliforniaFranchiseTaxBoardMember_zitnrZogdw3j" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-12-31_us-gaap_CaliforniaFranchiseTaxBoardMember" id="Fact001259" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">75.6</ix:nonFraction></span> million,
respectively, net of the NOLs that will expire due to Internal Revenue Code (IRC) Section 382 limitations. The federal net operating
losses generated in 2018 and after of $<span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20181231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zWlWjCFeEuvd"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2018-12-31_us-gaap_DomesticCountryMember" id="Fact001260" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">34.9</ix:nonFraction></span> million will <span id="xdx_90C_eus-gaap--TaxCreditCarryforwardDescription_c20240101__20241231_zAQ3JpnZ9fFa" title="Tax credit carryforward, description"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact001262" name="us-gaap:TaxCreditCarryforwardDescription">carryforward indefinitely and be available to offset up to 80% of future taxable
income each year</ix:nonNumeric></span>. The federal net operating losses generated prior to 2018 of $<span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20171231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zwgOvUAcPrm"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2017-12-31_us-gaap_DomesticCountryMember" id="Fact001263" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">81.6</ix:nonFraction></span> million will begin to <span id="xdx_90A_eus-gaap--OperatingLossCarryforwardsLimitationsOnUse_c20170101__20171231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zHTKICxMvaD9" title="Operating loss carryforwards expiration"><ix:nonNumeric contextRef="From2017-01-012017-12-31_us-gaap_DomesticCountryMember" id="Fact001265" name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse">expire in 2025</ix:nonNumeric></span> unless previously
utilized. The California NOL carryforwards will begin to <span id="xdx_901_eus-gaap--OperatingLossCarryforwardsLimitationsOnUse_c20240101__20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--CaliforniaFranchiseTaxBoardMember_z9RjMd9ZKbwe" title="Operating loss carryforwards expiration"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_CaliforniaFranchiseTaxBoardMember" id="Fact001267" name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse">expire in 2028</ix:nonNumeric></span>, unless previously utilized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 6; Value: 15 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ensysce
Biosciences, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to the Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, as of December 31, 2024, the Company had federal and state research and development (R&amp;D) tax credit carryforwards of $<span id="xdx_908_eus-gaap--TaxCreditCarryforwardAmount_iI_pn5n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember__us-gaap--TaxCreditCarryforwardAxis__us-gaap--ResearchMember_zPZVLwhzXUE5" title="Tax credit carryforward amount"><ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="AsOf2024-12-31_us-gaap_DomesticCountryMember_us-gaap_ResearchMember" id="Fact001269" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.6</ix:nonFraction></span>
million and $<span id="xdx_903_eus-gaap--TaxCreditCarryforwardAmount_iI_pn5n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--TaxCreditCarryforwardAxis__us-gaap--ResearchMember_zTkauLAjEBck" title="Tax credit carryforward amount"><ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="AsOf2024-12-31_us-gaap_StateAndLocalJurisdictionMember_us-gaap_ResearchMember" id="Fact001271" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.7</ix:nonFraction></span> million, respectively. The federal tax credit carryforwards will begin to <span id="xdx_904_eus-gaap--TaxCreditCarryforwardLimitationsOnUse_c20240101__20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--CaliforniaFranchiseTaxBoardMember_zzjnF69cve15" title="Tax credit carryforward expiration"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_CaliforniaFranchiseTaxBoardMember" id="Fact001273" name="us-gaap:TaxCreditCarryforwardLimitationsOnUse">expire in 2025</ix:nonNumeric></span> unless previously utilized.
The California research tax credits do not expire.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to IRC Sections 382 and 383, annual use of the Company&#8217;s NOL and R&amp;D credit carryforwards may be limited in the event that
a cumulative change in ownership of more than 50% occurs within a three-year period. Although the Company has not completed an IRC Section
382/383 analysis regarding the limitation of NOL and R&amp;D credit carryforwards as of December 31, 2024, the Company estimates that
approximately $<span id="xdx_90E_eus-gaap--TaxCreditCarryforwardAmount_iI_pn5n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zh1ghdYYPs73" title="Tax credit carryforward amount"><ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="AsOf2024-12-31_us-gaap_StateAndLocalJurisdictionMember" id="Fact001275" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.5</ix:nonFraction></span> million of tax benefits related to NOL and R&amp;D carryforwards acquired in 2015 will expire unused. Accordingly,
the related NOL and R&amp;D credit carryforwards have been removed from deferred tax assets accompanied by a corresponding reduction
of the valuation allowance. Due to the existence of the valuation allowance, limitations created by current and future ownership changes,
if any, related to the Company&#8217;s operations in the United States will not impact its effective tax rate. Any additional ownership
changes may further limit the ability to use the NOL and R&amp;D credit carryforwards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001277" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_zsvlQX1CuHtb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the activity related to the Company&#8217;s unrecognized tax benefits:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_z9jwHXM9uL3c" style="display: none">SCHEDULE
OF UNRECOGNIZED TAX BENEFITS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20240101__20241231_zICGxDjWgihi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_497_20230101__20231231_zoobMijdKGs4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    ending December 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--UnrecognizedTaxBenefits_iS_zg1EEFtUZrae" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Balance at beginning of year</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2023-12-31" id="Fact001279" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,685,360</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2022-12-31" id="Fact001280" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,428,261</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_zw3IHfOkSFki" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Increases related to current year tax positions</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="From2024-01-01to2024-12-31" id="Fact001282" format="ixt:numdotdecimal" decimals="0" unitRef="USD">141,023</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="From2023-01-012023-12-31" id="Fact001283" format="ixt:numdotdecimal" decimals="0" unitRef="USD">128,404</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_zDwD2MFhav37" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Increases related to prior year tax positions</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="From2024-01-01to2024-12-31" id="Fact001285" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,054</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="From2023-01-012023-12-31" id="Fact001286" format="ixt:numdotdecimal" decimals="0" unitRef="USD">128,695</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_iN_di_zuTR172tJSy3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Decreases related to prior
    year tax positions</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" contextRef="From2024-01-01to2024-12-31" id="Fact001288" format="ixt:numdotdecimal" decimals="0" unitRef="USD">444</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1289">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--UnrecognizedTaxBenefits_iE_zb3Ic7R5BVXj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance at end of year</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2024-12-31" id="Fact001291" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,826,993</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2023-12-31" id="Fact001292" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,685,360</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zNWOrtcCdIRb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024 and 2023, the Company had unrecognized tax benefits of $<span id="xdx_907_eus-gaap--UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_iI_pn5n6_c20241231_z0FZD3s4hYqg" title="Unrecognized tax benefits that would impact effective tax rate"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" contextRef="AsOf2024-12-31" id="Fact001294" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.8</ix:nonFraction></span> million and $<span id="xdx_90A_eus-gaap--UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_iI_pn5n6_c20231231_z0muZBS40P7d" title="Unrecognized tax benefits that would impact effective tax rate"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" contextRef="AsOf2023-12-31" id="Fact001296" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.7</ix:nonFraction></span> million, respectively. Due to the existence
of the valuation allowance, none of the unrecognized tax benefits would affect the effective tax rate. The Company&#8217;s policy is
to recognize interest and penalties from uncertain tax positions in income tax expense. The Company did not record any interest or penalties
for the years ended December 31, 2024 or 2023 and had <span id="xdx_900_eus-gaap--FinancingReceivableAccruedInterestWriteoff_do_c20240101__20241231_zZBDwNWQYMf8" title="Financing receivable accrued interest write off"><span id="xdx_90A_eus-gaap--FinancingReceivableAccruedInterestWriteoff_do_c20230101__20231231_z0kznfEtMKsh" title="Financing receivable accrued interest write off"><ix:nonFraction name="us-gaap:FinancingReceivableAccruedInterestWriteoff" contextRef="From2024-01-01to2024-12-31" id="Fact001298" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:FinancingReceivableAccruedInterestWriteoff" contextRef="From2023-01-012023-12-31" id="Fact001300" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> accrued interest on the consolidated balance sheets as of December 31, 2024
or 2023. The Company does not anticipate that the total amount of unrecognized tax benefits will significantly increase or decrease within
twelve months of the reporting date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company and its subsidiaries are subject to U.S. federal income tax as well as income tax in multiple state jurisdictions. With few exceptions,
the Company is no longer subject to United States federal income tax examinations for years before 2021 and state and local income tax
examinations before 2020. However, to the extent allowed by law, the tax authorities may have the right to examine prior periods where
net operating losses were generated and carried forward, and make adjustments up to the amount of the NOL carryforward amount. The Company
is not currently under examination by the Internal Revenue Service or any state or local tax authority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001302" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_800_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zhAtmqStucB4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
11 - <span id="xdx_822_zJKL2RHB16ne">RELATED PARTIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the Company held a $<span id="xdx_907_eus-gaap--SeniorLongTermNotes_iI_pn5n6_c20241231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zRKMZTt0bWk4" title="Debt financing amount"><ix:nonFraction name="us-gaap:SeniorLongTermNotes" contextRef="AsOf2024-12-31_custom_SecuritiesPurchaseAgreementMember" id="Fact001304" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million senior secured convertible promissory note plus accrued interest and <span id="xdx_900_ecustom--WarrantOrRightExercisable_iI_c20241231_zpqr6u3T6tEh" title="Warrants exercisable"><ix:nonFraction name="ENSC:WarrantOrRightExercisable" contextRef="AsOf2024-12-31" id="Fact001306" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">29,547</ix:nonFraction></span> warrants
exercisable for common stock at $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0UAo5juraDb" title="Warrant, exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_us-gaap_WarrantMember" id="Fact001308" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">23.51</ix:nonFraction></span> per share issued to a board member in connection to the issuance of the 2023 Notes. On April
25, 2024, the Company and the board member entered into a forbearance agreement that will expire on <span id="xdx_90A_ecustom--WarrantExpirationDate_dd_c20240425__20240425__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFJTRyszzeWb" title="Warrant, expiration date"><ix:nonNumeric contextRef="From2024-04-252024-04-25_us-gaap_WarrantMember" format="ixt:datemonthdayyearen" id="Fact001310" name="ENSC:WarrantExpirationDate">April 25, 2025</ix:nonNumeric></span>. Upon termination
of the forbearance period, the Company will owe the remaining outstanding principal balance together with unpaid interest. The Company
may pay the notes in full at any time prior to the conclusion of the forbearance period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001312" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80E_eus-gaap--SubsequentEventsTextBlock_z1Uv881EMegi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
12 - <span id="xdx_821_zh0Qi4By6Kul">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2025, the Company issued <span id="xdx_901_ecustom--StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares_c20250101__20250131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkLTLf5p1yXk" title="Number of shares issued upon exercise of warrants"><ix:nonFraction name="ENSC:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares" contextRef="From2025-01-012025-01-31_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember" id="Fact001314" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">49,361</ix:nonFraction></span> shares of common stock for $<span id="xdx_906_ecustom--StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants_pid_c20250101__20250131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zooSEUrAHrR4" title="Value of shares issued upon exercise of warrants"><ix:nonFraction name="ENSC:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants" contextRef="From2025-01-012025-01-31_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember" id="Fact001316" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">0.3</ix:nonFraction></span> million upon exercise of August 2024 warrants issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2025, the Company entered into a product development and supply agreement with Galephar Pharmaceutical Research, Inc., a Puerto
Rico specialty drug manufacturer (&#8220;Galephar&#8221;). Galephar will support the development, manufacture, packaging and testing
of the Company&#8217;s PF614 and PF614-MPAR drug products for use in clinical trials and potential future commercial launch. The Company
will pay Galephar upon achievement of defined milestones at up to 1.2 times Galephar&#8217;s costs, subject to a cap. Payment will be
in the form of common stock at fifty percent (50%) restricted shares and fifty percent (50%) freely tradeable registered shares, with
the number of shares to be issued by the Company determined by the trailing five-day average closing price of the Company&#8217;s common
stock upon achievement of each milestone. In addition, the Company will issue up to <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20250101__20250131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zl7iJs0qJYc5" title="Restricted common stock issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2025-01-012025-01-31_us-gaap_SubsequentEventMember_us-gaap_RestrictedStockMember" id="Fact001318" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,801</ix:nonFraction></span> shares (<span id="xdx_907_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_dp_uPure_c20250101__20250131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zUWyRFchx0ge" title="Shares outstanding percentage"><ix:nonFraction name="us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction" contextRef="From2025-01-012025-01-31_us-gaap_SubsequentEventMember_us-gaap_RestrictedStockMember" id="Fact001320" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1</ix:nonFraction></span>% of shares outstanding upon signing of agreement)
of restricted common stock to Galephar with vesting in three tranches through completion of defined milestones.</span></p>

</ix:nonNumeric><p id="xdx_819_z8baMTSGOdT1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 7; Value: 15 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
Index</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 0.1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description
    of Exhibit</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315221005991/forms-4.htm#mm_002" style="-sec-extract: exhibit">Agreement
    and Plan of Merger, dated January 31, 2021, by and among Leisure Acquisition Corp., Ensysce Biosciences, Inc. and EB Merger Sub,
    Inc. (incorporated by reference to Exhibit 2.1 filed with the registrant&#8217;s Registration Statement on Form S-4 (File No.333-254279)
    initially filed on March 15, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315221016378/ex3-1.htm" style="-sec-extract: exhibit">Third
    Amended and Restated Certificate of Incorporation of Ensysce Biosciences, Inc. (incorporated by reference to Exhibit 3.1 filed with
    the registrant&#8217;s Current Report on Form 8-K on July 7, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315222029755/ex3-1b.htm" style="-sec-extract: exhibit">Certificate
    of amendment to Third Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1(b) filed with the
    registrant&#8217;s Registration Statement on Form S-1 (File No. 333-268038) on October 28, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1(c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315222029729/ex3-1.htm" style="-sec-extract: exhibit">Certificate
    of Second Amendment to Third Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 filed with
    the registrant&#8217;s Current Report on Form 8-K (File No. 001-38306) on October 27, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1(d)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315223003256/ex3-1.htm" style="-sec-extract: exhibit">Certificate
    of Designation of the Series A Preferred Stock of Ensysce Biosciences, Inc., dated February 1, 2023 (incorporated by reference to
    Exhibit 3.1 to the registrant&#8217;s Registration Statement on Form 8-A, filed on February 1, 2023, File No. 000-56516)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1(e)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315223003845/ex3-2.htm" style="-sec-extract: exhibit">Certificate
    of Amendment to Certificate of Designation of the Series A Preferred Stock of Ensysce Biosciences, Inc., dated February 7, 2023 (incorporated
    by reference to Exhibit 3.2 to the Company&#8217;s Registration Statement on Form 8-A/A (Amendment No. 1), filed on February 7, 2023,
    File No. 000-56516)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315221016378/ex3-2.htm" style="-sec-extract: exhibit">Amended
    and Restated Bylaws of Ensysce Biosciences, Inc. (incorporated by reference to Exhibit 3.2 filed with the registrant&#8217;s Current
    Report on Form 8-K on July 7, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">3.2(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315224041589/ex3-2b.htm" style="-sec-extract: exhibit">Amendment
    to Amended and Restated Bylaws of Ensysce Biosciences, Inc. (incorporated by reference to Exhibit 3.2(b) filed with the registrant&#8217;s
    Current Report on Form 8-K on October 15, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000114420417062416/tv480817_ex4-1.htm" style="-sec-extract: exhibit">Warrant
    Agreement, dated December 1, 2017, between the Leisure Acquisition Corp. and Continental Stock Transfer &amp; Trust Company (incorporated
    by reference to Exhibit 4.1 filed with the registrant&#8217;s Current Report on Form 8-K on December 5, 2017)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315221009041/ex4-6.htm" style="-sec-extract: exhibit">Investor
    Rights Agreement between Ensysce Biosciences, Inc. and the Investors listed on the signature pages thereto dated as of May 11, 2018
    (incorporated by reference to Exhibit 4.6 filed with the registrant&#8217;s Registration Statement on Form S-4 (File No.333-254279)
    initially filed on March 15, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315221013848/ex4-8.htm" style="-sec-extract: exhibit">Form
    of Warrant Certificate issued to previous holders of Private Placement Warrants and other private warrants (incorporated by reference
    to Exhibit 4.8 filed with the registrant&#8217;s Registration Statement on Form S-4 (File No.333-254279) initially filed on March
    15, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315221023828/ex4-7.htm" style="-sec-extract: exhibit">Form
    of Common Stock Purchase Warrant to be issued by the Company pursuant to and in accordance with the Securities Purchase Agreement
    (incorporated by reference to Exhibit 4.7 filed with the registrant&#8217;s Current Report on Form 8-K initially filed on September
    27, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315222021792/ex4-7.htm" style="-sec-extract: exhibit">Form
    of Common Stock Purchase Warrant issued by Ensysce Biosciences, Inc. pursuant to and in accordance with a 2022 Securities Purchase
    Agreement (incorporated by reference to Exhibit 4.7 filed with the registrant&#8217;s Current Report on Form 8-K on August 9, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315222034837/ex4-10.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif"><span style="font-size: 10pt">Form of warrant delivered by Ensysce Biosciences, Inc. in December 2022 in connection with an underwritten offering (incorporated by reference to Exhibit 4.10 filed with the registrant&#8217;s Post-Effective Amendment No. 1 to the registrant&#8217;s Registration Statement on Form S-1 filed December 8, 2022)</span></span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315222034837/ex4-11.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Form
    of pre-funded warrant delivered by Ensysce Biosciences, Inc. in December 2022 in connection with an underwritten offering (incorporated
    by reference to Exhibit 4.11 filed with the registrant&#8217;s Post-Effective Amendment No. 1 to the registrant&#8217;s Registration
    Statement on Form S-1 filed December 8, 2022)</span></a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315223003873/ex4-1.htm" style="-sec-extract: exhibit">Form
    of warrant issued in connection with a private placement conducted concurrently with a public offering (incorporated by reference
    to Exhibit 4.1 filed with the registrant&#8217;s Current Report on Form 8-K on February 7, 2023)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315223003873/ex4-2.htm" style="-sec-extract: exhibit">Form
    of warrant issued to a placement agent or its designees in connection with a private placement conducted concurrently with a public
    offering (incorporated by reference to Exhibit 4.2 filed with the registrant&#8217;s Current Report on Form 8-K on February 7, 2023)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315223017907/ex4-12.htm" style="-sec-extract: exhibit">Form
    of common warrant (incorporated by reference to Exhibit 4.12 filed with the registrant&#8217;s Post-Effective Amendment No. 1 to
    the Registration Statement on Form S-1 (File No. 333-271480) on May 17, 2023)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315223017907/ex4-13.htm" style="-sec-extract: exhibit">Form
    of pre-funded warrant (incorporated by reference to Exhibit 4.13 filed with the registrant&#8217;s Post-Effective Amendment No. 1
    to the Registration Statement on Form S-1 (File No. 333-271480) on May 17, 2023)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315223017907/ex4-14.htm" style="-sec-extract: exhibit">Form
    of placement agent warrant (incorporated by reference to Exhibit 4.14 filed with the registrant&#8217;s Post-Effective Amendment
    on Form S-1 (File No. 333-271480) on May 17, 2023)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315223017907/ex4-15.htm" style="-sec-extract: exhibit">Form
    of warrants amended in connection with the execution of a Securities Purchase Agreement on May 10, 2023 (incorporated by reference
    to Exhibit 4.15 filed with the registrant&#8217;s Post-Effective Amendment No. 1 to the Registration Statement on Form S-1 (File
    No. 333-271480) on May 17, 2023)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315223040104/ex4-16.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Form
    of common warrant issued in October 2023 and November 2023 (incorporated by reference to Exhibit 4.16 filed with the registrant&#8217;s
    Registration Statement on Form S-1 (File No. 333-275456) on November 9, 2023)</span></a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315223038049/ex4-6.htm" style="-sec-extract: exhibit">Form
    of October 2023 Secured Convertible Promissory Note (incorporated by reference to Exhibit 4.6 filed with the registrant&#8217;s Current
    Report on Form 8-K (File No. 001-38306) on October 24, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.16</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315224006773/ex4-1.htm" style="-sec-extract: exhibit">Form
    of Series A/B common stock purchase warrant issued February 14, 2024 (incorporated by reference to Exhibit 4.1 filed with the registrant&#8217;s
    Current Report on Form 8-K (File No. 001-38306) on February 14, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.17</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315224006773/ex4-2.htm" style="-sec-extract: exhibit">Form
    of placement agent warrant issued February 14, 2024 (incorporated by reference to Exhibit 4.2 filed with the registrant&#8217;s Current
    Report on Form 8-K (File No. 001-38306) on February 14, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000114420417062416/tv480817_ex10-2.htm" style="-sec-extract: exhibit">Registration
    Rights Agreement, dated December 1, 2017, among Leisure Acquisition Corp. and certain securityholders (incorporated by reference
    to Exhibit 10.2 filed with the registrant&#8217;s Current Report on Form 8-K on December 5, 2017)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000114420417062416/tv480817_ex10-3.htm" style="-sec-extract: exhibit">Warrant
    Purchase Agreement, dated December 1, 2017, between Leisure Acquisition Corp. and certain security holders (incorporated by reference
    to Exhibit 10.3 filed with the registrant&#8217;s Current Report on Form 8-K on December 5, 2017)</a></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 8; Options: NewSection; Value: 96 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3(a)
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000114420417056172/tv478082_ex10-8.htm" style="-sec-extract: exhibit">Form
    of Director and Officer Indemnity Agreement (incorporated by reference to Exhibit 10.8 filed with the registrant&#8217;s Registration
    Statement on Form S-1 (File No.333-221330) initially filed on November 3, 2017)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315221016378/ex10-2.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Form
    of Indemnification Agreement executed by each of the Ensysce directors and executive officers (incorporated by reference to Exhibit
    10.6 filed with the registrant&#8217;s Form 10-Q initially filed on November 15, 2021)</span></a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315221026770/ex10-44.htm" style="-sec-extract: exhibit">Executive
    Employment Agreement, by and between the Company and Dr. Lynn Kirkpatrick, dated September 14, 2021 (incorporated by reference to
    Exhibit 10.44 filed with the registrant&#8217;s Amendment Number 1 to its Registration Statement on Form S-1 (File No.333-260478)
    filed on October 29, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315221005991/ex10-21.htm" style="-sec-extract: exhibit">Agreement
    and Plan of Merger by and among the Signature Therapeutics, Inc., Signature Acquisition Corp. and the Company dated December 28,
    2015 (incorporated by reference to Exhibit 10.21 filed with the registrant&#8217;s Registration Statement on Form S-4 (File No.333-254279)
    initially filed on March 15, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315221026770/ex10-45.htm" style="-sec-extract: exhibit">Executive
    Employment Agreement, by and between the Company and Geoffrey Birkett, dated August 21, 2021 (incorporated by reference to Exhibit
    10.45 filed with the registrant&#8217;s Amendment Number 1 to its Registration Statement on Form S-1 (File No.333-260478) filed on
    October 29, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315221005991/ex10-26.htm" style="-sec-extract: exhibit">Employment
    Agreement between the Company and David Humphrey dated February 11, 2021 (incorporated by reference to Exhibit 10.26 filed with the
    registrant&#8217;s Registration Statement on Form S-4 (File No.333-254279) initially filed on March 15, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315221005991/ex10-27.htm" style="-sec-extract: exhibit">Amendment
    to Offer Letter between the Company and David Humphrey dated February 23, 2021 (incorporated by reference to Exhibit 10.27 filed
    with the the registrant&#8217;s Registration Statement on Form S-4 (File No.333-254279) initially filed on March 15, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9(a)+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315222008438/ex10-22.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated 2021 Omnibus Incentive Plan (incorporated by reference to Exhibit Notes filed with the registrant&#8217;s Annual Report on Form 10-K filed on March 31, 2022)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9(b)+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315222008438/ex10-22a.htm" style="-sec-extract: exhibit">Amended
    and Restated 2021 Omnibus Incentive Plan Form of Stock Option Grant Notice and Award Agreement (incorporated by reference to Exhibit
    10.22(a) filed with the registrant&#8217;s Annual Report on Form 10-K filed on March 31, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315221009041/ex10-30.htm" style="-sec-extract: exhibit">Technology Transfer Agreement by and among the Company, Covistat, Inc., Mucokinetica, Ltd., Roderick Hall and Peter Cole dated August 5, 2020 (incorporated by reference to Exhibit 10.30, filed on April 16, 2021 in an amendment to the registrant&#8217;s Registration Statement on Form S-4 (File No.333-254279))</a></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315221010356/ex10-35.htm" style="-sec-extract: exhibit">Manufacturing
    Agreement between Recro Gaineville LLC and the Company dated September 11, 2019 (incorporated by reference to Exhibit 10.35 filed
    with the registrant&#8217;s Registration Statement on Form S-4 (File No.333-254279) initially filed on March 15, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315221013848/ex10-36a.htm" style="-sec-extract: exhibit">Form
    of Exchange Agreement between Leisure Acquisition Corp. and the holders of Private Placement Warrants (incorporated by reference
    to Exhibit 10.36(a) filed with the registrant&#8217;s Registration Statement on Form S-4 (File No.333-254279) initially filed on
    March 15, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315221013848/ex10-36b.htm" style="-sec-extract: exhibit">Form
    of Exchange Agreement to be entered into by the Company with each of the Sponsors and the Strategic Investor (incorporated by reference
    to Exhibit 10.36(b) filed with the registrant&#8217;s Registration Statement on Form S-4 (File No.333-254279) initially filed on
    March 15, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13(a)&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315221023828/ex10-1.htm" style="-sec-extract: exhibit">Securities
    Purchase Agreement, dated September 24, 2021 by and among the Company and the purchasers signatory thereto (incorporated by reference
    to Exhibit 10.1 filed with the registrant&#8217;s Current Report on Form 8-K initially filed on September 27, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315221023828/ex10-2.htm" style="-sec-extract: exhibit">Registration
    Rights Agreement, dated September 24, 2021, by and among the Company and the parties signatory thereto (incorporated by reference
    to Exhibit 10.2 filed with the registrant&#8217;s Current Report on Form 8-K initially filed on September 27, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13(c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315221023828/ex10-3.htm" style="-sec-extract: exhibit">Subsidiary
    Guarantee, dated September 24, 2021, by and among the Company and the purchasers signatory thereto (incorporated by reference to
    Exhibit 10.3 filed with the registrant&#8217;s Current Report on Form 8-K initially filed on September 27, 2021)</a></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 9; Value: 96 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13(d)&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315221023828/ex10-4.htm" style="-sec-extract: exhibit">Security
    Agreement, dated September 24, 2021, by and among the Company, EBI OpCo, Inc., Covistat, Inc. and the other parties signatory thereto
    (incorporated by reference to Exhibit 10.4 filed with the registrant&#8217;s Current Report on Form 8-K initially filed on September
    27, 2021)</a></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13(e)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315221023828/ex10-5.htm" style="-sec-extract: exhibit">Patent
    Security Agreement, dated September 24, 2021, by and among the Company, EBI OpCo, Inc., Covistat, Inc. and the other parties signatory
    thereto (incorporated by reference to Exhibit 10.5 filed with the registrant&#8217;s Current Report on Form 8-K initially filed on
    September 27, 2021)</a></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13(f)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315221032515/ex10-6.htm" style="-sec-extract: exhibit">Letter
    Agreement, dated December 27, 2021, by and among the Company and the parties signatory thereto (incorporated by reference to Exhibit
    10.6 filed with the registrant&#8217;s Current Report on Form 8-K initially filed on December 27, 2021)</a></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13(g)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315222001379/ex10-7.htm" style="-sec-extract: exhibit">Second
    Letter Agreement, dated January 16, 2022, by and among the Company and the parties signatory thereto (incorporated by reference to
    Exhibit 10.7 filed with the registrant&#8217;s Current Report on Form 8-K initially filed on January 18, 2022)</a></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315222018686/ex10-1.htm" style="-sec-extract: exhibit">Securities
    Purchase Agreement, dated June 30, 2022, by and among the Company and the purchasers signatory thereto (incorporated by reference
    to Exhibit 10.1 filed with the registrant&#8217;s Current Report on Form 8-K on July 6, 2022)</a></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315222018686/ex10-2.htm" style="-sec-extract: exhibit">Registration
    Rights Agreement, dated June 30, 2022, by and among the Company and the parties signatory thereto (incorporated by reference to Exhibit
    10.2 filed with the registrant&#8217;s Current Report on Form 8-K on July 6, 2022)</a></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14(c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315222018686/ex10-3.htm" style="-sec-extract: exhibit">Subsidiary
    Guarantee, dated June 30, 2022, by and among the Company and the purchasers signatory thereto (incorporated by reference to Exhibit
    10.3 filed with the registrant&#8217;s Current Report on Form 8-K on July 6, 2022)</a></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14(d)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315222018686/ex10-4.htm" style="-sec-extract: exhibit">Security
    Agreement, dated June 30, 2022, by and among the Company, EBI OpCo, Inc., Covistat, Inc. and the other parties signatory thereto
    (incorporated by reference to Exhibit 10.4 filed with the registrant&#8217;s Current Report on Form 8-K on July 6, 2022)</a></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14(e)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315222018686/ex10-5.htm" style="-sec-extract: exhibit">Patent
    Security Agreement, dated June 30, 2022, by and among the Company, EBI OpCo, Inc., Covistat, Inc. and the other parties signatory
    thereto (incorporated by reference to Exhibit 10.5 filed with the registrant&#8217;s Current Report on Form 8-K on July 6, 2022)</a></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14(f)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315223001345/ex10-6.htm" style="-sec-extract: exhibit">Letter
    Agreement, dated January 12, 2023, by and among the Company and the parties signatory thereto (incorporated by reference to Exhibit
    10.6 filed with the registrant&#8217;s Current Report on Form 8-K on January 13, 2023)</a></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315223038049/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">October
    2023 Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 filed with the registrant&#8217;s Current Report on
    Form 8-K (File No. 001-38306) on October 24, 2023)</span></a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315223038049/ex10-2.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Form
    of Registration Rights Agreement (incorporated by reference to Exhibit 10.2 filed with the registrant&#8217;s Current Report on Form
    8-K (File No. 001-38306) on October 24, 2023)</span></a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315223038049/ex10-3.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Form
    of Subsidiary Guaranty (incorporated by reference to Exhibit 10.3 filed with the registrant&#8217;s Current Report on Form 8-K (File
    No. 001-38306) on October 24, 2023)</span></a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315223038049/ex10-4.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Form
    of Security Agreement (incorporated by reference to Exhibit 10.4 filed with the registrant&#8217;s Current Report on Form 8-K (File
    No. 001-38306) on October 24, 2023)</span></a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315223038049/ex10-5.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Form
    of Patent Security Agreement (incorporated by reference to Exhibit 10.5 filed with the registrant&#8217;s Current Report on Form
    8-K (File No. 001-38306) on October 24, 2023)</span></a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315224006773/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Form
    of Inducement Letter Agreement, dated as of February 12, 2024 (incorporated by reference to Exhibit 10.1 filed with the registrant&#8217;s
    Current Report on Form 8-K (File No. 001-38306) on February 14, 2024)</span></a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315224006773/ex10-2.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Form
    of Waiver, dated February 12, 2024, under the Securities Purchase Agreement dated October 23, 2023 ((incorporated by reference to
    Exhibit 10.2 filed with the registrant&#8217;s Current Report on Form 8-K (File No. 001-38306) on February 14, 2024)</span></a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.22</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315225004880/ex10-1.htm" style="-sec-extract: exhibit">Product
    Development and Commercial Manufacturing Supply Master Services Agreement with Galephar Pharmaceutical Research, Inc. (incorporated
    by reference to Exhibit 10.1 filed with the registrant&#8217;s Current Report on Form 8-K (File No. 001-38306) on February 4, 2025)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315223009844/ex14.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Company&#8217;s
    Code of Business Conduct (incorporated by reference to Exhibit 14 filed with the registrant&#8217;s Annual Report on Form 10-K (File
    No. 001-38306) on March 30, 2023)</span></a></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315222029755/ex21.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">List
    of Subsidiaries (incorporated by reference to Exhibit 21 filed with the Registration Statement on Form S-1 (333-268038) filed on
    October 28, 2022)</span></a></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex23-1.htm">Consent of Moss Adams LLP, Independent Registered Public Accounting Firm</a></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*++</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-1.htm">Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*++</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-2.htm">Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1*++</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-1.htm">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2*++</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-2.htm">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1716947/000149315224009993/ex97.htm" style="-sec-extract: exhibit">Policy
    relating to recovery of erroneously awarded compensation (incorporated by reference to Exhibit 97 filed with the registrant&#8217;s
    Annual Report on Form 10-K (File No. 001-38306) on March 15, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(101)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interactive
    Data File</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(104)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)</span></td>
    </tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    herewith.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
    schedules (or similar attachments) to this Exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5) or 601(b)(2),
    as applicable. The registrant agrees to furnish supplementally a copy of all omitted schedules to the Securities and Exchange Commission
    upon its request.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Denotes
    compensatory plans or arrangements or management contracts.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">++</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    certificate accompanies this report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed filed by Ensysce
    for purposes of Section 18 or any other provisions of the Exchange Act.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aj_001"></span>Item
16. Form 10-K Summary.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 10; Value: 96 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aj_002"></span>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized, in San Diego, State of California, on March 10, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENSYSCE
    BIOSCIENCES, INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Dr. Lynn Kirkpatrick</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Lynn Kirkpatrick</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President,
    Chief Executive Officer and Director</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons in the capacities indicated
on March 10, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 46%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Dr. Lynn Kirkpatrick</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President,
    Chief Executive Officer and Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Lynn Kirkpatrick</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    David Humphrey</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer, Secretary and Treasurer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Humphrey</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;(Principal
    Financial and Accounting Officer)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Andrew Benton</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Andrew
    Benton</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    William Chang</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">William
    Chang</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Bob Gower</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    and Chairman of the Board</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bob
    Gower</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Adam Levin</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adam
    Levin</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Steve Martin</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve
    Martin</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Lee Rauch</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lee
    Rauch</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Curtis Rosebraugh</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Curtis
    Rosebraugh</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 11; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the incorporation by reference in the Registration Statements on Forms S-8 (No. 333-275095, No. 333-262419 and No. 333-260116)
and Forms S-3 (No. 333-282563, No. 333-269472, No. 333-269157, and No. 333-267001) of Ensysce Biosciences, Inc. (the &ldquo;Company&rdquo;),
of our report dated March 10, 2025, relating to the financial statements of the Company (which expresses an unqualified opinion and includes
an explanatory paragraph relating to going concern uncertainty), appearing in this Annual Report on Form 10-K for the year ended December
31, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
Moss Adams LLP</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">San
Diego, California</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
10, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF CHIEF EXECUTIVE OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Lynn Kirkpatrick, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this Annual Report on Form 10-K of Ensysce Biosciences, Inc.;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
    (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
    Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
    or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
    reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing
    the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 10, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Lynn Kirkpatrick</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lynn
    Kirkpatrick</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
                                            Executive Officer</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF CHIEF FINANCIAL OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
David Humphrey, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this Annual Report on Form 10-K of Ensysce Biosciences, Inc.;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
    (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
    Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
    or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
    reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing
    the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 10, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    David Humphrey</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Humphrey</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
                                            Financial Officer</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial Officer)</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF CHIEF EXECUTIVE OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO 18 U.S.C. SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Annual Report of Ensysce Biosciences, Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the year ended December 31,
2024, as filed with the Securities and Exchange Commission (the &ldquo;Report&rdquo;), I, Lynn Kirkpatrick, Chief Executive Officer of
the Company, certify, pursuant to 18 U.S.C. &sect;1350, as added by &sect;906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
    of the Company as of and for the period covered by the Report.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 10, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Lynn Kirkpatrick</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lynn
    Kirkpatrick</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
                                            Executive Officer</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>ex32-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF CHIEF FINANCIAL OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO 18 U.S.C. SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Annual Report of Ensysce Biosciences, Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the year ended December 31,
2024, as filed with the Securities and Exchange Commission (the &ldquo;Report&rdquo;), I, David Humphrey, Chief Financial Officer of
the Company, certify, pursuant to 18 U.S.C. &sect;1350, as added by &sect;906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
    of the Company as of and for the period covered by the Report.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 10, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    David Humphrey</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Humphrey</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
                                            Financial Officer</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial Officer)</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>form10-k_001.jpg
<TEXT>
begin 644 form10-k_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &S M # 2(  A$! Q$!_\0
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M (5KX!_Z%'0O_ "'_"E^&_\ R(7A+_L!V/\ Z*%=M0!Q'_"M? /_ $*.A?\
M@!#_ (4?\*U\ _\ 0HZ%_P" $/\ A7;T4 <1_P *U\ _]"CH7_@!#_A1_P *
MU\ _]"CH7_@!#_A7;T4 <1_PK7P#_P!"CH7_ ( 0_P"%'_"M? /_ $*.A?\
M@!#_ (5V]% '$?\ "M? /_0HZ%_X 0_X4?\ "M? /_0HZ%_X 0_X5V]% '$?
M\*U\ _\ 0HZ%_P" $/\ A1_PK7P#_P!"CH7_ ( 0_P"%=O10!Q'_  K7P#_T
M*.A?^ $/^%'_  K7P#_T*.A?^ $/^%=O10!Q'_"M? /_ $*.A?\ @!#_ (4?
M\*U\ _\ 0HZ%_P" $/\ A7;T4 <1_P *U\ _]"CH7_@!#_A1_P *U\ _]"CH
M7_@!#_A7;T4 <1_PK7P#_P!"CH7_ ( 0_P"%'_"M? /_ $*.A?\ @!#_ (5V
M]% '$?\ "M? /_0HZ%_X 0_X4?\ "M? /_0HZ%_X 0_X5V]% '$?\*U\ _\
M0HZ%_P" $/\ A1_PK7P#_P!"CH7_ ( 0_P"%=O10!Q'_  K7P#_T*.A?^ $/
M^%'_  K7P#_T*.A?^ $/^%=O10!Q'_"M? /_ $*.A?\ @!#_ (4?\*U\ _\
M0HZ%_P" $/\ A7;T4 <1_P *U\ _]"CH7_@!#_A1_P *U\ _]"CH7_@!#_A7
M;T4 <1_PK7P#_P!"CH7_ ( 0_P"%'_"M? /_ $*.A?\ @!#_ (5V]% '$?\
M"M? /_0HZ%_X 0_X4?\ "M? /_0HZ%_X 0_X5V]% '$?\*U\ _\ 0HZ%_P"
M$/\ A1_PK7P#_P!"CH7_ ( 0_P"%=O10!Q'_  K7P#_T*.A?^ $/^%'_  K7
MP#_T*.A?^ $/^%=O10!Q'_"M? /_ $*.A?\ @!#_ (4?\*U\ _\ 0HZ%_P"
M$/\ A7;T4 <1_P *U\ _]"CH7_@!#_A1_P *U\ _]"CH7_@!#_A7;T4 <1_P
MK7P#_P!"CH7_ ( 0_P"%'_"M? /_ $*.A?\ @!#_ (5V]% '$?\ "M? /_0H
MZ%_X 0_X4?\ "M? /_0HZ%_X 0_X5V]% '$?\*U\ _\ 0HZ%_P" $/\ A1_P
MK7P#_P!"CH7_ ( 0_P"%=O10!Q'_  K7P#_T*.A?^ $/^%'_  K7P#_T*.A?
M^ $/^%=O10!Q'_"M? /_ $*.A?\ @!#_ (4?\*U\ _\ 0HZ%_P" $/\ A7;T
M4 <1_P *U\ _]"CH7_@!#_A1_P *U\ _]"CH7_@!#_A7;T4 <1_PK7P#_P!"
MCH7_ ( 0_P"%'_"M? /_ $*.A?\ @!#_ (5V]% '$?\ "M? /_0HZ%_X 0_X
M4?\ "M? /_0HZ%_X 0_X5V]% '$?\*U\ _\ 0HZ%_P" $/\ A1_PK7P#_P!"
MCH7_ ( 0_P"%=O10!Q'_  K7P#_T*.A?^ $/^%'_  K7P#_T*.A?^ $/^%=O
M10!Q'_"M? /_ $*.A?\ @!#_ (4?\*U\ _\ 0HZ%_P" $/\ A7;T4 <1_P *
MU\ _]"CH7_@!#_A1_P *U\ _]"CH7_@!#_A7;T4 <1_PK7P#_P!"CH7_ ( 0
M_P"%'_"M? /_ $*.A?\ @!#_ (5V]% '$?\ "M? /_0HZ%_X 0_X4?\ "M?
M/_0HZ%_X 0_X5V]% '$?\*U\ _\ 0HZ%_P" $/\ A1_PK7P#_P!"CH7_ ( 0
M_P"%=O10!Q'_  K7P#_T*.A?^ $/^%'_  K7P#_T*.A?^ $/^%=O10!Q'_"M
M? /_ $*.A?\ @!#_ (4?\*U\ _\ 0HZ%_P" $/\ A7;T4 <1_P *U\ _]"CH
M7_@!#_A1_P *U\ _]"CH7_@!#_A7;T4 <1_PK7P#_P!"CH7_ ( 0_P"%'_"M
M? /_ $*.A?\ @!#_ (5V]% '$?\ "M? /_0HZ%_X 0_X4?\ "M? /_0HZ%_X
M 0_X5V]% '$?\*U\ _\ 0HZ%_P" $/\ A1_PK7P#_P!"CH7_ ( 0_P"%=O10
M!Q'_  K7P#_T*.A?^ $/^%'_  K7P#_T*.A?^ $/^%=O10!Q'_"M? /_ $*.
MA?\ @!#_ (4?\*U\ _\ 0HZ%_P" $/\ A7;T4 <1_P *U\ _]"CH7_@!#_A7
M*>.O G@W3/!WB34-/\-:19WUGI-W<6EW;V<<4]O/%&6CFAD0!HY$8!E92"".
M*]BKB?B1_P B%XM_[ =]_P"BC0 ?#?\ Y$+PE_V ['_T4*[:N)^&_P#R(7A+
M_L!V/_HH5VU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"LG7M T+Q3HVI>'/$^BZ3XC\/:U9S:?K&A:]IUGJ^C:M87"E+BQU+2]0AN+&
M_LYT)2:VNH)895)5T8<5K44 >5_#OX%_!7X0SZC=?"GX1?#3X:W6L*8]5NO
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MK?A.\U"W%K?W7AK5;ZTGO]"N;ZV5;:\GTN>UEN8%$,S/& M=310!R'C7X?\
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M_@G^SO$7B*PDO9;#7M<LCH?V;5=9L9=2U&2SU._BGO+5]0O6@FC:ZG,GM-%
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M5U1FLK2^AMBVI7Y,1-Y<&3L:* .+G^&WP[NO&UG\2[GP#X+N/B/IU@^EZ?\
M$"?PMH<OC:QTR2"ZMI-.L_%4E@VNVM@]M?7MN]G!?I;M!>7431F.XE5^THHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *XGXD?\B%XM_P"P'??^BC7;5Q/Q(_Y$+Q;_ -@.
M^_\ 11H /AO_ ,B%X2_[ =C_ .BA7;5Q/PW_ .1"\)?]@.Q_]%"NVH ****
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M/^>.N_\ A8^,?_E]0!W=%<)_PK;PI_SQUW_PL?&/_P OJ/\ A6WA3_GCKO\
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M .%CXQ_^7U '=T5PG_"MO"G_ #QUW_PL?&/_ ,OJ/^%;>%/^>.N_^%CXQ_\
ME]0!W=%<)_PK;PI_SQUW_P +'QC_ /+ZC_A6WA3_ )XZ[_X6/C'_ .7U '=T
M5PG_  K;PI_SQUW_ ,+'QC_\OJ/^%;>%/^>.N_\ A8^,?_E]0!W=%<)_PK;P
MI_SQUW_PL?&/_P OJ/\ A6WA3_GCKO\ X6/C'_Y?4 =W17"?\*V\*?\ /'7?
M_"Q\8_\ R^H_X5MX4_YXZ[_X6/C'_P"7U '=T5PG_"MO"G_/'7?_  L?&/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3:UIGB/3)[G4/'FE0^&IO"'BNY\5MH>FZ+/?-\R?$[]ASXD_&&&Z\/7?A/\
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M_P#0?\=_^%YXK_\ EK0!W=%<)_PK_3?^@_X[_P#"\\5__+6C_A7^F_\ 0?\
M'?\ X7GBO_Y:T =W17"?\*_TW_H/^.__  O/%?\ \M:/^%?Z;_T'_'?_ (7G
MBO\ ^6M '=T5PG_"O]-_Z#_CO_PO/%?_ ,M:/^%?Z;_T'_'?_A>>*_\ Y:T
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M/?%+L_[(X?U2?P9OU2?_ $'Z'^@W_P /G/\ @FI_T=5X3_\ ",^+/_SO:/\
MA\Y_P34_Z.J\)X_[$OXLG_WGOY"O\^0@8/7\"<_AS2$<?0<CMQST/TXXQCL1
MQ1_Q+MPC9O\ MKB;_P &93V;_P"@#R&O'KBEV7]C\/ZM+X<V[^>//]0KX+?&
M_P"&'[0GP[\.?%?X/^++/QO\/?%J:K)X=\36%IJEA;:I'HFNZKX8U5X[+6[#
M2]5@%GKVAZKIK"[T^W,DEE)- );9X9I/6*_!K_@AQI/]N_L/?"FWN]<\86\%
MH_Q#CAM-,\8>(=,T^)6^+/Q!F806-EJ$%K!OED>6011)YDLDDKYDE=S^U7_"
MO]-_Z#_CO_PO/%?_ ,M:_E;B#+J649]G>4T)U:M#*\WS++J-2LX.M4HX+&U\
M-2G5=.,*;JSA2C*IR1C#F;Y8I62_IK(L?5S3(\FS.O"G3K9CE678^M3I<_LH
M5<9@Z&(J0I>TE*I[.,ZK4.>4I\JCS2E*[?=T5PG_  K_ $W_ *#_ ([_ /"\
M\5__ "UH_P"%?Z;_ -!_QW_X7GBO_P"6M>0>J=W17"?\*_TW_H/^._\ PO/%
M?_RUH_X5_IO_ $'_ !W_ .%YXK_^6M '=T5PG_"O]-_Z#_CO_P +SQ7_ /+6
MC_A7^F_]!_QW_P"%YXK_ /EK0!W=%<)_PK_3?^@_X[_\+SQ7_P#+6C_A7^F_
M]!_QW_X7GBO_ .6M '=T5PG_  K_ $W_ *#_ ([_ /"\\5__ "UH_P"%?Z;_
M -!_QW_X7GBO_P"6M '=T5PG_"O]-_Z#_CO_ ,+SQ7_\M:/^%?Z;_P!!_P =
M_P#A>>*__EK0!W=%<)_PK_3?^@_X[_\ "\\5_P#RUH_X5_IO_0?\=_\ A>>*
M_P#Y:T =W17"?\*_TW_H/^.__"\\5_\ RUH_X5_IO_0?\=_^%YXK_P#EK0!W
M=%<)_P *_P!-_P"@_P"._P#PO/%?_P M:/\ A7^F_P#0?\=_^%YXK_\ EK0!
MW=%<)_PK_3?^@_X[_P#"\\5__+6C_A7^F_\ 0?\ '?\ X7GBO_Y:T =W17"?
M\*_TW_H/^.__  O/%?\ \M:/^%?Z;_T'_'?_ (7GBO\ ^6M '=T5PG_"O]-_
MZ#_CO_PO/%?_ ,M:/^%?Z;_T'_'?_A>>*_\ Y:T =W17"?\ "O\ 3?\ H/\
MCO\ \+SQ7_\ +6C_ (5_IO\ T'_'?_A>>*__ ):T =W17"?\*_TW_H/^._\
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M_C]];BL-;UGXCW?QY\):3K'AZVO7UGPHUEXOF\5Z?X?LM)TR>^_;6B@#X@^
MT?B7Q[\?O&/QID^&?CCX6>#X/V?/A!\'(]+^(>@S>%-?U3QMX9\6?$GQAXCT
M^PT*:[E>\\-^ K7Q?IFC6'BVW@/A[Q'JNL:ZOA'5M=TG39-0?Z:^+]_X*TGX
M3?%'5?B2;L?#K3?AUXVU#Q\;&XU2TOAX+L_#6I7'BDV5WHEU9:U:W0T**_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*O!+#X5>'/B#\'-5N_A]\8_!FF0S+\3?'!\):3\0_ VB:'K=W?\ @SQ5X?\
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MV\=_^#FS_P#E70!W=%<)_P (/+_T.WCO_P '-G_\JZ/^$'E_Z';QW_X.;/\
M^5= '=T5PG_"#R_]#MX[_P#!S9__ "KH_P"$'E_Z';QW_P"#FS_^5= '=T5P
MG_"#R_\ 0[>._P#P<V?_ ,JZ/^$'E_Z';QW_ .#FS_\ E70!W=%<)_P@\O\
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M_0[>._\ P<V?_P JZ/\ A!Y?^AV\=_\ @YL__E70!W=%<)_P@\O_ $.WCO\
M\'-G_P#*NC_A!Y?^AV\=_P#@YL__ )5T =W17"?\(/+_ -#MX[_\'-G_ /*N
MC_A!Y?\ H=O'?_@YL_\ Y5T =TW0_0_RK^87_@XN_P"2)_#C_LM/AS_U"?B9
M7]'Y\#RX/_%;>.^A_P"8U9__ "JK^:+_ (.&=!;2_@S\.IFU_P 2ZMN^,GAZ
M+R=9U&"\MUSX+^)#>:D<5C:E9EV;%?>0$DD4J2P*_=>&/_)PN#_^QYAO_3.8
M'Q?B+_R0G%O_ &):_P#Z?P!_)Q1117^@R/X36P4444 ?U,_\&YO_ "!?C;_V
M4/2O_4.TVOZQ1_#_ +I_]EK^1_\ X-X]%;5=(^-3+KGB+2/+^(&E(4T34(+)
M)/\ BD=/?S)5FLKO?)AM@8%<*J@#()/]4P\#R\?\5MX[Y&?^0U9^W_4*]Z_@
M+Q7_ .3C<7?]C.'_ *K<H/[C\+O^2 X7_P"Q=5_]6.:G>45PG_"#R_\ 0[>.
M_P#P<V?_ ,JZ/^$'E_Z';QW_ .#FS_\ E77YX?>G=T5PG_"#R_\ 0[>._P#P
M<V?_ ,JZ/^$'E_Z';QW_ .#FS_\ E70!W=%<)_P@\O\ T.WCO_P<V?\ \JZ/
M^$'E_P"AV\=_^#FS_P#E70!W=%<)_P (/+_T.WCO_P '-G_\JZ/^$'E_Z';Q
MW_X.;/\ ^5= '=T5PG_"#R_]#MX[_P#!S9__ "KK=T30GT4W1;7->UG[4( !
MK=[#>"V\@SDFU$5I;>69_. GW>9O$,&W9L.X W3R"#T(.<$@_F,$?4$$=17Y
MQZ1^Q)\1+_XH3>(?B+^T!KGB/POX-T+4=+^$OBC1_#T7A_X_:?/KOP^^)/PT
M^U^+OC')KVL7>KWOA/PW\0[V\LK_ $7PYX7?Q1XNL/#7BGQ)%<W7ALP:K^CM
M% 'QKH7[//QN@^(-A\6_%/Q^\':Y\2-%\,>'/AKIFKZ+\"#X8T>_^%Z?$+PS
MXV^(.F^+]%;XK:Y<^(?'/C*R\-C0O#_BVRUG0/#/PXFUK7M:\/?#FXGU:^LY
M\'XF?L@^,OCF)O!_QL^.,?C7X.V6L_$C7_#?AK2OA=I/@SXD6E_X_P#!/CWP
M#86WB'XCZ+XF/AK6]*\#>'_B/K\?AV+1_A3X3U?4[FST.Y\9ZWXGDM]9.O?=
M'^?\_D** /F?X,? SQKX)\:^(_B=\6?BAIGQ6^(FL>!/!'PMTW5] ^'\GPTT
M32O G@6\\0ZS:BX\/R^-?'<FH^,/$GB'Q5J^K^+?$46KZ;I%XL&B:?H/A3PY
M::9,NH>B_'+6?"GASX*?&'Q#X[T&?Q5X'T+X6_$#6?&7ABU$9N?$?A32_"6K
M7WB'0;<2W%G$T^KZ1!>:?")+NUC,ERH>X@7,J^IUY1\>&\%I\#OC,_Q)LM4U
M'X=)\*?B(WC[3]$DNHM:O_!2^$-8/BFSTB6RN+.]BU2ZT,7\%A):7=K=)=O$
MUO<02A)5 /YS=;^)G_!*;X2?LS^-]5TW]I?Q9\?;GXR^%_@%\//B'X4U_P#:
MVL+C]H/X;?LYZ%XPT;5)_A=X"?1(Y-=_L/P#;:I=#QY\-_"H3Q'XS\.6.N:4
M-6N+BQL(U_I>\!W/@^\\#^#+OX>/I,O@"Z\*>';GP/)H*HFAR>#Y](LY?#+Z
M,L2K&NDOHK63:<L:J@LS"$4* !_.]X>^-7QA\*_ 30_V@++_ ()^_P#!.]OV
M;/#GPYTWQE8^&;WXY>"=5^,__"L-(\.PW=I:WGBW4_!L_A?5/'RZ/;QV]U;W
MPDOK[7A)87$;:K,T)_H7^&OB/PYXP^'/@#Q;X/L&TKPEXI\%>%?$?A;2WT^+
M26TWPYK>A6&IZ)8-I4 $.F-9Z9=6MN=/A BLC&;:,!(Q0!VM<3\2/^1"\6_]
M@.^_]%&NVKB?B1_R(7BW_L!WW_HHT 'PW_Y$+PE_V ['_P!%"NVKB?AO_P B
M%X2_[ =C_P"BA7;4 %?S?_&7XK^,/V>?VA/VG[#X6?MV>.?A[X1U?XN:C\1/
MB[!\-/\ @G/J7QW^$OP)\3>)/#OAX26GQ(^+NDVNIZ)I6MGP_9:+J_C"5&>X
M&J37^K^(+2RUF[U4'^A7QYXUT#X;>"?%WQ"\5RW]OX8\#^&M;\6^(KC2M&UC
MQ%J5OH?A[3KC5=5GLM"\/V.IZYJ]S#8VL\L6GZ5I]Y?W3((K:VEE94/\X_[0
M?QD^ >C?%CX\^$OA_P#M]?M6_L__  P^,/BK4M;^.7P8\)?L,_$+XAP3^)O%
M.C:=IOQ&U+X9?$_6?A'=ZIX(E\>Z3#%<:ILMO%4.F>)+O4]4TV&TDD.FVP!_
M1I\/9KVX\!>")]2\6Z=X_P!1F\(>&IK_ ,>:1:6%AI/C:]ET:S>Z\7:78Z7+
M/IEGIWB2<R:S96FG3S6-O;7L4-I+);I&YZ_KUKSKX01>"H/A-\+H/AM;7-E\
M.8?AUX)B\ 6=[9:GIM[:>"X_#6FIX6MKS3M;@M=9L+F#0EL(I[+5K:WU.TE1
MX+^"*ZCEC7T6@ HHHH ,?CSGGVQC^6?K1110 4444 %%%% !1110 4444 %%
M%% !1110 52OM0MM.MY;FYE2*&%'DDD=@JQH@W,SDD *J@LQ)  !)J[7SS^T
MGJ]UHWPS\1W=G(T<J:==D,I*D;K><<8..,'.1T] >+IQYZE.%[*=2G!M=%4J
MTJ;?R51M=VDMKF5:;I4:U1*[IT:]5)[-TJ&(JI.VMG*C&+MJE)M:I&4?VO?@
M$"0GQ"TJ1></'9ZTZ, 2 R,NF%75NJNC,C @J6!S2?\ #7OP$_Z'_3?_  !U
MO_Y65^+FG<:?8J"0%M+8 =3Q"HZ D= ,>WX8N<_WC_WP?\*_HVIX/\+TZDZ?
M]H<0RY)SAS>WRF/-R3E"]O[,=K\M[7=KVN[7?\<4/I#\<5J-&M_9?",/;4J5
M7E^IY^^55:4*JC=YXG+E4U'FLN;EYK*]E^R__#7OP$_Z'_3?_ '6_P#Y64?\
M->_ 3_H?]-_\ =;_ /E97XT<_P!X_P#?!_PHY_O'_O@_X5'_ !"+A?\ Z#^(
M?_"G*?\ YUFG_$P7''_0MX1_\(L^_P#GZ?M%I_[6/P*U*^L].MO'^E&ZO[JW
MLK6.2UU>%9;FZE2"WB\V;3XX8S+-(D:M+)&FYU#, <U]$P7,4\:R1NK*W(((
M((SC.0<=>#R>0>M?SE7=Q):Q1W4;$2VMYIMS$<%2LEOJ5I,C ^JNBD#VK][?
MA=?7&I>"M&N[AR\DME SL<EBQ&2<DDXR>F>.<YSFOS;Q!X1RWA2IDZRW$X^O
M#,:./G56/GA*DH3PF(PM*'LI87#8=6G'$-R52,GS03C))M'[-X2>(6=<>4N(
MGG.$RG#3R?$9/3P\LKIX^C&K3S+"9A7J^VACL9C&YTJF#@H2I3A%PG)3@Y*,
MCU"BD'0=N!QZ4M?G9^Q!1110 4444 %%%% !1110 R3[C?2OY!_^#BW_ )#?
MP&_[#/CW_P!-VBU_7Q)]QOI7\@__  <6_P#(;^ W_89\>_\ INT6OTCPA_Y.
M3PM_V%8S_P!4^<'YYXJ_\D!Q)_V#8/\ ]6V5'\S(Z?BW\S2T@Z?BW\S2U_?+
MW?J_S9_$*V7HOR04T=1_P/\ ]"%.IHZC_@?_ *$*E_I+\D5'XH?XX?\ I<#^
MJC]DC_DV3X"_]DG\#?\ J.:97T57SK^R1_R;)\!?^R3^!O\ U'-,KZ*K\NS/
M_D8X[_L*K_\ I;/FL!_NE'_N+_ZD8H****X3L*&I_P#(/OO^O2;_ - >OVM_
M9>_Y)3X9_P"P?:_^BUK\4M3_ .0???\ 7I-_Z ]?M;^R]_R2GPS_ -@^U_\
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M_P!1<G/Z-^CC_P C/C?_ +%G"_\ ZLN(3Z2HHHK\&/ZK"BBB@ HHHH ****
M"BBB@!&Z'Z'^5?S"_P#!Q=_R1/X<?]EI\.?^H3\3*_IZ;H?H?Y5_,+_P<7?\
MD3^''_9:?#G_ *A/Q,K[KPQ_Y.%P?_V/,-_Z9S ^+\1?^2$XM_[$E?\ ]/X
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M4L+""&QT^!C]GT^SC6ULHH(!Y=7?BKJ7]C?"_P").KCQIIGPV.E> O&&I?\
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M5VU !]/\_P J_GI\?VOP OOVF?VM/$WPT_9__P""I'Q;UV3_ (6?\#]<\4_
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MK;*C^;(=/Q;^9I:0=/Q;^9I:_OE[OU?YL_B!;+T7Y(*:.H_X'_Z$*=31U'_
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MU^XNK72/&7AFR\<:%H5QXA\-W-U:/;7&H:7'<?V5<36$&LQ:?+J>FI=TM/\
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MXS_Z*'<_^$QH'_QJ@#NZ^8_VJO\ DE'B?_L&W7_HBYKV'_A'?&?_ $4.Y_\
M"8T#_P"-5\V?M1Z%XMC^%/B4R^/KF91I]R60^%_#Z[E$%QE=XB#KNP1D<CJ.
M<UM0_CT?^O\ A_\ U(PQSXO_ '7%?]@F,_\ 4/&_U\S\C]/_ ./*R_Z];?\
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M%#N?_"8T#_XU7X,?U6=W17"?\([XS_Z*'<_^$QH'_P :H_X1WQG_ -%#N?\
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M^_H_]?\ #_\ J1ACGQ?^ZXK_ + \9_ZAXP_&'3_^/*R_Z];?_P!$U>JCI_\
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M#B[_ )(G\./^RT^'/_4)^)E?=>&/_)PN#_\ L>8;_P!,Y@?%^(O_ "0G%O\
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M:[U&>YN)&9Y"2 >DUQ/Q(_Y$+Q;_ -@.^_\ 11KMJXGXD?\ (A>+?^P'??\
MHHT 'PW_ .1"\)?]@.Q_]%"NVKB?AO\ \B%X2_[ =C_Z*%=M0 4444 %%%%
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M;_P4#[_MB_'H>W_"9S>_K;'V'X'ZT?\ #RW_ (*!?]'C_'K_ ,+.;_Y%KXB
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M 4444 ,D^XWTK^0?_@XM_P"0W\!O^PSX]_\ 3=HM?U\2?<;Z5_(/_P '%O\
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M]_Z*- !\-_\ D0O"7_8#L?\ T4*[:N)^&_\ R(7A+_L!V/\ Z*%=M0 4444
M%?/^K_M1? K0_C+I'P%U3XB^'[/XDZQ;R"'29KZV2TMM;>70ETKP;J&J/,ME
M9>.?$5MK]EJ/A_PC-(-;U/362[BM%2^T<:G] 'D8/(/!^AK\</B-I/Q)TG]L
MZT3X:_"SXG^#_%WBOQS!XEUKPX(/#7Q(_9R^,O@#3/B%^S=9^)/CCK6L^*=#
M2R^$7B[2O!.@7;:UHWA3Q!X8^(%EX\^&'PPU#3M*\;_\)/:S>* #]2D^+OPN
M?Q3XW\$K\0?"!\5_#3PYIGB[XB:&=>TY;WP+X:UF/4YM,UGQ:&G$?AZRO+;1
MM3O8GU62U8:?:MJ#JEE)#/)QFB?M/?L_^(O /B?XH:1\6/"%SX#\%S65MXK\
M0RW[V,&A7.J0Z;<:);ZA9W\-KJ4-QXC@UG1Y?"\'V-I?%":OI1\/IJ7]I67G
M_G;\>O -_P".OBE^V+\-OA)\&?'6FS_%']DVR^'^A7J?![QCX$^&/Q ^+FB^
M./CA\1/&^C7GQ*N?#^@>!%G\=V'BK1=.D\<:KXCM=$\1:OXBDMSK]W?6]\D.
MYX]T?QY\4_B#XS_:2\,_!GXIV_@;PWXR_8;U.X\%^)_!NL>$_B7X\M?@1XX^
M,OBGXG:MHOPYUNXTW7]2E^'MM\7/#&K:) =.$_CO7/AKJ5AX%B\6 ^&9]3 /
MTX\%?$CP)\1?",'CSP3XJT?Q#X0N/[34:]9706RMYM$O+K3M;M=0^T"";2[[
M1-0L;VPUFPU**UO=*O;2ZM=0@MYX)8T\RTC]J[]G+7O!WBCQ_H_QA\%W_A#P
M9=:'9^(]9AU%O+L9O%4MO!X0:&U>%+_4[?QK<74%MX(O-*M;ZT\9W,@M_"\^
MK3JT:_%D%OXF\8?#S]L7X1:;X%\;^$O&G[;&G_M6?$3X):5XAT6Y\._V+X=T
MWX,_"7X)66I^/X-1U"QU?X=ZKX]\:W">,]%TC6;/2M1BL->E.NQ:!X@@O-/3
MS_Q1H?Q \>_%OX4_M&Z)\!/BMH'@#X$6'[..@^// NL>"=8TGQWKMYX8D^-<
M7BFU\(>!7N(]4\=Z5\ )OB3X?\2V>L>%].U[2?&]U+K-M\*[OQK>:6RJ ?H_
MK/[3OP T#X?>&OBGJOQ5\)P> O&-U>V/A;Q!#>2WT>NW^EIJDFMV&G6%A!<Z
MK/?^'4T/7&\3V2V(NO#*Z)K)U^+3O[*O_L_M.EZIIFN:9IVM:+J-CK&C:Q8V
MFJ:3JVEW=OJ&F:IIFH6\=W8:CIU_:236M[8WMK-%<VEW;2RV]S;RQS0R/&ZL
M?R<\%:)X[^&GQ-\'_M->(?@U\49_A[XE\??MI:Q%X,\->"]<\4_$KP#8_&O5
M?@G??#;Q%KGPST>2_P#%%A<_$$_!WQ5JNKV5MHUQJ'@?4/BGI]MXY@\)!/%D
MFF?<?[(?P^\4_"O]F7X*?#_QKID.A>*O#/@32;/6O#MO?P:I!X6NY_-OAX2B
MU*TNKZROE\*0W47AT7=A?7FG3_V9YNGW5Q9-!,X!]'44U@Q5@C!6*D*Q7<%8
M@X8KE=P!P2NY<CC(ZUPHTCXB8&?&_AXG R1X%N ">YQ_PF)QGTR<>IH [RBN
M$_LCXA_]#MX>_P#"%N/_ )L:/[(^(?\ T.WA[_PA;C_YL: .[HKA/[(^(?\
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M_P GS3?]D<\&_P#J;_%&O[VM1_X\KC_KD_\ Z":_@E_X+??\GS3?]D<\&_\
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M'XH?XX?^EP/ZJ/V2/^39/@+_ -DG\#?^HYIE?15?.O[)'_)LGP%_[)/X&_\
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M^IC0-'TXZGJ!N?7J** "BBB@ KB?B1_R(7BW_L!WW_HHUVU<3\2/^1"\6_\
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M+TWRC#^O_0V78F?@3QK*$XK$</7E"<5?-,0M90J17_,L>EY*_E??8R4QM7G
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MY!#^%M(R>Y^*GQ?8YX&6W3D'O_".ON2>*U3_ (-K_P!FG458)HFCVY8%2?\
MA9/Q7FR&ZY$DGS<8 !X.3D<"OQA^&/A?PY.=;PD\3/I ^$]:[E1PO#G$F.S'
M(82U<8RX?XESC-<M=%/E3HI<CBN56N?N<?'#Q2XFA"AXR>%?T=_&.C91K8SB
MCA# 99Q'..BE*'$G"N4Y1F:KV3E&LWS\WO/5GQ'\)_C(_P .?AMX'\#:')H_
MB'1?"GAK1M TG69-4MWDU/3M,L8+*UO&>PW6;R7,,,4C26S&!F8F-0I45Z?%
M^TIJ98AM L9!MX$6IMNR#U.Z!ACG& !VYYK[0T?_ ((1^'_#.AZ/X;\.:GX
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M.<8!QZAAQ6:S?Z15'^%](;+L4E\*Q_@EDSOR[<\L+G=-OGU]HTD](\MM;O\
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MQ/P]AYU,?.K6K8&>6<29/',Z6)P$J<:5:JYU<+75:E4PU3E]I3I_!7R_WO\
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M3]6^#7[2%OX5\,1Q:9J'Q1O/#WA'0X-+\1?$)_&G@KQQK.OZ9J5II'A.9+(
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MSX9\3:9I$OB/3[*Y\/&?7GT+0]6O_P"Q]2BLOO&@ HHHH *XGXD?\B%XM_[
M=]_Z*-=M7$_$C_D0O%O_ & [[_T4: #X;_\ (A>$O^P'8_\ HH5VU<3\-_\
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M% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q/Q(_Y$+Q;_ -@.^_\
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MJWWQ+\>:]X(\&>+-0TGXC1:)IG@>Z\+Z9X1ET?P?I,-WK[IXXU*^73[+^?\
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M_P#X;Z\)\ _##QMP.^I^%!QSZ:QCG_\ 72C]OKPF#Q\,/&V>>FJ>%,].<?\
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M.WBN;EVCL_V>OB=H3_";XC_#GX9?LU_!SXB_!R^^*>C:=\(_ VO:^OP6\9>
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M **** "BBB@ HHHH */3OQU[_IC\>*** "BBB@ HHHH **** "BBB@ HHHH
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M]T4>6G]T5\W_ ,2_^'7\G%G_ (GO&/\ \]3ZK_B9GQ7_ .?G G_BK_#_ /\
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ME>(+F3P/\*/AVMMXZE\0MXL^(/BS0KJ[NO%'GG@_]G;X\_"KX5?#9O ?P_\
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M  K^&2ZW_8QOM=UW5M#TN;XF6_CZ?^P]3?33!J$M_?:?ID.DZA8SW/T?110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<3\2/^1"\6_P#8
M#OO_ $4:[:N)^)'_ "(7BW_L!WW_ **- 'Q3#\2O'.CPII>F^(KNUL+ ?9+.
MV2*S9(+>%G2.)6DMG=@B@ %W9B ,L:?_ ,+<^(__ $--[_WXL/\ Y$HHH /^
M%N?$?_H:;W_OQ8?_ ")1_P +<^(__0TWO_?BP_\ D2BB@ _X6Y\1_P#H:;W_
M +\6'_R)1_PMSXC_ /0TWO\ WXL/_D2BB@ _X6Y\1_\ H:;W_OQ8?_(E'_"W
M/B/_ -#3>_\ ?BP_^1*** #_ (6Y\1_^AIO?^_%A_P#(E'_"W/B/_P!#3>_]
M^+#_ .1*** #_A;GQ'_Z&F]_[\6'_P B4?\ "W/B/_T--[_WXL/_ )$HHH /
M^%N?$?\ Z&F]_P"_%A_\B4?\+<^(_P#T--[_ -^+#_Y$HHH /^%N?$?_ *&F
M]_[\6'_R)1_PMSXC_P#0TWO_ 'XL/_D2BB@ _P"%N?$?_H:;W_OQ8?\ R)1_
MPMSXC_\ 0TWO_?BP_P#D2BB@ _X6Y\1_^AIO?^_%A_\ (E'_  MSXC_]#3>_
M]^+#_P"1*** #_A;GQ'_ .AIO?\ OQ8?_(E'_"W/B/\ ]#3>_P#?BP_^1***
M #_A;GQ'_P"AIO?^_%A_\B4?\+<^(_\ T--[_P!^+#_Y$HHH /\ A;GQ'_Z&
MF]_[\6'_ ,B4?\+<^(__ $--[_WXL/\ Y$HHH /^%N?$?_H:;W_OQ8?_ ")1
M_P +<^(__0TWO_?BP_\ D2BB@ _X6Y\1_P#H:;W_ +\6'_R)1_PMSXC_ /0T
MWO\ WXL/_D2BB@ _X6Y\1_\ H:;W_OQ8?_(E'_"W/B/_ -#3>_\ ?BP_^1**
M* #_ (6Y\1_^AIO?^_%A_P#(E'_"W/B/_P!#3>_]^+#_ .1*** #_A;GQ'_Z
M&F]_[\6'_P B4?\ "W/B/_T--[_WXL/_ )$HHH /^%N?$?\ Z&F]_P"_%A_\
MB4?\+<^(_P#T--[_ -^+#_Y$HHH /^%N?$?_ *&F]_[\6'_R)1_PMSXC_P#0
MTWO_ 'XL/_D2BB@ _P"%N?$?_H:;W_OQ8?\ R)1_PMSXC_\ 0TWO_?BP_P#D
M2BB@ _X6Y\1_^AIO?^_%A_\ (E'_  MSXC_]#3>_]^+#_P"1*** #_A;GQ'_
M .AIO?\ OQ8?_(E'_"W/B/\ ]#3>_P#?BP_^1*** #_A;GQ'_P"AIO?^_%A_
M\B4?\+<^(_\ T--[_P!^+#_Y$HHH /\ A;GQ'_Z&F]_[\6'_ ,B4?\+<^(__
M $--[_WXL/\ Y$HHH /^%N?$?_H:;W_OQ8?_ ")1_P +<^(__0TWO_?BP_\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>form10-k_002.jpg
<TEXT>
begin 644 form10-k_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" '- M # 2(  A$! Q$!_\0
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M  &_^RKNJ* .%_X5EX _Z%/1_P#P&_\ LJ/^%9> /^A3T?\ \!O_ +*NZHH
MX7_A67@#_H4]'_\  ;_[*C_A67@#_H4]'_\  ;_[*NZHH X7_A67@#_H4]'_
M / ;_P"RH_X5EX _Z%/1_P#P&_\ LJ[JB@#A?^%9> /^A3T?_P !O_LJ/^%9
M> /^A3T?_P !O_LJ[JB@#A?^%9> /^A3T?\ \!O_ +*C_A67@#_H4]'_ / ;
M_P"RKNJ* .%_X5EX _Z%/1__  &_^RH_X5EX _Z%/1__  &_^RKNJ* .%_X5
MEX _Z%/1_P#P&_\ LJ/^%9> /^A3T?\ \!O_ +*NZHH X7_A67@#_H4]'_\
M ;_[*C_A67@#_H4]'_\  ;_[*NZHH X7_A67@#_H4]'_ / ;_P"RH_X5EX _
MZ%/1_P#P&_\ LJ[JB@#A?^%9> /^A3T?_P !O_LJ/^%9> /^A3T?_P !O_LJ
M[JB@#A?^%9> /^A3T?\ \!O_ +*C_A67@#_H4]'_ / ;_P"RKNJ* .%_X5EX
M _Z%/1__  &_^RH_X5EX _Z%/1__  &_^RKNJ* .%_X5EX _Z%/1_P#P&_\
MLJ/^%9> /^A3T?\ \!O_ +*NZHH X7_A67@#_H4]'_\  ;_[*C_A67@#_H4]
M'_\  ;_[*NZHH X7_A67@#_H4]'_ / ;_P"RH_X5EX _Z%/1_P#P&_\ LJ[J
MB@#A?^%9> /^A3T?_P !O_LJ/^%9> /^A3T?_P !O_LJ[JB@#A?^%9> /^A3
MT?\ \!O_ +*C_A67@#_H4]'_ / ;_P"RKNJ* .%_X5EX _Z%/1__  &_^RH_
MX5EX _Z%/1__  &_^RKNJ* .%_X5EX _Z%/1_P#P&_\ LJ/^%9> /^A3T?\
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M%9> /^A3T?\ \!O_ +*NZHH X7_A67@#_H4]'_\  ;_[*C_A67@#_H4]'_\
M ;_[*NZHH X7_A67@#_H4]'_ / ;_P"RH_X5EX _Z%/1_P#P&_\ LJ[JB@#A
M?^%9> /^A3T?_P !O_LJ/^%9> /^A3T?_P !O_LJ[JB@#A?^%9> /^A3T?\
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MPXTYO']RWA&35M.\)Z587=O:76I>-9[;4;Z"/48KB']7O^"H]UJ5I_P3Q_;
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MN?\ V6@ ^&7_ "('A/\ [ ]M_P"S5W5<+\,O^1 \)_\ 8'MO_9J[J@ HHHH
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MU7"_$W_D0/%G_8'N?_9: #X9?\B!X3_[ ]M_[-7=5POPR_Y$#PG_ -@>V_\
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M_P *Q\&_\^&I?^%-XH_^7-'_  K'P;_SX:E_X4WBC_Y<T =]17 _\*Q\&_\
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M?^%-XH_^7-'_  K'P;_SX:E_X4WBC_Y<T =]17 _\*Q\&_\ /AJ7_A3>*/\
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M+BFAMFFDN"D]]?7[^;($5V\_4+FZG"D1KB,2B-<$JBEF) +]U.+:VN+DQ3W
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N%^)O_ "('BS_L#W/_
M ++7=5POQ-_Y$#Q9_P!@>Y_]EH /AE_R('A/_L#VW_LU=U7"_#+_ )$#PG_V
M![;_ -FKNJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBFEL9S^'O\
MX4FTMP'44P.#GCI[C\0<XY]J7</\E?\ XJES1[_U]X?UU_R'44W</\E?_BJ4
M-DXQV]OZ$T<T>X?UU_R%HHHJ@"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "N%^)O_ "('BS_L#W/_ ++7=5POQ-_Y$#Q9_P!@>Y_]
MEH /AE_R('A/_L#VW_LU=U7"_#+_ )$#PG_V![;_ -FKNJ "BBB@ KXD_;<_
M:=\3?LV^#O#,GA31/"YUKQU=:]IFG>./B-XOC\#_  U\):AHNGV^I6FFZSKA
M\/>*)+SQ5XN$D]EX+\-_V9;0:S)I^M33:S8OIL%KJ/VW7R%^V!\,/C=\1O T
MT7P8USPM?R_\(YXG\.>)_A%X_P!,AG\&?$FQ\17/ANYL;YM<2ZL[WPWXI\'W
M&@S2:%=S-J/A[4=.UWQ#I>M:/+<7.DZMHP!YS\1/VS?%O@"'X.V/B#P-\%_A
MOXG^)/@3XG>.]=MOC5^TEIWA7PEX>L?A]XI\"^&M,3PSXU\"?#OXG6OCFT\<
M6GC5?&.AZB-,\.'3?".GFY\2V6C:U+>:'ID_C+]L_P 3>%[OQYKFG_"WPOXH
M^%/P+'PC@^/WQ!TGXI7;SZ'<?$WP_P"%O&6L:C\*M!B^'5U:_$WPO\// OC7
MPUXVUK6=4\0^ KG7-$U"2#P[I5YJUI)8N[P-^SM^T%\$_!?A+P_\*/%?P"U<
MP1_%MO$OA7Q=\-M<\.^"?#EY\6/B?K_Q-6V^%4OAO6=6\0:#X"\$MKX\'6'P
MRU.XNM)U_P .Z%H$\6L^$[ZTE\[RK2/V ?B#X+\$:]\!O!WQ1\,W7P)^+.B_
M!O2/C/>:]HFO6OQ(CB^&WA+PAX!\;P?#N/3M6N/#-E8_%GP1X(T7PY%;:J8X
MOAN)+V^LX?&4;6VFVX![7=_M?Z_!XZO9(/A787/P'TW]HW0?V6+[XH#QW<Q^
M,C\3]=U;2/!2:K9_#,^"&T^X\!:?\6-=T_X97^L2_$&VUP:FM]KUOX<GT&T6
MYN.]^,?QZ\>^$OB+I?PF^#WPOT/XI>//^%8^*?C#XFL_$_Q!NOAOH^A^#= U
M73O#^C:?9ZM:>!O'CZKXN\<Z]=:E8^&]-EL=,T>WA\.ZS>Z]KVEQ+8+?>27_
M .RC\33XRU/P_:>.?":_L]ZG^TWHO[6L^E?V9X@;XIVWC30O$VC?$[_A7=E<
MMJB^%KCP=JOQD\/V?CJ?6YOLFHPZ3?:EX,CT5B]OXIMY+GX2_M6^(I?A[\<[
M/5_@]X(_:$U;X)>(O@]\7_"^L:9XKO?AW;V>L^)(?%/A#Q-X8&A>+-;OXO$O
MPXOUU-;G0;C7-9T;Q5'XGU:P@\8:/'IVGZM= '/0_M_SZ_X>U'XM^!_A/%K7
M[/?@FW^",_Q3\=ZSXXGT'QQX<7XS>&_!?C.ZG\,?#NV\%:Y8^*K3X8>$?B'X
M2U[QU)?^-_"]Q-'<:O8^&+76[[1S#>=XW[7^O#QS)*GPLL7^ L/[1L'[+$OQ
M1_X3JY'C,?%"XU>'P.-53X9?\(0=/?P#'\7+B+X7R:T?B$FN#4R_B!?#3:!'
M]H;R.S_8-\=^$_">L_ ?P3\2/#;?L\_$FV^!UO\ %&;Q%IGB!OBI;6_PC\&^
M / /BNP\'7%CJ;>&9H_C!X5^&GAW3M2O-52S/@B[U#Q'J=I8>+?MME8:?Z#_
M ,,G_$O_ (3>7PY_PG?A+_AG>?\ :@B_:S?3!IOB%?BDGC&#Q7#\4$^'B7C:
MA+X7;P:_QDM8?'DFO&%-3_LAIO!B:"C,GBB, ^_AGN<\\<8X]/?Z\5%//!;1
M-/<S16\*8WS3R)%$FY@B[I)"J+N9E49(RS!1R0*E'?C'/Y^_%5+ZPL=3M9;'
M4K*TU"RGV>=9WUO#=VLWER)-'YMO.DD4GERQQRIO0[9$1UPR@@ K?VYHO_08
MTO\ \&%I_P#'J/[<T7_H,:7_ .#"T_\ CU9'_"!^!_\ H3/"G_A.Z1_\AT?\
M('X'_P"A,\*?^$[I'_R'0!K_ -N:+_T&-+_\&%I_\>H_MS1?^@QI?_@PM/\
MX]61_P ('X'_ .A,\*?^$[I'_P AT?\ "!^!_P#H3/"G_A.Z1_\ (= &O_;F
MB_\ 08TO_P &%I_\>H_MS1?^@QI?_@PM/_CU9'_"!^!_^A,\*?\ A.Z1_P#(
M='_"!^!_^A,\*?\ A.Z1_P#(= &O_;FB_P#08TO_ ,&%I_\ 'J/[<T7_ *#&
ME_\ @PM/_CU9'_"!^!_^A,\*?^$[I'_R'1_P@?@?_H3/"G_A.Z1_\AT :_\
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M#&Y&"R@X/;/.._3..IZ5/44*A(U5> ,C\B1^7''MUYJ6OG3^Q0HHHH ****
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M?_$T?\+4^'7_ $.&B?\ @4/_ (FN_HH X#_A:GPZ_P"APT3_ ,"A_P#$T?\
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MI>2/D+Q!9_ C3/#>IK9ZSX9#BSE"_O5W=&X&(.G(&/UXX_@%_;OBTF?]L?\
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M_+_)K_0F\1?\@>__ .O:;_T&O\]C_@K2<?MV?%SG&-.\$GGIQX:M!GUP,_\
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M-GX0LO$?C"6_U:YU)]7OK37?%FC6M]JVIW^B^&_$>BZ%>W;7.FR11?;77I0
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MI_PX?X(?^D0"BBBD6%%%% !1110 4444 %%%% !1110 444?Y_+K0 5\$_\
M!1GXKV?PF^ FB7C^"?@GXQUOQS\7?AW\,O"%Y^TC% /@/X"\3>,[V^L[;XA?
M%+49M/U*31O#7A_3H-3@74+2!+N35M1TS2XID&I.K_>U?!'_  4@^)4/P_\
MV<!H<G@OX->-9OC-\2?A[\$K*']HV,/^S]X<O?'.KL\'B[XPDVUSL\):$=):
M6U"(DUQXIF\.6=M*ES<PY /$?V/_ !!\;/@_^TUJ_P"RW\>_A]^QI8^*O&7P
M3N_CIH/C+]C[PEK7@,VGAWPWXOT+P4VB_%+PCKEJ]_:PZOK&NZC+X"\0_P!I
MMI^NCPYXIM;6 WFF:E;Z;^LM?D]^RA\8/C;'^UOX@^#'[2%S^R)\4?B;XA^
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M6ZOY-*\.BX\2V>H>*O'GQ$U)?"NIQ);V>EVR:]%:17NF:L\6G6\DLTUSB?\
M!0O5/C?I?PPTVX^%FL>+](\'Q1^))_BM+\*]/^'^J?%R+34M-/A\*:AX>LOB
M3'=Z1+X/LM=N'7QT/#NEZCX]*W7AX>&H5MCK1.__ ,$_=,^+=I\%/%&L?%;1
M/B1X/@\;_&WXN>/_ (6_#WXPW]MJ/Q3^'/PD\7^)I-7\+>$?'$MK=ZC'9:I%
M?S:[K5CH#:GJ,GA70-:T?PLUQ&-&%I;>G_M(?LR^&/VB=%L/M'B;Q7\//'GA
MW3/$.C^$?B3X(U&:SU[0M(\7/HC^+- O-/>7^Q_$OAGQ(?#F@RZKH&O6EY9O
M?:+H^JV?V/5=+L;V$ ^=;CQ9\:/&?P'\,?$;P3^T1\5/%H\*Z)X]T[Q+I?P3
M_9R^&/ASX\>.?'NA>-]7\+V]CXM\$_'5/$V@>#KCP"V@:MX2^(7@S2/"'A?6
MM<\=Z;JFJZ+J_AG2A:^#$\ M?VGOV@O%'PE^+'[1NF?&O0DTG]F7PU^S[>:O
M\/O!GAOP+-\/?C9>:K\*/AE\8/C++K^J^+?"NH?$CPY=>(;+XAWG@?P'8^&/
M$/@JX\+>(/#\=QK6E:_<37>C+]R']B_X8:=8^'5\"^*OB[\,/$>AV'BS2=1\
M?^"/B'J2>._&VF>//%^K_$'QM;>/-<\4V_B=?$UUX@\>^(-=\8QZ[<V<?B3P
MQKFM:M-X'UGPO;:G?6UQFC]@_P" EI>:)%H$/CCPOX+L(/AM#XC^%NB^-=5;
MX=_$E_A!<VMY\.;KXCZ9K']K:QXCO-#NK&P?5KE-=L'\?PV-I8?$O_A,]-A2
MS !X->?&_P".#>(M7^--M\3Y+?X?Z1^W7X6_9.B^ K:!\/9/"UUX'U/XJ>&/
MV>]5\47WB=_#+?$Y/B*_C37[KXE::+;QK:^'(O#EKI_AV;PE=":?69?:?C5X
ME^+GC/X_6OP-^&?Q;U/X(V?AS]GWQ+\9]7\3Z#X=^'/B?6O$_B/4/%L/@[P/
MH=Q9_$CPKXNTVU\%:!+I7B'5O&8T>PT[7]6DU/PY8V'BCPW'%<R:CW%]^R-\
M,+SXFW/Q,_M#QPB7?CVQ^+UW\-!XKNA\)[[XR:3HMKH6D_%&Z\*B#[6OB6QM
M-/TR[2SL]9M?"TGB+3;+QG/X<F\9VZ>(*YJ7]C?1=<\$_#/2/%_Q<^,]]\1?
M '@?Q/\ #O5/C'X>\=:CHGC[QSX,\=7=AJ/C7PEXIU/4CXBFU'0M6OM(T:73
M+VYFG\:>%'T>SN_"WB_1]3GU._U  ^(_#_[67[0/Q%^"WCW]K&R^(L'@W1?@
MEI_[.%YJ'P.TC0/A]?>#/B-#XL^%_P (OBI\6QXD\1Z_X<UGXA:=J&OV7Q5N
M_#WPS;PCXO\ #%MHUUH.C:AJ=AXM&IWEG+[ WQO^-[^(+GXUK\3G3X?6W[==
MI^R;_P *$_L#X?'PM)X&E^*]I^SK+XI?Q0?#1^)P^(W_  FUV?B;&J>-D\-K
MX<C3PVWA%E9]9KZ*OOV)?@C<:_I>H:<GC'PYX2MA\+3K_P )?#_BJZL_A5XZ
MG^"4&E6WPGG\9>&;B"\NKW_A#K?0/#UJ;/2]6T?3?%MCX>T/3/']CXLTO3+6
MR3;_ .&2/A;_ ,+2/Q.^W>.?(?X@K\8)/AD?%4[_  HE^,2:0-$C^*#^%)+9
M[@>)HK-([J.R35T\)+XBAB\9#PS_ ,)E&OB  'U!5#5-1CTJQGOY;:_NX[?R
MMUOI=A=:G?2>;-'"/(L;..:YGV-('E\J-O+A629\1QLPOT4 <#_PL/3_ /H7
M/'W_ (0GB?\ ^5U'_"P]/_Z%SQ]_X0GB?_Y75WU% ' _\+#T_P#Z%SQ]_P"$
M)XG_ /E=1_PL/3_^A<\??^$)XG_^5U=]10!P/_"P]/\ ^A<\??\ A">)_P#Y
M74?\+#T__H7/'W_A">)__E=7?44 <#_PL/3_ /H7/'W_ (0GB?\ ^5U'_"P]
M/_Z%SQ]_X0GB?_Y75WU% ' 'XAZ?@_\ %.>/NA_YD/Q/_P#*ZORP_;(\10:S
MXY\*PPZ5XFT\H;J8R:YX;U?18&"*R&))M0MH8WG8S*R0JQD:-)I NR)R/V-;
MH?H?Y5^2/[;_ /R.?A+_ *[S_P#HJ>OL/#[_ )+?A?\ [&L?_4#-C\W\8/\
MDV/&_P#V(W_ZM,@/CP=O]YO_ &:G4T=O]YO_ &:G5_6"V7I'_P!)@?P>]WZO
M_P!*F%5+T9M;S_KSN/H/W;]3VJW5.^_X]+S_ *\[C_T4X_K^GID';#_[QA_^
MPC#_ /J3ACFQO^YXS_L#QO\ ZA8T_4[]D3QM96?PLT:)] \<RF.-D,EMX)\1
M7-NY6:0%HYX;%XY(SM)21"5<8*D@@U]8?\+#T_\ Z%SQ]_X0GB?_ .5U> ?L
M<_\ ))]"_P"N'_M5Z^O:_B+&_P"_8[_L-QG_ *EXL_TSRS_D79;_ -BK*?\
MU5Y:<#_PL/3_ /H7/'W_ (0GB?\ ^5U'_"P]/_Z%SQ]_X0GB?_Y75WU%<QW'
M _\ "P]/_P"A<\??^$)XG_\ E=1_PL/3_P#H7/'W_A">)_\ Y75WU% ' _\
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M>'K""QT^VB@B@C6-1&@7A54#&W' QQWSTP!SI:9IEKIEM%;6L2111H%5%0*
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MWAROW[Z._P#R5V<_]DU5_P#5QEY^'>/?_)+9/_V44/\ U4XX^.J***_L(_E
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M7.%+ !R!N )*AB!N"DXXR..!GK@$F@!U<+\3?^1 \6?]@>Y_]EKNJX7XF_\
M(@>+/^P/<_\ LM !\,O^1 \)_P#8'MO_ &:NZKA?AE_R('A/_L#VW_LU=U0
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M">BBB@ HHSV_SV_QZ44 %%&><<_EQV_Q[>_I10 4444 %%%% !1110 4444
M%%%% "-T/T/\J_)']M__ )'/PE_UWG_]%3U^MS=#]#_*OR1_;?\ ^1S\)?\
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MU_GL_P#!6?\ Y/M^+?\ V#O!/_J-6E?N'T?_ /DNL1_V3F:?^I.5'XUXZ?\
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MW0_0_P J_)']M_\ Y'/PE_UWG_\ 14]?8>'W_);\+_\ 8UC_ .H.;'YOXO\
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M\P)(>1@H )4A,E5499C^Z'@7X?Z)X)TJVT[2[."!((D3,<4:$A1QRJ@'GTR
M,\Y)KY3A_@[,<QS*EQ=Q[.ECL\5IY3DD/WF3\,49-5*=.C1<JE'$9E%\DJN)
MDJRIUH^T53$8J*KX;Y3@GPPSW/,]PWB;XQU</FW%\$JO#7"-%JOPQX?X6<U6
MHT<)AIRKX;'9["].>(S"HL3&ABJ?M56QN84XXO >-?"CP!)\--%M-/TSX2:O
M%)!%$C.FL>!4):,8R=NOYZYR"<]LX KVE?$WBI>!\,_$ ''37?!7;_N8J[T
M#@#%+7Z?_7]?U^;O_07]?U_7_!X/_A*/%?\ T33Q!_X/?!7_ ,T='_"4>*_^
MB:>(/_![X*_^:.N\HH X/_A*/%?_ $33Q!_X/?!7_P T='_"4>*_^B:>(/\
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M_P#FCKO**T,S@_\ A*/%?_1-/$'_ (/?!7_S1T?\)1XK_P"B:>(/_![X*_\
MFCKO** .#_X2CQ7_ -$T\0?^#WP5_P#-'1_PE'BO_HFGB#_P>^"O_FCKO**
M.#_X2CQ7_P!$T\0?^#WP5_\ -'1_PE'BO_HFGB#_ ,'O@K_YHZ[RB@#Q?QKX
ME\4OX=U0-\-M?4?8YOF.O^"@!\K=O^$A9CZ\#M7^>%^WU//<_MG?M%3W-E+I
MUQ+X\B:6QGFMIYK9AX8\/*$DFLYI[60E0'S#-(H#!2VX,!_HZ^.?^1;U7_KS
MF_\ 0&K_ #E/^"@__)['[2/_ &/\/_J+>'*_??H[_P#)79S_ -DU5_\ 5QEY
M^'>/?_)+91_V45/_ -5../CJBBBO[#/Y0&]_^!?^R5_1I_P33_Y-7\+_ /8S
M>./_ %+-9K^<OO\ \"_]DK^C3_@FG_R:OX7_ .QF\<?^I9K->+Q%_P BFM_U
M\H_^G8GE9I\67?\ 8PE_ZKL<??U%%%?G) UNGY_^@M5S0+BYM/%W@V>ST^?5
M;B/7(/+L;:>SMIIMS!'V37\]M:KY:,TK>9.FY4*IN<JC4VZ?G_Z"U;'A#_D>
MO!'_ &'(_P#T%J\3B7_DF^)/^R=SW_U58H^AX/\ ^2RX-_[+/A+_ -:'+3]P
MO#OB?Q4-'L@/AKX@/[E.1K_@H@\>@\1 C'3G.<9!P16Y_P )1XK_ .B:>(/_
M  >^"O\ YHZWO#7_ "![+_KBG\JWJ_CR7Q2_Q2_]*D?Z*4_X</\ !#_TB!P?
M_"4>*_\ HFGB#_P>^"O_ )HZ/^$H\5_]$T\0?^#WP5_\T==Y14EG!_\ "4>*
M_P#HFGB#_P 'O@K_ .:.NGT>^O\ 4+1I]2T2[T&X$SQBQO;K3+R9HE"%+@2Z
M5>7UJ$D+,JH9A*IC8O&H*%M6B@"&YF^SV]Q<;"_D0RS;%.&?RD9]@.#@MMP#
M@\GH:_$+XH:'XV\8?L>_L^WFB?$/4];UKQIX)^(/Q]^)WPDTSXU:[\'/'OQ9
M?XB>(?#'B;7O&&@^+/"P37M6TKX1>*OB'9Z1#X#NM1T+P0^G>+/#=GK&M6"^
M&O#-C=_N$1GZ=P1G(P>/\_2OD'6?V+/A%XQ^$.E_!GQ]:W/B30?"&M^+;SX:
M>([![GPUXY^&_AWQ)XCO-9LO"GACQ;I=\=7L+#1-&N+3P5OLI[*WUOPIHVDV
M.MZ?=S6K7$P!\3^(Q>^+OA-I6H^'OCK^UGK'QFU;PUXV^#O[-GP5/Q%U/PG\
M2O#?QT^%'Q#\>>#O'OB_XT:S\*?$EGX#^+7A7P'XUL]!\.>-/'WQ,T[Q%\,]
M.\"^"8)YV\;^+_B#(?%>C\9?$?Q)M$_:U^,E]\6OB#IOQ&_93\;_   \-?#?
MPEX:\;^-O#GPRUL/X ^#?C7Q'I7B7X7:->V'A#X@I\;O%?Q%\3^#?MWBK0-?
MU'2=/_L.#PE?>'=6T<W2?9\_["_[+SZI;ZSIGPZU/P?J-KX7T[P5!+\.?B7\
M5_AA"OA;2M1U/6+/1WLOAWXY\,64UN=;UK6-?O'FMY+C4O$&KZIKVI2W6KZA
M>7DO=:E^R_\  ?6?&GACXBZM\/+'4?&/A*/P@-,U>\U;Q'.=1N?AZ[3_  ^U
M;QAI\NLG2O'_ (A\!W;'4O!'B/QY8^(]?\(ZNS:OX?U/3M3)NZ /)?VBX=3\
M=?'_ /9I^!=[XS\>>#/A[XY\,?'[QYXJ;X;^.O&?PQ\4>)]>^&5G\,--\'^&
M1X[\ :KX?\5:;I2Q_$7Q+XKOM+TS7]-.M7'A2P2]6^TNUU"RF^+?A7XB\=_M
M%CP3\/\ XB_&WXJ^'M$^'7[-/QI\4:)XW^'_ ,1/&_PR\0_$WQ)X/_:$\;?!
M/PY\6_%VO^#K_P /R^+O^$6\#_#OPQXMN="U22Z\(:YK7Q2N-7\1>&M7M9-&
MCM/T*B_9 ^!T_@*U^'_B#PW=>(=.L?B%X^^*.G:O)K>M^'_%&A>,OB7XB\1>
M(O%=[X5\3^#]0\/:_P"$[*]/BC5M!.F^'M3T^VN/"L[:!J0U"SGO/M6WXR_9
M4_9Z\?>'? WA'Q+\+/#TGASX::!<>$? ^E:,VJ>%(/#_ (+OK#3=,U;P';R>
M%+_1)[GX?:]IVC:+9^)/ 5_-=^#_ !+!H^E1Z]HFHC3+,0 'Y1>%?BY\6?B+
M^S]XW_:X\2?%/XBZ1\7?A/=_L?P>$?!6A^,O&OAKX97\/C#X5_LZ^-O%.B>)
MOA%I-Y8>#?&T_P :]?\ B_XLT4ZEXH\.Z[JVB6]WX=B\'ZCX>OO#\,T?Z'?M
M"V5_\0/V@/V=O@?J'C7X@>#/ 'B_P3\?_B!XC7X:>/O&GPM\2^*/$7PZ_P"%
M3Z)X1T)O'/P^U;P]XJLM+L8/B1XD\47>CZ?K]A%K5YH&F?VE!J&EV-[93>MZ
MK^S'\!=:\?Z%\3=0^&6@-XP\.MX7DTZZM&U'3=&GNO J2+X!U+7/".FWUIX0
M\3:O\/C(9/A]K/B70M6U3P+-';3^$[S1Y[6VDBY6Z_8\^!FLV/BVS\4>&[SQ
M#+XM^+?B[XT2:K_;FM^&]>\/>,?&FF6GA_6V\(^(_!NH>'?$7AG3]1\-V,&A
M:W9Z3JUNGB6RFU./Q"=1BU6\A< _/#X8>*/'O[1ECX8\'_$7XX_%+PSI?PU_
M9,\?^-= \<_#_P"(/C7X8ZS\1?%F@?'+XE_"'2?C/XOU7PA?:"/&,>B>#?A=
MX1\8S>&]8%[X)U/5/B;?:CK/A74;*ZTB*UYCPI\6_BO\0_@)XI_;!\1_$WXB
M:)\8/ASXV_8]T/PUX"T7QEXW\/?"PZ9X[^'G[,'B+Q;X7\1?!S3[VR\%>,;W
MXNZK\;O&=J-<\4>'-;U[0QJOA8>$M8T"Z\+6#VOZJ>-OV5/V>?B%H7@CPQXI
M^%7AN?P_\-_#C^#/!>DZ/_:7A6ST3P'+9:;IMW\.TC\*7VB_;OAQJ>GZ+H]G
MK7PZU(WO@K6[?2-*AU;0;U-/LQ#?U3]F;X$:S\1='^*NH?#;0Y/&VAS>'+NS
MOH)-3L='N=1\&6\UKX(UK7/"%A?VW@[Q-XA\"6\WE^!?$?B/0=5UWP7Y%D_A
M?4-)DT^Q:V .*^ VI26/QC_:W^'<'GMHGACXJ^$O&.DB::26.QG^*OPO\*>*
M/$NEVBLQ2"VD\60ZWXE:*-4_TSQ/=R,&,GF-YS_P4)T?0]6^$GPX>7XG>)_A
M'\1]-_:'^#UQ\!O&/A'X=6GQ<UB#XT:CK-WX<\/63?#34)[/3_%NE7/A_7/%
M3ZY;7VIZ7;:1HT%]XD>^4Z(L%Q]0_#KX:6_@+5/B?K\NJMKFO_%3XB7_ (\U
MW4Y-/@T]X88]#T'PCX6\/Q)%+</+:>&/!WA;0='CN99MU_=P7VJ_9[-M1>TA
M^"/^"A_Q6^ L6GZ=\)/VA+G]JWX(Z3IEUX7^+7P\_:K^!'PU\<>)],\"^.M&
MNM;L;.#1O&7@#P?\2[C0O%\.FC7--UW2?$G@A](G\)^(R7OXWU6VEMP#P[_@
MG]HO[,.A?M)7WPR^'/QG\?\ Q(^)W[-WPJ^*_P ,_$%_XE^&T?A/PQ\6?B3X
MK^-ECXM_:C^,NA>.8XYQX\UR/XAIX)\%^(-%_M6]M_!L>FV(LKW7QJMUK1_;
M>OP(_9Y_:-_X)P?![5/A]+^R[XH_:F_:F\?_  V^$&K?!OP3X!\$_"3XR^,[
MO4!XU\?7GQ*^(OCO5-0UCX9^"/ &G?$SXC^)[;3[[XA>*-;\4Z*MYH_AS08;
M31[6TL(EF_?5"2JDJ4)4,58@E2W)4D$C*GC@E?0XH =7"_$W_D0/%G_8'N?_
M &6NZKA?B;_R('BS_L#W/_LM !\,O^1 \)_]@>V_]FKNJX7X9?\ (@>$_P#L
M#VW_ +-7=4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44R1PB
MEO8XSZX)^G;O@5^)7_!3G_@K-KW[ OC+X5>$O"WP:T/XLO\ $/0O&>KZE<ZO
M\0-0\%OX>D\+ZCX;L+2WAM[+P?XH&I+J:ZW<S/+)-8?96L418[A;AFA];(\C
MS/B/,Z&3Y/AXXK,<3&O.A0E7H8:,XX:A/$UFZV)G"C'DHTYSM*2<K<L;R:3\
MK.LZR[A[+J^;9M7EA\#AI4(5JL*-;$2C+$UXX>BE2H1G5ES59QBW&+44^:5H
MIL_;BBOY"1_P<O?$P]/V0O!G_A\]>_\ G44O_$2[\3/^C0O!G_A]->_^=17W
MW_$%?$A:?V%A]&T_^%O)MTVG_P Q/='PW_$8?#[_ *'.([_\B?-NNO\ T#^9
M_7HW0_0_RK\D?VX/^1S\(_\ 7>?_ -%38_.OQX/_  <N_$T@C_AD+P9SQ_R7
M37OQ_P":4>F?QJ'X7?\ !4#Q/^WK\:4\)Z]\&M#^&4/ASP3K/C&._P!*\>ZC
MXNDNIK#Q!X4T,6#VUYX2\.K#'-%XFEN6NEFE9&LTA$#+.\D7T/"?A1QWDO$N
M2YMF644*& R[&O%XRM'-LJKRI4*>#S*$IJC1KRJU&I5J:Y::<GS-I6C*WP_B
M7XG<%9SP#Q7E67YK6K8['Y4L-A*,LKS*C&K6GF>1RC!U:M"-*FFJ4_>J2459
M)O5'V4.W^\W_ +-3J8>HP<#./H3DYS^/8_\ UV%L#))QQW(^HQW_  YQR<FO
MVM+1>B5O2,5^C/Y-EHWZO_TJ??U7WCBP&<\ '.>3QGJ>W7ZDG@8.#7%^+O$]
MCH>FW0FD4SS6TL5O &S)++)"ZHN "1@D'GA0=V0!N&=XP\<6GA^$Q0LMQ?R
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M9_V![G_V6@ ^&7_(@>$_^P/;?^S5W5<+\,O^1 \)_P#8'MO_ &:NZH ****
M"BBLO6=:TKP[I=]K6N7UOINDZ; US?W]R^RWM+=6"F69@"50%@"V"!SG H U
M**** "BC\,__ *Q_]<_AZT9YQ[9_S_GM0 44=OZ=_P!<?KBB@ HH_P _E10
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M._\ R5V<_P#9-5?_ %<9>?AWCW_R2V3_ /910_\ 53CCXZHHHK^PC^4!O?\
MX%_[)7]&G_!-/_DU?PO_ -C-XX_]2S6:_G+[_P# O_9*_HT_X)I_\FK^%_\
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M4TZXDMI)$AO]-OK>>RO[.0K<6=W#+;7$<<T;HM^@ HHHH *X7XF_\B!XL_[
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MKI+#+1V Q+< +)?'@6D?WI\/OAQHG@K3(+2PM8HFC106"KE<+D;2%!R ,XX
MZ=<$]-X=\*:7X=MH[:PM8X44;?D !P>F.!@< ]^G'/3JP .P_+WS_/U)/J2>
M:_(^ /#OAKPYR+#9%PYE\,)AZ*4ZU9VJ8S'8J4(QK8[,,4XJIB\97<6YU9\L
M(0<:-"CA\-3IT2:%/ Y7@:63Y+AE@<MH-RY5)SKXNL_=J8O&UVHSQ.*K<MYU
M)V48M4J-*C1A"F(JA1@=/PY^OKZ_C56]Q]EN_3[)<9QUYC?-7*IWW_'I>?\
M7G<?^BWK]!P_^\8?_L(P_P#ZDX4XL;_N>,_[ \;_ .H6-/U._9#N?B"OPMT8
M66C>#)+<1-Y3W/B/7(9FC\^78TD<7ABXC20IMW(LCJK%@&( 8_6?VKXF?] /
MP-_X5&O?_,C7S[^QS_R2?0O^N'_M5Z^O:_B+&_[]C?\ L-QG_J7BS_3/+/\
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M3^+_ .T7^SG\./BGJ7P_\>?!I=)_:>M_$OA#Q#J7A_7? 5U\=/ >E_"F;0=
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M7,=P4444 %%%% !1110!B>(O^0/?_P#7M-_Z#7^>S_P5G_Y/M^+?_8.\$_\
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M_P!%:?\ #A_@A_Z1 ****DL**** "BBB@ HHHH **** "BBB@ HHHH ****
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MG_D%?M3_ ,$D_P#D"_'#_L-^"/\ TV:_7XK5^U/_  23_P"0+\</^PWX(_\
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M_P#"(O?_ )L:[JB@#@WTCXANI4^,/#.""/\ D2+SOQQGQ@1[=#UK\W/VLO\
M@DI\%_VSO%7AOQC\9O&WC6+6?"VGZKIFECP/):^&[)K;6;JQN[S[9;7JZ^\\
MJRZ?;B"1)X1&AD1DD+AE_5^D(SCD\>E=V79GF.3XREF&4XW$Y=CZ,:L:.+PE
M3V5>G&M2E1K1A4Y*EE5HRE3FN5WA)K2]SAS'+<!FV$J8#,\'A\?@JSIRJX7%
M4_:T*DJ-2-:DYPYH7=.K&,X>\K32=G8_GT'_  ;F_L;?]#W\;N./^1HTGG'&
M>/#W_P!>C_B',_8V_P"A[^-W_A4Z5_\ ,]7]!@X_^O17TW_$2?$+_HL^(O\
MPX/KK_T#>;/G%X>\#I?\DGD/_A"O_FD_GS_XAS/V-O\ H>_C=_X5.E?_ #/5
M[#\$/^"'_P"S9^SYXQN_'?P^\<?$^37KWPY?^%IQXDU6PU?3QI>H:IH>L7!C
MM+?3],D6[%WX>T\).;AT2$W*&%FE5T_:OG^7\^?TINT=23U[GCD]/Q)QCO4R
M\1O$"I&4)\8\03A.+C*,L>W&49)J2:^K:IIM-:73W,ZOASP'6A*G5X0X?J4Y
M6YH2P"<9<LX3C=?65M.G"2U5G"+Z6?P0?V$/"QQ_Q6NJYQ_T#E''?&+WIG'.
M._;@4G_#!_AC_H==6_\ !>/_ ),K[XV^[>G'O]!P/T'T% 7_ &FZ^I_#MSQU
MQQG-<7^N?%W_ $4F;?\ A2O_ )G8O^(;\ O_ )H_A[_P@7_S2? __#!_AC_H
M==6_\%X_^3*9)^P9X5DCDB?QKJ^V6.2-L6"@[778VTF]X)#8!P0"0>>!7WWM
M_P!IOSI=HY!).?4TX\:<7Q:E'B7-TXM236*2:<91DFG]7T:E&,D^Z78F?AKX
M?SA*$^#>'I0G&4)Q>7IJ4)QE"<6OK2NI0G.,E=7C)KJ>#_#[X1:_\,]!M/#O
MACQAI?\ 9MI&$B_M3PI/?7.W+-EYXO$UHK-ECDB)<YZ=J[_^R_B)_P!#CX9_
M\(B]_P#FQKN0,=^/_P!0_I^M+7S4I2G*4YR<ISE*<Y2=Y2G.4ISE)]7*4Y2;
MZN3VV7VM.$*4(4Z<5"G3A"G3A%6C"G3A"E3A%:VC"G3IPBKNT815W:YPO]E_
M$3_H<?#/_A$7O_S8T?V7\1/^AQ\,_P#A$7O_ ,V-=U12+.%_LOXB?]#CX9_\
M(B]_^;&C^R_B)_T./AG_ ,(B]_\ FQKNJ* .%_LOXB?]#CX9_P#"(O?_ )L:
M/[+^(G_0X^&?_"(O?_FQKNJ* .%_LOXB?]#CX9_\(B]_^;&C^R_B)_T./AG_
M ,(B]_\ FQKNJ* //;K0?B!>02VTWC#PV8ID9'V^"KQ6PW!VD^+W R,\X./0
M]OR8^/G_  0__9N_:0^*&O?%[XC^./B;'XN\1P:9!J2^%]3L-%T41Z3916%J
M;;3KBPU66%VAB!G9KZ4/(3(JH#L'[4T=:]+*LZS?(L4\;DN8XO*\9*C/#RQ.
M"K>QK.A5E3E4I.?LZEX3E2IN4>57<(NZM9^;FF497G>&6#S?+\+F6%C6AB(X
M?&4O;4E7IJ<:=51YZ=IPC5J*,N;13DK.^G\^?_$.9^QKV\=_&[/&?^*HTH>O
M_4O9^G].Y_Q#F?L;?]#W\;O_  J=*_\ F>K^@L#&<=^?\]Z6OHO^(D^(7_19
M\0_^'#_+#(\#_B'O _\ T2>0_P#A"O\ YI/Y\_\ B',_8V_Z'OXW?^%3I7_S
M/5](? 3_ (([? G]FZU\36?PX\;^/WB\6W.FW>K'Q1=VFLL)=)ANX+46;6UO
MI7D*8[V;SE=9_,.S!3!!_7RD/;KU ."1P2.> 3_^LY(&2(J>(O'U:$J57C#/
MZE.:M.$\>W&2NG9KZLKJZ3M?HB*GASP'52C5X0X?J1C.%2*E@$TJE-N5.:_V
ME>]"3;B[Z-WLSX&_X8/\+9_Y'35<\=-.4]>>?],.,]>PSVH_X8/\,?\ 0ZZM
M_P""\?\ R97WQM XYYSDYQCCU'?T_$T;>?O-T/?Z?_7KC_USXN?_ #4F;_\
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M(G_0X^&?_"(O?_FQH_LOXB?]#CX9_P#"(O?_ )L:[JB@#A?[+^(G_0X^&?\
MPB+W_P";&C^R_B)_T./AG_PB+W_YL:[JB@#S;4O#/CO5;.>QN_&'AWR+B-HI
M/*\%W:/L8%3M9O%S@'!.#M.T] >:_(#XM?\ !!O]ESXT_$OQE\5O&?CCXKQ^
M*O'6JIK.N)H.M:?IFCK>)86>G*+"PFTK4);:'[/8P$QR7MPQE,C[P'"+^Y!^
MN.?S]J/ZUZF4Y[G608BKBLCS3&Y3B:U%X>K7P%;V%6KAW4A5=&<O9U+TW5IP
MJ<ME[T(N^ECS,UR7*<\H4\-G&78/,\/2K*O2H8VC[:E3K*G*DJL(\].U14YS
MIJ5W[LI*VMS^?/\ XAS/V-O^A[^-W_A4Z5_\SU'_ !#F?L;?]#W\;O\ PJ=*
M_P#F>K^@RBOH/^(D^(7_ $6?$7_AP?\ \S'@_P#$/N!_^B3R'_PA7_S2?SY_
M\0YO[&H_YGSXV]._BG2<XS_V+W3CG]>M?7_P;_X)6_"3X$^!K+X>> _&WC%O
M#]A>ZG?P-X@^S:KJ1N-7O[G4KOS+RW&G1M']INI?)5;1&2/:A9]I<_J81G/)
MYZ\]![<=^_\ D4A4$YR0?8^G'^?_ -=9UO$/CW$4W2K\7Y]5IR:<H5,=S1?*
MTTVOJRNT]5KNKZF=3PXX"JN#J<'\/S=.?M(.6 3Y*G).'/'_ &E6ER5)QOK[
MLI*VMSX'_P"&#_#'_0ZZM_X+Q_\ )E'_  P?X8_Z'75O_!>/_DROO<@CNQZ#
M@\\G!/3H.OYTNW_:;\ZY/]<^+O\ HI,V_P#"E?\ S.+_ (AOP#_T1_#W_A O
M_FD^!_\ A@_PL.OC75O;.GKP>QYO?\?IZ6M/_8:\-Z;JVEZO;^,]2-YI5U]J
MM?.TU9(?.08'G1_V@AE3'.T.G/.:^[P,=R?J<T;1G..V/\^]9UN+N*<11K8:
MOQ!FE:AB:-7#XBE4Q*=.M0KPE2K4:D?8+FIU:4I0G&ZYHR:NMS;#^'_!&#Q.
M&Q>%X3R*ABL'B</C,+B*6!4*N'Q6$K0Q&&Q%*?UE\M6A6IPJTI<LN6<(RY96
ML>>V>@>/K&WCM8/&'AORHE")O\$WC-@=,E?%Z@G\!5G^R_B)_P!#CX9_\(B]
M_P#FQKNJ*^>_K^OO/L$K)):)))+LDDDODDCA?[+^(G_0X^&?_"(O?_FQH_LO
MXB?]#CX9_P#"(O?_ )L:[JB@#A?[+^(G_0X^&?\ PB+W_P";&NET>#6+>T,>
MN:C9:I>F:1EN;#3)=)@$!">7$;674=38R(0Y:7[2 X90(DVDMJT4 07)F%M<
M&W -P()3 " 09A&WE @\$;]N0>,=:_"3XJ-\-]&_8U_9$\1ZYK7B;X7>*-#^
M$/BR30_C,W@_P[XJ^%&A>+]?F\#6_P 4OAE\7AKL>H1Z#K_Q.UQ]2U'2+^!O
M#6OSZUX%\4:3;>/-%U*]N= \4_O%7$Z5\./!&B^'M7\)V'ARP7PSKNN^(_$F
MJ:!=>?J.DW.L^+O$%[XJ\1W*V.HS75O:Q:KXDU&_UJ>QM$@T]-0O+FX@M8GF
MD+ 'XK>)?'/PWU;]FCQWX,U?PIX5_9E^*GCGP'XT\.>']0TS]G,^'_#_ .V+
M\,K/QQ\7M.\+>#O@EX2U2/4_'MD_Q-N=4'C-OAWI-M/\2O!9^+&GZ_X4LM2M
M_$.D>)[N[\2+^PDTG]IWX:Z[X*U/PA^TK\=O%'[(/B#]F_P+?6]_=^+=^B_#
MCX(V?A"3P9KTVDF34-)_9W^*_A_XAZ[\0=>M+FXM/ ,-EK7BKQ9>Z):Z\ES<
M?NE1_P#7]^OUS_@.G2@#\U?C-\9/A!??'']F'XX^(?$5E<? 'P)-^UI\,?%/
MC?7-,U2S\%^!/CC:S^!O".D)XL?6-&A@T.]2V\)_&/P%I&LZHUC97FK:V="T
MJ[O[CQ+I\-U\C?"^Y\(?!RP^&?B+]I/PUJ7A_P"$GBW]D3X^^#O@CHWC;P]J
MES;Z'IGB[X_^*/&&F_!2/1+G0GFT;XA>//@-JOP4T/PO\/+B"U\4:_9?#W5/
M"NEZ%>7?AG4+.#]S-#T#1?#.GKI/A_2[+2-.6ZU"^^QV,"00O?:OJ%SJVJWT
MH0 S7NIZI>WFHZA=RE[B\OKJXNKB22>:1VUZ /YY_"NE:GX2^ _CKX!?$G1=
M9M_VQ_B'JW["VH?"?1M6L+^3QWXANO!?PK_9OTW2/%'A;5Y-&$MWH_P,\>^#
M_B9J_P 1M9L9KBP^'[Z7XGU;Q/>Z1#KJRWGWC\:?C3\&$_:1^"/Q(\8>(=//
MPC^#Y_:D^#/C_P 5>(-*U2V\'?#?X]:CH_P:OO#^G>*+S5M&CT_3[_6? D7C
MWP_X9UN6Y33-:F\1OX<T2]U*_P#$=O97'Z3UCZ/X?T3P^NHKHFEV6EC6-7U'
MQ!JILX$A;4M;U:83:CJM\ZC?=7UTZHKW$S.XAB@MT*V\$,48!^%?PVE\*?!S
M1/ FJ?M+^%=7T+X9^,_V(?B3X%^"/ASQIX?U6\?3-/\ $/QK\>^*;+X#6FBS
MZ%)<:5\3/%/P0USX&>'M$^&\MO;^+-8A\!WOAJQT&YN_"FH6UMSWA73-5\+?
M _Q=^S[\2M*U8?MJ^.?B/^POK_P_TC4;*^G\>^*1X(^&_P"RQ;0^.O"VM-I&
M_4/#'P8\0> _BI=_$+7M/GN-*\$R>'?&5UXCO],_MPB[_H-]??\ SQ1Z\]>G
MMQ_D\^OI0!\H? R6^/Q]_;/@@1E\,0_$_P"%K6ICB*6C>+Y_@'\.)/%AA? C
MDN3IO_"(M?F+(6X;]\?M1GKZOKF/#'@WPUX-374\-:6FFCQ-XGUOQEKSBXO+
MN?5/$OB&X%QJVJ75Q?7%U.SS%(;>WMTD2ST[3[6RTS3;>TTVRM+2'IZ "BBB
M@ KA?B;_ ,B!XL_[ ]S_ .RUW5<+\3?^1 \6?]@>Y_\ 9: #X9?\B!X3_P"P
M/;?^S5W5<+\,O^1 \)_]@>V_]FKNJ "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "C_/K_ "HHH _,73/AIH>J_M,>'+KX-^)O'?B_XA^
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M76=.\1>'-?TVUU/1M<TFY2\TW5+"YB#P7ME<QDI-;S*=R..HZ@$$#%L/A?\
M#;2_ ,GPJT[P#X-L?AC+I.HZ!+\/+7PUH\'@F70]7-R=5T>3PO'9KHLFEZD;
MV\-_8/9-:W?VJX\^*3SI-W=#_/.?U_S]* "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *X7XF_\B!XL_P"P/<_^RUW5<+\3
M?^1 \6?]@>Y_]EH /AE_R('A/_L#VW_LU=U7"_#+_D0/"?\ V![;_P!FKNJ
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[X0:S#X_:]TOXP?$OXE?%:Q\%IXQM[,Z_P"&OB#XALUL]?F^TR>#=#%Y";H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\1?"CXC_  E\4K<>'M4FU'5_"'C#X=>(D<LEWH=_)<W&H^&M75C&R7&F7!N
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M &?>K)):2+/%.)&A8,?BSX<_LC>+]'\>?"#QIXNTWX8)I?ASXH_M-_%;Q!X
MTBYO=9\.> +SXUV>DP>&O#_PX;4O".DP:R=,NK/4=7\3:_<:3X+:;Q!XB\0:
MAI>E>3J+6YL^"?V/_&OAC]FKQ%\-9/'>IP>,[WX+?&/X6:)X'TWQA?K\![&?
MQM/XV'A*_&B'PK;ZA9OIMCKVD6MW=VNG.NEPVT]KINF7=O;6XG (=5_;PUGP
M;X,\2>(?B1\ ->\*:[;_  +'[0/@3P_IWQ"\)^)[+QWX-@U[P?X9U;3FUZU@
ML6\+>(]%U;Q_X/6\M-7T>33;FSUG[3I.K:C)IVJ6]G[!JW[17CKX?^#=8\5?
M&+X(W/A*_N/$?@CP/\,_!_@WXB^&OB'XD^*?CWQ[K#Z!HGA/2=UEX3T?0;DZ
ME-ISW.J>(-5M-$T_2)]2U_5]1TS1]"U*[3Q#QI^P?X9M?V2OB)\*/A7X*\!V
M?QC\?_!SPC\.]9U_Q9XA\4ZKH^MS>&_[+NI?#E]XLUVP\8^(M.\"3ZA!JDD>
ME6.A2:<7O3=R^'C/)(JR2_LM^)=6\$36G@W]GW]F+]E_QOX&^*GPI^-/P\7X
M4:T=8\'^._&/P[U+4I9]'^*4&@?!/X47]AI%]X=O]2\-6>KV-OXGU/2F\23:
MY:6?FZ%'IFL@'T9\-/CSKGB+X@S_  C^*GPMU?X.?$N?PG<^/O"VF7/B70O&
M_AGQQX-TS4]-T3Q'?>'/%GA[R8EUKP?J^M:#9^*?#FLZ9I-]:Q>(M"U+1I->
MTRYO;O3O*HOVZ? TNA_M:WK^#_$]GK_[)FL^*;?6?"]_);6=S\1/"_ASSK2#
MQSX'U.1#IM[X?U'Q#IOB3PI<JTKWV@Z_X=N[;6K>UBOM'GU'L?!/PX^,'B[X
M[:+\=OC5I'P\\#/\/OAGXO\ AMX \#?#OQEK_P 0_M4GQ'\0>#M?\<>+/%/B
MW7? WPX$8"?#SPII/AKPWI_AJX6T4Z_JNHZY=2W]CI^F_+_QH_8<^*OCCX2_
M%ZS\#>(_ WA_XS^(_C!\>-<\&ZGJU_K<W@_7/@O\??$%A'XW^'?CZ6TT ZM:
M37OAR"V\4:/_ &39:E;^'?BGX0\#ZP;K6-%M=8T_4@#Z;3]H?XG^(?BM\3?A
MY\./@+%XNT3X3>-/"_@?Q7XSU7XK>'_"6=3\1>!_!_Q!N+C2_#=SH6J7]Y::
M5H'C/3PSO=6[7U[;W5M; ",R#D9/VUMNAR_%Z/X->+YOV6K;Q%/H-Q\?(_$7
MA1G&E6OB5O!]U\38?ADEZ_BV?X36WB%)/,\2[X_$;^&X+GQI;^"Y_"@MM5NN
M%F_9F\7Z9^TA\8/BU??LS_LK_&>V\=_$WX?^./!'Q'^(GBH:=\4OAYIOAGX:
M?#KP9=V&EPWW[/OCF:SGTG7O!^I^*/#ZZ3XXLK8W>I>>&TN^N+JX&4?V7?V@
M8_@#>_L4P+\)S\![H7O@F'XQS>,/%9^)=K\%-0\2/JDWAZ3X6#P%_8-W\0X?
M"\UQX-A\6#XH6VC->-;^-I=#,\4WA:< _0@?$#P&WC)_AROC;PBWQ"32QKC^
M!!XDT8^,DT4E0-8?PP+W^VUTLEE U V(M"64>=DBNNKX-'[/?Q/L/VH;3XF>
M%]%^'7AKP!=?$[4?B+XVO;GQ5=^,+KQ?)>_"F?X=?VIIGP[\1_"^6X^&_P 4
M&2+0],G\;^ /B]H^F7OA/2[ZQUKP]K:Z_J&FC[Q!!''2@!:*** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KA?B;_R('BS_L#W
M/_LM=U7"_$W_ )$#Q9_V![G_ -EH /AE_P B!X3_ .P/;?\ LU=U7"_#+_D0
M/"?_ &![;_V:NZH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "O$/C)^T)\)/@1;Z1/\3?%:^'WUV>XCTFRM]+UC6]2OQ9B+[5/%
MIVA6&HWBVEOYT,<MW-"ENLDL<8<N2*]OKPCXS_LY_"/X]+H9^)OA>37)_#KW
MG]D7EGK&M:%?6L-]L%W:F\T/4-/N+BSF:*&9[6XDEA6:))HT61=U>9G']L_V
M=B?[ 67/-K4_JBS;ZRL!?VM/VSK?5+U[JA[3V2C[KJ\BJ-0NSY_BG_6C^PL=
M_J8LCEQ)RT?[-7$;QRR=-XBBL2\5_9R>+;CA/;N@H6@\0J:JM4^9GA@_X*)_
MLH9/_%P=8[_\T\^(@/;' \*']?7BG?\ #Q/]E#_HH.L?^&\^(G_S)U%_P[L_
M92_Z$'7,Y_Z*%X^R?J/^$E[ CD\G(].#_AW;^RE_T(.N_P#AP?'W_P TE?!I
M>,MOA\.__,]^OS/QFWTIOY?!)>CXP?YV??\ #S'C_@HG^RAD?\7!UGON_P"+
M>?$3\,9\*'IWYQ@\9S1XJ_;L^%$WP3^.WQ-^#FHVOQ%\6?!KX7^*?B+'X&UB
M#7_!,NMKH.GRW%I;O=:WH4-S;Z;=ZA]DTZ[U:TL;U-.DO(?M$>Z2)7C_ .'=
MG[*7_0@:]_X</Q__ /-+C_\ 51XB_8.^$-O\(/CG\/?A+I:>!?$WQD^&'B/X
M;/XOUO4?$GC Z19ZY:/&I6VU?7)IQ8K>"UO+VSL+FR:^>RM/-E)MX63TLH7B
M=_:.%_MV/!7]D\\_KSRQYPL>J?LZG*\+[?\ <>T]K[&ZJ^Y[/VEVI*-_?X8_
MXF 6>Y=_KA#PI_U:=6:S7^P7Q/\ VPJ/L*[IO ?7%]4=;ZU]5NL1:E['V_,^
M94SK/!W[66F>,O$7P)TR#P]'H&G_ !/\%_'W6?'P\2:K'8ZS\)O&G[/VK^!_
M#GC?P+KMLL4FGRW>A>)O$7B+1]<U%M0M[*W_ .$<CU"PDO\ 3M1BN5O^*?VW
M?V</#/P\U7XFV_CH>+O#>B>)?A[X8U*+P;IM[K&LV\_Q/\0VOA[PAK TB6.R
MNI?#.I//=ZG9^(H0^EZSINCZL/#EQK6IV\6FW'G7Q4_8=L?B1\<O%_Q-L_'M
M]X8\&?$_X%_&CX6_$7P+8Z<DDEUXU^+/A+P+\/'^+'AS5Q/$^D^((_ 7@70_
M#NM6DD4]KJJ>'/"UY']DN[*]FO>4T_\ 8J\=_P#"M_'7A_4O$?PHM/'VIZ?\
M%;+PGXSTC0?BQJ<L[?!/XC:;\3=-@\8S^./BQXKOE\->(-<TFVA7PMX4.D+X
M86]UN^M]8UVXU""*P^]/V?3I<^LO&7QA_P"$=\??L^^$].TNVU31_C?K'C&Q
MEUN>ZNK"?1+#PU\,/$7Q$L[^WT^6R+W;Z@VB0V$UM>26$EI#=23G?-#]F;,T
M7]J_]F[Q VM#2/C1X!N8O#W@W4_B'J]ZVMPVFE6W@G1!:GQ#XGCU:]%OIEYI
M7AJ6^L[;Q/<V5W<_\(U>W<%AKHT^]F2 Z'C7X5:WXW\>?L_^.[O6M+T^Z^$.
MK>--:U[3[:PNY[?7;OQC\+_$7@.2#1YY;N.33[:QU'7_ .TD:]CNY9[.V^RL
M(YI!.ORMXB_83UOQ'\)?V>/AK+\2M-LK[X$_!CQ!\.TUU/#-U=VNL>*Y+OX3
MZWX1\1'2)-:@W>'=,\0?"RT;Q#X9GOO.U[0M2NM(AU;36=KN@#Z>M?VI_P!G
MF]\':EX]M_BQX4;PUH_B'2_"&ISR7%S!JEIXKUN"UN]"\+R>&KBVB\2GQ%KM
ME?6>H:%HB:0^IZSIMU!J.F6MW8R).34OVJ/V=M)\-^$O%U_\7_!<7A_Q[!XF
MF\%WD>I&YF\4/X+GCMO%]CH>G6L4VJ:CK'ABYD-MK^AVUG)K&DSV]Y#?6,$E
MA?+!P7B7X3?M ^-;;X?^+_$7C?X/6GQ4^$OQ+F\=>!+?0_!'C5/ %SI6J?#_
M ,1?#KQ'X?\ %JZAX\NM?O[[4],\7^(=1T?7](;1X_#MV-)M;C1?$=O:W\NJ
M8?PT_95\2>#_ (C^ _BIX@\<:+JWB:Q\4_M#^._B%9:+X?OM)T'5/$GQTB\"
MV=M9>#[2[UG4[K1M"\*Z;X&L+68ZO>:OJ&OZA)=:U++I\MZ]E;@'J>B_M8?L
MU^)(]9N-#^-OP[U.R\/^#9OB'JFI6OB*S;28?!=G'I\FI>(X-7++IFH:=HYU
M?2(->;3KN[DT&\U;3+'68[&]U"S@F]#\#?%;X=_$K0=1\3^!_%>F:_H^CWEU
MIVM3P?:+6YT34+.T@U"XL-;TS4(+35='O4TZZM-22UU*SM9Y=,O;/488Y+*\
MM9Y?A/Q-^P%JOBGX0? [X7W?Q)TZSN/@]\'_ !OX!;6K30-6BBUCQ3K/C7X-
M^/\ PQKZVUCXCTW4;;0[#7?A)#;^(])M]9MM5UC2]8N8;#7=(NT%Y7TS\"O@
M??\ P\\/_$"W\7P^!?[?^(NI1S:Y>> H?B 9+K3K7P]:>'K*/6O$'Q)\<>.-
M?U_4[:"*Z^QWB-HMEING3V>D0Z9<'3WU.^ //OAE^T[XP\6S_LFQZ_X1T&U@
M_:J\-_%GXD:9+I]]>P7'@_P'HVFZ9XW^%FGWEK,VIQ:QXGU'P'XF\/6_C:ZB
MOM-TZ#Q+#JDND6,=A);V<'NFO_M!?!3PQX_L?A9X@^)7A;2O'VH7>A:=#X<N
MK_;<0:GXJ:1/"ND:G=(C:=HVL^*GB9/#&CZM>6.I^(G:)-&M;UIX!)\B^&/@
M#\>!X-_8\U3PSJG@3PG\1?V4?"/CSX0:UI_Q%T+Q)KGAWQQ80:!H_P +;7QE
MHL_AW7=$U&SL/$NG^";'QQHBW<ES,NE^([?3M3@M-4M+J.+5U7]E3XR^)]/^
M(/A#Q!\0_AE;>!OCM\0?!7Q2^,2:-X-\5'Q5IGB3P[9^ =/\1:1\--4U#Q=+
MI]KHWB2T^&7AE='U'Q+IFH:KX.N+S6YT3Q HT>#30#Z6/[2WP$7Q+XJ\(R_%
M?P;;:]X)L?%.I>*+6]U1+*VTJT\#K$_C9FU6[6#2+J7P:LT?_"6VMC?7-WX;
M)*ZU!9,CA> \1_M0>%+K0?!WC_X8>)_"GC#P#8_&SP%\*/C"LMOJL'B3PW%\
M4;C3O!OA"2QL[NYTBYT35X/'GCSX8:Q?Q:[HM[#J7P^U35=0TR&.273=27SV
M]_97^)%W\0OB+K=IXP^&&A^ _&]O\6FU3P'9^$?B%J7@OXCW?Q&T^XM-'/Q=
M^&>I_%%_!%_>>'[JX75/$OBCP-%X.\2_$+48;J>]N=!AUK4+4<E<_LY_&&S\
M&:1\+/$'B23Q;HOC[]H[X'>-9+'2=1\9ZUX/^"/P_P#@?K?A3XKZS;Z?X@^)
M/BGQ3XXN+?QYK_PKL?#^F:0+^ZL-$\1^.+0:7IMCH-KK&HP 'Z/#Z'(X)..W
M3H>^<\#ZXX%+110 48XQSTQGO_\ KHHH **** "C_/YT44 %%%% !1@8QV.?
MUZ_G110 ?Y_+I1110 F/<]<__6^E+110 4444 %%%%  1GBC_/Y=*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KA?B;_ ,B!XL_[ ]S_ .RUW5<+\3?^1 \6?]@>Y_\ 9: #X9?\B!X3
M_P"P/;?^S5W5?&NA_'+4O#&DV/AZ'0+&[CT> 6"7,EY<1O.(&9?-:-8V6,OU
M*AF Z;C6K_PTAJW_ $+&G?\ @?<__&: /K6BODK_ (:0U;_H6-._\#[G_P",
MT?\ #2&K?]"QIW_@?<__ !F@#ZUHKY*_X:0U;_H6-._\#[G_ .,T?\-(:M_T
M+&G?^!]S_P#&: /K6BODK_AI#5O^A8T[_P #[G_XS1_PTAJW_0L:=_X'W/\
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M:=_X'W/_ ,9H_P"&D-6_Z%C3O_ ^Y_\ C- 'UK17R5_PTAJW_0L:=_X'W/\
M\9H_X:0U;_H6-._\#[G_ .,T ?6M%?)7_#2&K?\ 0L:=_P"!]S_\9H_X:0U;
M_H6-._\  ^Y_^,T ?6M%?)7_  TAJW_0L:=_X'W/_P 9H_X:0U;_ *%C3O\
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.BHT2JY7'"E@#W- '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>ensc-20241231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWa2CKbP9z5Z8SekhvWB1bWlKryclwWb+5CutC262gacG -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ENSC="http://ensysce.com/20241231" elementFormDefault="qualified" targetNamespace="http://ensysce.com/20241231">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://ensysce.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/StatementsOfOperations" id="StatementsOfOperations">
          <link:definition>00000004 - Statement - Consolidated Statements of Operations</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit" id="StatementsOfChangesInStockholdersEquityDeficit">
          <link:definition>00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Deficit)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000006 - Statement - Consolidated Statements of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/OrganizationAndPrincipalActivities" id="OrganizationAndPrincipalActivities">
          <link:definition>999014 - Disclosure - ORGANIZATION AND PRINCIPAL ACTIVITIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/BasisOfPresentation" id="BasisOfPresentation">
          <link:definition>999015 - Disclosure - BASIS OF PRESENTATION</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
          <link:definition>999016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/PrepaidExpensesAndOtherCurrentAssets" id="PrepaidExpensesAndOtherCurrentAssets">
          <link:definition>999017 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/AccruedExpensesAndOtherLiabilities" id="AccruedExpensesAndOtherLiabilities">
          <link:definition>999018 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>999019 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/NotesPayable" id="NotesPayable">
          <link:definition>999020 - Disclosure - NOTES PAYABLE</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/StockholdersEquity" id="StockholdersEquity">
          <link:definition>999021 - Disclosure - STOCKHOLDERS&#8217; EQUITY</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/Stock-basedCompensation" id="Stock-basedCompensation">
          <link:definition>999022 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>999023 - Disclosure - INCOME TAXES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/RelatedParties" id="RelatedParties">
          <link:definition>999024 - Disclosure - RELATED PARTIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>999025 - Disclosure - SUBSEQUENT EVENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>999026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
          <link:definition>999027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" id="PrepaidExpensesAndOtherCurrentAssetsTables">
          <link:definition>999028 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/AccruedExpensesAndOtherLiabilitiesTables" id="AccruedExpensesAndOtherLiabilitiesTables">
          <link:definition>999029 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/NotesPayableTables" id="NotesPayableTables">
          <link:definition>999030 - Disclosure - NOTES PAYABLE (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
          <link:definition>999031 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/Stock-basedCompensationTables" id="Stock-basedCompensationTables">
          <link:definition>999032 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>999033 - Disclosure - INCOME TAXES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative" id="OrganizationAndPrincipalActivitiesDetailsNarrative">
          <link:definition>999034 - Disclosure - ORGANIZATION AND PRINCIPAL ACTIVITIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/BasisOfPresentationDetailsNarrative" id="BasisOfPresentationDetailsNarrative">
          <link:definition>999035 - Disclosure - BASIS OF PRESENTATION (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" id="ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails">
          <link:definition>999036 - Disclosure - SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/ScheduleOfChangeInFairValueOfCompanysLevel3Details" id="ScheduleOfChangeInFairValueOfCompanysLevel3Details">
          <link:definition>999037 - Disclosure - SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY&#8217;S LEVEL 3 (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/ScheduleOfRevenueRecognitionUnderGrantsDetails" id="ScheduleOfRevenueRecognitionUnderGrantsDetails">
          <link:definition>999038 - Disclosure - SCHEDULE OF REVENUE RECOGNITION UNDER GRANTS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/ScheduleOfWeightedAverageSharesOfAnti-dilutiveSecuritiesDetails" id="ScheduleOfWeightedAverageSharesOfAnti-dilutiveSecuritiesDetails">
          <link:definition>999039 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>999040 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" id="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails">
          <link:definition>999041 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" id="ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails">
          <link:definition>999042 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>999043 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/ScheduleOfDebtDetails" id="ScheduleOfDebtDetails">
          <link:definition>999044 - Disclosure - SCHEDULE OF DEBT (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/NotesPayableDetailsNarrative" id="NotesPayableDetailsNarrative">
          <link:definition>999045 - Disclosure - NOTES PAYABLE (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/ScheduleOfOutstandingWarrantDetails" id="ScheduleOfOutstandingWarrantDetails">
          <link:definition>999046 - Disclosure - SCHEDULE OF OUTSTANDING WARRANT (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical" id="ScheduleOfOutstandingWarrantDetailsParenthetical">
          <link:definition>999047 - Disclosure - SCHEDULE OF OUTSTANDING WARRANT (Details) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
          <link:definition>999048 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/ScheduleOfStockOptionActivityDetails" id="ScheduleOfStockOptionActivityDetails">
          <link:definition>999049 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails" id="ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails">
          <link:definition>999050 - Disclosure - SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/ScheduleOfCommonStockFutureIssuanceDetails" id="ScheduleOfCommonStockFutureIssuanceDetails">
          <link:definition>999051 - Disclosure - SCHEDULE OF COMMON STOCK FUTURE ISSUANCE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/Stock-basedCompensationDetailsNarrative" id="Stock-basedCompensationDetailsNarrative">
          <link:definition>999052 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/ScheduleOfIncomeTaxesBenefitDetails" id="ScheduleOfIncomeTaxesBenefitDetails">
          <link:definition>999053 - Disclosure - SCHEDULE OF INCOME TAXES BENEFIT (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/ScheduleOfFederalAndStateIncomeTaxProvisionBenefitDetails" id="ScheduleOfFederalAndStateIncomeTaxProvisionBenefitDetails">
          <link:definition>999054 - Disclosure - SCHEDULE OF FEDERAL AND STATE INCOME TAX PROVISION (BENEFIT) (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/ScheduleOfFederalIncomeTaxRateReconciliationDetails" id="ScheduleOfFederalIncomeTaxRateReconciliationDetails">
          <link:definition>999055 - Disclosure - SCHEDULE OF FEDERAL INCOME TAX RATE RECONCILIATION (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/ScheduleOfDeferredTaxAssetsDetails" id="ScheduleOfDeferredTaxAssetsDetails">
          <link:definition>999056 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails" id="ScheduleOfUnrecognizedTaxBenefitsDetails">
          <link:definition>999057 - Disclosure - SCHEDULE OF UNRECOGNIZED TAX BENEFITS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>999058 - Disclosure - INCOME TAXES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/RelatedPartiesDetailsNarrative" id="RelatedPartiesDetailsNarrative">
          <link:definition>999059 - Disclosure - RELATED PARTIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://ensysce.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>999060 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="ensc-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="ensc-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="ensc-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="ensc-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/cyd/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" />
    <element id="ENSC_CommonStock0.0001ParValuePerShareMember" name="CommonStock0.0001ParValuePerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_WarrantsToPurchaseOneShareOfCommonStockMember" name="WarrantsToPurchaseOneShareOfCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_EBIRIncMember" name="EBIRIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_KeyPersonnelMember" name="KeyPersonnelMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_UnrelatedPartyMember" name="UnrelatedPartyMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_CustomerMember" name="CustomerMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_LiabilityClassifiedWarrantsMember" name="LiabilityClassifiedWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_MPARMember" name="MPARMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_TAAPOUDMember" name="TAAPOUDMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_TwoThousandTwentyThreeNotesMember" name="TwoThousandTwentyThreeNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_FinancedInsuranceMember" name="FinancedInsuranceMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_FirstClosingSecuritiesPurchaseAgreementMember" name="FirstClosingSecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_SecondClosingSecuritiesPurchaseAgreementMember" name="SecondClosingSecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_RegisteredDirectOfferingMember" name="RegisteredDirectOfferingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_PrefundedWarrantMember" name="PrefundedWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_SeriesAandBWarrantsMember" name="SeriesAandBWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_SeriesAWarrantsMember" name="SeriesAWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_SeriesBWarrantsMember" name="SeriesBWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_WarrantOneMember" name="WarrantOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_WarrantTwoMember" name="WarrantTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_WarrantThreeMember" name="WarrantThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_WarrantFourMember" name="WarrantFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_InstitutionalInvestorMember" name="InstitutionalInvestorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_InvestorWarrantsMember" name="InvestorWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_PlacementAgentWarrantsMember" name="PlacementAgentWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_PublicWarrantMember" name="PublicWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_Notes2021And2022Member" name="Notes2021And2022Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_TwoThousandTwentyOneOmnibusIncentivePlanMember" name="TwoThousandTwentyOneOmnibusIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_BoardOfMembersMember" name="BoardOfMembersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_StockOptionAvailableForFutureGrantUnder2021OmnibusIncentivePlanMember" name="StockOptionAvailableForFutureGrantUnder2021OmnibusIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_WarrantOutstandingMember" name="WarrantOutstandingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_LossOnConversionsAndChangeInFairValueOfConvertibleNotes" name="LossOnConversionsAndChangeInFairValueOfConvertibleNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_ChangeInFairValueOfLiabilityClassifiedWarrants" name="ChangeInFairValueOfLiabilityClassifiedWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_StockIssuedDuringPeriodValueCommitmentFee" name="StockIssuedDuringPeriodValueCommitmentFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_StockIssuedDuringPeriodSharesCommitmentFee" name="StockIssuedDuringPeriodSharesCommitmentFee" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_TransactionCostsAssociatedWithPublicOffering" name="TransactionCostsAssociatedWithPublicOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants" name="StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares" name="StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_StockIssuedDuringPeriodValueReverseStockSplits" name="StockIssuedDuringPeriodValueReverseStockSplits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_IssuanceOfCommonStockUponWarrantInducements" name="IssuanceOfCommonStockUponWarrantInducements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_IssuanceOfCommonStockUponWarrantInducementsShares" name="IssuanceOfCommonStockUponWarrantInducementsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_TransactionCostsAssociatedWithPublicOfferingAndWarrantInducements" name="TransactionCostsAssociatedWithPublicOfferingAndWarrantInducements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_IncreaseDecreaseInUnbilledReceivable" name="IncreaseDecreaseInUnbilledReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_ProceedsFromWarrantInducementNetOfIssuanceCosts" name="ProceedsFromWarrantInducementNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_TransactionCostsFromPublicOfferings" name="TransactionCostsFromPublicOfferings" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_TransactionCostAssociatedWithWarrantInducement" name="TransactionCostAssociatedWithWarrantInducement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_RepaymentInsurancePremiums" name="RepaymentInsurancePremiums" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_IncrementalFairValueOfWarrantInducement1" name="IncrementalFairValueOfWarrantInducement1" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_IncrementalFairValueOfWarrantInducement2" name="IncrementalFairValueOfWarrantInducement2" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_ConversionsOfConvertibleNotesIntoCommonStock" name="ConversionsOfConvertibleNotesIntoCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_OriginalDebtDiscountFromConvertibleNotes" name="OriginalDebtDiscountFromConvertibleNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_DebtDiscountFromWarrantsIssuance" name="DebtDiscountFromWarrantsIssuance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_IssuanceCostFromConvertibleNotes" name="IssuanceCostFromConvertibleNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_FinancedInsurancePremiums" name="FinancedInsurancePremiums" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_SettlementOfCommitmentFeeInShares" name="SettlementOfCommitmentFeeInShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_DeemedDividendRelatedToWarrantsDownRoundProvision" name="DeemedDividendRelatedToWarrantsDownRoundProvision" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_ScheduleOfRevenueRecognitionUnderGrantsTableTextBlock" name="ScheduleOfRevenueRecognitionUnderGrantsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_ScheduleOfCommonStockFutureIssuanceTableTextBlock" name="ScheduleOfCommonStockFutureIssuanceTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_ScheduleOfFederalAndStateIncomeTaxProvisionBenefitTableTextBlock" name="ScheduleOfFederalAndStateIncomeTaxProvisionBenefitTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_PrepaidResearchAndDevelopment" name="PrepaidResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_AccruedResearchAndDevelopment" name="AccruedResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_IssuanceOfCommonStockValueUponWarrantInducementNetOfIssuanceCosts" name="IssuanceOfCommonStockValueUponWarrantInducementNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_TransactionCostsAssociatedWithWarrantInducement" name="TransactionCostsAssociatedWithWarrantInducement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_WarrantDescription" name="WarrantDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_AgentFeesAndOfferingExpensesPerShare" name="AgentFeesAndOfferingExpensesPerShare" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_CombinedOfferingPricePerShare" name="CombinedOfferingPricePerShare" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_OfferingPricePerShare" name="OfferingPricePerShare" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_SharebasedCompensationArrangementBySharebasedPaymentAwardWeightedAveragePeriodExpectedToBeRecognized" name="SharebasedCompensationArrangementBySharebasedPaymentAwardWeightedAveragePeriodExpectedToBeRecognized" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_IncomeTaxReconciliationExpiringAttributes" name="IncomeTaxReconciliationExpiringAttributes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_WarrantOrRightExercisable" name="WarrantOrRightExercisable" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ENSC_WarrantExpirationDate" name="WarrantExpirationDate" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>ensc-20241231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://ensysce.com/role/Cover" xlink:href="ensc-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/BalanceSheets" xlink:href="ensc-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/BalanceSheetsParenthetical" xlink:href="ensc-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/StatementsOfOperations" xlink:href="ensc-20241231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit" xlink:href="ensc-20241231.xsd#StatementsOfChangesInStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/StatementsOfCashFlows" xlink:href="ensc-20241231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/OrganizationAndPrincipalActivities" xlink:href="ensc-20241231.xsd#OrganizationAndPrincipalActivities" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/BasisOfPresentation" xlink:href="ensc-20241231.xsd#BasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="ensc-20241231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="ensc-20241231.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/AccruedExpensesAndOtherLiabilities" xlink:href="ensc-20241231.xsd#AccruedExpensesAndOtherLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/CommitmentsAndContingencies" xlink:href="ensc-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/NotesPayable" xlink:href="ensc-20241231.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/StockholdersEquity" xlink:href="ensc-20241231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/Stock-basedCompensation" xlink:href="ensc-20241231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/IncomeTaxes" xlink:href="ensc-20241231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/RelatedParties" xlink:href="ensc-20241231.xsd#RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/SubsequentEvents" xlink:href="ensc-20241231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ensc-20241231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="ensc-20241231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="ensc-20241231.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/AccruedExpensesAndOtherLiabilitiesTables" xlink:href="ensc-20241231.xsd#AccruedExpensesAndOtherLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/NotesPayableTables" xlink:href="ensc-20241231.xsd#NotesPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/StockholdersEquityTables" xlink:href="ensc-20241231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/Stock-basedCompensationTables" xlink:href="ensc-20241231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/IncomeTaxesTables" xlink:href="ensc-20241231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative" xlink:href="ensc-20241231.xsd#OrganizationAndPrincipalActivitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/BasisOfPresentationDetailsNarrative" xlink:href="ensc-20241231.xsd#BasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:href="ensc-20241231.xsd#ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfChangeInFairValueOfCompanysLevel3Details" xlink:href="ensc-20241231.xsd#ScheduleOfChangeInFairValueOfCompanysLevel3Details" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfRevenueRecognitionUnderGrantsDetails" xlink:href="ensc-20241231.xsd#ScheduleOfRevenueRecognitionUnderGrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfWeightedAverageSharesOfAnti-dilutiveSecuritiesDetails" xlink:href="ensc-20241231.xsd#ScheduleOfWeightedAverageSharesOfAnti-dilutiveSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="ensc-20241231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="ensc-20241231.xsd#ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" xlink:href="ensc-20241231.xsd#ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="ensc-20241231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfDebtDetails" xlink:href="ensc-20241231.xsd#ScheduleOfDebtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/NotesPayableDetailsNarrative" xlink:href="ensc-20241231.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfOutstandingWarrantDetails" xlink:href="ensc-20241231.xsd#ScheduleOfOutstandingWarrantDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical" xlink:href="ensc-20241231.xsd#ScheduleOfOutstandingWarrantDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/StockholdersEquityDetailsNarrative" xlink:href="ensc-20241231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="ensc-20241231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:href="ensc-20241231.xsd#ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfCommonStockFutureIssuanceDetails" xlink:href="ensc-20241231.xsd#ScheduleOfCommonStockFutureIssuanceDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="ensc-20241231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfIncomeTaxesBenefitDetails" xlink:href="ensc-20241231.xsd#ScheduleOfIncomeTaxesBenefitDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfFederalAndStateIncomeTaxProvisionBenefitDetails" xlink:href="ensc-20241231.xsd#ScheduleOfFederalAndStateIncomeTaxProvisionBenefitDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfFederalIncomeTaxRateReconciliationDetails" xlink:href="ensc-20241231.xsd#ScheduleOfFederalIncomeTaxRateReconciliationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfDeferredTaxAssetsDetails" xlink:href="ensc-20241231.xsd#ScheduleOfDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails" xlink:href="ensc-20241231.xsd#ScheduleOfUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/IncomeTaxesDetailsNarrative" xlink:href="ensc-20241231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/RelatedPartiesDetailsNarrative" xlink:href="ensc-20241231.xsd#RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/SubsequentEventsDetailsNarrative" xlink:href="ensc-20241231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnbilledReceivablesCurrent" xlink:label="loc_us-gaapUnbilledReceivablesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapUnbilledReceivablesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapMinorityInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_LossOnConversionsAndChangeInFairValueOfConvertibleNotes" xlink:label="loc_ENSCLossOnConversionsAndChangeInFairValueOfConvertibleNotes" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_ENSCLossOnConversionsAndChangeInFairValueOfConvertibleNotes" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_ChangeInFairValueOfLiabilityClassifiedWarrants" xlink:label="loc_ENSCChangeInFairValueOfLiabilityClassifiedWarrants" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_ENSCChangeInFairValueOfLiabilityClassifiedWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaapInterestExpenseNonoperating" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpenseNonoperating" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount" xlink:label="loc_us-gaapWarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapWarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity (Deficit)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaapIncreaseDecreaseInInterestPayableNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInterestPayableNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_LossOnConversionsAndChangeInFairValueOfConvertibleNotes" xlink:label="loc_ENSCLossOnConversionsAndChangeInFairValueOfConvertibleNotes" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ENSCLossOnConversionsAndChangeInFairValueOfConvertibleNotes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_ChangeInFairValueOfLiabilityClassifiedWarrants" xlink:label="loc_ENSCChangeInFairValueOfLiabilityClassifiedWarrants" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ENSCChangeInFairValueOfLiabilityClassifiedWarrants" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForLoanLeaseAndOtherLosses" xlink:label="loc_us-gaapProvisionForLoanLeaseAndOtherLosses" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProvisionForLoanLeaseAndOtherLosses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_IncreaseDecreaseInUnbilledReceivable" xlink:label="loc_ENSCIncreaseDecreaseInUnbilledReceivable" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ENSCIncreaseDecreaseInUnbilledReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccruedLiabilities" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_ProceedsFromWarrantInducementNetOfIssuanceCosts" xlink:label="loc_ENSCProceedsFromWarrantInducementNetOfIssuanceCosts" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ENSCProceedsFromWarrantInducementNetOfIssuanceCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_TransactionCostsFromPublicOfferings" xlink:label="loc_ENSCTransactionCostsFromPublicOfferings" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ENSCTransactionCostsFromPublicOfferings" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_TransactionCostAssociatedWithWarrantInducement" xlink:label="loc_ENSCTransactionCostAssociatedWithWarrantInducement" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ENSCTransactionCostAssociatedWithWarrantInducement" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaapRepaymentsOfConvertibleDebt" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfConvertibleDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_RepaymentInsurancePremiums" xlink:label="loc_ENSCRepaymentInsurancePremiums" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ENSCRepaymentInsurancePremiums" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000012 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000013 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/OrganizationAndPrincipalActivities" xlink:title="999014 - Disclosure - ORGANIZATION AND PRINCIPAL ACTIVITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/BasisOfPresentation" xlink:title="999015 - Disclosure - BASIS OF PRESENTATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="999017 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/AccruedExpensesAndOtherLiabilities" xlink:title="999018 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/CommitmentsAndContingencies" xlink:title="999019 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/NotesPayable" xlink:title="999020 - Disclosure - NOTES PAYABLE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/StockholdersEquity" xlink:title="999021 - Disclosure - STOCKHOLDERS&#8217; EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/Stock-basedCompensation" xlink:title="999022 - Disclosure - STOCK-BASED COMPENSATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/IncomeTaxes" xlink:title="999023 - Disclosure - INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/RelatedParties" xlink:title="999024 - Disclosure - RELATED PARTIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/SubsequentEvents" xlink:title="999025 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="999028 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/AccruedExpensesAndOtherLiabilitiesTables" xlink:title="999029 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/NotesPayableTables" xlink:title="999030 - Disclosure - NOTES PAYABLE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/StockholdersEquityTables" xlink:title="999031 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/Stock-basedCompensationTables" xlink:title="999032 - Disclosure - STOCK-BASED COMPENSATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/IncomeTaxesTables" xlink:title="999033 - Disclosure - INCOME TAXES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative" xlink:title="999034 - Disclosure - ORGANIZATION AND PRINCIPAL ACTIVITIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/BasisOfPresentationDetailsNarrative" xlink:title="999035 - Disclosure - BASIS OF PRESENTATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:title="999036 - Disclosure - SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfChangeInFairValueOfCompanysLevel3Details" xlink:title="999037 - Disclosure - SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY&#8217;S LEVEL 3 (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfRevenueRecognitionUnderGrantsDetails" xlink:title="999038 - Disclosure - SCHEDULE OF REVENUE RECOGNITION UNDER GRANTS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfWeightedAverageSharesOfAnti-dilutiveSecuritiesDetails" xlink:title="999039 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999040 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="999041 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_PrepaidResearchAndDevelopment" xlink:label="loc_ENSCPrepaidResearchAndDevelopment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseCurrent" xlink:to="loc_ENSCPrepaidResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseCurrent" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseCurrent" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseCurrent" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" xlink:title="999042 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_AccruedResearchAndDevelopment" xlink:label="loc_ENSCAccruedResearchAndDevelopment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:to="loc_ENSCAccruedResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrentAndNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrentAndNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999043 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfDebtDetails" xlink:title="999044 - Disclosure - SCHEDULE OF DEBT (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/NotesPayableDetailsNarrative" xlink:title="999045 - Disclosure - NOTES PAYABLE (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfOutstandingWarrantDetails" xlink:title="999046 - Disclosure - SCHEDULE OF OUTSTANDING WARRANT (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical" xlink:title="999047 - Disclosure - SCHEDULE OF OUTSTANDING WARRANT (Details) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/StockholdersEquityDetailsNarrative" xlink:title="999048 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="999049 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:title="999050 - Disclosure - SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfCommonStockFutureIssuanceDetails" xlink:title="999051 - Disclosure - SCHEDULE OF COMMON STOCK FUTURE ISSUANCE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999052 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfIncomeTaxesBenefitDetails" xlink:title="999053 - Disclosure - SCHEDULE OF INCOME TAXES BENEFIT (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfFederalAndStateIncomeTaxProvisionBenefitDetails" xlink:title="999054 - Disclosure - SCHEDULE OF FEDERAL AND STATE INCOME TAX PROVISION (BENEFIT) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfFederalIncomeTaxRateReconciliationDetails" xlink:title="999055 - Disclosure - SCHEDULE OF FEDERAL INCOME TAX RATE RECONCILIATION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseOther" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxCreditsResearch" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_IncomeTaxReconciliationExpiringAttributes" xlink:label="loc_ENSCIncomeTaxReconciliationExpiringAttributes" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_ENSCIncomeTaxReconciliationExpiringAttributes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxContingencies" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxContingencies" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfDeferredTaxAssetsDetails" xlink:title="999056 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwards" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaapDeferredTaxLiabilities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaapDeferredTaxLiabilitiesOther" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxLiabilities" xlink:to="loc_us-gaapDeferredTaxLiabilitiesOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxLiabilities" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails" xlink:title="999057 - Disclosure - SCHEDULE OF UNRECOGNIZED TAX BENEFITS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/IncomeTaxesDetailsNarrative" xlink:title="999058 - Disclosure - INCOME TAXES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/RelatedPartiesDetailsNarrative" xlink:title="999059 - Disclosure - RELATED PARTIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ensysce.com/role/SubsequentEventsDetailsNarrative" xlink:title="999060 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>ensc-20241231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://ensysce.com/role/Cover" xlink:href="ensc-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/BalanceSheets" xlink:href="ensc-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/BalanceSheetsParenthetical" xlink:href="ensc-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/StatementsOfOperations" xlink:href="ensc-20241231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit" xlink:href="ensc-20241231.xsd#StatementsOfChangesInStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/StatementsOfCashFlows" xlink:href="ensc-20241231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/OrganizationAndPrincipalActivities" xlink:href="ensc-20241231.xsd#OrganizationAndPrincipalActivities" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/BasisOfPresentation" xlink:href="ensc-20241231.xsd#BasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="ensc-20241231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="ensc-20241231.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/AccruedExpensesAndOtherLiabilities" xlink:href="ensc-20241231.xsd#AccruedExpensesAndOtherLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/CommitmentsAndContingencies" xlink:href="ensc-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/NotesPayable" xlink:href="ensc-20241231.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/StockholdersEquity" xlink:href="ensc-20241231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/Stock-basedCompensation" xlink:href="ensc-20241231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/IncomeTaxes" xlink:href="ensc-20241231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/RelatedParties" xlink:href="ensc-20241231.xsd#RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/SubsequentEvents" xlink:href="ensc-20241231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ensc-20241231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="ensc-20241231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="ensc-20241231.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/AccruedExpensesAndOtherLiabilitiesTables" xlink:href="ensc-20241231.xsd#AccruedExpensesAndOtherLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/NotesPayableTables" xlink:href="ensc-20241231.xsd#NotesPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/StockholdersEquityTables" xlink:href="ensc-20241231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/Stock-basedCompensationTables" xlink:href="ensc-20241231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/IncomeTaxesTables" xlink:href="ensc-20241231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative" xlink:href="ensc-20241231.xsd#OrganizationAndPrincipalActivitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/BasisOfPresentationDetailsNarrative" xlink:href="ensc-20241231.xsd#BasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:href="ensc-20241231.xsd#ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfChangeInFairValueOfCompanysLevel3Details" xlink:href="ensc-20241231.xsd#ScheduleOfChangeInFairValueOfCompanysLevel3Details" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfRevenueRecognitionUnderGrantsDetails" xlink:href="ensc-20241231.xsd#ScheduleOfRevenueRecognitionUnderGrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfWeightedAverageSharesOfAnti-dilutiveSecuritiesDetails" xlink:href="ensc-20241231.xsd#ScheduleOfWeightedAverageSharesOfAnti-dilutiveSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="ensc-20241231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="ensc-20241231.xsd#ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" xlink:href="ensc-20241231.xsd#ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="ensc-20241231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfDebtDetails" xlink:href="ensc-20241231.xsd#ScheduleOfDebtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/NotesPayableDetailsNarrative" xlink:href="ensc-20241231.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfOutstandingWarrantDetails" xlink:href="ensc-20241231.xsd#ScheduleOfOutstandingWarrantDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical" xlink:href="ensc-20241231.xsd#ScheduleOfOutstandingWarrantDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/StockholdersEquityDetailsNarrative" xlink:href="ensc-20241231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="ensc-20241231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:href="ensc-20241231.xsd#ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfCommonStockFutureIssuanceDetails" xlink:href="ensc-20241231.xsd#ScheduleOfCommonStockFutureIssuanceDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="ensc-20241231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfIncomeTaxesBenefitDetails" xlink:href="ensc-20241231.xsd#ScheduleOfIncomeTaxesBenefitDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfFederalAndStateIncomeTaxProvisionBenefitDetails" xlink:href="ensc-20241231.xsd#ScheduleOfFederalAndStateIncomeTaxProvisionBenefitDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfFederalIncomeTaxRateReconciliationDetails" xlink:href="ensc-20241231.xsd#ScheduleOfFederalIncomeTaxRateReconciliationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfDeferredTaxAssetsDetails" xlink:href="ensc-20241231.xsd#ScheduleOfDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails" xlink:href="ensc-20241231.xsd#ScheduleOfUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/IncomeTaxesDetailsNarrative" xlink:href="ensc-20241231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/RelatedPartiesDetailsNarrative" xlink:href="ensc-20241231.xsd#RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/SubsequentEventsDetailsNarrative" xlink:href="ensc-20241231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosureWithAdditionalMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpTable" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsToCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListsByExecutiveCategory" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpExecutiveCategoriesOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTypeOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TradingArrangmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ForgoneRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#OutstandingRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardsCloseToMnpiDisc" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangemenstByInd" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/Defaults" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#Defaults" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_CommonStock0.0001ParValuePerShareMember" xlink:label="loc_ENSCCommonStock0.0001ParValuePerShareMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENSCCommonStock0.0001ParValuePerShareMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_WarrantsToPurchaseOneShareOfCommonStockMember" xlink:label="loc_ENSCWarrantsToPurchaseOneShareOfCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENSCWarrantsToPurchaseOneShareOfCommonStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey_60" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber_60" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_60" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_60" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1_60" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2_60" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3_60" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown_60" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_60" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry_60" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_60" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion_60" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode_60" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber_60" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension_60" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications_60" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial_60" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer_60" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_60" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle_60" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag_60" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol_60" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName_60" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle_60" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation_60" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm_60" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_60" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_60" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers_60" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_60" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_60" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory_60" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness_60" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_60" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod_60" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard_60" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_60" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany_60" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat_60" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_60" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_60" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_60" xlink:type="arc" order="57" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiIcfrAuditorAttestationFlag_60" xlink:type="arc" order="58" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag_60" xlink:type="arc" order="59" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorFirmId_60" xlink:type="arc" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorName_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorLocation_60" xlink:type="arc" order="62" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity (Deficit)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaapNoncontrollingInterestMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapNoncontrollingInterestMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_StockIssuedDuringPeriodValueCommitmentFee" xlink:label="loc_ENSCStockIssuedDuringPeriodValueCommitmentFee_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENSCStockIssuedDuringPeriodValueCommitmentFee_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_StockIssuedDuringPeriodSharesCommitmentFee" xlink:label="loc_ENSCStockIssuedDuringPeriodSharesCommitmentFee_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENSCStockIssuedDuringPeriodSharesCommitmentFee_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_TransactionCostsAssociatedWithPublicOffering" xlink:label="loc_ENSCTransactionCostsAssociatedWithPublicOffering_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENSCTransactionCostsAssociatedWithPublicOffering_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants" xlink:label="loc_ENSCStockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENSCStockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares" xlink:label="loc_ENSCStockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENSCStockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_StockIssuedDuringPeriodValueReverseStockSplits" xlink:label="loc_ENSCStockIssuedDuringPeriodValueReverseStockSplits_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENSCStockIssuedDuringPeriodValueReverseStockSplits_60" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits_60" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:label="loc_us-gaapWarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_60" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss_60" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_IssuanceOfCommonStockUponWarrantInducements" xlink:label="loc_ENSCIssuanceOfCommonStockUponWarrantInducements_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENSCIssuanceOfCommonStockUponWarrantInducements_60" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_IssuanceOfCommonStockUponWarrantInducementsShares" xlink:label="loc_ENSCIssuanceOfCommonStockUponWarrantInducementsShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENSCIssuanceOfCommonStockUponWarrantInducementsShares_60" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_TransactionCostsAssociatedWithPublicOfferingAndWarrantInducements" xlink:label="loc_ENSCTransactionCostsAssociatedWithPublicOfferingAndWarrantInducements_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENSCTransactionCostsAssociatedWithPublicOfferingAndWarrantInducements_60" xlink:type="arc" order="22" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000012 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000013 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/OrganizationAndPrincipalActivities" xlink:title="999014 - Disclosure - ORGANIZATION AND PRINCIPAL ACTIVITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/BasisOfPresentation" xlink:title="999015 - Disclosure - BASIS OF PRESENTATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="999017 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/AccruedExpensesAndOtherLiabilities" xlink:title="999018 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/CommitmentsAndContingencies" xlink:title="999019 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/NotesPayable" xlink:title="999020 - Disclosure - NOTES PAYABLE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/StockholdersEquity" xlink:title="999021 - Disclosure - STOCKHOLDERS&#8217; EQUITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/Stock-basedCompensation" xlink:title="999022 - Disclosure - STOCK-BASED COMPENSATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/IncomeTaxes" xlink:title="999023 - Disclosure - INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/RelatedParties" xlink:title="999024 - Disclosure - RELATED PARTIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/SubsequentEvents" xlink:title="999025 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="999028 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/AccruedExpensesAndOtherLiabilitiesTables" xlink:title="999029 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/NotesPayableTables" xlink:title="999030 - Disclosure - NOTES PAYABLE (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/StockholdersEquityTables" xlink:title="999031 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/Stock-basedCompensationTables" xlink:title="999032 - Disclosure - STOCK-BASED COMPENSATION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/IncomeTaxesTables" xlink:title="999033 - Disclosure - INCOME TAXES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative" xlink:title="999034 - Disclosure - ORGANIZATION AND PRINCIPAL ACTIVITIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_EBIRIncMember" xlink:label="loc_ENSCEBIRIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_ENSCEBIRIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_KeyPersonnelMember" xlink:label="loc_ENSCKeyPersonnelMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_ENSCKeyPersonnelMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_UnrelatedPartyMember" xlink:label="loc_ENSCUnrelatedPartyMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_ENSCUnrelatedPartyMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_50" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/BasisOfPresentationDetailsNarrative" xlink:title="999035 - Disclosure - BASIS OF PRESENTATION (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:title="999036 - Disclosure - SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapFinancialLiabilitiesFairValueDisclosure_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapFinancialLiabilitiesFairValueDisclosure_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="loc_us-gaapFairValueNetAssetLiability_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapFairValueNetAssetLiability_90" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfChangeInFairValueOfCompanysLevel3Details" xlink:title="999037 - Disclosure - SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY&#8217;S LEVEL 3 (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaapFairValueByLiabilityClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="loc_us-gaapFairValueByLiabilityClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_LiabilityClassifiedWarrantsMember" xlink:label="loc_ENSCLiabilityClassifiedWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_ENSCLiabilityClassifiedWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_40" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfRevenueRecognitionUnderGrantsDetails" xlink:title="999038 - Disclosure - SCHEDULE OF REVENUE RECOGNITION UNDER GRANTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapScheduleOfProductInformationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_MPARMember" xlink:label="loc_ENSCMPARMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_ENSCMPARMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_TAAPOUDMember" xlink:label="loc_ENSCTAAPOUDMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_ENSCTAAPOUDMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfWeightedAverageSharesOfAnti-dilutiveSecuritiesDetails" xlink:title="999039 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaapConvertibleDebtSecuritiesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapConvertibleDebtSecuritiesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999040 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapScheduleOfProductInformationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtMajorCustomersAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_CustomerMember" xlink:label="loc_ENSCCustomerMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_ENSCCustomerMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDescription" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDescription_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDescription_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaapNumberOfReportableSegments_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapNumberOfReportableSegments_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaapNumberOfOperatingSegments_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapNumberOfOperatingSegments_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapDepreciation_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrantsReceivable" xlink:label="loc_us-gaapGrantsReceivable_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapGrantsReceivable_90" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="999041 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" xlink:title="999042 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999043 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfDebtDetails" xlink:title="999044 - Disclosure - SCHEDULE OF DEBT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_TwoThousandTwentyThreeNotesMember" xlink:label="loc_ENSCTwoThousandTwentyThreeNotesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_ENSCTwoThousandTwentyThreeNotesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_FinancedInsuranceMember" xlink:label="loc_ENSCFinancedInsuranceMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_ENSCFinancedInsuranceMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapInterestPayableCurrentAndNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestPayableCurrentAndNoncurrent_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapNotesPayable_70" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/NotesPayableDetailsNarrative" xlink:title="999045 - Disclosure - NOTES PAYABLE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_TwoThousandTwentyThreeNotesMember" xlink:label="loc_ENSCTwoThousandTwentyThreeNotesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_ENSCTwoThousandTwentyThreeNotesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_SecuritiesPurchaseAgreementMember" xlink:label="loc_ENSCSecuritiesPurchaseAgreementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENSCSecuritiesPurchaseAgreementMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_FirstClosingSecuritiesPurchaseAgreementMember" xlink:label="loc_ENSCFirstClosingSecuritiesPurchaseAgreementMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENSCFirstClosingSecuritiesPurchaseAgreementMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_SecondClosingSecuritiesPurchaseAgreementMember" xlink:label="loc_ENSCSecondClosingSecuritiesPurchaseAgreementMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENSCSecondClosingSecuritiesPurchaseAgreementMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestExpenseDebt_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestExpense_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt_150" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_150" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_150" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_150" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium_150" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapAmortizationOfFinancingCosts_150" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_150" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts_150" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_150" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_150" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_ProceedsFromWarrantInducementNetOfIssuanceCosts" xlink:label="loc_ENSCProceedsFromWarrantInducementNetOfIssuanceCosts_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_ENSCProceedsFromWarrantInducementNetOfIssuanceCosts_150" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_IssuanceOfCommonStockValueUponWarrantInducementNetOfIssuanceCosts" xlink:label="loc_ENSCIssuanceOfCommonStockValueUponWarrantInducementNetOfIssuanceCosts_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_ENSCIssuanceOfCommonStockValueUponWarrantInducementNetOfIssuanceCosts_150" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_TransactionCostsAssociatedWithWarrantInducement" xlink:label="loc_ENSCTransactionCostsAssociatedWithWarrantInducement_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_ENSCTransactionCostsAssociatedWithWarrantInducement_150" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_FinancedInsurancePremiums" xlink:label="loc_ENSCFinancedInsurancePremiums_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_ENSCFinancedInsurancePremiums_150" xlink:type="arc" order="15" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfOutstandingWarrantDetails" xlink:title="999046 - Disclosure - SCHEDULE OF OUTSTANDING WARRANT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_WarrantOneMember" xlink:label="loc_ENSCWarrantOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ENSCWarrantOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_WarrantTwoMember" xlink:label="loc_ENSCWarrantTwoMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ENSCWarrantTwoMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_WarrantThreeMember" xlink:label="loc_ENSCWarrantThreeMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ENSCWarrantThreeMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_WarrantFourMember" xlink:label="loc_ENSCWarrantFourMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ENSCWarrantFourMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_160" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice" xlink:label="loc_ENSCShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENSCShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_160" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_WarrantDescription" xlink:label="loc_ENSCWarrantDescription_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENSCWarrantDescription_160" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical" xlink:title="999047 - Disclosure - SCHEDULE OF OUTSTANDING WARRANT (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_InstitutionalInvestorMember" xlink:label="loc_ENSCInstitutionalInvestorMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENSCInstitutionalInvestorMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_InvestorWarrantsMember" xlink:label="loc_ENSCInvestorWarrantsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENSCInvestorWarrantsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_PlacementAgentWarrantsMember" xlink:label="loc_ENSCPlacementAgentWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENSCPlacementAgentWarrantsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_PlacementAgentWarrantsMember" xlink:label="loc_ENSCPlacementAgentWarrantsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENSCPlacementAgentWarrantsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_SeriesBWarrantsMember" xlink:label="loc_ENSCSeriesBWarrantsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENSCSeriesBWarrantsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_SeriesAWarrantsMember" xlink:label="loc_ENSCSeriesAWarrantsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENSCSeriesAWarrantsMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_PublicWarrantMember" xlink:label="loc_ENSCPublicWarrantMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ENSCPublicWarrantMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_Notes2021And2022Member" xlink:label="loc_ENSCNotes2021And2022Member_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ENSCNotes2021And2022Member_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_220" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_220" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_220" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharePrice_220" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_220" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/StockholdersEquityDetailsNarrative" xlink:title="999048 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_RegisteredDirectOfferingMember" xlink:label="loc_ENSCRegisteredDirectOfferingMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ENSCRegisteredDirectOfferingMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_PrefundedWarrantMember" xlink:label="loc_ENSCPrefundedWarrantMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ENSCPrefundedWarrantMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_SeriesAandBWarrantsMember" xlink:label="loc_ENSCSeriesAandBWarrantsMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ENSCSeriesAandBWarrantsMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_SeriesAWarrantsMember" xlink:label="loc_ENSCSeriesAWarrantsMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENSCSeriesAWarrantsMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_SeriesBWarrantsMember" xlink:label="loc_ENSCSeriesBWarrantsMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENSCSeriesBWarrantsMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_230" xlink:type="arc" order="231" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_290" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_290" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_290" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_290" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_290" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_290" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_290" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_290" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharePrice_290" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_AgentFeesAndOfferingExpensesPerShare" xlink:label="loc_ENSCAgentFeesAndOfferingExpensesPerShare_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENSCAgentFeesAndOfferingExpensesPerShare_290" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_290" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_290" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_290" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_290" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapLegalFees_290" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:label="loc_us-gaapClassOfWarrantOrRightReasonForIssuingToNonemployees_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightReasonForIssuingToNonemployees_290" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_290" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_290" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants_290" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityClassifiedWrittenCallOptionModificationEquityIssuanceIncreaseDecreaseInEquityAmount" xlink:label="loc_us-gaapEquityClassifiedWrittenCallOptionModificationEquityIssuanceIncreaseDecreaseInEquityAmount_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEquityClassifiedWrittenCallOptionModificationEquityIssuanceIncreaseDecreaseInEquityAmount_290" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_290" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_CombinedOfferingPricePerShare" xlink:label="loc_ENSCCombinedOfferingPricePerShare_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENSCCombinedOfferingPricePerShare_290" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction_290" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaapOtherExpenses_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapOtherExpenses_290" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_OfferingPricePerShare" xlink:label="loc_ENSCOfferingPricePerShare_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENSCOfferingPricePerShare_290" xlink:type="arc" order="24" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="999049 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:title="999050 - Disclosure - SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_40" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfCommonStockFutureIssuanceDetails" xlink:title="999051 - Disclosure - SCHEDULE OF COMMON STOCK FUTURE ISSUANCE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_StockOptionAvailableForFutureGrantUnder2021OmnibusIncentivePlanMember" xlink:label="loc_ENSCStockOptionAvailableForFutureGrantUnder2021OmnibusIncentivePlanMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ENSCStockOptionAvailableForFutureGrantUnder2021OmnibusIncentivePlanMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_WarrantOutstandingMember" xlink:label="loc_ENSCWarrantOutstandingMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ENSCWarrantOutstandingMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_50" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999052 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_TwoThousandTwentyOneOmnibusIncentivePlanMember" xlink:label="loc_ENSCTwoThousandTwentyOneOmnibusIncentivePlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ENSCTwoThousandTwentyOneOmnibusIncentivePlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_BoardOfMembersMember" xlink:label="loc_ENSCBoardOfMembersMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_ENSCBoardOfMembersMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_120" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_SharebasedCompensationArrangementBySharebasedPaymentAwardWeightedAveragePeriodExpectedToBeRecognized" xlink:label="loc_ENSCSharebasedCompensationArrangementBySharebasedPaymentAwardWeightedAveragePeriodExpectedToBeRecognized_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ENSCSharebasedCompensationArrangementBySharebasedPaymentAwardWeightedAveragePeriodExpectedToBeRecognized_120" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfIncomeTaxesBenefitDetails" xlink:title="999053 - Disclosure - SCHEDULE OF INCOME TAXES BENEFIT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="loc_countryUS_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_30" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfFederalAndStateIncomeTaxProvisionBenefitDetails" xlink:title="999054 - Disclosure - SCHEDULE OF FEDERAL AND STATE INCOME TAX PROVISION (BENEFIT) (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfFederalIncomeTaxRateReconciliationDetails" xlink:title="999055 - Disclosure - SCHEDULE OF FEDERAL INCOME TAX RATE RECONCILIATION (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfDeferredTaxAssetsDetails" xlink:title="999056 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails" xlink:title="999057 - Disclosure - SCHEDULE OF UNRECOGNIZED TAX BENEFITS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/IncomeTaxesDetailsNarrative" xlink:title="999058 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:label="loc_us-gaapCaliforniaFranchiseTaxBoardMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapCaliforniaFranchiseTaxBoardMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:label="loc_us-gaapCaliforniaFranchiseTaxBoardMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_us-gaapCaliforniaFranchiseTaxBoardMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaapTaxCreditCarryforwardAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapTaxCreditCarryforwardAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaapTaxCreditCarryforwardNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTaxCreditCarryforwardAxis" xlink:to="loc_us-gaapTaxCreditCarryforwardNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaapTaxCreditCarryforwardNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTaxCreditCarryforwardAxis" xlink:to="loc_us-gaapTaxCreditCarryforwardNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaapResearchMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxCreditCarryforwardNameDomain" xlink:to="loc_us-gaapResearchMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardDescription" xlink:label="loc_us-gaapTaxCreditCarryforwardDescription_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardDescription_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="loc_us-gaapOperatingLossCarryforwardsLimitationsOnUse_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsLimitationsOnUse_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaapTaxCreditCarryforwardAmount_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardAmount_140" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:label="loc_us-gaapTaxCreditCarryforwardLimitationsOnUse_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardLimitationsOnUse_140" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="loc_us-gaapUnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapUnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_140" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivableAccruedInterestWriteoff" xlink:label="loc_us-gaapFinancingReceivableAccruedInterestWriteoff_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapFinancingReceivableAccruedInterestWriteoff_140" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/RelatedPartiesDetailsNarrative" xlink:title="999059 - Disclosure - RELATED PARTIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_SecuritiesPurchaseAgreementMember" xlink:label="loc_ENSCSecuritiesPurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENSCSecuritiesPurchaseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorLongTermNotes" xlink:label="loc_us-gaapSeniorLongTermNotes_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSeniorLongTermNotes_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_WarrantOrRightExercisable" xlink:label="loc_ENSCWarrantOrRightExercisable_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_ENSCWarrantOrRightExercisable_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_WarrantExpirationDate" xlink:label="loc_ENSCWarrantExpirationDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_ENSCWarrantExpirationDate_50" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ensysce.com/role/SubsequentEventsDetailsNarrative" xlink:title="999060 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares" xlink:label="loc_ENSCStockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_ENSCStockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants" xlink:label="loc_ENSCStockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_ENSCStockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:label="loc_us-gaapSaleOfStockPercentageOfOwnershipAfterTransaction_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockPercentageOfOwnershipAfterTransaction_30" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_WarrantOneMember" xlink:label="loc_ENSCWarrantOneMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ENSCWarrantOneMember" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_WarrantTwoMember" xlink:label="loc_ENSCWarrantTwoMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ENSCWarrantTwoMember" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_WarrantThreeMember" xlink:label="loc_ENSCWarrantThreeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ENSCWarrantThreeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_WarrantFourMember" xlink:label="loc_ENSCWarrantFourMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ENSCWarrantFourMember" xlink:type="arc" order="30" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>ensc-20241231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_CommonStock0.0001ParValuePerShareMember" xlink:label="ENSC_CommonStock0.0001ParValuePerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_CommonStock0.0001ParValuePerShareMember" xlink:to="ENSC_CommonStock0.0001ParValuePerShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_CommonStock0.0001ParValuePerShareMember_lbl" xml:lang="en-US">Common Stock Par Value [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_WarrantsToPurchaseOneShareOfCommonStockMember" xlink:label="ENSC_WarrantsToPurchaseOneShareOfCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_WarrantsToPurchaseOneShareOfCommonStockMember" xlink:to="ENSC_WarrantsToPurchaseOneShareOfCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_WarrantsToPurchaseOneShareOfCommonStockMember_lbl" xml:lang="en-US">Warrants, to purchase one share of Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_EBIRIncMember" xlink:label="ENSC_EBIRIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_EBIRIncMember" xlink:to="ENSC_EBIRIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_EBIRIncMember_lbl" xml:lang="en-US">EBIR, Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_KeyPersonnelMember" xlink:label="ENSC_KeyPersonnelMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_KeyPersonnelMember" xlink:to="ENSC_KeyPersonnelMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_KeyPersonnelMember_lbl" xml:lang="en-US">Key Personnel [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_UnrelatedPartyMember" xlink:label="ENSC_UnrelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_UnrelatedPartyMember" xlink:to="ENSC_UnrelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_UnrelatedPartyMember_lbl" xml:lang="en-US">Unrelated Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US">Accounts Receivable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_CustomerMember" xlink:label="ENSC_CustomerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_CustomerMember" xlink:to="ENSC_CustomerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_CustomerMember_lbl" xml:lang="en-US">Customer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xml:lang="en-US">Liability Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_LiabilityClassifiedWarrantsMember" xlink:label="ENSC_LiabilityClassifiedWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_LiabilityClassifiedWarrantsMember" xlink:to="ENSC_LiabilityClassifiedWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_LiabilityClassifiedWarrantsMember_lbl" xml:lang="en-US">Liability Classified Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_MPARMember" xlink:label="ENSC_MPARMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_MPARMember" xlink:to="ENSC_MPARMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_MPARMember_lbl" xml:lang="en-US">MPAR [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_TAAPOUDMember" xlink:label="ENSC_TAAPOUDMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_TAAPOUDMember" xlink:to="ENSC_TAAPOUDMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_TAAPOUDMember_lbl" xml:lang="en-US">TAAP/OUD [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_TwoThousandTwentyThreeNotesMember" xlink:label="ENSC_TwoThousandTwentyThreeNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_TwoThousandTwentyThreeNotesMember" xlink:to="ENSC_TwoThousandTwentyThreeNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_TwoThousandTwentyThreeNotesMember_lbl" xml:lang="en-US">2023 Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_FinancedInsuranceMember" xlink:label="ENSC_FinancedInsuranceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_FinancedInsuranceMember" xlink:to="ENSC_FinancedInsuranceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_FinancedInsuranceMember_lbl" xml:lang="en-US">Financed Insurance [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_SecuritiesPurchaseAgreementMember" xlink:label="ENSC_SecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_SecuritiesPurchaseAgreementMember" xlink:to="ENSC_SecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_FirstClosingSecuritiesPurchaseAgreementMember" xlink:label="ENSC_FirstClosingSecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_FirstClosingSecuritiesPurchaseAgreementMember" xlink:to="ENSC_FirstClosingSecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_FirstClosingSecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">First Closing Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_SecondClosingSecuritiesPurchaseAgreementMember" xlink:label="ENSC_SecondClosingSecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_SecondClosingSecuritiesPurchaseAgreementMember" xlink:to="ENSC_SecondClosingSecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_SecondClosingSecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Second Closing Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_RegisteredDirectOfferingMember" xlink:label="ENSC_RegisteredDirectOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_RegisteredDirectOfferingMember" xlink:to="ENSC_RegisteredDirectOfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_RegisteredDirectOfferingMember_lbl" xml:lang="en-US">Registered Direct Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_PrefundedWarrantMember" xlink:label="ENSC_PrefundedWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_PrefundedWarrantMember" xlink:to="ENSC_PrefundedWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_PrefundedWarrantMember_lbl" xml:lang="en-US">Prefunded Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_SeriesAandBWarrantsMember" xlink:label="ENSC_SeriesAandBWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_SeriesAandBWarrantsMember" xlink:to="ENSC_SeriesAandBWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_SeriesAandBWarrantsMember_lbl" xml:lang="en-US">Series A and B Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_SeriesAWarrantsMember" xlink:label="ENSC_SeriesAWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_SeriesAWarrantsMember" xlink:to="ENSC_SeriesAWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_SeriesAWarrantsMember_lbl" xml:lang="en-US">Series A Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_SeriesBWarrantsMember" xlink:label="ENSC_SeriesBWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_SeriesBWarrantsMember" xlink:to="ENSC_SeriesBWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_SeriesBWarrantsMember_lbl" xml:lang="en-US">Series B Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_WarrantOneMember" xlink:label="ENSC_WarrantOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_WarrantOneMember" xlink:to="ENSC_WarrantOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_WarrantOneMember_lbl" xml:lang="en-US">Warrant One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_WarrantTwoMember" xlink:label="ENSC_WarrantTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_WarrantTwoMember" xlink:to="ENSC_WarrantTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_WarrantTwoMember_lbl" xml:lang="en-US">Warrant Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_WarrantThreeMember" xlink:label="ENSC_WarrantThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_WarrantThreeMember" xlink:to="ENSC_WarrantThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_WarrantThreeMember_lbl" xml:lang="en-US">Warrant Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_WarrantFourMember" xlink:label="ENSC_WarrantFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_WarrantFourMember" xlink:to="ENSC_WarrantFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_WarrantFourMember_lbl" xml:lang="en-US">Warrant Four [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_InstitutionalInvestorMember" xlink:label="ENSC_InstitutionalInvestorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_InstitutionalInvestorMember" xlink:to="ENSC_InstitutionalInvestorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_InstitutionalInvestorMember_lbl" xml:lang="en-US">Institutional Investor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_InvestorWarrantsMember" xlink:label="ENSC_InvestorWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_InvestorWarrantsMember" xlink:to="ENSC_InvestorWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_InvestorWarrantsMember_lbl" xml:lang="en-US">Investor Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_PlacementAgentWarrantsMember" xlink:label="ENSC_PlacementAgentWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_PlacementAgentWarrantsMember" xlink:to="ENSC_PlacementAgentWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_PlacementAgentWarrantsMember_lbl" xml:lang="en-US">Placement Agent Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_PublicWarrantMember" xlink:label="ENSC_PublicWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_PublicWarrantMember" xlink:to="ENSC_PublicWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_PublicWarrantMember_lbl" xml:lang="en-US">Public Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_Notes2021And2022Member" xlink:label="ENSC_Notes2021And2022Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_Notes2021And2022Member" xlink:to="ENSC_Notes2021And2022Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_Notes2021And2022Member_lbl" xml:lang="en-US">Notes 2021 and 2022 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_TwoThousandTwentyOneOmnibusIncentivePlanMember" xlink:label="ENSC_TwoThousandTwentyOneOmnibusIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_TwoThousandTwentyOneOmnibusIncentivePlanMember" xlink:to="ENSC_TwoThousandTwentyOneOmnibusIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_TwoThousandTwentyOneOmnibusIncentivePlanMember_lbl" xml:lang="en-US">2021 Omnibus Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_BoardOfMembersMember" xlink:label="ENSC_BoardOfMembersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_BoardOfMembersMember" xlink:to="ENSC_BoardOfMembersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_BoardOfMembersMember_lbl" xml:lang="en-US">Board of Members [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_StockOptionAvailableForFutureGrantUnder2021OmnibusIncentivePlanMember" xlink:label="ENSC_StockOptionAvailableForFutureGrantUnder2021OmnibusIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_StockOptionAvailableForFutureGrantUnder2021OmnibusIncentivePlanMember" xlink:to="ENSC_StockOptionAvailableForFutureGrantUnder2021OmnibusIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_StockOptionAvailableForFutureGrantUnder2021OmnibusIncentivePlanMember_lbl" xml:lang="en-US">Stock Option Available For Future Grant Under 2021 Omnibus Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_WarrantOutstandingMember" xlink:label="ENSC_WarrantOutstandingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_WarrantOutstandingMember" xlink:to="ENSC_WarrantOutstandingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_WarrantOutstandingMember_lbl" xml:lang="en-US">Warrant Outstanding [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="country_US" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US">UNITED STATES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:label="us-gaap_CaliforniaFranchiseTaxBoardMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:to="us-gaap_CaliforniaFranchiseTaxBoardMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CaliforniaFranchiseTaxBoardMember_lbl" xml:lang="en-US">California Franchise Tax Board [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnbilledReceivablesCurrent" xlink:label="us-gaap_UnbilledReceivablesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnbilledReceivablesCurrent" xlink:to="us-gaap_UnbilledReceivablesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnbilledReceivablesCurrent_lbl" xml:lang="en-US">Unbilled receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and stockholders&#8217; equity (deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Notes payable and accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Long-term liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other long-term liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total long-term liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (Note 6)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity (deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.0001 par value, 1,500,000 shares authorized, no shares issued and outstanding at December 31, 2024 and December 31, 2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.0001 par value, 250,000,000 shares authorized at December 31, 2024 and December 31, 2023; 1,355,779 and 209,745 shares issued at December 31, 2024 and December 31, 2023, respectively; 1,355,773 and 209,739 shares outstanding at December 31, 2024 and December 31, 2023, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Ensysce Biosciences, Inc. stockholders&#8217; equity (deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterest_lbl" xml:lang="en-US">Noncontrolling interests in stockholders&#8217; deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Total stockholders&#8217; equity (deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity (deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Federal grants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense):</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_LossOnConversionsAndChangeInFairValueOfConvertibleNotes" xlink:label="ENSC_LossOnConversionsAndChangeInFairValueOfConvertibleNotes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_LossOnConversionsAndChangeInFairValueOfConvertibleNotes" xlink:to="ENSC_LossOnConversionsAndChangeInFairValueOfConvertibleNotes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ENSC_LossOnConversionsAndChangeInFairValueOfConvertibleNotes_lbl" xml:lang="en-US">Loss on conversions and change in fair value of convertible notes</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_ChangeInFairValueOfLiabilityClassifiedWarrants" xlink:label="ENSC_ChangeInFairValueOfLiabilityClassifiedWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_ChangeInFairValueOfLiabilityClassifiedWarrants" xlink:to="ENSC_ChangeInFairValueOfLiabilityClassifiedWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_ChangeInFairValueOfLiabilityClassifiedWarrants_lbl" xml:lang="en-US">Change in fair value of liability classified warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xml:lang="en-US">Interest expense, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income and expense, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expense), net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Net loss attributable to noncontrolling interests</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount" xlink:label="us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount" xlink:to="us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount_lbl" xml:lang="en-US">Deemed dividend related to warrants down round provision</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Net loss per basic and diluted share:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per share attributable to common stockholders, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per share attributable to common stockholders, diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average common shares outstanding, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average common shares outstanding, diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Settlement of restricted stock units</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Settlement of restricted stock units, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_StockIssuedDuringPeriodValueCommitmentFee" xlink:label="ENSC_StockIssuedDuringPeriodValueCommitmentFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_StockIssuedDuringPeriodValueCommitmentFee" xlink:to="ENSC_StockIssuedDuringPeriodValueCommitmentFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_StockIssuedDuringPeriodValueCommitmentFee_lbl" xml:lang="en-US">Settlement of commitment fee</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_StockIssuedDuringPeriodSharesCommitmentFee" xlink:label="ENSC_StockIssuedDuringPeriodSharesCommitmentFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_StockIssuedDuringPeriodSharesCommitmentFee" xlink:to="ENSC_StockIssuedDuringPeriodSharesCommitmentFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_StockIssuedDuringPeriodSharesCommitmentFee_lbl" xml:lang="en-US">Settlement of commitment fee, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of convertible notes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversions of convertible notes, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Public offering, net, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Issuance of warrants - debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_TransactionCostsAssociatedWithPublicOffering" xlink:label="ENSC_TransactionCostsAssociatedWithPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_TransactionCostsAssociatedWithPublicOffering" xlink:to="ENSC_TransactionCostsAssociatedWithPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_TransactionCostsAssociatedWithPublicOffering_lbl" xml:lang="en-US">Transaction costs associated with public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants" xlink:label="ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants" xlink:to="ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants_lbl" xml:lang="en-US">Issuance of common stock upon exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares" xlink:label="ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares" xlink:to="ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares_lbl" xml:lang="en-US">Issuance of common stock upon exercise of warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_StockIssuedDuringPeriodValueReverseStockSplits" xlink:label="ENSC_StockIssuedDuringPeriodValueReverseStockSplits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_StockIssuedDuringPeriodValueReverseStockSplits" xlink:to="ENSC_StockIssuedDuringPeriodValueReverseStockSplits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_StockIssuedDuringPeriodValueReverseStockSplits_lbl" xml:lang="en-US">Reverse split fractional shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xml:lang="en-US">Reverse split fractional shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:to="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_lbl" xml:lang="en-US">Deemed dividend related to warrants down round provision</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_IssuanceOfCommonStockUponWarrantInducements" xlink:label="ENSC_IssuanceOfCommonStockUponWarrantInducements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_IssuanceOfCommonStockUponWarrantInducements" xlink:to="ENSC_IssuanceOfCommonStockUponWarrantInducements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_IssuanceOfCommonStockUponWarrantInducements_lbl" xml:lang="en-US">Issuance of common stock upon warrant inducements</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_IssuanceOfCommonStockUponWarrantInducementsShares" xlink:label="ENSC_IssuanceOfCommonStockUponWarrantInducementsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_IssuanceOfCommonStockUponWarrantInducementsShares" xlink:to="ENSC_IssuanceOfCommonStockUponWarrantInducementsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_IssuanceOfCommonStockUponWarrantInducementsShares_lbl" xml:lang="en-US">Issuance of common stock upon warrant inducements , shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_TransactionCostsAssociatedWithPublicOfferingAndWarrantInducements" xlink:label="ENSC_TransactionCostsAssociatedWithPublicOfferingAndWarrantInducements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_TransactionCostsAssociatedWithPublicOfferingAndWarrantInducements" xlink:to="ENSC_TransactionCostsAssociatedWithPublicOfferingAndWarrantInducements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_TransactionCostsAssociatedWithPublicOfferingAndWarrantInducements_lbl" xml:lang="en-US">Transaction costs associated with public offering and warrant inducements</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xml:lang="en-US">Accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of orginal issue discount and debt issuance costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_LossOnConversionsAndChangeInFairValueOfConvertibleNotes" xlink:to="ENSC_LossOnConversionsAndChangeInFairValueOfConvertibleNotes_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_LossOnConversionsAndChangeInFairValueOfConvertibleNotes_2_lbl" xml:lang="en-US">Loss on conversions and change in fair value of convertible notes</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_ChangeInFairValueOfLiabilityClassifiedWarrants" xlink:to="ENSC_ChangeInFairValueOfLiabilityClassifiedWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ENSC_ChangeInFairValueOfLiabilityClassifiedWarrants_2_lbl" xml:lang="en-US">Change in fair value of liability classified warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForLoanLeaseAndOtherLosses" xlink:label="us-gaap_ProvisionForLoanLeaseAndOtherLosses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForLoanLeaseAndOtherLosses" xlink:to="us-gaap_ProvisionForLoanLeaseAndOtherLosses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForLoanLeaseAndOtherLosses_lbl" xml:lang="en-US">Lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_IncreaseDecreaseInUnbilledReceivable" xlink:label="ENSC_IncreaseDecreaseInUnbilledReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_IncreaseDecreaseInUnbilledReceivable" xlink:to="ENSC_IncreaseDecreaseInUnbilledReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ENSC_IncreaseDecreaseInUnbilledReceivable_lbl" xml:lang="en-US">Unbilled receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xml:lang="en-US">Prepaid expenses and other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Proceeds from public offerings, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from warrant exercises</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_ProceedsFromWarrantInducementNetOfIssuanceCosts" xlink:label="ENSC_ProceedsFromWarrantInducementNetOfIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_ProceedsFromWarrantInducementNetOfIssuanceCosts" xlink:to="ENSC_ProceedsFromWarrantInducementNetOfIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_ProceedsFromWarrantInducementNetOfIssuanceCosts_lbl" xml:lang="en-US">Proceeds from warrant inducement, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_TransactionCostsFromPublicOfferings" xlink:label="ENSC_TransactionCostsFromPublicOfferings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_TransactionCostsFromPublicOfferings" xlink:to="ENSC_TransactionCostsFromPublicOfferings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ENSC_TransactionCostsFromPublicOfferings_lbl" xml:lang="en-US">Transaction costs from public offerings</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_TransactionCostAssociatedWithWarrantInducement" xlink:label="ENSC_TransactionCostAssociatedWithWarrantInducement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_TransactionCostAssociatedWithWarrantInducement" xlink:to="ENSC_TransactionCostAssociatedWithWarrantInducement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ENSC_TransactionCostAssociatedWithWarrantInducement_lbl" xml:lang="en-US">Transaction costs associated with public offering and warrant inducements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Proceeds from issuance of convertible notes, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xml:lang="en-US">Repayment of convertible notes</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_RepaymentInsurancePremiums" xlink:label="ENSC_RepaymentInsurancePremiums" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_RepaymentInsurancePremiums" xlink:to="ENSC_RepaymentInsurancePremiums_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ENSC_RepaymentInsurancePremiums_lbl" xml:lang="en-US">Repayment of financed insurance premiums</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Increase (decrease) in cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash and cash equivalents beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Cash and cash equivalents end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental cash flow information:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income tax payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_IncrementalFairValueOfWarrantInducement1" xlink:label="ENSC_IncrementalFairValueOfWarrantInducement1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_IncrementalFairValueOfWarrantInducement1" xlink:to="ENSC_IncrementalFairValueOfWarrantInducement1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_IncrementalFairValueOfWarrantInducement1_lbl" xml:lang="en-US">Incremental fair value of August 2024 Warrant Inducement</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_IncrementalFairValueOfWarrantInducement2" xlink:label="ENSC_IncrementalFairValueOfWarrantInducement2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_IncrementalFairValueOfWarrantInducement2" xlink:to="ENSC_IncrementalFairValueOfWarrantInducement2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_IncrementalFairValueOfWarrantInducement2_lbl" xml:lang="en-US">Incremental fair value of February 2024 Warrant Inducement</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_ConversionsOfConvertibleNotesIntoCommonStock" xlink:label="ENSC_ConversionsOfConvertibleNotesIntoCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_ConversionsOfConvertibleNotesIntoCommonStock" xlink:to="ENSC_ConversionsOfConvertibleNotesIntoCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_ConversionsOfConvertibleNotesIntoCommonStock_lbl" xml:lang="en-US">Conversion of convertible notes into common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_OriginalDebtDiscountFromConvertibleNotes" xlink:label="ENSC_OriginalDebtDiscountFromConvertibleNotes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_OriginalDebtDiscountFromConvertibleNotes" xlink:to="ENSC_OriginalDebtDiscountFromConvertibleNotes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_OriginalDebtDiscountFromConvertibleNotes_lbl" xml:lang="en-US">Original debt discount from convertible notes</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_DebtDiscountFromWarrantsIssuance" xlink:label="ENSC_DebtDiscountFromWarrantsIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_DebtDiscountFromWarrantsIssuance" xlink:to="ENSC_DebtDiscountFromWarrantsIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_DebtDiscountFromWarrantsIssuance_lbl" xml:lang="en-US">Debt discount from warrants issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_IssuanceCostFromConvertibleNotes" xlink:label="ENSC_IssuanceCostFromConvertibleNotes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_IssuanceCostFromConvertibleNotes" xlink:to="ENSC_IssuanceCostFromConvertibleNotes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_IssuanceCostFromConvertibleNotes_lbl" xml:lang="en-US">Issuance cost from convertible notes</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_FinancedInsurancePremiums" xlink:label="ENSC_FinancedInsurancePremiums" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_FinancedInsurancePremiums" xlink:to="ENSC_FinancedInsurancePremiums_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_FinancedInsurancePremiums_lbl" xml:lang="en-US">Financed insurance premiums</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_SettlementOfCommitmentFeeInShares" xlink:label="ENSC_SettlementOfCommitmentFeeInShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_SettlementOfCommitmentFeeInShares" xlink:to="ENSC_SettlementOfCommitmentFeeInShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_SettlementOfCommitmentFeeInShares_lbl" xml:lang="en-US">Settlement of commitment fee in shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_DeemedDividendRelatedToWarrantsDownRoundProvision" xlink:label="ENSC_DeemedDividendRelatedToWarrantsDownRoundProvision" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_DeemedDividendRelatedToWarrantsDownRoundProvision" xlink:to="ENSC_DeemedDividendRelatedToWarrantsDownRoundProvision_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ENSC_DeemedDividendRelatedToWarrantsDownRoundProvision_lbl" xml:lang="en-US">Deemed dividend related to warrants down round provision</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="ecd_ExecutiveCategoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ExecutiveCategoryAxis" xlink:to="ecd_ExecutiveCategoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ExecutiveCategoryAxis_lbl" xml:lang="en-US">Executive Category [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="ecd_MeasureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureAxis" xlink:to="ecd_MeasureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureAxis_lbl" xml:lang="en-US">Measure [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="ecd_PnsnBnftsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PnsnBnftsAdjFnTextBlock" xlink:to="ecd_PnsnBnftsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PnsnBnftsAdjFnTextBlock_lbl" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement does not require Recovery</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Underlying Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Fair Value as of Grant Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_InsiderTradingArrLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingArrLineItems_lbl" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="ecd_TrdArrExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xml:lang="en-US">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Role of Management [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="cyd_MaterialCybersecurityIncidentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentAbstract" xlink:to="cyd_MaterialCybersecurityIncidentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentAbstract_lbl" xml:lang="en-US">Material Cybersecurity Incident [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Nature [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Scope [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Timing [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US">ORGANIZATION AND PRINCIPAL ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccounting" xlink:label="us-gaap_BasisOfAccounting" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccounting" xlink:to="us-gaap_BasisOfAccounting_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccounting_lbl" xml:lang="en-US">BASIS OF PRESENTATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">ACCRUED EXPENSES AND OTHER LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">NOTES PAYABLE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates and Assumptions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentrations of Credit Risk and Off-Balance Sheet Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xml:lang="en-US">General and Administrative Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US">SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY&#8217;S LEVEL 3</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_ScheduleOfRevenueRecognitionUnderGrantsTableTextBlock" xlink:label="ENSC_ScheduleOfRevenueRecognitionUnderGrantsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_ScheduleOfRevenueRecognitionUnderGrantsTableTextBlock" xlink:to="ENSC_ScheduleOfRevenueRecognitionUnderGrantsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_ScheduleOfRevenueRecognitionUnderGrantsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF REVENUE RECOGNITION UNDER GRANTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF DEBT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">SCHEDULE OF OUTSTANDING WARRANT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK OPTION ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_ScheduleOfCommonStockFutureIssuanceTableTextBlock" xlink:label="ENSC_ScheduleOfCommonStockFutureIssuanceTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_ScheduleOfCommonStockFutureIssuanceTableTextBlock" xlink:to="ENSC_ScheduleOfCommonStockFutureIssuanceTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_ScheduleOfCommonStockFutureIssuanceTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF COMMON STOCK FUTURE ISSUANCE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF INCOME TAXES BENEFIT</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_ScheduleOfFederalAndStateIncomeTaxProvisionBenefitTableTextBlock" xlink:label="ENSC_ScheduleOfFederalAndStateIncomeTaxProvisionBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_ScheduleOfFederalAndStateIncomeTaxProvisionBenefitTableTextBlock" xlink:to="ENSC_ScheduleOfFederalAndStateIncomeTaxProvisionBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_ScheduleOfFederalAndStateIncomeTaxProvisionBenefitTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FEDERAL AND STATE INCOME TAX PROVISION (BENEFIT)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FEDERAL INCOME TAX RATE RECONCILIATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF DEFERRED TAX ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF UNRECOGNIZED TAX BENEFITS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Ownership percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="srt_PlatformOperatorCryptoAssetTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PlatformOperatorCryptoAssetTable" xlink:to="srt_PlatformOperatorCryptoAssetTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PlatformOperatorCryptoAssetTable_lbl" xml:lang="en-US">Platform Operator, Crypto Asset [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="srt_PlatformOperatorCryptoAssetLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PlatformOperatorCryptoAssetLineItems" xlink:to="srt_PlatformOperatorCryptoAssetLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PlatformOperatorCryptoAssetLineItems_lbl" xml:lang="en-US">Platform Operator, Crypto Asset [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Liability classified warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="us-gaap_FairValueNetAssetLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetAssetLiability" xlink:to="us-gaap_FairValueNetAssetLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetAssetLiability_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US">Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xml:lang="en-US">Change in fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2_lbl" xml:lang="en-US">Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="us-gaap_ScheduleOfProductInformationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_ScheduleOfProductInformationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfProductInformationTable_lbl" xml:lang="en-US">Nature of Operation, Product Information, Concentration of Risk [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductInformationLineItems" xlink:label="us-gaap_ProductInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ProductInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductInformationLineItems_lbl" xml:lang="en-US">Product Information [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDescription" xlink:label="us-gaap_ConcentrationRiskBenchmarkDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDescription" xlink:to="us-gaap_ConcentrationRiskBenchmarkDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDescription_lbl" xml:lang="en-US">Concentration of risk, description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration of risk</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Number of reportable segments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of operating segments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivable" xlink:to="us-gaap_GrantsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrantsReceivable_lbl" xml:lang="en-US">Grants receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_PrepaidResearchAndDevelopment" xlink:label="ENSC_PrepaidResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_PrepaidResearchAndDevelopment" xlink:to="ENSC_PrepaidResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_PrepaidResearchAndDevelopment_lbl" xml:lang="en-US">Prepaid research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Total prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_AccruedResearchAndDevelopment" xlink:label="ENSC_AccruedResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_AccruedResearchAndDevelopment" xlink:to="ENSC_AccruedResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_AccruedResearchAndDevelopment_lbl" xml:lang="en-US">Accrued research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued professional fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Other accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xml:lang="en-US">Total accrued expenses and other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US">Contractual obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Future lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Rent expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Short-Term Debt [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-Term Debt [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Principal balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US">Unamortized Debt Discount &amp; Issuance Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US">Net debt balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US">Aggregate purchase price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_2_lbl" xml:lang="en-US">Aggregate principal amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants to purchase common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of debt discount premium</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization of financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrant, exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US">Payments of debt issuance costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2_lbl" xml:lang="en-US">Conversion of shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_2_lbl" xml:lang="en-US">Conversion of shares value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_ProceedsFromWarrantInducementNetOfIssuanceCosts" xlink:to="ENSC_ProceedsFromWarrantInducementNetOfIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ENSC_ProceedsFromWarrantInducementNetOfIssuanceCosts_2_lbl" xml:lang="en-US">Transaction cost</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_IssuanceOfCommonStockValueUponWarrantInducementNetOfIssuanceCosts" xlink:label="ENSC_IssuanceOfCommonStockValueUponWarrantInducementNetOfIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_IssuanceOfCommonStockValueUponWarrantInducementNetOfIssuanceCosts" xlink:to="ENSC_IssuanceOfCommonStockValueUponWarrantInducementNetOfIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_IssuanceOfCommonStockValueUponWarrantInducementNetOfIssuanceCosts_lbl" xml:lang="en-US">Warrant inducement cost</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_TransactionCostsAssociatedWithWarrantInducement" xlink:label="ENSC_TransactionCostsAssociatedWithWarrantInducement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_TransactionCostsAssociatedWithWarrantInducement" xlink:to="ENSC_TransactionCostsAssociatedWithWarrantInducement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_TransactionCostsAssociatedWithWarrantInducement_lbl" xml:lang="en-US">Transaction cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Outstanding warrant</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice" xlink:label="ENSC_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice" xlink:to="ENSC_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_WarrantDescription" xlink:label="ENSC_WarrantDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_WarrantDescription" xlink:to="ENSC_WarrantDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_WarrantDescription_lbl" xml:lang="en-US">Warrant description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xml:lang="en-US">Warrants issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Warrant exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US">Warrant expiration date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Class of warrant or right, outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Purchase of shares through securities purchase agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_AgentFeesAndOfferingExpensesPerShare" xlink:label="ENSC_AgentFeesAndOfferingExpensesPerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_AgentFeesAndOfferingExpensesPerShare" xlink:to="ENSC_AgentFeesAndOfferingExpensesPerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_AgentFeesAndOfferingExpensesPerShare_lbl" xml:lang="en-US">Agent fees and offering expenses , per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Common stock, gross proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Stock issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalFees_lbl" xml:lang="en-US">Legal fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:label="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:to="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees_lbl" xml:lang="en-US">Warrants issue, description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Warrants to purchase common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_2_lbl" xml:lang="en-US">Warrant maturity date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Proceeds from warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityClassifiedWrittenCallOptionModificationEquityIssuanceIncreaseDecreaseInEquityAmount" xlink:label="us-gaap_EquityClassifiedWrittenCallOptionModificationEquityIssuanceIncreaseDecreaseInEquityAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityClassifiedWrittenCallOptionModificationEquityIssuanceIncreaseDecreaseInEquityAmount" xlink:to="us-gaap_EquityClassifiedWrittenCallOptionModificationEquityIssuanceIncreaseDecreaseInEquityAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityClassifiedWrittenCallOptionModificationEquityIssuanceIncreaseDecreaseInEquityAmount_lbl" xml:lang="en-US">Equity issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of stock number of shares issued in transaction</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_CombinedOfferingPricePerShare" xlink:label="ENSC_CombinedOfferingPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_CombinedOfferingPricePerShare" xlink:to="ENSC_CombinedOfferingPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_CombinedOfferingPricePerShare_lbl" xml:lang="en-US">Combined offering price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xml:lang="en-US">Sale of stock, consideration received per transaction</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenses_lbl" xml:lang="en-US">Related costs</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_OfferingPricePerShare" xlink:label="ENSC_OfferingPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_OfferingPricePerShare" xlink:to="ENSC_OfferingPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ENSC_OfferingPricePerShare_lbl" xml:lang="en-US">Combined offering price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Option outstanding, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price. beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Option outstanding, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Option outstanding, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Option outstanding, expired or forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, expired or forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue" xlink:label="ENSC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue" xlink:to="ENSC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, expired or forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Option outstanding, ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate intrinsic value, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Option, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate intrinsic value, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xml:lang="en-US">Option vested or expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, vested or expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual term, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, vested or expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Expected stock price volatility, minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Expected stock price volatility, maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Total shares of common stock reserved for future issuance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2_lbl" xml:lang="en-US">Common stock, capital shares reserved for future issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share based compensation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Number of restricted stock granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average fair value per share , grant</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_SharebasedCompensationArrangementBySharebasedPaymentAwardWeightedAveragePeriodExpectedToBeRecognized" xlink:label="ENSC_SharebasedCompensationArrangementBySharebasedPaymentAwardWeightedAveragePeriodExpectedToBeRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_SharebasedCompensationArrangementBySharebasedPaymentAwardWeightedAveragePeriodExpectedToBeRecognized" xlink:to="ENSC_SharebasedCompensationArrangementBySharebasedPaymentAwardWeightedAveragePeriodExpectedToBeRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_SharebasedCompensationArrangementBySharebasedPaymentAwardWeightedAveragePeriodExpectedToBeRecognized_lbl" xml:lang="en-US">Weighted average period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">Current state provision</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Income (benefit) taxes at statutory rates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income tax, net of federal benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_lbl" xml:lang="en-US">Warrants and convertible debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xml:lang="en-US">Nondeductible executive compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">Research and development tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_IncomeTaxReconciliationExpiringAttributes" xlink:label="ENSC_IncomeTaxReconciliationExpiringAttributes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_IncomeTaxReconciliationExpiringAttributes" xlink:to="ENSC_IncomeTaxReconciliationExpiringAttributes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_IncomeTaxReconciliationExpiringAttributes_lbl" xml:lang="en-US">Expiring attributes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:to="us-gaap_IncomeTaxReconciliationTaxContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingencies_lbl" xml:lang="en-US">Change in tax rates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss tax carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US">Tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Capitalized research costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Gross deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Total deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US">Total deferred tax liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Balance at beginning of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US">Increases related to current year tax positions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US">Increases related to prior year tax positions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US">Decreases related to prior year tax positions</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_2_lbl" xml:lang="en-US">Balance at end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardDescription" xlink:label="us-gaap_TaxCreditCarryforwardDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardDescription" xlink:to="us-gaap_TaxCreditCarryforwardDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardDescription_lbl" xml:lang="en-US">Tax credit carryforward, description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xml:lang="en-US">Operating loss carryforwards expiration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US">Tax credit carryforward amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl" xml:lang="en-US">Tax credit carryforward expiration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivableAccruedInterestWriteoff" xlink:label="us-gaap_FinancingReceivableAccruedInterestWriteoff" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingReceivableAccruedInterestWriteoff" xlink:to="us-gaap_FinancingReceivableAccruedInterestWriteoff_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancingReceivableAccruedInterestWriteoff_lbl" xml:lang="en-US">Financing receivable accrued interest write off</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorLongTermNotes" xlink:label="us-gaap_SeniorLongTermNotes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeniorLongTermNotes" xlink:to="us-gaap_SeniorLongTermNotes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeniorLongTermNotes_lbl" xml:lang="en-US">Debt financing amount</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_WarrantOrRightExercisable" xlink:label="ENSC_WarrantOrRightExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_WarrantOrRightExercisable" xlink:to="ENSC_WarrantOrRightExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_WarrantOrRightExercisable_lbl" xml:lang="en-US">Warrants exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_WarrantExpirationDate" xlink:label="ENSC_WarrantExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_WarrantExpirationDate" xlink:to="ENSC_WarrantExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_WarrantExpirationDate_lbl" xml:lang="en-US">Warrant, expiration date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares" xlink:to="ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares_2_lbl" xml:lang="en-US">Number of shares issued upon exercise of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants" xlink:to="ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants_2_lbl" xml:lang="en-US">Value of shares issued upon exercise of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2_lbl" xml:lang="en-US">Restricted common stock issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:label="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:to="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_lbl" xml:lang="en-US">Shares outstanding percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_WarrantsToPurchaseOneShareOfCommonStockMember" xlink:to="ENSC_WarrantsToPurchaseOneShareOfCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_WarrantsToPurchaseOneShareOfCommonStockMember_doc" xml:lang="en-US">Warrants To Purchase One Share Of Common Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_CommonStock0.0001ParValuePerShareMember" xlink:to="ENSC_CommonStock0.0001ParValuePerShareMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_CommonStock0.0001ParValuePerShareMember_doc" xml:lang="en-US">Common Stock Par Value [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_ChangeInFairValueOfLiabilityClassifiedWarrants" xlink:to="ENSC_ChangeInFairValueOfLiabilityClassifiedWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_ChangeInFairValueOfLiabilityClassifiedWarrants_doc" xml:lang="en-US">Change in fair value of liability classified warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_LossOnConversionsAndChangeInFairValueOfConvertibleNotes" xlink:to="ENSC_LossOnConversionsAndChangeInFairValueOfConvertibleNotes_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_LossOnConversionsAndChangeInFairValueOfConvertibleNotes_doc" xml:lang="en-US">Loss on conversions and change in fairvalue of convertible notes.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_AccruedResearchAndDevelopment" xlink:to="ENSC_AccruedResearchAndDevelopment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_AccruedResearchAndDevelopment_doc" xml:lang="en-US">Accrued research and development.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_StockIssuedDuringPeriodValueCommitmentFee" xlink:to="ENSC_StockIssuedDuringPeriodValueCommitmentFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_StockIssuedDuringPeriodValueCommitmentFee_doc" xml:lang="en-US">Stock issued during period value commitment fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_StockIssuedDuringPeriodSharesCommitmentFee" xlink:to="ENSC_StockIssuedDuringPeriodSharesCommitmentFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_StockIssuedDuringPeriodSharesCommitmentFee_doc" xml:lang="en-US">Stock issued during period shares commitment fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_TransactionCostsAssociatedWithPublicOffering" xlink:to="ENSC_TransactionCostsAssociatedWithPublicOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_TransactionCostsAssociatedWithPublicOffering_doc" xml:lang="en-US">Transaction cost associated with public offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants" xlink:to="ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants_doc" xml:lang="en-US">Stock issued during period issuance of common stock upon exercise of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_StockIssuedDuringPeriodValueReverseStockSplits" xlink:to="ENSC_StockIssuedDuringPeriodValueReverseStockSplits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_StockIssuedDuringPeriodValueReverseStockSplits_doc" xml:lang="en-US">Reverse stock splits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares" xlink:to="ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares_doc" xml:lang="en-US">Stock issued during period issuance of common stock upon exercise of warrants, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_FinancedInsuranceMember" xlink:to="ENSC_FinancedInsuranceMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_FinancedInsuranceMember_doc" xml:lang="en-US">Financed Insurance [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_IssuanceOfCommonStockUponWarrantInducements" xlink:to="ENSC_IssuanceOfCommonStockUponWarrantInducements_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_IssuanceOfCommonStockUponWarrantInducements_doc" xml:lang="en-US">Issuance of common stock upon warrant inducements, value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_IssuanceOfCommonStockUponWarrantInducementsShares" xlink:to="ENSC_IssuanceOfCommonStockUponWarrantInducementsShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_IssuanceOfCommonStockUponWarrantInducementsShares_doc" xml:lang="en-US">Issuance of common stock upon warrant inducements , shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_TransactionCostsAssociatedWithPublicOfferingAndWarrantInducements" xlink:to="ENSC_TransactionCostsAssociatedWithPublicOfferingAndWarrantInducements_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_TransactionCostsAssociatedWithPublicOfferingAndWarrantInducements_doc" xml:lang="en-US">Transaction costs associated with public offering and warrant inducements.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_IncreaseDecreaseInUnbilledReceivable" xlink:to="ENSC_IncreaseDecreaseInUnbilledReceivable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_IncreaseDecreaseInUnbilledReceivable_doc" xml:lang="en-US">Increase decrease in unbilled receivables.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_ProceedsFromWarrantInducementNetOfIssuanceCosts" xlink:to="ENSC_ProceedsFromWarrantInducementNetOfIssuanceCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_ProceedsFromWarrantInducementNetOfIssuanceCosts_doc" xml:lang="en-US">Proceeds from warrant inducement, net of issuance costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_TransactionCostsFromPublicOfferings" xlink:to="ENSC_TransactionCostsFromPublicOfferings_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_TransactionCostsFromPublicOfferings_doc" xml:lang="en-US">Transaction costs from public offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_TransactionCostAssociatedWithWarrantInducement" xlink:to="ENSC_TransactionCostAssociatedWithWarrantInducement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_TransactionCostAssociatedWithWarrantInducement_doc" xml:lang="en-US">Transaction cost associated with warrant inducement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_RepaymentInsurancePremiums" xlink:to="ENSC_RepaymentInsurancePremiums_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_RepaymentInsurancePremiums_doc" xml:lang="en-US">Repayment of insurance premiums.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_IncrementalFairValueOfWarrantInducement1" xlink:to="ENSC_IncrementalFairValueOfWarrantInducement1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_IncrementalFairValueOfWarrantInducement1_doc" xml:lang="en-US">Incremental fair value of warrant inducement1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_IncrementalFairValueOfWarrantInducement2" xlink:to="ENSC_IncrementalFairValueOfWarrantInducement2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_IncrementalFairValueOfWarrantInducement2_doc" xml:lang="en-US">Incremental fair value of warrant inducement2.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_ConversionsOfConvertibleNotesIntoCommonStock" xlink:to="ENSC_ConversionsOfConvertibleNotesIntoCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_ConversionsOfConvertibleNotesIntoCommonStock_doc" xml:lang="en-US">Conversions of convertible notes into common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_OriginalDebtDiscountFromConvertibleNotes" xlink:to="ENSC_OriginalDebtDiscountFromConvertibleNotes_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_OriginalDebtDiscountFromConvertibleNotes_doc" xml:lang="en-US">Original debt discount from convertible notes.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_DebtDiscountFromWarrantsIssuance" xlink:to="ENSC_DebtDiscountFromWarrantsIssuance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_DebtDiscountFromWarrantsIssuance_doc" xml:lang="en-US">Debt discount from warrants issuance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_IssuanceCostFromConvertibleNotes" xlink:to="ENSC_IssuanceCostFromConvertibleNotes_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_IssuanceCostFromConvertibleNotes_doc" xml:lang="en-US">Issuance cost from convertible notes</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_FinancedInsurancePremiums" xlink:to="ENSC_FinancedInsurancePremiums_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_FinancedInsurancePremiums_doc" xml:lang="en-US">Financed insurance premiums.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_SettlementOfCommitmentFeeInShares" xlink:to="ENSC_SettlementOfCommitmentFeeInShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_SettlementOfCommitmentFeeInShares_doc" xml:lang="en-US">Settlement of commitment fee in shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_DeemedDividendRelatedToWarrantsDownRoundProvision" xlink:to="ENSC_DeemedDividendRelatedToWarrantsDownRoundProvision_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_DeemedDividendRelatedToWarrantsDownRoundProvision_doc" xml:lang="en-US">Deemed dividend related to warrants down round provision.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_EBIRIncMember" xlink:to="ENSC_EBIRIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_EBIRIncMember_doc" xml:lang="en-US">EBIR, Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_KeyPersonnelMember" xlink:to="ENSC_KeyPersonnelMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_KeyPersonnelMember_doc" xml:lang="en-US">Key Personnel [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_UnrelatedPartyMember" xlink:to="ENSC_UnrelatedPartyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_UnrelatedPartyMember_doc" xml:lang="en-US">Unrelated Party [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_PrepaidResearchAndDevelopment" xlink:to="ENSC_PrepaidResearchAndDevelopment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_PrepaidResearchAndDevelopment_doc" xml:lang="en-US">Prepaid research and development.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_CustomerMember" xlink:to="ENSC_CustomerMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_CustomerMember_doc" xml:lang="en-US">Customer [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_LiabilityClassifiedWarrantsMember" xlink:to="ENSC_LiabilityClassifiedWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_LiabilityClassifiedWarrantsMember_doc" xml:lang="en-US">Liability classified warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_ScheduleOfRevenueRecognitionUnderGrantsTableTextBlock" xlink:to="ENSC_ScheduleOfRevenueRecognitionUnderGrantsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_ScheduleOfRevenueRecognitionUnderGrantsTableTextBlock_doc" xml:lang="en-US">Schedule of Revenue Recognition Under Grants [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_SecuritiesPurchaseAgreementMember" xlink:to="ENSC_SecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_SecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_FirstClosingSecuritiesPurchaseAgreementMember" xlink:to="ENSC_FirstClosingSecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_FirstClosingSecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">First Closing Securities Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_SecondClosingSecuritiesPurchaseAgreementMember" xlink:to="ENSC_SecondClosingSecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_SecondClosingSecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">Second Closing Securities Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_IssuanceOfCommonStockValueUponWarrantInducementNetOfIssuanceCosts" xlink:to="ENSC_IssuanceOfCommonStockValueUponWarrantInducementNetOfIssuanceCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_IssuanceOfCommonStockValueUponWarrantInducementNetOfIssuanceCosts_doc" xml:lang="en-US">Issuance of common stock value upon warrant inducement, net of issuance costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_TransactionCostsAssociatedWithWarrantInducement" xlink:to="ENSC_TransactionCostsAssociatedWithWarrantInducement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_TransactionCostsAssociatedWithWarrantInducement_doc" xml:lang="en-US">Transaction costs associated with warrant inducement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_RegisteredDirectOfferingMember" xlink:to="ENSC_RegisteredDirectOfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_RegisteredDirectOfferingMember_doc" xml:lang="en-US">Registered Direct Offering [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_PrefundedWarrantMember" xlink:to="ENSC_PrefundedWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_PrefundedWarrantMember_doc" xml:lang="en-US">Prefunded Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_AgentFeesAndOfferingExpensesPerShare" xlink:to="ENSC_AgentFeesAndOfferingExpensesPerShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_AgentFeesAndOfferingExpensesPerShare_doc" xml:lang="en-US">Agent fees and offering expenses per share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_SeriesAandBWarrantsMember" xlink:to="ENSC_SeriesAandBWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_SeriesAandBWarrantsMember_doc" xml:lang="en-US">Series A and B Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_SeriesAWarrantsMember" xlink:to="ENSC_SeriesAWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_SeriesAWarrantsMember_doc" xml:lang="en-US">Series A Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_SeriesBWarrantsMember" xlink:to="ENSC_SeriesBWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_SeriesBWarrantsMember_doc" xml:lang="en-US">Series B Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_CombinedOfferingPricePerShare" xlink:to="ENSC_CombinedOfferingPricePerShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_CombinedOfferingPricePerShare_doc" xml:lang="en-US">Combined offering price per share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_OfferingPricePerShare" xlink:to="ENSC_OfferingPricePerShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_OfferingPricePerShare_doc" xml:lang="en-US">Offering price per share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_WarrantOneMember" xlink:to="ENSC_WarrantOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_WarrantOneMember_doc" xml:lang="en-US">Warrant One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_WarrantTwoMember" xlink:to="ENSC_WarrantTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_WarrantTwoMember_doc" xml:lang="en-US">Warrant Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_WarrantThreeMember" xlink:to="ENSC_WarrantThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_WarrantThreeMember_doc" xml:lang="en-US">Warrant Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_WarrantFourMember" xlink:to="ENSC_WarrantFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_WarrantFourMember_doc" xml:lang="en-US">Warrant Four [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice" xlink:to="ENSC_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_doc" xml:lang="en-US">Exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_WarrantDescription" xlink:to="ENSC_WarrantDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_WarrantDescription_doc" xml:lang="en-US">Warrant Description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_InstitutionalInvestorMember" xlink:to="ENSC_InstitutionalInvestorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_InstitutionalInvestorMember_doc" xml:lang="en-US">Institutional Investor [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_InvestorWarrantsMember" xlink:to="ENSC_InvestorWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_InvestorWarrantsMember_doc" xml:lang="en-US">Investor Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_PlacementAgentWarrantsMember" xlink:to="ENSC_PlacementAgentWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_PlacementAgentWarrantsMember_doc" xml:lang="en-US">Placement Agent Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_PublicWarrantMember" xlink:to="ENSC_PublicWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_PublicWarrantMember_doc" xml:lang="en-US">Public Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_Notes2021And2022Member" xlink:to="ENSC_Notes2021And2022Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_Notes2021And2022Member_doc" xml:lang="en-US">Notes 2021 And 2022 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_TwoThousandTwentyOneOmnibusIncentivePlanMember" xlink:to="ENSC_TwoThousandTwentyOneOmnibusIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_TwoThousandTwentyOneOmnibusIncentivePlanMember_doc" xml:lang="en-US">2021 Omnibus Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_BoardOfMembersMember" xlink:to="ENSC_BoardOfMembersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_BoardOfMembersMember_doc" xml:lang="en-US">Board of Members [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue" xlink:to="ENSC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue_doc" xml:lang="en-US">Total Intrinsic value of share based payment forfeiture and expiration.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_SharebasedCompensationArrangementBySharebasedPaymentAwardWeightedAveragePeriodExpectedToBeRecognized" xlink:to="ENSC_SharebasedCompensationArrangementBySharebasedPaymentAwardWeightedAveragePeriodExpectedToBeRecognized_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_SharebasedCompensationArrangementBySharebasedPaymentAwardWeightedAveragePeriodExpectedToBeRecognized_doc" xml:lang="en-US">Share based payment award weighted average period expected to be recognized.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_ScheduleOfCommonStockFutureIssuanceTableTextBlock" xlink:to="ENSC_ScheduleOfCommonStockFutureIssuanceTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_ScheduleOfCommonStockFutureIssuanceTableTextBlock_doc" xml:lang="en-US">Schedule of Common Stock Future Issuance [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_StockOptionAvailableForFutureGrantUnder2021OmnibusIncentivePlanMember" xlink:to="ENSC_StockOptionAvailableForFutureGrantUnder2021OmnibusIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_StockOptionAvailableForFutureGrantUnder2021OmnibusIncentivePlanMember_doc" xml:lang="en-US">Stock Option Available For Future Grant Under 2021 Omnibus Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_WarrantOutstandingMember" xlink:to="ENSC_WarrantOutstandingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_WarrantOutstandingMember_doc" xml:lang="en-US">Warrant Outstanding [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_ScheduleOfFederalAndStateIncomeTaxProvisionBenefitTableTextBlock" xlink:to="ENSC_ScheduleOfFederalAndStateIncomeTaxProvisionBenefitTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_ScheduleOfFederalAndStateIncomeTaxProvisionBenefitTableTextBlock_doc" xml:lang="en-US">Schedule of Federal and State Income Tax Provision (Benefit) [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_IncomeTaxReconciliationExpiringAttributes" xlink:to="ENSC_IncomeTaxReconciliationExpiringAttributes_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_IncomeTaxReconciliationExpiringAttributes_doc" xml:lang="en-US">Income tax reconciliation expiring attributes</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_WarrantOrRightExercisable" xlink:to="ENSC_WarrantOrRightExercisable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_WarrantOrRightExercisable_doc" xml:lang="en-US">Warrant or right exercisable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_WarrantExpirationDate" xlink:to="ENSC_WarrantExpirationDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_WarrantExpirationDate_doc" xml:lang="en-US">Warrant expiration date.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_TAAPOUDMember" xlink:to="ENSC_TAAPOUDMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_TAAPOUDMember_doc" xml:lang="en-US">TAAP/OUD [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_MPARMember" xlink:to="ENSC_MPARMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_MPARMember_doc" xml:lang="en-US">MPAR [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_TwoThousandTwentyThreeNotesMember" xlink:to="ENSC_TwoThousandTwentyThreeNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENSC_TwoThousandTwentyThreeNotesMember_doc" xml:lang="en-US">2023 Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_2_lbl" xml:lang="en-US">Liabilities, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4_lbl" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseNonoperating_2_lbl" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:to="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_2_lbl" xml:lang="en-US">Warrant, Down Round Feature, Increase (Decrease) in Equity, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_IncreaseDecreaseInUnbilledReceivable" xlink:to="ENSC_IncreaseDecreaseInUnbilledReceivable_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_IncreaseDecreaseInUnbilledReceivable_3_lbl" xml:lang="en-US">IncreaseDecreaseInUnbilledReceivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expenses, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_TransactionCostsFromPublicOfferings" xlink:to="ENSC_TransactionCostsFromPublicOfferings_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_TransactionCostsFromPublicOfferings_3_lbl" xml:lang="en-US">TransactionCostsFromPublicOfferings</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_TransactionCostAssociatedWithWarrantInducement" xlink:to="ENSC_TransactionCostAssociatedWithWarrantInducement_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_TransactionCostAssociatedWithWarrantInducement_3_lbl" xml:lang="en-US">TransactionCostAssociatedWithWarrantInducement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_2_lbl" xml:lang="en-US">Repayments of Convertible Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_RepaymentInsurancePremiums" xlink:to="ENSC_RepaymentInsurancePremiums_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_RepaymentInsurancePremiums_3_lbl" xml:lang="en-US">RepaymentInsurancePremiums</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_DeemedDividendRelatedToWarrantsDownRoundProvision" xlink:to="ENSC_DeemedDividendRelatedToWarrantsDownRoundProvision_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_DeemedDividendRelatedToWarrantsDownRoundProvision_3_lbl" xml:lang="en-US">DeemedDividendRelatedToWarrantsDownRoundProvision</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_2_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_2_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_2_lbl" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3_lbl" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_2_lbl" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_2_lbl" xml:lang="en-US">Prepaid Expense, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_2_lbl" xml:lang="en-US">Accrued Liabilities and Other Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_2_lbl" xml:lang="en-US">Interest Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_2_lbl" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense, Operating and Nonoperating</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENSC_OfferingPricePerShare" xlink:to="ENSC_OfferingPricePerShare_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENSC_OfferingPricePerShare_3_lbl" xml:lang="en-US">OfferingPricePerShare</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_2_lbl" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilities_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_3_lbl" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_2_lbl" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>ensc-20241231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://ensysce.com/role/Cover" xlink:href="ensc-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/BalanceSheets" xlink:href="ensc-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/BalanceSheetsParenthetical" xlink:href="ensc-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/StatementsOfOperations" xlink:href="ensc-20241231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit" xlink:href="ensc-20241231.xsd#StatementsOfChangesInStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/StatementsOfCashFlows" xlink:href="ensc-20241231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/OrganizationAndPrincipalActivities" xlink:href="ensc-20241231.xsd#OrganizationAndPrincipalActivities" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/BasisOfPresentation" xlink:href="ensc-20241231.xsd#BasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="ensc-20241231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="ensc-20241231.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/AccruedExpensesAndOtherLiabilities" xlink:href="ensc-20241231.xsd#AccruedExpensesAndOtherLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/CommitmentsAndContingencies" xlink:href="ensc-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/NotesPayable" xlink:href="ensc-20241231.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/StockholdersEquity" xlink:href="ensc-20241231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/Stock-basedCompensation" xlink:href="ensc-20241231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/IncomeTaxes" xlink:href="ensc-20241231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/RelatedParties" xlink:href="ensc-20241231.xsd#RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/SubsequentEvents" xlink:href="ensc-20241231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ensc-20241231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="ensc-20241231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="ensc-20241231.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/AccruedExpensesAndOtherLiabilitiesTables" xlink:href="ensc-20241231.xsd#AccruedExpensesAndOtherLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/NotesPayableTables" xlink:href="ensc-20241231.xsd#NotesPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/StockholdersEquityTables" xlink:href="ensc-20241231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/Stock-basedCompensationTables" xlink:href="ensc-20241231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/IncomeTaxesTables" xlink:href="ensc-20241231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative" xlink:href="ensc-20241231.xsd#OrganizationAndPrincipalActivitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/BasisOfPresentationDetailsNarrative" xlink:href="ensc-20241231.xsd#BasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:href="ensc-20241231.xsd#ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfChangeInFairValueOfCompanysLevel3Details" xlink:href="ensc-20241231.xsd#ScheduleOfChangeInFairValueOfCompanysLevel3Details" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfRevenueRecognitionUnderGrantsDetails" xlink:href="ensc-20241231.xsd#ScheduleOfRevenueRecognitionUnderGrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfWeightedAverageSharesOfAnti-dilutiveSecuritiesDetails" xlink:href="ensc-20241231.xsd#ScheduleOfWeightedAverageSharesOfAnti-dilutiveSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="ensc-20241231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="ensc-20241231.xsd#ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" xlink:href="ensc-20241231.xsd#ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="ensc-20241231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfDebtDetails" xlink:href="ensc-20241231.xsd#ScheduleOfDebtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/NotesPayableDetailsNarrative" xlink:href="ensc-20241231.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfOutstandingWarrantDetails" xlink:href="ensc-20241231.xsd#ScheduleOfOutstandingWarrantDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical" xlink:href="ensc-20241231.xsd#ScheduleOfOutstandingWarrantDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/StockholdersEquityDetailsNarrative" xlink:href="ensc-20241231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="ensc-20241231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:href="ensc-20241231.xsd#ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfCommonStockFutureIssuanceDetails" xlink:href="ensc-20241231.xsd#ScheduleOfCommonStockFutureIssuanceDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="ensc-20241231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfIncomeTaxesBenefitDetails" xlink:href="ensc-20241231.xsd#ScheduleOfIncomeTaxesBenefitDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfFederalAndStateIncomeTaxProvisionBenefitDetails" xlink:href="ensc-20241231.xsd#ScheduleOfFederalAndStateIncomeTaxProvisionBenefitDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfFederalIncomeTaxRateReconciliationDetails" xlink:href="ensc-20241231.xsd#ScheduleOfFederalIncomeTaxRateReconciliationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfDeferredTaxAssetsDetails" xlink:href="ensc-20241231.xsd#ScheduleOfDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails" xlink:href="ensc-20241231.xsd#ScheduleOfUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/IncomeTaxesDetailsNarrative" xlink:href="ensc-20241231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/RelatedPartiesDetailsNarrative" xlink:href="ensc-20241231.xsd#RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://ensysce.com/role/SubsequentEventsDetailsNarrative" xlink:href="ensc-20241231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_CommonStock0.0001ParValuePerShareMember" xlink:label="loc_ENSCCommonStock0.0001ParValuePerShareMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENSCCommonStock0.0001ParValuePerShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_WarrantsToPurchaseOneShareOfCommonStockMember" xlink:label="loc_ENSCWarrantsToPurchaseOneShareOfCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENSCWarrantsToPurchaseOneShareOfCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnbilledReceivablesCurrent" xlink:label="loc_us-gaapUnbilledReceivablesCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapUnbilledReceivablesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapMinorityInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_LossOnConversionsAndChangeInFairValueOfConvertibleNotes" xlink:label="loc_ENSCLossOnConversionsAndChangeInFairValueOfConvertibleNotes" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:to="loc_ENSCLossOnConversionsAndChangeInFairValueOfConvertibleNotes" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_ChangeInFairValueOfLiabilityClassifiedWarrants" xlink:label="loc_ENSCChangeInFairValueOfLiabilityClassifiedWarrants" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:to="loc_ENSCChangeInFairValueOfLiabilityClassifiedWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaapInterestExpenseNonoperating" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpenseNonoperating" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount" xlink:label="loc_us-gaapWarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity (Deficit)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaapNoncontrollingInterestMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapNoncontrollingInterestMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_StockIssuedDuringPeriodValueCommitmentFee" xlink:label="loc_ENSCStockIssuedDuringPeriodValueCommitmentFee" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENSCStockIssuedDuringPeriodValueCommitmentFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_StockIssuedDuringPeriodSharesCommitmentFee" xlink:label="loc_ENSCStockIssuedDuringPeriodSharesCommitmentFee" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENSCStockIssuedDuringPeriodSharesCommitmentFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_TransactionCostsAssociatedWithPublicOffering" xlink:label="loc_ENSCTransactionCostsAssociatedWithPublicOffering" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENSCTransactionCostsAssociatedWithPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants" xlink:label="loc_ENSCStockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENSCStockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares" xlink:label="loc_ENSCStockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENSCStockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_StockIssuedDuringPeriodValueReverseStockSplits" xlink:label="loc_ENSCStockIssuedDuringPeriodValueReverseStockSplits" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENSCStockIssuedDuringPeriodValueReverseStockSplits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:label="loc_us-gaapWarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_IssuanceOfCommonStockUponWarrantInducements" xlink:label="loc_ENSCIssuanceOfCommonStockUponWarrantInducements" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENSCIssuanceOfCommonStockUponWarrantInducements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_IssuanceOfCommonStockUponWarrantInducementsShares" xlink:label="loc_ENSCIssuanceOfCommonStockUponWarrantInducementsShares" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENSCIssuanceOfCommonStockUponWarrantInducementsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_TransactionCostsAssociatedWithPublicOfferingAndWarrantInducements" xlink:label="loc_ENSCTransactionCostsAssociatedWithPublicOfferingAndWarrantInducements" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENSCTransactionCostsAssociatedWithPublicOfferingAndWarrantInducements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaapIncreaseDecreaseInInterestPayableNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInterestPayableNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_LossOnConversionsAndChangeInFairValueOfConvertibleNotes" xlink:label="loc_ENSCLossOnConversionsAndChangeInFairValueOfConvertibleNotes" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_ENSCLossOnConversionsAndChangeInFairValueOfConvertibleNotes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_ChangeInFairValueOfLiabilityClassifiedWarrants" xlink:label="loc_ENSCChangeInFairValueOfLiabilityClassifiedWarrants" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_ENSCChangeInFairValueOfLiabilityClassifiedWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForLoanLeaseAndOtherLosses" xlink:label="loc_us-gaapProvisionForLoanLeaseAndOtherLosses" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProvisionForLoanLeaseAndOtherLosses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_IncreaseDecreaseInUnbilledReceivable" xlink:label="loc_ENSCIncreaseDecreaseInUnbilledReceivable" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_ENSCIncreaseDecreaseInUnbilledReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccruedLiabilities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_ProceedsFromWarrantInducementNetOfIssuanceCosts" xlink:label="loc_ENSCProceedsFromWarrantInducementNetOfIssuanceCosts" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_ENSCProceedsFromWarrantInducementNetOfIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_TransactionCostsFromPublicOfferings" xlink:label="loc_ENSCTransactionCostsFromPublicOfferings" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_ENSCTransactionCostsFromPublicOfferings" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_TransactionCostAssociatedWithWarrantInducement" xlink:label="loc_ENSCTransactionCostAssociatedWithWarrantInducement" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_ENSCTransactionCostAssociatedWithWarrantInducement" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaapRepaymentsOfConvertibleDebt" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfConvertibleDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_RepaymentInsurancePremiums" xlink:label="loc_ENSCRepaymentInsurancePremiums" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_ENSCRepaymentInsurancePremiums" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_IncrementalFairValueOfWarrantInducement1" xlink:label="loc_ENSCIncrementalFairValueOfWarrantInducement1" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_ENSCIncrementalFairValueOfWarrantInducement1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_IncrementalFairValueOfWarrantInducement2" xlink:label="loc_ENSCIncrementalFairValueOfWarrantInducement2" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_ENSCIncrementalFairValueOfWarrantInducement2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_ConversionsOfConvertibleNotesIntoCommonStock" xlink:label="loc_ENSCConversionsOfConvertibleNotesIntoCommonStock" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_ENSCConversionsOfConvertibleNotesIntoCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_OriginalDebtDiscountFromConvertibleNotes" xlink:label="loc_ENSCOriginalDebtDiscountFromConvertibleNotes" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_ENSCOriginalDebtDiscountFromConvertibleNotes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_DebtDiscountFromWarrantsIssuance" xlink:label="loc_ENSCDebtDiscountFromWarrantsIssuance" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_ENSCDebtDiscountFromWarrantsIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_IssuanceCostFromConvertibleNotes" xlink:label="loc_ENSCIssuanceCostFromConvertibleNotes" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_ENSCIssuanceCostFromConvertibleNotes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_FinancedInsurancePremiums" xlink:label="loc_ENSCFinancedInsurancePremiums" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_ENSCFinancedInsurancePremiums" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_SettlementOfCommitmentFeeInShares" xlink:label="loc_ENSCSettlementOfCommitmentFeeInShares" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_ENSCSettlementOfCommitmentFeeInShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_DeemedDividendRelatedToWarrantsDownRoundProvision" xlink:label="loc_ENSCDeemedDividendRelatedToWarrantsDownRoundProvision" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_ENSCDeemedDividendRelatedToWarrantsDownRoundProvision" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="loc_ecdExecutiveCategoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdExecutiveCategoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember" xlink:label="loc_ecdAllExecutiveCategoriesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdExecutiveCategoryAxis" xlink:to="loc_ecdAllExecutiveCategoriesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="loc_ecdMeasureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdMeasureAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="loc_ecdPnsnBnftsAdjFnTextBlock" />
      <link:presentationArc order="2280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPnsnBnftsAdjFnTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="loc_ecdAwardsCloseToMnpiDiscTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="loc_ecdTrdArrExpirationDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000012 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="loc_cydCybersecurityRiskRoleOfManagementTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskRoleOfManagementTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000013 - Disclosure - Material Cybersecurity Incident Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="loc_cydMaterialCybersecurityIncidentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentNatureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentNatureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentScopeTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentScopeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentTimingTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentTimingTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/OrganizationAndPrincipalActivities" xlink:title="999014 - Disclosure - ORGANIZATION AND PRINCIPAL ACTIVITIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/BasisOfPresentation" xlink:title="999015 - Disclosure - BASIS OF PRESENTATION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccounting" xlink:label="loc_us-gaapBasisOfAccounting" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapBasisOfAccounting" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="999017 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="loc_us-gaapOtherCurrentAssetsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherCurrentAssetsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/AccruedExpensesAndOtherLiabilities" xlink:title="999018 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/CommitmentsAndContingencies" xlink:title="999019 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/NotesPayable" xlink:title="999020 - Disclosure - NOTES PAYABLE">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/StockholdersEquity" xlink:title="999021 - Disclosure - STOCKHOLDERS&#8217; EQUITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/Stock-basedCompensation" xlink:title="999022 - Disclosure - STOCK-BASED COMPENSATION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/IncomeTaxes" xlink:title="999023 - Disclosure - INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/RelatedParties" xlink:title="999024 - Disclosure - RELATED PARTIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/SubsequentEvents" xlink:title="999025 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_ScheduleOfRevenueRecognitionUnderGrantsTableTextBlock" xlink:label="loc_ENSCScheduleOfRevenueRecognitionUnderGrantsTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_ENSCScheduleOfRevenueRecognitionUnderGrantsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="999028 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/AccruedExpensesAndOtherLiabilitiesTables" xlink:title="999029 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/NotesPayableTables" xlink:title="999030 - Disclosure - NOTES PAYABLE (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaapScheduleOfDebtTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDebtTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/StockholdersEquityTables" xlink:title="999031 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/Stock-basedCompensationTables" xlink:title="999032 - Disclosure - STOCK-BASED COMPENSATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_ScheduleOfCommonStockFutureIssuanceTableTextBlock" xlink:label="loc_ENSCScheduleOfCommonStockFutureIssuanceTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_ENSCScheduleOfCommonStockFutureIssuanceTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/IncomeTaxesTables" xlink:title="999033 - Disclosure - INCOME TAXES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_ScheduleOfFederalAndStateIncomeTaxProvisionBenefitTableTextBlock" xlink:label="loc_ENSCScheduleOfFederalAndStateIncomeTaxProvisionBenefitTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_ENSCScheduleOfFederalAndStateIncomeTaxProvisionBenefitTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaapScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative" xlink:title="999034 - Disclosure - ORGANIZATION AND PRINCIPAL ACTIVITIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_EBIRIncMember" xlink:label="loc_ENSCEBIRIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_ENSCEBIRIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_KeyPersonnelMember" xlink:label="loc_ENSCKeyPersonnelMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_ENSCKeyPersonnelMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_UnrelatedPartyMember" xlink:label="loc_ENSCUnrelatedPartyMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_ENSCUnrelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/BasisOfPresentationDetailsNarrative" xlink:title="999035 - Disclosure - BASIS OF PRESENTATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:title="999036 - Disclosure - SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_srtPlatformOperatorCryptoAssetLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapFinancialLiabilitiesFairValueDisclosure" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapFinancialLiabilitiesFairValueDisclosure" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="loc_us-gaapFairValueNetAssetLiability" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapFairValueNetAssetLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfChangeInFairValueOfCompanysLevel3Details" xlink:title="999037 - Disclosure - SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY&#8217;S LEVEL 3 (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaapFairValueByLiabilityClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="loc_us-gaapFairValueByLiabilityClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_LiabilityClassifiedWarrantsMember" xlink:label="loc_ENSCLiabilityClassifiedWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_ENSCLiabilityClassifiedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfRevenueRecognitionUnderGrantsDetails" xlink:title="999038 - Disclosure - SCHEDULE OF REVENUE RECOGNITION UNDER GRANTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfProductInformationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapProductInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_MPARMember" xlink:label="loc_ENSCMPARMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_ENSCMPARMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_TAAPOUDMember" xlink:label="loc_ENSCTAAPOUDMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_ENSCTAAPOUDMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfWeightedAverageSharesOfAnti-dilutiveSecuritiesDetails" xlink:title="999039 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaapConvertibleDebtSecuritiesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapConvertibleDebtSecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999040 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfProductInformationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapProductInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtMajorCustomersAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_CustomerMember" xlink:label="loc_ENSCCustomerMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_ENSCCustomerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDescription" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDescription" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaapNumberOfReportableSegments" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapNumberOfReportableSegments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaapNumberOfOperatingSegments" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapNumberOfOperatingSegments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrantsReceivable" xlink:label="loc_us-gaapGrantsReceivable" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapGrantsReceivable" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="999041 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_PrepaidResearchAndDevelopment" xlink:label="loc_ENSCPrepaidResearchAndDevelopment" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_ENSCPrepaidResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" xlink:title="999042 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_AccruedResearchAndDevelopment" xlink:label="loc_ENSCAccruedResearchAndDevelopment" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_ENSCAccruedResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrentAndNoncurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999043 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaapContractualObligation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapContractualObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapPaymentsForRent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfDebtDetails" xlink:title="999044 - Disclosure - SCHEDULE OF DEBT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_TwoThousandTwentyThreeNotesMember" xlink:label="loc_ENSCTwoThousandTwentyThreeNotesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_ENSCTwoThousandTwentyThreeNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_FinancedInsuranceMember" xlink:label="loc_ENSCFinancedInsuranceMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_ENSCFinancedInsuranceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapInterestPayableCurrentAndNoncurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestPayableCurrentAndNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/NotesPayableDetailsNarrative" xlink:title="999045 - Disclosure - NOTES PAYABLE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_TwoThousandTwentyThreeNotesMember" xlink:label="loc_ENSCTwoThousandTwentyThreeNotesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_ENSCTwoThousandTwentyThreeNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_SecuritiesPurchaseAgreementMember" xlink:label="loc_ENSCSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENSCSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_FirstClosingSecuritiesPurchaseAgreementMember" xlink:label="loc_ENSCFirstClosingSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENSCFirstClosingSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_SecondClosingSecuritiesPurchaseAgreementMember" xlink:label="loc_ENSCSecondClosingSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENSCSecondClosingSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestExpenseDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_ProceedsFromWarrantInducementNetOfIssuanceCosts" xlink:label="loc_ENSCProceedsFromWarrantInducementNetOfIssuanceCosts" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_ENSCProceedsFromWarrantInducementNetOfIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_IssuanceOfCommonStockValueUponWarrantInducementNetOfIssuanceCosts" xlink:label="loc_ENSCIssuanceOfCommonStockValueUponWarrantInducementNetOfIssuanceCosts" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_ENSCIssuanceOfCommonStockValueUponWarrantInducementNetOfIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_TransactionCostsAssociatedWithWarrantInducement" xlink:label="loc_ENSCTransactionCostsAssociatedWithWarrantInducement" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_ENSCTransactionCostsAssociatedWithWarrantInducement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_FinancedInsurancePremiums" xlink:label="loc_ENSCFinancedInsurancePremiums" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_ENSCFinancedInsurancePremiums" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfOutstandingWarrantDetails" xlink:title="999046 - Disclosure - SCHEDULE OF OUTSTANDING WARRANT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_WarrantOneMember" xlink:label="loc_ENSCWarrantOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ENSCWarrantOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_WarrantTwoMember" xlink:label="loc_ENSCWarrantTwoMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ENSCWarrantTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_WarrantThreeMember" xlink:label="loc_ENSCWarrantThreeMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ENSCWarrantThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_WarrantFourMember" xlink:label="loc_ENSCWarrantFourMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ENSCWarrantFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice" xlink:label="loc_ENSCShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENSCShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_WarrantDescription" xlink:label="loc_ENSCWarrantDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENSCWarrantDescription" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical" xlink:title="999047 - Disclosure - SCHEDULE OF OUTSTANDING WARRANT (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_InstitutionalInvestorMember" xlink:label="loc_ENSCInstitutionalInvestorMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENSCInstitutionalInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_InvestorWarrantsMember" xlink:label="loc_ENSCInvestorWarrantsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENSCInvestorWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_PlacementAgentWarrantsMember" xlink:label="loc_ENSCPlacementAgentWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENSCPlacementAgentWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_PlacementAgentWarrantsMember" xlink:label="loc_ENSCPlacementAgentWarrantsMember_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENSCPlacementAgentWarrantsMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_SeriesBWarrantsMember" xlink:label="loc_ENSCSeriesBWarrantsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENSCSeriesBWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_SeriesAWarrantsMember" xlink:label="loc_ENSCSeriesAWarrantsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENSCSeriesAWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_PublicWarrantMember" xlink:label="loc_ENSCPublicWarrantMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ENSCPublicWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_Notes2021And2022Member" xlink:label="loc_ENSCNotes2021And2022Member" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ENSCNotes2021And2022Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_srtRangeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/StockholdersEquityDetailsNarrative" xlink:title="999048 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_RegisteredDirectOfferingMember" xlink:label="loc_ENSCRegisteredDirectOfferingMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ENSCRegisteredDirectOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_PrefundedWarrantMember" xlink:label="loc_ENSCPrefundedWarrantMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ENSCPrefundedWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_SeriesAandBWarrantsMember" xlink:label="loc_ENSCSeriesAandBWarrantsMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ENSCSeriesAandBWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_SeriesAWarrantsMember" xlink:label="loc_ENSCSeriesAWarrantsMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENSCSeriesAWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_SeriesBWarrantsMember" xlink:label="loc_ENSCSeriesBWarrantsMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENSCSeriesBWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_AgentFeesAndOfferingExpensesPerShare" xlink:label="loc_ENSCAgentFeesAndOfferingExpensesPerShare" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENSCAgentFeesAndOfferingExpensesPerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:label="loc_us-gaapClassOfWarrantOrRightReasonForIssuingToNonemployees" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityClassifiedWrittenCallOptionModificationEquityIssuanceIncreaseDecreaseInEquityAmount" xlink:label="loc_us-gaapEquityClassifiedWrittenCallOptionModificationEquityIssuanceIncreaseDecreaseInEquityAmount" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEquityClassifiedWrittenCallOptionModificationEquityIssuanceIncreaseDecreaseInEquityAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_CombinedOfferingPricePerShare" xlink:label="loc_ENSCCombinedOfferingPricePerShare" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENSCCombinedOfferingPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaapOtherExpenses" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapOtherExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_OfferingPricePerShare" xlink:label="loc_ENSCOfferingPricePerShare" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENSCOfferingPricePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="999049 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue" xlink:label="loc_ENSCShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_ENSCShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:title="999050 - Disclosure - SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfCommonStockFutureIssuanceDetails" xlink:title="999051 - Disclosure - SCHEDULE OF COMMON STOCK FUTURE ISSUANCE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_StockOptionAvailableForFutureGrantUnder2021OmnibusIncentivePlanMember" xlink:label="loc_ENSCStockOptionAvailableForFutureGrantUnder2021OmnibusIncentivePlanMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ENSCStockOptionAvailableForFutureGrantUnder2021OmnibusIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_WarrantOutstandingMember" xlink:label="loc_ENSCWarrantOutstandingMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ENSCWarrantOutstandingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999052 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_TwoThousandTwentyOneOmnibusIncentivePlanMember" xlink:label="loc_ENSCTwoThousandTwentyOneOmnibusIncentivePlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ENSCTwoThousandTwentyOneOmnibusIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_BoardOfMembersMember" xlink:label="loc_ENSCBoardOfMembersMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_ENSCBoardOfMembersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_SharebasedCompensationArrangementBySharebasedPaymentAwardWeightedAveragePeriodExpectedToBeRecognized" xlink:label="loc_ENSCSharebasedCompensationArrangementBySharebasedPaymentAwardWeightedAveragePeriodExpectedToBeRecognized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ENSCSharebasedCompensationArrangementBySharebasedPaymentAwardWeightedAveragePeriodExpectedToBeRecognized" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfIncomeTaxesBenefitDetails" xlink:title="999053 - Disclosure - SCHEDULE OF INCOME TAXES BENEFIT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="loc_countryUS" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfFederalAndStateIncomeTaxProvisionBenefitDetails" xlink:title="999054 - Disclosure - SCHEDULE OF FEDERAL AND STATE INCOME TAX PROVISION (BENEFIT) (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfFederalIncomeTaxRateReconciliationDetails" xlink:title="999055 - Disclosure - SCHEDULE OF FEDERAL INCOME TAX RATE RECONCILIATION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseOther" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxCreditsResearch" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_IncomeTaxReconciliationExpiringAttributes" xlink:label="loc_ENSCIncomeTaxReconciliationExpiringAttributes" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_ENSCIncomeTaxReconciliationExpiringAttributes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxContingencies" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfDeferredTaxAssetsDetails" xlink:title="999056 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaapDeferredTaxLiabilitiesOther" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaapDeferredTaxLiabilities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails" xlink:title="999057 - Disclosure - SCHEDULE OF UNRECOGNIZED TAX BENEFITS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapUnrecognizedTaxBenefits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaapUnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapUnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaapUnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapUnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaapUnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapUnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapUnrecognizedTaxBenefits_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/IncomeTaxesDetailsNarrative" xlink:title="999058 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:label="loc_us-gaapCaliforniaFranchiseTaxBoardMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapCaliforniaFranchiseTaxBoardMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:label="loc_us-gaapCaliforniaFranchiseTaxBoardMember_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_us-gaapCaliforniaFranchiseTaxBoardMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaapTaxCreditCarryforwardAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapTaxCreditCarryforwardAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaapTaxCreditCarryforwardNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxCreditCarryforwardAxis" xlink:to="loc_us-gaapTaxCreditCarryforwardNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaapResearchMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxCreditCarryforwardNameDomain" xlink:to="loc_us-gaapResearchMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardDescription" xlink:label="loc_us-gaapTaxCreditCarryforwardDescription" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="loc_us-gaapOperatingLossCarryforwardsLimitationsOnUse" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsLimitationsOnUse" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaapTaxCreditCarryforwardAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:label="loc_us-gaapTaxCreditCarryforwardLimitationsOnUse" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardLimitationsOnUse" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="loc_us-gaapUnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapUnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivableAccruedInterestWriteoff" xlink:label="loc_us-gaapFinancingReceivableAccruedInterestWriteoff" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapFinancingReceivableAccruedInterestWriteoff" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/RelatedPartiesDetailsNarrative" xlink:title="999059 - Disclosure - RELATED PARTIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_SecuritiesPurchaseAgreementMember" xlink:label="loc_ENSCSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENSCSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorLongTermNotes" xlink:label="loc_us-gaapSeniorLongTermNotes" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSeniorLongTermNotes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_WarrantOrRightExercisable" xlink:label="loc_ENSCWarrantOrRightExercisable" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_ENSCWarrantOrRightExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_WarrantExpirationDate" xlink:label="loc_ENSCWarrantExpirationDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_ENSCWarrantExpirationDate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ensysce.com/role/SubsequentEventsDetailsNarrative" xlink:title="999060 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares" xlink:label="loc_ENSCStockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_ENSCStockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ensc-20241231.xsd#ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants" xlink:label="loc_ENSCStockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_ENSCStockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:label="loc_us-gaapSaleOfStockPercentageOfOwnershipAfterTransaction" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockPercentageOfOwnershipAfterTransaction" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231324953024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 07, 2025</div></th>
<th class="th"><div>Jun. 28, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ENSYSCE
BIOSCIENCES, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001716947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-2755287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7946
                                            Ivanhoe Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">La
    Jolla<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">263-4196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,405,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference [Text Block]</a></td>
<td class="text">None<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Moss Adams LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San
Diego, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ENSC_CommonStock0.0001ParValuePerShareMember', window );">Common Stock Par Value [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ENSC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ENSC_WarrantsToPurchaseOneShareOfCommonStockMember', window );">Warrants, to purchase one share of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants,
    to purchase one share of Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ENSCW<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ENSC_CommonStock0.0001ParValuePerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ENSC_CommonStock0.0001ParValuePerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ENSC_WarrantsToPurchaseOneShareOfCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ENSC_WarrantsToPurchaseOneShareOfCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231324604752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 3,502,077<span></span>
</td>
<td class="nump">$ 1,123,604<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnbilledReceivablesCurrent', window );">Unbilled receivable</a></td>
<td class="nump">124,115<span></span>
</td>
<td class="nump">97,561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,718,490<span></span>
</td>
<td class="nump">1,067,703<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">5,344,682<span></span>
</td>
<td class="nump">2,288,868<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">252,550<span></span>
</td>
<td class="nump">419,217<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">5,597,232<span></span>
</td>
<td class="nump">2,708,085<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,357,079<span></span>
</td>
<td class="nump">1,936,007<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">548,458<span></span>
</td>
<td class="nump">542,260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable and accrued interest</a></td>
<td class="nump">301,660<span></span>
</td>
<td class="nump">854,697<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,207,197<span></span>
</td>
<td class="nump">3,332,964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">10,096<span></span>
</td>
<td class="nump">26,388<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long-term liabilities</a></td>
<td class="nump">10,096<span></span>
</td>
<td class="nump">26,388<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,217,293<span></span>
</td>
<td class="nump">3,359,352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 6)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity (deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value, 1,500,000 shares authorized, no shares issued and outstanding at December 31, 2024 and December 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value, 250,000,000 shares authorized at December 31, 2024 and December 31, 2023; 1,355,779 and 209,745 shares issued at December 31, 2024 and December 31, 2023, respectively; 1,355,773 and 209,739 shares outstanding at December 31, 2024 and December 31, 2023, respectively</a></td>
<td class="nump">136<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">133,252,585<span></span>
</td>
<td class="nump">121,234,195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(129,544,299)<span></span>
</td>
<td class="num">(121,557,074)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Ensysce Biosciences, Inc. stockholders&#8217; equity (deficit)</a></td>
<td class="nump">3,708,422<span></span>
</td>
<td class="num">(322,858)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests in stockholders&#8217; deficit</a></td>
<td class="num">(328,483)<span></span>
</td>
<td class="num">(328,409)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; equity (deficit)</a></td>
<td class="nump">3,379,939<span></span>
</td>
<td class="num">(651,267)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity (deficit)</a></td>
<td class="nump">$ 5,597,232<span></span>
</td>
<td class="nump">$ 2,708,085<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnbilledReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnbilledReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231330829776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">1,355,779<span></span>
</td>
<td class="nump">209,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">1,355,773<span></span>
</td>
<td class="nump">209,739<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231427675408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Federal grants</a></td>
<td class="nump">$ 5,210,031<span></span>
</td>
<td class="nump">$ 2,230,520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">7,219,437<span></span>
</td>
<td class="nump">7,587,473<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">4,720,728<span></span>
</td>
<td class="nump">5,361,234<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">11,940,165<span></span>
</td>
<td class="nump">12,948,707<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(6,730,134)<span></span>
</td>
<td class="num">(10,718,187)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_LossOnConversionsAndChangeInFairValueOfConvertibleNotes', window );">Loss on conversions and change in fair value of convertible notes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">146,479<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_ChangeInFairValueOfLiabilityClassifiedWarrants', window );">Change in fair value of liability classified warrants</a></td>
<td class="nump">16,292<span></span>
</td>
<td class="nump">283,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense, net</a></td>
<td class="num">(1,290,444)<span></span>
</td>
<td class="num">(353,945)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income and expense, net</a></td>
<td class="nump">17,277<span></span>
</td>
<td class="nump">15,420<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="num">(1,256,875)<span></span>
</td>
<td class="nump">91,912<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(7,987,009)<span></span>
</td>
<td class="num">(10,626,275)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interests</a></td>
<td class="num">(74)<span></span>
</td>
<td class="num">(13,201)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount', window );">Deemed dividend related to warrants down round provision</a></td>
<td class="nump">290<span></span>
</td>
<td class="nump">12,937<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (7,987,225)<span></span>
</td>
<td class="num">$ (10,626,011)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per basic and diluted share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders, basic</a></td>
<td class="num">$ (11.45)<span></span>
</td>
<td class="num">$ (70.40)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders, diluted</a></td>
<td class="num">$ (11.45)<span></span>
</td>
<td class="num">$ (70.40)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic</a></td>
<td class="nump">697,686<span></span>
</td>
<td class="nump">150,937<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted</a></td>
<td class="nump">697,686<span></span>
</td>
<td class="nump">150,937<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENSC_ChangeInFairValueOfLiabilityClassifiedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of liability classified warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENSC_ChangeInFairValueOfLiabilityClassifiedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENSC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENSC_LossOnConversionsAndChangeInFairValueOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss on conversions and change in fairvalue of convertible notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENSC_LossOnConversionsAndChangeInFairValueOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENSC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in net income available to common shareholder for down round feature triggered for warrant classified as equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-12B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231330674336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Noncontrolling Interest [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 107,216,615<span></span>
</td>
<td class="num">$ (110,931,063)<span></span>
</td>
<td class="num">$ (315,208)<span></span>
</td>
<td class="num">$ (4,029,652)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">35,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Settlement of restricted stock units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Settlement of restricted stock units, shares</a></td>
<td class="nump">4,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_StockIssuedDuringPeriodValueCommitmentFee', window );">Settlement of commitment fee</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_StockIssuedDuringPeriodSharesCommitmentFee', window );">Settlement of commitment fee, shares</a></td>
<td class="nump">2,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible notes</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">3,056,889<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,056,892<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversions of convertible notes, shares</a></td>
<td class="nump">27,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Public offering</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">9,049,995<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">9,050,004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Public offering, net, shares</a></td>
<td class="nump">92,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">879,160<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">879,160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of warrants - debt discount</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,066,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,066,483<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_TransactionCostsAssociatedWithPublicOffering', window );">Transaction costs associated with public offering</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(447,879)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(447,879)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants', window );">Issuance of common stock upon exercise of warrants</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares', window );">Issuance of common stock upon exercise of warrants, shares</a></td>
<td class="nump">47,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_StockIssuedDuringPeriodValueReverseStockSplits', window );">Reverse split fractional shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Reverse split fractional shares, shares</a></td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1', window );">Deemed dividend related to warrants down round provision</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">12,937<span></span>
</td>
<td class="num">(12,937)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,613,074)<span></span>
</td>
<td class="num">(13,201)<span></span>
</td>
<td class="num">(10,626,275)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">121,234,195<span></span>
</td>
<td class="num">(121,557,074)<span></span>
</td>
<td class="num">(328,409)<span></span>
</td>
<td class="num">(651,267)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="nump">209,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Settlement of restricted stock units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Settlement of restricted stock units, shares</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible notes</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">1,168,595<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,168,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversions of convertible notes, shares</a></td>
<td class="nump">49,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,702<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Public offering</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">1,669,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,670,001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Public offering, net, shares</a></td>
<td class="nump">236,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">110,723<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">110,723<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants', window );">Issuance of common stock upon exercise of warrants</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">2,433,066<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,433,080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares', window );">Issuance of common stock upon exercise of warrants, shares</a></td>
<td class="nump">139,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_StockIssuedDuringPeriodValueReverseStockSplits', window );">Reverse split fractional shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Reverse split fractional shares, shares</a></td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1', window );">Deemed dividend related to warrants down round provision</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">290<span></span>
</td>
<td class="num">(290)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7,986,935)<span></span>
</td>
<td class="num">(74)<span></span>
</td>
<td class="num">(7,987,009)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_IssuanceOfCommonStockUponWarrantInducements', window );">Issuance of common stock upon warrant inducements</a></td>
<td class="nump">$ 72<span></span>
</td>
<td class="nump">8,103,870<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,103,942<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_IssuanceOfCommonStockUponWarrantInducementsShares', window );">Issuance of common stock upon warrant inducements , shares</a></td>
<td class="nump">720,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_TransactionCostsAssociatedWithPublicOfferingAndWarrantInducements', window );">Transaction costs associated with public offering and warrant inducements</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,468,131)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,468,131)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 136<span></span>
</td>
<td class="nump">$ 133,252,585<span></span>
</td>
<td class="num">$ (129,544,299)<span></span>
</td>
<td class="num">$ (328,483)<span></span>
</td>
<td class="nump">$ 3,379,939<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2024</a></td>
<td class="nump">1,355,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENSC_IssuanceOfCommonStockUponWarrantInducements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock upon warrant inducements, value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENSC_IssuanceOfCommonStockUponWarrantInducements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENSC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENSC_IssuanceOfCommonStockUponWarrantInducementsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock upon warrant inducements , shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENSC_IssuanceOfCommonStockUponWarrantInducementsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENSC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period issuance of common stock upon exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENSC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period issuance of common stock upon exercise of warrants, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENSC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENSC_StockIssuedDuringPeriodSharesCommitmentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares commitment fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENSC_StockIssuedDuringPeriodSharesCommitmentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENSC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENSC_StockIssuedDuringPeriodValueCommitmentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value commitment fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENSC_StockIssuedDuringPeriodValueCommitmentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENSC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENSC_StockIssuedDuringPeriodValueReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse stock splits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENSC_StockIssuedDuringPeriodValueReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENSC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENSC_TransactionCostsAssociatedWithPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction cost associated with public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENSC_TransactionCostsAssociatedWithPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENSC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENSC_TransactionCostsAssociatedWithPublicOfferingAndWarrantInducements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction costs associated with public offering and warrant inducements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENSC_TransactionCostsAssociatedWithPublicOfferingAndWarrantInducements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENSC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in equity for down round feature triggered for warrant classified as equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231326272048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (7,987,009)<span></span>
</td>
<td class="num">$ (10,626,275)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Accrued interest</a></td>
<td class="nump">43,927<span></span>
</td>
<td class="nump">18,648<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of orginal issue discount and debt issuance costs</a></td>
<td class="nump">1,197,200<span></span>
</td>
<td class="nump">326,151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_LossOnConversionsAndChangeInFairValueOfConvertibleNotes', window );">Loss on conversions and change in fair value of convertible notes</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(146,479)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_ChangeInFairValueOfLiabilityClassifiedWarrants', window );">Change in fair value of liability classified warrants</a></td>
<td class="num">(16,292)<span></span>
</td>
<td class="num">(283,958)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">110,723<span></span>
</td>
<td class="nump">879,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForLoanLeaseAndOtherLosses', window );">Lease cost</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(150)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_IncreaseDecreaseInUnbilledReceivable', window );">Unbilled receivable</a></td>
<td class="num">(26,554)<span></span>
</td>
<td class="nump">179,260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther', window );">Prepaid expenses and other assets</a></td>
<td class="num">(251,965)<span></span>
</td>
<td class="nump">1,392,181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(578,928)<span></span>
</td>
<td class="num">(1,234,287)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">6,198<span></span>
</td>
<td class="num">(1,284,233)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(7,502,700)<span></span>
</td>
<td class="num">(10,779,982)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from public offerings, net</a></td>
<td class="nump">1,670,001<span></span>
</td>
<td class="nump">9,050,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercises</a></td>
<td class="nump">2,433,080<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_ProceedsFromWarrantInducementNetOfIssuanceCosts', window );">Proceeds from warrant inducement, net of issuance costs</a></td>
<td class="nump">8,103,942<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_TransactionCostsFromPublicOfferings', window );">Transaction costs from public offerings</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(447,879)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_TransactionCostAssociatedWithWarrantInducement', window );">Transaction costs associated with public offering and warrant inducements</a></td>
<td class="num">(1,468,131)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,605,635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayment of convertible notes</a></td>
<td class="num">(485,190)<span></span>
</td>
<td class="num">(1,000,208)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_RepaymentInsurancePremiums', window );">Repayment of financed insurance premiums</a></td>
<td class="num">(372,529)<span></span>
</td>
<td class="num">(451,668)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">9,881,173<span></span>
</td>
<td class="nump">8,755,884<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">2,378,473<span></span>
</td>
<td class="num">(2,024,098)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents beginning of period</a></td>
<td class="nump">1,123,604<span></span>
</td>
<td class="nump">3,147,702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents end of period</a></td>
<td class="nump">3,502,077<span></span>
</td>
<td class="nump">1,123,604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income tax payments</a></td>
<td class="nump">3,200<span></span>
</td>
<td class="nump">3,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_IncrementalFairValueOfWarrantInducement1', window );">Incremental fair value of August 2024 Warrant Inducement</a></td>
<td class="nump">10,210,616<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_IncrementalFairValueOfWarrantInducement2', window );">Incremental fair value of February 2024 Warrant Inducement</a></td>
<td class="nump">5,167,372<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_ConversionsOfConvertibleNotesIntoCommonStock', window );">Conversion of convertible notes into common stock</a></td>
<td class="nump">1,168,600<span></span>
</td>
<td class="nump">3,056,892<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_OriginalDebtDiscountFromConvertibleNotes', window );">Original debt discount from convertible notes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">136,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_DebtDiscountFromWarrantsIssuance', window );">Debt discount from warrants issuance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,066,483<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_IssuanceCostFromConvertibleNotes', window );">Issuance cost from convertible notes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">226,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_FinancedInsurancePremiums', window );">Financed insurance premiums</a></td>
<td class="nump">232,155<span></span>
</td>
<td class="nump">445,737<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_SettlementOfCommitmentFeeInShares', window );">Settlement of commitment fee in shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_DeemedDividendRelatedToWarrantsDownRoundProvision', window );">Deemed dividend related to warrants down round provision</a></td>
<td class="nump">$ 290<span></span>
</td>
<td class="nump">$ 12,937<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENSC_ChangeInFairValueOfLiabilityClassifiedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of liability classified warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENSC_ChangeInFairValueOfLiabilityClassifiedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENSC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENSC_ConversionsOfConvertibleNotesIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversions of convertible notes into common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENSC_ConversionsOfConvertibleNotesIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENSC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENSC_DebtDiscountFromWarrantsIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt discount from warrants issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENSC_DebtDiscountFromWarrantsIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENSC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENSC_DeemedDividendRelatedToWarrantsDownRoundProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend related to warrants down round provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENSC_DeemedDividendRelatedToWarrantsDownRoundProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENSC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENSC_FinancedInsurancePremiums">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financed insurance premiums.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENSC_FinancedInsurancePremiums</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENSC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENSC_IncreaseDecreaseInUnbilledReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in unbilled receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENSC_IncreaseDecreaseInUnbilledReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENSC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENSC_IncrementalFairValueOfWarrantInducement1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incremental fair value of warrant inducement1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENSC_IncrementalFairValueOfWarrantInducement1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENSC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENSC_IncrementalFairValueOfWarrantInducement2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incremental fair value of warrant inducement2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENSC_IncrementalFairValueOfWarrantInducement2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENSC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENSC_IssuanceCostFromConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance cost from convertible notes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENSC_IssuanceCostFromConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENSC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENSC_LossOnConversionsAndChangeInFairValueOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss on conversions and change in fairvalue of convertible notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENSC_LossOnConversionsAndChangeInFairValueOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENSC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENSC_OriginalDebtDiscountFromConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Original debt discount from convertible notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENSC_OriginalDebtDiscountFromConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENSC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENSC_ProceedsFromWarrantInducementNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from warrant inducement, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENSC_ProceedsFromWarrantInducementNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENSC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENSC_RepaymentInsurancePremiums">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayment of insurance premiums.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENSC_RepaymentInsurancePremiums</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENSC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENSC_SettlementOfCommitmentFeeInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Settlement of commitment fee in shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENSC_SettlementOfCommitmentFeeInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENSC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENSC_TransactionCostAssociatedWithWarrantInducement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction cost associated with warrant inducement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENSC_TransactionCostAssociatedWithWarrantInducement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENSC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENSC_TransactionCostsFromPublicOfferings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction costs from public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENSC_TransactionCostsFromPublicOfferings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENSC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpensesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForLoanLeaseAndOtherLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related loan transactions, lease transactions, credit loss from transactions other than loan and lease transactions, and other loss based on assessment of uncollectability from the counterparty to reduce the account to their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForLoanLeaseAndOtherLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231325307792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231326935824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_904_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20240101__20241231_zUKS2abTeTnl">We
have developed and implemented cybersecurity risk management <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90E_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_zHF0Co8bNU5i">processes</span> intended to protect the confidentiality, integrity and availability
of our critical systems and information.</span></span>Our
cybersecurity risk management program includes:<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">physical,
    technological and administrative controls intended to support our cybersecurity and data governance framework, including protections
    designed to protect the confidentiality, integrity and availability of our key information systems;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">risk
    assessments designed to help identify material cybersecurity risks to our critical systems and information;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">designated
    team members are responsible for managing our cybersecurity risk assessment processes, our security controls, and our response to
    cybersecurity incidents; and</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_900_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240101__20241231_zcYWaDPcQxKl">the
    use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of our security controls.</span><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_903_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_c20240101__20241231_zVdSnzIvXkNe">We
have <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90B_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20240101__20241231_zfiiJoTFjLdl">no</span>t identified risks from known cybersecurity threats that have materially affected or are reasonably likely to materially affect
us, including our operations, business strategy, results of operations, or financial condition</span>. See Item 1A. &#8220;Risk Factors &#8211;
Cyber-attacks or other failures in our telecommunications or information technology systems, or those of our collaborators, CROs,
third-party logistics providers, distributors or other contractors or consultants, could result in information theft, data corruption
and significant disruption of our business operations.&#8221;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">We
have developed and implemented cybersecurity risk management <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90E_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_zHF0Co8bNU5i">processes</span> intended to protect the confidentiality, integrity and availability
of our critical systems and information.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</a></td>
<td class="text">We
have <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90B_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20240101__20241231_zfiiJoTFjLdl">no</span>t identified risks from known cybersecurity threats that have materially affected or are reasonably likely to materially affect
us, including our operations, business strategy, results of operations, or financial condition<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board considers cybersecurity risk as part of its risk oversight function. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_904_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_c20240101__20241231_zoYYvSunh82i">The <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_905_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_dbT_c20240101__20241231_zqU5TW3cZ1Y8">Audit Committee</span> oversees our cybersecurity and other information
technology risks and management&#8217;s implementation of our cybersecurity risk management program</span>. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_907_ecyd--CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_c20240101__20241231_zELxueJrRiN1">The Audit Committee receives periodic
reports from management on our cybersecurity risks. In addition, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90E_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_dbT_c20240101__20241231_zGUxsf9VJjVe">management</span> updates the Board and the Audit Committee, as necessary,
regarding any material cybersecurity incidents, as well as any incidents with lesser impact potential.</span></span><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90B_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240101__20241231_zdeUgQwC1NF9">Our
management team, including our Chief Financial Officer, is responsible for assessing and managing our material risks from cybersecurity
threats.</span> Our Chief Financial Officer has primary responsibility for our overall cybersecurity risk management program. Our Chief Financial
Officer has experience supervising and managing company information technology departments.Our
management team supervises efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means,
which may include briefings from external security personnel; threat intelligence and other information obtained from governmental, public
or private sources; and alerts and reports produced by security tools deployed in the information technology environment.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Our
management team, including our Chief Financial Officer, is responsible for assessing and managing our material risks from cybersecurity
threats.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text">The <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_905_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_dbT_c20240101__20241231_zqU5TW3cZ1Y8">Audit Committee</span> oversees our cybersecurity and other information
technology risks and management&#8217;s implementation of our cybersecurity risk management program<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text">The Audit Committee receives periodic
reports from management on our cybersecurity risks. In addition, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90E_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_dbT_c20240101__20241231_zGUxsf9VJjVe">management</span> updates the Board and the Audit Committee, as necessary,
regarding any material cybersecurity incidents, as well as any incidents with lesser impact potential.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231326179120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND PRINCIPAL ACTIVITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">ORGANIZATION AND PRINCIPAL ACTIVITIES</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zdVDDbnm08oh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1 &#8211; <span id="xdx_82A_z1F2juPiW7ai">ORGANIZATION AND PRINCIPAL ACTIVITIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ensysce
Biosciences, Inc. (&#8220;Ensysce&#8221;), along with its <span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EBIRIncMember_zGfKa5m4dwXc" title="Ownership percentage">79.2</span>%-owned subsidiary, EBIR, Inc. (&#8220;EBIR&#8221;, formerly known as Covistat,
Inc.) and its wholly-owned subsidiaries EBI Operating, Inc. and EBI OpCo, Inc. (collectively, the &#8220;Company&#8221;), is a clinical-stage
biotech company using its proprietary technology platforms to develop safer prescription drugs. The primary focus of the Company is its
program developing abuse and overdose resistant pain technology with a clinical stage program being the abuse resistant, TAAP (Trypsin
Activated Abuse Protection) opioid product candidate, PF614. In addition, the Company is developing its MPAR&#174; (Multi-Pill Abuse Resistant)
technology for overdose protection which will be applied to the PF614 program. The Company is also applying its TAAP and MPAR&#174; technology
to a methadone prodrug for use in the treatment of Opioid Use Disorder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2020, the Company commenced an initiative to develop a therapeutic for the treatment of certain coronavirus infections through the formation
of a separate entity, EBIR, a Delaware corporation. Pursuant to the articles of incorporation, EBIR was authorized to issue <span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20201231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EBIRIncMember_zHhfUxzBMnxf" title="Common stock, shares authorized">1,000,000</span>
shares of common stock, $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20201231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EBIRIncMember_z20W3jsIvVhi" title="Common stock, par value">0.001</span> par value per share, and <span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20201231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EBIRIncMember_zfEbD7IYdRQ7" title="Preferred stock, shares authorized">100,000</span> shares of preferred stock, $<span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pp3d_c20201231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EBIRIncMember_zO5JsYwZgeO6" title="Preferred stock, par value">0.001</span> par value per share. Ensysce is a <span id="xdx_901_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EBIRIncMember_zkuWFW9jSI79" title="Ownership percentage">79.2</span>%
stockholder in EBIR, with <span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20241231__srt--TitleOfIndividualAxis__custom--KeyPersonnelMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EBIRIncMember_zd9VSnMZrrCj" title="Ownership percentage">19.8</span>% and <span id="xdx_901_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20241231__srt--TitleOfIndividualAxis__custom--UnrelatedPartyMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EBIRIncMember_zBPTRgK0rZAg" title="Ownership percentage">1.0</span>% of the shares held by certain key personnel of the Company and an unrelated party, respectively.
The non-Ensysce owned shares and the activity are reflected on the financial statements as noncontrolling interests.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231326080352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">BASIS OF PRESENTATION</a></td>
<td class="text"><p id="xdx_803_eus-gaap--BasisOfAccounting_zTa9y2uZumCd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 - <span id="xdx_82F_z2pKzmMjd7Xk">BASIS OF PRESENTATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States
of America (&#8220;GAAP&#8221;) and pursuant to the rules and regulations of the United States Securities Exchange Commission (&#8220;SEC&#8221;).
The consolidated financial statements include the accounts of Ensysce Biosciences, Inc. and its subsidiaries. All intercompany balances
and transactions have been eliminated in the consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reverse
Stock Split</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2023, the Company completed a <span id="xdx_90F_eus-gaap--StockholdersEquityReverseStockSplit_c20230301__20230331_zTRBRKzcP2F2" title="Reverse stock split">1-for-12</span> reverse split of its outstanding common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2024, the Company completed a <span id="xdx_900_eus-gaap--StockholdersEquityReverseStockSplit_c20241201__20241231_zoFw0d9CiXJ4" title="Reverse stock split">1-for-15</span> reverse split of its outstanding common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
references in these consolidated financial statements to shares and per share amounts in all periods have been retrospectively restated
to reflect the effects of both reverse splits noted above. The number of authorized shares and the par value of the shares did not change
as a result of the reverse stock splits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going
Concern</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates,
among other things, the realization of assets and satisfaction of liabilities in the normal course of business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not generated any product revenue. There is no assurance that profitable operations will ever be achieved, and, if achieved,
would be sustained on a continuing basis. Product development activities, clinical and pre-clinical testing, and commercialization of
the Company&#8217;s product candidates are necessary to develop the Company&#8217;s products and will require significant additional
financing. There can be no assurance the Company will be able to obtain such funds. These matters, among others, raise substantial doubt
about the Company&#8217;s ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the Company believes in the viability of its strategy to ultimately realize revenues and in its ability to raise additional funds, management
cannot be certain that additional funding will be available on acceptable terms, or at all. The Company&#8217;s ability to continue as
a going concern is dependent upon its ability to obtain adequate financing and achieve profitable operations. As a result, these plans
do not alleviate substantial doubt about the Company&#8217;s ability to continue as a going concern for a period of 12 months following
the date these consolidated financial statements were issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as
a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2in; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ensysce
Biosciences, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to the Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231326428032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_802_eus-gaap--SignificantAccountingPoliciesTextBlock_zJcd5sazGsg9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3 - <span id="xdx_82C_zF7s4AJ9g82f">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--UseOfEstimates_zveVvBY9DfX5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zxqeiaUXWuV2">Use
of Estimates and Assumptions</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preparation
of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the
amounts reported in the consolidated financial statements and disclosed in the accompanying notes. Actual results may differ from those
estimates and such differences may be material to the consolidated financial statements. The more significant estimates and assumptions
by management include, but are not limited to, the expense recognition for certain accrued research and development services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z5Hk2uib2D14" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zygQMHvUosyg">Cash
and Cash Equivalents</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of the consolidated balance sheets and consolidated statements of cash flows, the Company considers all highly liquid instruments
with maturity of three months or less at the time of issuance to be cash equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_zo3lGgLiIgy9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 11pt; text-align: justify; text-indent: -11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zB4hMW0F5Oqf">Concentrations
of Credit Risk and Off-Balance Sheet Risk</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents are financial instruments that are potentially subject to concentrations of credit risk. The Company&#8217;s cash
and cash equivalents are deposited in accounts at large financial institutions and amounts currently exceed federally insured limits.
The Company has no financial instruments with off-balance sheet risk of loss. Additionally, the Company had a concentration in accounts
payable, as <span id="xdx_909_eus-gaap--ConcentrationRiskBenchmarkDescription_c20240101__20241231_zmw5YXQYZ8Hi" title="Concentration of risk, description">three and two research and development vendors made up greater than 10% individually, and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerMember_zEZI17ZmWnC8" title="Concentration of risk">74</span>% and <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerMember_zs976MComFLb" title="Concentration of risk">38</span>% in aggregate</span>, of the
outstanding accounts payable balance as of December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zwleZMKpskh6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zaBuj1PHHCUh">Segments</span></i></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 11pt; text-align: justify; text-indent: -11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates and manages its business as <span id="xdx_901_eus-gaap--NumberOfReportableSegments_dc_uSegment_c20240101__20241231_zYDclMDTWv76" title="Number of reportable segments"><span id="xdx_904_eus-gaap--NumberOfOperatingSegments_dc_uSegment_c20240101__20241231_zSrs0LpfcAm6" title="Number of operating segments">one</span></span> reportable and operating segment. Operating segments are defined as components of an
enterprise where separate financial information is evaluated regularly by the chief operating decision maker (CODM) in deciding how to
allocate resources and assess performance. The Company&#8217;s CODM is the Chief Executive Officer, who reviews consolidated financial
information on a company-wide basis for purposes of allocating resources and assessing financial performance and does not regularly review
expenses or financial results on a more granular level.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zfuggtEVtZz8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zS2zZSGaYFt5">Property
and Equipment</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are fully depreciated as such there is <span id="xdx_902_eus-gaap--Depreciation_do_c20240101__20241231_zW34HL8zFf9k" title="Depreciation"><span id="xdx_904_eus-gaap--Depreciation_do_c20230101__20231231_z93sEe2bE0od" title="Depreciation">no</span></span> depreciation expense recognized in the years ended December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zgdfIF1FSFS" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.15in; text-align: justify; text-indent: -0.15in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_z2J6dQFu7Vl3">Fair
Value Measurement</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
820, <i>Fair Value Measurements</i>, (&#8220;ASC 820&#8221;) provides guidance on the development and disclosure of fair value measurements.
Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset
or paid to transfer a liability in an orderly transaction between willing market participants at the measurement date. As such, fair
value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset
or a liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ensysce
Biosciences, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to the Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted
    prices in active markets for identical assets or liabilities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs
    other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable
    inputs which are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies,
    or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at
which to classify them for each reporting period. This determination requires significant judgments to be made by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024 and 2023, the recorded values of cash and cash equivalents, prepaid expenses, accounts payable, and accrued expenses
and other liabilities approximate their fair values due to the short-term nature of these items.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company issued liability classified warrants in connection with the issuance of the 2021 Notes and 2022 Notes. The warrants were liability
classified due to certain cash settlement features and included in &#8220;Other long-term liabilities&#8221; on the consolidated balance
sheets. The Company uses a Black Scholes model to estimate the fair value of the warrants. Changes in the fair value of the warrants
are recognized in other income (expense) for each reporting period. Refer to Note 8 for additional details of the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zqcg3Cg06c27" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables present assets and liabilities measured and recorded at fair value on the Company&#8217;s consolidated balance sheet
as of December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zTJxTK8lOqqa" style="display: none">SCHEDULE
OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_492_20241231_zbJyGlmmJLo3" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_494_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zoWIcGw7gQAd" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zVPzC8Y445B4" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z19LhJzyVOAf" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pp0p0_zSNe1jUc3jbb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left; padding-bottom: 1pt">Liability classified warrants</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">10,096</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0639">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0640">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">10,096</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_z8S9YHvRoyU7" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,096</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0644">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0645">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,096</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20231231_zIgq62KQtgkl" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_492_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zOVXH1TTIcnf" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zWv1Jl7p1Noe" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_496_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zIhTClXTKzl7" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pp0p0_zPGmgVRe3Otf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left; padding-bottom: 1pt">Liability classified warrants</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">26,388</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0649">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0650">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">26,388</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_z5k42qIGqpu4" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">26,388</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0654">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0655">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">26,388</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_z6ZttRgJPGj8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ensysce
Biosciences, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to the Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zErV5LTICKG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the change in fair value of the Company&#8217;s Level 3 liabilities for the year ended December 31, 2024 (no
level 3 assets as of the year ended December 31, 2024):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_z5EbIprVn8Ke" style="display: none">SCHEDULE
OF CHANGE IN FAIR VALUE OF COMPANY&#8217;S LEVEL 3</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Liability classified warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Fair value, December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pp0p0_c20240101__20241231__us-gaap--FairValueByLiabilityClassAxis__custom--LiabilityClassifiedWarrantsMember_zV4N38CxRu87" style="width: 16%; text-align: right" title="Beginning balance">26,388</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_pp0p0_c20240101__20241231__us-gaap--FairValueByLiabilityClassAxis__custom--LiabilityClassifiedWarrantsMember_zKkx2wpiMFZb" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value">(16,292</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Fair value, December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pp0p0_c20240101__20241231__us-gaap--FairValueByLiabilityClassAxis__custom--LiabilityClassifiedWarrantsMember_zLQych732CG3" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">10,096</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_zWYSi7SyxWI1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Federal
Grants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2019, the NIH/NIDA awarded the Company a second research and development grant related to the development of its TAAP/MPAR
abuse deterrent technology for Opioid Use Disorder (the &#8220;OUD Grant&#8221;). The total approved budget was approximately $<span id="xdx_90D_eus-gaap--GrantsReceivable_iI_pn5n6_c20190930_zncQAFem5bdf" title="Grants receivable">5.4</span> million,
and the grant period ended August 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2018, the National Institutes of Health (&#8220;NIH&#8221;) through the National Institute on Drug Abuse (&#8220;NIDA&#8221;)
awarded the Company a research and development grant related to the development of its MPAR<sup>&#174;</sup> overdose prevention technology
(the &#8220;MPAR Grant&#8221;). The initial grant was extended several times and cumulative funding under this grant of approximately
$<span id="xdx_90B_eus-gaap--GrantsReceivable_iI_pn5n6_c20231231_zRI4sbUT3RDh" title="Grants receivable">10.7</span> million was completed in December 2023. A new multi-year MPAR Grant was awarded by NIH through NIDA in August 2024, providing total
funding of $<span id="xdx_902_eus-gaap--GrantsReceivable_iI_pn6n6_c20240831_zI3h2GAO9uSi" title="Grants receivable">14</span> million through May 2027. As December 31, 2024, the remaining cash funding under the grant is $<span id="xdx_90D_eus-gaap--GrantsReceivable_iI_pn5n6_c20241231_zYzjz6bhtdqk" title="Grants receivable">1.6</span> million, covering the
period through May 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes revenue when costs related to the grants are incurred and assessed as reimbursable. The Company believes this policy
is consistent with the overarching premise in Accounting Standards Codification Topic 606, <i>Revenue from Contracts with </i>Customers
(&#8220;ASC 606&#8221;), applied by analogy, to ensure that it recognizes revenues to reflect the transfer of promised goods or services
to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services,
even though there is no &#8220;exchange&#8221; as defined in ASC 606. The Company believes the recognition of revenue as costs are incurred
and reimbursable amounts become due is analogous to the concept of transfer of control of a service over time under ASC 606.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_898_ecustom--ScheduleOfRevenueRecognitionUnderGrantsTableTextBlock_zvfS50tgNAKh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
revenue recognized under the MPAR Grant and OUD Grant was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zICynLUDum6k" style="display: none">SCHEDULE
OF REVENUE RECOGNITION UNDER GRANTS</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20240101__20241231_zQTKndyhkRdl" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20230101__20231231_zOdYbHvG8Kqa" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_hsrt--ProductOrServiceAxis__custom--MPARMember_zflyx04Dq5Cg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">MPAR</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">3,086,464</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,293,238</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_hsrt--ProductOrServiceAxis__custom--TAAPOUDMember_zl7OjoxNxWKk" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">TAAP/OUD</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,123,567</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">937,282</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_zIJOxmHgytAa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,210,031</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,230,520</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zrt76Hy71T1h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts
requested or eligible to be requested through the NIH payment management system, but for which cash has not been received, are presented
as an unbilled receivable on the Company&#8217;s consolidated balance sheet. As all amounts are expected to be remitted timely, no valuation
allowances are recorded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ensysce
Biosciences, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to the Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_843_eus-gaap--ResearchAndDevelopmentExpensePolicy_zPwxZtQDdRsd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span><span><span id="xdx_864_zuSnCCjjiYI4">Research
and Development Costs</span></span></span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s research and development expenses consist primarily of third-party research and development expenses, consulting expenses,
preclinical and clinical studies, and any allocable direct overhead, including facilities and depreciation costs, as well as salaries,
payroll taxes, and employee benefits for those individuals directly involved in ongoing research and development efforts. Research and
development expenses are charged to expense as incurred. Payments made prior to the receipt of goods or services to be used in research
and development are capitalized until the goods or services are received.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zvJ1IjIA6APg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zcuFmWgXI5g4">General
and Administrative Expenses</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of personnel costs associated with the Company&#8217;s executive, finance, human resources,
compliance, and other administrative personnel, as well as accounting and legal professional services fees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zucMljGhmxLj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zWpvL49RS8d6">Stock-based
Compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expenses stock-based compensation over the requisite service period based on the estimated grant-date fair value of the awards
using a graded amortization approach. The Company accounts for forfeitures as they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company estimates the fair value of stock option grants using the Black-Scholes option pricing model. The assumptions used in calculating
the fair value of stock-based awards represent management&#8217;s best estimates and involve inherent uncertainties and the application
of management&#8217;s judgment. Stock-based compensation costs are recorded in research and development and general and administrative
expenses in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time-to-time equity classified awards may be modified. On the modification date, the Company estimates the fair value of the awards immediately
before and immediately after modification. The incremental increase in fair value is recognized as expense immediately to the extent
the underlying equity awards are vested and on a straight-line basis over the same remaining amortization schedule as the unvested underlying
equity awards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_z5abU6pNVae4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_z9agJgAiu3sl">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
taxes are recorded in accordance with ASC 740, <i>Income Taxes</i> (&#8220;ASC 740&#8221;), which provides for deferred taxes using an
asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of
events that have been included in the consolidated financial statements or tax returns. Deferred tax assets and liabilities are determined
based on the difference between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates
in effect for the year in which the differences are expected to reverse. Valuation allowances are provided if, based upon the weight
of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company
recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination
by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical
merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and
penalties accrued related to unrecognized tax benefits as income tax expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ensysce
Biosciences, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to the Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zpbniCRCshqg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zA7mwy9Prx82">Earnings
per Share</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
basic earnings per share is calculated by dividing the Company&#8217;s net income or loss attributable to common stockholders by the
weighted average number of common shares outstanding during the period. The diluted earnings per share is calculated by dividing the
Company&#8217;s net earnings attributable to common stockholders by the diluted weighted average number of common shares outstanding
during the period, determined using the treasury stock method and the average stock price during the period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ztFHVlIk9OWh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following weighted average shares have been excluded from the calculations of diluted weighted average common shares outstanding because
they would have been anti-dilutive (the Company has utilized the principal balance outstanding and the end of period conversion price
for the Convertible Notes for the purposes of the weighted average share calculation below):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zZtpZSMxpsv6" style="display: none">SCHEDULE
OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20240101__20241231_zA7NsW5MKaOk" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_497_20230101__20231231_zqx6boqTHPy5" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zfqHftzvbIn6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right">38,734</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right">8,784</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zXL6kro0wmf2" style="vertical-align: bottom; background-color: White">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">551,287</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">253,208</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zwgsLK7HnB17" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Convertible Notes</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">9,187</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">78,086</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zqIJ72JozqZj" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">599,208</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">340,078</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_ze8nSfeAfvJ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zIzPEraSHQZ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zsxBNeZKd276">Recently
Issued Accounting Pronouncements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the FASB issued ASU 2023-07, &#8220;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&#8221;,
which sets forth improvements to the current segment disclosure requirements in accordance with Topic 280 &#8220;Segment Reporting,&#8221;
including clarifying that entities with a single reportable segment are subject to both new and existing segment reporting requirements.
ASU 2023-07 will be effective retrospectively for fiscal years beginning after December 15, 2023, and interim periods beginning after
December 15, 2024. The Company adopted the standard with an effective date of January 1, 2024 and the adoption did not have a significant
impact on the consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued ASU No. 2023-09, &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&#8221; ASU 2023-09
requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as information on income
taxes paid. ASU 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted.
The Company is currently evaluating the impact of this guidance on its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU 2024-03, Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement Expenses (&#8220;ASU 2024-03&#8221;), which requires disclosure about the types
of costs and expenses included in certain expense captions presented on the income statement. The new disclosure requirements are effective
for the Company&#8217;s annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with
early adoption permitted. The Company is currently evaluating the impact of this pronouncement on our related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU 2024-04, &#8220;Debt &#8211; Debt with Conversion and other Options (Subtopic 470-20) &#8220;, which
set forth to improve the relevance and consistency in the application of induced conversion guidance in Subtopic 470-20, Debt&#8212;
Debt with Conversion and Other Options such as clarifying the requirements for determining whether certain settlements of convertible
debt instruments should be accounted for as an induced conversion. ASU 2024-04 is effective for all entities after December 15, 2025,
with early adoption permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.</span></p>

<p id="xdx_85E_zryUSNiPk6R6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ensysce
Biosciences, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to the Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231327404688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">PREPAID EXPENSES AND OTHER CURRENT ASSETS</a></td>
<td class="text"><p id="xdx_808_eus-gaap--OtherCurrentAssetsTextBlock_ziQn7hWltTf9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4 &#8211; <span id="xdx_82E_zeFWHpBN5mVb">PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zhZWYehENRfl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses and other current assets consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zTOmKgfzXjV4" style="display: none">SCHEDULE
OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_497_20241231_zsJ6JB7ZzWE8" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_497_20231231_zOg38WjypbNl" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_ecustom--PrepaidResearchAndDevelopment_iI_pp0p0_maOPECzDNl_zX69uge2qLT5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Prepaid research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,342,461</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">535,474</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PrepaidInsurance_iI_pp0p0_maOPECzDNl_z3i4vqRGFku3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">315,306</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">441,871</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0p0_maOPECzDNl_zMlmPQ5H6G54" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,723</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72,358</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherAssetsCurrent_iI_pp0p0_maOPECzDNl_zEOzzEPap5c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Other current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">18,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">18,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PrepaidExpenseCurrent_iTI_pp0p0_mtOPECzDNl_zJP3hFCAOgRf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,718,490</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,067,703</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p id="xdx_8A8_z3lPfhNaewUg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231326397392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES AND OTHER LIABILITIES</a></td>
<td class="text"><p id="xdx_803_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zcxvTJ4bKsV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5 &#8211; <span id="xdx_82B_zrybOIUkKSZ7">ACCRUED EXPENSES AND OTHER LIABILITIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zyYzX8ee1iMg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses and other liabilities consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_z2VFAiYHpf8d" style="display: none">SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20241231_z6UyDzuT5hZk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20231231_znNSDBaLHgx5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_ecustom--AccruedResearchAndDevelopment_iI_maALAOLzFDV_zzYz7el2CYQ6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Accrued research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">324,521</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">329,228</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AccruedProfessionalFeesCurrentAndNoncurrent_iI_maALAOLzFDV_zKpDrbEp3Pu4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">88,995</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">110,202</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherAccruedLiabilitiesCurrentAndNoncurrent_iI_maALAOLzFDV_znsy9GWYpIvc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other accrued liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">134,942</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">102,830</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iTI_mtALAOLzFDV_z799HnM7bElk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total accrued expenses and other liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">548,458</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">542,260</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zRQSHJP66Pq1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_8A1_zoP5PQLzdP51" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231326160416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p id="xdx_804_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zh3ulZPAYho4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6 - <span id="xdx_82B_zHeM1V6AEDC3">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Purchase
Commitments</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the Company&#8217;s commitments included an estimated $<span id="xdx_903_eus-gaap--ContractualObligation_iI_pn5n6_c20241231_z1LgkISEQIgg" title="Contractual obligation">12.0</span> million related to the Company&#8217;s open purchase
orders and contractual obligations that occurred in the ordinary course of business, including commitments with contract research organizations
for multi-year pre-clinical and clinical research studies. Although open purchase orders are considered enforceable and legally binding,
the terms generally allow the Company the option to cancel, reschedule, and adjust its requirements based on its business needs prior
to the delivery of goods or the performance of services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Litigation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024 and 2023, there were no pending legal proceedings against the Company that are expected to have a material adverse
effect on cash flows, financial condition or results of operations. From time to time, the Company could become involved in disputes
and various litigation matters that arise in the normal course of business. These may include disputes and lawsuits related to intellectual
property, licensing, contract law and employee relations matters. Periodically, the Company reviews the status of significant matters,
if any exist, and assesses its potential financial exposure. If the potential loss from any claim or legal claim is considered probable
and the amount can be estimated, the Company accrues a liability for the estimated loss. Legal proceedings are subject to uncertainties,
and the outcomes are difficult to predict. Because of such uncertainties, accruals are based on the best information available at the
time. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ensysce
Biosciences, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to the Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Lease</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s current lease agreement (as amended) has a term that extends through October 31, 2025, with no option to renew. As of
December 31, 2024, the future lease payments totaled $<span id="xdx_901_eus-gaap--OperatingLeasePayments_c20240101__20241231_zGXcYyDsqZOc" title="Future lease payments">29,545</span>. The Company recognized total rent expense of $<span id="xdx_90E_eus-gaap--PaymentsForRent_c20240101__20241231_zaHvxCpJFsFh" title="Rent expense">35,217</span> and $<span id="xdx_903_eus-gaap--PaymentsForRent_c20230101__20231231_z6crpAeTybtj" title="Rent expense">33,747</span> in the
year ended December 31, 2024, and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231330821136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTES PAYABLE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">NOTES PAYABLE</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--DebtDisclosureTextBlock_ztHWQcqbfxh3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7 - <span id="xdx_82B_zg5VubIMHgea">NOTES PAYABLE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfDebtTableTextBlock_zRdvCmgkuhr1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a summary of the Company&#8217;s outstanding debt as of December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_zxqkAlQYmA68" style="display: none">SCHEDULE OF DEBT</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Principal balance</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accrued interest</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net debt balance</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%">2023 Notes</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zU60fbBhchl5" style="width: 14%; text-align: right" title="Principal balance">216,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zQwwIJ88fsjb" style="width: 14%; text-align: right" title="Accrued interest">14,368</td><td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_pp0p0_di_c20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zvNzNBWlPKJd" style="width: 2%" title="Unamortized Debt Discount &amp; Issuance Costs">&#160;<span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,197,200</span></td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--NotesPayable_iI_pp0p0_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zYbjz8oyRlw3" style="width: 14%; text-align: right" title="Net debt balance">230,368</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Financed insurance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20241231__us-gaap--DebtInstrumentAxis__custom--FinancedInsuranceMember_zi1MOHF1prN" style="border-bottom: Black 1pt solid; text-align: right" title="Principal balance">71,292</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20241231__us-gaap--DebtInstrumentAxis__custom--FinancedInsuranceMember_zX7cjlkEPmle" style="border-bottom: Black 1pt solid; text-align: right" title="Accrued interest"><span style="-sec-ix-hidden: xdx2ixbrl0770">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--NotesPayable_iI_pp0p0_c20241231__us-gaap--DebtInstrumentAxis__custom--FinancedInsuranceMember_zjfPcpqvL9g2" style="border-bottom: Black 1pt solid; text-align: right" title="Net debt balance">71,292</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20241231_zN6dblsf1W9" style="border-bottom: Black 2.5pt double; text-align: right" title="Principal balance">287,292</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20241231_zbT8QYGR1xKj" style="border-bottom: Black 2.5pt double; text-align: right" title="Accrued interest">14,368</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--NotesPayable_iI_pp0p0_c20241231_zKyk7jAmrqDe" style="border-bottom: Black 2.5pt double; text-align: right" title="Net debt balance">301,660</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a summary of the Company&#8217;s outstanding debt as of December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>balance</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accrued</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>interest</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unamortized Debt</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Discount &amp; Issuance Costs</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net debt</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>balance</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">2023 Notes</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_z6ApS99mzxnd" style="width: 12%; text-align: right" title="Principal balance">1,836,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zuQoFuAWg6S2" style="width: 12%; text-align: right" title="Accrued interest">13,078</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_pp0p0_di_c20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zpsKqhY4hFsa" style="width: 12%; text-align: right" title="Unamortized Debt Discount &amp; Issuance Costs">(1,197,200</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--NotesPayable_iI_pp0p0_c20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zgo6IaYfBrL5" style="width: 12%; text-align: right" title="Net debt balance">651,878</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Financed insurance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20231231__us-gaap--DebtInstrumentAxis__custom--FinancedInsuranceMember_zZYBHGxwKeM3" style="border-bottom: Black 1pt solid; text-align: right" title="Principal balance">197,249</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20231231__us-gaap--DebtInstrumentAxis__custom--FinancedInsuranceMember_zOneN2YGSs8l" style="border-bottom: Black 1pt solid; text-align: right" title="Accrued interest">5,570</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_pp0p0_di_c20231231__us-gaap--DebtInstrumentAxis__custom--FinancedInsuranceMember_z3EUfu8HSr32" style="border-bottom: Black 1pt solid; text-align: right" title="Unamortized Debt Discount &amp; Issuance Costs"><span style="-sec-ix-hidden: xdx2ixbrl0792">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--NotesPayable_iI_pp0p0_c20231231__us-gaap--DebtInstrumentAxis__custom--FinancedInsuranceMember_zkf50oewR1ta" style="border-bottom: Black 1pt solid; text-align: right" title="Net debt balance">202,819</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20231231_z1UV83Pl5Crf" style="border-bottom: Black 2.5pt double; text-align: right" title="Principal balance">2,033,249</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20231231_zRKee8TWZVyd" style="border-bottom: Black 2.5pt double; text-align: right" title="Accrued interest">18,648</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_pp0p0_di_c20231231_zdnuLAFZdHMc" style="border-bottom: Black 2.5pt double; text-align: right" title="Unamortized Debt Discount &amp; Issuance Costs">(1,197,200</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--NotesPayable_iI_pp0p0_c20231231_zXNq56k5z4id" style="border-bottom: Black 2.5pt double; text-align: right" title="Net debt balance">854,697</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zan8qF5u4ao1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Interest
expense</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
interest expense recognized for financed insurance was $<span id="xdx_902_eus-gaap--InterestExpenseDebt_c20240101__20241231_zdv0ZCGKFl0l" title="Interest expense">8,848</span> and $<span id="xdx_90F_eus-gaap--InterestExpenseDebt_c20230101__20231231_zAxb6hqFheed" title="Interest expense">14,716</span> for the year ended December 31, 2024 and 2023, respectively.
Interest expense recognized for the 2023 Notes was $<span id="xdx_903_eus-gaap--InterestExpense_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zazvpgU2aZg8" title="Interest expense">1,281,597</span> and $<span id="xdx_907_eus-gaap--InterestExpense_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zETvqSJ1YjP7" title="Interest expense">339,230</span> for the year-ended December 31, 2024 and 2023, respectively,
which consists of amortization of the debt discount and debt issuance costs and accrued interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ensysce
Biosciences, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to the Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2023
Notes</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 23, 2023, the Company entered into a Securities Purchase Agreement (&#8220;SPA&#8221;) for an aggregate financing of $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfDebt_pn5n6_c20231022__20231023__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zp7p0hxFUQ73" title="Debt financing amount">1.8</span> million
with investors, including $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfDebt_pn5n6_c20231022__20231023__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zr1xVxeaqvL2" title="Debt financing amount">0.2</span> million with a board member. At the first closing under the SPA, which occurred on October 25, 2023, the
Company issued to the investors (i) senior secured convertible promissory notes in the aggregate principal amount of $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20231025__us-gaap--TypeOfArrangementAxis__custom--FirstClosingSecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zbbfr8W7tcdl" title="Aggregate principal amount">612,000</span> for an
aggregate purchase price of $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfDebt_c20231024__20231025__us-gaap--TypeOfArrangementAxis__custom--FirstClosingSecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zVTuPS6WcGU" title="Aggregate purchase price">566,667</span> and (ii) warrants to purchase <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231025__us-gaap--TypeOfArrangementAxis__custom--FirstClosingSecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_z0Hg2M4kvoJ3" title="Warrants to purchase common shares">83,714</span> shares of the Company&#8217;s common stock, par value $<span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231025__us-gaap--TypeOfArrangementAxis__custom--FirstClosingSecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zZNmyPVzSY92" title="Common stock, par value">0.0001</span>
per share in the aggregate. At the second closing under the SPA, which occurred on November 29, 2023, the Company issued to the investors
referenced above, (i) additional notes in the aggregate principal amount of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20231129__us-gaap--TypeOfArrangementAxis__custom--SecondClosingSecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zXh6GJVNDM2e" title="Aggregate principal amount">1,224,000</span> for an aggregate purchase price of $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfDebt_c20231129__20231129__us-gaap--TypeOfArrangementAxis__custom--SecondClosingSecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_znDCO1BygGmg" title="Aggregate purchase price">1,133,333</span>
and (i) additional warrants to purchase <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231129__us-gaap--TypeOfArrangementAxis__custom--SecondClosingSecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zMtyK4wa4mMg" title="Warrants to purchase common shares">167,427</span> shares of the common stock in the aggregate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reflected the outstanding principal amount, the remaining unamortized discount (both original issue discount and the relative
fair value discount associated with the warrants discussed below) and the remaining debt issuance costs as a net amount on the face of
the balance sheet. The amortization of the original debt discount (approximately $<span id="xdx_903_eus-gaap--AmortizationOfDebtDiscountPremium_pn5n6_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zZrOI3gczxp" title="Amortization of debt discount premium">0.1</span> million) and issuance costs (approximately $<span id="xdx_901_eus-gaap--AmortizationOfFinancingCosts_pn5n6_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_znoBURwnBXp" title="Amortization of financing costs">0.3</span>
million) were recorded as interest expense within the consolidated statements of operations. As of December 31, 2024, the original debt
discount and issuance costs were fully amortized to interest expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrants have an exercise price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231023__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zGQi6NF1g2of" title="Warrant, exercise price">23.5125</span>, the same as the conversion price, and are exercisable for five years following the issuance
date. The warrants were equity classified as they are indexed to the Company&#8217;s stock and only settleable in shares. The warrants
were initially measured at fair value using a Black-Scholes valuation model and were allocated along with the 2023 Notes using the relative
fair value method. The initial fair value of $<span id="xdx_904_eus-gaap--PaymentsOfDebtIssuanceCosts_pn5n6_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkykbIhTvnla" title="Payments of debt issuance costs">1.1</span> million allocated to the warrants was considered a debt discount and was amortized
to interest expense over the remaining term of the notes. As of December 31, 2024, the discount associated with the warrants was fully
amortized to interest expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2024, the Company converted <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20240101__20241231_z2O30PcjZcU9" title="Conversion of shares">49,702</span> shares of common stock with a conversion value of $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_pn5n6_c20240101__20241231_zle77cfFJId3" title="Conversion of shares value">1.2</span> million related to the 2023 Notes. In addition,
in connection with the SPA, the Company incurred a $<span id="xdx_90D_ecustom--ProceedsFromWarrantInducementNetOfIssuanceCosts_pn5n6_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zXFvSxJxpLnj" title="Transaction cost">1.0</span> million waiver fee as a result of the 2024 February Warrant Inducement (see Note
8) to pay down $<span id="xdx_904_ecustom--IssuanceOfCommonStockValueUponWarrantInducementNetOfIssuanceCosts_pn5n6_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zN8scmQ2jArc" title="Warrant inducement cost">0.5</span> million of the 2023 Notes and incurred $<span id="xdx_90D_ecustom--TransactionCostsAssociatedWithWarrantInducement_pn5n6_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zZEY9dScflk5" title="Transaction cost">0.5</span> million in transaction costs recorded as such in the consolidated statement
of stockholders&#8217; equity. As of December 31, 2024, the remaining amount of the 2023 Notes relates to senior secured convertible
promissory notes held by a Company board member (see Note 11).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Financed
Insurance Premiums</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2024, the Company renewed and financed its directors&#8217; and officers&#8217; liability insurance in the amount of $<span id="xdx_902_ecustom--FinancedInsurancePremiums_pn5n6_c20240601__20240630_zA0fv0x4kAt1" title="Financed insurance premiums">0.2</span> million.
Monthly payments are scheduled from July 2024 through March 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231327456384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text"><p id="xdx_809_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zWTGyPa8IOd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8 - <span><span id="xdx_82F_zYuABdEVbHF3">STOCKHOLDERS&#8217; EQUITY</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s current Certificate of Incorporation authorizes <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_c20241231_zrV2WUXLqlIf" title="Common stock, shares authorized">250,000,000</span> shares of common stock and <span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_c20241231_zteT8gZgWyJ4" title="Preferred stock, shares authorized">1,500,000</span> shares of preferred
stock, both with par value equal to $<span id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20241231_z9tCfdW3PySl" title="Preferred stock, par value">0.0001</span>. As of December 31, 2024, and December 31, 2023, there were <span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_do_c20241231_zGmajhTfvq3j" title="Preferred stock, shares issued"><span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20241231_z9Zb7qDoIgAa" title="Preferred stock, shares outstanding"><span id="xdx_904_eus-gaap--PreferredStockSharesIssued_iI_do_c20231231_zIDwjrdIbxD" title="Preferred stock, shares issued"><span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20231231_zBCrP6cNUYKd" title="Preferred stock, shares outstanding">no</span></span></span></span> shares of preferred stock
issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ensysce
Biosciences, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to the Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reverse
Stock Split</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 27, 2024, the Company filed an amendment to the Company&#8217;s Third Amended and Restated Certificate of Incorporation (as
amended to date, the &#8220;Certificate of Incorporation&#8221;), with the Secretary of State of the State of Delaware to effect a one-for-fifteen
(<span id="xdx_906_eus-gaap--StockholdersEquityReverseStockSplit_c20241127__20241127_z5RC4Vt5IaK" title="Reverse stock split">1-for-15</span>) reverse stock split (the &#8220;Reverse Stock Split&#8221;) of our common stock, par value $<span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20241127_zuinUQtztzPh" title="Common stock par value">0.0001</span> (the &#8220;Common Stock&#8221;).
The Reverse Stock Split was effective as of 12:01 am on December 6, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described in detail in our definitive proxy statement filed with the SEC on October 18, 2024, the Board authorized a <span id="xdx_90B_eus-gaap--StockholdersEquityReverseStockSplit_c20241018__20241018_z8x7qnNMc7Bg" title="Reverse stock split">1-for-15</span> reverse
stock split ratio and directed the implementation of the Reverse Stock Split. As a result of the Reverse Stock Split, at the Effective
Time, every fifteen (15) shares of our pre-Reverse Stock Split Common Stock will be combined and reclassified into one (1) share of our
Common Stock. The post-Reverse Stock Split Common Stock began trading on December 6, 2024, with a new CUSIP number of 293602504. The
Reverse Stock Split does not affect any stockholder&#8217;s ownership percentage of the Common Stock and does not change our authorized
number of shares, alter the par value of the Common Stock or modify any voting rights or other terms of the Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise prices, and the number of shares of Common Stock issuable upon exercise of the Company&#8217;s warrants automatically adjusted,
in accordance with their terms, in proportion to the Reverse Stock Split ratio, and proportionate adjustments were also made to the per
share exercise price and/or the number of shares issuable upon the exercise or vesting of all stock options and restricted stock unit
awards issued by the Company and outstanding immediately prior to the effective time of the Reverse Stock Split, which resulted in a
proportionate decrease in the number of shares of Common Stock reserved for issuance upon exercise or vesting of such stock options and
restricted stock unit awards, and a proportionate increase in the exercise price of all such stock options and restricted stock unit
awards. Concurrently, the number of shares reserved for issuance under the Company&#8217;s Amended and Restated 2021 Omnibus Incentive
Plan immediately prior to the effective time of the Reverse Stock Split were reduced proportionately.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
fractional shares were issued in connection with the Reverse Stock Split. In lieu of the issuance of fractional shares, the Company
rounded up any fractional shares resulting from the Reverse Stock Split to the nearest whole share. Fractional shares will be rounded
up at the participant (per broker) level, with such rounding adjustment subject to each broker&#8217;s particular processes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2024
Registered Direct Offering and 2024 August Warrant Inducement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2024, the Company entered into a definitive Securities Purchase Agreement with certain institutional investors, pursuant to which
the Company agreed to issue and sell in a registered direct offering, (i) an aggregate of <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240801__20240831__us-gaap--StatementEquityComponentsAxis__custom--RegisteredDirectOfferingMember_zMDPs6ZH6uFk" title="Purchase of shares through securities purchase agreement">166,054</span> shares of common stock, par value $<span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240831__us-gaap--StatementEquityComponentsAxis__custom--RegisteredDirectOfferingMember_zHrnkP27SJxk" title="Common stock, par value">0.0001</span>
per share at an offering price of $<span id="xdx_90F_eus-gaap--SharePrice_iI_c20240831__us-gaap--StatementEquityComponentsAxis__custom--RegisteredDirectOfferingMember_zHxXYICrGoab" title="Common stock, share price">7.05</span> per share, (ii) pre-funded warrants to purchase up to <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240801__20240831__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zyXM4NFckifa" title="Purchase of shares through securities purchase agreement">70,827</span> shares of common stock, at a price
per pre-funded warrant equal to $<span id="xdx_90A_eus-gaap--SharePrice_iI_c20240831__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_z0CawEybjKc" title="Common stock , share price">7.0485</span>, the price per share less $<span id="xdx_908_ecustom--AgentFeesAndOfferingExpensesPerShare_iI_c20240831__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zjvbuUdhoHZf" title="Agent fees and offering expenses , per share">0.0015</span>, for gross proceeds of approximately $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn4n6_c20240801__20240831__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zYP4YjzkYVr3" title="Common stock, gross proceeds">1.67</span> million before the
deduction of placement agent fees and offering expenses. The pre-funded warrants were subsequently exercised in full and were not outstanding
as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also entered into the August Inducement Letter with certain warrant holders for the exercise of certain outstanding warrants
to purchase up to an aggregate of <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240229__us-gaap--StatementEquityComponentsAxis__custom--SeriesAandBWarrantsMember_zWgE0XnKYRJg" title="Warrants to purchase shares">480,234</span> shares of common stock of the Company originally issued in February 2024, having an exercise
price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240229__us-gaap--StatementEquityComponentsAxis__custom--SeriesAandBWarrantsMember_zlFMkjGmzJ7j" title="Warrant, exercise price">15.90</span> per share, at a reduced exercise price of $<span id="xdx_905_eus-gaap--SharePrice_iI_pid_c20240229__us-gaap--StatementEquityComponentsAxis__custom--SeriesAandBWarrantsMember_zP21DxvwHphf" title="Share price">7.05</span> per share. The Company also agreed to amend certain existing warrants
to purchase up to an aggregate of <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231130_zR66BDEGu974" title="Warrants to purchase common shares">133,334 </span>shares of common stock that were previously issued in November 2023 and have an exercise price
of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231130_zzncqRn5F0J" title="Warrant, exercise price">23.51</span> per share such that the amended warrants will have a reduced exercise price of $<span id="xdx_900_eus-gaap--SharePrice_iI_pid_c20231130_z5UmzlHe2fW4" title="Share price">7.05</span> per share effective upon the closing of
the offering and will be exercisable from the date on which stockholder approval is received with respect to the issuance of the shares
of common stock issuable upon exercise of such warrants. As the existing November 2023 and February 2024 warrants and their related newly
issued warrants upon inducement were equity classified before and after the exchange, and as the exchange is directly attributable to
an equity offering, the Company recognized the effect of the modification of approximately $<span id="xdx_90C_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20240201__20240229_zGgjQRCV2e0l" title="Stock issuance costs">10.2</span> million as an equity issuance cost.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
a concurrent private placement, pursuant to the terms of the August Inducement Letter and Securities Purchase Agreement, the Company
utilized an exclusive placement agent for the 2024 Registered Direct Offering and 2024 August Warrant Inducement and incurred approximately
$<span id="xdx_90C_eus-gaap--LegalFees_pn5n6_c20240801__20240831_zd571bwMMWvg" title="Legal fees">0.6</span> million in legal fees and other closing costs. Additionally, <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240801__20240831_zyLPZZZ75MEc" title="Warrants issue, description">the Company issued to the placement agent as compensation unregistered
warrants to purchase up to <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20240831_zjVKmcCjhfUk" title="Warrants to purchase common stock">50,200</span> shares of Common Stock.</span> The placement agent warrants expire on <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_pid_dd_c20240831__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjj8096w4L91" title="Warrant maturity date">August 28, 2029</span>, and have an exercise
price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240831__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zj8c3RQbGKf2" title="Warrant exercise price">8.81</span> per share of Common Stock. The warrants will become exercisable upon stockholder approval and contain customary anti-dilution
adjustments to the exercise price, including for share splits, share dividends, rights offering and pro rata distributions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ensysce
Biosciences, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to the Consolidated Financial Statements</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2024
February Warrant Inducement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2024, the Company executed an Inducement Letter with certain holders of existing warrants to purchase up to an aggregate of
<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240229__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZ2nDbej97D4" title="Warrants to purchase shares">240,120</span> shares of the Company&#8217;s common stock issued to the holders in connection with the 2023 May Offering. Pursuant to the Inducement
Letter, the holders agreed to exercise for cash their existing warrants to purchase an aggregate of <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240229__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNcS7ZaG4JA1" title="Warrants to purchase common shares">240,120</span> shares of Common Stock at
a reduced exercise price of $<span id="xdx_909_eus-gaap--SharePrice_iI_pid_c20240229__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znmKsujBCeXe" title="Share price">15.90</span> per share in consideration of the Company&#8217;s agreement to issue new unregistered Series A Warrants
(the &#8220;Series A Warrants&#8221;) to purchase up to <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240229__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsMember_zfVCqlxIhNC2" title="Warrants to purchase common shares">240,120</span> shares of Common Stock and new unregistered Series B Warrants (the &#8220;Series
B Warrants&#8221;) to purchase up to<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240229__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zNScdBfwMU24" title="Warrants to purchase common shares"> 240,120</span> shares of Common Stock (collectively, the &#8220;New Warrant Shares&#8221;). The Series
A Warrants have an exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240229__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsMember_z5xM6DN4cmSi" title="Warrant, exercise price">15.90</span> per share and have a term equal to eighteen months from the date of issuance. The Series
B Warrants have an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240229__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_z6FS3gStJm67" title="Warrant, exercise price">15.90</span> per share and will expire on <span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20240229__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zDHWRkDV8KVk" title="Warrants expiration date">May 12, 2028</span>. The gross proceeds to the Company from the exercise
of the warrants were approximately $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20240201__20240229__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWptwzDrXoY3" title="Proceeds from warrants">4.7</span> million, prior to deducting placement agent fees and estimated offering expenses. As the existing
warrants and the new warrants were equity classified before and after the exchange, and as the exchange is directly attributable to an
equity offering, the Company recognized the effect of the modification of approximately $<span id="xdx_90A_eus-gaap--EquityClassifiedWrittenCallOptionModificationEquityIssuanceIncreaseDecreaseInEquityAmount_pn5n6_c20240201__20240229__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOGbxXSrtFIl" title="Equity issuance costs">5.2</span> million as an equity issuance cost.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the execution of the Inducement Letter, the Company executed a waiver related to the 2023 Notes&#8217; SPA it had entered
into as of October 23, 2023. The SPA contained restrictions on the Company&#8217;s ability to undertake certain transactions, which included
the execution of the Inducement Letter. The Waiver permitted the Company to execute the Inducement Letter but required repayment of the
certain investor held notes issued under the SPA with a premium following closing of the transaction contemplated thereby. Refer to Note
7 for the details of the waiver fee and the application of the amounts to the outstanding notes and as a transaction cost of the warrant
inducement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilized an exclusive placement agent for the 2024 Warrant Inducement and incurred approximately $<span id="xdx_90C_eus-gaap--LegalFees_pn5n6_c20240201__20240229_zF9uCIklDMN6" title="Legal fees">0.3</span> million in legal fees and
other closing costs. Additionally, <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_pid_c20240201__20240229_zkuKtZJCrPBb" title="Warrants issue, description">the Company issued to the placement agent as compensation unregistered warrants to purchase up to
<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20240229_zw1WmjWwJFs3" title="Warrants to purchase common stock">16,811</span> shares of Common Stock, equal to 7.0% of the aggregate number of shares of Common Stock (or warrants) placed in the transaction</span>.
The placement agent warrants expire on <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_pid_dd_c20240229__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIAt1ngothKd" title="Warrant maturity date">May 12, 2028</span>, and have an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240229__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zN0yS4UPZuLa" title="Warrant exercise price">24.56</span> per share of Common Stock (equal to 125% of
the reduced exercise price per Existing Warrant). The closing of the offering occurred on February 14, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2023
May Offering</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 12, 2023, the Company completed a public offering of an aggregate of <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230511__20230512_z8VEGjvliRzd" title="Sale of stock number of shares issued in transaction">120,059 </span>shares of its common stock at par value $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230512_zieH72sCICV7" title="Common stock, par value">0.0001</span> per
share (including pre-funded warrants in lieu thereof) at a combined offering price of $<span id="xdx_909_ecustom--CombinedOfferingPricePerShare_iI_c20230512_z37pZwZ8kCLe" title="Combined offering price">58.305</span> per share, gross proceeds from this offering
were approximately $<span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_pn5n6_c20230511__20230512_zik9BFAOJlL4">7.0</span> million before the deduction of placement agent fees and related costs of $<span id="xdx_903_eus-gaap--OtherExpenses_pn5n6_c20230511__20230512_zNJCPdjLS3n7" title="Related costs">0.7</span> million. The warrants issued in
connection with the 2023 May Offering are described further below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the offering, the Company also agreed to amend certain existing warrants to purchase up to an aggregate of <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230512_zXDbBddXDXHe" title="Warrants to purchase common shares">14,006</span> shares
of the Company&#8217;s common stock that were previously issued in September 2021 through December 2022 to purchasers in the offering
at exercise prices ranging from $<span id="xdx_907_eus-gaap--SharePrice_iI_pid_c20230512__srt--RangeAxis__srt--MinimumMember_zdTzae4jkZ96" title="Share price">252.00</span> to $<span id="xdx_901_eus-gaap--SharePrice_iI_pid_c20230512__srt--RangeAxis__srt--MaximumMember_zOgxnFntbxSa" title="Share price">2,808.00</span> per share, such that effective upon the closing of the offering, the amended warrants
had a reduced exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230512_zFd35NDbQAV5" title="Warrant, exercise price">54.60</span> per share at an additional offering price of $<span id="xdx_903_ecustom--OfferingPricePerShare_iI_c20230512__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMr1snJEmzC5" title="Combined offering price">1.875</span> per amended warrant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2023
February Offering</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 2, 2023, the Company agreed to issue and sell in a registered direct offering an aggregate of <span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230201__20230202_zGegmGchM5E8" title="Sale of stock number of shares issued in transaction">19,842</span> shares of common stock
of the Company, par value $<span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230202_zU2eQ6W6QRv4" title="Common stock, par value">0.0001</span> per share, at an offering price of $<span id="xdx_902_ecustom--CombinedOfferingPricePerShare_iI_c20230202_zksNFHUNxmv8" title="Combined offering price">151.20</span> per share, for gross proceeds of approximately $<span id="xdx_907_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_pn5n6_c20230206__20230206_zTcbsblTicn7" title="Sale of stock, consideration received per transaction">3.0</span> million
before the deduction of placement agent fees and related costs of $<span id="xdx_90B_eus-gaap--OtherExpenses_pn5n6_c20230206__20230206_z2Yg7VM3pJFd" title="Related costs">0.3</span> million. The closing occurred on February 6, 2023. The warrants
issued in connection with the 2023 February Offering are described further below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ensysce
Biosciences, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to the Consolidated Financial Statements</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zHn5nlaenwRe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a summary of outstanding warrants to purchase shares of common stock as of December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zXazZfoKgjmh" style="display: none">SCHEDULE
OF OUTSTANDING WARRANT</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Reference</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares
    Underlying Outstanding Warrants</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise
    Price</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Description</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Classification</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(a)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantOneMember_fYSk___z5mcVPdfxjK6" title="Outstanding warrant">1,913,906</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantOneMember__srt--RangeAxis__srt--MinimumMember_fYSk___z1fzs5eKzkL6" title="Exercise price">7.05</span>
                                            - $<span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantOneMember__srt--RangeAxis__srt--MaximumMember_fYSk___zYSSfkKFHT16" title="Exercise price">8.8125</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_ecustom--WarrantDescription_c20240101__20241231__us-gaap--AwardTypeAxis__custom--WarrantOneMember_fYSk___zBi4QCTIPhtb" title="Warrant description">August 2024 Warrants</span></span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Equity</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">(b)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantTwoMember_fYik___zuqMtLVpfG7d" title="Outstanding warrant">16,811</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantTwoMember_fYik___zDDK2IHj4vDc" title="Exercise price">24.56</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_ecustom--WarrantDescription_c20240101__20241231__us-gaap--AwardTypeAxis__custom--WarrantTwoMember_fYik___zILx7s0ngawa" title="Warrant description">February 2024 Warrants</span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Equity</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">(c)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantThreeMember_fYyk___zseDhakt9JB6" title="Outstanding warrant">162,881</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantThreeMember__srt--RangeAxis__srt--MinimumMember_fYyk___z0db45Uz6Jfd" title="Exercise price">7.05</span>
                                       - $<span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantThreeMember__srt--RangeAxis__srt--MaximumMember_fYSk___z9VbRgENyBca" title="Exercise price">23.51</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_ecustom--WarrantDescription_c20240101__20241231__us-gaap--AwardTypeAxis__custom--WarrantThreeMember_fYyk___zh7PO0s0NUXl" title="Warrant description">2023 Notes Warrants</span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Equity</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">(d)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantFourMember_fZCk___zx1bn6tK0Puj" title="Outstanding warrant">73,474</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantFourMember__srt--RangeAxis__srt--MinimumMember_fYyk___z70BJWkvuapc" title="Exercise price">54.56</span>
                                       - $<span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantFourMember__srt--RangeAxis__srt--MaximumMember_fYSk___zECjXJ627D37" title="Exercise price">41,400</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_ecustom--WarrantDescription_c20240101__20241231__us-gaap--AwardTypeAxis__custom--WarrantFourMember_fZCk___zWCcFWYok1tj" title="Warrant description">Other Warrants</span></span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Equity &amp; Liability</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJTzDJCL87mj" title="Outstanding warrant">2,167,072</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0B_zHttwTJw466l" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1F_zzEUMgyiqUNc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    August 29, 2024, in connection with the 2024 Registered Direct Offering and 2024 August Warrant Inducement<b><i>,</i></b> the Company
    issued equity classified warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240829__us-gaap--ClassOfWarrantOrRightAxis__custom--InstitutionalInvestorMember_zNG3PCMr6ec2" title="Warrants issued">1,964,658</span> shares to certain institutional investors and the placement agent. The warrants
    were issued in connection with the 2024 Registered Direct Offering and the 2024 August Warrant Inducement. The <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240829__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantsMember_zCcwEySoITL6" title="Warrants issued">1,914,466</span> investor
    warrants have an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240829__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantsMember_zKC9jmetdTd9" title="Warrant exercise price">7.05 </span>per share and are exercisable from the date on which stockholder approval is received. One
    half of the warrants will expire eighteen months after they are exercisable, and the other half will expire five years after they
    are exercisable. The <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240829__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zXGowZWvK2tl" title="Warrants issued">50,200</span> placement agent warrants have an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240829__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zxoN3w5rZkN7" title="Warrant exercise price">8.8125</span> per share, are exercisable upon stockholder
    approval and expire <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20240829__us-gaap--StatementClassOfStockAxis__custom--PlacementAgentWarrantsMember_zcyag8G0Zdfk" title="Warrant expiration date">August 28, 2029</span>. In December 2024, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantsMember_zuUEfDSwdiP2" title="Investor warrants exercised">50,760</span> investor warrants were exercised.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F09_z7hCESe76193" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_F1E_zn22odATDlzh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                            February 12, 2024, the Company issued <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240212__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__custom--PlacementAgentWarrantsMember_zDxa1qEyCZYj" title="Warrants issued">497,042</span> equity classified warrants (Series A Warrants,
                                            Series B Warrants and placement agent warrants) in connection with the Inducement Letter
                                            for the 2024 February warrant inducement and related warrant restructuring. The Series A
                                            and Series B Warrants were immediately exercisable with an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240212__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zR9dfSKJaEJ6" title="Warrants, exercise price">15.90</span> per share
                                            and expire on <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20240212__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsMember_zZOTCaPZu5Pi" title="Warrant expiration date">August 14, 2025</span> and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20240212__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zaaTSgBzpBSd" title="Warrant expiration date">May 12, 2028</span>, respectively. The placement agent warrants
                                            were immediately exercisable with an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240212__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCmYK51xOsxl" title="Warrant exercise price">24.56</span> per share and expire on <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20240212__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zHgYiFEHje1l" title="Warrant expiration date">May
                                            12, 2028</span>. In connection with the 2024 August Warrant Inducement, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240831__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__custom--PlacementAgentWarrantsMember_zaRXUZi5a449" title="Warrants issued">480,234</span> warrants were exercised.
                                            As of December 31, 2024, the placement agents remain outstanding.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F03_zsyzqHHpCIGb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_F15_zRUWJm7e3Vlj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                            October 25, 2023, and November 28, 2023, the Company issued warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231025__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z10EZER6bSc1" title="Warrants issued">83,714</span> shares
                                            and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231128__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zM5GcBQqU1Vd" title="Warrants issued">167,427</span> shares, respectively. The warrants were immediately exercisable with an exercise
                                            price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pp4d_c20231025__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGVJ31xafQXb" title="Warrants, exercise price"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pp4d_c20231128__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLgwkQtyqAdc" title="Warrants, exercise price">23.51</span></span> per share and expire on <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20231025__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKB6m7xuUk91" title="Warrant expiration date">October 25, 2028</span>, and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20231128__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztlLffHDnze5" title="Warrant expiration date">November 28, 2028</span>, respectively.
                                            In January 2024, a holder of the warrants exercised <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240131__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zonkSPUuw3Eb" title="Warrants exercisable">88,261</span> warrants at an exercise price
                                            of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240131__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuaKVnF1utl" title="Warrant, exercise price">23.51</span> per share. In August 2024, an inducement letter was issued to a holder of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240831_zAsZNrYfFeFc" title="Warrants to purchase common shares">133,334</span>
                                            warrants to reduce the exercise price from $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--SharePrice_iI_pid_c20240830_zwEOqsMWCRwj" title="Share price">23.51</span> to $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--SharePrice_iI_pid_c20240831_z1RxZeUk6qOa" title="Share price">7.05</span> per share.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F08_zrT6I50Hspde" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F11_zMnLjdxbjTVh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
    various dates from the Closing of the Business Combination through September 30, 2023, the Company assumed or issued a total of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230930_ze0v1hh7LLhh" title="Warrants issued">73,474</span>
    warrants to provide holders the right to purchase common stock at exercise prices ranging from $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__srt--RangeAxis__srt--MinimumMember_zVIcsZe1mFXd" title="Warrant exercise price">54.60</span> - $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__srt--RangeAxis__srt--MaximumMember_zVdRSVUA0kk" title="Warrant exercise price">41,400</span> per share. A total
    of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230930__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantMember_zTdEAKVUFAk2" title="Class of warrant or right, outstanding">2,778</span> of the outstanding warrants are public warrants which trade on the OTC Pink Open Market under the ticker symbol ENSCW. A
    total of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230930__us-gaap--StatementEquityComponentsAxis__custom--Notes2021And2022Member_zypGz5J7nhb9" title="Class of warrant or right, outstanding">2,901</span> outstanding warrants (issued in connection with the 2021 and 2022 Notes) are liability-classified due to certain cash
    settlement features embedded within the warrant agreements. The remaining warrants are equity classified. The warrants expire beginning
    <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230929__us-gaap--StatementEquityComponentsAxis__custom--Notes2021And2022Member_zscjcC1ZwVac" title="Warrant expiration date">June 30, 2026</span>, through <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230930__us-gaap--StatementEquityComponentsAxis__custom--Notes2021And2022Member_zUzYNP45Z9a9" title="Warrant expiration date">August 7, 2028</span></span></td></tr>
  </table>
<p id="xdx_8A5_zvPN3HK5znT4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231325740464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zvNMD7NB2Dmb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9 - <span id="xdx_822_zJh5UIxtsbC9">STOCK-BASED COMPENSATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Business Combination, the Company assumed the 2021 Omnibus Incentive Plan. In February 2024, the Company&#8217;s
Board approved an annual increase of <span id="xdx_902_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20240229__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneOmnibusIncentivePlanMember_ze0sw0iTkTxl" title="Common stock, capital shares reserved for future issuance">10,487</span> shares available for future grant under the 2021 Omnibus Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognized within general and administrative expense stock-based compensation expense of $<span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zuVm0gTmtYFi" title="Share based compensation expense">75,494</span> and $<span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zc2UqTqsQkW" title="Share based compensation expense">627,406</span> for the year ended
December 31, 2024 and 2023, respectively. During the year ended December 31, 2024 and 2023, the company recognized within research and
development expense stock-based compensation expense of $<span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zrSly4VU8tt" title="Share based compensation expense">35,229</span> and $<span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zEbEtzMALUtb" title="Share based compensation expense">251,754</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ensysce
Biosciences, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to the Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Option
Activity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, the Company did not grant any stock options. During the year ended December 31, 2023, the Company granted
stock options to purchase an aggregate of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__srt--TitleOfIndividualAxis__custom--BoardOfMembersMember_zMmuRotliVLb" title="Number of restricted stock granted">37,000</span> shares of common stock to employees and members of the board of directors. The options
vested immediately and have an exercise price of between $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20231231__srt--RangeAxis__srt--MinimumMember_zX4whuzhOu2k" title="Weighted average exercise price, vested or expected to vest">16.95</span> and $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20231231__srt--RangeAxis__srt--MaximumMember_zyfJUHchePHj" title="Weighted average exercise price, vested or expected to vest">17.70</span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zSoo4paadGYi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s stock option activity during the year ended December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zumGmWQcnou3" style="display: none">SCHEDULE OF STOCK OPTION ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    average</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise
    price</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Remaining
    contractual life</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Intrinsic
    value</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%"><span style="font-family: Times New Roman, Times, Serif">Outstanding at December 31, 2023</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231_z3l9JqbA6p3a" style="width: 12%; text-align: right" title="Option outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif">38,785</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231_zezRuMLV5NA6" style="width: 12%; text-align: right" title="Weighted average exercise price. beginning balance"><span style="font-family: Times New Roman, Times, Serif">501.65</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zooWRqc7cmp7" title="Weighted average remaining contractual term">9.57</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240101__20241231_zgzhArCAcr8d" style="width: 12%; text-align: right" title="Aggregate intrinsic value, beginning balance"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1097">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231_zMNI7fHiKiXj" style="text-align: right" title="Option outstanding, granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1099">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zoQqZkWNioJh" style="text-align: right" title="Weighted average exercise price, granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1101">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_pp0p0_c20240101__20241231_zov7cyppPoQ7" style="text-align: right" title="Aggregate intrinsic value, granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1103">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20240101__20241231_z8u3AK8QefA2" style="text-align: right" title="Option outstanding, exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1105">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20241231_zVjKu15zBDKa" style="text-align: right" title="Weighted average exercise price, exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1107">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20240101__20241231_zSDXyiP2r521" style="text-align: right" title="Aggregate intrinsic value, exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1109">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Expired / Forfeited</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20240101__20241231_z2Afjhn6Et57" style="border-bottom: Black 1pt solid; text-align: right" title="Option outstanding, expired or forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1111">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zMqLUqBFLRQb" style="text-align: right" title="Weighted average exercise price, expired or forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1113">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue_pp0p0_c20240101__20241231_z6V4kuznpLqc" style="text-align: right" title="Aggregate intrinsic value, expired or forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1115">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding at December 31, 2024</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20241231_zgDwmLoCOs0k" style="border-bottom: Black 2.5pt double; text-align: right" title="Option outstanding, ending balance"><span style="font-family: Times New Roman, Times, Serif">38,785</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231_zPlDVN10Yp31" style="text-align: right" title="Weighted average exercise price, ending balance"><span style="font-family: Times New Roman, Times, Serif">501.65</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_zziDb8xbESG8" title="Weighted average remaining contractual term">8.58</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20240101__20241231_zQG69ztPbRae" style="text-align: right" title="Aggregate intrinsic value, ending balance"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1123">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Exercisable at December 31, 2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20241231_z9qExBSCGcyl" style="text-align: right" title="Option, exercisable"><span style="font-family: Times New Roman, Times, Serif">38,734</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20240101__20241231_zBKI5C4aWqI4" style="text-align: right" title="Weighted average exercise price, exercisable"><span style="font-family: Times New Roman, Times, Serif">493.54</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20240101__20241231_zf9zZYpnXOea" style="text-align: right" title="Aggregate intrinsic value, Exercisable"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1129">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Vested and expected to vest</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20241231_zPw9sME9h5L4" style="text-align: right" title="Option vested or expected to vest"><span style="font-family: Times New Roman, Times, Serif">38,785</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20241231_zEU3q1Ptdym9" style="text-align: right" title="Weighted average exercise price, vested or expected to vest"><span style="font-family: Times New Roman, Times, Serif">501.65</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_zxz8jWI1HIDf" title="Weighted average remaining contractual term, exercisable">8.58</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_pp0p0_c20241231_z68lzkM2M505" style="text-align: right" title="Aggregate intrinsic value, vested or expected to vest"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1137">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A9_zC6ulsxu0Td6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Option
Valuation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zYYRmefYhdH8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of each stock option granted has been determined using the Black-Scholes option-pricing model. The material assumptions used
in the Black-Scholes model in estimating the fair value of the options granted for the periods presented were as follows (no stock options
were granted during the year ended December 31, 2024):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_z2oPX5VQwyVd" style="display: none">SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Exercise price</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231231__srt--RangeAxis__srt--MinimumMember_zZcUquZc0jL4" title="Exercise price">16.95</span>
                                       - <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231231__srt--RangeAxis__srt--MaximumMember_zHEjPXhcWan8" title="Exercise price">17.70</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected stock price volatility</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20230101__20231231_ziENiitsN581" title="Expected stock price volatility, minimum">106.77</span>%
                                            - <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20230101__20231231_zJFMwOgQg5Ae" title="Expected stock price volatility, maximum">106.82</span>%</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected term (years)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zk4OslyzUpj4" title="Expected term (years)">5.00</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free interest rate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20230101__20231231_zGpGxcLgkT16" title="Risk-free interest rate, minimum">4.62</span>%
                                            - <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20230101__20231231_z9sv64O57Lxc" title="Risk-free interest rate, maximum">4.89</span>%</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected dividend yield</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231_ztwCi9YKlaLl" title="Expected dividend rate">0</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>

<p id="xdx_8A0_zfoTvSLUuMk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
    stock-price volatility. </i>The expected volatility is derived from the historical volatilities of comparable publicly traded companies
    within the Company&#8217;s industry that the Company considers comparable to the Company&#8217;s business over a period approximately
    equal to the expected term. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
    term.</i> The expected term represents the period that the stock-based awards are expected to be outstanding. The Company&#8217;s
    historical share option exercise experience does not provide a reasonable basis upon which to estimate an expected term due to a
    lack of sufficient data. Therefore, the Company estimates the expected term for employees by using the simplified method provided
    by the Securities and Exchange Commission. The simplified method calculates the expected term as the average of the time-to-vesting
    and the contractual life of the options. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risk-free
    interest rate. </i>The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon
    U.S. Treasury notes with maturities approximately equal to the expected term.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
    dividend yield. </i>The expected dividend is assumed to be zero as the Company has never paid dividends and has no current plans
    to pay any dividends on the Company&#8217;s common stock.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ensysce
Biosciences, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to the Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted-average grant date fair value of options granted during the year ended December 31, 2023 was $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231_zE9zS42j7ZM7" title="Weighted-average fair value per share , grant">13.98</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the Company had an aggregate of $<span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20241231_z82Eu9qbx6T8" title="Unrecognized stock based compensation">27,860</span> of unrecognized share-based compensation cost, which is expected to be
recognized over the weighted average period of <span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardWeightedAveragePeriodExpectedToBeRecognized_dtY_c20240101__20241231_z1erjG8Kif41" title="Weighted average period">0.75</span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Shares
Reserved for Future Issuance</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_ecustom--ScheduleOfCommonStockFutureIssuanceTableTextBlock_zuUtL05IOrE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following shares of common stock are reserved for future issuance:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_z3b6beliuu5l" style="display: none">SCHEDULE OF COMMON STOCK FUTURE ISSUANCE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Awards outstanding under the 2021
    Omnibus Incentive Plan</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOvxi2CvahC4" style="width: 16%; text-align: right" title="Common Stock, capital shares reserved for future issuance"><span style="font-family: Times New Roman, Times, Serif">38,785</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Awards available for future grant under 2021
    Omnibus Incentive Plan</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--StockOptionAvailableForFutureGrantUnder2021OmnibusIncentivePlanMember_zM6typmi2vlf" style="text-align: right" title="Common Stock, capital shares reserved for future issuance"><span style="font-family: Times New Roman, Times, Serif">10,596</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Warrants outstanding</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantOutstandingMember_zVYWMclqlRwj" style="border-bottom: Black 1pt solid; text-align: right" title="Common Stock, capital shares reserved for future issuance"><span style="font-family: Times New Roman, Times, Serif">2,167,072</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total shares of common
    stock reserved for future issuance</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20241231_zjzknOyBbv54" style="border-bottom: Black 2.5pt double; text-align: right" title="Total shares of common stock reserved for future issuance"><span style="font-family: Times New Roman, Times, Serif">2,216,453</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A2_zRAHVVu5xSPg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231326178496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p id="xdx_800_eus-gaap--IncomeTaxDisclosureTextBlock_zv5PBNLwc2L7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10 - <span id="xdx_825_zNk4j5t7Q4Gg">INCOME TAXES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zZTnJWwXv5j5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
before provision for income taxes consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zNaBR3oaIq67" style="display: none">SCHEDULE OF INCOME TAXES BENEFIT</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    ending December 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">United States</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pp0p0_c20240101__20241231__srt--StatementGeographicalAxis__country--US_z59Nsq1xf00f" style="width: 16%; text-align: right" title="Loss before provision for income taxes"><span style="font-family: Times New Roman, Times, Serif">(7,987,009</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pp0p0_c20230101__20231231__srt--StatementGeographicalAxis__country--US_zNmX9uvzzBW4" style="width: 16%; text-align: right" title="Loss before provision for income taxes"><span style="font-family: Times New Roman, Times, Serif">(10,626,275</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>

<p id="xdx_8A8_z932wY5APsOg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_ecustom--ScheduleOfFederalAndStateIncomeTaxProvisionBenefitTableTextBlock_z1fo87DK9eY" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal and state income tax provision (benefit), included in general and administrative expenses in the Consolidated Statement of Operations,
is summarized as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zjSbCT2gWjT1" style="display: none">SCHEDULE OF FEDERAL AND STATE INCOME TAX PROVISION (BENEFIT)</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    ending December 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current state provision</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pp0p0_c20240101__20241231_zBH57HOWOXO6" style="width: 16%; text-align: right" title="Current state provision"><span style="font-family: Times New Roman, Times, Serif">3,300</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pp0p0_c20230101__20231231_zN4vWxoXWq42" style="width: 16%; text-align: right" title="Current state provision"><span style="font-family: Times New Roman, Times, Serif">3,200</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8AE_zGfgfCcNbDnj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ensysce
Biosciences, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to the Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zWMZoPdyyyf3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
effective tax rate of the Company&#8217;s provision (benefit) for income taxes differs from the federal statutory rate as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zugETMXcPwmj" style="display: none">SCHEDULE OF FEDERAL INCOME TAX RATE RECONCILIATION</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_493_20240101__20241231_zZ614y3olEhe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_491_20230101__20231231_zDgddKBZFF6k" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    ending December 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzZ0P_zhlP8LGZwU57" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Income (benefit) taxes at statutory
    rates</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,677,271</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,231,518</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzZ0P_z0qboDzTYj1a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">State income tax, net of federal benefit</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(62,342</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(77,243</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_maITEBzZ0P_zAyOgibPmStc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Warrants and convertible debt</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,421</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(90,392</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_maITEBzZ0P_zp0RWO7SZeX5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Nondeductible executive compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,325</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,107</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_maITEBzZ0P_z4mBefHk9VP8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock based compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">22,633</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">580,823</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_di_msITEBzZ0P_zwGgLNGQpVgh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development tax credits</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(428,675</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(629,239</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_407_ecustom--IncomeTaxReconciliationExpiringAttributes_maITEBzZ0P_zXztURcte3Jg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expiring attributes</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">183,912</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1208">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationTaxContingencies_maITEBzZ0P_zvXAllxY2oM1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Change in tax rates</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(296</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,848</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzZ0P_zMAGBoN4Jbbl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,282</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">77,162</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzZ0P_zOU4xy55K7f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Change in valuation allowance</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,936,853</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,372,148</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzZ0P_ziFgkx0EaDB8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1219">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1220">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A1_zyNViFpVYzKl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income taxes reflect the net tax effects of (a) temporary differences between the carrying amounts of assets and liabilities for financial
reporting purposes and the amounts used for income tax purposes, and (b) operating losses and tax credit carryforwards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zLqQhhHqop98" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s deferred tax assets were comprised of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zxXcPdtKig97" style="display: none">SCHEDULE OF DEFERRED TAX ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_490_20241231_zzn5Gwrmdoj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_491_20231231_z2Obiskxomuh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As
    of December 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred tax assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTAGz96z_zv1N7PxqF0E7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net operating
    loss tax carryforwards</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">29,728,009</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">28,485,164</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_iI_pp0p0_maDTAGz96z_zaldXCXze6s8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Tax credits</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,212,263</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,793,138</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pp0p0_maDTAGz96z_ze4nAv8EZuk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Capitalized research costs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,655,425</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,368,767</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0_maDTAGz96z_z6tTMzyXUgmb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">729,318</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">746,444</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsOther_iI_pp0p0_maDTAGz96z_zImKrQrVvbN7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">36,630</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">31,279</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsGross_iTI_pp0p0_mtDTAGz96z_maDTANzp9G_zZuSG6xTp9N9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross deferred tax assets</span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">40,361,645</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">38,424,792</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTANzp9G_zX63HUeRvA79" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Valuation allowance</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(40,361,645</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(38,424,792</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsNet_iTI_pp0p0_mtDTANzp9G_maDTALNzQQ7_z0mX2Ur829ag" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total deferred tax assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1245">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1246">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred tax liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxLiabilitiesOther_iNI_pp0p0_di_maDTLzuel_zC1227LKsT65" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1248">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1249">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxLiabilities_iNTI_di_mtDTLzuel_msDTALNzQQ7_zFdEMqEMnLz6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Total
    deferred tax liabilities</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1251">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1252">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pp0p0_mtDTALNzQQ7_zVNxT8wB5ZJ3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net deferred tax assets</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1254">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1255">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A9_zWY9G2P2h109" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the Company had federal and California net operating loss (NOL) carryforwards of $<span id="xdx_90A_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zYEOYpWWdzFa" title="Operating loss carryforwards">116.4</span> million and $<span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--CaliforniaFranchiseTaxBoardMember_zitnrZogdw3j" title="Operating loss carryforwards">75.6</span> million,
respectively, net of the NOLs that will expire due to Internal Revenue Code (IRC) Section 382 limitations. The federal net operating
losses generated in 2018 and after of $<span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20181231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zWlWjCFeEuvd">34.9</span> million will <span id="xdx_90C_eus-gaap--TaxCreditCarryforwardDescription_c20240101__20241231_zAQ3JpnZ9fFa" title="Tax credit carryforward, description">carryforward indefinitely and be available to offset up to 80% of future taxable
income each year</span>. The federal net operating losses generated prior to 2018 of $<span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20171231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zwgOvUAcPrm">81.6</span> million will begin to <span id="xdx_90A_eus-gaap--OperatingLossCarryforwardsLimitationsOnUse_c20170101__20171231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zHTKICxMvaD9" title="Operating loss carryforwards expiration">expire in 2025</span> unless previously
utilized. The California NOL carryforwards will begin to <span id="xdx_901_eus-gaap--OperatingLossCarryforwardsLimitationsOnUse_c20240101__20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--CaliforniaFranchiseTaxBoardMember_z9RjMd9ZKbwe" title="Operating loss carryforwards expiration">expire in 2028</span>, unless previously utilized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ensysce
Biosciences, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to the Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, as of December 31, 2024, the Company had federal and state research and development (R&amp;D) tax credit carryforwards of $<span id="xdx_908_eus-gaap--TaxCreditCarryforwardAmount_iI_pn5n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember__us-gaap--TaxCreditCarryforwardAxis__us-gaap--ResearchMember_zPZVLwhzXUE5" title="Tax credit carryforward amount">5.6</span>
million and $<span id="xdx_903_eus-gaap--TaxCreditCarryforwardAmount_iI_pn5n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--TaxCreditCarryforwardAxis__us-gaap--ResearchMember_zTkauLAjEBck" title="Tax credit carryforward amount">1.7</span> million, respectively. The federal tax credit carryforwards will begin to <span id="xdx_904_eus-gaap--TaxCreditCarryforwardLimitationsOnUse_c20240101__20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--CaliforniaFranchiseTaxBoardMember_zzjnF69cve15" title="Tax credit carryforward expiration">expire in 2025</span> unless previously utilized.
The California research tax credits do not expire.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to IRC Sections 382 and 383, annual use of the Company&#8217;s NOL and R&amp;D credit carryforwards may be limited in the event that
a cumulative change in ownership of more than 50% occurs within a three-year period. Although the Company has not completed an IRC Section
382/383 analysis regarding the limitation of NOL and R&amp;D credit carryforwards as of December 31, 2024, the Company estimates that
approximately $<span id="xdx_90E_eus-gaap--TaxCreditCarryforwardAmount_iI_pn5n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zh1ghdYYPs73" title="Tax credit carryforward amount">1.5</span> million of tax benefits related to NOL and R&amp;D carryforwards acquired in 2015 will expire unused. Accordingly,
the related NOL and R&amp;D credit carryforwards have been removed from deferred tax assets accompanied by a corresponding reduction
of the valuation allowance. Due to the existence of the valuation allowance, limitations created by current and future ownership changes,
if any, related to the Company&#8217;s operations in the United States will not impact its effective tax rate. Any additional ownership
changes may further limit the ability to use the NOL and R&amp;D credit carryforwards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_zsvlQX1CuHtb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the activity related to the Company&#8217;s unrecognized tax benefits:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_z9jwHXM9uL3c" style="display: none">SCHEDULE
OF UNRECOGNIZED TAX BENEFITS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20240101__20241231_zICGxDjWgihi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_497_20230101__20231231_zoobMijdKGs4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    ending December 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--UnrecognizedTaxBenefits_iS_zg1EEFtUZrae" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Balance at beginning of year</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,685,360</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,428,261</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_zw3IHfOkSFki" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Increases related to current year tax positions</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">141,023</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">128,404</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_zDwD2MFhav37" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Increases related to prior year tax positions</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,054</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">128,695</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_iN_di_zuTR172tJSy3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Decreases related to prior
    year tax positions</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(444</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1289">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--UnrecognizedTaxBenefits_iE_zb3Ic7R5BVXj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance at end of year</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,826,993</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,685,360</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A5_zNWOrtcCdIRb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024 and 2023, the Company had unrecognized tax benefits of $<span id="xdx_907_eus-gaap--UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_iI_pn5n6_c20241231_z0FZD3s4hYqg" title="Unrecognized tax benefits that would impact effective tax rate">1.8</span> million and $<span id="xdx_90A_eus-gaap--UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_iI_pn5n6_c20231231_z0muZBS40P7d" title="Unrecognized tax benefits that would impact effective tax rate">1.7</span> million, respectively. Due to the existence
of the valuation allowance, none of the unrecognized tax benefits would affect the effective tax rate. The Company&#8217;s policy is
to recognize interest and penalties from uncertain tax positions in income tax expense. The Company did not record any interest or penalties
for the years ended December 31, 2024 or 2023 and had <span id="xdx_900_eus-gaap--FinancingReceivableAccruedInterestWriteoff_do_c20240101__20241231_zZBDwNWQYMf8" title="Financing receivable accrued interest write off"><span id="xdx_90A_eus-gaap--FinancingReceivableAccruedInterestWriteoff_do_c20230101__20231231_z0kznfEtMKsh" title="Financing receivable accrued interest write off">no</span></span> accrued interest on the consolidated balance sheets as of December 31, 2024
or 2023. The Company does not anticipate that the total amount of unrecognized tax benefits will significantly increase or decrease within
twelve months of the reporting date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company and its subsidiaries are subject to U.S. federal income tax as well as income tax in multiple state jurisdictions. With few exceptions,
the Company is no longer subject to United States federal income tax examinations for years before 2021 and state and local income tax
examinations before 2020. However, to the extent allowed by law, the tax authorities may have the right to examine prior periods where
net operating losses were generated and carried forward, and make adjustments up to the amount of the NOL carryforward amount. The Company
is not currently under examination by the Internal Revenue Service or any state or local tax authority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231326410992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTIES</a></td>
<td class="text"><p id="xdx_800_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zhAtmqStucB4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
11 - <span id="xdx_822_zJKL2RHB16ne">RELATED PARTIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the Company held a $<span id="xdx_907_eus-gaap--SeniorLongTermNotes_iI_pn5n6_c20241231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zRKMZTt0bWk4" title="Debt financing amount">0.2</span> million senior secured convertible promissory note plus accrued interest and <span id="xdx_900_ecustom--WarrantOrRightExercisable_iI_c20241231_zpqr6u3T6tEh" title="Warrants exercisable">29,547</span> warrants
exercisable for common stock at $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0UAo5juraDb" title="Warrant, exercise price">23.51</span> per share issued to a board member in connection to the issuance of the 2023 Notes. On April
25, 2024, the Company and the board member entered into a forbearance agreement that will expire on <span id="xdx_90A_ecustom--WarrantExpirationDate_dd_c20240425__20240425__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFJTRyszzeWb" title="Warrant, expiration date">April 25, 2025</span>. Upon termination
of the forbearance period, the Company will owe the remaining outstanding principal balance together with unpaid interest. The Company
may pay the notes in full at any time prior to the conclusion of the forbearance period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231327773280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--SubsequentEventsTextBlock_z1Uv881EMegi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
12 - <span id="xdx_821_zh0Qi4By6Kul">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2025, the Company issued <span id="xdx_901_ecustom--StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares_c20250101__20250131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkLTLf5p1yXk" title="Number of shares issued upon exercise of warrants">49,361</span> shares of common stock for $<span id="xdx_906_ecustom--StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants_pid_c20250101__20250131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zooSEUrAHrR4" title="Value of shares issued upon exercise of warrants">0.3</span> million upon exercise of August 2024 warrants issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2025, the Company entered into a product development and supply agreement with Galephar Pharmaceutical Research, Inc., a Puerto
Rico specialty drug manufacturer (&#8220;Galephar&#8221;). Galephar will support the development, manufacture, packaging and testing
of the Company&#8217;s PF614 and PF614-MPAR drug products for use in clinical trials and potential future commercial launch. The Company
will pay Galephar upon achievement of defined milestones at up to 1.2 times Galephar&#8217;s costs, subject to a cap. Payment will be
in the form of common stock at fifty percent (50%) restricted shares and fifty percent (50%) freely tradeable registered shares, with
the number of shares to be issued by the Company determined by the trailing five-day average closing price of the Company&#8217;s common
stock upon achievement of each milestone. In addition, the Company will issue up to <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20250101__20250131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zl7iJs0qJYc5" title="Restricted common stock issued">13,801</span> shares (<span id="xdx_907_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_dp_uPure_c20250101__20250131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zUWyRFchx0ge" title="Shares outstanding percentage">1</span>% of shares outstanding upon signing of agreement)
of restricted common stock to Galephar with vesting in three tranches through completion of defined milestones.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231326403856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates and Assumptions</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--UseOfEstimates_zveVvBY9DfX5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zxqeiaUXWuV2">Use
of Estimates and Assumptions</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preparation
of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the
amounts reported in the consolidated financial statements and disclosed in the accompanying notes. Actual results may differ from those
estimates and such differences may be material to the consolidated financial statements. The more significant estimates and assumptions
by management include, but are not limited to, the expense recognition for certain accrued research and development services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_840_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z5Hk2uib2D14" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zygQMHvUosyg">Cash
and Cash Equivalents</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of the consolidated balance sheets and consolidated statements of cash flows, the Company considers all highly liquid instruments
with maturity of three months or less at the time of issuance to be cash equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk and Off-Balance Sheet Risk</a></td>
<td class="text"><p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_zo3lGgLiIgy9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 11pt; text-align: justify; text-indent: -11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zB4hMW0F5Oqf">Concentrations
of Credit Risk and Off-Balance Sheet Risk</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents are financial instruments that are potentially subject to concentrations of credit risk. The Company&#8217;s cash
and cash equivalents are deposited in accounts at large financial institutions and amounts currently exceed federally insured limits.
The Company has no financial instruments with off-balance sheet risk of loss. Additionally, the Company had a concentration in accounts
payable, as <span id="xdx_909_eus-gaap--ConcentrationRiskBenchmarkDescription_c20240101__20241231_zmw5YXQYZ8Hi" title="Concentration of risk, description">three and two research and development vendors made up greater than 10% individually, and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerMember_zEZI17ZmWnC8" title="Concentration of risk">74</span>% and <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerMember_zs976MComFLb" title="Concentration of risk">38</span>% in aggregate</span>, of the
outstanding accounts payable balance as of December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><p id="xdx_848_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zwleZMKpskh6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zaBuj1PHHCUh">Segments</span></i></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 11pt; text-align: justify; text-indent: -11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates and manages its business as <span id="xdx_901_eus-gaap--NumberOfReportableSegments_dc_uSegment_c20240101__20241231_zYDclMDTWv76" title="Number of reportable segments"><span id="xdx_904_eus-gaap--NumberOfOperatingSegments_dc_uSegment_c20240101__20241231_zSrs0LpfcAm6" title="Number of operating segments">one</span></span> reportable and operating segment. Operating segments are defined as components of an
enterprise where separate financial information is evaluated regularly by the chief operating decision maker (CODM) in deciding how to
allocate resources and assess performance. The Company&#8217;s CODM is the Chief Executive Officer, who reviews consolidated financial
information on a company-wide basis for purposes of allocating resources and assessing financial performance and does not regularly review
expenses or financial results on a more granular level.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zfuggtEVtZz8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zS2zZSGaYFt5">Property
and Equipment</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are fully depreciated as such there is <span id="xdx_902_eus-gaap--Depreciation_do_c20240101__20241231_zW34HL8zFf9k" title="Depreciation"><span id="xdx_904_eus-gaap--Depreciation_do_c20230101__20231231_z93sEe2bE0od" title="Depreciation">no</span></span> depreciation expense recognized in the years ended December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zgdfIF1FSFS" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.15in; text-align: justify; text-indent: -0.15in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_z2J6dQFu7Vl3">Fair
Value Measurement</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
820, <i>Fair Value Measurements</i>, (&#8220;ASC 820&#8221;) provides guidance on the development and disclosure of fair value measurements.
Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset
or paid to transfer a liability in an orderly transaction between willing market participants at the measurement date. As such, fair
value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset
or a liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ensysce
Biosciences, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to the Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted
    prices in active markets for identical assets or liabilities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs
    other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable
    inputs which are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies,
    or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at
which to classify them for each reporting period. This determination requires significant judgments to be made by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024 and 2023, the recorded values of cash and cash equivalents, prepaid expenses, accounts payable, and accrued expenses
and other liabilities approximate their fair values due to the short-term nature of these items.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company issued liability classified warrants in connection with the issuance of the 2021 Notes and 2022 Notes. The warrants were liability
classified due to certain cash settlement features and included in &#8220;Other long-term liabilities&#8221; on the consolidated balance
sheets. The Company uses a Black Scholes model to estimate the fair value of the warrants. Changes in the fair value of the warrants
are recognized in other income (expense) for each reporting period. Refer to Note 8 for additional details of the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zqcg3Cg06c27" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables present assets and liabilities measured and recorded at fair value on the Company&#8217;s consolidated balance sheet
as of December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zTJxTK8lOqqa" style="display: none">SCHEDULE
OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_492_20241231_zbJyGlmmJLo3" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_494_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zoWIcGw7gQAd" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zVPzC8Y445B4" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z19LhJzyVOAf" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pp0p0_zSNe1jUc3jbb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left; padding-bottom: 1pt">Liability classified warrants</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">10,096</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0639">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0640">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">10,096</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_z8S9YHvRoyU7" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,096</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0644">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0645">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,096</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20231231_zIgq62KQtgkl" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_492_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zOVXH1TTIcnf" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zWv1Jl7p1Noe" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_496_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zIhTClXTKzl7" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pp0p0_zPGmgVRe3Otf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left; padding-bottom: 1pt">Liability classified warrants</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">26,388</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0649">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0650">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">26,388</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_z5k42qIGqpu4" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">26,388</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0654">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0655">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">26,388</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_z6ZttRgJPGj8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ensysce
Biosciences, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to the Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zErV5LTICKG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the change in fair value of the Company&#8217;s Level 3 liabilities for the year ended December 31, 2024 (no
level 3 assets as of the year ended December 31, 2024):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_z5EbIprVn8Ke" style="display: none">SCHEDULE
OF CHANGE IN FAIR VALUE OF COMPANY&#8217;S LEVEL 3</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Liability classified warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Fair value, December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pp0p0_c20240101__20241231__us-gaap--FairValueByLiabilityClassAxis__custom--LiabilityClassifiedWarrantsMember_zV4N38CxRu87" style="width: 16%; text-align: right" title="Beginning balance">26,388</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_pp0p0_c20240101__20241231__us-gaap--FairValueByLiabilityClassAxis__custom--LiabilityClassifiedWarrantsMember_zKkx2wpiMFZb" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value">(16,292</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Fair value, December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pp0p0_c20240101__20241231__us-gaap--FairValueByLiabilityClassAxis__custom--LiabilityClassifiedWarrantsMember_zLQych732CG3" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">10,096</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_zWYSi7SyxWI1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Federal
Grants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2019, the NIH/NIDA awarded the Company a second research and development grant related to the development of its TAAP/MPAR
abuse deterrent technology for Opioid Use Disorder (the &#8220;OUD Grant&#8221;). The total approved budget was approximately $<span id="xdx_90D_eus-gaap--GrantsReceivable_iI_pn5n6_c20190930_zncQAFem5bdf" title="Grants receivable">5.4</span> million,
and the grant period ended August 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2018, the National Institutes of Health (&#8220;NIH&#8221;) through the National Institute on Drug Abuse (&#8220;NIDA&#8221;)
awarded the Company a research and development grant related to the development of its MPAR<sup>&#174;</sup> overdose prevention technology
(the &#8220;MPAR Grant&#8221;). The initial grant was extended several times and cumulative funding under this grant of approximately
$<span id="xdx_90B_eus-gaap--GrantsReceivable_iI_pn5n6_c20231231_zRI4sbUT3RDh" title="Grants receivable">10.7</span> million was completed in December 2023. A new multi-year MPAR Grant was awarded by NIH through NIDA in August 2024, providing total
funding of $<span id="xdx_902_eus-gaap--GrantsReceivable_iI_pn6n6_c20240831_zI3h2GAO9uSi" title="Grants receivable">14</span> million through May 2027. As December 31, 2024, the remaining cash funding under the grant is $<span id="xdx_90D_eus-gaap--GrantsReceivable_iI_pn5n6_c20241231_zYzjz6bhtdqk" title="Grants receivable">1.6</span> million, covering the
period through May 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes revenue when costs related to the grants are incurred and assessed as reimbursable. The Company believes this policy
is consistent with the overarching premise in Accounting Standards Codification Topic 606, <i>Revenue from Contracts with </i>Customers
(&#8220;ASC 606&#8221;), applied by analogy, to ensure that it recognizes revenues to reflect the transfer of promised goods or services
to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services,
even though there is no &#8220;exchange&#8221; as defined in ASC 606. The Company believes the recognition of revenue as costs are incurred
and reimbursable amounts become due is analogous to the concept of transfer of control of a service over time under ASC 606.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_898_ecustom--ScheduleOfRevenueRecognitionUnderGrantsTableTextBlock_zvfS50tgNAKh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
revenue recognized under the MPAR Grant and OUD Grant was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zICynLUDum6k" style="display: none">SCHEDULE
OF REVENUE RECOGNITION UNDER GRANTS</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20240101__20241231_zQTKndyhkRdl" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20230101__20231231_zOdYbHvG8Kqa" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_hsrt--ProductOrServiceAxis__custom--MPARMember_zflyx04Dq5Cg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">MPAR</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">3,086,464</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,293,238</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_hsrt--ProductOrServiceAxis__custom--TAAPOUDMember_zl7OjoxNxWKk" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">TAAP/OUD</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,123,567</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">937,282</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_zIJOxmHgytAa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,210,031</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,230,520</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zrt76Hy71T1h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts
requested or eligible to be requested through the NIH payment management system, but for which cash has not been received, are presented
as an unbilled receivable on the Company&#8217;s consolidated balance sheet. As all amounts are expected to be remitted timely, no valuation
allowances are recorded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ensysce
Biosciences, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to the Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p id="xdx_843_eus-gaap--ResearchAndDevelopmentExpensePolicy_zPwxZtQDdRsd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span><span><span id="xdx_864_zuSnCCjjiYI4">Research
and Development Costs</span></span></span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s research and development expenses consist primarily of third-party research and development expenses, consulting expenses,
preclinical and clinical studies, and any allocable direct overhead, including facilities and depreciation costs, as well as salaries,
payroll taxes, and employee benefits for those individuals directly involved in ongoing research and development efforts. Research and
development expenses are charged to expense as incurred. Payments made prior to the receipt of goods or services to be used in research
and development are capitalized until the goods or services are received.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and Administrative Expenses</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zvJ1IjIA6APg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zcuFmWgXI5g4">General
and Administrative Expenses</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of personnel costs associated with the Company&#8217;s executive, finance, human resources,
compliance, and other administrative personnel, as well as accounting and legal professional services fees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Compensation</a></td>
<td class="text"><p id="xdx_848_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zucMljGhmxLj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zWpvL49RS8d6">Stock-based
Compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expenses stock-based compensation over the requisite service period based on the estimated grant-date fair value of the awards
using a graded amortization approach. The Company accounts for forfeitures as they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company estimates the fair value of stock option grants using the Black-Scholes option pricing model. The assumptions used in calculating
the fair value of stock-based awards represent management&#8217;s best estimates and involve inherent uncertainties and the application
of management&#8217;s judgment. Stock-based compensation costs are recorded in research and development and general and administrative
expenses in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time-to-time equity classified awards may be modified. On the modification date, the Company estimates the fair value of the awards immediately
before and immediately after modification. The incremental increase in fair value is recognized as expense immediately to the extent
the underlying equity awards are vested and on a straight-line basis over the same remaining amortization schedule as the unvested underlying
equity awards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_z5abU6pNVae4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_z9agJgAiu3sl">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
taxes are recorded in accordance with ASC 740, <i>Income Taxes</i> (&#8220;ASC 740&#8221;), which provides for deferred taxes using an
asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of
events that have been included in the consolidated financial statements or tax returns. Deferred tax assets and liabilities are determined
based on the difference between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates
in effect for the year in which the differences are expected to reverse. Valuation allowances are provided if, based upon the weight
of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company
recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination
by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical
merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and
penalties accrued related to unrecognized tax benefits as income tax expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ensysce
Biosciences, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to the Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings per Share</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zpbniCRCshqg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zA7mwy9Prx82">Earnings
per Share</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
basic earnings per share is calculated by dividing the Company&#8217;s net income or loss attributable to common stockholders by the
weighted average number of common shares outstanding during the period. The diluted earnings per share is calculated by dividing the
Company&#8217;s net earnings attributable to common stockholders by the diluted weighted average number of common shares outstanding
during the period, determined using the treasury stock method and the average stock price during the period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ztFHVlIk9OWh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following weighted average shares have been excluded from the calculations of diluted weighted average common shares outstanding because
they would have been anti-dilutive (the Company has utilized the principal balance outstanding and the end of period conversion price
for the Convertible Notes for the purposes of the weighted average share calculation below):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zZtpZSMxpsv6" style="display: none">SCHEDULE
OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20240101__20241231_zA7NsW5MKaOk" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_497_20230101__20231231_zqx6boqTHPy5" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zfqHftzvbIn6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right">38,734</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right">8,784</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zXL6kro0wmf2" style="vertical-align: bottom; background-color: White">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">551,287</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">253,208</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zwgsLK7HnB17" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Convertible Notes</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">9,187</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">78,086</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zqIJ72JozqZj" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">599,208</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">340,078</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_ze8nSfeAfvJ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zIzPEraSHQZ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zsxBNeZKd276">Recently
Issued Accounting Pronouncements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the FASB issued ASU 2023-07, &#8220;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&#8221;,
which sets forth improvements to the current segment disclosure requirements in accordance with Topic 280 &#8220;Segment Reporting,&#8221;
including clarifying that entities with a single reportable segment are subject to both new and existing segment reporting requirements.
ASU 2023-07 will be effective retrospectively for fiscal years beginning after December 15, 2023, and interim periods beginning after
December 15, 2024. The Company adopted the standard with an effective date of January 1, 2024 and the adoption did not have a significant
impact on the consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued ASU No. 2023-09, &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&#8221; ASU 2023-09
requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as information on income
taxes paid. ASU 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted.
The Company is currently evaluating the impact of this guidance on its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU 2024-03, Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement Expenses (&#8220;ASU 2024-03&#8221;), which requires disclosure about the types
of costs and expenses included in certain expense captions presented on the income statement. The new disclosure requirements are effective
for the Company&#8217;s annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with
early adoption permitted. The Company is currently evaluating the impact of this pronouncement on our related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU 2024-04, &#8220;Debt &#8211; Debt with Conversion and other Options (Subtopic 470-20) &#8220;, which
set forth to improve the relevance and consistency in the application of induced conversion guidance in Subtopic 470-20, Debt&#8212;
Debt with Conversion and Other Options such as clarifying the requirements for determining whether certain settlements of convertible
debt instruments should be accounted for as an induced conversion. ASU 2024-04 is effective for all entities after December 15, 2025,
with early adoption permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231326182608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zqcg3Cg06c27" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables present assets and liabilities measured and recorded at fair value on the Company&#8217;s consolidated balance sheet
as of December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zTJxTK8lOqqa" style="display: none">SCHEDULE
OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_492_20241231_zbJyGlmmJLo3" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_494_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zoWIcGw7gQAd" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zVPzC8Y445B4" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z19LhJzyVOAf" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pp0p0_zSNe1jUc3jbb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left; padding-bottom: 1pt">Liability classified warrants</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">10,096</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0639">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0640">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">10,096</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_z8S9YHvRoyU7" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,096</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0644">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0645">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,096</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20231231_zIgq62KQtgkl" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_492_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zOVXH1TTIcnf" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zWv1Jl7p1Noe" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_496_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zIhTClXTKzl7" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pp0p0_zPGmgVRe3Otf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left; padding-bottom: 1pt">Liability classified warrants</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">26,388</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0649">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0650">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">26,388</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_z5k42qIGqpu4" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">26,388</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0654">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0655">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">26,388</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY&#8217;S LEVEL 3</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zErV5LTICKG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the change in fair value of the Company&#8217;s Level 3 liabilities for the year ended December 31, 2024 (no
level 3 assets as of the year ended December 31, 2024):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_z5EbIprVn8Ke" style="display: none">SCHEDULE
OF CHANGE IN FAIR VALUE OF COMPANY&#8217;S LEVEL 3</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Liability classified warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Fair value, December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pp0p0_c20240101__20241231__us-gaap--FairValueByLiabilityClassAxis__custom--LiabilityClassifiedWarrantsMember_zV4N38CxRu87" style="width: 16%; text-align: right" title="Beginning balance">26,388</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_pp0p0_c20240101__20241231__us-gaap--FairValueByLiabilityClassAxis__custom--LiabilityClassifiedWarrantsMember_zKkx2wpiMFZb" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value">(16,292</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Fair value, December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pp0p0_c20240101__20241231__us-gaap--FairValueByLiabilityClassAxis__custom--LiabilityClassifiedWarrantsMember_zLQych732CG3" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">10,096</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_ScheduleOfRevenueRecognitionUnderGrantsTableTextBlock', window );">SCHEDULE OF REVENUE RECOGNITION UNDER GRANTS</a></td>
<td class="text"><p id="xdx_898_ecustom--ScheduleOfRevenueRecognitionUnderGrantsTableTextBlock_zvfS50tgNAKh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
revenue recognized under the MPAR Grant and OUD Grant was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zICynLUDum6k" style="display: none">SCHEDULE
OF REVENUE RECOGNITION UNDER GRANTS</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20240101__20241231_zQTKndyhkRdl" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20230101__20231231_zOdYbHvG8Kqa" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_hsrt--ProductOrServiceAxis__custom--MPARMember_zflyx04Dq5Cg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">MPAR</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">3,086,464</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,293,238</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_hsrt--ProductOrServiceAxis__custom--TAAPOUDMember_zl7OjoxNxWKk" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">TAAP/OUD</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,123,567</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">937,282</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_zIJOxmHgytAa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,210,031</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,230,520</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ztFHVlIk9OWh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following weighted average shares have been excluded from the calculations of diluted weighted average common shares outstanding because
they would have been anti-dilutive (the Company has utilized the principal balance outstanding and the end of period conversion price
for the Convertible Notes for the purposes of the weighted average share calculation below):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zZtpZSMxpsv6" style="display: none">SCHEDULE
OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20240101__20241231_zA7NsW5MKaOk" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_497_20230101__20231231_zqx6boqTHPy5" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zfqHftzvbIn6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right">38,734</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right">8,784</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zXL6kro0wmf2" style="vertical-align: bottom; background-color: White">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">551,287</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">253,208</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zwgsLK7HnB17" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Convertible Notes</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">9,187</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">78,086</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zqIJ72JozqZj" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">599,208</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">340,078</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENSC_ScheduleOfRevenueRecognitionUnderGrantsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Revenue Recognition Under Grants [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENSC_ScheduleOfRevenueRecognitionUnderGrantsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENSC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231326401328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</a></td>
<td class="text"><p id="xdx_890_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zhZWYehENRfl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses and other current assets consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zTOmKgfzXjV4" style="display: none">SCHEDULE
OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_497_20241231_zsJ6JB7ZzWE8" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_497_20231231_zOg38WjypbNl" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_ecustom--PrepaidResearchAndDevelopment_iI_pp0p0_maOPECzDNl_zX69uge2qLT5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Prepaid research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,342,461</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">535,474</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PrepaidInsurance_iI_pp0p0_maOPECzDNl_z3i4vqRGFku3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">315,306</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">441,871</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0p0_maOPECzDNl_zMlmPQ5H6G54" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,723</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72,358</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherAssetsCurrent_iI_pp0p0_maOPECzDNl_zEOzzEPap5c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Other current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">18,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">18,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PrepaidExpenseCurrent_iTI_pp0p0_mtOPECzDNl_zJP3hFCAOgRf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,718,490</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,067,703</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231435299776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zyYzX8ee1iMg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses and other liabilities consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_z2VFAiYHpf8d" style="display: none">SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20241231_z6UyDzuT5hZk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20231231_znNSDBaLHgx5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_ecustom--AccruedResearchAndDevelopment_iI_maALAOLzFDV_zzYz7el2CYQ6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Accrued research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">324,521</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">329,228</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AccruedProfessionalFeesCurrentAndNoncurrent_iI_maALAOLzFDV_zKpDrbEp3Pu4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">88,995</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">110,202</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherAccruedLiabilitiesCurrentAndNoncurrent_iI_maALAOLzFDV_znsy9GWYpIvc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other accrued liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">134,942</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">102,830</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iTI_mtALAOLzFDV_z799HnM7bElk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total accrued expenses and other liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">548,458</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">542,260</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231327063968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTES PAYABLE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">SCHEDULE OF DEBT</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfDebtTableTextBlock_zRdvCmgkuhr1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a summary of the Company&#8217;s outstanding debt as of December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_zxqkAlQYmA68" style="display: none">SCHEDULE OF DEBT</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Principal balance</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accrued interest</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net debt balance</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%">2023 Notes</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zU60fbBhchl5" style="width: 14%; text-align: right" title="Principal balance">216,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zQwwIJ88fsjb" style="width: 14%; text-align: right" title="Accrued interest">14,368</td><td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_pp0p0_di_c20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zvNzNBWlPKJd" style="width: 2%" title="Unamortized Debt Discount &amp; Issuance Costs">&#160;<span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,197,200</span></td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--NotesPayable_iI_pp0p0_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zYbjz8oyRlw3" style="width: 14%; text-align: right" title="Net debt balance">230,368</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Financed insurance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20241231__us-gaap--DebtInstrumentAxis__custom--FinancedInsuranceMember_zi1MOHF1prN" style="border-bottom: Black 1pt solid; text-align: right" title="Principal balance">71,292</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20241231__us-gaap--DebtInstrumentAxis__custom--FinancedInsuranceMember_zX7cjlkEPmle" style="border-bottom: Black 1pt solid; text-align: right" title="Accrued interest"><span style="-sec-ix-hidden: xdx2ixbrl0770">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--NotesPayable_iI_pp0p0_c20241231__us-gaap--DebtInstrumentAxis__custom--FinancedInsuranceMember_zjfPcpqvL9g2" style="border-bottom: Black 1pt solid; text-align: right" title="Net debt balance">71,292</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20241231_zN6dblsf1W9" style="border-bottom: Black 2.5pt double; text-align: right" title="Principal balance">287,292</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20241231_zbT8QYGR1xKj" style="border-bottom: Black 2.5pt double; text-align: right" title="Accrued interest">14,368</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--NotesPayable_iI_pp0p0_c20241231_zKyk7jAmrqDe" style="border-bottom: Black 2.5pt double; text-align: right" title="Net debt balance">301,660</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a summary of the Company&#8217;s outstanding debt as of December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>balance</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accrued</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>interest</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unamortized Debt</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Discount &amp; Issuance Costs</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net debt</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>balance</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">2023 Notes</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_z6ApS99mzxnd" style="width: 12%; text-align: right" title="Principal balance">1,836,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zuQoFuAWg6S2" style="width: 12%; text-align: right" title="Accrued interest">13,078</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_pp0p0_di_c20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zpsKqhY4hFsa" style="width: 12%; text-align: right" title="Unamortized Debt Discount &amp; Issuance Costs">(1,197,200</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--NotesPayable_iI_pp0p0_c20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zgo6IaYfBrL5" style="width: 12%; text-align: right" title="Net debt balance">651,878</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Financed insurance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20231231__us-gaap--DebtInstrumentAxis__custom--FinancedInsuranceMember_zZYBHGxwKeM3" style="border-bottom: Black 1pt solid; text-align: right" title="Principal balance">197,249</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20231231__us-gaap--DebtInstrumentAxis__custom--FinancedInsuranceMember_zOneN2YGSs8l" style="border-bottom: Black 1pt solid; text-align: right" title="Accrued interest">5,570</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_pp0p0_di_c20231231__us-gaap--DebtInstrumentAxis__custom--FinancedInsuranceMember_z3EUfu8HSr32" style="border-bottom: Black 1pt solid; text-align: right" title="Unamortized Debt Discount &amp; Issuance Costs"><span style="-sec-ix-hidden: xdx2ixbrl0792">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--NotesPayable_iI_pp0p0_c20231231__us-gaap--DebtInstrumentAxis__custom--FinancedInsuranceMember_zkf50oewR1ta" style="border-bottom: Black 1pt solid; text-align: right" title="Net debt balance">202,819</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20231231_z1UV83Pl5Crf" style="border-bottom: Black 2.5pt double; text-align: right" title="Principal balance">2,033,249</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20231231_zRKee8TWZVyd" style="border-bottom: Black 2.5pt double; text-align: right" title="Accrued interest">18,648</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_pp0p0_di_c20231231_zdnuLAFZdHMc" style="border-bottom: Black 2.5pt double; text-align: right" title="Unamortized Debt Discount &amp; Issuance Costs">(1,197,200</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--NotesPayable_iI_pp0p0_c20231231_zXNq56k5z4id" style="border-bottom: Black 2.5pt double; text-align: right" title="Net debt balance">854,697</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231326419040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">SCHEDULE OF OUTSTANDING WARRANT</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zHn5nlaenwRe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a summary of outstanding warrants to purchase shares of common stock as of December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zXazZfoKgjmh" style="display: none">SCHEDULE
OF OUTSTANDING WARRANT</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Reference</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares
    Underlying Outstanding Warrants</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise
    Price</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Description</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Classification</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(a)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantOneMember_fYSk___z5mcVPdfxjK6" title="Outstanding warrant">1,913,906</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantOneMember__srt--RangeAxis__srt--MinimumMember_fYSk___z1fzs5eKzkL6" title="Exercise price">7.05</span>
                                            - $<span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantOneMember__srt--RangeAxis__srt--MaximumMember_fYSk___zYSSfkKFHT16" title="Exercise price">8.8125</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_ecustom--WarrantDescription_c20240101__20241231__us-gaap--AwardTypeAxis__custom--WarrantOneMember_fYSk___zBi4QCTIPhtb" title="Warrant description">August 2024 Warrants</span></span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Equity</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">(b)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantTwoMember_fYik___zuqMtLVpfG7d" title="Outstanding warrant">16,811</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantTwoMember_fYik___zDDK2IHj4vDc" title="Exercise price">24.56</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_ecustom--WarrantDescription_c20240101__20241231__us-gaap--AwardTypeAxis__custom--WarrantTwoMember_fYik___zILx7s0ngawa" title="Warrant description">February 2024 Warrants</span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Equity</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">(c)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantThreeMember_fYyk___zseDhakt9JB6" title="Outstanding warrant">162,881</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantThreeMember__srt--RangeAxis__srt--MinimumMember_fYyk___z0db45Uz6Jfd" title="Exercise price">7.05</span>
                                       - $<span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantThreeMember__srt--RangeAxis__srt--MaximumMember_fYSk___z9VbRgENyBca" title="Exercise price">23.51</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_ecustom--WarrantDescription_c20240101__20241231__us-gaap--AwardTypeAxis__custom--WarrantThreeMember_fYyk___zh7PO0s0NUXl" title="Warrant description">2023 Notes Warrants</span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Equity</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">(d)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantFourMember_fZCk___zx1bn6tK0Puj" title="Outstanding warrant">73,474</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantFourMember__srt--RangeAxis__srt--MinimumMember_fYyk___z70BJWkvuapc" title="Exercise price">54.56</span>
                                       - $<span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantFourMember__srt--RangeAxis__srt--MaximumMember_fYSk___zECjXJ627D37" title="Exercise price">41,400</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_ecustom--WarrantDescription_c20240101__20241231__us-gaap--AwardTypeAxis__custom--WarrantFourMember_fZCk___zWCcFWYok1tj" title="Warrant description">Other Warrants</span></span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Equity &amp; Liability</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJTzDJCL87mj" title="Outstanding warrant">2,167,072</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0B_zHttwTJw466l" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1F_zzEUMgyiqUNc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    August 29, 2024, in connection with the 2024 Registered Direct Offering and 2024 August Warrant Inducement<b><i>,</i></b> the Company
    issued equity classified warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240829__us-gaap--ClassOfWarrantOrRightAxis__custom--InstitutionalInvestorMember_zNG3PCMr6ec2" title="Warrants issued">1,964,658</span> shares to certain institutional investors and the placement agent. The warrants
    were issued in connection with the 2024 Registered Direct Offering and the 2024 August Warrant Inducement. The <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240829__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantsMember_zCcwEySoITL6" title="Warrants issued">1,914,466</span> investor
    warrants have an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240829__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantsMember_zKC9jmetdTd9" title="Warrant exercise price">7.05 </span>per share and are exercisable from the date on which stockholder approval is received. One
    half of the warrants will expire eighteen months after they are exercisable, and the other half will expire five years after they
    are exercisable. The <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240829__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zXGowZWvK2tl" title="Warrants issued">50,200</span> placement agent warrants have an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240829__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zxoN3w5rZkN7" title="Warrant exercise price">8.8125</span> per share, are exercisable upon stockholder
    approval and expire <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20240829__us-gaap--StatementClassOfStockAxis__custom--PlacementAgentWarrantsMember_zcyag8G0Zdfk" title="Warrant expiration date">August 28, 2029</span>. In December 2024, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantsMember_zuUEfDSwdiP2" title="Investor warrants exercised">50,760</span> investor warrants were exercised.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F09_z7hCESe76193" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_F1E_zn22odATDlzh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                            February 12, 2024, the Company issued <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240212__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__custom--PlacementAgentWarrantsMember_zDxa1qEyCZYj" title="Warrants issued">497,042</span> equity classified warrants (Series A Warrants,
                                            Series B Warrants and placement agent warrants) in connection with the Inducement Letter
                                            for the 2024 February warrant inducement and related warrant restructuring. The Series A
                                            and Series B Warrants were immediately exercisable with an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240212__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zR9dfSKJaEJ6" title="Warrants, exercise price">15.90</span> per share
                                            and expire on <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20240212__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsMember_zZOTCaPZu5Pi" title="Warrant expiration date">August 14, 2025</span> and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20240212__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zaaTSgBzpBSd" title="Warrant expiration date">May 12, 2028</span>, respectively. The placement agent warrants
                                            were immediately exercisable with an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240212__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCmYK51xOsxl" title="Warrant exercise price">24.56</span> per share and expire on <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20240212__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zHgYiFEHje1l" title="Warrant expiration date">May
                                            12, 2028</span>. In connection with the 2024 August Warrant Inducement, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240831__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__custom--PlacementAgentWarrantsMember_zaRXUZi5a449" title="Warrants issued">480,234</span> warrants were exercised.
                                            As of December 31, 2024, the placement agents remain outstanding.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F03_zsyzqHHpCIGb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_F15_zRUWJm7e3Vlj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                            October 25, 2023, and November 28, 2023, the Company issued warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231025__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z10EZER6bSc1" title="Warrants issued">83,714</span> shares
                                            and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231128__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zM5GcBQqU1Vd" title="Warrants issued">167,427</span> shares, respectively. The warrants were immediately exercisable with an exercise
                                            price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pp4d_c20231025__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGVJ31xafQXb" title="Warrants, exercise price"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pp4d_c20231128__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLgwkQtyqAdc" title="Warrants, exercise price">23.51</span></span> per share and expire on <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20231025__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKB6m7xuUk91" title="Warrant expiration date">October 25, 2028</span>, and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20231128__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztlLffHDnze5" title="Warrant expiration date">November 28, 2028</span>, respectively.
                                            In January 2024, a holder of the warrants exercised <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240131__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zonkSPUuw3Eb" title="Warrants exercisable">88,261</span> warrants at an exercise price
                                            of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240131__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuaKVnF1utl" title="Warrant, exercise price">23.51</span> per share. In August 2024, an inducement letter was issued to a holder of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240831_zAsZNrYfFeFc" title="Warrants to purchase common shares">133,334</span>
                                            warrants to reduce the exercise price from $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--SharePrice_iI_pid_c20240830_zwEOqsMWCRwj" title="Share price">23.51</span> to $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--SharePrice_iI_pid_c20240831_z1RxZeUk6qOa" title="Share price">7.05</span> per share.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F08_zrT6I50Hspde" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F11_zMnLjdxbjTVh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
    various dates from the Closing of the Business Combination through September 30, 2023, the Company assumed or issued a total of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230930_ze0v1hh7LLhh" title="Warrants issued">73,474</span>
    warrants to provide holders the right to purchase common stock at exercise prices ranging from $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__srt--RangeAxis__srt--MinimumMember_zVIcsZe1mFXd" title="Warrant exercise price">54.60</span> - $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__srt--RangeAxis__srt--MaximumMember_zVdRSVUA0kk" title="Warrant exercise price">41,400</span> per share. A total
    of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230930__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantMember_zTdEAKVUFAk2" title="Class of warrant or right, outstanding">2,778</span> of the outstanding warrants are public warrants which trade on the OTC Pink Open Market under the ticker symbol ENSCW. A
    total of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230930__us-gaap--StatementEquityComponentsAxis__custom--Notes2021And2022Member_zypGz5J7nhb9" title="Class of warrant or right, outstanding">2,901</span> outstanding warrants (issued in connection with the 2021 and 2022 Notes) are liability-classified due to certain cash
    settlement features embedded within the warrant agreements. The remaining warrants are equity classified. The warrants expire beginning
    <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230929__us-gaap--StatementEquityComponentsAxis__custom--Notes2021And2022Member_zscjcC1ZwVac" title="Warrant expiration date">June 30, 2026</span>, through <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230930__us-gaap--StatementEquityComponentsAxis__custom--Notes2021And2022Member_zUzYNP45Z9a9" title="Warrant expiration date">August 7, 2028</span></span></td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231327101968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">SCHEDULE OF STOCK OPTION ACTIVITY</a></td>
<td class="text"><p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zSoo4paadGYi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s stock option activity during the year ended December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zumGmWQcnou3" style="display: none">SCHEDULE OF STOCK OPTION ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    average</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise
    price</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Remaining
    contractual life</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Intrinsic
    value</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%"><span style="font-family: Times New Roman, Times, Serif">Outstanding at December 31, 2023</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231_z3l9JqbA6p3a" style="width: 12%; text-align: right" title="Option outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif">38,785</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231_zezRuMLV5NA6" style="width: 12%; text-align: right" title="Weighted average exercise price. beginning balance"><span style="font-family: Times New Roman, Times, Serif">501.65</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zooWRqc7cmp7" title="Weighted average remaining contractual term">9.57</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240101__20241231_zgzhArCAcr8d" style="width: 12%; text-align: right" title="Aggregate intrinsic value, beginning balance"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1097">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231_zMNI7fHiKiXj" style="text-align: right" title="Option outstanding, granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1099">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zoQqZkWNioJh" style="text-align: right" title="Weighted average exercise price, granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1101">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_pp0p0_c20240101__20241231_zov7cyppPoQ7" style="text-align: right" title="Aggregate intrinsic value, granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1103">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20240101__20241231_z8u3AK8QefA2" style="text-align: right" title="Option outstanding, exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1105">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20241231_zVjKu15zBDKa" style="text-align: right" title="Weighted average exercise price, exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1107">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20240101__20241231_zSDXyiP2r521" style="text-align: right" title="Aggregate intrinsic value, exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1109">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Expired / Forfeited</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20240101__20241231_z2Afjhn6Et57" style="border-bottom: Black 1pt solid; text-align: right" title="Option outstanding, expired or forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1111">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zMqLUqBFLRQb" style="text-align: right" title="Weighted average exercise price, expired or forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1113">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue_pp0p0_c20240101__20241231_z6V4kuznpLqc" style="text-align: right" title="Aggregate intrinsic value, expired or forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1115">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding at December 31, 2024</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20241231_zgDwmLoCOs0k" style="border-bottom: Black 2.5pt double; text-align: right" title="Option outstanding, ending balance"><span style="font-family: Times New Roman, Times, Serif">38,785</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231_zPlDVN10Yp31" style="text-align: right" title="Weighted average exercise price, ending balance"><span style="font-family: Times New Roman, Times, Serif">501.65</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_zziDb8xbESG8" title="Weighted average remaining contractual term">8.58</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20240101__20241231_zQG69ztPbRae" style="text-align: right" title="Aggregate intrinsic value, ending balance"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1123">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Exercisable at December 31, 2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20241231_z9qExBSCGcyl" style="text-align: right" title="Option, exercisable"><span style="font-family: Times New Roman, Times, Serif">38,734</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20240101__20241231_zBKI5C4aWqI4" style="text-align: right" title="Weighted average exercise price, exercisable"><span style="font-family: Times New Roman, Times, Serif">493.54</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20240101__20241231_zf9zZYpnXOea" style="text-align: right" title="Aggregate intrinsic value, Exercisable"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1129">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Vested and expected to vest</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20241231_zPw9sME9h5L4" style="text-align: right" title="Option vested or expected to vest"><span style="font-family: Times New Roman, Times, Serif">38,785</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20241231_zEU3q1Ptdym9" style="text-align: right" title="Weighted average exercise price, vested or expected to vest"><span style="font-family: Times New Roman, Times, Serif">501.65</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_zxz8jWI1HIDf" title="Weighted average remaining contractual term, exercisable">8.58</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_pp0p0_c20241231_z68lzkM2M505" style="text-align: right" title="Aggregate intrinsic value, vested or expected to vest"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1137">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS</a></td>
<td class="text"><p id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zYYRmefYhdH8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of each stock option granted has been determined using the Black-Scholes option-pricing model. The material assumptions used
in the Black-Scholes model in estimating the fair value of the options granted for the periods presented were as follows (no stock options
were granted during the year ended December 31, 2024):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_z2oPX5VQwyVd" style="display: none">SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Exercise price</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231231__srt--RangeAxis__srt--MinimumMember_zZcUquZc0jL4" title="Exercise price">16.95</span>
                                       - <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231231__srt--RangeAxis__srt--MaximumMember_zHEjPXhcWan8" title="Exercise price">17.70</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected stock price volatility</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20230101__20231231_ziENiitsN581" title="Expected stock price volatility, minimum">106.77</span>%
                                            - <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20230101__20231231_zJFMwOgQg5Ae" title="Expected stock price volatility, maximum">106.82</span>%</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected term (years)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zk4OslyzUpj4" title="Expected term (years)">5.00</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free interest rate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20230101__20231231_zGpGxcLgkT16" title="Risk-free interest rate, minimum">4.62</span>%
                                            - <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20230101__20231231_z9sv64O57Lxc" title="Risk-free interest rate, maximum">4.89</span>%</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected dividend yield</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231_ztwCi9YKlaLl" title="Expected dividend rate">0</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_ScheduleOfCommonStockFutureIssuanceTableTextBlock', window );">SCHEDULE OF COMMON STOCK FUTURE ISSUANCE</a></td>
<td class="text"><p id="xdx_899_ecustom--ScheduleOfCommonStockFutureIssuanceTableTextBlock_zuUtL05IOrE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following shares of common stock are reserved for future issuance:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_z3b6beliuu5l" style="display: none">SCHEDULE OF COMMON STOCK FUTURE ISSUANCE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Awards outstanding under the 2021
    Omnibus Incentive Plan</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOvxi2CvahC4" style="width: 16%; text-align: right" title="Common Stock, capital shares reserved for future issuance"><span style="font-family: Times New Roman, Times, Serif">38,785</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Awards available for future grant under 2021
    Omnibus Incentive Plan</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--StockOptionAvailableForFutureGrantUnder2021OmnibusIncentivePlanMember_zM6typmi2vlf" style="text-align: right" title="Common Stock, capital shares reserved for future issuance"><span style="font-family: Times New Roman, Times, Serif">10,596</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Warrants outstanding</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantOutstandingMember_zVYWMclqlRwj" style="border-bottom: Black 1pt solid; text-align: right" title="Common Stock, capital shares reserved for future issuance"><span style="font-family: Times New Roman, Times, Serif">2,167,072</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total shares of common
    stock reserved for future issuance</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20241231_zjzknOyBbv54" style="border-bottom: Black 2.5pt double; text-align: right" title="Total shares of common stock reserved for future issuance"><span style="font-family: Times New Roman, Times, Serif">2,216,453</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENSC_ScheduleOfCommonStockFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Common Stock Future Issuance [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENSC_ScheduleOfCommonStockFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENSC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231326599376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">SCHEDULE OF INCOME TAXES BENEFIT</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zZTnJWwXv5j5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
before provision for income taxes consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zNaBR3oaIq67" style="display: none">SCHEDULE OF INCOME TAXES BENEFIT</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    ending December 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">United States</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pp0p0_c20240101__20241231__srt--StatementGeographicalAxis__country--US_z59Nsq1xf00f" style="width: 16%; text-align: right" title="Loss before provision for income taxes"><span style="font-family: Times New Roman, Times, Serif">(7,987,009</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pp0p0_c20230101__20231231__srt--StatementGeographicalAxis__country--US_zNmX9uvzzBW4" style="width: 16%; text-align: right" title="Loss before provision for income taxes"><span style="font-family: Times New Roman, Times, Serif">(10,626,275</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_ScheduleOfFederalAndStateIncomeTaxProvisionBenefitTableTextBlock', window );">SCHEDULE OF FEDERAL AND STATE INCOME TAX PROVISION (BENEFIT)</a></td>
<td class="text"><p id="xdx_899_ecustom--ScheduleOfFederalAndStateIncomeTaxProvisionBenefitTableTextBlock_z1fo87DK9eY" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal and state income tax provision (benefit), included in general and administrative expenses in the Consolidated Statement of Operations,
is summarized as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zjSbCT2gWjT1" style="display: none">SCHEDULE OF FEDERAL AND STATE INCOME TAX PROVISION (BENEFIT)</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    ending December 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current state provision</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pp0p0_c20240101__20241231_zBH57HOWOXO6" style="width: 16%; text-align: right" title="Current state provision"><span style="font-family: Times New Roman, Times, Serif">3,300</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pp0p0_c20230101__20231231_zN4vWxoXWq42" style="width: 16%; text-align: right" title="Current state provision"><span style="font-family: Times New Roman, Times, Serif">3,200</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">SCHEDULE OF FEDERAL INCOME TAX RATE RECONCILIATION</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zWMZoPdyyyf3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
effective tax rate of the Company&#8217;s provision (benefit) for income taxes differs from the federal statutory rate as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zugETMXcPwmj" style="display: none">SCHEDULE OF FEDERAL INCOME TAX RATE RECONCILIATION</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_493_20240101__20241231_zZ614y3olEhe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_491_20230101__20231231_zDgddKBZFF6k" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    ending December 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzZ0P_zhlP8LGZwU57" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Income (benefit) taxes at statutory
    rates</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,677,271</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,231,518</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzZ0P_z0qboDzTYj1a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">State income tax, net of federal benefit</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(62,342</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(77,243</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_maITEBzZ0P_zAyOgibPmStc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Warrants and convertible debt</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,421</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(90,392</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_maITEBzZ0P_zp0RWO7SZeX5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Nondeductible executive compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,325</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,107</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_maITEBzZ0P_z4mBefHk9VP8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock based compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">22,633</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">580,823</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_di_msITEBzZ0P_zwGgLNGQpVgh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development tax credits</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(428,675</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(629,239</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_407_ecustom--IncomeTaxReconciliationExpiringAttributes_maITEBzZ0P_zXztURcte3Jg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expiring attributes</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">183,912</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1208">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationTaxContingencies_maITEBzZ0P_zvXAllxY2oM1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Change in tax rates</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(296</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,848</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzZ0P_zMAGBoN4Jbbl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,282</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">77,162</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzZ0P_zOU4xy55K7f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Change in valuation allowance</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,936,853</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,372,148</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzZ0P_ziFgkx0EaDB8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1219">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1220">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">SCHEDULE OF DEFERRED TAX ASSETS</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zLqQhhHqop98" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s deferred tax assets were comprised of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zxXcPdtKig97" style="display: none">SCHEDULE OF DEFERRED TAX ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_490_20241231_zzn5Gwrmdoj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_491_20231231_z2Obiskxomuh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As
    of December 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred tax assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTAGz96z_zv1N7PxqF0E7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net operating
    loss tax carryforwards</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">29,728,009</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">28,485,164</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_iI_pp0p0_maDTAGz96z_zaldXCXze6s8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Tax credits</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,212,263</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,793,138</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pp0p0_maDTAGz96z_ze4nAv8EZuk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Capitalized research costs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,655,425</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,368,767</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0_maDTAGz96z_z6tTMzyXUgmb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">729,318</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">746,444</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsOther_iI_pp0p0_maDTAGz96z_zImKrQrVvbN7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">36,630</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">31,279</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsGross_iTI_pp0p0_mtDTAGz96z_maDTANzp9G_zZuSG6xTp9N9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross deferred tax assets</span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">40,361,645</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">38,424,792</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTANzp9G_zX63HUeRvA79" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Valuation allowance</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(40,361,645</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(38,424,792</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsNet_iTI_pp0p0_mtDTANzp9G_maDTALNzQQ7_z0mX2Ur829ag" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total deferred tax assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1245">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1246">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred tax liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxLiabilitiesOther_iNI_pp0p0_di_maDTLzuel_zC1227LKsT65" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1248">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1249">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxLiabilities_iNTI_di_mtDTLzuel_msDTALNzQQ7_zFdEMqEMnLz6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Total
    deferred tax liabilities</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1251">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1252">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pp0p0_mtDTALNzQQ7_zVNxT8wB5ZJ3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net deferred tax assets</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1254">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1255">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">SCHEDULE OF UNRECOGNIZED TAX BENEFITS</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_zsvlQX1CuHtb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the activity related to the Company&#8217;s unrecognized tax benefits:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_z9jwHXM9uL3c" style="display: none">SCHEDULE
OF UNRECOGNIZED TAX BENEFITS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20240101__20241231_zICGxDjWgihi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_497_20230101__20231231_zoobMijdKGs4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    ending December 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--UnrecognizedTaxBenefits_iS_zg1EEFtUZrae" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Balance at beginning of year</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,685,360</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,428,261</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_zw3IHfOkSFki" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Increases related to current year tax positions</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">141,023</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">128,404</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_zDwD2MFhav37" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Increases related to prior year tax positions</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,054</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">128,695</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_iN_di_zuTR172tJSy3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Decreases related to prior
    year tax positions</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(444</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1289">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--UnrecognizedTaxBenefits_iE_zb3Ic7R5BVXj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance at end of year</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,826,993</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,685,360</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENSC_ScheduleOfFederalAndStateIncomeTaxProvisionBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Federal and State Income Tax Provision (Benefit) [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENSC_ScheduleOfFederalAndStateIncomeTaxProvisionBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENSC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231324586160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ORGANIZATION AND PRINCIPAL ACTIVITIES (Details Narrative) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Nov. 27, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>May 12, 2023</div></th>
<th class="th"><div>Feb. 02, 2023</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ENSC_EBIRIncMember', window );">EBIR, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">79.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ENSC_EBIRIncMember', window );">EBIR, Inc [Member] | Key Personnel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">19.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ENSC_EBIRIncMember', window );">EBIR, Inc [Member] | Unrelated Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ENSC_EBIRIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ENSC_EBIRIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ENSC_KeyPersonnelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ENSC_KeyPersonnelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ENSC_UnrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ENSC_UnrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231325352560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 27, 2024</div></th>
<th class="th"><div>Oct. 18, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">1-for-15<span></span>
</td>
<td class="text">1-for-15<span></span>
</td>
<td class="text">1-for-15<span></span>
</td>
<td class="text">1-for-12<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231317869600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Liability classified warrants</a></td>
<td class="nump">$ 10,096<span></span>
</td>
<td class="nump">$ 26,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="nump">10,096<span></span>
</td>
<td class="nump">26,388<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Liability classified warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Liability classified warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Liability classified warrants</a></td>
<td class="nump">10,096<span></span>
</td>
<td class="nump">26,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="nump">$ 10,096<span></span>
</td>
<td class="nump">$ 26,388<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_PlatformOperatorCryptoAssetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.FF.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476188/405-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_PlatformOperatorCryptoAssetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset after deduction of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231326575824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY&#8217;S LEVEL 3 (Details) - Liability Classified Warrants [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 26,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value</a></td>
<td class="num">(16,292)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 10,096<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=ENSC_LiabilityClassifiedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=ENSC_LiabilityClassifiedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231318512736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF REVENUE RECOGNITION UNDER GRANTS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total</a></td>
<td class="nump">$ 5,210,031<span></span>
</td>
<td class="nump">$ 2,230,520<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ENSC_MPARMember', window );">MPAR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total</a></td>
<td class="nump">3,086,464<span></span>
</td>
<td class="nump">1,293,238<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ENSC_TAAPOUDMember', window );">TAAP/OUD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total</a></td>
<td class="nump">$ 2,123,567<span></span>
</td>
<td class="nump">$ 937,282<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ENSC_MPARMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ENSC_MPARMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ENSC_TAAPOUDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ENSC_TAAPOUDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231324586928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">599,208<span></span>
</td>
<td class="nump">340,078<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">38,734<span></span>
</td>
<td class="nump">8,784<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">551,287<span></span>
</td>
<td class="nump">253,208<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">9,187<span></span>
</td>
<td class="nump">78,086<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231318514448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskBenchmarkDescription', window );">Concentration of risk, description</a></td>
<td class="text">three and two research and development vendors made up greater than 10% individually, and 74% and 38% in aggregate<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Grants receivable | $</a></td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="nump">$ 10,700,000<span></span>
</td>
<td class="nump">$ 14,000,000<span></span>
</td>
<td class="nump">$ 5,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of risk</a></td>
<td class="nump">74.00%<span></span>
</td>
<td class="nump">38.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskBenchmarkDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identifies or describes the benchmark that serves as the denominator in the calculation of the percentage of concentration risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskBenchmarkDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ENSC_CustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ENSC_CustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231327459936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_PrepaidResearchAndDevelopment', window );">Prepaid research and development</a></td>
<td class="nump">$ 1,342,461<span></span>
</td>
<td class="nump">$ 535,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">315,306<span></span>
</td>
<td class="nump">441,871<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses</a></td>
<td class="nump">42,723<span></span>
</td>
<td class="nump">72,358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">18,000<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 1,718,490<span></span>
</td>
<td class="nump">$ 1,067,703<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENSC_PrepaidResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENSC_PrepaidResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENSC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231326747504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_AccruedResearchAndDevelopment', window );">Accrued research and development</a></td>
<td class="nump">$ 324,521<span></span>
</td>
<td class="nump">$ 329,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent', window );">Accrued professional fees</a></td>
<td class="nump">88,995<span></span>
</td>
<td class="nump">110,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent', window );">Other accrued liabilities</a></td>
<td class="nump">134,942<span></span>
</td>
<td class="nump">102,830<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total accrued expenses and other liabilities</a></td>
<td class="nump">$ 548,458<span></span>
</td>
<td class="nump">$ 542,260<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENSC_AccruedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENSC_AccruedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENSC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231325424192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Future lease payments</a></td>
<td class="nump">29,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Rent expense</a></td>
<td class="nump">$ 35,217<span></span>
</td>
<td class="nump">$ 33,747<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231330801936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF DEBT (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal balance</a></td>
<td class="nump">$ 287,292<span></span>
</td>
<td class="nump">$ 2,033,249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued interest</a></td>
<td class="nump">14,368<span></span>
</td>
<td class="nump">18,648<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized Debt Discount &amp; Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,197,200)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Net debt balance</a></td>
<td class="nump">301,660<span></span>
</td>
<td class="nump">854,697<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ENSC_TwoThousandTwentyThreeNotesMember', window );">2023 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal balance</a></td>
<td class="nump">216,000<span></span>
</td>
<td class="nump">1,836,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued interest</a></td>
<td class="nump">14,368<span></span>
</td>
<td class="nump">13,078<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized Debt Discount &amp; Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,197,200)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Net debt balance</a></td>
<td class="nump">230,368<span></span>
</td>
<td class="nump">651,878<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ENSC_FinancedInsuranceMember', window );">Financed Insurance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal balance</a></td>
<td class="nump">71,292<span></span>
</td>
<td class="nump">197,249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued interest</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,570<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized Debt Discount &amp; Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Net debt balance</a></td>
<td class="nump">$ 71,292<span></span>
</td>
<td class="nump">$ 202,819<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ENSC_TwoThousandTwentyThreeNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ENSC_TwoThousandTwentyThreeNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ENSC_FinancedInsuranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ENSC_FinancedInsuranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231318428336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTES PAYABLE (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 29, 2023</div></th>
<th class="th"><div>Oct. 25, 2023</div></th>
<th class="th"><div>Oct. 23, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Nov. 27, 2024</div></th>
<th class="th"><div>Aug. 31, 2024</div></th>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Feb. 12, 2024</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 28, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>May 12, 2023</div></th>
<th class="th"><div>Feb. 02, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,848<span></span>
</td>
<td class="nump">$ 14,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 287,292<span></span>
</td>
<td class="nump">$ 2,033,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,474<span></span>
</td>
<td class="nump">14,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant, exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of shares value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,168,600<span></span>
</td>
<td class="nump">$ 3,056,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_ProceedsFromWarrantInducementNetOfIssuanceCosts', window );">Transaction cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,103,942<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_FinancedInsurancePremiums', window );">Financed insurance premiums</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 232,155<span></span>
</td>
<td class="nump">445,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant, exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.81<span></span>
</td>
<td class="nump">$ 24.56<span></span>
</td>
<td class="nump">$ 24.56<span></span>
</td>
<td class="nump">$ 23.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ENSC_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant, exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.5125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_ProceedsFromWarrantInducementNetOfIssuanceCosts', window );">Transaction cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_IssuanceOfCommonStockValueUponWarrantInducementNetOfIssuanceCosts', window );">Warrant inducement cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_TransactionCostsAssociatedWithWarrantInducement', window );">Transaction cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ENSC_TwoThousandTwentyThreeNotesMember', window );">2023 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,281,597<span></span>
</td>
<td class="nump">339,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216,000<span></span>
</td>
<td class="nump">1,836,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ENSC_TwoThousandTwentyThreeNotesMember', window );">2023 Notes [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ENSC_TwoThousandTwentyThreeNotesMember', window );">2023 Notes [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ENSC_TwoThousandTwentyThreeNotesMember', window );">2023 Notes [Member] | First Closing Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 566,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 612,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ENSC_TwoThousandTwentyThreeNotesMember', window );">2023 Notes [Member] | Second Closing Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Aggregate purchase price</a></td>
<td class="nump">$ 1,133,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="nump">$ 1,224,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common shares</a></td>
<td class="nump">167,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENSC_FinancedInsurancePremiums">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financed insurance premiums.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENSC_FinancedInsurancePremiums</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENSC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENSC_IssuanceOfCommonStockValueUponWarrantInducementNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock value upon warrant inducement, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENSC_IssuanceOfCommonStockValueUponWarrantInducementNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENSC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENSC_ProceedsFromWarrantInducementNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from warrant inducement, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENSC_ProceedsFromWarrantInducementNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENSC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENSC_TransactionCostsAssociatedWithWarrantInducement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction costs associated with warrant inducement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENSC_TransactionCostsAssociatedWithWarrantInducement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENSC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ENSC_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ENSC_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ENSC_TwoThousandTwentyThreeNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ENSC_TwoThousandTwentyThreeNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ENSC_FirstClosingSecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ENSC_FirstClosingSecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ENSC_SecondClosingSecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ENSC_SecondClosingSecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231317936880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF OUTSTANDING WARRANT (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Outstanding warrant | shares</a></td>
<td class="nump">2,167,072<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ENSC_WarrantOneMember', window );">Warrant One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Outstanding warrant | shares</a></td>
<td class="nump">1,913,906<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_WarrantDescription', window );">Warrant description</a></td>
<td class="text">August 2024 Warrants<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ENSC_WarrantOneMember', window );">Warrant One [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 7.05<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ENSC_WarrantOneMember', window );">Warrant One [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 8.8125<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ENSC_WarrantTwoMember', window );">Warrant Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Outstanding warrant | shares</a></td>
<td class="nump">16,811<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 24.56<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_WarrantDescription', window );">Warrant description</a></td>
<td class="text">February 2024 Warrants<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ENSC_WarrantThreeMember', window );">Warrant Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Outstanding warrant | shares</a></td>
<td class="nump">162,881<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_WarrantDescription', window );">Warrant description</a></td>
<td class="text">2023 Notes Warrants<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ENSC_WarrantThreeMember', window );">Warrant Three [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 7.05<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ENSC_WarrantThreeMember', window );">Warrant Three [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 23.51<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ENSC_WarrantFourMember', window );">Warrant Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Outstanding warrant | shares</a></td>
<td class="nump">73,474<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_WarrantDescription', window );">Warrant description</a></td>
<td class="text">Other Warrants<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ENSC_WarrantFourMember', window );">Warrant Four [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 54.56<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ENSC_WarrantFourMember', window );">Warrant Four [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 41,400<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">On
    August 29, 2024, in connection with the 2024 Registered Direct Offering and 2024 August Warrant Inducement<b><i>,</i></b> the Company
    issued equity classified warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240829__us-gaap--ClassOfWarrantOrRightAxis__custom--InstitutionalInvestorMember_zNG3PCMr6ec2" title="Warrants issued">1,964,658</span> shares to certain institutional investors and the placement agent. The warrants
    were issued in connection with the 2024 Registered Direct Offering and the 2024 August Warrant Inducement. The <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240829__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantsMember_zCcwEySoITL6" title="Warrants issued">1,914,466</span> investor
    warrants have an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240829__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantsMember_zKC9jmetdTd9" title="Warrant exercise price">7.05 </span>per share and are exercisable from the date on which stockholder approval is received. One
    half of the warrants will expire eighteen months after they are exercisable, and the other half will expire five years after they
    are exercisable. The <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240829__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zXGowZWvK2tl" title="Warrants issued">50,200</span> placement agent warrants have an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240829__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zxoN3w5rZkN7" title="Warrant exercise price">8.8125</span> per share, are exercisable upon stockholder
    approval and expire <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20240829__us-gaap--StatementClassOfStockAxis__custom--PlacementAgentWarrantsMember_zcyag8G0Zdfk" title="Warrant expiration date">August 28, 2029</span>. In December 2024, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantsMember_zuUEfDSwdiP2" title="Investor warrants exercised">50,760</span> investor warrants were exercised.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">On
                                            February 12, 2024, the Company issued <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240212__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__custom--PlacementAgentWarrantsMember_zDxa1qEyCZYj" title="Warrants issued">497,042</span> equity classified warrants (Series A Warrants,
                                            Series B Warrants and placement agent warrants) in connection with the Inducement Letter
                                            for the 2024 February warrant inducement and related warrant restructuring. The Series A
                                            and Series B Warrants were immediately exercisable with an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240212__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zR9dfSKJaEJ6" title="Warrants, exercise price">15.90</span> per share
                                            and expire on <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20240212__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsMember_zZOTCaPZu5Pi" title="Warrant expiration date">August 14, 2025</span> and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20240212__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zaaTSgBzpBSd" title="Warrant expiration date">May 12, 2028</span>, respectively. The placement agent warrants
                                            were immediately exercisable with an exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240212__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCmYK51xOsxl" title="Warrant exercise price">24.56</span> per share and expire on <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20240212__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zHgYiFEHje1l" title="Warrant expiration date">May
                                            12, 2028</span>. In connection with the 2024 August Warrant Inducement, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240831__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__custom--PlacementAgentWarrantsMember_zaRXUZi5a449" title="Warrants issued">480,234</span> warrants were exercised.
                                            As of December 31, 2024, the placement agents remain outstanding.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">On
                                            October 25, 2023, and November 28, 2023, the Company issued warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231025__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z10EZER6bSc1" title="Warrants issued">83,714</span> shares
                                            and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231128__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zM5GcBQqU1Vd" title="Warrants issued">167,427</span> shares, respectively. The warrants were immediately exercisable with an exercise
                                            price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pp4d_c20231025__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGVJ31xafQXb" title="Warrants, exercise price"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pp4d_c20231128__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLgwkQtyqAdc" title="Warrants, exercise price">23.51</span></span> per share and expire on <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20231025__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKB6m7xuUk91" title="Warrant expiration date">October 25, 2028</span>, and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20231128__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztlLffHDnze5" title="Warrant expiration date">November 28, 2028</span>, respectively.
                                            In January 2024, a holder of the warrants exercised <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240131__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zonkSPUuw3Eb" title="Warrants exercisable">88,261</span> warrants at an exercise price
                                            of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240131__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuaKVnF1utl" title="Warrant, exercise price">23.51</span> per share. In August 2024, an inducement letter was issued to a holder of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240831_zAsZNrYfFeFc" title="Warrants to purchase common shares">133,334</span>
                                            warrants to reduce the exercise price from $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--SharePrice_iI_pid_c20240830_zwEOqsMWCRwj" title="Share price">23.51</span> to $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--SharePrice_iI_pid_c20240831_z1RxZeUk6qOa" title="Share price">7.05</span> per share.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">At
    various dates from the Closing of the Business Combination through September 30, 2023, the Company assumed or issued a total of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230930_ze0v1hh7LLhh" title="Warrants issued">73,474</span>
    warrants to provide holders the right to purchase common stock at exercise prices ranging from $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__srt--RangeAxis__srt--MinimumMember_zVIcsZe1mFXd" title="Warrant exercise price">54.60</span> - $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__srt--RangeAxis__srt--MaximumMember_zVdRSVUA0kk" title="Warrant exercise price">41,400</span> per share. A total
    of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230930__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantMember_zTdEAKVUFAk2" title="Class of warrant or right, outstanding">2,778</span> of the outstanding warrants are public warrants which trade on the OTC Pink Open Market under the ticker symbol ENSCW. A
    total of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230930__us-gaap--StatementEquityComponentsAxis__custom--Notes2021And2022Member_zypGz5J7nhb9" title="Class of warrant or right, outstanding">2,901</span> outstanding warrants (issued in connection with the 2021 and 2022 Notes) are liability-classified due to certain cash
    settlement features embedded within the warrant agreements. The remaining warrants are equity classified. The warrants expire beginning
    <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230929__us-gaap--StatementEquityComponentsAxis__custom--Notes2021And2022Member_zscjcC1ZwVac" title="Warrant expiration date">June 30, 2026</span>, through <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230930__us-gaap--StatementEquityComponentsAxis__custom--Notes2021And2022Member_zUzYNP45Z9a9" title="Warrant expiration date">August 7, 2028</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENSC_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENSC_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENSC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENSC_WarrantDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENSC_WarrantDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENSC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ENSC_WarrantOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ENSC_WarrantOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ENSC_WarrantTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ENSC_WarrantTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ENSC_WarrantThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ENSC_WarrantThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ENSC_WarrantFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ENSC_WarrantFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231318655008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF OUTSTANDING WARRANT (Details) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Aug. 31, 2024</div></th>
<th class="th"><div>Aug. 30, 2024</div></th>
<th class="th"><div>Aug. 29, 2024</div></th>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Feb. 12, 2024</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 28, 2023</div></th>
<th class="th"><div>Oct. 25, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 29, 2023</div></th>
<th class="th"><div>May 12, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.05<span></span>
</td>
<td class="nump">$ 23.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">252.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,808.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167,427<span></span>
</td>
<td class="nump">83,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 23.51<span></span>
</td>
<td class="nump">$ 8.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.56<span></span>
</td>
<td class="nump">$ 24.56<span></span>
</td>
<td class="nump">$ 23.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.51<span></span>
</td>
<td class="nump">$ 23.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrant expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 28,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 12,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 28,  2028<span></span>
</td>
<td class="text">Oct. 25,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=ENSC_PublicWarrantMember', window );">Public Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=ENSC_Notes2021And2022Member', window );">Notes 2021 and 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrant expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug.  07,  2028<span></span>
</td>
<td class="text">Jun. 30,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ENSC_PlacementAgentWarrantsMember', window );">Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrant expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 28,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ENSC_PlacementAgentWarrantsMember', window );">Placement Agent Warrants [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">480,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">497,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ENSC_SeriesBWarrantsMember', window );">Series B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.90<span></span>
</td>
<td class="nump">$ 15.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrant expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 12,  2028<span></span>
</td>
<td class="text">May 12,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ENSC_SeriesAWarrantsMember', window );">Series A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrant expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 14,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ENSC_InstitutionalInvestorMember', window );">Institutional Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,964,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ENSC_InvestorWarrantsMember', window );">Investor Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="nump">50,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,914,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ENSC_PlacementAgentWarrantsMember', window );">Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.8125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=ENSC_PublicWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=ENSC_PublicWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=ENSC_Notes2021And2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=ENSC_Notes2021And2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ENSC_PlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ENSC_PlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ENSC_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ENSC_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ENSC_SeriesAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ENSC_SeriesAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ENSC_InstitutionalInvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ENSC_InstitutionalInvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ENSC_InvestorWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ENSC_InvestorWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ENSC_PlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ENSC_PlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231317658400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 27, 2024</div></th>
<th class="th"><div>Oct. 18, 2024</div></th>
<th class="th"><div>May 12, 2023</div></th>
<th class="th"><div>Feb. 06, 2023</div></th>
<th class="th"><div>Feb. 02, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Aug. 31, 2024</div></th>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Aug. 30, 2024</div></th>
<th class="th"><div>Feb. 12, 2024</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 28, 2023</div></th>
<th class="th"><div>Oct. 25, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">1-for-15<span></span>
</td>
<td class="text">1-for-15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock, gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,670,001<span></span>
</td>
<td class="nump">$ 9,050,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,474<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant, exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees', window );">Warrants issue, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company issued to the placement agent as compensation unregistered
warrants to purchase up to 50,200 shares of Common Stock.<span></span>
</td>
<td class="text">the Company issued to the placement agent as compensation unregistered warrants to purchase up to
16,811 shares of Common Stock, equal to 7.0% of the aggregate number of shares of Common Stock (or warrants) placed in the transaction<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,200<span></span>
</td>
<td class="nump">16,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock number of shares issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_CombinedOfferingPricePerShare', window );">Combined offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58.305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 151.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Sale of stock, consideration received per transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000.0<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 252.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant, exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54.60<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,808.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant, exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ENSC_SeriesAWarrantsMember', window );">Series A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant, exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrant maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 14,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ENSC_SeriesBWarrantsMember', window );">Series B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant, exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrant maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 12,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 12,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=ENSC_RegisteredDirectOfferingMember', window );">Registered Direct Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Purchase of shares through securities purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=ENSC_PrefundedWarrantMember', window );">Prefunded Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Purchase of shares through securities purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.0485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_AgentFeesAndOfferingExpensesPerShare', window );">Agent fees and offering expenses , per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock, gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,670,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=ENSC_SeriesAandBWarrantsMember', window );">Series A and B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">480,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant, exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167,427<span></span>
</td>
<td class="nump">83,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant, exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.51<span></span>
</td>
<td class="nump">$ 8.81<span></span>
</td>
<td class="nump">$ 24.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.56<span></span>
</td>
<td class="nump">$ 23.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.51<span></span>
</td>
<td class="nump">$ 23.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrant maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 28,  2029<span></span>
</td>
<td class="text">May 12,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 28,  2028<span></span>
</td>
<td class="text">Oct. 25,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassifiedWrittenCallOptionModificationEquityIssuanceIncreaseDecreaseInEquityAmount', window );">Equity issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_OfferingPricePerShare', window );">Combined offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENSC_AgentFeesAndOfferingExpensesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agent fees and offering expenses per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENSC_AgentFeesAndOfferingExpensesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENSC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENSC_CombinedOfferingPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Combined offering price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENSC_CombinedOfferingPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENSC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENSC_OfferingPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offering price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENSC_OfferingPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENSC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of reason for issuing warrant or right.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityClassifiedWrittenCallOptionModificationEquityIssuanceIncreaseDecreaseInEquityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in equity for freestanding written call option classified as equity from modification recognized as equity issuance cost. Includes, but is not limited to, exchange by issuer and holder. Excludes share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 17<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480299/815-40-35-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityClassifiedWrittenCallOptionModificationEquityIssuanceIncreaseDecreaseInEquityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ENSC_SeriesAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ENSC_SeriesAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ENSC_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ENSC_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=ENSC_RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=ENSC_RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=ENSC_PrefundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=ENSC_PrefundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=ENSC_SeriesAandBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=ENSC_SeriesAandBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231325438752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK OPTION ACTIVITY (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option outstanding, beginning balance</a></td>
<td class="nump">38,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price. beginning balance</a></td>
<td class="nump">$ 501.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term</a></td>
<td class="text">8 years 6 months 29 days<span></span>
</td>
<td class="text">9 years 6 months 25 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, beginning balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Option outstanding, granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue', window );">Aggregate intrinsic value, granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Option outstanding, exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value, exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Option outstanding, expired or forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, expired or forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue', window );">Aggregate intrinsic value, expired or forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option outstanding, ending balance</a></td>
<td class="nump">38,785<span></span>
</td>
<td class="nump">38,785<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, ending balance</a></td>
<td class="nump">$ 501.65<span></span>
</td>
<td class="nump">$ 501.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Option, exercisable</a></td>
<td class="nump">38,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, exercisable</a></td>
<td class="nump">$ 493.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, Exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option vested or expected to vest</a></td>
<td class="nump">38,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, vested or expected to vest</a></td>
<td class="nump">$ 501.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, exercisable</a></td>
<td class="text">8 years 6 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate intrinsic value, vested or expected to vest</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENSC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total Intrinsic value of share based payment forfeiture and expiration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENSC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENSC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231325429408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected stock price volatility, minimum</a></td>
<td class="nump">106.77%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected stock price volatility, maximum</a></td>
<td class="nump">106.82%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">4.62%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.89%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 16.95<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 17.70<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231326608992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF COMMON STOCK FUTURE ISSUANCE (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved for future issuance</a></td>
<td class="nump">2,216,453<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=ENSC_WarrantOutstandingMember', window );">Warrant Outstanding [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved for future issuance</a></td>
<td class="nump">2,167,072<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved for future issuance</a></td>
<td class="nump">38,785<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Stock Option Available For Future Grant Under 2021 Omnibus Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved for future issuance</a></td>
<td class="nump">10,596<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=ENSC_WarrantOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=ENSC_WarrantOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ENSC_StockOptionAvailableForFutureGrantUnder2021OmnibusIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ENSC_StockOptionAvailableForFutureGrantUnder2021OmnibusIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231324607520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 29, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance</a></td>
<td class="nump">2,216,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of restricted stock granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, vested or expected to vest</a></td>
<td class="nump">$ 501.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value per share , grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock based compensation</a></td>
<td class="nump">$ 27,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_SharebasedCompensationArrangementBySharebasedPaymentAwardWeightedAveragePeriodExpectedToBeRecognized', window );">Weighted average period</a></td>
<td class="text">9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, vested or expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, vested or expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ENSC_BoardOfMembersMember', window );">Board of Members [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of restricted stock granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="nump">$ 75,494<span></span>
</td>
<td class="nump">$ 627,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="nump">$ 35,229<span></span>
</td>
<td class="nump">$ 251,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ENSC_TwoThousandTwentyOneOmnibusIncentivePlanMember', window );">2021 Omnibus Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,487<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENSC_SharebasedCompensationArrangementBySharebasedPaymentAwardWeightedAveragePeriodExpectedToBeRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based payment award weighted average period expected to be recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENSC_SharebasedCompensationArrangementBySharebasedPaymentAwardWeightedAveragePeriodExpectedToBeRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENSC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ENSC_BoardOfMembersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ENSC_BoardOfMembersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ENSC_TwoThousandTwentyOneOmnibusIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ENSC_TwoThousandTwentyOneOmnibusIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231427510240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF INCOME TAXES BENEFIT (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income taxes</a></td>
<td class="num">$ (7,987,009)<span></span>
</td>
<td class="num">$ (10,626,275)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231326171776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF FEDERAL AND STATE INCOME TAX PROVISION (BENEFIT) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">Current state provision</a></td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231329300496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF FEDERAL INCOME TAX RATE RECONCILIATION (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income (benefit) taxes at statutory rates</a></td>
<td class="num">$ (1,677,271)<span></span>
</td>
<td class="num">$ (2,231,518)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income tax, net of federal benefit</a></td>
<td class="num">(62,342)<span></span>
</td>
<td class="num">(77,243)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges', window );">Warrants and convertible debt</a></td>
<td class="num">(3,421)<span></span>
</td>
<td class="num">(90,392)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Nondeductible executive compensation</a></td>
<td class="nump">17,325<span></span>
</td>
<td class="nump">2,107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="nump">22,633<span></span>
</td>
<td class="nump">580,823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development tax credits</a></td>
<td class="num">(428,675)<span></span>
</td>
<td class="num">(629,239)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_IncomeTaxReconciliationExpiringAttributes', window );">Expiring attributes</a></td>
<td class="nump">183,912<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxContingencies', window );">Change in tax rates</a></td>
<td class="num">(296)<span></span>
</td>
<td class="num">(3,848)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">11,282<span></span>
</td>
<td class="nump">77,162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">1,936,853<span></span>
</td>
<td class="nump">2,372,148<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENSC_IncomeTaxReconciliationExpiringAttributes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation expiring attributes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENSC_IncomeTaxReconciliationExpiringAttributes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENSC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible restructuring charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(8)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231325986928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF DEFERRED TAX ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss tax carryforwards</a></td>
<td class="nump">$ 29,728,009<span></span>
</td>
<td class="nump">$ 28,485,164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits</a></td>
<td class="nump">5,212,263<span></span>
</td>
<td class="nump">4,793,138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Capitalized research costs</a></td>
<td class="nump">4,655,425<span></span>
</td>
<td class="nump">4,368,767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">729,318<span></span>
</td>
<td class="nump">746,444<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">36,630<span></span>
</td>
<td class="nump">31,279<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">40,361,645<span></span>
</td>
<td class="nump">38,424,792<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(40,361,645)<span></span>
</td>
<td class="num">(38,424,792)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231326565312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF UNRECOGNIZED TAX BENEFITS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at beginning of year</a></td>
<td class="nump">$ 1,685,360<span></span>
</td>
<td class="nump">$ 1,428,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases related to current year tax positions</a></td>
<td class="nump">141,023<span></span>
</td>
<td class="nump">128,404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increases related to prior year tax positions</a></td>
<td class="nump">1,054<span></span>
</td>
<td class="nump">128,695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Decreases related to prior year tax positions</a></td>
<td class="num">(444)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at end of year</a></td>
<td class="nump">$ 1,826,993<span></span>
</td>
<td class="nump">$ 1,685,360<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231318508320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardDescription', window );">Tax credit carryforward, description</a></td>
<td class="text">carryforward indefinitely and be available to offset up to 80% of future taxable
income each year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableAccruedInterestWriteoff', window );">Financing receivable accrued interest write off</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember', window );">California Franchise Tax Board [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">75,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">116,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,600,000<span></span>
</td>
<td class="nump">$ 34,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Operating loss carryforwards expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">expire in 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member] | Research Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward amount</a></td>
<td class="nump">$ 5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_CaliforniaFranchiseTaxBoardMember', window );">California Franchise Tax Board [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Operating loss carryforwards expiration</a></td>
<td class="text">expire in 2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse', window );">Tax credit carryforward expiration</a></td>
<td class="text">expire in 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward amount</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member] | Research Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward amount</a></td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableAccruedInterestWriteoff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of writeoff of accrued interest on financing receivable recognized by reversing interest income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-3D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableAccruedInterestWriteoff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the origin, nature, and characteristics of the tax credit carryforward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the limitation related to use of the tax credit carryforward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_CaliforniaFranchiseTaxBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_CaliforniaFranchiseTaxBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231325331296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>RELATED PARTIES (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th"><div>Apr. 25, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Aug. 31, 2024</div></th>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Feb. 12, 2024</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Nov. 28, 2023</div></th>
<th class="th"><div>Oct. 25, 2023</div></th>
<th class="th"><div>Oct. 23, 2023</div></th>
<th class="th"><div>May 12, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_WarrantOrRightExercisable', window );">Warrants exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant, exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54.60<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant, exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.51<span></span>
</td>
<td class="nump">$ 8.81<span></span>
</td>
<td class="nump">$ 24.56<span></span>
</td>
<td class="nump">$ 24.56<span></span>
</td>
<td class="nump">$ 23.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.51<span></span>
</td>
<td class="nump">$ 23.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_WarrantExpirationDate', window );">Warrant, expiration date</a></td>
<td class="text">Apr. 25,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ENSC_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorLongTermNotes', window );">Debt financing amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant, exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.5125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENSC_WarrantExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant expiration date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENSC_WarrantExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENSC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENSC_WarrantOrRightExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant or right exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENSC_WarrantOrRightExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENSC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorLongTermNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Senior note holders are paid off in full before any payments are made to junior note holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeniorLongTermNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ENSC_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ENSC_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46231324950656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants', window );">Value of shares issued upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,433,080<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares', window );">Number of shares issued upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139,028<span></span>
</td>
<td class="nump">47,792<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants', window );">Value of shares issued upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">4,064<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted common stock issued</a></td>
<td class="nump">13,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction', window );">Shares outstanding percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares', window );">Number of shares issued upon exercise of warrants</a></td>
<td class="nump">49,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants', window );">Value of shares issued upon exercise of warrants</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period issuance of common stock upon exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENSC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period issuance of common stock upon exercise of warrants, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENSC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>70
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( )B":EH'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " "8@FI:2Q0=B^X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2L0P$(9?17)O)VU1)'1S43PI""XHWD(RNQMLFI",M/OVIG&WB^@#"+EDYL\W
MWT!Z'83V$9^C#QC)8KJ:W3 FH<.&'8B" $CZ@$ZE.B?&W-SYZ!3E:]Q#4/I#
M[1%:SF_ (2FC2,$"K,)*9+(W6NB(BGP\X8U>\>$S#@5F-." #D=*T-0-,+E,
M#,=YZ.$"6&"$T:7O IJ56*I_8DL'V"DY)[NFIFFJIZ[D\@X-O#T]OI1U*SLF
M4J/&_"I90<> &W:>_-K=W6\?F&QY>UWQKFKXMN4BG^[V?7']X7<1=M[8G?W'
MQF=!V<.O?R&_ %!+ P04    " "8@FI:F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M )B":EI9,.Y37P@  )PX   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MM9MK<Z,V%(:_[Z_0N#N=W9DXYF;'V2:9<;#=>IMXW3C=G6VG'Q20;68!N4(X
MR;^OP!>9C#A 1]X/&\"<%_2@RWDEN'JF[$>R(H2CERB,D^O6BO/UITXG\58D
MPLDY79-8_+*@+,)<[+)E)UDS@OT\* H[EF'T.A$.XM;-57YLQFZN:,K#("8S
MAI(TBC![O24A?;YNF:W]@8=@N>+9@<[-U1HOR9SP/]<S)O8Z!Q4_B$B<!#1&
MC"RN6P/ST]#I9@'Y&5\#\IP<;:.L*$^4_LAV)OYUR\CNB(3$XYD$%G\VQ"5A
MF"F)^_AW)]HZ7#,+/-[>JX_SPHO"/.&$N#3\%OA\==WJMY!/%C@-^0-]_HWL
M"I3?H$?#)/\?/6_/[=HMY*4)I]$N6-Q!%,3;O_AE!^(HH.>4!%B[ .M-@%D6
M8.\"[+H!SB[ R<ELBY)S&&*.;ZX8?48L.UNH91LYS#Q:%#^(L^<^YTS\&H@X
M?N/2#6&HC?Z<#]&']Q_1>Q3$Z#X(0_%0DJL.%Y?(3NQX.[G;K9Q5(F=:Z)[&
M?)6@4>P3ORC0$?=VN$%K?X.W%J@X)-XYLLTS9!F6H[@A%PZ_Q^P<&1=Y>%<1
M/H3#/Z?Q.;+ZJJL72F,?<-NYGEU6&NJEHM5P]/BZ)BJ\<+AIM']7,0"CLJ[C
M4[+&'KENB;XA(6Q#6C<__V3VC%]41#2)%?@X!SX.6,"!@./G@,8A7JH P?$+
M'"8JKBX8UI20)K$"H>Z!4+=>#1K$<8I#]$#6E'$5*5B'LU0)"HQJ"DJ36 %4
M[P"J5[.I,2R&J7R4*8<%:Y56*S"L*2U-8@5:%P=:%_5HS0@+J)]UWT@,*,H^
MJD)IWV&7]MA@?%-HFL0*T/H':/UZT,9!XHFVN&,W%H>58R>L-OZN@@7&-(6E
M2:P Z_( Z[(1K.\$LW)4L%99S0*CFL+2)%: 91HR+S/ (KHI8V]I08VR0J[=
M-JVV;:J@P9%-J>E2*V([2F=-L)RCF ?\55 +"9JFT1-A2EBPB&&8;;MO&STE
M+C"V,2Y-:D5<EL1EU<'U0)9!PL4XR=$41^KZ52$TG7^?NZ-WMY,O<W<RFKJC
M^1F:3-US)4)0JS%"36I%A#*C-^&<?(?0%8V5B88Z$;[G!?U.7I4082E#5+P+
MLW?I7"BI:<WR=:D5J<D\WX03]1VU1_R")KY %RP"#^<Y&M!J8<F^U;8NNEVK
MKZ:GU0'H4BO2DQ[ A)/W';U)[%$F,MH<W!F:<S$V(,J02U-1&46=I+ZZ+5=8
MC)$2H%9GH$NM"%!Z Q-.Z'< ![XOU).S_0:Z$^>A+[&:&BQY<>GTWJ$&_R8;
M'*\H08,-B=5>#+YB8^2G\!>F-!@F[ M Y(_/5(D<EIRG@:CPEJ%.:[3:#%UJ
M17C2:)BP-W@+S\WV1$M_I,^Q$APL=X?SFOJ9AB%6LM/J.G2I%=E)WV'"9N$M
MNT,W.6-T$\2>NK'#FNY B4VK_]"E5IQVE0;$@AW#6VPSFG"1W_P5K$O'E0K%
M2\NPE6,S'->4FRZU(C?I0"S8/.1-<\ (+L<$"WSH=_L?E9BT.@]=:D5,TGE8
ML&&XH_F,R8K&D%&K$+%Z=MLQ+Y4^#0YM3.L4)L.2)L.J93*^D3!L_XA%IX_F
M!">"G8\F29*6P(,UIZHAUX6#&F,[A<NPI,NP:KF,KS04"3%FVWD!IIQPJE J
M@:755.A2*\*2IL*J92KV$T_;N?(@7N8#IGJ6KD+Q.U%%N7!48VJG<!*6=!)6
M+2<QB3EAVT7L;(H.[S$JJ<&*9=2TF@%=:D5JT@Q8M<Q WAR1*_*Q)67*&9,*
MG2F-V]CSB) 1(OY64$E/JQO0I5:D)]V 5<L-S",<AN@V3<3/B;I]PCIE:X!P
M6&-8ITC_+9G^6[72_U%$V#+KS7X5"GPEDK-HC6-UG8,%2Q<#X;C&V$Z1_MLR
M_;=KI?_SE4@Y(%@5,J6PX+C&[RR<(N>W9<YOUUIUF*5/8>"A<4BQLN.'51J6
MV=6J-MRI.;E:]K;8YL:YZFQ46&2.;]=:71"U)Z(B8^74^R'L]PJ+VT%?4B[\
M9.R+)JE$I3-[=W=JW:/"F8[1-6U9Q!V%4Z3Y]M';07!*OE\C38ZF=L6H]I2M
MT"R(R"<\@OY^)"\<W88"YC]*<E59OW)VTX7#&M>F4^3]MLS[;3A;G[CC!S1(
M_8!3A@:<$U'5\L6%LK>**O3*>S&M!D"76I&:- !VS5>+QD&,8R\0_CR?*\N/
MC1C+5Q9$5KM]8_/OC*6Z!L*7*8>IU1?H4BO"E+[ AK/X?>T;!RQ"DZ&2$ZS0
MZUXJ*6GU ;K4BI2D#[#A_'U/J6S5N2+\GB8)&O@X2M#=W4Q)2VO>KTNM2$OF
M_3:<K^]I97-G61M4$H,EYCA^-PR$W3H3MBL,%I3%@7() -9I#.X4'L"6'L"N
MF*X_RD#0##/T%8>I&$KO23;QJ.[$=";SKE:UH2ZUXBNZTAHX<$[_&/"0(+I
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MRR@4J3& ]VL!.^KZQDS0'* N_@502P,$%     @ F()J6@FVB=+M"   .$0
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M;4S@4,L3>RT_9Z_.#C4GF3/4ZNW97G5;"&K & J(O6SY^%3P4*Q3>[$.L]%
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MUVT#^?FVJL3WB_:7&LX_%G+W?U!+ P04    " "8@FI:325D4!0(   0)
M&    'AL+W=O<FMS:&5E=',O<VAE970V+GAM;*U:;6_C-A+^*X3O4+1 LQ9)
MO>82 UGG%K= VPLVM]?/M$3'[$JB*]+QYGY]AY0CV1+%Q+E\B6UE.)J',YSG
M(:6KO6R^J0WG&GVOREI=SS9:;R_G<Y5O>,74![GE-?QG+9N*:?C9/,S5MN&L
ML(.J<DZ"()Y73-2SQ96]=M<LKN1.EZ+F=PU2NZIBS=-'7LK]]0S/GB]\$0\;
M;2[,%U=;]L#ON?ZZO6O@U[SS4HB*UTK(&C5\?3V[P9?+T ZP%O\5?*^.OB,#
M927E-_/C<W$]"TQ$O.2Y-BX8?#SR)2]+XPGB^//@=-;=TPP\_O[L_9,%#V!6
M3/&E+'\7A=Y<S](9*OB:[4K]1>[_Q0^ (N,OEZ6R?]&^M4WB&<IW2LOJ,!@B
MJ$3=?K+OAXDX&H"G!I## #(<$$X,H(<!U )M([.P;IEFBZM&[E%CK,&;^6+G
MQHX&-*(V:;S7#?Q7P#B]6,I:R5(43/,"W6OX@!QIA>0:+9G:H$^09X4NT-?[
M6_3CWW^ZFFNXJ1DZSP\W^-C>@$S< !/TJZSU1J%_U@4O3AW,(=HN9/(<\D?B
M]7C+\P^(XI\1"4CH"&CY^N'4$P[M9I!:?_'4#)II6MMI6C>R0K#"&J9%_="6
MJ-""JTO7O+5NJ=NM6;Z7:LMR?CV#]:EX\\AGBQ_^AN/@'R[,[^3L9 ;";@9"
MG_?%;]!M2JF4"V0[,K0C34MY7%PD69H$078U?SP&X##$04QBDD2=Y4ET41==
MY,W/3?$'+*.VJK6$UI/+.A<E1_4A;'/5?,]-(G<*UH&H7Y_%Z#VS^$[.3N8I
M[N8I]F;Q)L^;G06O.7C7+K"MA^@H22'-2#)(Y=@*IW&8NM.8=.$E_O JV6CQ
M/V:;/W0G8"Y1LQ()I78<%4+E<E=KQ.H"NOA*V^NLSCG*I=+.TDS&8>(L ?X;
MP!G;41+C"+OQI!V>U(OG%U-Y  6J\9$WAA65#3[?L/J!FQ)<,]&@1U8"/,#;
MVFFQ,I4K-7="\M[273_(58?I"/(%#N,PR=R8LPYSYL6\G,!6"K82I=!/*"^9
M4F(MH [WK&E8[4Y=YH@O)AD99,YA1E*:11.EB(.>- ,OD'LM\V\71CY PF0%
MFDK9PG328^"HLR QW',2K,,N33)8W!/!'C$\]E<:ASCM,G"&YQU\1LT<')TF
M)9J*GO31$V_T7VLHC1+F&1HW%X\,ZM\)@SAR'4=1.)SEL1U.,C(YR[T*P%Z*
M7=PU?,M$@?AW4PV\7<Q2;WB#H*2YNXX//D^CCG 61\.PQX88.B].)[H0[KD;
M^\D;VKYIG IMV=/DY(;C,*,DS4@Z#--AB D-29I,Q-FS./:27T=/COE];A_"
MW10/CH^#BG$V"GUL!:&G(:%T(O2>6+&?67][C;AP1CYFTHLD"D@RXBB7)329
M),M2,A%^3[PX.4O@KH%W04&]+(VPE]'/U4;OY>UT%GJZQGZ^OFMDSGEQF(/M
M;E6*'+AKS1N8"?6S49#..1A3*8XA?P$>9G!LF 41&(83^>M)%_M9]S3R ZW"
M.N)-+M1$X8V9DX24!NFH[KRW?A5[G.X!>PHF?@IVHQ)UL<OM%M9FQ(B+EX4@
M<3 O#F@6#O6$/Z0WH.TYG/@Y_#^ 3K'VY,/B<)>A$]U[$3QQ$'P8)NF4*B0]
MQQ,_QX_1 67*7-A#B;W0FR%0V_S'.7?C=R@#$+,IIL,EZ(_R#>GMQ0-Y23P<
M%W-7L2[9/]EI_+<X)\\.K1$'44PG-N*DUQK$KS6^@$1Z,HEZ]8:&. 1%F()"
M&C8BER&&[DF"";%/>N5!_,KC).J6_"R-JUUCLP3368E=Y8[?H2IH0B(R//YP
M&881CN.I\'OU05ZI/K:-?!0%A+YZ<G*X,_ZQKLC2%.-DN'MQ&*9)%*7I!'V1
M7GX0_\;_<YTW=@?S8\';;S\9#64AV0VS^<+_W,'>H)SL >,]/*%)&HYAC TO
MS#%CD$WEH1<0Q"\@EE,!HQ5_$'5MD@$%!M)0R,()PB$E0%S'P7"/XS"D.$R2
M8$(*DEY*D!<V\),8N%'CWNC'DH*"E 6-.HQ^;#B$>7I.VTL&&GB%[/UNNRTM
M4;"R16!4+113^S0$V,=]3OL&UO<<U+Z3M],YZ(4$]0L)6$VRXDBS[^C0U9P+
MAHZYGHY/QEZR.HVQEP.4O#Y/YF2OE-!K+1W6LKZPF1- 'DH_2X%7;TGH&RC>
MD\MW\G8Z3T</'ORJP7;&PS2='JC=[!YV2ML').CW@TSZW,DDY\0X2#\@.(AQ
M/$SZ_Z\S3O'V\H'ZY<,TWD]\U>Q8\W06XK%B +Y-@)V'@+U1O0%PKSRH7WDL
MN[-AIV R1_72G#]68*#,D:03YUA98!RG\7@UCPTIR+XTFZ -VDL0ZI<@_VY$
M>UAO3^:[LWHK=E\E _W^S]"VU/%L JAELF?U*H7Z5<KM&-GS 7:GYYW(WG"J
MX4;F>)P1Q'&83AQ?T5ZX4+]P^7R\@3XG:>_U-(*.]0PA<11,(>OE#/7+F4_G
MB7GJ.!6A!$?#PUJ'71A&T%G<\8:]@ E?>.S M6Z)L>T'527L@TVTYO:IBMJP
MQIT+O^,S<A&.STK"()A<0&$O3$*_,+GE *R )63V*+4Y[B_M]A\Z7+>0"KFO
M40,KK&@W,VKBD<OA5L</D\EHQ^@PPB0;)6E^]&Y%Q9L'^\J)0G:=M^\L=%>[
MUUIN[,L<@^L?\>6R?3FE=].^*_,K,\\R%2KY&EP&'Q*8W:9]_:3]H>76OL&Q
MDEK+RG[=<%;PQAC _]<2UN#AA[E!]Q+0XB]02P,$%     @ F()J6G,_?0I#
M @  D08  !@   !X;"]W;W)K<VAE971S+W-H965T-RYX;6R=E5UOFS 40/^*
MY4E[6L-'$C)E 2EI-RW2.D5IMSU,>W#@ E:-S6Q3VG\_VQ"630V5\@*VN??X
M7",NJU;(!U4":/14,:YB7&I=+SU/I2541$U$#=P\R86LB#9367BJED REU0Q
M+_3]R*L(Y3A9N;6=3%:BT8QRV$FDFJHB\GD#3+0Q#O!Q84^+4ML%+UG5I( [
MT-_JG30S;Z!DM *NJ.!(0A[C=;#<+&R\"_A.H54G8V0K.0CQ8"?;+,:^%0(&
MJ;8$8FZ/< V,69#1^-TS\;"E33P='^F?7.VFE@-1<"W8#YKI,L;O,<H@)PW3
M>]%^AKZ>N>6E@BEW16T7.PLQ2ANE1=4G&X.*\NY.GOIS.$D(HC,)89\0.N]N
M(V=Y0S1)5E*T2-IH0[,#5ZK+-G*4VY=RIZ5Y2DV>3K;F>#.0Z%Z2C/("K:4D
MO !S[%JM/&UVL'%>VM,V'2T\0PM"="NX+A7ZR#/(_@5X1FWP"X]^FW"4> /I
M!$V#=RCTP]D(;SK4.W6\Z()ZT<\O)AIM-53JUTO%=^CIRVC[^2Q535*(L?D^
M%,A'P,G;-T'D?Q@1GPWBLS%ZLF\8H, _S*^"4VFTSD2M_S_J3G<<F!.F8$1L
M/HC-1SE?!;^Z0&X<^II<-,A%%YW:/4CS,9$S;N/,U]P6@]OBXH,;]QOGGO7S
M3MI$!;)PS5"A5#1<=QUC6!WZ[;IK,W_#NV9]2V1!N4(,<I/J3Q;F=<JN 783
M+6K7= Y"FQ;FAJ7Y9X"T >9Y+H0^3NP&PU\H^0-02P,$%     @ F()J6C!C
M\6M;!0  C!,  !@   !X;"]W;W)K<VAE971S+W-H965T."YX;6S56%EOVS@0
M?O>O(%R@3T9\Y&J:Q$".=C= BP9)=OM0[ ,MC20BDJ@E*;O^]_L-)4M.X\I)
M$^QB7VP>PYEO;HHG"VWN;4+DQ/<LS>UI/W&N>#\<VB"A3-H=75".G4B;3#I,
M33RTA2$9^D-9.IR,1@?#3*J\/SWQ:]=F>J)+EZJ<KHVP999)LSRG5"].^^/^
M:N%&Q8GCA>'TI) QW9+[H[@VF T;+J'**+=*Y\)0=-H_&[\_'^_S 4_QIZ*%
M71L+5F6F]3U/KL+3_H@144J!8Q82?W.ZH#1E3L#Q=\VTW\CD@^OC%?>/7GDH
M,Y.6+G3Z584N.>V_ZXN0(EFF[D8O?J=:(0\PT*GUOV)1TX[Z(BBMTUE]& @R
ME5?_\GMMB*<<F-0')AYW)<BCO)1.3D^,7@C#U.#& Z^J/PUP*F>OW#J#785S
M;GJQG)&Q%)1&N:6X4?9>?)8Y_ '+.R'S4(!:.HJ7XE+9(-6V-'0R=!#-#(9!
M+>:\$C/YB9CQ1'S6N4NL^)"'%#YD, 3F!OAD!?Q\TLGQDH(=L3L>B,EHLM?!
M;[<QQ*[G=_ KAA@T5AAXF_RFYV1RF0<DOIW-+/8"]]<FJU0R=S?+Y(Q[;PL9
MT&D?*67)S*D_??MF?# Z[M!HK]%HKXO[%M=>&QV0M60%4EN<\<BJ/!Z(JQ#;
M*EKZ"2OK#V$F[A+DO;/BVQU]=^(\U<']1J6[87VE7B+GA-29HR84%'HA*BM2
M#PSSX %PP\"S%GC1 '_[YNC@\.A8%,G2JD"F@YZC(,EUJF.>>KXR1-(H]A!G
MOP@0A 8I(Q0D<20*IU&1BD(;)W1I?I#-'$*DE8A;AT=&9L2E9@ F05J&;!J
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MXIZ.VXW1V7I&HXMN;D.HSE?X2@C!&*('ZV=8J;4I-[SUYL_\+A)%D?BH^([
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M&O5/CP,P7;WK.J1K7V/N-''%\LV"/Q%H7 "_7VE-CQTWP?:C,_X-4$L#!!0
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MX-6+GG#I_I9>@JWCG0F[.VY@\;'$E9<<&^#[W"*>]H47Z"[1I_\"4$L#!!0
M   ( )B":EIG6IR1;A,   XV   9    >&PO=V]R:W-H965T<R]S:&5E=#$Q
M+GAM;*U;6W/;.+)^YZ] >>=L)56RK)LON58IMISHE"-[+3M34UOG 2(AB1N*
MU!"D;>VO/U\W !*4+$\R,P^)11%H=#>^O@)Z_YCEW_52J4(\K9)4?SA8%L7Z
M[=&1#I=J)74[6ZL4;^99OI(%'O/%D5[G2D8\:94<]3J=DZ.5C-.#C^_YNYO\
MX_NL+)(X53>YT.5J)?/-)Y5DCQ\.N@?NB]MXL2SHBZ./[]=RH::JN%_?Y'@Z
MJJA$\4JE.LY2D:OYAX-A]^VG 8WG =]B]:B]SX(DF679=WH81Q\..L202E18
M$ 6)/P_J7"4)$0(;OUN:!]62--'_[*A?LNR092:U.L^27^.H6'XX.#L0D9K+
M,BENL\<ORLIS3/3"+-'\OW@T8P?] Q&6NLA6=C(X6,6I^2N?K!Z\"6>=/1-Z
M=D*/^38+,9<7LI ?W^?9H\AI-*C1!Q:59X.Y.*5-F18YWL:85WR<WG_].KS]
M35Q?BNGX\V1\.3X?3N[$\/S\^GYR-YY\%C?75^/S\6CZ_JC >C3K*+2T/QG:
MO3VTNSWQ-4N+I1:C-%)1D\ 1&*VX[3EN/_5>I'BAPK;H=UNBU^D-7J#7KZ3O
M,[V3/?2&89B5:1&G"W&3)7$8*RW^/9SI(@=:_N\YB0V]_O/TR(+>ZK4,U8<#
MF(A6^8,Z^/C/?W1/.N]>X'90<3MXB?I?W*L7:3_/^>3Z;A3TQ:'X\97%O59!
M-A<C7<2P&>A3II$8:AC]FLQ0BYM<K64NZ8$&%DLE0GP/]4<8'XEYG,HTC&4B
M=($OX  *+>*4!I$/BHL-3*18BL_#X0W<PN]E#'YA$BE\" T618:G[TJH!@O2
M8Z%8RD+(^1R>@=8/Y(I0H$%MG>7$ Y;[,;Z(<A3K,,ET/4T"5:NU3#>$JS0#
M!VTQ#(L24\$JW 6QN\$\<)"+>9ZM, T$@B;'N@R7=I!*0V4FS92@$3GQ 4%_
MB,NVN,.P598KH>-%&L_C4$)/>_43S#:^/N,T3,I(M<2LA-9 !"*)),9.8+TB
M:S$3Z@EA0BL(&&98@CTNMDN$*B\0&D@G>8GQA"V90S#6G'I 5%CS*@2Y."15
MG4N]#.@U?1 C;/"#3%C;\,/!NLS7T)46SV%G)A-(#S')'QJY&N^]G</TD.C/
M$9:TD>'<[!I/B2.5@T"2B"7\>K*!P&"$MAC.H602 <,0&BQS B7SDRM2-/L\
M")\H#1J,,0%=*QH30\_,(W8/F\D\J%I&B)_A;5H8"]%D(N>YBN)"W,;Z.XMT
M/9\??K*23CER\ZM*;]LT>=-J8'@B6$O ZS5@"D<(@3< WNP_;!H9J<)CAI5F
MF,FQHL&5U=H__W'6ZYZ^T[SZ?C8BF)B.K8U)XWY91XG,%]M<QD5IUF6 6B,-
MRQSV4(!/]10J@KS"7C'CF%."/0-.W0X\]L12:@!WCQIX)S.HM0$@%I)DAG63
M"4<1XYJ6:@)F*<%>4U>^>,%:;N0L@05);3%" A6/V7YS>%!IE.5D\Y$2Y5HL
MD''![&G#4M'M_ _H1_%#')6&&YI^.A#],S%5"R,3A \<@\CA\LK2C6G#IV+0
MK-0(!(12;&ZJX)QI:+'A#233,]PTOE;5UXRKDC2/;87EQVQD(,6N"QK"^YC5
M?BGC//@FDU*)KTK2+C&!X?0\..MU6OQ>[+RGQ$%O=*B"3W&F$9W)#;;$.$46
M,"&_&E@7>.X;^66UQ=/:W$D;LH[V"]@R;W28P/'!(T(?<^+A@7E8^3Q@)TDU
MUM_,LP0>@VB8G0RQQ"++F0!,W@:#DDS*>JJWP15M;-!]*_Y5@NLH6.?DZ0Q$
M*"G%EN3?R6$1!7@>\!B"?7!&7Y(CB>4L3H ^^$=+K?<6>EB70%=&BC; X%>B
M*^P"1$[#%F!;SQ.K[3]"% W)J(B#M'Z:D5\F\+K@9EA=)T@5'"O]M^(^K4<&
M,?,E'I<Q 9NB3KFV@75&CK0H0 [KI)FE9M1 3I3PQ5N@ 2G@'1DO9A%(%RP4
M_5UED4H  U(U[:>*:D^.G4,HC;(D6T"\5N IH%#A,H43)P0!HH\H!.BO[P9(
M7X9KDM0Q8.P9V^\!I,H[_(#ZGS)BVR/9;'#%S';#$A7--Z9H-H0D]G?$<[[[
M $G%# 5:.$+2!XH2&!G&5QHS6<AZ#:O-R281B @7L@BL=)G#_8:&KEAP)?'&
M9$"L;>08643,QWI+%2\*KVU@8\<UV_A^$BZ4XQFR>+6: ;,NDV<EX$/?N%7*
M(7(4# X)+E0_%U1:@ 7R241FFX'0[KJP4OM=BA\V W'CV)<9V_'USVI[XL2(
MF,$.U-L 193*I5UZ"4T=DEY$2CF \Q!(@A#?5@@8O\H\E]NNF.*_JK=\4WN@
M2#RZ"2;=36WERM&)EJQR!^N+H+*N<81.@SWS:")S1>Z1''&U8N"M:.5Q61IK
M%["$@3*0YXHE,^1M'LB1FZ)]K_/NVJ@O2Q=&$9XB>43W'8%U7YH6F#2MD4;
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M1M6YAG5F>V7?OXTS%4JD+@$G4<81U2LB+8H/F2@EJ*^:Q_M(>9"U&TMBMPH
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M'P$*$Z#W<\[5<6$*]+^6Z7]02P,$%     @ F()J6E,\NF,$!0  V0H  !D
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M@)?T#B8.+_LAWM+ )==E)76C$/Z:+K51E Q_/^=MBY4\CV4+Y$3O6(GG/E6
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M"M#^6E*1=Q-[0-\I3_X%4$L#!!0    ( )B":EIAH$%$3PH  ! <   9
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MZJ<Z$\&)5'4F196).B1I/7:AC*@#HYB9"7:JJEH5,H>ZG'V0%:\RR0MV8_
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M!I(:!4*1(]-$YYS4S A=PBZ\!PX(E VRSQF?@VPY!VTDG1^+#10II\LE[X-
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M&R2#*(R3B+5_7?)N?^K^_\*?6)Q8U%(VZ(W9T"7TMC;C_*!'/G$WG'G.;_B
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M00ED?D?*7[18V7O)5&BZY=C'!5TK49H%]'TFJ#F*%V-@=U$]_Q=02P,$%
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MG%Q-;F\GE[8?SV>SR=VLT5_GQH/Z*\UW^?+L8V]*?;.)RZ.X7$3-4%!9P&X
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M&7;_9NFY*FE'1%PDM2$)P0&*)V"##0.<)8C9+ <ALM[N[?#_-W*O"X^G "X
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MTU<W4TVQD[GKHA0:Q,ANB;PK =;4#Q*01WA45I=VW+BL-[/TU&'[OK(<-;Z
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MYX4B;I!QE;<VQUQ[$1UG.+JH[A'8@B@29)TWIBI<3HLTHZBO'[M3%868@@
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M6;')/GN8KD$PV"R4A&OJ_(,$SZ1?IFNLB"F.$<8P-M8R_ QNF'(U !&2 AK
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M4'9D2LP;,T_7+B6-Y3Q]2:6#O_3$S'REOZA3L;)\14B$?S,5FB(,IV?P,1^
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MFBJE ?A^EH#)FS<T0?F[Y __!U!+ P04    " "8@FI:?E_*LET%   E#@
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M]?O  ]4LK48PLG:+8BL-K1UWS&G/H[(&=)]):8Z"#=#].29_ U!+ P04
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M6M(H63==37OAP E!!<QL)]FD??AK&T)#2EDBD1<!S#D_'_\/'&SW]X0^LPT
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M'5L]>1?A0/@$PJDJW[4Q7IKO)F%N0[!2OMM%OMNUN9EMXY706"8:4D(Y7D6
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MC&)"0;/=C.R"DU0MUU>$BRJF3C<@)N54&HC[:T+XX4)V4.PI#?\'4$L#!!0
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M!73.SI5]7C7H*I"L-#UNR:3JF&:8J3L-N$Y0ZRO&Y#[0;;.Y)>._4$L#!!0
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M:<UXK%MJJI?]I^K?_TF2XN%Z9R>I::BFHYJ!:B:J6:AFHYJ#:BZJ>:CFHUJ
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M[XOY,K\XN2^*AY\&@_SF/ETD^>GJ(5V6__-UE2V2HKR9W0WRARQ-;M=%B_G
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MS4,U']4$J@6H%J):A&HQJDE*:W:6.EUJOE>ZU$33I:AFHYJ#:BZJ>:CFHYI
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M2_7/!= (>'Z".CYC3#YMY V4JYN&_P)02P,$%     @ F()J6ADO[I5I @
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MYIBI=8I<!ZC[)6-R9^@$[8(._P!02P,$%     @ F()J6AYELZ5] @  PP4
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MNOI\;0!K(J,I!*WTU*VID#.LEZE,662J09YO*!6'0KV@RVWO#U!+ P04
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M.WC0@ >MX-^H$)0IG6B6H)BS+0B5+C+0=6UAI0U.,33K<9XM5CW/[Q$[;-C
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MZ \)$"9 OY]QKAXZYJK:?IID/P!02P,$%     @ F()J6A4];2@& P  N0@
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MM,Y:<@]862C+CJ"%KC53*F3ETLV%_+< I@SD]QFE8MM1$U1_*]%O4$L#!!0
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MW);CG6Z[AAL3%B'!K'#[_:9XZ3L#'NH!(16+BT'QRT8PF;"R '5E+3>TZU!
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M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ F()J6L6(9.GX!   RB0   \
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MF);?V5SFLF5D>-2\)R#?FX4,PEON>U]Y[ 4^X_Z8+4+/=[T%GS'NQAZ"_$!
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M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ F()J6DL4'8ON    *P(  !$
M             ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
MF()J6IE<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    " "8@FI:63#N4U\(  "<.   &
M    @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
MF()J6GN?]&W0!0  GQ@  !@              ("!HA   'AL+W=O<FMS:&5E
M=',O<VAE970R+GAM;%!+ 0(4 Q0    ( )B":EJ8^EJVY@(  -T)   8
M          " @:@6  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M    " "8@FI:QRO\YF0%  !,%0  &               @('$&0  >&PO=V]R
M:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ F()J6@FVB=+M"   .$0
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M965T.2YX;6Q02P$"% ,4    " "8@FI:V-\9LDH&  !0#P  &0
M    @($8/   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (
M )B":EIG6IR1;A,   XV   9              " @9E"  !X;"]W;W)K<VAE
M971S+W-H965T,3$N>&UL4$L! A0#%     @ F()J6C65PYC_ @  P08  !D
M             ("!/E8  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"
M% ,4    " "8@FI:N;Q\,=P"  !F!@  &0              @(%T60  >&PO
M=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( )B":EI3/+IC! 4
M -D*   9              " @8=<  !X;"]W;W)K<VAE971S+W-H965T,30N
M>&UL4$L! A0#%     @ F()J6HJKBB$8!0  -0L  !D              ("!
MPF$  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " "8@FI:
M8:!!1$\*   0'   &0              @($19P  >&PO=V]R:W-H965T<R]S
M:&5E=#$V+GAM;%!+ 0(4 Q0    ( )B":EIJ2:3R.@8  +0.   9
M      " @9=Q  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%
M  @ F()J6H)#+802"0  ;!4  !D              ("!"'@  'AL+W=O<FMS
M:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " "8@FI:UK4=DTD"   /!0
M&0              @(%1@0  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+
M 0(4 Q0    ( )B":EIS&Z7#[P,  &((   9              " @=&#  !X
M;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ F()J6L%@:YA7
M%   HSP  !D              ("!]X<  'AL+W=O<FMS:&5E=',O<VAE970R
M,2YX;6Q02P$"% ,4    " "8@FI:?E_*LET%   E#@  &0
M@(&%G   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( )B"
M:EJ=$R>4 0,  )T&   9              " @1FB  !X;"]W;W)K<VAE971S
M+W-H965T,C,N>&UL4$L! A0#%     @ F()J6AO_/@+6 @  108  !D
M         ("!4:4  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
M    " "8@FI:SZ?I>BD#   K!P  &0              @(%>J   >&PO=V]R
M:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( )B":EJ9MEC,500  !<)
M   9              " @;ZK  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL
M4$L! A0#%     @ F()J6K4-TIOE!   ^@L  !D              ("!2K
M 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " "8@FI:YSK^
M14<&  !3$   &0              @(%FM0  >&PO=V]R:W-H965T<R]S:&5E
M=#(X+GAM;%!+ 0(4 Q0    ( )B":EJVAZX-9 0  #4A   9
M  " @>2[  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @
MF()J6HNWRO.@ @  W@<  !D              ("!?\   'AL+W=O<FMS:&5E
M=',O<VAE970S,"YX;6Q02P$"% ,4    " "8@FI:>S&CJV$#  #.$   &0
M            @(%6PP  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4
M Q0    ( )B":EI8NR$,R (  "(&   9              " @>[&  !X;"]W
M;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ F()J6KKA;<3\ @
MK0H  !D              ("![<D  'AL+W=O<FMS:&5E=',O<VAE970S,RYX
M;6Q02P$"% ,4    " "8@FI:HJ'/&X8#  !&#@  &0              @($@
MS0  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( )B":EHZ
MR<HX'P0  %\2   9              " @=W0  !X;"]W;W)K<VAE971S+W-H
M965T,S4N>&UL4$L! A0#%     @ F()J6H":IOKW @  _0<  !D
M     ("!,]4  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )B":EJ>5$A$! 8  /PA   9              "
M@>SP  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ F()J
M6KMG7XIL#0  >N(  !D              ("!)_<  'AL+W=O<FMS:&5E=',O
M<VAE970T,BYX;6Q02P$"% ,4    " "8@FI:C7IT&7$5  !5<0$ &0
M        @('*! $ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0
M   ( )B":EKW++,7IP0  ! ;   9              " @7(: 0!X;"]W;W)K
M<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ F()J6E$\[>)Q P  R0L
M !D              ("!4!\! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q0
M2P$"% ,4    " "8@FI:;'FY<1P#  "%"P  &0              @('X(@$
M>&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( )B":EKJOPT=
MI 4  .DD   9              " @4LF 0!X;"]W;W)K<VAE971S+W-H965T
M-#<N>&UL4$L! A0#%     @ F()J6ADO[I5I @  K 4  !D
M ("!)BP! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " "8
M@FI:'F6SI7T"  ##!0  &0              @('&+@$ >&PO=V]R:W-H965T
M<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( )B":EIF?9@\$@0  .$,   9
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M970U-"YX;6Q02P$"% ,4    " "8@FI:/;9)QA($  #.%@  &0
M    @($'2 $ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    (
M )B":EI0+2I-3 ,  / 4   -              "  5!, 0!X;"]S='EL97,N
M>&UL4$L! A0#%     @ F()J6I>*NQS     $P(   L              ( !
MQT\! %]R96QS+RYR96QS4$L! A0#%     @ F()J6L6(9.GX!   RB0   \
M             ( !L% ! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( )B"
M:EJ\ =;!X $  .P@   :              "  =55 0!X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( )B":EH4U''DT $  *T@   3
M          "  >U7 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     _ #\
*,!$  .Y9 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>160</ContextCount>
  <ElementCount>322</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>59</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/StatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>999014 - Disclosure - ORGANIZATION AND PRINCIPAL ACTIVITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/OrganizationAndPrincipalActivities</Role>
      <ShortName>ORGANIZATION AND PRINCIPAL ACTIVITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>999015 - Disclosure - BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/BasisOfPresentation</Role>
      <ShortName>BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>999016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>999017 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/PrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>999018 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/AccruedExpensesAndOtherLiabilities</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>999019 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>999020 - Disclosure - NOTES PAYABLE</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://ensysce.com/role/NotesPayable</Role>
      <ShortName>NOTES PAYABLE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>999021 - Disclosure - STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>999022 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/Stock-basedCompensation</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>999023 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>999024 - Disclosure - RELATED PARTIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/RelatedParties</Role>
      <ShortName>RELATED PARTIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>999025 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>999026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>999027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ensysce.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>999028 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/PrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ensysce.com/role/PrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>999029 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/AccruedExpensesAndOtherLiabilitiesTables</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ensysce.com/role/AccruedExpensesAndOtherLiabilities</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>999030 - Disclosure - NOTES PAYABLE (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://ensysce.com/role/NotesPayableTables</Role>
      <ShortName>NOTES PAYABLE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ensysce.com/role/NotesPayable</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>999031 - Disclosure - STOCKHOLDERS??? EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/StockholdersEquityTables</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ensysce.com/role/StockholdersEquity</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>999032 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/Stock-basedCompensationTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ensysce.com/role/Stock-basedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>999033 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ensysce.com/role/IncomeTaxes</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>999034 - Disclosure - ORGANIZATION AND PRINCIPAL ACTIVITIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative</Role>
      <ShortName>ORGANIZATION AND PRINCIPAL ACTIVITIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ensysce.com/role/OrganizationAndPrincipalActivities</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>999035 - Disclosure - BASIS OF PRESENTATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/BasisOfPresentationDetailsNarrative</Role>
      <ShortName>BASIS OF PRESENTATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ensysce.com/role/BasisOfPresentation</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>999036 - Disclosure - SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails</Role>
      <ShortName>SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>999037 - Disclosure - SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY???S LEVEL 3 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/ScheduleOfChangeInFairValueOfCompanysLevel3Details</Role>
      <ShortName>SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY???S LEVEL 3 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>999038 - Disclosure - SCHEDULE OF REVENUE RECOGNITION UNDER GRANTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/ScheduleOfRevenueRecognitionUnderGrantsDetails</Role>
      <ShortName>SCHEDULE OF REVENUE RECOGNITION UNDER GRANTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>999039 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/ScheduleOfWeightedAverageSharesOfAnti-dilutiveSecuritiesDetails</Role>
      <ShortName>SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>999040 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>999041 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>999042 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>999043 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ensysce.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>999044 - Disclosure - SCHEDULE OF DEBT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/ScheduleOfDebtDetails</Role>
      <ShortName>SCHEDULE OF DEBT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>999045 - Disclosure - NOTES PAYABLE (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://ensysce.com/role/NotesPayableDetailsNarrative</Role>
      <ShortName>NOTES PAYABLE (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ensysce.com/role/NotesPayableTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>999046 - Disclosure - SCHEDULE OF OUTSTANDING WARRANT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/ScheduleOfOutstandingWarrantDetails</Role>
      <ShortName>SCHEDULE OF OUTSTANDING WARRANT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>999047 - Disclosure - SCHEDULE OF OUTSTANDING WARRANT (Details) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical</Role>
      <ShortName>SCHEDULE OF OUTSTANDING WARRANT (Details) (Parenthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>999048 - Disclosure - STOCKHOLDERS??? EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ensysce.com/role/StockholdersEquityTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>999049 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/ScheduleOfStockOptionActivityDetails</Role>
      <ShortName>SCHEDULE OF STOCK OPTION ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>999050 - Disclosure - SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails</Role>
      <ShortName>SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>999051 - Disclosure - SCHEDULE OF COMMON STOCK FUTURE ISSUANCE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/ScheduleOfCommonStockFutureIssuanceDetails</Role>
      <ShortName>SCHEDULE OF COMMON STOCK FUTURE ISSUANCE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>999052 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/Stock-basedCompensationDetailsNarrative</Role>
      <ShortName>STOCK-BASED COMPENSATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ensysce.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>999053 - Disclosure - SCHEDULE OF INCOME TAXES BENEFIT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/ScheduleOfIncomeTaxesBenefitDetails</Role>
      <ShortName>SCHEDULE OF INCOME TAXES BENEFIT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>999054 - Disclosure - SCHEDULE OF FEDERAL AND STATE INCOME TAX PROVISION (BENEFIT) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/ScheduleOfFederalAndStateIncomeTaxProvisionBenefitDetails</Role>
      <ShortName>SCHEDULE OF FEDERAL AND STATE INCOME TAX PROVISION (BENEFIT) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>999055 - Disclosure - SCHEDULE OF FEDERAL INCOME TAX RATE RECONCILIATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/ScheduleOfFederalIncomeTaxRateReconciliationDetails</Role>
      <ShortName>SCHEDULE OF FEDERAL INCOME TAX RATE RECONCILIATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>999056 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/ScheduleOfDeferredTaxAssetsDetails</Role>
      <ShortName>SCHEDULE OF DEFERRED TAX ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>999057 - Disclosure - SCHEDULE OF UNRECOGNIZED TAX BENEFITS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>SCHEDULE OF UNRECOGNIZED TAX BENEFITS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>999058 - Disclosure - INCOME TAXES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>INCOME TAXES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ensysce.com/role/IncomeTaxesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>999059 - Disclosure - RELATED PARTIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/RelatedPartiesDetailsNarrative</Role>
      <ShortName>RELATED PARTIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ensysce.com/role/RelatedParties</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>999060 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ensysce.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ensysce.com/role/SubsequentEvents</ParentRole>
      <Position>55</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>ensc-20241231.xsd</File>
    <File>ensc-20241231_cal.xml</File>
    <File>ensc-20241231_def.xml</File>
    <File>ensc-20241231_lab.xml</File>
    <File>ensc-20241231_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="form10-k.htm">form10-k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>form10-k_001.jpg</File>
    <File>form10-k_002.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="589">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="12">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="41">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>76
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form10-k.htm": {
   "nsprefix": "ENSC",
   "nsuri": "http://ensysce.com/20241231",
   "dts": {
    "schema": {
     "local": [
      "ensc-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "ensc-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ensc-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "ensc-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ensc-20241231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "form10-k.htm"
     ]
    }
   },
   "keyStandard": 280,
   "keyCustom": 42,
   "axisStandard": 23,
   "axisCustom": 0,
   "memberStandard": 23,
   "memberCustom": 32,
   "hidden": {
    "total": 113,
    "http://fasb.org/us-gaap/2024": 73,
    "http://ensysce.com/20241231": 37,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 160,
   "entityCount": 1,
   "segmentCount": 59,
   "elementCount": 591,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 589,
    "http://xbrl.sec.gov/dei/2024": 41,
    "http://xbrl.sec.gov/cyd/2024": 12,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://ensysce.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://ensysce.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://ensysce.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://ensysce.com/role/StatementsOfOperations",
     "longName": "00000004 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit",
     "longName": "00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Deficit)",
     "shortName": "Consolidated Statements of Changes in Stockholders' Equity (Deficit)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://ensysce.com/role/StatementsOfCashFlows",
     "longName": "00000006 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncreaseDecreaseInInterestPayableNet",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://ensysce.com/role/OrganizationAndPrincipalActivities",
     "longName": "999014 - Disclosure - ORGANIZATION AND PRINCIPAL ACTIVITIES",
     "shortName": "ORGANIZATION AND PRINCIPAL ACTIVITIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://ensysce.com/role/BasisOfPresentation",
     "longName": "999015 - Disclosure - BASIS OF PRESENTATION",
     "shortName": "BASIS OF PRESENTATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:BasisOfAccounting",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:BasisOfAccounting",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://ensysce.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "999016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://ensysce.com/role/PrepaidExpensesAndOtherCurrentAssets",
     "longName": "999017 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS",
     "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://ensysce.com/role/AccruedExpensesAndOtherLiabilities",
     "longName": "999018 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES",
     "shortName": "ACCRUED EXPENSES AND OTHER LIABILITIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://ensysce.com/role/CommitmentsAndContingencies",
     "longName": "999019 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://ensysce.com/role/NotesPayable",
     "longName": "999020 - Disclosure - NOTES PAYABLE",
     "shortName": "NOTES PAYABLE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://ensysce.com/role/StockholdersEquity",
     "longName": "999021 - Disclosure - STOCKHOLDERS\u2019 EQUITY",
     "shortName": "STOCKHOLDERS\u2019 EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://ensysce.com/role/Stock-basedCompensation",
     "longName": "999022 - Disclosure - STOCK-BASED COMPENSATION",
     "shortName": "STOCK-BASED COMPENSATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://ensysce.com/role/IncomeTaxes",
     "longName": "999023 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://ensysce.com/role/RelatedParties",
     "longName": "999024 - Disclosure - RELATED PARTIES",
     "shortName": "RELATED PARTIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://ensysce.com/role/SubsequentEvents",
     "longName": "999025 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "999026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "999027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://ensysce.com/role/PrepaidExpensesAndOtherCurrentAssetsTables",
     "longName": "999028 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)",
     "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://ensysce.com/role/AccruedExpensesAndOtherLiabilitiesTables",
     "longName": "999029 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)",
     "shortName": "ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://ensysce.com/role/NotesPayableTables",
     "longName": "999030 - Disclosure - NOTES PAYABLE (Tables)",
     "shortName": "NOTES PAYABLE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://ensysce.com/role/StockholdersEquityTables",
     "longName": "999031 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Tables)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://ensysce.com/role/Stock-basedCompensationTables",
     "longName": "999032 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://ensysce.com/role/IncomeTaxesTables",
     "longName": "999033 - Disclosure - INCOME TAXES (Tables)",
     "shortName": "INCOME TAXES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://ensysce.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative",
     "longName": "999034 - Disclosure - ORGANIZATION AND PRINCIPAL ACTIVITIES (Details Narrative)",
     "shortName": "ORGANIZATION AND PRINCIPAL ACTIVITIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_custom_EBIRIncMember",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R30": {
     "role": "http://ensysce.com/role/BasisOfPresentationDetailsNarrative",
     "longName": "999035 - Disclosure - BASIS OF PRESENTATION (Details Narrative)",
     "shortName": "BASIS OF PRESENTATION (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2024-11-272024-11-27",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R31": {
     "role": "http://ensysce.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails",
     "longName": "999036 - Disclosure - SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE (Details)",
     "shortName": "SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://ensysce.com/role/ScheduleOfChangeInFairValueOfCompanysLevel3Details",
     "longName": "999037 - Disclosure - SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY\u2019S LEVEL 3 (Details)",
     "shortName": "SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY\u2019S LEVEL 3 (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_custom_LiabilityClassifiedWarrantsMember",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_custom_LiabilityClassifiedWarrantsMember",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://ensysce.com/role/ScheduleOfRevenueRecognitionUnderGrantsDetails",
     "longName": "999038 - Disclosure - SCHEDULE OF REVENUE RECOGNITION UNDER GRANTS (Details)",
     "shortName": "SCHEDULE OF REVENUE RECOGNITION UNDER GRANTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ENSC:ScheduleOfRevenueRecognitionUnderGrantsTableTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ENSC:ScheduleOfRevenueRecognitionUnderGrantsTableTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://ensysce.com/role/ScheduleOfWeightedAverageSharesOfAnti-dilutiveSecuritiesDetails",
     "longName": "999039 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES (Details)",
     "shortName": "SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "999040 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ConcentrationRiskBenchmarkDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ConcentrationRiskBenchmarkDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://ensysce.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
     "longName": "999041 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)",
     "shortName": "SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "ENSC:PrepaidResearchAndDevelopment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "ENSC:PrepaidResearchAndDevelopment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://ensysce.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails",
     "longName": "999042 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES (Details)",
     "shortName": "SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "ENSC:AccruedResearchAndDevelopment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "ENSC:AccruedResearchAndDevelopment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://ensysce.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "999043 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ContractualObligation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ContractualObligation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://ensysce.com/role/ScheduleOfDebtDetails",
     "longName": "999044 - Disclosure - SCHEDULE OF DEBT (Details)",
     "shortName": "SCHEDULE OF DEBT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:InterestPayableCurrentAndNoncurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://ensysce.com/role/NotesPayableDetailsNarrative",
     "longName": "999045 - Disclosure - NOTES PAYABLE (Details Narrative)",
     "shortName": "NOTES PAYABLE (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:InterestExpenseDebt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:InterestExpenseDebt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetails",
     "longName": "999046 - Disclosure - SCHEDULE OF OUTSTANDING WARRANT (Details)",
     "shortName": "SCHEDULE OF OUTSTANDING WARRANT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_WarrantMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_WarrantMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical",
     "longName": "999047 - Disclosure - SCHEDULE OF OUTSTANDING WARRANT (Details) (Parenthetical)",
     "shortName": "SCHEDULE OF OUTSTANDING WARRANT (Details) (Parenthetical)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "AsOf2024-08-31",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30_custom_PublicWarrantMember",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://ensysce.com/role/StockholdersEquityDetailsNarrative",
     "longName": "999048 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Details Narrative)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-02-012024-02-29",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://ensysce.com/role/ScheduleOfStockOptionActivityDetails",
     "longName": "999049 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)",
     "shortName": "SCHEDULE OF STOCK OPTION ACTIVITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://ensysce.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails",
     "longName": "999050 - Disclosure - SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS (Details)",
     "shortName": "SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://ensysce.com/role/ScheduleOfCommonStockFutureIssuanceDetails",
     "longName": "999051 - Disclosure - SCHEDULE OF COMMON STOCK FUTURE ISSUANCE (Details)",
     "shortName": "SCHEDULE OF COMMON STOCK FUTURE ISSUANCE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ENSC:ScheduleOfCommonStockFutureIssuanceTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_custom_WarrantOutstandingMember",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ENSC:ScheduleOfCommonStockFutureIssuanceTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative",
     "longName": "999052 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)",
     "shortName": "STOCK-BASED COMPENSATION (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ENSC:ScheduleOfCommonStockFutureIssuanceTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://ensysce.com/role/ScheduleOfIncomeTaxesBenefitDetails",
     "longName": "999053 - Disclosure - SCHEDULE OF INCOME TAXES BENEFIT (Details)",
     "shortName": "SCHEDULE OF INCOME TAXES BENEFIT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31_country_US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_country_US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://ensysce.com/role/ScheduleOfFederalAndStateIncomeTaxProvisionBenefitDetails",
     "longName": "999054 - Disclosure - SCHEDULE OF FEDERAL AND STATE INCOME TAX PROVISION (BENEFIT) (Details)",
     "shortName": "SCHEDULE OF FEDERAL AND STATE INCOME TAX PROVISION (BENEFIT) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ENSC:ScheduleOfFederalAndStateIncomeTaxProvisionBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ENSC:ScheduleOfFederalAndStateIncomeTaxProvisionBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://ensysce.com/role/ScheduleOfFederalIncomeTaxRateReconciliationDetails",
     "longName": "999055 - Disclosure - SCHEDULE OF FEDERAL INCOME TAX RATE RECONCILIATION (Details)",
     "shortName": "SCHEDULE OF FEDERAL INCOME TAX RATE RECONCILIATION (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://ensysce.com/role/ScheduleOfDeferredTaxAssetsDetails",
     "longName": "999056 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details)",
     "shortName": "SCHEDULE OF DEFERRED TAX ASSETS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://ensysce.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails",
     "longName": "999057 - Disclosure - SCHEDULE OF UNRECOGNIZED TAX BENEFITS (Details)",
     "shortName": "SCHEDULE OF UNRECOGNIZED TAX BENEFITS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://ensysce.com/role/IncomeTaxesDetailsNarrative",
     "longName": "999058 - Disclosure - INCOME TAXES (Details Narrative)",
     "shortName": "INCOME TAXES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:TaxCreditCarryforwardDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:TaxCreditCarryforwardDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://ensysce.com/role/RelatedPartiesDetailsNarrative",
     "longName": "999059 - Disclosure - RELATED PARTIES (Details Narrative)",
     "shortName": "RELATED PARTIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "ENSC:WarrantOrRightExercisable",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "ENSC:WarrantOrRightExercisable",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://ensysce.com/role/SubsequentEventsDetailsNarrative",
     "longName": "999060 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)",
     "shortName": "SUBSEQUENT EVENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "ENSC:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-01-31_us-gaap_SubsequentEventMember_us-gaap_RestrictedStockMember",
      "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://ensysce.com/role/AccruedExpensesAndOtherLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ACCRUED EXPENSES AND OTHER LIABILITIES",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r41",
      "r44",
      "r882"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://ensysce.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r666"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://ensysce.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ensysce.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total accrued expenses and other liabilities",
        "label": "Accrued Liabilities and Other Liabilities",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://ensysce.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued professional fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "ENSC_AccruedResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "AccruedResearchAndDevelopment",
     "crdr": "credit",
     "calculation": {
      "http://ensysce.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued research and development",
        "documentation": "Accrued research and development."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetails",
      "http://ensysce.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r123",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetails",
      "http://ensysce.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r123",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://ensysce.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r666",
      "r953"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r520",
      "r829",
      "r830",
      "r831",
      "r832",
      "r896",
      "r954"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r284"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of warrants - debt discount",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r24",
      "r72"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://ensysce.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ENSC_AgentFeesAndOfferingExpensesPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "AgentFeesAndOfferingExpensesPerShare",
     "presentation": [
      "http://ensysce.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Agent fees and offering expenses , per share",
        "documentation": "Agent fees and offering expenses per share."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r723",
      "r734",
      "r748",
      "r774"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r726",
      "r737",
      "r751",
      "r777"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r762"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r769"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r727",
      "r738",
      "r752",
      "r769",
      "r778",
      "r782",
      "r790"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r325"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "presentation": [
      "http://ensysce.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of debt discount premium",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r59",
      "r249",
      "r907"
     ]
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "presentation": [
      "http://ensysce.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of financing costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r249",
      "r823",
      "r907"
     ]
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://ensysce.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of orginal issue discount and debt issuance costs",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r644",
      "r645",
      "r823",
      "r907"
     ]
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfWeightedAverageSharesOfAnti-dilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfWeightedAverageSharesOfAnti-dilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfWeightedAverageSharesOfAnti-dilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfWeightedAverageSharesOfAnti-dilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://ensysce.com/role/NotesPayableDetailsNarrative",
      "http://ensysce.com/role/RelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://ensysce.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ensysce.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets [Default Label]",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r93",
      "r112",
      "r134",
      "r165",
      "r169",
      "r183",
      "r184",
      "r194",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r375",
      "r379",
      "r409",
      "r474",
      "r557",
      "r635",
      "r636",
      "r666",
      "r693",
      "r851",
      "r852",
      "r910"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://ensysce.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://ensysce.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r118",
      "r134",
      "r194",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r375",
      "r379",
      "r409",
      "r666",
      "r851",
      "r852",
      "r910"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://ensysce.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r705",
      "r707",
      "r730"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r705",
      "r707",
      "r730"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r705",
      "r707",
      "r730"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "auth_ref": [
      "r781"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfCommonStockFutureIssuanceDetails",
      "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetails",
      "http://ensysce.com/role/SubsequentEventsDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r288",
      "r289",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "us-gaap_BasisOfAccounting": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccounting",
     "presentation": [
      "http://ensysce.com/role/BasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BASIS OF PRESENTATION",
        "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "ENSC_BoardOfMembersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "BoardOfMembersMember",
     "presentation": [
      "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board of Members [Member]",
        "documentation": "Board of Members [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://ensysce.com/role/OrganizationAndPrincipalActivities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ORGANIZATION AND PRINCIPAL ACTIVITIES",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r65",
      "r66"
     ]
    },
    "us-gaap_CaliforniaFranchiseTaxBoardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CaliforniaFranchiseTaxBoardMember",
     "presentation": [
      "http://ensysce.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "California Franchise Tax Board [Member]",
        "documentation": "Designated tax department of the government of the state of California."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://ensysce.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r110",
      "r626"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://ensysce.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents beginning of period",
        "periodEndLabel": "Cash and cash equivalents end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r62",
      "r130"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://ensysce.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ensysce.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (decrease) in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r62"
     ]
    },
    "ENSC_ChangeInFairValueOfLiabilityClassifiedWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "ChangeInFairValueOfLiabilityClassifiedWarrants",
     "crdr": "credit",
     "calculation": {
      "http://ensysce.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      },
      "http://ensysce.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/StatementsOfCashFlows",
      "http://ensysce.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of liability classified warrants",
        "negatedLabel": "Change in fair value of liability classified warrants",
        "documentation": "Change in fair value of liability classified warrants."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://ensysce.com/role/Cover",
      "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical",
      "http://ensysce.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r113",
      "r114",
      "r115",
      "r134",
      "r155",
      "r156",
      "r159",
      "r161",
      "r167",
      "r168",
      "r194",
      "r218",
      "r220",
      "r221",
      "r222",
      "r225",
      "r226",
      "r256",
      "r257",
      "r259",
      "r262",
      "r268",
      "r409",
      "r509",
      "r510",
      "r511",
      "r512",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r545",
      "r566",
      "r586",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r809",
      "r824",
      "r833"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://ensysce.com/role/NotesPayableDetailsNarrative",
      "http://ensysce.com/role/RelatedPartiesDetailsNarrative",
      "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical",
      "http://ensysce.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant, exercise price",
        "verboseLabel": "Warrant exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://ensysce.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to purchase common stock",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://ensysce.com/role/NotesPayableDetailsNarrative",
      "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical",
      "http://ensysce.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to purchase common shares",
        "verboseLabel": "Warrants issued",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of warrant or right, outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightReasonForIssuingToNonemployees",
     "presentation": [
      "http://ensysce.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants issue, description",
        "documentation": "Description of reason for issuing warrant or right."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://ensysce.com/role/RelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "ENSC_CombinedOfferingPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "CombinedOfferingPricePerShare",
     "presentation": [
      "http://ensysce.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined offering price",
        "documentation": "Combined offering price per share."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://ensysce.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies (Note 6)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r84",
      "r475",
      "r544"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://ensysce.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r210",
      "r211",
      "r611",
      "r843",
      "r848"
     ]
    },
    "ENSC_CommonStock0.0001ParValuePerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "CommonStock0.0001ParValuePerShareMember",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Par Value [Member]",
        "documentation": "Common Stock Par Value [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfCommonStockFutureIssuanceDetails",
      "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total shares of common stock reserved for future issuance",
        "verboseLabel": "Common stock, capital shares reserved for future issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit",
      "http://ensysce.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r683",
      "r684",
      "r685",
      "r687",
      "r688",
      "r689",
      "r690",
      "r829",
      "r830",
      "r832",
      "r896",
      "r952",
      "r954"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://ensysce.com/role/BalanceSheetsParenthetical",
      "http://ensysce.com/role/NotesPayableDetailsNarrative",
      "http://ensysce.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative",
      "http://ensysce.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://ensysce.com/role/BalanceSheetsParenthetical",
      "http://ensysce.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative",
      "http://ensysce.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r545"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://ensysce.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://ensysce.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r48",
      "r545",
      "r563",
      "r954",
      "r955"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://ensysce.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $0.0001 par value, 250,000,000 shares authorized at December 31, 2024 and December 31, 2023; 1,355,779 and 209,745 shares issued at December 31, 2024 and December 31, 2023, respectively; 1,355,773 and 209,739 shares outstanding at December 31, 2024 and December 31, 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r477",
      "r666"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "us-gaap_ConcentrationRiskBenchmarkDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDescription",
     "presentation": [
      "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration of risk, description",
        "documentation": "Identifies or describes the benchmark that serves as the denominator in the calculation of the percentage of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r35",
      "r36"
     ]
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r35",
      "r36",
      "r189",
      "r610"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r35",
      "r36",
      "r189",
      "r506",
      "r610"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r35",
      "r36",
      "r189",
      "r610",
      "r813"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentrations of Credit Risk and Off-Balance Sheet Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r98"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration of risk",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r35",
      "r36",
      "r189"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r35",
      "r36",
      "r189",
      "r610"
     ]
    },
    "us-gaap_ContractualObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractualObligation",
     "crdr": "credit",
     "presentation": [
      "http://ensysce.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual obligation",
        "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments."
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "ENSC_ConversionsOfConvertibleNotesIntoCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "ConversionsOfConvertibleNotesIntoCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://ensysce.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of convertible notes into common stock",
        "documentation": "Conversions of convertible notes into common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtSecuritiesMember",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfWeightedAverageSharesOfAnti-dilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt Securities [Member]",
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfFederalAndStateIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current state provision",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r814",
      "r827",
      "r891"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r189"
     ]
    },
    "ENSC_CustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "CustomerMember",
     "presentation": [
      "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Member]",
        "documentation": "Customer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r715",
      "r800"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r715",
      "r800"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r717",
      "r802"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r719",
      "r804"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r717",
      "r802"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r710",
      "r795"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r711",
      "r796"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r711",
      "r796"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r709",
      "r794"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r712",
      "r797"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r714",
      "r799"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r714",
      "r799"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r715",
      "r800"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r718",
      "r803"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r716",
      "r801"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r713",
      "r798"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://ensysce.com/role/NotesPayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NOTES PAYABLE",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r132",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r216",
      "r217",
      "r227",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r243",
      "r250",
      "r251",
      "r252",
      "r419"
     ]
    },
    "ENSC_DebtDiscountFromWarrantsIssuance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "DebtDiscountFromWarrantsIssuance",
     "crdr": "credit",
     "presentation": [
      "http://ensysce.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt discount from warrants issuance",
        "documentation": "Debt discount from warrants issuance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://ensysce.com/role/NotesPayableDetailsNarrative",
      "http://ensysce.com/role/ScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r40",
      "r41",
      "r81",
      "r83",
      "r136",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r234",
      "r239",
      "r240",
      "r241",
      "r242",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r665",
      "r825",
      "r844",
      "r845",
      "r846",
      "r906",
      "r908"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://ensysce.com/role/NotesPayableDetailsNarrative",
      "http://ensysce.com/role/ScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal balance",
        "verboseLabel": "Aggregate principal amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r419",
      "r420",
      "r642",
      "r643",
      "r665"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://ensysce.com/role/NotesPayableDetailsNarrative",
      "http://ensysce.com/role/ScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r136",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r234",
      "r239",
      "r240",
      "r241",
      "r242",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r665",
      "r825",
      "r844",
      "r845",
      "r846",
      "r906",
      "r908"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unamortized Debt Discount &amp; Issuance Costs",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r253",
      "r418",
      "r419",
      "r420",
      "r642",
      "r643",
      "r665"
     ]
    },
    "ENSC_DeemedDividendRelatedToWarrantsDownRoundProvision": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "DeemedDividendRelatedToWarrantsDownRoundProvision",
     "crdr": "credit",
     "presentation": [
      "http://ensysce.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deemed dividend related to warrants down round provision",
        "documentation": "Deemed dividend related to warrants down round provision.",
        "label": "DeemedDividendRelatedToWarrantsDownRoundProvision"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://ensysce.com/role/PrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://ensysce.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://ensysce.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ensysce.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://ensysce.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://ensysce.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss tax carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://ensysce.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://ensysce.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax credits",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://ensysce.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized research costs",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://ensysce.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://ensysce.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://ensysce.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://ensysce.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "label": "Deferred Tax Liabilities, Other",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r23"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://ensysce.com/role/Stock-basedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCK-BASED COMPENSATION",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r286",
      "r317",
      "r318",
      "r320",
      "r654"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r705",
      "r707",
      "r730"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r705",
      "r707",
      "r730",
      "r770"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://ensysce.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "ENSC_EBIRIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "EBIRIncMember",
     "presentation": [
      "http://ensysce.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "EBIR, Inc [Member]",
        "documentation": "EBIR, Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://ensysce.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per basic and diluted share:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://ensysce.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share attributable to common stockholders, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r151",
      "r155",
      "r159",
      "r160",
      "r161",
      "r164",
      "r369",
      "r372",
      "r392",
      "r393",
      "r472",
      "r487",
      "r629"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://ensysce.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share attributable to common stockholders, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r155",
      "r159",
      "r160",
      "r161",
      "r164",
      "r369",
      "r372",
      "r392",
      "r393",
      "r472",
      "r487",
      "r629"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r163"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationLineItems",
     "presentation": [
      "http://ensysce.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r335",
      "r656"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTable",
     "presentation": [
      "http://ensysce.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Table]",
        "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r335",
      "r656"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized stock based compensation",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfCommonStockFutureIssuanceDetails",
      "http://ensysce.com/role/ScheduleOfWeightedAverageSharesOfAnti-dilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityClassifiedWrittenCallOptionModificationEquityIssuanceIncreaseDecreaseInEquityAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityClassifiedWrittenCallOptionModificationEquityIssuanceIncreaseDecreaseInEquityAmount",
     "crdr": "credit",
     "presentation": [
      "http://ensysce.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity issuance costs",
        "documentation": "Amount of increase (decrease) in equity for freestanding written call option classified as equity from modification recognized as equity issuance cost. Includes, but is not limited to, exchange by issuer and holder. Excludes share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r387",
      "r389",
      "r390"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://ensysce.com/role/NotesPayableDetailsNarrative",
      "http://ensysce.com/role/RelatedPartiesDetailsNarrative",
      "http://ensysce.com/role/ScheduleOfCommonStockFutureIssuanceDetails",
      "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetails",
      "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical",
      "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit",
      "http://ensysce.com/role/StockholdersEquityDetailsNarrative",
      "http://ensysce.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r105",
      "r122",
      "r123",
      "r124",
      "r137",
      "r138",
      "r139",
      "r141",
      "r146",
      "r148",
      "r150",
      "r166",
      "r195",
      "r196",
      "r200",
      "r271",
      "r358",
      "r359",
      "r366",
      "r367",
      "r368",
      "r370",
      "r371",
      "r372",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r391",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r421",
      "r423",
      "r426",
      "r486",
      "r500",
      "r501",
      "r502",
      "r520",
      "r586"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://ensysce.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative"
     ],
     "auth_ref": [
      "r191",
      "r192",
      "r193",
      "r365",
      "r810",
      "r811",
      "r812",
      "r892",
      "r893",
      "r894",
      "r895"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://ensysce.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r723",
      "r734",
      "r748",
      "r774"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r720",
      "r731",
      "r745",
      "r771"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r405",
      "r406",
      "r408",
      "r435",
      "r436",
      "r437",
      "r642",
      "r643",
      "r650",
      "r651",
      "r652",
      "r659",
      "r661"
     ]
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfChangeInFairValueOfCompanysLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r407"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r275",
      "r280",
      "r395",
      "r406",
      "r435",
      "r650",
      "r651",
      "r652",
      "r659"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r275",
      "r280",
      "r395",
      "r396",
      "r406",
      "r436",
      "r642",
      "r643",
      "r650",
      "r651",
      "r652",
      "r659"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r395",
      "r396",
      "r397",
      "r398",
      "r406",
      "r437",
      "r642",
      "r643",
      "r650",
      "r651",
      "r652",
      "r659",
      "r661"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfChangeInFairValueOfCompanysLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r407"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfChangeInFairValueOfCompanysLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfChangeInFairValueOfCompanysLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Disclosure of information about financial instrument liability measured at fair value on recurring basis using unobservable input."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r407"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY\u2019S LEVEL 3",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r404",
      "r407"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfChangeInFairValueOfCompanysLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value",
        "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r902",
      "r904"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfChangeInFairValueOfCompanysLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r407"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r405",
      "r406",
      "r408",
      "r435",
      "r436",
      "r437",
      "r642",
      "r643",
      "r650",
      "r651",
      "r652",
      "r659",
      "r661"
     ]
    },
    "us-gaap_FairValueNetAssetLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueNetAssetLiability",
     "crdr": "debit",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total",
        "documentation": "Fair value of asset after deduction of liability."
       }
      }
     },
     "auth_ref": [
      "r897",
      "r898"
     ]
    },
    "ENSC_FinancedInsuranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "FinancedInsuranceMember",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financed Insurance [Member]",
        "documentation": "Financed Insurance [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENSC_FinancedInsurancePremiums": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "FinancedInsurancePremiums",
     "crdr": "credit",
     "presentation": [
      "http://ensysce.com/role/NotesPayableDetailsNarrative",
      "http://ensysce.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financed insurance premiums",
        "documentation": "Financed insurance premiums."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability classified warrants",
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities."
       }
      }
     },
     "auth_ref": [
      "r897",
      "r898",
      "r903"
     ]
    },
    "us-gaap_FinancingReceivableAccruedInterestWriteoff": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancingReceivableAccruedInterestWriteoff",
     "crdr": "debit",
     "presentation": [
      "http://ensysce.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing receivable accrued interest write off",
        "documentation": "Amount of writeoff of accrued interest on financing receivable recognized by reversing interest income."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "ENSC_FirstClosingSecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "FirstClosingSecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://ensysce.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "First Closing Securities Purchase Agreement [Member]",
        "documentation": "First Closing Securities Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r727",
      "r738",
      "r752",
      "r778"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r727",
      "r738",
      "r752",
      "r778"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r727",
      "r738",
      "r752",
      "r778"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r727",
      "r738",
      "r752",
      "r778"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r727",
      "r738",
      "r752",
      "r778"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://ensysce.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r568"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_GrantsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrantsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grants receivable",
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants."
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r705",
      "r707",
      "r730"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfIncomeTaxesBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss before provision for income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r88",
      "r92",
      "r473",
      "r482",
      "r631",
      "r635",
      "r834",
      "r836",
      "r837",
      "r838",
      "r839"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r208",
      "r209",
      "r400",
      "r404",
      "r407",
      "r497",
      "r499",
      "r571",
      "r623",
      "r660",
      "r923"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r209",
      "r400",
      "r404",
      "r407",
      "r497",
      "r499",
      "r571",
      "r623",
      "r660",
      "r923"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://ensysce.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r334",
      "r335",
      "r343",
      "r355",
      "r656",
      "r888"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://ensysce.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r334",
      "r335",
      "r343",
      "r355",
      "r656",
      "r888"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityNameAxis",
     "presentation": [
      "http://ensysce.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority, Name [Axis]",
        "documentation": "Information by name of taxing authority."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r888"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityNameDomain",
     "presentation": [
      "http://ensysce.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r888"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://ensysce.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r329",
      "r334",
      "r340",
      "r341",
      "r342",
      "r348",
      "r353",
      "r360",
      "r362",
      "r363",
      "r364",
      "r514",
      "r656"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://ensysce.com/role/ScheduleOfFederalIncomeTaxRateReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ensysce.com/role/ScheduleOfFederalIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r103",
      "r149",
      "r150",
      "r165",
      "r173",
      "r184",
      "r333",
      "r334",
      "r361",
      "r488",
      "r656"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r331",
      "r332",
      "r348",
      "r349",
      "r352",
      "r357",
      "r508"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://ensysce.com/role/ScheduleOfFederalIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/ScheduleOfFederalIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in valuation allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r656",
      "r884"
     ]
    },
    "ENSC_IncomeTaxReconciliationExpiringAttributes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "IncomeTaxReconciliationExpiringAttributes",
     "crdr": "debit",
     "calculation": {
      "http://ensysce.com/role/ScheduleOfFederalIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/ScheduleOfFederalIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiring attributes",
        "documentation": "Income tax reconciliation expiring attributes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://ensysce.com/role/ScheduleOfFederalIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/ScheduleOfFederalIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (benefit) taxes at statutory rates",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r656"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOther",
     "crdr": "debit",
     "calculation": {
      "http://ensysce.com/role/ScheduleOfFederalIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/ScheduleOfFederalIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nondeductible executive compensation",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r656",
      "r884",
      "r886"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges",
     "crdr": "debit",
     "calculation": {
      "http://ensysce.com/role/ScheduleOfFederalIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/ScheduleOfFederalIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and convertible debt",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible restructuring charges."
       }
      }
     },
     "auth_ref": [
      "r884",
      "r886"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://ensysce.com/role/ScheduleOfFederalIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/ScheduleOfFederalIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock based compensation",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r656",
      "r884",
      "r886"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://ensysce.com/role/ScheduleOfFederalIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/ScheduleOfFederalIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r656",
      "r884",
      "r885"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://ensysce.com/role/ScheduleOfFederalIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/ScheduleOfFederalIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State income tax, net of federal benefit",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r656",
      "r884"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationTaxContingencies",
     "crdr": "debit",
     "calculation": {
      "http://ensysce.com/role/ScheduleOfFederalIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/ScheduleOfFederalIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in tax rates",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r656",
      "r884"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "crdr": "credit",
     "calculation": {
      "http://ensysce.com/role/ScheduleOfFederalIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/ScheduleOfFederalIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and development tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r656",
      "r884",
      "r886"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://ensysce.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax payments",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r129",
      "r354",
      "r355"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://ensysce.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInInterestPayableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInterestPayableNet",
     "crdr": "debit",
     "calculation": {
      "http://ensysce.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued interest",
        "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://ensysce.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses and other liabilities",
        "label": "Increase (Decrease) in Other Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidExpensesOther",
     "crdr": "credit",
     "calculation": {
      "http://ensysce.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expenses, Other",
        "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ENSC_IncreaseDecreaseInUnbilledReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "IncreaseDecreaseInUnbilledReceivable",
     "crdr": "credit",
     "calculation": {
      "http://ensysce.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unbilled receivable",
        "documentation": "Increase decrease in unbilled receivables.",
        "label": "IncreaseDecreaseInUnbilledReceivable"
       }
      }
     },
     "auth_ref": []
    },
    "ENSC_IncrementalFairValueOfWarrantInducement1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "IncrementalFairValueOfWarrantInducement1",
     "crdr": "credit",
     "presentation": [
      "http://ensysce.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental fair value of August 2024 Warrant Inducement",
        "documentation": "Incremental fair value of warrant inducement1."
       }
      }
     },
     "auth_ref": []
    },
    "ENSC_IncrementalFairValueOfWarrantInducement2": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "IncrementalFairValueOfWarrantInducement2",
     "crdr": "credit",
     "presentation": [
      "http://ensysce.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental fair value of February 2024 Warrant Inducement",
        "documentation": "Incremental fair value of warrant inducement2."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r727",
      "r738",
      "r752",
      "r769",
      "r778",
      "r782",
      "r790"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r708",
      "r793"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r708",
      "r793"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r708",
      "r793"
     ]
    },
    "ENSC_InstitutionalInvestorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "InstitutionalInvestorMember",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Institutional Investor [Member]",
        "documentation": "Institutional Investor [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://ensysce.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest expense",
        "label": "Interest Expense, Operating and Nonoperating",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r169",
      "r172",
      "r174",
      "r184",
      "r417",
      "r635",
      "r636"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://ensysce.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r247",
      "r254",
      "r644",
      "r645"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://ensysce.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense, net",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r820"
     ]
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued interest",
        "label": "Interest Payable",
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r919"
     ]
    },
    "ENSC_InvestorWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "InvestorWarrantsMember",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor Warrants [Member]",
        "documentation": "Investor Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENSC_IssuanceCostFromConvertibleNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "IssuanceCostFromConvertibleNotes",
     "crdr": "credit",
     "presentation": [
      "http://ensysce.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance cost from convertible notes",
        "documentation": "Issuance cost from convertible notes"
       }
      }
     },
     "auth_ref": []
    },
    "ENSC_IssuanceOfCommonStockUponWarrantInducements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "IssuanceOfCommonStockUponWarrantInducements",
     "crdr": "credit",
     "presentation": [
      "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock upon warrant inducements",
        "documentation": "Issuance of common stock upon warrant inducements, value."
       }
      }
     },
     "auth_ref": []
    },
    "ENSC_IssuanceOfCommonStockUponWarrantInducementsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "IssuanceOfCommonStockUponWarrantInducementsShares",
     "presentation": [
      "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock upon warrant inducements , shares",
        "documentation": "Issuance of common stock upon warrant inducements , shares."
       }
      }
     },
     "auth_ref": []
    },
    "ENSC_IssuanceOfCommonStockValueUponWarrantInducementNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "IssuanceOfCommonStockValueUponWarrantInducementNetOfIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://ensysce.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant inducement cost",
        "documentation": "Issuance of common stock value upon warrant inducement, net of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "ENSC_KeyPersonnelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "KeyPersonnelMember",
     "presentation": [
      "http://ensysce.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Key Personnel [Member]",
        "documentation": "Key Personnel [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LegalFees",
     "crdr": "debit",
     "presentation": [
      "http://ensysce.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal fees",
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://ensysce.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r134",
      "r194",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r376",
      "r379",
      "r380",
      "r409",
      "r543",
      "r630",
      "r693",
      "r851",
      "r910",
      "r911"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://ensysce.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ensysce.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity (deficit)",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r86",
      "r480",
      "r666",
      "r826",
      "r841",
      "r905"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://ensysce.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and stockholders\u2019 equity (deficit)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://ensysce.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r109",
      "r134",
      "r194",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r376",
      "r379",
      "r380",
      "r409",
      "r666",
      "r851",
      "r910",
      "r911"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://ensysce.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://ensysce.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total long-term liabilities",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r43",
      "r44",
      "r45",
      "r46",
      "r134",
      "r194",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r376",
      "r379",
      "r380",
      "r409",
      "r851",
      "r910",
      "r911"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://ensysce.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "ENSC_LiabilityClassifiedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "LiabilityClassifiedWarrantsMember",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfChangeInFairValueOfCompanysLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Classified Warrants [Member]",
        "documentation": "Liability classified warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "ENSC_LossOnConversionsAndChangeInFairValueOfConvertibleNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "LossOnConversionsAndChangeInFairValueOfConvertibleNotes",
     "crdr": "debit",
     "calculation": {
      "http://ensysce.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      },
      "http://ensysce.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/StatementsOfCashFlows",
      "http://ensysce.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on conversions and change in fair value of convertible notes",
        "label": "Loss on conversions and change in fair value of convertible notes",
        "documentation": "Loss on conversions and change in fairvalue of convertible notes."
       }
      }
     },
     "auth_ref": []
    },
    "ENSC_MPARMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "MPARMember",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfRevenueRecognitionUnderGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MPAR [Member]",
        "documentation": "MPAR [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r189",
      "r649",
      "r676",
      "r680",
      "r854",
      "r922",
      "r924",
      "r925",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951"
     ]
    },
    "cyd_MaterialCybersecurityIncidentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r741",
      "r742"
     ]
    },
    "cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r741",
      "r743"
     ]
    },
    "cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r741",
      "r744"
     ]
    },
    "cyd_MaterialCybersecurityIncidentNatureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentNatureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Nature [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r741",
      "r744"
     ]
    },
    "cyd_MaterialCybersecurityIncidentScopeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentScopeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Scope [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r741",
      "r744"
     ]
    },
    "cyd_MaterialCybersecurityIncidentTimingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentTimingTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Timing [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r741",
      "r744"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetails",
      "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical",
      "http://ensysce.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails",
      "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative",
      "http://ensysce.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r215",
      "r281",
      "r326",
      "r398",
      "r440",
      "r496",
      "r498",
      "r505",
      "r535",
      "r536",
      "r593",
      "r595",
      "r597",
      "r598",
      "r600",
      "r621",
      "r622",
      "r639",
      "r646",
      "r653",
      "r661",
      "r662",
      "r663",
      "r664",
      "r677",
      "r853",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetails",
      "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical",
      "http://ensysce.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails",
      "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative",
      "http://ensysce.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r215",
      "r281",
      "r326",
      "r398",
      "r440",
      "r496",
      "r498",
      "r505",
      "r535",
      "r536",
      "r593",
      "r595",
      "r597",
      "r598",
      "r600",
      "r621",
      "r622",
      "r639",
      "r646",
      "r653",
      "r661",
      "r662",
      "r663",
      "r677",
      "r853",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917"
     ]
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://ensysce.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling interests in stockholders\u2019 deficit",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r85",
      "r134",
      "r194",
      "r218",
      "r220",
      "r221",
      "r222",
      "r225",
      "r226",
      "r409",
      "r479",
      "r547"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "auth_ref": [
      "r189",
      "r649",
      "r676",
      "r680",
      "r854",
      "r922",
      "r924",
      "r925",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://ensysce.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://ensysce.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://ensysce.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r64"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://ensysce.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r64",
      "r89",
      "r107",
      "r119",
      "r120",
      "r124",
      "r134",
      "r140",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r149",
      "r150",
      "r157",
      "r194",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r369",
      "r372",
      "r393",
      "r409",
      "r485",
      "r565",
      "r584",
      "r585",
      "r691",
      "r851"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://ensysce.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss attributable to noncontrolling interests",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r79",
      "r119",
      "r120",
      "r146",
      "r149",
      "r150",
      "r484",
      "r819"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://ensysce.com/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ensysce.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss attributable to common stockholders",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r142",
      "r143",
      "r144",
      "r145",
      "r151",
      "r152",
      "r158",
      "r161",
      "r372"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently Issued Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://ensysce.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r271",
      "r829",
      "r830",
      "r831",
      "r832",
      "r954"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://ensysce.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income (expense), net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "ENSC_Notes2021And2022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "Notes2021And2022Member",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes 2021 and 2022 [Member]",
        "documentation": "Notes 2021 And 2022 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net debt balance",
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r83",
      "r920",
      "r921"
     ]
    },
    "us-gaap_NotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://ensysce.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes payable and accrued interest",
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41"
     ]
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of operating segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r636",
      "r835"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of reportable segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r632",
      "r638",
      "r835"
     ]
    },
    "ENSC_OfferingPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "OfferingPricePerShare",
     "presentation": [
      "http://ensysce.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Combined offering price",
        "documentation": "Offering price per share.",
        "label": "OfferingPricePerShare"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://ensysce.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://ensysce.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://ensysce.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r631",
      "r834",
      "r836",
      "r837",
      "r838",
      "r839"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://ensysce.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Future lease payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r425"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://ensysce.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLimitationsOnUse": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsLimitationsOnUse",
     "presentation": [
      "http://ensysce.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating loss carryforwards expiration",
        "documentation": "A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ENSC_OriginalDebtDiscountFromConvertibleNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "OriginalDebtDiscountFromConvertibleNotes",
     "crdr": "credit",
     "presentation": [
      "http://ensysce.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Original debt discount from convertible notes",
        "documentation": "Original debt discount from convertible notes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://ensysce.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses and other liabilities",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://ensysce.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/ScheduleOfAccruedExpensesAndOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other accrued liabilities",
        "documentation": "Amount of expenses incurred but not yet paid classified as other."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://ensysce.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current assets",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r666"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://ensysce.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCurrentAssetsTextBlock",
     "presentation": [
      "http://ensysce.com/role/PrepaidExpensesAndOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PREPAID EXPENSES AND OTHER CURRENT ASSETS",
        "documentation": "The entire disclosure for other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherExpenses",
     "crdr": "debit",
     "presentation": [
      "http://ensysce.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related costs",
        "documentation": "Amount of expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://ensysce.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other long-term liabilities",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://ensysce.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income and expense, net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://ensysce.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense):"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://ensysce.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r817",
      "r842"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r725",
      "r736",
      "r750",
      "r776"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r728",
      "r739",
      "r753",
      "r779"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r728",
      "r739",
      "r753",
      "r779"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r757"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRent",
     "crdr": "credit",
     "presentation": [
      "http://ensysce.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rent expense",
        "documentation": "Cash payments to lessor's for use of assets under operating leases."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://ensysce.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of debt issuance costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://ensysce.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issuance costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "ENSC_PlacementAgentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "PlacementAgentWarrantsMember",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agent Warrants [Member]",
        "documentation": "Placement Agent Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfCommonStockFutureIssuanceDetails",
      "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfCommonStockFutureIssuanceDetails",
      "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881"
     ]
    },
    "srt_PlatformOperatorCryptoAssetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "PlatformOperatorCryptoAssetLineItems",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Platform Operator, Crypto Asset [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r202"
     ]
    },
    "srt_PlatformOperatorCryptoAssetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "PlatformOperatorCryptoAssetTable",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Platform Operator, Crypto Asset [Table]"
       }
      }
     },
     "auth_ref": [
      "r202"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://ensysce.com/role/BalanceSheetsParenthetical",
      "http://ensysce.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative",
      "http://ensysce.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r256"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://ensysce.com/role/BalanceSheetsParenthetical",
      "http://ensysce.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative",
      "http://ensysce.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r545"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://ensysce.com/role/BalanceSheetsParenthetical",
      "http://ensysce.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r256"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://ensysce.com/role/BalanceSheetsParenthetical",
      "http://ensysce.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r545",
      "r563",
      "r954",
      "r955"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://ensysce.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, $0.0001 par value, 1,500,000 shares authorized, no shares issued and outstanding at December 31, 2024 and December 31, 2023",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r476",
      "r666"
     ]
    },
    "ENSC_PrefundedWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "PrefundedWarrantMember",
     "presentation": [
      "http://ensysce.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prefunded Warrant [Member]",
        "documentation": "Prefunded Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://ensysce.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://ensysce.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ensysce.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total prepaid expenses and other current assets",
        "label": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r198",
      "r199",
      "r627"
     ]
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://ensysce.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r628",
      "r640",
      "r842"
     ]
    },
    "ENSC_PrepaidResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "PrepaidResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://ensysce.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid research and development",
        "documentation": "Prepaid research and development."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "calculation": {
      "http://ensysce.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of convertible notes, net",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "calculation": {
      "http://ensysce.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from public offerings, net",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "presentation": [
      "http://ensysce.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate purchase price",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://ensysce.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://ensysce.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from warrant exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "ENSC_ProceedsFromWarrantInducementNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "ProceedsFromWarrantInducementNetOfIssuanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://ensysce.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/NotesPayableDetailsNarrative",
      "http://ensysce.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from warrant inducement, net of issuance costs",
        "verboseLabel": "Transaction cost",
        "documentation": "Proceeds from warrant inducement, net of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProductInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductInformationLineItems",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfRevenueRecognitionUnderGrantsDetails",
      "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfRevenueRecognitionUnderGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r186",
      "r441",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r624",
      "r647",
      "r675",
      "r677",
      "r678",
      "r681",
      "r682",
      "r849",
      "r850",
      "r854",
      "r922",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfRevenueRecognitionUnderGrantsDetails"
     ],
     "auth_ref": [
      "r186",
      "r441",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r624",
      "r647",
      "r675",
      "r677",
      "r678",
      "r681",
      "r682",
      "r849",
      "r850",
      "r854",
      "r922",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://ensysce.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 1.0
      },
      "http://ensysce.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/StatementsOfCashFlows",
      "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit",
      "http://ensysce.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r119",
      "r120",
      "r127",
      "r134",
      "r140",
      "r146",
      "r149",
      "r150",
      "r194",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r369",
      "r372",
      "r374",
      "r377",
      "r378",
      "r393",
      "r409",
      "r473",
      "r483",
      "r519",
      "r565",
      "r584",
      "r585",
      "r657",
      "r658",
      "r692",
      "r819",
      "r851"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r99",
      "r102",
      "r481"
     ]
    },
    "us-gaap_ProvisionForLoanLeaseAndOtherLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProvisionForLoanLeaseAndOtherLosses",
     "crdr": "debit",
     "calculation": {
      "http://ensysce.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease cost",
        "documentation": "Amount of expense related loan transactions, lease transactions, credit loss from transactions other than loan and lease transactions, and other loss based on assessment of uncollectability from the counterparty to reduce the account to their net realizable value."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r87",
      "r94"
     ]
    },
    "ENSC_PublicWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "PublicWarrantMember",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Warrant [Member]",
        "documentation": "Public Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetails",
      "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical",
      "http://ensysce.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails",
      "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative",
      "http://ensysce.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r215",
      "r274",
      "r281",
      "r312",
      "r313",
      "r314",
      "r326",
      "r398",
      "r438",
      "r439",
      "r440",
      "r496",
      "r498",
      "r505",
      "r535",
      "r536",
      "r593",
      "r595",
      "r597",
      "r598",
      "r600",
      "r621",
      "r622",
      "r639",
      "r646",
      "r653",
      "r661",
      "r662",
      "r663",
      "r664",
      "r677",
      "r685",
      "r847",
      "r853",
      "r900",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetails",
      "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical",
      "http://ensysce.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails",
      "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative",
      "http://ensysce.com/role/StockholdersEquityDetailsNarrative"
     ],
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r215",
      "r274",
      "r281",
      "r312",
      "r313",
      "r314",
      "r326",
      "r398",
      "r438",
      "r439",
      "r440",
      "r496",
      "r498",
      "r505",
      "r535",
      "r536",
      "r593",
      "r595",
      "r597",
      "r598",
      "r600",
      "r621",
      "r622",
      "r639",
      "r646",
      "r653",
      "r661",
      "r662",
      "r663",
      "r664",
      "r677",
      "r685",
      "r847",
      "r853",
      "r900",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r720",
      "r731",
      "r745",
      "r771"
     ]
    },
    "ENSC_RegisteredDirectOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "RegisteredDirectOfferingMember",
     "presentation": [
      "http://ensysce.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registered Direct Offering [Member]",
        "documentation": "Registered Direct Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://ensysce.com/role/RelatedParties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTIES",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r515",
      "r516",
      "r517",
      "r569",
      "r570",
      "r571",
      "r590",
      "r592"
     ]
    },
    "ENSC_RepaymentInsurancePremiums": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "RepaymentInsurancePremiums",
     "crdr": "credit",
     "calculation": {
      "http://ensysce.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of financed insurance premiums",
        "documentation": "Repayment of insurance premiums.",
        "label": "RepaymentInsurancePremiums"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfConvertibleDebt",
     "crdr": "credit",
     "calculation": {
      "http://ensysce.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of convertible notes",
        "label": "Repayments of Convertible Debt",
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://ensysce.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r623",
      "r635",
      "r918"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Costs",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchMember",
     "presentation": [
      "http://ensysce.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Tax Credit Carryforward [Member]",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r721",
      "r732",
      "r746",
      "r772"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r722",
      "r733",
      "r747",
      "r773"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r729",
      "r740",
      "r754",
      "r780"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://ensysce.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://ensysce.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r72",
      "r478",
      "r503",
      "r504",
      "r513",
      "r546",
      "r666"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r137",
      "r138",
      "r139",
      "r141",
      "r146",
      "r148",
      "r150",
      "r195",
      "r196",
      "r200",
      "r358",
      "r359",
      "r366",
      "r367",
      "r368",
      "r370",
      "r371",
      "r372",
      "r381",
      "r383",
      "r384",
      "r386",
      "r391",
      "r421",
      "r423",
      "r500",
      "r502",
      "r520",
      "r954"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://ensysce.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal grants",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r91",
      "r165",
      "r170",
      "r171",
      "r182",
      "r184",
      "r186",
      "r187",
      "r189",
      "r272",
      "r273",
      "r441"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfRevenueRecognitionUnderGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r91",
      "r165",
      "r170",
      "r171",
      "r182",
      "r184",
      "r186",
      "r187",
      "r189",
      "r272",
      "r273",
      "r441"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "crdr": "debit",
     "presentation": [
      "http://ensysce.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock, consideration received per transaction",
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://ensysce.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock number of shares issued in transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPercentageOfOwnershipAfterTransaction",
     "presentation": [
      "http://ensysce.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares outstanding percentage",
        "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://ensysce.com/role/AccruedExpensesAndOtherLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfWeightedAverageSharesOfAnti-dilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://ensysce.com/role/RelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "ENSC_ScheduleOfCommonStockFutureIssuanceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "ScheduleOfCommonStockFutureIssuanceTableTextBlock",
     "presentation": [
      "http://ensysce.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF COMMON STOCK FUTURE ISSUANCE",
        "documentation": "Schedule of Common Stock Future Issuance [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://ensysce.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF INCOME TAXES BENEFIT",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDebtTableTextBlock",
     "presentation": [
      "http://ensysce.com/role/NotesPayableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF DEBT",
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://ensysce.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF DEFERRED TAX ASSETS",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://ensysce.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF FEDERAL INCOME TAX RATE RECONCILIATION",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r656",
      "r884"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://ensysce.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r191",
      "r192",
      "r193",
      "r365",
      "r810",
      "r811",
      "r812",
      "r892",
      "r893",
      "r894",
      "r895"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r897",
      "r898"
     ]
    },
    "ENSC_ScheduleOfFederalAndStateIncomeTaxProvisionBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "ScheduleOfFederalAndStateIncomeTaxProvisionBenefitTableTextBlock",
     "presentation": [
      "http://ensysce.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF FEDERAL AND STATE INCOME TAX PROVISION (BENEFIT)",
        "documentation": "Schedule of Federal and State Income Tax Provision (Benefit) [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfProductInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfProductInformationTable",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfRevenueRecognitionUnderGrantsDetails",
      "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operation, Product Information, Concentration of Risk [Table]",
        "documentation": "Disclosure of information about concentration risk of product within nature of operation."
       }
      }
     },
     "auth_ref": []
    },
    "ENSC_ScheduleOfRevenueRecognitionUnderGrantsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "ScheduleOfRevenueRecognitionUnderGrantsTableTextBlock",
     "presentation": [
      "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF REVENUE RECOGNITION UNDER GRANTS",
        "documentation": "Schedule of Revenue Recognition Under Grants [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfCommonStockFutureIssuanceDetails",
      "http://ensysce.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails",
      "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r285",
      "r287",
      "r288",
      "r289",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://ensysce.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF STOCK OPTION ACTIVITY",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r8",
      "r74"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://ensysce.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShortTermDebtTable",
     "presentation": [
      "http://ensysce.com/role/NotesPayableDetailsNarrative",
      "http://ensysce.com/role/ScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Table]",
        "documentation": "Disclosure of information about short-term debt arrangement. Includes, but is not limited to, description of arrangement, lender, repayment term, weighted-average interest rate, borrowed amount, and description and amount of refinancing of short-term obligation when obligation is excluded from current liability."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://ensysce.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF OUTSTANDING WARRANT",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://ensysce.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF UNRECOGNIZED TAX BENEFITS",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r655"
     ]
    },
    "ENSC_SecondClosingSecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "SecondClosingSecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://ensysce.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Second Closing Securities Purchase Agreement [Member]",
        "documentation": "Second Closing Securities Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENSC_SecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "SecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://ensysce.com/role/NotesPayableDetailsNarrative",
      "http://ensysce.com/role/RelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Purchase Agreement [Member]",
        "documentation": "Securities Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfIncomeTaxesBenefitDetails"
     ],
     "auth_ref": [
      "r187",
      "r188",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r532",
      "r533",
      "r534",
      "r594",
      "r596",
      "r599",
      "r601",
      "r609",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r625",
      "r648",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r679",
      "r685",
      "r854",
      "r922",
      "r924",
      "r925",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r185",
      "r187",
      "r633",
      "r634",
      "r637"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "presentation": [
      "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expenses",
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption."
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "us-gaap_SeniorLongTermNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeniorLongTermNotes",
     "crdr": "credit",
     "presentation": [
      "http://ensysce.com/role/RelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt financing amount",
        "documentation": "Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Senior note holders are paid off in full before any payments are made to junior note holders."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r666"
     ]
    },
    "ENSC_SeriesAWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "SeriesAWarrantsMember",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical",
      "http://ensysce.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Warrants [Member]",
        "documentation": "Series A Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENSC_SeriesAandBWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "SeriesAandBWarrantsMember",
     "presentation": [
      "http://ensysce.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A and B Warrants [Member]",
        "documentation": "Series A and B Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENSC_SeriesBWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "SeriesBWarrantsMember",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical",
      "http://ensysce.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Warrants [Member]",
        "documentation": "Series B Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENSC_SettlementOfCommitmentFeeInShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "SettlementOfCommitmentFeeInShares",
     "crdr": "credit",
     "presentation": [
      "http://ensysce.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settlement of commitment fee in shares",
        "documentation": "Settlement of commitment fee in shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://ensysce.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercise price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected dividend rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r313"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected stock price volatility, maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected stock price volatility, minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate, maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate, minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfCommonStockFutureIssuanceDetails",
      "http://ensysce.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails",
      "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r285",
      "r287",
      "r288",
      "r289",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding warrant",
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r76"
     ]
    },
    "ENSC_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price",
        "documentation": "Exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Option, exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r293"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted average exercise price, exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r293"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate intrinsic value, exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Option outstanding, expired or forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "ENSC_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate intrinsic value, expired or forfeited",
        "documentation": "Total Intrinsic value of share based payment forfeiture and expiration."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, expired or forfeited",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate intrinsic value, granted",
        "documentation": "The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfStockOptionActivityDetails",
      "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option outstanding, granted",
        "verboseLabel": "Number of restricted stock granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r295"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average fair value per share , grant",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Aggregate intrinsic value, beginning balance",
        "periodEndLabel": "Aggregate intrinsic value, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Option outstanding, beginning balance",
        "periodEndLabel": "Option outstanding, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r292"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price. beginning balance",
        "periodEndLabel": "Weighted average exercise price, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r292"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate intrinsic value, vested or expected to vest",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option vested or expected to vest",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfStockOptionActivityDetails",
      "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, vested or expected to vest",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfCommonStockFutureIssuanceDetails",
      "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetails",
      "http://ensysce.com/role/SubsequentEventsDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r288",
      "r289",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r296"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r295"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r290",
      "r309",
      "r310",
      "r311",
      "r312",
      "r315",
      "r321",
      "r322",
      "r323",
      "r324"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical",
      "http://ensysce.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected term (years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Aggregate intrinsic value, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual term, exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "ENSC_SharebasedCompensationArrangementBySharebasedPaymentAwardWeightedAveragePeriodExpectedToBeRecognized": {
     "xbrltype": "durationItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardWeightedAveragePeriodExpectedToBeRecognized",
     "presentation": [
      "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average period",
        "documentation": "Share based payment award weighted average period expected to be recognized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtLineItems",
     "presentation": [
      "http://ensysce.com/role/NotesPayableDetailsNarrative",
      "http://ensysce.com/role/ScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://ensysce.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r131"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://ensysce.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://ensysce.com/role/Cover",
      "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical",
      "http://ensysce.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r113",
      "r114",
      "r115",
      "r134",
      "r155",
      "r156",
      "r159",
      "r161",
      "r167",
      "r168",
      "r194",
      "r218",
      "r220",
      "r221",
      "r222",
      "r225",
      "r226",
      "r256",
      "r257",
      "r259",
      "r262",
      "r268",
      "r409",
      "r509",
      "r510",
      "r511",
      "r512",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r545",
      "r566",
      "r586",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r809",
      "r824",
      "r833"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://ensysce.com/role/NotesPayableDetailsNarrative",
      "http://ensysce.com/role/RelatedPartiesDetailsNarrative",
      "http://ensysce.com/role/ScheduleOfCommonStockFutureIssuanceDetails",
      "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetails",
      "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical",
      "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit",
      "http://ensysce.com/role/StockholdersEquityDetailsNarrative",
      "http://ensysce.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r48",
      "r51",
      "r52",
      "r105",
      "r122",
      "r123",
      "r124",
      "r137",
      "r138",
      "r139",
      "r141",
      "r146",
      "r148",
      "r150",
      "r166",
      "r195",
      "r196",
      "r200",
      "r271",
      "r358",
      "r359",
      "r366",
      "r367",
      "r368",
      "r370",
      "r371",
      "r372",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r391",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r421",
      "r423",
      "r426",
      "r486",
      "r500",
      "r501",
      "r502",
      "r520",
      "r586"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfIncomeTaxesBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r187",
      "r188",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r532",
      "r533",
      "r534",
      "r594",
      "r596",
      "r599",
      "r601",
      "r609",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r625",
      "r648",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r679",
      "r685",
      "r854",
      "r922",
      "r924",
      "r925",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://ensysce.com/role/Cover",
      "http://ensysce.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative",
      "http://ensysce.com/role/ScheduleOfIncomeTaxesBenefitDetails",
      "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r138",
      "r139",
      "r166",
      "r423",
      "r441",
      "r507",
      "r531",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r545",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r564",
      "r567",
      "r568",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r586",
      "r686"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://ensysce.com/role/Cover",
      "http://ensysce.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative",
      "http://ensysce.com/role/ScheduleOfIncomeTaxesBenefitDetails",
      "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r138",
      "r139",
      "r166",
      "r190",
      "r423",
      "r441",
      "r507",
      "r531",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r545",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r564",
      "r567",
      "r568",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r586",
      "r686"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r724",
      "r735",
      "r749",
      "r775"
     ]
    },
    "ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit",
      "http://ensysce.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock upon exercise of warrants",
        "verboseLabel": "Value of shares issued upon exercise of warrants",
        "documentation": "Stock issued during period issuance of common stock upon exercise of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "ENSC_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares",
     "presentation": [
      "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit",
      "http://ensysce.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock upon exercise of warrants, shares",
        "verboseLabel": "Number of shares issued upon exercise of warrants",
        "documentation": "Stock issued during period issuance of common stock upon exercise of warrants, shares."
       }
      }
     },
     "auth_ref": []
    },
    "ENSC_StockIssuedDuringPeriodSharesCommitmentFee": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesCommitmentFee",
     "presentation": [
      "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settlement of commitment fee, shares",
        "documentation": "Stock issued during period shares commitment fee."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://ensysce.com/role/NotesPayableDetailsNarrative",
      "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversions of convertible notes, shares",
        "verboseLabel": "Conversion of shares",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r25",
      "r48",
      "r51",
      "r72",
      "r244"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit",
      "http://ensysce.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public offering, net, shares",
        "verboseLabel": "Purchase of shares through securities purchase agreement",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r47",
      "r48",
      "r72",
      "r509",
      "r586",
      "r603"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit",
      "http://ensysce.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settlement of restricted stock units, shares",
        "verboseLabel": "Restricted common stock issued",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r72"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesReverseStockSplits",
     "presentation": [
      "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse split fractional shares, shares",
        "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option outstanding, exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r47",
      "r48",
      "r72",
      "r296"
     ]
    },
    "ENSC_StockIssuedDuringPeriodValueCommitmentFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "StockIssuedDuringPeriodValueCommitmentFee",
     "crdr": "credit",
     "presentation": [
      "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settlement of commitment fee",
        "documentation": "Stock issued during period value commitment fee."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://ensysce.com/role/NotesPayableDetailsNarrative",
      "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of convertible notes",
        "verboseLabel": "Conversion of shares value",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r48",
      "r51",
      "r52",
      "r72"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit",
      "http://ensysce.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public offering",
        "verboseLabel": "Common stock, gross proceeds",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r47",
      "r48",
      "r72",
      "r520",
      "r586",
      "r603",
      "r692"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settlement of restricted stock units",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r47",
      "r48",
      "r72"
     ]
    },
    "ENSC_StockIssuedDuringPeriodValueReverseStockSplits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "StockIssuedDuringPeriodValueReverseStockSplits",
     "crdr": "debit",
     "presentation": [
      "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse split fractional shares",
        "documentation": "Reverse stock splits."
       }
      }
     },
     "auth_ref": []
    },
    "ENSC_StockOptionAvailableForFutureGrantUnder2021OmnibusIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "StockOptionAvailableForFutureGrantUnder2021OmnibusIncentivePlanMember",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfCommonStockFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Available For Future Grant Under 2021 Omnibus Incentive Plan [Member]",
        "documentation": "Stock Option Available For Future Grant Under 2021 Omnibus Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://ensysce.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Ensysce Biosciences, Inc. stockholders\u2019 equity (deficit)",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r51",
      "r52",
      "r68",
      "r547",
      "r563",
      "r587",
      "r588",
      "r666",
      "r693",
      "r826",
      "r841",
      "r905",
      "r954"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://ensysce.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 equity (deficit)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://ensysce.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/BalanceSheets",
      "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity (deficit)",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r33",
      "r105",
      "r106",
      "r123",
      "r137",
      "r138",
      "r139",
      "r141",
      "r146",
      "r148",
      "r195",
      "r196",
      "r200",
      "r271",
      "r358",
      "r359",
      "r366",
      "r367",
      "r368",
      "r370",
      "r371",
      "r372",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r391",
      "r410",
      "r411",
      "r415",
      "r422",
      "r426",
      "r501",
      "r502",
      "r518",
      "r547",
      "r563",
      "r587",
      "r588",
      "r607",
      "r692",
      "r826",
      "r841",
      "r905",
      "r954"
     ]
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://ensysce.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS\u2019 EQUITY",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r133",
      "r255",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r271",
      "r388",
      "r589",
      "r591",
      "r608"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://ensysce.com/role/BasisOfPresentationDetailsNarrative",
      "http://ensysce.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse stock split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://ensysce.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r433"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://ensysce.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r433"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://ensysce.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r433"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://ensysce.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r433"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://ensysce.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r433"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://ensysce.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r432",
      "r434"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://ensysce.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "ENSC_TAAPOUDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "TAAPOUDMember",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfRevenueRecognitionUnderGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "TAAP/OUD [Member]",
        "documentation": "TAAP/OUD [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://ensysce.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax credit carryforward amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://ensysce.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "us-gaap_TaxCreditCarryforwardDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardDescription",
     "presentation": [
      "http://ensysce.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax credit carryforward, description",
        "documentation": "A description of the origin, nature, and characteristics of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_TaxCreditCarryforwardLimitationsOnUse": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardLimitationsOnUse",
     "presentation": [
      "http://ensysce.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax credit carryforward expiration",
        "documentation": "Description of the limitation related to use of the tax credit carryforward."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://ensysce.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://ensysce.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative",
      "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r840",
      "r909"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://ensysce.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative",
      "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ENSC_TransactionCostAssociatedWithWarrantInducement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "TransactionCostAssociatedWithWarrantInducement",
     "crdr": "credit",
     "calculation": {
      "http://ensysce.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Transaction costs associated with public offering and warrant inducements",
        "documentation": "Transaction cost associated with warrant inducement.",
        "label": "TransactionCostAssociatedWithWarrantInducement"
       }
      }
     },
     "auth_ref": []
    },
    "ENSC_TransactionCostsAssociatedWithPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "TransactionCostsAssociatedWithPublicOffering",
     "crdr": "credit",
     "presentation": [
      "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction costs associated with public offering",
        "documentation": "Transaction cost associated with public offering."
       }
      }
     },
     "auth_ref": []
    },
    "ENSC_TransactionCostsAssociatedWithPublicOfferingAndWarrantInducements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "TransactionCostsAssociatedWithPublicOfferingAndWarrantInducements",
     "crdr": "credit",
     "presentation": [
      "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction costs associated with public offering and warrant inducements",
        "documentation": "Transaction costs associated with public offering and warrant inducements."
       }
      }
     },
     "auth_ref": []
    },
    "ENSC_TransactionCostsAssociatedWithWarrantInducement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "TransactionCostsAssociatedWithWarrantInducement",
     "crdr": "credit",
     "presentation": [
      "http://ensysce.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction cost",
        "documentation": "Transaction costs associated with warrant inducement."
       }
      }
     },
     "auth_ref": []
    },
    "ENSC_TransactionCostsFromPublicOfferings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "TransactionCostsFromPublicOfferings",
     "crdr": "credit",
     "calculation": {
      "http://ensysce.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Transaction costs from public offerings",
        "documentation": "Transaction costs from public offering.",
        "label": "TransactionCostsFromPublicOfferings"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "ENSC_TwoThousandTwentyOneOmnibusIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "TwoThousandTwentyOneOmnibusIncentivePlanMember",
     "presentation": [
      "http://ensysce.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2021 Omnibus Incentive Plan [Member]",
        "documentation": "2021 Omnibus Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENSC_TwoThousandTwentyThreeNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "TwoThousandTwentyThreeNotesMember",
     "presentation": [
      "http://ensysce.com/role/NotesPayableDetailsNarrative",
      "http://ensysce.com/role/ScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2023 Notes [Member]",
        "documentation": "2023 Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://ensysce.com/role/NotesPayableDetailsNarrative",
      "http://ensysce.com/role/RelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfIncomeTaxesBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnbilledReceivablesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnbilledReceivablesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://ensysce.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unbilled receivable",
        "documentation": "Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning of year",
        "periodEndLabel": "Balance at end of year",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r344",
      "r655"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decreases related to prior year tax positions",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r655"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increases related to current year tax positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r655"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increases related to prior year tax positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r655"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "crdr": "credit",
     "presentation": [
      "http://ensysce.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized tax benefits that would impact effective tax rate",
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r655"
     ]
    },
    "ENSC_UnrelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "UnrelatedPartyMember",
     "presentation": [
      "http://ensysce.com/role/OrganizationAndPrincipalActivitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrelated Party [Member]",
        "documentation": "Unrelated Party [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://ensysce.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates and Assumptions",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r22",
      "r96",
      "r97",
      "r100",
      "r101"
     ]
    },
    "ENSC_WarrantDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "WarrantDescription",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant description",
        "documentation": "Warrant Description."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount",
     "crdr": "debit",
     "calculation": {
      "http://ensysce.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ensysce.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deemed dividend related to warrants down round provision",
        "documentation": "Amount of decrease in net income available to common shareholder for down round feature triggered for warrant classified as equity."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r161"
     ]
    },
    "us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1",
     "crdr": "credit",
     "presentation": [
      "http://ensysce.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deemed dividend related to warrants down round provision",
        "label": "Warrant, Down Round Feature, Increase (Decrease) in Equity, Amount",
        "documentation": "Amount of increase (decrease) in equity for down round feature triggered for warrant classified as equity."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r270"
     ]
    },
    "ENSC_WarrantExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "WarrantExpirationDate",
     "presentation": [
      "http://ensysce.com/role/RelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant, expiration date",
        "documentation": "Warrant expiration date."
       }
      }
     },
     "auth_ref": []
    },
    "ENSC_WarrantFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "WarrantFourMember",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Four [Member]",
        "documentation": "Warrant Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://ensysce.com/role/NotesPayableDetailsNarrative",
      "http://ensysce.com/role/RelatedPartiesDetailsNarrative",
      "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetails",
      "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical",
      "http://ensysce.com/role/ScheduleOfWeightedAverageSharesOfAnti-dilutiveSecuritiesDetails",
      "http://ensysce.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r683",
      "r684",
      "r687",
      "r688",
      "r689",
      "r690"
     ]
    },
    "ENSC_WarrantOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "WarrantOneMember",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant One [Member]",
        "documentation": "Warrant One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENSC_WarrantOrRightExercisable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "WarrantOrRightExercisable",
     "presentation": [
      "http://ensysce.com/role/RelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercisable",
        "documentation": "Warrant or right exercisable."
       }
      }
     },
     "auth_ref": []
    },
    "ENSC_WarrantOutstandingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "WarrantOutstandingMember",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfCommonStockFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Outstanding [Member]",
        "documentation": "Warrant Outstanding [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENSC_WarrantThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "WarrantThreeMember",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Three [Member]",
        "documentation": "Warrant Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENSC_WarrantTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "WarrantTwoMember",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Two [Member]",
        "documentation": "Warrant Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "presentation": [
      "http://ensysce.com/role/ScheduleOfOutstandingWarrantDetailsParenthetical",
      "http://ensysce.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant expiration date",
        "verboseLabel": "Warrant maturity date",
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r899",
      "r900",
      "r901"
     ]
    },
    "ENSC_WarrantsToPurchaseOneShareOfCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ensysce.com/20241231",
     "localname": "WarrantsToPurchaseOneShareOfCommonStockMember",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants, to purchase one share of Common Stock",
        "documentation": "Warrants To Purchase One Share Of Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://ensysce.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common shares outstanding, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r161"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://ensysce.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common shares outstanding, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r161"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://ensysce.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-12B"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-3D"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.FF.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476188/405-10-S99-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3A"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "17",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480299/815-40-35-17"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 6-K",
   "Section": "General Instruction",
   "Subsection": "B"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "Instruction",
   "Paragraph": "2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "a"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>77
<FILENAME>0001493152-25-009703-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-25-009703-xbrl.zip
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MTE17)P-U*H\E>3!3/Z@S53%:Z$J\%(I!>:8):6/W))\A ,YU%IR^;*B&I(T
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M="_AM=\AD_6S+?LC$WO\.Y2H9Z,)\-32 E#G8S*#=\IP#MXEH!TMXI@&)]<
M=XILS'68.^69-))57?H@C^?*?CBT@^#8( C/;:ID#Q@D@6=CDAT=HP?D7)7
M+UQ. /A\M"8!_."=/+E58$I.XLO2P5F2)Y\B%]>0QLH'92Q=M= +0Z\#3B1
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M9>2J$MKVMH(3-\Y+%J?'Z03@S$>E*C;36WM;6UTY2MJ6;_F%VWR[$H-;02F
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M.D)U'+17!2>2,E_W_]_#QOYA2WH=+27^&L -NZG^[1G%[#V&LRAM[:'EVS-
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M5JL3[;3>L)>6ASDTOT4HCJJ&+VS</!I3*T1^?(MBU[8\(9P*>S:"()XN: /
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M069>6"M$V\]/"'YR6>1/749J#MP,>]NO3RDI[)9#%1;/S4Z-RHR)#RE=_WE
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M!%Q>DL-R;GVR<PBLN2(O:MIZ$2XY0@=9 >>YXLJJA\KE^-FGDX;R2N>.S:(
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M80\VJ4X"MR5Y7U!]M3J2$^%[F)SO:'-IDSW%P!N>3'RT]_ ?R>SENG@ ?GQ
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MI5<DTL1B5?\?4>C:EE<4EO2Y=EA2[\][@RL*4RK,<\EA*YCZ<ZTZ!*F0JI*
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M:/9C0<+!Q:+#"SY]:^6&EI?4-9BB )$GY&P/XXV7"%Y(E8=2]2YY8W;\>A*
M)L4[-8Y"1OU9+E@J=>.-V.QFVE>1E_ BYR5D+L$T_[0_OIG0]9$DF6Z\@KWM
M>"?_X,D_>/(/GOR#)PM?70N?<FOLR<*GN<AUOM3H;>&;/^/Y(XX"JM#/GRD;
MZ[&/*IORJ@VBR.=4;K*KSH9V.U92+F=[C[[&26D__F'#[?1JSQX!46GD; *H
M+=LF2[JI.:A$)"^$E;['6!-PZ7S(2894T\B+K\A'Q/(,WS&<)15[$"97_+3B
M6UD4AE!W51XML26&:S($'I3*3DIFN:*4/%+B!^@)>7@5&Y[%D!3H?-?VP^M'
MX"C*#K@B6ZT",F>&N?'#T'=88D)$YQ]8O EH^OIT&IC7=KR+52'[[H:/4^3%
M3 >/[FJ.3:I>AVOP@"QBL&R0]HM#\3'@8"4F#]7%I%3 J*76TQS4K5[^+S'=
M3\8/R0X?<*_X14U;]W(=L7*P "N0V#^V7P#O5(^0<W3)3>(^U2/459RZ;OU_
M@'J$G[0KG)<C#Y+L)[U+$G[63K(Y\B#)?OYCQO*<*PK,TBB8YYP7XJ7,'&=X
M\;C(*994:K^ IX)8_]>'?Q6^M?-PU99*^@I!''H?#/WD;?.O! =-!#K!'WM]
MTZDQ(6GGA#N6TV\HH*O.\)UMI37,?I068647HN^(/=](VSPA8BU0T]5SI=!U
MFM%-R+,=NZVRC?=  /$OV0NEVT)$;6W*I82<IK<4 ;9CS*F23+-)#*<Z+UUU
MQ4(98?\I6<R,_V".J;*<_7T?!^$(A[^B<(ILO/#=_^RBT3EI^+(_^?KF:,.B
M DV]DO-GZY9G/5A4R4K;G2:7B#O=XOS3%C[]BJ9=NR(#;5>**^@EP0-SZP4%
ME\BGXX><TGGO>:7SAJ/^^,;LS8U_FK/>I3DRKX9SY27SMD$1 BDN!6T5)UN7
MY9T<M-,G>004.Y0GK4%&1XG9=TOJ5X07Q%H]NC8O#H737)T3KUC:6(3H=JQ"
M91@D\RY+'2_N@-.\?:]=N6RQ".%Z^/1D :&KOT\*6"UX P-D_[# 3V]M'/DA
M62>0I?_8(9;^X.YV5@!/^LO;F8(7R<KG.2X@4CL#]>[%XBO*79_.,]>/7'\Q
M7J7/>%/5Z@$3E-&US)>06)1NU[?(.CXAZ<V&S5 J.4K:8E,L'#[\&_RHJD!6
M8;6A:=X%_%Y*E/4KY*31U[&HMNQ-"'YRV:97KL)_X*GP5^; G!K7/6,TZ,WF
MQMS,*/6]R73\;3B+,]Y3[?XOK;XWG3*_99H5)V>W+-]V/3>;UU_$]D<1MC/,
M3AGS4[,_'O6'U\/]1/\VF!V@!T0(O4I:+T80H)#W;/8G'F\#\\J<3LU!S)4Q
MFYGS6:N,W/ID>Q.FS*03E,?.9QX[MR,&RM?1\%\I2^E4;(.IS&XB4D'BQT,^
M]B[(VE2-,!\>$'N+'G$6EL#MN>(PB@S  D26W+DK#*'-=;P6Q(?6V:JBT[XL
MPY81(PH?,7'#M4C.;+Z]LNM\=4B*M"A( -KIUUE"Q;(JBWJHS'\%15V&B^Y9
MKS*@T=(4(!,^33-<*7'TVN/:_>2*798'6=A<47V'TH6"Q4C7;L/K6YY+[Z^^
M:UT1R[<?W8!Q&6>QE.%3VK7U0.]Z8(GQ 7K5U 4KLHLYO:!?T]&]_Q<1-W!<
MFPFV#+B2CG<_=@(V$2X@T'[42,$HK]?%Z_.*5$*-J_$7$UM=_U!?QTM ["(X
M=4E-/!:J;JF+1\"IJ=K8J(JBM"!*R:JJJJ;H60N%$MDGR''#OD7(FG(0O[3#
M/? X73I[WI6*0:-H[$):1;;1THYJ#KURV0M@I?>QUQ1D.A]^DF'5]/C;U$\2
M+1NE*!6XXM(IKA$EDB>L[!*0NOS]!8L&R++'.<G@/G?GBMX'E^&B*6,+ D^O
M[7&  INX<=I)Q?TQT[/3.(HQIYW1$IY^U^[2#9.XG+%_R\O/%A^CTPA795,[
MTTOQ(;]DAO6J%XBX4Z?1+.6K&U<)\54JU/WU05IM;2K+<@0BKN:/5O@=1YXS
M7*XL.]Q**94/C':]\3H-_S$L0_.A;I[AT?/ARO4MRKJ_H#) [A.SAABV32+D
M;&)>OQ,W1/CA 9X#XF-T&O>J;(+N1R5QPG%-1):F2$)7+$3QRV&(XM2\-N;F
MH#<QIO.A3E&*?>S168D3&K+%!@W?B0.YBW\]IW\+K-@!&>3 +ZH4)?,KJM^[
MDL"-\,-7\KZE3=1D$U,.? M+-E;:1U_.Z=CCAPPK)<Z'XN8:U$.5CAP685R[
MVW^><ZN8V3*+:>6!%'DON+C@XUC2SY.A"EZM/1W-38%6:X+/D!U1M9;JC).(
MV(]6@(P%03%EW +AI?T4A87676ZX(FO:[<%"CVESRD@4=WO]9ZS8(^3Z6%]E
M/ JOZMR4]N"[CJ>D#&!T/O&D@:>I5S]][[Y,A]EK=J>H(!9_4> 2@L&UH^[P
M0KZ+R37V%W-$EB,<(MZ1E6_<^M,D+9H) &YE._0!_3"=/6,R937/,B5- ;T0
M;/\:(2IG6#LUL>]903!^**0ZJ4>[_660_C8XYQA-ZPSW&J?"T?*0K6CRU[/Y
MLG*3:BF#8O]?9FKOMWV-X/&9%?#@MUD0)KH/T.\1T\.>&/L"KIY/[W)5-6XO
M9^8_;LW1O&=^H__5R-ESP%\.LP)] .RA2)G9IZ?,C5+86AM'2!D<A]H*AW?M
MW1*'Q--/E1A/H [JS"8\^?.A.N!6(YVE@-*RVS6GBR+31XFT2['1U_ A$QZM
M#2!R(-34_'% ;VG&>E%S13;_\M7"A>9DU-?Q=#J9Y4]F>5V T?I4>N5F^<SK
MA:6YY8=-%9U'5:SSA31KM[LE3SB7WH<.FG7AG"GD3*-LC?HO;N\X\YV)9_DB
MJ<?-?$W-J5:,;,6GL8Z0KDZ'8/=GD<Y'L*J9INF)/45!2%SV%I+0J5W87%45
MF$8WA%R&/< W> V5[ N*O\L>?4;.("*NOTA>LMH\ \U"K[;*R>V*O12<^+%V
M+JSD(6DH1%#2\,I>)! T?4OGM277_O$T-P;\'P-R+M@*;4Z%?&W?C,]N6O&F
M5_:H=JWQ=)\!QS.GW25O9K%PVYA4RH5-N;<6] ?C9Q^1X-%=&0\A(AE_.@?R
MBB-U!>PZ;"F-'MA[)PK93A)",'E:T<W(CIB7OV^%:(&)BX*Q[ZUE/9\!?M=P
M_AT%8:Q(-?^]H>^X3ZX365ZS']NJ?O%73A<\268"&6&+/N)FL>2;O=([1S&S
M+2F:Z8?GSU@$C$RSUP]&3B;%03)-H$$;"2V.O89_ $3R<I%HR>-C<H4C(@))
MMMWK1R0O%;ZUJVUUBFI\#M7\L_SOU(V4&/8?]HXX_<G_!U!+ P04    " "8
M@FI:MBGT[U1V  ",Q@8 %0   &5N<V,M,C R-#$R,S%?;&%B+GAM;.2];7/C
M.)8F^OU&['_ K;DQ417AK*K,G-[9ZI[9#=F6LW7':7ED9=7T5$Q4T"0D<XHB
MU2#E3/>O7P!\)UY)2<!Q]L;N=I9USN%S@ <'[P?_\G^^[!+TC$D>9^F_?O/V
M^Q^_03@-LRA.M__ZS:>'-[.'J\7B&Y0701H%29;B?_TFS;[Y/__[?_P_B/Z?
M?_E_W[Q!-S%.HC^BZRQ\LT@WV9_07;##?T0?<(I)4&3D3^CG(#FPOV0W<8()
MNLIV^P07F/Y0?OB/Z _?O_O#(WKSQL+NSSB-,O)IM6CL/A7%/O_C#S]\_OSY
M^S1[#CYGY/?\^S#;V1E\*(+BD#?6?OSR8_5_2O5_2>+T]S^R_^\QR#&BY97F
M?_R2Q__Z#?MN]=G/[[_/R/:'=S_^^/:'__AX^Q ^X5WP)DY9N87XFUJ+69'I
MO?WIIY]^X+_6HH+DET>2U-]X_T,-I[%,?XTU\ATD>?S'G,.[S<*@X-5N_ Q2
M2K#_>E.+O6%_>O/VW9OW;[__DD??U(7/2Y!D"5[A#>)N_K%XV5,JY3%CPC?5
MWYX(WLC!)(3\P/1_2/$V*'#$/O03^]#;_\D^] _5GV^#1YQ\@Y@DY8?2KY]Z
MMBJE'UR#O<<DSJ)Y.@WU4-L3?-IV2'&$ UU]YRZLLR)()H'O:CJ'?8>GE7BK
MY[ZD:9S'TTJZHWD6V(4(>73QRLLU87^\I?_J0<1?"MJ!X:@&R4QH(C#_ N\8
M*MN-]2SLV4U8-,^(Z#OK&;G-39 _<L.'_,TV"/;T ^_^Z0><%'G]ES?L+[P0
MJC_\QOI&O,-I<94$>;[</!19^/OL2YS7W^%._NLW%O(_#!U@FC-2>Q&0T% 4
ME<0/848[LGWQ)BD+O53?D&QG!:,JL\Q"^+?DL;%?%C*%H'"D)T9PGAU(B$?5
M<=<;VU*M$.X2JL$&;#A]\^GAF__-Q5"V05P0_<I$_^M??FA-3^$23O.0$^3M
MN[)[_X?YW</5;W0PM\M2_J$?OZ>#IK?W >$C*1K@'YX"@C_BW2,F \_&J;J@
MSA1G&(O&Z'DGU 2P K>X=L4LJED.F]&OI=*Y6/9+0$B0%ODZNZ?E\$3'FLL4
M<[#+3<<?-==&&G#&N$F.-;P;I0V#?5,@#SE8V[A 18;VE1E$)Z<H9X98Y.O2
M]%A.GJX7G?_U$!<O;/Y+P5(';'I2N8Z7WE0'7]JCRA2\TW ,RB'S2E'4RIZH
M<SV:8J8@J)%S225M2%,*@:&,;8#J=9*GZAJ/YL@LBF*VX!,D]T$<+=*K8!_3
M>:R6+P8=E]RQ@M_ED58!#*=L4 [YU>H@IO0F3E&E!H=M*UP$<8JC>4#2.-WF
M6IJIA%WR2P^X2RRY)!A&:>$-J50+HUH:#H/N:)UE:4']I5:WB[3 M*0*+8_T
M*B[99 .^RRF=/!AF68 <\JNO@FJ=,[,L)T6'8?2_6G;1__B-[<]$AX1..<H!
MW4=</&4T]CY39.V(L/M7C-EFD62\?KPY%ZP\E=.,L<?:\L[F$SDP9'JK?,%W
M%L^[[C:_7*P6::A>\1@(.%O1D )K5BQZOWIG@A*2,.^C,A<T>(5^X]8Z+AAE
M%VD4/\?1(4@4 4DAYRK2:&'6(40JY)T1)F1#8G!9%*01NL]R/B8_;[/_-_QR
MCTF>I2F63]R44LX"@!IB$P5$$>\5K\<UK'8JB!K)<R]^?TH)3OB>>4!8GZ2J
M=;F<LWK7P6QJ7B8$H^XUR(:UWX@B+@MGQG3%JH@.MOFYGE6<_W[YLJ:?TRPS
M:S7<K@P:H??7")7BWNEDCU%<-^QH(*:"F :81>9#7F0[3 3']$O.)BVG-+-S
MH4<UO0H<NEGA%"A7:2$)]R#'M4N<AD^[@.A.HYC5/$<XJ1.&,-?3@4,^.Z 6
M :]1@Q+U9F&8'=(B7^$0Q\_!8R(_TF(6=[I98@#=VR=1R((AEP&@L#M2B:-6
MWN^T_6/PWQFI ZULTU\EY&K"K@98S]9%">_LT,)2=G/G/0Q7?45SYFT@X>YH
MFQ1:>X*M][/WNE5C4E<LE,'*31"7Y^DN7YI__CG&A!;AT\LM?L:R5;NQRB[[
MDG$.=7L6.TWO;)L$=TA$IE$=AFQT^,+@W>QG*$.9QJM%NC\4.7?IK78TH]7P
M0D(U="GS1'%X=%-B5'.,;48PI0O$U=!;@/&OX]:[T21[!X5D[\:1[-TK(-F[
MB21[!YMD[T>3[#T4DKT?1[+WKX!D[R>2[#U DEV^W,;!8YRP8\+L;HW= $ZF
MXVG<IH:O&*Z)"O#(ID$YI%LCB,J[46>=!?91Q9L81_6-!?7$T$+)V5S1VH%F
M^FC4\,Z>43 -].&*J-;TN[9T3[+H$!9+\H#)<QRJCJC)Q5RM+^E UBM,,AGO
MK#$ &_*D$N73ODKZO*'FX_ULI8XIW5^=!0\14A,EVI^\5ZP<S[ ^F<"Y3W>L
M9[/[Y:=K=2T.!)Q5I!184Y>]7V%4IPR2<%Z+ROQ A> ,,F=I$4=Q<BCB9_R
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MZ.%M2IDL( II 2KO3S8Z+%5,4'/*6\H8<D6'6MM,<TI\(.4^<8P 4<P=TX@
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M!1!'ER\KO,&$W3M8XR_%)?W0[YH9AH6NZ]F;M3O#R9Q1$00)QZ)53?5RU#6
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M*H*)8BZ)I0+9I=50!DPL4@ 3M\93MNQ"S25LK%7OA]/Q72IE$MSH1,F?'-B
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MLFWT]MP76O6!L,YZJ.#)#W=D0O<'AROEG.4VRXULZ4IZX8L(5<J85@PH9P2
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M_\>WAD[I0J)"UB>AE.%-*@B62E91BO&(L\8F7EV4E /'K^N2_I;ETDC[Y-@
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M)UI]0+[.F7"N"R,2H.V9?QKPEYNZT? M9=EZVF@3SM8S)SK7+&V.U/?.OB-
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M&7&G&_;4#HXL"$6#F&@58LLXSA5=$^&YD-#ROGP?L7P1T7^^/)GK57:GV>>
M1%W7V9)R^>I=>X-R<H,YYB.^&\_Q!61J2-._ +I1'>V6MH&Q5:(JV=C]["\?
M^727=D;7%[VV]W#!=R:J=TH?'CY]+/]\]NT(EJN\BB4WAX).[=EI 787;\Q6
MA+41#]L0(QV4;$%86O#.\:-@:[?0EA\_4EJ6?+WYM/ZTFJ,%Y>CL[LK_1G;/
MX7V6LA,MRTUSD+ Z+7V)4[R)Q\Y=)UCTTPM,=ET>\D>;\\[]T_F@:PC=U&OH
M<GXWOUD</:,P1N@;'%47"OC3NNT169(]QSGME&RX?2*;'N+W<>Y+PODT@]X9
M?DHO=!R_F5_/5^QY]+MK&O%GZWF']>A^M?QY\<#&*-]6]/\.4 <PWVPPFPBU
MI;&B13,X.C*N!YABTD\7,-UY>1\PWI[W)G)")VQ:2*==K%@[82<S[JX6MPL8
MV82[:\3E)A]U7W8"<O2"_BAKOM;Z)[BLV@8880I@&YB"7[]Y<#-?L0.MC/C@
M=FX_I:0\;_4W[G'5"^:K+$EN,L*F^"/I/MZ@'\9/=5Q.^K'6 /)^H@LZZG^Z
MJT[?_6=%_VH0Y+\!E!LF'W'QE$6+]!GG_/FYY><4D_PIWM]CPBZ#!%NL*+81
M^NY?4AKAEOC(DH4R&/*.13SD:B/)[JM5HMZI*>[KL8.Q),?\AX<][894;=E&
MT^^+3$I7]&\Q"6I@*&B/5;QOQN50S@11SB3/P[V<%!W>T?]J.4?_X[?[)"@V
M&=DM:1M@)J_(R[[(^-"'!_R!XW8J+E@V!CRCEXV\=UZ- "EDP:K44*UW@4I-
MQ%71KUSY3&F9IY/L-D[QHL"[86)=>S4 9!.<L"!<HP.==$.@HXG'#"!NP7]2
M\)LX#=(P#I+.G*ZY:M6>V%6$>VMMI]?MQKG4NT%GI^J=H=/P#HE:*[V@, GR
M/-[$.$*?JQ-3_IE9^W&'BZK=57!5A:%1\'+=4PE<>FE3D(;#,A/$(;'661$D
M< AT@ANCDI'?^3[S6N\F#T>8Y_H&O(9Q6L?4*3,O4.=+=?[,"&4I:CZ&^-<N
M4/=[B'\0];]XW@&PGW:J&CR?]U.OM+U*!^GG_,[7V&Y-DX%SM5U0<PA)2N!?
MXN))*+J\[T7>+^EF5,%MF:KNM-_RG3#Z9,5E2BY]](><-F(Z@8XS=D2%%+<V
M[?D,C@X;]"7>QBF[!HX>RU<G7FWS4SA_S\M\D8:$FL/7N/S?$Y?\R&^_AN8Y
MJ3A/T5Q'?1A>'^S 6^%5F2?VF#V*4[1AW?,S@Z%KQ@#9!J0S>.>A.YBGD?O.
MX)V"2A0,I+Z@/;]P3[+H$!:+E"U%&Q<Q+/3\G$LQN"$_?J)0 A/[;)$.R787
ML(L8[!6L<FN!BE^@R@3JV+A O7>SF )_+PO*C%_TVC1QUVHX?H?(!'WP])!*
M' P;S1@E#PP-*0=K1EKE3BLS.*7\_5W6!5P=\B+;84*'"<F!Q6VVFDW_+SO@
MI2B<29;<OO8RV=7^ZR^CS3@E\#,FCUF.=1W_=!=@[E^<+D^95<=_FH^\SDQX
MYB'%*;X )N*?Q:UA(^J:1I7MEPM4VT;S^P=T%23A(8&U'7%DD9A&,J<S[[*I
MG;I0NHWL5+;!-*\3.V33L-B60M.R6-6ASB?X<^'U4Q3W]5,4L$9L1Y;9;,?2
MJYVG/FK;KZB]]8OCA(VM- QMY'=*IV".!867LR]Q&C[M O+[-<Y#$O/T(HK2
ML=3U^K:YSAWM*^<R13 =P1BTVI?/600G5/\"1:TB/%*V-TS>VI9(3\4K!27@
MM<SKR,,EG C2BF?>J75WV#UBPI+@LY?8V<2@?EY=X;E.P>G34T;@O4>FE-)@
M*&6$*"Q2<P7.I$8%Y94.&&)5"^CIUI)7$GD?M%+"EK%*$ 9'*A5"-:>R6@,.
MI:[QGN"PW$14^-L7<9N^7@373T7?_@Z&'A)00T9T1;PSH'R3A;V8%S]KUEI%
M,9=,4('LLF$H X81"F#"N]=<C'8\M=R9TFM5[QO(GZ$?N&"CX"PQEA7P)NN5
M5MH[-ZPABMN77(?2I%3BSZ1'K9KW>%(!7*3Y@;!C)<J-VZ&8VYUP.<C^]G=?
MQCMG#,!43(EK.>_4X.^I5+"J=(17!T+$L&.CX)(N9N!=XJBEP5#("%%(K\$4
MT+ZB%"Y5_ ]?.R_T6#!I(.B<05*@ G-Z4K 8(X,F9TI8RJ" :WCGR9B@ R#>
M6(<:_U&F8%L,NOV-,5&&[U<(488/<;(ST$HQ0*Y>-[(?(!L4G V0K8 W V2M
MM/>X8PU1V&$N=> .D"N ]R3;X)REJPV2&XSKJ$I]O*/5K(U0HRPXW?D=[UIO
M?]=>W3L_IV-6$7;?,8$V&,SH2GCK;0131UEP/QX;Y9HX4+-2!\/4\9CE0[N@
MXFO2VO#.5-&M^OG.SI_T+=BDZR&.VKDCB:!Z15CCPS&0Y>/%FI"2\2(DCM;G
MN@]!LGQ,XJUNST4AZ_B,@1KNX'"!* @FZNG028X3U+(H:X2]$Z?9:+QEUT*K
M)YM4T4PE[+1SU0+N]:-223#DT<(3LF7PEX90PD31OI+U3IX:]$U&5IHUCZ&4
MT]4..<3>.D=?! Q!Y+C$]+!I4?=.W@G1?08N(\4:DUWSD*["2[V*K\?_5.!5
M3_D-Y<&0R *DD)F=";YADHB)@KE_TG/@UG";1"7LE%!:P#TJ227AD$@'STB?
M6T"W*1BB19H7Y,!"ZTT0ZB](J,7='E72@^X?6Y++@N&2 :"XT1RG8;RG@V8H
MF206:8%IH12T>V9Q<<2"E96F2V*-<*7+,0LU:!=A["&K5E#CRH)W_O4;T*<T
MV-%XRQYC86F-64NZ)W@7'W9\0X.*5J^37F5YD=]ANT@WP:J_@#BY"-1Q<[1)
M-WS_J>1[BK=!@;6Y?D[CSK M=.R4?7MM#?UCL-O_"=5F$+?CO:7<907.JQ:O
M**>^B-.#ZQ)PO;/JG=_!=-X24,*)=%R@B'$#6G]='1)@O#5T$CU)'_VQ!*JL
M_^V(@6&(&MN0*+4DF,6+ 70[![T2Q((<4 =B?7C@N7%/LA#C*&=7INM>CCT!
MJ8PE.@7':;D,P =9N1328 *,$:(P@-]N"1\PH3W%\<07T$FL[YB@3^;=9I>T
M:-9&I)I::6;X 5?QWM:OV)LOR\TOY7LO2[**MT]%?3&OS:)P%20)CBY?*KF\
M$E0M2!YMU>G^[&F*H+>3>YQ),/'G-'X,FT,MAHJL#5-AMMME*<I9*@[_LZE9
M.?6K4H6P!C^82ZK.8)CUG!Y_L76C=_3%I 2&GK9(A7C<T6/7B?D4+JJG]_M2
M%Q@'JT>^TBU?;K JD*&*/^;)P:M)UY<'RC<I2!/5-K42#7@0EHVD$7[^!9,P
MSO$]&SHV/S9A79G699HM[WV]K;O&'MYD" R1CT&OZ,TOZ/2UU#?/.)R>URD[
MAMZBK^$,BE3#QSD>#739F1Z).!C&F3$*FZ&51M-!Q_6"NS%RGO.8 WN8FL''
MT?6!/1-0/CG!,\CE5UG*GJ_FO4/Y[R+FJ7+J@;+T.,11%N'-CD_DC^1(::7)
M"&&>)KCG '\BXI04L#/X:A@PTAT; GAYM*7*.-&NS%4]X"*-#B%_:.0.%\N-
M,FQ/T8=3R4>A%ZX=4,T\"/G@F$7U,]U#;9=.K_@J R<HI^.G?9:.J+YN&9S
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MI>5KUL$^+H*$>Y^O<([),XYN,G)S8.E86+)E=JU;4:P3[+AL5)/=[#:2T4;
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MH&\?2R/?E:$=!64;XV;X'K7_:*\HC5X<Z72!X\I4;05 .S&Y:-$25":@<]V
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M%*#BUH!3I?VAHK[YW(%R1Z6MRKX5A%G\$GS:&FCE_5>"H>AA%KA-,7LJ6K[
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M\3<?+LUZ6ZSE;\FSO8$K=FLC"'DA7AWR(MMAT@R^V95/^G^C=?!%OH@[V@R
M@'(*].(2([>%6#&CVEI)D]I>=TY3FV3Y=7S=2Z;SIRA.#BPA5_N8]?_M[EIR
M&X=AZ%6TG *^1#$HNAFTJQZ@@SB= (D#. AF,*>O2(DV97VLM)9%9U,$CB12
M>2^**CV23__ Q79G/I23YC02^77_]-YW<'=$1:.,*"U$BD4&%D239>?C;1O8
MZ+RH.(U/C!HLP*4"V8##(856*JL$745/(B [V% 0V&G_ D5JN0BI=FBV+^*
M.JZ@RY@1LF1U%(32;?YZ7SE?HX*G2D;!4E^Y0K$Q5AEE.:5GF(ZWS^@F",);
MO(T&#]75CL%U+A1_Z3%/S%OW?H+8V/^M.335B[&]981C5&AJLZFB*N.E#6+X
MS2$%X;O43/RCPM\0R$(#-XH-K6AL]<.._F".B[$/);-%$XW21F0$ ::^R_)"
MRF*>S0?XC=HQP*1BN-^W2[K6_V\XP[E8.5>GM:B@DOPD_>P<].4ZS256S(@
MW,O/+14%PVWQ0S;0802C9<!B8Y-%NP%N>OU%N]LGX"0??[0@Y<JF[Y.L63->
MC<+DC;+NJ*$0)CJT?6['"\T4-W:?_(W,<37&CA5I:IX^%Z_14X*ILT8%;=+7
MFVM)YC(O3+*BT0^, $1/-DIAE@B\W [6,W)'%(W/K20EF=6-[V#93-;>P6::
MOD^R9LUX-0H+WL%^I3::_W&[&ZY@JI)RUJ0QN.PD5R/MQC>Q@X+E\7*YGIR/
MM\":.VM-&DG+3K( 24>-D&+F&QE+::1@D'[PLV]W!XP1:/5X?\*W$)F=!7'H
M=I^]G+<8/ -R#%8#"\-JIN(N>,.,BA$..&QE(<8P?7OM8@MV)=%UFTK$,N)A
MI+H5P&)[C!7+JMT1[]N^1^V8*9^@7] S$IGPM:[;68<OX<40+B_#%\?+VQ'$
MA*+3\Z^8S<!()"HB J^'-T:]#__)@#,*,MNHZ"\+V);"QFB6J7!+R8Q(9Y$*
M8EHS8Y3G_W,?R<4<;BD9"M?!+"BPBQ0H8#-GUI'C\?P71"-9N/C=)(.4\#8+
ML:&_&@:0@E]47.6WDXQ06@85@ 02))SW,I%ALLJ<'YUI<YDX1;U,PN64$A+R
M&S0C$ ZW% _*%_"H)POTOO^\0%7FBN9VD8E/TM/<=:X21F\=E$W^Z$!MJCVB
MW7X(FTA30;J&.0^G6/#VB ?UD 4&Y4>!DY[K$?2EF *O/YQ[<V4,!=//ET,T
M@<@2XPKZZBTZG6Q.-(H,J,& B65"$Y36!NO+DY4 C_BC7_J5?DR/]!^XK=!/
M/@%02P,$%     @ F()J6L[@2"+K4P  BFH% !4   !E;G-C+3(P,C0Q,C,Q
M7W!R92YX;6SMO6V3XS:2+OK]1IS_H.N-V)B-.&V[J^V9Z9F=>T(EJ=JZ4R5I
M)57W>+\X6"2DPIHB99"J+OG7'X"D)(HDWDB0"94UL>ONK@) 9#Z)!)!O^,__
M\[KQ>R^(1#@,_O'-^V^__Z:' C?T<+#^QS>/BW?]Q6 \_J87Q4[@.7X8H']\
M$X3?_)__[W_]/SWZO__\?]^]Z]UAY'M_ZPU#]]TX6(5_[TV<#?I;[Q,*$''B
MD/R]]]GQ=^PGX1WV$>D-PLW61S&BOT@__+?>C]_>_/C4>_=.8=S/*/!"\C@?
M'\=]CN-M]+?OOOOZ]>NW0?CB? W)K]&W;KA1&W 1._$N.H[V_>OWV?_2[O_I
MX^#7O['_/#D1ZE%^!='?7B/\CV_8=[//?OWP;4C6W]U\__W[[_[U<+]PG]'&
M>8<#QC<7?7/HQ4:IZO?^X\>/WR6_/30MM7Q](O[A&Q^^.TSG.#+]+1:TS\TD
MPG^+DNG=AZX3)[!+/]/CMF#_>G=H]H[]Z-W[FW<?WG_[&GG?')B?<)"$/IJC
M58_]2=$[?A4%T3YR$</K._:[[P8AE4<ZT:37,T&K?WQ#V[AT\)L?WM^D0__;
M6:-XOZ5R&6$F5M_TOJOWV5O'9QQ:/",41[+/5S8V/XV90U 0/Z,8NXZO-:?*
MGD8FR)8+VM#!H^EJNF5+G,J0E&'B7L8G-GAV@C6*QL$B#MU?GT/?HYIF]-L.
MQ_LA6F$7QSH35A_-/"%.]'SGAU^U&%SJ5&=:R3J/D/OM.GSYSMU[V>+</U':
MD;LCE/@YCGY]< )GG7RX'WB+F *+UOLACEP_C'8$G4_[H*E+8S-2V%\2FM(%
M7O-#YDA]H%\@V/'/9C(.7.S1.1B@4'-\(Z(U)6LGP+\GJX^R<48P_=[6\?MN
MC%]PC)%4SM1',*0.(TPE>D901+F2?%6N![E=S"S/W6;CD/UTM<#K -/E[U"1
M=-UP%\3TU#0+?:H0Y'S4&\7(Q"E'M@[V1J];^BL44?2F=(<@@QUA>T4_BA0V
M/ITQC$R:\H3L4.F#]]AYPKZ2Q*J/8&3"]'2[P7&BB>FG!F&")SU3*\Q4H:N1
M*4["&-$3PMYY\I%L3E5M#>URQ;U4OL7Q>IB;T#MVCO78#87^7DG=2+H9F1K=
M%<(-6CJO<AFJ:&ID"G/DT_W*H^=*E357W=J0^GV*T&\[NDA&+VRER!5M=?L.
M]P*S>T(K>X/:IY=,"Q@BXWRLSC8X-1+T1^IHLU.;ONXXQG<5M6GR>[2TPRC*
MKZ1?F[N-Q@QEG4WO/&I3XW;HZ/XR1+&#_6CB$&9C>)&>;^J/V-;]1I<"C2',
M2*[[C+R=CZ:K5 ]2KN44RP-RV*W5Z\=W#B:)336;C52H&XYKF+C4Z#,.CI^C
M/Z)KS0GVT3UZ0?X';;)T1S1,T)Q^(]C17FY(MV4F)H\!57&?"-V>(VUB=$8S
M3,@7A-?/]'39?T'$6:/%LT-%GTH-/5Z\\["_8Q*_2.TII^6K3EFCX3L\C.GJ
MB6:C&L90Y8"EC5R-04UK1.G!2U\9Z@[9MA5#5^YJ#&48E2%ZBK7Y7M')^#%9
MEY4J?0WS;KJ+$^<OQ>P+^U2@STGI$%U-6<N=5G>\EJXNVMI>>03#W$\^/-TF
MY^GT#+W7EACY&*8GS3;Y]$)%EU?B9/KJ$"\WCXB=V-);0A3M-NG/] DS\AW3
M)UVJH,/4MWFWB^DA>TR_S%S)^B=<Q9':O$'76BCJPQCF?>ZZ?(L"M,+ZZE4Z
MA.$IWR&J4^@%F7EAG1@=/S\CX0MFX3QU":DY<#OD';\^IU-AMQQZ8/%Q7C2T
M"5,?TOCY9X7H$=BCGZYYLI:-8'C"CP%)[Y6_)Y_,<->?MMHXI@UENAI(H6L+
M+AS=6:KU;L7%HW_35>O?.%8$N5FLR.QEJQ41PCHF$2'T+Z>(D,I1S$UR1 C;
MX0Q,E#N2N<DFYZ(EWM!#MX$)"T<S-^EQ$&&JZI?$89>%/KLKI"%+4>V9RX=L
M:_I'?R,)74/3KQI2-/UMSJ9]3W]PU@6]QBCPD'<8B)&@&%4:XYBUS>)\W_?>
ML:#@'>,J_6O:,IO'829^Z)Y]W&?!LR%1X(N'<,H7^I<37^@_?DD^U'^*8N*X
MQPA"WWE"?C+^+[1-H<EWC6>U<J*G)'IW%[U;.\XV@\R/H\-/3G/,?O#+,;1P
MF0\"R4TT:UAL5YQM'LT^.9^Y0XX"0?]Z!F4YZ#AK\=TVN7^_<Y^Q?Y2"%0DW
M//9E'PR%LPX)E==_?//^^^_!^4U%'HWI7R,%GN?: O.=PU<Q\W/3SP"XL0"
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MCO>LZ-9DQS$1TV;E5JK,AKW.\J@#8?+!F!'$K*B8B-'%EJK,AKW%BJ@$8?B
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ME02&5,C\<,O(RJ8K6G+";M"7;#G?B^M+@0O@6'U" 27+IY/L>QL<8$82>UU
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MZ6=9U$VI-.QAM$+XS6&\CD-MA+2)XVH4NW:QZ(53F3BQY+5F&3&E$0 #7K0
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M<1?H,AF:3%>A']X,=C"E9L0E"0J*%OUR%XN5OY+MODP1>#7<_)04-^:SMG9
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MA$850@<OJ**DL)Q1-#JL,T$B>IVQH'/KVA&AVDR%EX>FROI $O2VJSD/Z Q
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M;!OWK:)*X_.H*7Z<$T4F*U,RQ^OG>/2*B(LCCGF!=1"TASY!M(F/A'1+EMC
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MJY*GP>J.![[;*(I.0S+?@L0X+$0KH8P2[3*0UO0'TZ\!(M$SWO97,2(YSYI
M5K1'@O8SZDI)359I>12SW[#_/-&3$/W)_P502P,$%     @ F()J6C8K@)-@
M P  :PX   H   !E>#(S+3$N:'1M[5=KC^(V%/T>*?_A%JFC&8D,KWGL0!8)
M2-B-R@"";*O]:!(GN$WLC&TZ0W]]KP.9A>E*554T$FJ1B./'O?><<VW'=C^'
MCY.^;;F?_8&')9B?&P;AQ.^[C5V)O8U]MSN<>5]A&7Z=^!]KB>"Z"ZUFH2%D
M.54PI<^P$#GA]5U#'994LJ2&AF@Z_Z=V/<B)3!EWM"BZ@,-?&U9":Y'OVS1]
MT0[)6,J[$%&NJ:SUW?%L&A[&<Q*2LVS;_;N(Y5C%_J [@+7^!5^IHN<VC$-4
M9/XON928O_V/T4N6KO4IP;O#OO^R9BNF;:O=N6ZYC6'_9%3^,VDY/7K,RV@V
M7?K3T+9F8PBFGC_W\8'N%_ZG8!GZ"]^#^9?A)!C!8#2:?9F&P?03C(/%XTES
M^,Z\WS-KOVZ49LGVE/!_H;85":Y0%] "])H"XY&0A9!$,\%AM05)$RHICTQ7
M.6)!4Z;T?L!2$TUSM%> M;&0N8*E\P$NI^(:.IV.T[Z_;3[<UN&U?M>^:3T
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M0RM5S#Q4F:J PF,0*7QH, Q^P/9POMHA^;UU$+)R$._B5=FFK,N# #$C 8^
M<DC-)=4*0&&?"#@M5\[S*  O236'<GCDA8D/] )RKM"K .CE,IR3&,"'X$:@
MA^&"S%9'"D7UJ'Z8 7R.I1<P11)" L"Q %R:.I41Y5$U)D$H9BICM60CKK2D
M4!O%+ZUXD%I8H:W*%!G)&8MSZAZ6K)RZNWA5MBGKYSVAKCMF&>LR.OTDU;=$
MU%3*U32:ADY1! &'0\.M+J&2&4("\?@P9$@RPH#-PY"K,2;'9!.PRFB7\=CG
MR@N%2B ?FF@I0HO*6 J/^?"ULE). 8\^ ]Y:;#L/WIA&(T::X$\'20CMJUS2
M8N7JE)V9_)4KWQ[90XY!TLAR&BLAZ%]7\&U)BH*>J<BJV*@M6*LM@-JPQ8_)
M#BDPVE%]^MXKF?A=8XMQR#SD^.$AQQ\RXGA*S_:#:!VFH.C,2IIE\,O@*> R
MW:,)6-#79L&%^I !/VQUZ>);)!(* "\WY0H=XF)-SR)3&#Z36*[_5YVJ9"$U
M5(+$ZU II"X63W(PFR!(B9#[5!NU0\5]3B7'5G ;*##>.<*2$H7K=D/RE*ZX
MW#=F6"@&JC0X6<P94[Q;DI"B*X8&&B7+( #DL'&%U9@(_#9DF! \*^1G?NXX
M#D)6;D]W\:ILE>;#_:7YJ_W=!M1?[PR?8WLF8PEX3 J3PI3[B&RJ1$31#%,%
MN,>H+'*<2C_#*5">TR$/N9YC7."ING&:,>0U4+63PUK29?S#RC'&^R%M6IS(
M&,BN3$3#\\!7&14FR#MB$9,T!,##&1;C](%)DDA;B,,TPV-PO/F=>1"R<HSO
MXE79*L:]/<&X,Z5A@GYU^72)!0'S-)\"D]03,=)%%.(53MP>+L.F:R85'3ED
M! .M;'!V*!+]@HS7+!CH(C7#&'3P\B,S,L00-T:WS6S$;)^ J)J5 S7D]](A
MR,K!NXM79:O@]?<$O!U+L@R\C]B(>QC2X*HY\R2 W^":,;@A/"^1"+^5(,)F
MJ5;.1"@-)W%?*Q2H8 22;PF54!\Y?49- #P'*_LH=:K> \":/1BX/</L+[/B
MSJRT,56+V N:8(-^YJ=!&G#1IF=2#S\G(;]G\&$V9#S*5/C;G55['O=YD/@
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M=9K5QLA,H\[*SK<(QC/V1RUU-(_2GIO/XY+*9F0/W(B-E7-T9+2G&BOGYWB
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M>NL#O9QQ/:,Y%G![$-S&9JO@;@_C;@7$\@>QG'&Q0^E=<Q6(CLN/>"=(YK8
MW8- =\_\%9SNH55>"QBN(PQ7BQO.=HM<W<BKO@Q]YCE7-S#2T55?<7XF@W5
M'Z+AU/,#%>(STI:.^T:]=KZ0V6[V8O57:?67'F0QL?=/A,<\FSLP2:'"3VN\
MYG/&NB'[O%CI]=O3]WJP"M[^TKP]CTI)@9Z51,]JZ1(Q>FK52KT>?VI$Z$E4
ML*BE>:L'$XDSDG_T8'IMN]M">UN/3P#HWH&_((!HK1X+(%S550301O"IY2)M
M[3GF*@$^D<OA!3N)7*[\X-"5OO!Z!>3O@_RC9FL#X3^N=B#.EJ=VZ!<T"T@7
MD'YFCMY\ D??62I'KU7J!RG!17I.@?^'2S&/F*X-W #C/!V1ME2>CB\H0%V
M^GFY>AK6#^7JZ7N6):<7]HR5LF=,R;>-Y?'"IYO5UR^ ;8E,Y3%D/+#[P&I$
MPJVDM7\NJ O^M@K\+1< VHT !)_R5"5P<G)W'S^Y-.)E3BX*-7O)I]Q.+E'_
M6.2F[UE*V%N^IG0\6B0].<L0=D":JNTGG_(S39/(0^H?B[ST/4OAF?LQS]Q/
M';H7O"=\[(WD' G%[:#=[<);O%[^3]Q[)#4Z>>\>_4L>N_M/.!GVEQRS6P!G
M!8'S++5U[^,BYXIW0\^)B[EL!@AFC[K@&G=PC0(H+P.4YZW 7:V/V>T5)LLP
MS_FX/K6N'K+J<P?^<@M?7X[K)NV%S),Z/NG76DK1_N3LC!LET3KD9YHF3YDG
M-$H:0]XSJ#?YG=S5/<+7SJ6PZK;\ESBTBT5>XP-ZMF2VAE(951=M=ZFRSK1$
MMAG2V,S%7D<1_,[%7G?1>YYT63#RE[;%K)"4/,X1\B,;/^<.:E2J.Z #QI_J
M^9FFR1P]',>CD&=&O#SDY6Y*QRP#8Y.S#+,)O>"'KX(?7X4G!N$@O]P:J[M>
M8(R+YLK4 #,]IA<Z@)]W$=GM^BUB>DSKOHB%[+2.BYP<]/6HV@!^RM&I-'G0
M/UK$-"->ZD&?KRD=1UYZ<I:%O-WD4WZF:0;R=I^ O-WE(6\BF-BPLK:W!E6&
M6C=,.4D_=;)N3([OQ0P;SULM;'+8ZR$T9[K0.9;25P-->9?>5P)-*Z NO%Q/
MK^+PV<C\E#N9S-6-7&LPQ./;U-U>+'"QVQ,P8 [J>L,A&>':[?B'+NW&:!^/
M6>Q"_U@841N@@3P'H@H=I#B("LED A G,E1KC8=D@&NWYQ^XL!LCECQBJ0NI
M9%$\;8!0\@QX*F22X@C:>(FDB*]9Q]V?3A=+\@ZP9IL(0FRMQ]Q3[YK#MVNP
M^TW20>0)41>BUT_7]+ICV"^V\+0NS[CP>M#KDW%R_YK/&O&&+/>YRVQ=V*X'
M_]F<1;]KW,72JUIMM[&SM_]""=D9G^YS,LTV$P)CDGW![-=>J*O/C8Q?]R-@
M*=+]^C.@^E)S-2)$%NG-F[K81>&"]5[LPDJTWHL\OZA0(5 4 L5,C6;)W<JI
MA5S!=EYND9?7,7"L4=I^L<@ON\BX!DL]6VJ%F^G%!8C:\MU,.2TV:FA?)INK
M'N1U<@SM2Y^<]8B26M&8I>==Q+R')JUHH-"S+6*D[H4=&-VFG-9:T9H>\H8L
M-C7H@Z]K+<^!?^J;L=ZS1[W62Y[XB8LE7XTE?\:JLU/-.=L>;P\\T0G]4\_&
M05SS<Y=Y^8<"CN*,#=+1H(\;_$M:>I=<FG8B&CC2RS]QCROFPKYH.0,06OU
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M?,0C#N;,Q6,>L?A #N9,Y\[.PQ\Q!Q?Q(][0,WP)2C3WX1OZHL^9@^?T^S?
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MV-T[R(CT)=/ZW;0(!4['+-L5U"V[X@<H- Z1XP C"PE$<7U]W4G+<L5 H$_
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ME-HE],#8:_YKHX7<C,%4K]8:1,J)@J/M1JJ?64%J57&T[/9\D8I/%*;4?"6
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M#@?4PZ.'M%IFCF%0T03'&$TA+UG[X=C#TR0AJ;3,JYGL^%[$8Q ?<BK-X,G
MZ6BSN5]Z@,@"#-,<*C>\; Z1Z!LXA2>_"OWX&SP7S+>'6@:)?@'6:'XX]OR1
M;W/S0ZG'/:[H %9()+[<7$''IM#R%NUM,GIB4SOA"*: 66X_UZH\3QVIO-#^
MOF,>)IQ?MC[+']5J<RM:AO/6Q57I]/V;3K$N+[#3IQ9F)UZ84Y!M2K7MV%?P
M7$M4Z)93:W0HU1 +9/'2:2)+%NOQ,L1_YZ4;5)*E$O!V.HA(C]$K%.DAUF5
M"D37.N(@H:/&!C^TADJX5KU:;:"4?]YGL):VA(,4=*93S][&$ZR,%WYF<-B"
M^E.OUNIE5*%UT+ZV_'@@LY$.5)KQ!#@.+V'HC-2,*RH$RT/JWT(_OTJTO_BR
ME.KW>ALN Y)M2EG'U^^44\\;<-6+_(ATV'J!+$6G[T<A*6G*QMF;?!D*"_!
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M%)43@_L94D-AA5I4(,C@":] Q_%DZ ,8,+8?O_"83^"(\S5@.5*FEM#!F21
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M@]B_OTYJ]YV.JUJU\%QEY[FJ50O7U<+YO.,%"'*;"J*'0G)#*>=#R?5)K%<
M)"89N=7&=-3XD#"NQG1H3M?$IXR%?3$[U(5U;! M/70+4IB7\;*@E =B\O_/
MWKLVQVTE:<+?SZ] ]'9OD!L@AZ0NEML['4%3E*WIEL61Y/:[L;$?P"J0A585
M4 T42-&__LTG+^>" BG*EDW2JHB9MEB%.CC7/'EY\LGB*G)#Q>]S8X')H'1+
M'^PBNR[R6+63?B$1BDZCCFSA-4PK@;[L/WW,NK"IIE.!O K D4;L!M[P<1.
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M8A43R\(6,D>@#VW32_6^ 70!,!(TV#(IN/[;@$N">NNX'Z+]C1D,RAG1!:^
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M]L5%>]?*/H^:H[3M5MFCT?>RTK%H>O'$A7>'_HA*(#=S? 2*[*LG5KG3A;
MO>E9<N%XTJ<BS;PT[_V6AXP]0JZIJG>L/P':.V2O'&I2G)07U21WC/M@9<5&
MP-/4UWJK^M0=J\\<5U>V7T%0'@S"$3)A'4?$!8^1AQHM!<Q]#DL 'E0P@,/=
MK,AP 1752C6<HI\G09H1=>R/=/_>C.WX:H/M^(S8CJ\VV(XO]^H*,DSH_UJ2
MPB15OL6"&DD.&/J*Y96:5M[*,#1E:KQ V/..RY[[*%&+/27Q9-1"[=7UD(2+
M2 ZC9%! J@5]BS3&!>"<+.Q\T!Z(/@2.V7KA]@,EJ<>!T@]>E*=MZ-P#7:8'
MO<>&#L1-D<)[UOE;>1"M@.$GNA!C#^*UCD.QV((UZ>*@CD<>%7&E0;$ RP_+
M>6.&UE!G9M\2TVCN%(@@3+VAJZ7%(H^B#XM%OA\'B:'=F\\SK>%<>O*P3=3Y
M[@ EJ!!-FPTR?P,EN3NI,:_.D$]8&3G*E%[3LH-^0D*AF, %^;/ YTF%J*:<
M%'U1U)S:1';7K&[FS7F%UPA62WRVNK*YUB-%*7=ZOEP@>18$/W4FN1GE"@PI
MZG'MV.4K,!%(J+-BDK0F=E01>4 [,M(F\FXKX+*, JL*8CFM&M]3J:%:U-QC
M)O:M)NSV=='G[ 96,93\0'+/BVD)I)_J,!*=K6I:GE4O3.39*]"TB_2%/^]#
M)4%E3IWR2;8VLH;LS%EQ4:99;.Z<2^UQKABF6\<B:1WT6AFY! 4ND9GV>PHR
M_;#BI-V_:BVIS;F*SM7[\BILW0MP3$]XH250/T!#B5]A+9-$O9.+LN7E5U\4
M7\Y]Z\,4M%VFU933E;0@@4>>UG";@*-:2O_FFNO-?]S0#/6(J?VS&3-G#)+#
M\V%%88MRD7S@4Y>@2J-7N/"*'"OSOEQ%&2Z:O0/00<W22",<=FZFP+M6I[V$
M8\P[1K<ZYP^-BXHP>1!;TN5YZ>S8LVP QAJU>8<!3'Q)VLWY3B')7)J,+L0Z
M<@J'F;->".4,I(#'B.>1%QDER.I545_-49%I2MUKVN6,\ZVH"?^'.8EGA;0)
MUV Y9Q>A]"#:0I.^A7=YSO&NL:2FC6YS-Q@M<#*5DN9%U\ I*FIH'(_/TLX4
MY'H<&&#^)J^/FD$.$]H.#N\W27>U ';?^63AR/,:2QN^HE?%><E ]5903@UJ
M(I^AW?%SD6VID_;'FO?L6\Z!W$YW/KJ6Y*@IV)N'RK?8=:/DKG2EMH,.O<*F
M+[YMZNG__!_/'C\[^"8[?F.205E0BJJ:S*KL;5&_OZ(CY,G\UQ%3QV_XZ'Q_
MQ9D*Q=@#.:/1X=0.H-3X;2=].^T-Y)9G_SB1TWB$*-AYU2\2T!8$X<MZLFOD
M4]G_]ZY8+']>?_'QF]WL^^82Q;_SL!G<M9NAJB^:.:RW(IN7]3DB;A:FXF1+
MSAMH^"80M$:33<H6S8I0UVN"=2G;B,,WJ2AQ;0DL =\UB01'/%QP7^RPI]V=
M+#;#X!CT)AOB<D;"5K=)2"BI.A/O /E+DJW/BF<?>M6]QW7FY(81*:^8LXWH
MN@MLN0NJM5QQ7O?]V.5V<D;MM'PB\K5C>UQ/&P5A>B0G=>.'\CVI_^J=%"0D
M=;&\*-S80:-FSHLYZ0S_6$WIC[^7"W[*O@,[(AW1N#']B@LKT5U9K)U?EE=E
MQ2-=4P":U@V/C=DI.  7@#/VB.B0F&6E++YXL]>#Z6N0R1TWH <C%JAYUD%*
MT*W/B@>]=<''3N V]D)OEZ36UZD47>_*\!*:="R32.7!4)0OL#'./I8])#3^
M2:*D_$"_89H_T2Z*NFYZTLBF'/GB9'>MTUFP"UA//DL(?3E2RW\N26&C7<R<
M(D*U5YTB=OA#\<_]W6?#7&P$RO2&8Z48BB+W(\P5-Q,U["PP9S<CR=N20_BQ
MM(JCFX(HX^YJZER&/90XRC3)82.![D9YTET;="BOOPR.E)XW-OIMRR=JB =>
M+>BDT&^ZA2_R!T0S*4+C*._@+/A=]H $ C=;(/@&7]*$S(&,ZXNY.VD;.M0H
M+[;Q$MY%YU_WK1OQ0@AG6V<I$;A)<*+,)X #QKJN&+303O5Z,*]?#(?$)3CB
MB&!W6VU^!'?6K\ 'N_Y@3A(#.!K$)G'H^4*TQQ)NCN3*1/-@EMV9-9??<(^7
M7,_+HVZJ^@R0$3;_#7H;O)9T!\T$>,.2J?O&R%=(I[Y@+9L_%E=$W)3RR=@\
M2#ND,N!S0,/8_<J)'^5[!2YCHM9^N&PZ=G:X4U O+>!A%1D)_T$SI1&>57.A
MWJ/W[U#+R*6EOQ,#S[*.2]I 4.M9JV=/)?\[)GGIA!!.KM)!;UR0FCD76ZE5
MRV/:X@5NZ%+@;MY_$0BS]&8>.K\JH%0Y==Q LWCI*=)KS,)A[T^+TI58H1:N
M6;+HNMSQOP':;4N4T[9USBT*E/JO)UPAAG91$=S6P5.;3%[#-#A 057B*]->
MIQM].#NV5ANMXFZHI@[[<VH7$;\],A:^??DFXUN7XX6,>GL7(@2<J05U_?"\
M+4L!34,#?]7[$&G!;MO)O_L*^U@3O>S*XH7'E24"C+UW'>U"1_]I)A*E#'AT
M)9".</>*I-C-WB[+";MW&)3&O=9W3K,3.9W')P?[!X^_/GCZ[;Y_&ZO2_ >_
M-AN\UHT=M?(#37870=-OZI<X<K1U7P7WZ/4_7S[?V?]:W!578 @D 73:-HCX
M<$B%3L*Y_.0/ZJ6\&?7V;(-Z^XRHMV<;U-L7+=&9R65:*F)8N BJ:P1QGLIN
MCRXKLOV_9"@]#=?II:7UDGB"K%75A7V<G+M%_7G3 *1-Q_)[%NOUU)UPH9RC
M9E[FZ95R1/T#=*4^#_>(NFS1NK@_KGD()F_7GRHHF=.2VP62K\11_8JTGY;T
M']\)O/X/)$8?3N>%&47NXDY25>1>/HRTY@U=RITZE% ZA EIX3V-#9S$LAF+
M?0F-4QIC,SM8 D==X- \[B%L\NQH1@=59,=_%4MT45BTZW,7K*:AI9N$<B/=
M* T LW$W%K"'1:6LI_KCJ+HU6\VFM"VCK9J,OQ#+^E\>E$ :(91;*XQ$FO,S
M'M3!WN.#W)+ A&OTRFQ%=ED74ZRCL,"H7[WS' 4+&+O,SNK#\8SR@P^AFO3P
MS?VK;ZMN6DTL\5(T'%5+@:O0E_&6,-I/\6*3A.S!4";N!!T+#^0J4XA$EVG(
MBRN"S9O+/SQN)FB(L48XU!@_>=2)PGBM8ODG*$:1]GC[]H=ZIJB]]"K2BI'I
M6D_QNJ;]*T*+*WD17C7]U%?]AO-/>NC#Z-7 ]#@=FAYWT>LCI*_!E\>=I?/_
M@KU9W?_:3._GZ/4/(BME<MOLQ,O+8Y&7STE>QF-B@^JW/\S_X^CH^/C%B_MQ
MG$6]>W=X>,*]P47#$/632(N(-3TV0UX+N&)-ZWLPNW73JX?6J]_I;/[*B];K
M#$\._O)Y+XJ%N=?EKL 'I$/"JCZN?[Y:E#M'\Y(43NA!?R]735WNO+)BMW):
M(?X4F%;C,V7I>BF0!0!W&4?7G'V.O>#GX?-.P^?;K*&#CS]K#W_<?;N;<Z<.
MD69 ^XT,I6_;XN=J3G9341?3PMM/9DY]C[#6WQO@CEYV;5$R&FB*'ZIU]:K\
M4$V:/'O3=UU5?&'KL_=9>WBP]VCO2[_R/TF8C F/WT9FW,^-^+F%PWWKT_V<
MJ3LZIO?(S/ZT0^HS6>V<WK<%O9_;[#>YK3_?+?W'7P ZYP>;Z_@33GIR#R-1
M1 G,C$7XAXC;$*:\P*3@6OJ1OMW<UK](.)P<O:.GB^JRJ.];)^_GU"& \F5?
MWX?,3R%7RSGSX_E$-X3'OT=(O9E<34"3]X^J?E^VFRM[<V4_A 787-E_^MOP
M6N8^O;*4YO22WES!G^T*MO/LC[L<<SW$?V_:L@@RP)QFD9C00R\RX+Z-]7ZN
MP.8FEP#9K8O(! 5<]NTU830_I_<S@B:#CLM!;OKXI?;Q2[S@]=(V6 :76(0]
M?M2T35U<5&V/U.LSR>U28UQS ^[;\M[/>R7<['9?R^5^W_IY/V>/;N7]+_M6
M?FVXGK.X$!8=U7#_WK=%NY];:=3+M5&UOQQ5^T'<NV_*;EFU4@'T>=7!U=V%
MC$4Z[5VU\9_=JE??E2T]=B5'_D5;U!,ZY2]7!=(O-3/@[S3CTV9QWWI^/^<3
M20-?]E7\BQ"DAXOEK%S1&^MR R/=].IWZ]67>*E^4H Y.I@;T-?G5; W%NXG
M19F^< MW<VKOTZF-@LCWK:OW<P+)FAU'<"I?Q1\Q#?5SC6B7^OJ;IXW_+ZT0
M3[J[74R( O!GKBW/P.L%9JX1BJRS:L[)UWE$HH6\XZYG\@8A89=&J;-*%_ :
ME.EEML6OV./7GKR.WKF=*V?QI*B-[9)Y?$ZYG@*,!J4CJVJIF+)$SJ]E4 ;.
MK0471O&E88;].&J,N>N/0WUX,RG/UQM2GL](RO/UAI3GW@K.WYYK Q3?[K(4
MXL+3MBG LDM;$W,NU<]!?^'+H8Q(SUSY7E%H:GY97($%'33A*L!J^G1EE#]*
M&NBY7X7T >249>? AA%8@2%=05<>B<LBJK_"+!87#5>A3VD:I8="ECPH*:J2
M/<^J,ZNZEQMI!I><*E'P(F8G!E%&0?< ^Q5M1%?^BN!J%J>E715,&\F=T,)7
MZ#0]KBR8R9W#Y$?6G-$6@DR$FW+)&XHIG4KZ8'XU))8<T(IL"(7NA-B*Y%8U
M!?&MK9HPD_.FO2C:*SXY]&O YH2$->(G9=)LNMN-^%-N^?6#)CLF/*]/8+_P
MYE1*%;HVSJDG3.OBG_)<.4&]H ]$/:&/I<"<D+^6T]WL.U1;*9C!<* ,L=92
MGH/T!94I6&^ZGI/'&2</M6Y5+HO,NG:PEUV5A;&MXE?T%]AA5EIN#F4Q0%;.
MA[&3]%Z=)4S"X'"CH(H45>#*3I@36K1"1R 3 E7LM/3$\1 B;3DIEG(\=8TR
M5)1@DM Y^'FN1DB&5/7"E+\S M,1A?#'MR?O$I40Q#F822NG8*L<"(.H$TV[
MBD@=N=]^/FC2YRA4Q4]*^6M[$%5(9&DXJM26%Q5M81E25,ZBZ)Q*8?P  K6I
MF;5(2B1W*P6!V62H0*19 \.]E= YP]K(ZMF^6S4KT+=%K$*APM=XVVX!?D^T
M7GZ8E+R[^G8%YB+=%Z14-9?X/;IJ)/;"PC;MM2F<G $3+FCW98<7DPEI:GP\
M.+CF=Q)KT[IQ@7>=-Z"3G1>7RLI_M10*3[G5NN8S;%:_ LS([\GNC$^Y.#N#
M4CEUM.%LT]I(&J9;$FF_<WJU8X*?K\;<"B?A9#.+L_Y3K!DC?>YIG;,%WT92
MURH?K,\*]6.]Q,C95.DFC7P(2CW3"W0$<3DI>B)LO1UC'/8\4MWX3UA2T0\7
MY=36*R:5LF$XVV&T^-74JE>5-<W7I(R:"P=J<PW>']+Q4/!+=F+,/HZC'ZEO
MO$4'E-U9H.Q>S:IV*ANDA&:'NR]#D0L1^I>S4DM\E<Y?BCCE]97\= <_]51D
M4I\)59*A_?7L&V!-E56KF&NW:9.2;BAX7X*-/*GYM*;.YDZ45*54%S+JDI^9
M<&:;]1O%RBXJ&1/XQ&%,T;6L/=??946@FJ06SN@@]5(3UBC;_9/"/CZD/&==
M\[)DRCD;=$2$G8P1M8,PKI2\O>/?^GI14U3]84+P8L*+V6--!JL$XC84\N C
M#&UAU/TRRN,GRC'V#:OR484']%M4E\M2^B-CS&U\_!F[>B!+*KPR8ZV 5O>,
M3!7:&%@<T()>Z'V$52LA"D-O<'?+% F3)R:B:EH5-IXN?3=[06TM4!"W@DA:
M%&IK2/XBV5594 C>P"YZ(?*7JU =?(./.O<FD+1C#\35%+)03:'ZVZXYN1ZF
MC'C0 B["!1@F0&J0_#)NJ8<U^ >]<C^1 &I+J20$RN#(?/*,E%KO2*MQ0E.C
MHV=&"Z(GP7L0J>OV0%*$0>V[$5$'_=_SFIK:&I-G)EK9[1,"T^P_=$(R  .1
M*>N%,Q3!A5KK%L:EI&7E B=J5!PSKFE)3:8E,*$.%G,A0)TCX7.:]1S+ZY0!
M7SX5IWN1G1<H* P1#$<236TI(;^)3SE;-)560!T6!)Y$D4.N!:'%&:5VUOI0
M?M7/A6;UNOY:1:RF#64_-1E.1L]:<['@^V<%M!_7M8+-0O=WJ"^\QH=*VW-*
M=[(RN;KW3'D5]]9*B4IA0=J>6E"5"8Q#)7;^6C4+OWX9A-:U++1X-PUR/K>K
MSVJR7#G4?O8\M"L>@N^R]LT\ P-'PSHIK_7J%VQ[]XG;WLHCI&2XC_:4#/?1
M.AEN, 43"S9EPG7K3+ABM*3TMU;B!"3&)@N2Z<A#Z$;*U^ %# V]RK9.CMYM
MRU@$NIRJ2K9'F)<8$FH(%P];P<)/%<FZON4U8G)T62Y1?W6.JOH:BF!?3F6<
M+-B-D 4+I?&M)PB[,SX,5XD@7A>P8]N++,1?+)&SSRN1W2^5R$$.R='?B8Y^
M<2[WSJ>*:/>9170F(OK3!*R[Q<!^F<"^KKUL7(*[7R7!<STQ(GI_A81U7KIF
M+%UC6<7G\-$!G1"NO'K)ZLKXC9%[XP=&=+^<LOG0(H=SZD^)U9_4WS;LH,1J
M(QX^MS!"J*)PW?5$-DXP..5=LAG#3\6N9'\D%Q#CTDP3KL#9MQ,,M$W"'%(4
M!PSK(0C.3=JY]1-GEJ8RL;,51TN*3O4M+'[87JR4T4Q R)W2[*;38YYMA'+H
M?"]\%5Q;1_41K]?-TG,JI3CIM57'Q:^*".W[A43=R8#=1-T_6]3]8&\3=?^B
M[=&TWGQ0@J08(DD=T>XMP$Q/GU<X*I!:_1(R*0K!!'-VH+5>JXQ#BM:L18IN
M*++7_S )K46HJ?(#:4(=W)5764^BG#2N509'UTK5:H$,J \W"K7@D^^+U62V
M\U/Q@:8H.T3!87;XDJ+I?('B4?4.LCR9KQOF!K.R@UGAY3A2_2H[ILY"<Z$G
M?C@ZSN- 632FW$U[GGR-C-(JHE;[D[TG6Z?;6P?;W.9SE$6+O#S2Z/-#_N_A
MZ2D";WP97_OP(3^ML4@9NE5*5F6F<UX+*22T9-9Q)V%<&U?)X[)IDWFAUH>A
M4?B2^;5X?1B.WG?PAI=RN;./%L&>Z"H4\!R))]..T [F6EXG DA4&!^28_=Q
M,$V\YJV1G/!B5*1K?:'H*";*=:$XXH,^L_+E-!"I(0. -RIO<<2FBPZ<YN>R
MJ%9Q])U=N%D(@+(3]JMONE B>RMH^T6&M-N>=PG<VJNKG06MS\S1Q[27Z'];
M;EP[CN"&;O5H%QX=7[/9M$^\.@#@]+*!;7!22H91+]VL:1&8T(ALQ>]P_DA"
M=;1#IG673:_IRM5J'L(&_Z)Q<1!C2OI_%_O>M;$YS=8YK]BVUL:D<SZG<R#@
MD]/28@?LJ<;D.A$#:*/62B[K.R%1Z+TE%T?LQ /"1;O0\JD&^U16Z7);+)[4
MR3F9-1PS\CMIUXWYX4?<\.IW#S6@LFMJ0 5?>[7QVMZ9OSWBG['UVA3JNA^=
MUT)=YET9C>DA[4!])'S.Q#\2^SKY.3*O6%BT8AQ.R;(B4XLK\]4I ZAA=X R
MX*,=>\ <M1&>W\W>-@M?ADH0@4-/Z_#M\>O.%''%7@ )!2/PYUE2)@7]D*72
M)-"HP!T5KA C4<D3/]30&PBB@LCC-^:FBKL\ZOB+A_U3N:[@B6%_N_II4K7L
MYBIJOM)W8K#K93SB9'3B9-R/"I+1M;4T6--M/;+752K[2$4RKQ'0FP!W]35Y
MH7I[1+VY/8"G2:I/_F,UW57'9'?=[K$[ER\[NL<2QV%8G=RVE:,CU@.+ [\*
MHOT9<#"3@L<VNO7:B#1@FI &+#QI &,0&MR$_:2G+4IGA+&K<.)7WA-T671R
MP4)1Q<I8%OTP@]X4MC23/O)9=>*T.GCVRUSJOKB<2SS&*B7HK8)[3%^_FQU9
M[3VV#:8->WD4FG"51B1X0M8E5+**P0?H5L;0<(MSGHV=<UZ/]4K,@BN34^D5
M[5')":/()?@3[(VNKU8Z.]1T8054O8*]+@$^:F%&DNX:,]/]6C-3US%8G-FO
ML#AS]\NLR^P3K<N/S(N[C7*?9Q^S),468YOL1DLP&[<$W<V68#2&SVT.9I$Y
MZ&)S,'KGM39A'YS+O\X6S-9L07<GMF"6VH+N3FS!++4%W1W9@MF:+>CNR!8<
MQ62YC]N"UYF"=P2]>M!)G_<5CW4C4\O#FH$'O7QCH*R/H0%N-#77M \?U_<*
M_FB WWTL(A]'^T9@3Y\O>.[28/=X#SXE7'[-&&Z$.#D?(+]M?+RP"W<M<!TL
M#EG.\:BU9(>,1:[-R1DBU]D-D>OAVSY_V-KYL'7VR\/6B2ZF4S7J&8A4Z'&O
M@(N-F%ONBM]L@\< OH)VQM6R8]#UK]A,'PWAPU"GH9BJ):#LIC4-:.CP )J;
M9M$GYHLB64++X=0J [/3>EE>2;!7X&Z0G!/9:E'+#'P7JS-/$!0IHB#!7$6X
M-.\3V?NU7I ;Z[4G+I$O!+2POP$M?$;0POX&M/ 9--9KF,D?EO:FRK<EOPIL
MFO^DGTS:<K71K>]6MU[SMZU\HG);GE><QO89H@"#'+@8^E@PBH$I"\Y;I *N
M9J2-G].]2WH%ZRB1EY-O>U)FRNJ"<8RAA^8X"/W'.QGL3E^^(@5N_VD.%_2C
M3=KG'70^!F$BLM)"D9),3I8&G4B#/'M?-Y<[L^8R9VVTJB4)WK+Z>#] ^;Y0
MG S'RSS^G*X'R6^45 CDR/<U)TW&68SBIJI8UW7F; )?"/RFI@WS3F.Z$\F4
MC.DT?-9IDLJG&:NYZJS4_;-J*AVS;&2?#ACIIU'.IN.H@/;(CA#:A!V2BTIP
MVG!HA_XL%\MY<U4R?0%G>]0P4.@ =I:*$66#<CRSQ#O5#/CXB""K<\\(471E
MJC]?.XH<[3.^'OFRJ?'EUS'&/.NZL(DG1[]06"T-B7XITT(;T48L/LZ00GHU
M,F#U\4J:+!1N86[AST,82!E30G;YF7*QR.]2*\QY^6+;E5MC 7A9=5#6)X@D
M8PMS/(H=SY+/+):2@;HM3&0T-5@Q<3"SDK[2:,PU&\'=>B.P([V*LT27FB7*
MZ\*]X.Z;?*_@-U?9V5-[U.%E#RF-@9*QC3GNU!D>0;(ME9]I/_!R'  [R>G.
MWY#/W)T>]LJ'DCD&0<ORMB?+\6JC@]VI#J:!Z8E%JS,5'Y+U!9$5+1MX.>!S
M,&$5$66I%N3UII21@ 0=8G^5@ "O(89R2"L'C2H\#,*.(_0@^,AG^#/=8( E
M3%5<0)H<O7HM%P!>8 E$"I3+#DFPIH.A)LD*7!AIT;SI.+Q>H!UUO)QRIF';
M+_EZUI9]0MQ&G-P5B<>\+*;K6R@7N&_.C#A9MX#;;='0[=//2TU.Y1_1?J+]
MT+%7E/&Y_#Q4/JWL[/>?1V&':![#I8_%R\8)AH>*!%-3(.)6>GY\&#,K\69&
MB%82PH;ORHI^-0-Y@Z?9P'[V\?TXDLE_GAOZ#!J*HW>)EN$?[TC![3Q20IR3
M')@PO>/??;,J&%L2H7R\5<5*Q8S^G)>C4[/9_'<DL8.H+NMS.)-2.A/1KYD9
MT OC#C>M"M^0DCT XPB1R;!QD891H[$T'N+#]/@-<KT'[PFO8#4XHE'\6#=A
M3,\*):UC!56:<GZ@JQ:W35V64Y7XI!Q6PK)36_.M*)2D%#;SB\"C #[(!"]5
M)+9=Y&Q7.IL)CNJ$_0QT#NDI<3#1B>PGY=3.3,;)F-$E"10<E%OJ&&=8=K 0
M2$!UN716WB/:-)U3_+$Y:7>FM7Z'Y6,CTWT'JW+C,KQ;X2=<2N:#.^LE)"F@
MN[-R&AA1LN*R:*?BV"L6P;%W[A>4GD0R]H0SE2UOG<%B+[_GT_?#2\#27JAZ
MR/ HAG6[Y_1^\%UGC_;9J_>88Z2A5TD_K(_,/8A__/G)[D%&$S 7:5!WREM+
M0N_/CW;W_5<<.41?VD"\Q!E4G)*]/Q1Z/MLI"-X_'ZPWIT"X)?5VQ,5IVKDJ
M2[#@2?^5\!":_=\D0_\F"!;:0_1O%SBO/.05#@W5-=(%\OE?TD69'YX7&MV?
M]W>?^LX6? >,S+-'AK+I(0 S75H'/RL]]438%]=>Y!$:1=3!/W^]N^??*GR+
M G#TRZ;[1AO_BJ\P=DC >!673<#O\9N<_=9X&#MV&G45O8?VT.@.-%>7\)G]
M@03^S;'/@TWL\S/&/@\VL<]?>^7;&![L!4]CB'26-V*]DG!ZP$-ZT#K+R]J-
MX/D'0*C$N17!:Q0UPRJ/+:3Y(5X@05L Z@W /->T:($.-^YR:-7NN^5+GQ\?
MRNWZ0G6<%PT@X?")2&>.FFZ!?"2D-V1;^$EPA[QX?N3HX[3^"!XY"EU[Z]T+
MTD+X]=';P_27(?ZK"E<NSA7Y1MB2!1"OP>(PG"YW<@O3LPO4&&J4EA7LFIYF
MFA0^^(<B]8B^8F@9#3:R?/'>1EB'!2+XOBR7_)"A]/-L7B!_ Y\MP7XD :QZ
MZB1&S5],X4.J3GOEYJ0.D(5Y:E\M);"8(T9(^]7@_]1[Q'#87N4A,C4WGNN*
MQ5+>R"&0!;ZPI"C\$YDRR9YQMF=VH6*.;B;.,0J.WU+#*GG( >,4@(E/%],4
M,/$&UYHYP]_,^@6GE'#/PZYW#)_TVR[HC;1YL",2O"1B6*2#280NH-"8"5'=
M92$>9SM<*C0PXRXP@TQ?+7RI1>3(NV#Z59^ T-&65*8MLQ2\^CQKYG0$A-K\
MK.^@D#>F1WK0Y _/#]G OVB,*?\L"]%B\_P!?%JTM99E0*K"B@Z%FY>K%0=A
MS>,)0GC29L('75G]3)/"WN^5>-_9'\2^']D[\L[86]\.MEQ5_ZOWPSP3'.^D
MNJCF&$4QAW=)B*YI7RX87TFM=>6D_]W0>IO+913A-"L=MI\1>8AD.!&6YXV_
MX@YQ)\\/(]J8+KCP-?<,0JBFUMBEJAEV<B&@PL5A^ XYL[6 C,^M[@7?-><U
MO8Y#$R35R0KIQ&7(B.E3^!;A5T44S)%44_>_7 '4Y9(#'"3*NN),.=Y\F0!.
M[>+XNI:AZ)5DT]C#(4RX;['WH.I$)I<?Y XNZ_/53  2$8>XY$BNBO=E[6>"
MQSJNPQB:PF9F' T6YD7M?,EFQ=6":9N3Q!(?2A[[/ERWZ@&]^ ;7PZ+JNBI4
M ,*18H;S[.4/SPV/S>4@%&JAR8XZ!+G04J>,W#P<!V7[S8=>! \RGT>!(#?>
M !2R#B9;U<T4BGYF$/82GO-B$BH+R(3=/!BZB;X9%')!=B3M%GKF&]?1]=1)
M^84K74Q_:=?<#$W?3I2N*OGQH1C(P"W55:9^C4:2KX0JWD>5D="*B79DTLMX
M=9;I-RU0,I8S=8:K>E:FT6%>;OFWY@2 YEXW9>5K;(QK?4L:.6]B1B&)![^#
M$16K$OG8&(%G:B8-+F2-2&3?D5Z<'=EC)RU&P<5>:+C?'9V(4O;=JQ/:>?B7
M: ]<#85S$VQZPP(YGPH*J1&3_1=S#9-'E_E@1XP>F<V-?0>=/UF7/9[1V\.J
M2)K3XO=>4?2!;N3%=*B@HD$P2ZU7'9^Z"+D$N!S#L:H%FT#RE@@NJY]P4*^<
MLR[75L@<DM/"&\>'OCXN;T( 7B2]H+ D%S]R,X?7GDL5#*&%2*1"C&DD5;.8
M7\E50(T75BMF56@IS,"@%()V_BBJE[LA<XD>'I>MFMM7B[Q<13YV+N;3*5V'
M\[< 8HKX;W(-^$LS3\^N/A/2@B05B!JH:5NM>G49OY%C_VV#<$5D[[Y\\VU2
MEBE)!;<KQ7SVH^.3U4!WI:===+\_VJ,YO8KK%^&VYQ &G8/@8B C9&Y[ NI,
MPT94Q_<H@K >*4#J12>,VQ.RJSE]^]\]C&7@M\T"[=C[GEA.\*?GP:&AMB4-
M7HVVC@NRX&.N<,&7YS#TH27J5A4NY3.DGE? 6'9^FGR]+-W,2$BRO1SW^"Q%
M+9%1VS%VZ*6(3[9W_51<,R 9#&:= 1A,<X)J6-,I \S1T:9?P<DQM;)1XY.F
M2^TOY$BLXT>B=KCAGM9*KERK2A&1B]\UGK!)"+^I\]_CH*XM&@LB7\\+GI)^
MXC5=,-IW[,L7FO,9<^IX*B.(_!7W AZM>;%4\"_MXU.(G;\^T)EZT,O\LG8:
MILT5M5XICF25P"7QG5AXM?#)5$')]+I;QU['1*$5.99GTZ9C!% S+Y44B38#
MJ1%D+2R\E]DXHKK<V2>6S5!XKQ:@/7(]("NF:R9"$,IW-/<0;L..O9V%Y.PH
M#*;D,HLEL$%6S2JBA)(FF>"_Z1B-MJLS<T F9:\&&R-Q.CL-6BI*##;3RI?-
MTIR"2<$CELMVK=5JF/IIE9*L$><6B26C.76AD6:Y8EUIVBC9.=!UU'\_5LFE
M.!/%NPFEI?R, =DG=POCB#C;MO \6]1?^I64Y>J2N4JZ+G4]N"1@N90HIC9*
M>T%X;NK,9B^HB*!GXP\?Q?(D,K*C$EPA5!WK3[1C^I6_QEP\*LXDD?*.<E]&
M0Y6%H@-&-V[=<Z1>^)=L%WN15L!Q 23&<J:?L$N[A6XV9C#"C^F66!U_W[(E
M+&-61@;&;0'L6)=GU6J'"_K&J1O)3M"%]$5SS1*/I\$\V^:L9[*M<!)9#P 2
MS31LZYD:B+2!+YL;;7R_3B-6?K1%KK/S730@[DQ;,'U,5$D4[N1YF>Z'0#GD
MD7:7T'K+BM7PK?UMY7&KQ$VE:YI+Q7<)3^NWH9, \3-A0,V)_(QBH4UMN?4(
MO #7(HLMI01HN?N" TMGE9:7/8NT)V3[EP5\5&?]W 0'"D(V[:H03%S5(N;0
M"JJ5/C_E6HM<QBY$(]+(@P0'$E[_KI22 [3GQ8\3MGD1"^:(= $Y-PUV$,_"
MI6'#EV+7<ZM-Z\BLL9*<"Q-WN(U!7,5+*HOC)QJ Q*9=1:DPH1]B!8J@^%(R
MX1]MT""?$0WR:(,&^:(5T$#@PBP[(5[=JC,7:7&=$:A!N(LB2M+.= Q "D=O
M+%6LO"1M25\[*W=@K( "A"L*BP!V<=R#<PW>1ZP?(9QZ>L61[4J*CL,9<5F>
M0A?(^8\EG7 XGFJO]_B(-\QL15CRF\!@P_TCC;7@V$7!95X16N:WC8U[XPR]
M@\X?PE?CTB"#7+RZ7\*F,]B%!#!P>6K95N'<&W/@[28EN>-8QWHH+N P/NI*
M%V7JO!JG%!6?&U["7A]S[09U0JIZS^>Q:S3W Y7XNL8E9,RJ4&&6JD"D"H=H
M4OXGZJ(GB8RL/5*>O/=X %Y1]0<JJG8?*0I.O+<TQ=8'G6/YT^91H430K.2W
M4>B)6F!M&=@'UBLCAN.$1"AN):'Q[$G N+.RS..\E ]:!G> EJ8#_Z+JL%G^
M#Y#:!WL'![NT-L"/2(4ZP?5R78N4T]/JIR>\1O1_M>8L T!^4R\>[>5[>WN6
M!DX/=G%Q]GK2LB(J[8'Q2SIE!NZD:B?](JCP==0S5=S+#^5B*9S/4'69&*
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MC#L%"#W9 (0^(T#HR08@]!GT QO&@[[] YG_]\5J,MOYJ?@ /.@A4K8X2O7
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MPN)1N$R=^*,C$BWEQ[<G[U[GKI+JROU\52A[DD;5N=" D:*$D@TI##,D(2.
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M(3J5J37>Y"AJXNW\0=?B^*+,@[_&!_[MQM(5J5G%Q#M?75JD9-5R^>22\;>
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M&'S '@CG^Q!-1M1E2F] #\8?)5O*F.1%FWYD/I1H9.),Y= 1=X^533LT<V*
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MON_Y7][J]7+JQ*N,?5Y<*D!H#28YK5M9VEM8]X]\&LEEARZ1O8\ 74^4EY?
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M'O^!<SL5N:Z8Z<FK[BK]49A3,H;KI"OGZ9O=U8NK]&4S +S.H  %>P1%BR3
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M<2,VVUGB:-H_4&97B749-C4Y.&-H@BE8@@SJE*8\^ZI4UQ13G*6:B@$NUI3
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M50U\LO[@^IEYQ!'%%(2J;A[KOLH/(V LRNXS6]6B[,YN2QZKLHMS?J:R"HW
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MBMJ]MF/PM[NZ*3?@H!!8 =H8Q3<OK="-H*9.7"VAI_7@@P)Z19N*N 4B0 J
M/$1%XYL'1@A?I,I8!_"D<)!MB&>9".ZQ7E^'-/TSRWQF9MU?AC D2#%!T$2
M]J9O-KU)W]"#9^F?WV3I<^L#F9NBW\MO]75DZ:MJ?46/^'^MSV/>#_[>)J^
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M!_OD>J+'YUD!]3(]V9D3.U/=V!.;J:B2'UQW'!2S+,*O?>(%,CCBB3O8GDA
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M4N\(MRO9 $9\ _L/2E7;FSVO*R*_&HQN!'E%[7Y"4CV)94$+*79!LF!ZW>B
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MC1&"C?0Z6=7I]M4&87[42I-Y:"R1U5/MBHN&**H.I"P+P 3#B2T"3*![#KY
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MP&X,LNKE^"DIV]>C^G.7D]Z0WNJZ"3#6R-Q+>HZN!>CJ>W#<$LV1>4 "X*T
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M...Q8DJU,VGIA["3@5(TDSKB^P(^#569[4$JN^,)"R;UC,U5^MRG-Z<<>H4
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M$6B219HUG^K))E/+O.QU56#HLKI)>$*^,V+4/2&PIZRE.]QWZ4W/(6Y0?9G
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M\J/S]2&KT2H8/UG#3J?#^_?M8"S6+H(8P+#M97::D&4Y#)(95J#>L:^,;E_
M@,J;GVA7BP'1$OF& /Q5!2.E3'DSIZ;Q+U)K7K3*%TX>QL^I"(X0C'H%%#:V
MUUZ,FR))U'-I%!0J^!&L>YP."H$9/$"WP\PCV6+UX]1%XAW9G,)%<F07D(:'
MQ$J5EB2%&.#DP428.4R+R"F7!H*-0:8&3563;,]#W<A"!\0VETU,QJ1IA*8G
ME#-*34]S"TS- @= X_6Z6O3+PW"9#L$O0MT"@N-\Q$LTK5X$2/XDJ.T"A+
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MNRCVH";TQ8U]N.&XM*H2K !KW33YW=Q[LAY.T>F^293(FQ!\!F\R+>L*)"1
MCL0D.T6^@+]*"/MH=H[6KM*^M_W]&W73Y_1^9:^LA/W%/@.]>W'1#E;.FJ)S
M6BVXS%7R:IOZ*?$@<ERO^R;#,RJ 4.C&:V1-_KNGS9LJD-[4CHY[\&F\:EY1
MFR6A-PH\U"ZGRBC!40@F P2B:L6?]9XW1(EU?C!7/V "^%7#S 6"[GY[_FJ;
MZ&ES@LSSNQN1X[5U12&\\[ =K97@=GOTI/**QJ9EZ[>"N_;M5]]^L?KRBV=?
M3@50R%_L[O(CH2$4V^FK43)F8@G,=CZ^#S(L[!XHC,BZRWP;$[D3?%M9;-V:
M9 [TJ2S>(5#M\G=F@'W"JB6CJ';P)SIK9 50)"L'?[UI $0F9/*NM&\_GG#K
M 7'\>(*?329$]*DI..&9MUY1$Y&FXELLWL_#>C^$QHC40>B2.@U\[ZD(I7+R
MV*G[,+Z*8I$:>$]E\K*NK=B\:/H;DIWG=;LWR'%?KQEL^>6+Y_SS 7".72N(
MTJM]T;8*6RBF; <7+"?_O?797&Y,L0O=YQ/C7'JZD<9AW+[4T1-P!XL<T3@C
MW3CE(4"JXDOAMVRBXK_M<M9=SM_,!76&(%&(%G9MKI+1VV*T'8_5RKPPK$Y8
M,<K;X51;3L T^C[D/5&B'=M,O91D*5/ ?@/51P!:.375K^QMK)Y%Q1S0/G6E
MKDXXX,:<#H*@ $C)&R2FB&7'*)(3*11*F(%A#$DLWB;7,23RPM R18O7RJB.
MH7V/'-,)G^<4#)[=)-<V91]Y8\@YT&7F>\":8%'T AR&$=U6 8Q<*@S6!3F3
MQ&>SHD .R'\C*T58Z=[?.WF*K ,8MJW"D!"^!2EB+)]U0,%"F]#1\CZP<?[K
MD&@CA)H<\QY;!8$'0,8_^ Z]$-;B[LRP6B?:(O_)!+[7!F3UPI\Q,IG6)[5_
M *O& ;A1H=L\>$/V42@<D_7@>/@W %2ES0U=@+43>^V4F$U612UE$DXX8OG9
M&' L1X*Y+ B*I-:9<H@R8/0!-T+,@BR\6+.BDS' 1""AV"NW&[+S19N0FH!X
ML#OL_$W2"9SNI!QL:\756L IN*]($;-V*=JQ:&<>;BTTR-P+F.1M6Z\+ @^5
MCNCI:["DB\<P[4<SI%AT(J:!R>SKB\YM,I/P+\I>&P_Q?NH[>[S:77%@]'P3
M8*]UB)S-^X(!U&(@LR'>*4'+IGB='2R:??T$*I2PFJ)$)13GQJRZ"9"T8]T/
M3C_Z&D73RN,R".Y4^AH/0X3A(?<XETL))"VQ+_0J?6U=+ #49F**@MPX@8>:
M#S>W<;D"79FNP'MK/.X8L:.KKN,(G$LH]BVMW\%'A-]V&E$LDA!E8D =9( K
M.JS,TD(44YB*>\+ ;J/H'ZPQ2!@RC^J;L%8L61_Y(DCYQ3N)-4Q#WLTA^6F*
MPGGRA*;L ?J&L6(>MU]<ELMWT?YJU&]A]QRJC:R/L^<!E%R(Z>U.1)  GHO%
M<$3I0R6\QZU=W-'D@!+2"'/5V#L^J?*]#<& M9>OJ1M#TTB5#IE0);V5A@CB
MJC4.""_TI4CM61/=Y0JA-5I4Z%K,?"^9^AZL5(PEJ,S?F]@.*YR_?47^RXY%
M@(\OD-K67C&P2>"\"DPE*&0/5"WL7*Q.?C1OBK:0PR/U(.WDEL[L! -S#EZQ
M-=-6KAKRE< R6QY#C<-&4:Z4^">Q-^4V!B$-IE2M54:%+XAR\,ZI+M%%C74<
M&>H=^@9VAGQU]A$.UN 2(?J6GKJH^[8\>L?6=\DGN*_S[;F!8F*G[!+I@=M!
M.@&[<\/HE SG+4L!B0^S1$IW*S##H1H]\FAP&JA#B-X"M%E_P(6^_@J(^O8$
MD?/-64?&8E.;!NOL*]O8/7]7*Y(=9RRQ@="/DB;/(Q:A@</ODA9(1Q<E0?+;
M2_X#LN/[DV2$"Q*$V%2@V%G4@H?B% R0ZR//=5CJ=FD9Q([T<(F;T_ )/YPP
M?U0R2>'(FEH8C4%.A):3#44_&^DA:NZQ6D3NQ-;/^@7ND'BL3,+'-*UX&N[N
M\5&-O;3!2[%'LS2<A:W0P],X\$\KKQL_22)7ODJBA+;AE3F[K'Y,5Q#TZ(=;
MY8Y"<,YGA_GF0GM!@F=&E0T1%7RGD@(M%Q8."VY6#Y>%F2(.N2P[]M'= K]?
MN@4^8;? [Y=N@<?K0[HH+%%M-Q,;D 94<S[CH@RTO<S#!4X&=4))="X658;C
M<-'6QJ=QIM YJG(I#MH8"M<-ZB'#4SA")[T[F2)I8Q7(]$%5 FG_$OFPMGOB
MZ[&"3TY]"C:"NC4V)J+\"%"KF7$G3.F%69%XXG#IS7QHF&;QI_.PLG1P^2%-
M?XDGBC)ZR/WH4K$>C#X0Y%S]SJ+: MR<NQ]:S.-SD[D_!LF@!"<7$U#GI>#S
MD 'T1XA)*2B\=[NZ%(:C*/QT&=-1;C1S/  #0@-$T(#\[VKG_-+-N$KXA_2+
MIU]&KJ,7.5>UD=L4$R4)*EOPIZY5;U,]Z8TJ58HL?O8#%,D/=FU68LG\_X!6
MUEQ8D!Q5 !T7.@!<<?JQH4#YCW7]+E..+TIKJ6L=O(?O4[Q:'SZV@]7SM1)<
MB[,$YOT!K\I^[^LOPXOIU^E#TNN"#V;IJA<F)/X-;$Q.11WTW>?$FV;B;F)D
M!) ][X1M@:^=T/?IZ;_'7G_QS>0"9(#;"BA9),?U0*2JK!<VFF,)HL LI7;A
MAOJ+!Q7ZJ_1:Y$(V+W$).YTV]_?1FPRWXLE@G8.B'/S<2#ZU]8B#O/'#90EF
M9G(:U*+WF=]8F=FEK_YOO%:*&L,3-?_1(/.3(3=5(YGBT2;GOI;LK19(B=D"
M"AG'02Z$1 KG..VNKSGQ.7V@BY9B[4V0_>+<"JG_5*E_CYQO]W0N:9G?D8:W
MYW5CSX'H>7U?Q88+,UZ@^:'XVO:.E$;8SI@.O;8T>7WSK955YI.@?.S!#<#)
MF\I[&[KD'1?"$HFV6]_.&6>:YE\&X[]3[8"BR99N%.5"J,Q(!;@J=,WX(?B@
MM>3Y)?H0.%2FZTH<2;G VBZAXPP\F=J-61=4J%;&O:F7(7-2Q GF<G[A+KFR
MHB1/Y/2>>K-!@\K&ON8G]C5+*V%VXC6%1SMP W"QK[]Z0N_*6J2<?,!!-^M%
M6L:+-NOL SYGICZP+^Y-MP/QC4]]!QT9^X@=G%L8]@IR&U>60M9!)D42"L#%
MBWO Q5^W4[U?U*8*/TNJXU/\DHA([8=GF F[^H[*^ '.C'H-,;6[U,"LE235
M)\E?LJC@8*A[#*52K4^5^$37AJ18\W8@D"J[TD:CDIE)J1 E8C2XU%+RN<N/
M"34)R] 7A<D'C&;]PVC/KXDHD*[2MS0K*<26Z[QII"G0C6MWH*!R*A!%5.ZV
M1G8>91?JQ^::3G&+ON#KZIBXEEAWY<&LU-2(;PU=C,>D:4E$9@C1R6.COAE1
MWXZ[:6:TS$UN)MN>F+:&?_=M2RZ]KL7<< ,H*T&E&GG1[@T.WAKT!'DEVN@;
MJ K)*&0)# /,M_.!J(\K[)CYF8>3HTJ2V/;3M#*9N[$\&19-#2(T-AQ_.*&^
M%)"I<F6#?-&I6<+,=P\/1FEE$'"TR/O)JP9S>\E@+,[-X,W/WBTV]<%L*B9?
M)[:4TFQTKI$8; LB<(V'IJV,<.674G9HZH);K^V$,R)O/UM,ME!E"<]4LF>I
M>AB7)4=PT%57YBO#^<#I%AP=9V4('$Y_(VA"'P9.R-0"*%,J78N+]7_ Q?_5
M2UP221P)) 5YP8#^A/"&9JEOA[R4 4MX5W./0=,?ND#U[:QM&&E8=A#B,6]B
M?BS(1%HSW53<7T?YZZ[)/4B<B[GT#J=I F.><VD"%'0$8]]Z,OTX-+Q#KT1,
M*#D8T]9R]N6Y[*C@(2!(1ENK8W$..E^3KD8]4U2]'E5JN;JS7D^(J""%3?'+
M'&.H<R@6)L2S/'%"4FJJ:#/G73W\,&B&G692E\[>^E#4Q2:V*^@P3?1V5^EK
MXDJW9Z!F:E@8%\[@H#N@W5%CG5W-OB#7]?]G[UN;XZ:RM;_K5W11O%50I7AL
M)TX"S*'*"0F$@23$@0SSA5*W=KM%U%*CBYWFU[_KNB^2NFV#@]V)3IV9<6Q=
MMO9>>^UU?1[W,I=.[T@=FMG$7PX3T3)I;_^HPR*2@OM43!I."N,=\8&&A<J,
M/A*F\N=ZD-&P]R:OG(%[U1UIM<Z92?(HH:(@VMIMX55C4E]F)A7I.#@)^F(E
M3^?4=M^%QBY6/<&=,#4S,O_J%14'>AM^:)='%VYNBNZ$0PPA5V2]NL[35LT4
M#RO&2!3C!CW/=SU[]:CF@IJ"BX HV-4LX+O)XLB:QAB+?X/P/5G3<A(RTS 9
MM65(*Y^SS#$HQ@7!=5OCDV,%B*BH;#8K*-8VR!IJ\43MD$2_2F:2,8)D=%84
MV*9.O3HS_[U1[[V=UVT\638=E/Q>JI#0AL<!'T*B)\5Z8Z;,DVIN_ET+R_"D
M <5G.'5@H57!>\*V+!2+.P8LPE.:GMY6Q)5(#5Q 6QD3<55[>H?@7XV<V1&?
MO +2HW+6!1/B*&!MT\P, Z6_Y41. /?4CR^ DUM+'[21- 4VC'%8-!JXI]]Q
M6W=VBM=5YO5.Y/0U)9B\?W+RG%NV;0B\J<09A&F1" GXVU@8'OF]%&2FV&O
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M-/<$Z!JY>!8E, SB7 JAEGUA#H=CDRV)<UHH=#I%G7;\E,H :;-+QXE3K#'
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M^=3*QLN#:E^_XT3U:V 9C<[K'J3H!V8/96U<Q23CD-!+.@B+KNM+&F+:3I=
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M@ID02&H&*) YH?MI2K["'OS/[@T.@"E];$K5!RUS3#^RFUWD#8FW:N8TQN2
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M64TDT[9>328O7)2HORBAB JC]U5795#1A6L2"&4T( JBD.%$@X..6G(<R;P
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M+]/6).VP0"6"R;9ZSBP[;M*#$HVAJ1X*;[E1K!C>&.?$CF)H;75DD>VA23G
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M,:$XB3K+EE,LGJ6@]JI$E#=3#W*H#-ERV=S2<+#6LT$]CE4KGA>.1!Q0-/O
MHFL)=4^Z7-'B,Y,M:,*CR._\J$;=>.N6Y&/5C0/V'O-\3VQWBL/%V^+J:JK
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M=4EGUG8E].W/[^KY%[]\__LONQ)VN9P2NG2_XE6G\I.OW2)O4D;MBHEML0&
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MKA$!<UP[>KRV8@=TL\>JPHLZ5]GX16#"S;O]&QWB2X35B4IM7'UWX [D?=%
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MTCT0(B V^3%,7KWMZC[%6FDZ!E+"B7@1X3R>H#'4.L?"4F$<.*_4+M@^!HX
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M5:W7-/6I(;.5*X<Z3MUZJCJ1MG%;\JV*-&M*$HESD$SD1DISL 5('XM3DX$
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M:R5$8S"$BQ:O E24"Z7(Y& CD\Q.FAOZP19X!V:SF<KA7DE@<>%B3.D&0I+
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MHKBN%T'???CV<NFOAXYYQ%5N*[JZ<YGV0\(2W(E4LX"P7_CIW[X[:E[YMR
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MN2XLS<HU\5%*)NST" O,7S)90V.@&L:ECF#&Y;43O^#46@)IX?1SFR([@UD
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M)O&,\OPD [?M-FJ3BICIBR%K84=B*V)"?Q87+CBERG.2V_"#<1Y6(ZST+;(
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MZLO&0X%G)O1)E.Z IO,)YG$5%^QQ>DF+VWC2S94Y&X_#6))*190V?[WT'LY
M=:4V1@1'F'7GGTL<C.)R9VT?!R2(Y81QYH__62W\&>=E"SNBYX6N!U+$LY6)
M<('__M69C[P,QX;8Y W\#9HWW-DAI7>]QEM"34! '1^\]'?"Y"J>92 YV.L&
MJSS'>Y':5//\X7K.XI'#93W_O*)T%_B-2SM)@D*<''RUZ8BZIY-YF@?%Y7,Z
M((WOY;YM1.P<7:86^@HDIAO B8_AK[=HZ9HO:3G.\%R"Z Q[-=IO4L E46^%
M+FV=(?Z/"C0M#&)1Y ^.-NOG+0]ZM0=W+T.)7Z$,>*0KCZHANGOOEGMO7:T
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M%JW[5W,R&C^4CA8[/K.6!/35_&97_SK4[!1C7D/IW<Y.K,C\;Q5]!KF\#(*
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MHH",26!/6FS4A^KVP/&PAO"- <[X'EJ&AP.+T=XT;>MN#P>)X$!BW@AV?*
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M:LQJN, D-ME^1F]F,0&'>O8^.>YVD6A@#GU6'4!8.,O4WT6XI*^RH^P#=E1
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MK11B=W[R<Q+@<%&Y&&Z/SVY#LX 'YOVH\YA;CB4$AN=1BL%U&MH,;/9.C&6
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M(%RGH!WYEH=]P/\C.8Q"<L-4MV=[JNGB%W4*JK%O6'3L:Z2M>4/5-!]!^1F
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MRI*]/OP@>*#.,G67JFI,5JL8@\TY\2> +S;^%7^$\YS=B7,EBL< @V_)S>,
MWM]VU(ZAO27G:I]R+)_;B,YF*_K4Z^ Q_-.(2P,6_><UX#V& B";O_8Z%%0)
MK#U@%(QBO1Z#=8Z.D),B_#'BN<'8"Z-@(OR,&5Z>T*S]P/G'>'=%3:86W9XQ
M*!U0[X%2:[STN:UY0S@ 'H&3#%Z<@W^& X"P\RKNK K&*=]<7P7CE/]Y;;PK
M*I8Z(94[6>UAMHYBGV6:L_^/T;\CKJ/A4TY?+N_]NBV7Y?V?@[L=.-F]_^WL
MO%[?MAR>Z9]HI]FZC05CLG2B>$X]<FJ!C4+)[IGMND+.MB5GL32-$3QE+8(W
MEU8KR=6S._,Z[XX,!UP&VRE%A2M#ILM#<*,PP&,GEU&?%FZ;#QP;_3(7_5O6
MB\6P4(*X$M1L,%H=YGUI4>4X0)T(#J2J:<Z0^71DR)J]P&?PYP[MJ68W\.HL
MV]JC_8%I/U(*KBWG![>$'K)+G7OP_[ Q##J*L!*L 2OQDL8CJM%^!TR=BBP1
M+.+:WR#>_0\-@ L77WLX1S2!26N+H.\E*DH3=0B@U&7P':N.19D$,^O& -M'
M=7MD]Z]9B53;+0S.,\UB";0>S;0&JZGS[F* &IUA(.G_@C9!8X<X*=*F&:./
M@;]IEA-*:A:T+-+Q3\=YS:',ETY*FO V.B6+<#4;X8(<@RMV_X)WO]Y,TR#C
MN!G>+N#G;X@!J@C#^QE&S@[L#GEO/]!9+5B*G/R<**N[G'$*M%*3RF+N5H$)
MB-<6LK+@K8*".:9@/D1P#074:SX+OAJF::A]PGJY%3,';RZ_9<EC#:DVD\5$
M/N1F:3%?8PMJO!3)6*]1OF;EV[9T!_YV0"T/;Z0$B^62Q00MA/+-,S6*J7RW
M8^Y>>_2>DL\J0"D4[OP7R?,\*B'C0N.^7&IL432*;>_J:I^<T7NA>Q<Q6%GH
MWMP00^C>/%%CBZ)1/'/WC%)RI0ZUGF"JO#*5((;0MWFF1D'U[=9MW<.AX\%?
M7-IQU.&=4,!YC6$)6@C]FV=J;#^Z^TSZOZP;^(4-#UIET? @AG$S:WC0*HN&
M!\]7O#(#_I^.OYBA_V^GK=Z69=:NA.WEU*/]DJSLP\/:T,%YU!</%G6P1!NK
M 0^!T57#P@M[VC4T0S7]O[/B[,^J!;1D36'P5U;?375RC:UD_(8)GU4/>'VR
M;J5(V"LTZ>.*3UWJL59)7F^L[/3!\,)N0U@1ROL A62WHVSA8DL,-[:#4.>1
M=6MBO8N"NE.)8%.D$OO, AVF$_H'V(TU-;*[\ +*OP+/J:8Y*E=E7#7U55:I
MJA+T?@82^\JN<>^_<0!_QKWT;/) R2_+?HCLP7S$7;BE/J@Z',AJD=K?\5V0
MV-8^JPZLV&!5L#6)#"V3NO 'P(OS8+#^33J< <CP'0H(WF2=K.!O'_B17BJ-
M&-1PB4Y!Z_0-BP]@534-#GT5CT;&Y<C:SM#D'(R_7!\?[A.0%3?X_ [6=1C'
M@/YRC,[0FR,,7',:%(NQ2YP#7<:" ]MUD6? F&&MOYC8Z.3>9M.A!UB0@!^/
M^I'YGTV+(GC5T?<@TQN69@YU&I'%* ^7#-<=,G$?#FS>: P$R=&0<1%FQN<V
M*T/TAQ/#*L3H@W :P-.P<?_K; T ,OHKP@=HK9>)KCX"-%V/:?J(N!# &#S"
M('1+PV"^^=AK]\GQ'XT"FZBQ4B4Q7> 3R-^D0[LFX&0T5I=K- 0]'@T,4[B.
M3Y:2:;BAQ)*>"EJ%$<<G"<?K0FJ$;YO4+;PJ'[[0EX@[[/STGU ' Q,VQ8Q4
M &YHP3E;&C@V  4'KJD^N(S[QM0Q,+%E>\2B&G"0ZH!T!*CAJC">';&^'SL7
M,7R2P= !%J1",VT!^%.KA-T;AHROD&6L(6NK,'9ZCI^<L<RD!F<:\B9KW@=R
M",R)1O28&F)"S+\KX>&G4[#,])(]]%P/GD4P9KPXPJF!1@ V>E ='&7NDAZ8
M[9RMPQ>,- :H) >@2:(O2H&^F#Q;]\E7[%&A,X9'L'&?[DBD1SN02 ]$\A[-
MA:#7H\_C_J8B^)Z!IU)$/-A>A'1L ?C+D#B1<SMH_\DX$.D[4\5%;3W\U?+0
M<T%^[*@N]EBPB"Q5RS5)KE1CV"C.P-LOS3V-Q@\<=GS  :7KL+++18H;ME,@
M\W/5@LTYC$F/+??1!4/DP+!=S4!W'=!T:FG[$FFTJO72Z;UJ]6Q*VO?4&E+
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M5I)*H[W-E!H5IHCM,KCG@T/3@ -THH">V?T>^@<QU?6L=I^['.X F[%WF..
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M=E;*#2163F_[ZN'32>\#_+=]^%1O]<&2^/GKY(?UHWKY_>=:)#G02'S^)"]
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M<O&=^WQ(WKA,*:E#E]G(U*STCJ7.4W^6,;<X;I_TD_N;ZJ7^N66ER9-,$PG
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M4G*)\%D]?=F (H.NKTIR@CKP9T'>[76]3^-EU)=(S9D9EY.E6JV1R,U(-_-
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MF-C6,&T/=)-"[1[_^4PVB%7V*:;O0:[Y-]]04YBUIOV(">$!1()RQ),!<TZ
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M^.L&SP@8 V%*[#?"(PP#F90Q&/A#H\_\U/A/BBQV985:M<S\4\%/#)NQ@ <
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M&&;!7<JF1=]+%%RFY/<L'>O3)MXG^N@A4)F1Q.I,R&@+_ E1;@U:QN%/PH@
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M0:*.]19L.4ESW U?279N6JIE9^*E=5'620?D:R1"X,251O/%FC<U,?8:G>E
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M]RL'2V-=WA+L)^Y<A-G,XUR)S\5(YCH$NM=P=^'<)[%1E\\)O%#84)+"<DW
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M-!I;I_*?CWH9,: =IR(=3P/?<=4PV,P)=S6+R_[9.=!3GK32!N<.[VQ$LTQ
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M6?7O=;;JFEQ&Z.OFWL@).'58!H0RX<,!$7%PIPM>D#9"C5$L03)<<Z3*7<L
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M &K='"X?_C1/Z1MZ2I'--= Z"X36Q(MOJ0<>_#L"YJQ+"#S7@-TEI@Q'C'E
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MCX;0AMXF#3?')E^CKP2<?%Y*XZYV=:%.-UAC)&O&7^5ZT9ZF.]H#W77(GJ^
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M.-#(T<-SQ;+B._Q((\:6*1\/BR5@[9$8+'B-PY5+](B7-&(>Y!&],N:AHNV
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M,VSI$T!K./-KGJ=QX+NTR0J-MQV-YW']YHH,H6A=@RU0)D:?S^'H0,L;1([
M*2/R<\""Q WXUXQA>1T5.!,FHCZ>]%("S[W1>463#VX%5B9@88; B-J"X!1]
M DY+TL> &G4%Z)?/L$2")K^;3T9_I;Y_.;+?A7.;8#VR@M.BCK66G$\K 3^$
M?68F*&X'W5Z(%"U-#D+PN&].:A2NW$)_.KRZ:=WB%1J'@C-5$&86.N4B\)M0
M=D0!>U%QQ88,,TUPVHL!JPM%.>0D\!.1T25VZG:5T$Z@KV3M#7$?PTX%L"5T
MS&"M:'(CN"%P^6 #0&RJT)/"J2+JB$;^E$HX#PQMAY55#1"%(RO'$,!A.")N
MF(5Q@VAZP($!VPN%BD_],##V.08W!9PP%@TYJ9+_?('%-6#;+$QN&1(880D'
M?'(,Z 70C:8P'(\"60KP&51,<OBK)41***TH>6T,L.B1%1LQDE=6IIS'SJ_]
M&_ 20827/19>^$/@@Q/,"Z_ "5$P*V(XMFPH'CO>^ '>>-!%H,F7UBT< =HF
M[(DR/A<;K=JX)J\"KSK=K&#U@\V&6^N@T<=:,/EWJLCJ]LU']*J [WE69&II
ML2Z<J^3?\S^L/=C!_JB;J/!]KHRAKW4NJ:KBP+UZU/%Z(4+3**3*I0:YTBC\
M')DG82"&,EK@#68]0/'7XVL30+L%AQ,[LH1#;C[4;X!TRAH)W3TL;D_8Z1LY
ML0<[]@VKV!F<LC:YDH(2GLRN:8>.B_:#:,=(X!S2#C*"UPB(*(Q^_G&(4N<1
M(N&&JH,P"IFEU;] W:B$L"V08PX=#+3_"]:G&/<=/ $*8*#C$)BU@L9'&*,B
MC,">7Y$=1<?%')$IJCE<-D;,U:!_>LT-J/Q'G0+G7$;,MJP7LRW3G6U)Y66V
M99ZBW=N88.G90]KS*=^FPDC0#LXDCG_+QZJ#O%2;D9V,ZV7LQ'MQ\74H_WLQ
MX>,_/T <^'M=X^"G)MH.>505I)W,!75/.0UH"XR_]L .:&M#E'=#VT]EK='D
M'G^W6[^;#J^RBH"*6M$N@'UBB +OE07@3Z=,X%DY%OJ(0O&62N0EK[?:O=!C
M9I;Z+T, "QE8[%--FZO?OGY]?7T]4GGV:"*_?&TI[%0 QO17GILPRE>.T9BO
M5)VJ-2OUKR1P%"K-,E6E:2"$J\TF]16Z#.IAY6BJS?Y[-AN2I(TTC3 6P$Z@
M'_"-X#$]?_IA59&A\T$1+I%!)OD5KTQ@J31N7#"CA$;1'OCW"!>,,, +F!"7
MO !K2XD6'*V%VX^(MJS,CTJ$,>69\$UY1E_O'ALO(H#/5$*+0+_[#.NYE;FL
MF).I%#@ZB\<%!R8[$H JB3%P&3CL=>"R!1A$@J%H*WIS:_P(K<I*-\ :E1,8
MV.H?5HC/)^ I!!#*Y7+YD*Y6Z'KS"UJ, /PI@1'%A?$>\*4K-'B1PD48U!<@
MQYD/*A3*1]1GYDLNN.S#"02J5JXWOO)OY4,*BH-5<F P%10.'4EKAIO[T)PT
M'M7[<T0;DB7L%T(-:9!%#>8T_/=P)H_'R&47(Z-UA#"S 8\)EH:"_"83-PXO
MX)_/=<"I]8(S(6>."L[,(&<"RFS6JU7,F:,XK.G@/=,<92"/XLI+F4"LNP;;
MQN9,0$D>+8O6L8ZFI6Q-2R!56VN0Y<87^(EK5I-ABH=N(/:EOWQL[F4+[LTJ
M]]+-^'HU@'G[/"M+!L/NC(<WUZXVXY(PV=$HDS4WW]8+O@5\RQ5\FT&^+9-D
MF:[6-N+;#@_S8I;)"SD(+AGLI47<*.9D9Y32BS2)39?ZA!\IR*?&+G4YFIG1
M*IP,;13()]?"C<-6R?9FO:LH$0X^)P^KM2I5^^ LS1<LG5&6;E2P(4VOR=(N
M'>Q1M%MC]WH0NZ,5A>MO.FS>\VI>_]HB/MO[A'Q-?0GB?V-9. 97R "7#*"+
M,%<F98 SS!5+!A@6MA7LMJSLXX7(O*KIA++H&#%IP]!&"XD1ROH@S(=Y+8N!
MJ^RR5CJ<5"$K5+6!'5LZ5EC*TBG8GY2#O==4^<H?B I@+;2<Z"BQZ;(:.9S*
M1V&O "E<.:*R1](?6+%1E0H-6+%.UN@*5?NJO50:9(.J#_FW2CS'U6@\PJD<
M,[EKVJ 6]@IR]BB@74:\]LKSN,P_-(F+6+H-]BG QBQ&-*Q>5!\+.)7X#S.;
M?P=_A<U 9J%[?.NV$BN)&\W1UL:J>&,?FJ/I7+#)1^%HNT2C"1C[*V3D6AQ&
M/I-@$;4QE0>CEM@,;?%M='4%1G3#SU$)$7;7<"8N)?9N(;_#ZE18F U8$[ E
MEA08F?**61 4EA4-M(YXJKIR5-M[6<9'%@#E7'#5AQ, 5+E1:2 !T(@C " 7
MF($J0ZN[8E0V+M!<X5\$65>)J2QRO()8]T817N"G;D2&Q8QEP6%!R2 CR):Y
M\2&K>3><OTTKW^;QQO9X/)2_T2H*'@<\7LD%XWPX'J?+#1KS>#TIC^/N?L.V
M-E'^+,Z/ZG>=ZPH$),"=O! +&/:G0CQW!))D\:>-(6@_WEW_&5>]US<SV .X
MN\_/-63!HW70'RSN%<CAU5RPS0?C<$B5]2:]#0ZW>3O<J(_!Z0RJP@AB=G=,
M8%?,#OYLX(0T/WR!"'",<L$IVV?J5%BQ7&F4ZX@5*3(.+Z8SK=)W6B<&/(9A
M11,<+X+E*ZMX67"$K1#+NO$\,3-+&*H=C@+1>)B(!BP*&ZOC,B]%QN#>&UG5
M#JW)/80G6[Q^I0FL]\1OMS9J%W<:M&7\A_EXHJ!>B(*]I[U<,B16?'VU*#"U
M/?#*#\<Z2HGM33*L"KS'B;RG(AW00M:3$!_76&ADC^UR)"&V67=6+W^-G9%S
MRH17MZT?Q-=64&YN1>Y@O;ANH*Y(]A 7\_/Z2!38.*:!/X:W>>;-6S_VH:W[
M9BZXX ,S;*PBL0B&Q4"(%F,R$Z3,%#1]BT,%HSROILG6QCH26OT)*M *ME[-
MUA29!K,4++P!"U/U)FF8Z8EYV( J,UDYMNL<AXM6&L=6MU7RWL@Z56F07W#N
M:T%0!2="AZ7@Q.QP8CDI)P:XQ+&YL;PQ-YKF;\&-:7%C*I5F!3>FPXV5Q-SH
ML6,3LV1E Y;$BRC8+0F[I5+75;!;.NQ67=.55#%Z1W#T!P\EYEG=;#MDHJLV
M+/X@5_80!P1_JJE%?^.J4[2(@L<C>#R5NJZ/P.-IL72%I,@*9NE8==GQ$T >
MO]..^5J0&9!C81E'3WZQLCTK< "<_!NCRMIH,$QL[%8K50SO82VM:7'GA\_+
M4*F49GT$)MV:(BXWR$HS?C.%DRU=W-<W!A>W'8.+;Q1K<#$<G)IJT\.*OM^5
M(#L5@PL_,+8=%'P%_^V5_RHD6:NOFP,U432^'KN'2,Q-Z]:C,&V$&DS\E?@*
M<O-NX3"&]"WJ8UNMJ=0R%0R9"D,FSH^$Q8$VYK\4@# *_EM-0!19-/%GBBG#
MF_@I,AY[^DKGO W X1W]*P#9D;_) O)F@".JXMC2PNP;C!\] C2W>9%!T;7O
MY.&B;3\W/!PK\>E$XO!';E=#<B1C86(M'HZ35$V+AXV!6;D9G!0Y<ZWQG;A&
M$V+4;_ M?1S$MP:Q-6O%(#;G(+9UQK U:Q]P#%LQ#&P7NGR7P[Z@E/W,8-B2
M=-1FQB9[O3-]7ZU1=1KJ^SI0^#36]XGQ.CJ" C2"K"!5?3T>"T!=$W".X$R"
MNCII$RZ@H:1H&Q$--V[$#9HJE\E Q TK]5,NS'/(Q%G$I<P1QZ8-^1K7EXZ?
ML#48%.'K0&O;9E-<DX$Y%,UZ-Q"AS1X^SN!W#*YC5'"\0!QIQ/I15KF#SS&Z
M#1DKD82X&1S!KTC.=4#E?/"L+3C6RO_+'E/DB'^WAYE3J]=)S-"56$6,79._
MT,%T9W-17B V=7C7QGA")[ZE"9<#?]Y1CHC+A201%X+R/&?@5/-GTR6WL&C,
MX#*58#0#I+,X=9&.0BH=OPL* MA'E*1: \]0(H&M@@U,2P)8">/FAT?2 3=2
M0.EDDO'QT%*LR6.ED5=-*W4/)4685Q;*Y6#**\R<!W*#5<W)#/9O@X-L3JGA
M"=?1#3PI 1C&U?A6/+W_>:4?6A#4"A,@DY+ :0+$*JQ.P00XY8%UKO +XAB8
M +QF1>0-M"J:BJ/[O:9[)4Y-=>JZWV)VM(Q"]SM9OEZP?"99WJG\8]5PVDSN
M ;(+M?&9%X$C?NJS^12RN7?J6B+^1LK;ZY>C=>P ];90WHB3&P4G9YZ38V%B
M^D;'7$. "^(2*&%HPZ_%SG0Y,3L;P)9H$9:ZWA&0=<'2B*6;GYDO!5>G"(E)
M-BIE,SB^9G1\W1,*G/^$6/)Z)@DC785.-R B&!=';GL\3H4M&&H<HUJ2=$;T
M5JF <[CPLEZ9"H*8^WBL-RI8+XL*U</$S$9S#:/XS\2MQ7C4N)R).$6EWX#I
M!,"&\%&M5P:.)D^6L3;=81I.SMP6\WY@O4F1\.CH2CZX8OL,G&+Y%:Z3VNR!
MN9 S]D0J6-$:"T![P+-321;ER<(>_N;PP[W!=\-Z+X$_O A0()EQ]RN=E9\%
MB8<\5R(N-0[\[%;F>)B%(WX"<QG']GGH#K1E8%6[(G/8<B;C6_IETC'PN#57
M!)&@:H:[ !'T)0S)8 Z"3M<%< NJ>;KUKZ@X\<,)OZ+;)9/BA"++U9HA3F(%
M\:\821^#'^D0W#(DJ'?+LXI,G#) 6KP((N"NR\MV2&[.D;?'Q?3-!"*B&A0,
M* (!.^/I8L1Z9MG:&%L'V;H6RQMQUM1UW]@I(TWX -:.;G"!_!=OGEVRCI=:
M/(\D/3Y'BRAXW<7K12EM#G@]UACX%;R.Q]8A*D+81_#O[N%UB F=-;7]N2RI
M9BDM^@%D0\".K#7+-C'+QQD<7[#\%ED>ML 4(8L,<[XYN!)P?JQ2/!N6<$6#
MJVV5TV8U;5B@P.)X$PH&" $\IAIB,9D#JA/Q_H8#+J(F5193*DW6+K1YYGDZ
M7=0)/T^78C UHR 4TPTY>D/8B8*CXW T6W!TUCDZ%@9%7Q^I B<PR@(=S*G.
M0#[A^<T8>3WM'- ILR'\Q(:\_*X *9H%]D2:V!/U GLB;?+-)_;$)IHZD)AW
MC#T!E#F7KN<=O:N\85*L%#AYL 5B=<T:'OO"G6A;QQ(H$=WC,^)ZWI;-A+X[
MP6]9"C*T"L(-?[22V"FZ.%VU:QH+N),OS& PH%O6]@!2%R&[$!I\2A[ /OBK
MD \>^1 K&W\#&- HR3=%Q7[%!';^X_@53C$1IP$OD9@P3F2E7_$AQ<2X$!,Y
M%Q-ENDI5L9B(U8:'NW2"C0B[.[Z^U;#@FI@YR:P#WV8*CH<</RDX/M<<3X,_
MENM-S/&QVO6 -2!+N#+.:-'S,?XY(^&F6EQ62V^/[[TAQ'KJ?&_MI1'2:? !
MV;Z26G5>P?;[8GNJ46O4MI'A/]<EGBB3\3D_*]E]R.PZ8/U:P>@VHZ>5S"\8
M/0.,GF[:/S&CIV/:;SYHHN!R+Y>GE> ON#P#7)Y**<".M'@ ?V\^A*+@;R]_
M<P5_OQ_^3B&]%Y.[<YG9*P1 @  H\G?O2 "DE[_;D1S82^JND ,!<J!(T.5;
M#I1AN+Z25H+.BFW3>(YX;O)SSKA\V9B!GC9_Y[!2/Q5@^ZRR;/:&SY3)<H.L
M-!,$T:.'SQA(S;C\#) T8<?< ^+M\17I6G%QM(J5@Y<M<.F*Q84.$+V/VC%3
M*_AP;WR8\A H5Q>X-Q*> %UV;7V'%E*P8%(6K!<LN#<6C!6 CL^"=JC:#%,O
M$B Y;69H(J9#"RD8+Q[C-0K&VQOCQ8H,)V \7]QH9T'<@N^2\EVSX+N]\5VL
M@&Q\OL.AVXW8;_W8:6%OKL-^-%FPWR[9KT*2M7J]G%KHQ3/W5S= !<,*G!D$
M0F@/#\+QTTJJ(1FTG%4J,H _[55A!JT4#(I&+18,NC<&33DF\\" !2@EWP@O
M@PM+A"YQ@&L16&!D!!4_P%)H1B:!^)RHY6##>L2"C</($ V,V"O7OG<FK9)D
MI=$@$VC1&T4&RA&G\3K\"R_*<\1),#W8EF<S7F$%1B2NG%#>1%^?S\4%^*$*
ME2E8_XO \LXP*F*=4T;DYU-&(6[ OV8,BV;SHBD@*@^Q,XU2 Q=OHG6DG?E(
MP)N8-:MI H3EK:R@DM^$?*X*"E*K'V@V*A7(\2D$BXSB +?%*G,\5-+'NBI(
MO KX2X;V=&S?-4[@*&(^4%3@R!@91$;[K1^L+HBFCE(:H%&P\$Y8&-!NLUZ%
M)4!T"H[O)> M7Z(%FLOQV-4_P3[.S&H\J[I!ED-G5=O-M@6/ AXM'U'_FQ,B
MSSN31A7N 98K&W8RT'V2B@A[3%S)0,VU.&:F$I>7-]!.Y?@YG,"'K$K(#@CN
M_D8?B0)+M%A6UB4-&L8G@C+[X*1=!NKG?_]?2I,G"^+>B+C+E$7<<"%CL!0D
MQ?&\%8D5YL#HZK[QK(ZF1EZ/P2> L+[1%55G\'0'1[S%'O\ C+];700_HLK,
M(0(/*,$(*L/)<PWQA>O[Z)5EDK8&0##*B &6Y.'UF\@OT-/ ;VB2I O6H0O6
MR0SKT"M9YT20& G%1PK6V3/KT(76R0SKT!MK':I!W!WUC]I'%A-0Y2JYDE.:
M9*W@E-6<4BB9['#*IDHF3YR2Y>Q4P$4U4RDYSA4_Y*!AKD*2S683YJ&;L=#M
M;F3@H^.&5847&>2F T90>%8&U+B M,XKBBSQLJZ*"X)Y910., TKSX#'KV)^
MC!<Z:\; JL-M>RNBW:&1;F/87.4#IZ<^4R15M+SN;?UG\#X!@P%&Q2ECP*4$
MI-D/;%$!DJP4)+FW];>A'$=+1C-3'!1J4R?Q>0Q$+*-I:$@I^(PH2#SQ^_CV
M$A4ZL."9< (Y^J5=;1 D:/(Z7&@'TUG6'<&2NEEH#2NAJX*4YKFFE++9,D.<
M6(/N82,_-$:.LEE>EB[)YV?X+'3V@+A!ZU/9*<^A@.!G&=R' )[(* 205 P[
MA7E6]0LT,;6IH%J":<H T3:"$];EF6"*-(8%%BK'0),4F9^W_$07L?7:!W;E
MF<;/B!I)?6:^?*X"BU)!?QE]^4Q_*:%U0']Q/@>F,A031\3 9;T2#*SL4N%*
MQKHB">J44&$)&,H$,Q!=F0$R=(Z,:?!7:UWVYM >7-6;4.Y:85%8:2:HJ@E0
MJ<_!L@5-!4OXJ_.J]@'H-Z6 S)8IM\-+LF8 !EL>$L0,F8N,I$*R8A0%WB@B
M7?AW\%0&_Q5I6:B9U8]PG?FXSP&0*_@RK?@3CT0)+ .#7(H$CX(=U?FZ<23$
MZ^H42@9 /G!@/ ?K1#G#70;^=%=2%ZH! 0TL-?BJN:SRJM&TB.-:#41?TL($
MI5(@9!7XC6JNP)EE"::QO%EMZ2UT^[&=D?$P@?N_3\S3D"2I3V:, FJ? ZIV
MY AT]/496.<"7-/HA]M0S<V.@ZSLW"R^)VL'#H6?TUTDG:)*D<48U33'J#8^
MX!C574A2<V.[D8WIA\3\RH"VE$'_[+37&MS==OOYW=_.1;_Q0P'5(!K39=/<
MD)DC/# <->AX"8IIQH^]SALPL$J># =P2U6"@_B<+*.K/.<R'<%3@=4'(0;Q
M#![HVXUX8!&.H?4''X0Z_/ '2@<(@5"7P+?0 QE=F\H*6"U7@JYN'^RY(_ 3
MN83+D>'ZVN"X@ 21!*;D2)?@QH#J3K3;;H@LES.6MYKWW6U$'!P%_.G_?:+7
M..7MZXUNK_^GW^ZBY1Z?7??;9]U>N]LO$6>]MMO4SI3G;1%@%=)?CO(=YK)S
MN>K*7I:=):K+T9UM>:G'BV]1Z_1X12.O5Y29??PK_/BJ?L6I:>6(N%Q($G$A
M*,]S1E,$]OG?KT)F16!!C%9L KJ9N5@IH#&T-C^=%326[9L;")J8$R*[47A5
M@'X?SM2UIP(_#JB?AD'V#O#96$U6=A/\#O%41T Y3!09>'30AY"5;\3K5-#X
M]^5_P]*"G6PUH6?NZC0!OZ::Y4K)Y8M#/QUECPUWW'# Q\#)DU]A=>0<..(P
MJP)<;?@+EH&>)GHXV#Y*$7$'._:QW>=>.-EKZ(H SW4[5MU6HHG0)/#ZKUG(
M\Z[6>#DZ9*03=Q@EV""8DDVKY2.N*DOFK2%AR__DTC4VPS*U5)>?T"/>^/#I
M5%>_C;!7,]45IF6=[YU]LGEMN_;6L[#.;)[>9ZLE$:W&1^)?"K(N5I6_5;U/
M2MV1T;(M0X5Y$3CBISZ;3Q5^D9:)\OZI&QD?:"&^IG'X)5;A-0AR"FV1@<(S
MJJ[PA3&R+V,$TCA:B$WGV5IA-L\-K\ICC-CD#FG; <A6V";%JO*[JO=)J?FV
M35H2IX#O'0./7Y8*TR2VNBMB'WM=%29;7!AHD&ZV%IC-8_LH,CDOIU^LZJ-3
M:KZMAP=!% 5F1K1AD49A/1360S[.WR!;(\.%2#=;"\SFL7T4F9R7TR]6]=$I
M-=_6P[$\(D[E5QBT+RR'9)8#!CF"0^VFC*" ;YJUL\<RHW#OG_"S>3N H-$R
M#*+.UN*R>60?15+GY?2+57UT2LVW30''7!&7_(M0)#.*<$1.SA_2+*[DQ'2;
MK=5E\\P^BC3.R^D7J_KHE)IONZ&O\2\\; +5"LNAL!SR<OZ(:M%"3,K-UOJR
M>6H?12+GY?2+57UT2LVW[7#)\\0MH[/3PG H#(=\G#\@6;0,@VRSM;AL'ME'
MD<5Y.?UB51^=4O-M-;1U<*PJ^)[*CQ1&GQ360V$]Y.3\,>EB \)!OME:9#:/
M+D(V;QG0<">([M'C2JCOQ/4<3C]2OQ&7C*H5(TLV'EG27'-D2=I31?!T$_!Q
MWP6AG^V>$,%FOHYD;@'XZ>M4FXD__C]02P,$%     @ F()J6A?!E9)% @$
MPCP! !    !F;W)M,3 M:U\P,#$N:G!G[+L)5%-IMS9X$ 45(0@""D)45%3
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M95T3O[FEM>WWUV^ZNGMZ^X3O/_2+)2-_?OH\.C8^ 7W]-CLWOP!_7_PK+A5
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MU(C4H!]VFB_L0WZ 'W?BMD[6Z=>R/,?1*ZGH'/D6-E$WIYV(&O0,[L]+%M=
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MDLZ$91DYC;-1'(WBN[(FOES"/ L).%Q1:5O^^+.G"Y&X[HM'^\;=N=-Y;U.
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MT&L5P-=%.NPVM$8!Y-G.(/JX70K@TQP0&>:^0@&L'&AB?&OS42YQ6RM>QBU
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MU'N5'.ZK56C@IO?#\Z/,?6\S'EIZ1::4J(G,/[M5+4XB: 6@ )9.*H#\$4D
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M@G OK?Q63 .L(8M7@RH\Z$D[;VHU"\')G)H,&,A!=^+MJ'*1 9\>"2=,LX?
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MRN]&JMN#8\3NR;X%RPRKC5?;]!/TT@H&RA?*&9C<<FXOR<U8OW9QSJ]!=C)
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MB2SFCN,%)L_/2_,?FID6$@LN9C?6LWO(\VF).W &@Y*%.%[T6^NOKPN[1#]
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M-N!IT98?,9$A<M#A5[D==?..-1UU-G!_Q5?I6J93T][TBZ9JK]U*&\+E@1O
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M37"C>&6:B0PH)\\&?RRW19>6]$O5*)I@'_$*;RKAGG)WC! 4J'>2!])IKV0
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MP:^AQ7M?]I.OTAJQSU74"<V[X)#)7G"G=!'XR;M6!DRL$8#20Z<5)O34JV7
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M ]T<K LOKI!!3)O6$!J$>=";%'*'Q?M)8 X8W97F&8#BC^"+(D$?(!688P/
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M,M+;^!=+OO^"IK'@P#R=C9[.NB0S7A5-4JAA]?(NY@N&+KC*M'JS!V)^#'D
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M(HT\_]12O<Q,3.SXT+UT@XT"@X?8_=M*ME19M9V3LZ[ZA1ZWIZ0H4]R4R9+
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M/!*$S'#!FS V#<(.?=;>% ?E=K4;4!NZNO?*Q2:.CW<\TM3K2?7-6+<QY_K
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M$O=^>%O^U%$[V_,-=;HN]W25S=:I3!)5(P"^8E'C?C#/ Q(#H-J4]OQ#M_
M6%VAS,8(\^VF*NA9<PM&MZ&,A-U!2/VG7B8$O<B3,G+=9XFMBQG]M&0;A@,C
M(0]0JV498<RPI/N!TRSU!IHK%46WA_:.K ;8+6[MU+,]E[DXHS&\$7;HV&)
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MN;J V_*SG3%+./G9KMF=!LIOKQB83^*FAL>L"C>6GKE[Z%FKXF<ZE0E<F,L
M+E6 =6TC[?/-+V"'Q4.T5*(%N8'+CD%O<DECZ$'3H8!I"@,-/9D7FMG?4E2T
M6ROG4_D="CLW4?Z:F]5CRXCU5#M>^FR(\WP(Y_"KG@==N$HH9$376N$IQ+.8
MVM'KIJ:B,:E\C5_?< PJF _ 5#MRM&A, C!5X#Z19APZ%>3NNLG>XHS-\;>O
M$=\]T!O[KV[O\*G0Z.*13_A5F,:]99&,35+8,U89Y//#W% TJ;;B(J^N^U)/
M51GIK]YIRDKLG<@?T[HW+"-V'WWKOQ[9;:SQ/ K@HL2+$V)?NY;=K(S.A*)U
MK44+C#)4<97PD=?F_*JII*@(X._.XS5;?5P5%W=Z6!K]MC6=6Z+8;.^5U0'\
MPMA6=2S5U_7<J'\Y<1-V-89,6.U'.]IA?&+??2?LZ3*CV\%3O8,9=\*%M.P<
M)?U5,OB.OZ$H713^5!QV4MC3$M;[Y?(QH=\?C[O_V'WZ]=E(X_M8HR<^+W?%
M[_QR-LMZYZ.7&KE-Y:[3X!/2_$>W,8;1YJC1R@N<943(SB5^XPXD6@=+*8R+
M+#3J.'%5 U><8W]7J#=^F4N<5 BT5TB(9N\,.YD]Z:-JQZ0Y[-(#"=S&,-8$
M:+=PX=S7M@;&:RBJ19?R2YC%94$_3)ROFJ,_9.ZWW[/PW0 1HV37,"'I"_.$
MS&5$6]DP,?;63)8<.(E<*S2Z@Q<B-]ON\=S>K?\8.ON[Q"PO%A'Y]T_&YU(0
MMX^\O]0T/I>\5(JU672#K;OY-N/#%B ^PY:7[7_@Z5- GC+RM$#D<&Z8).7O
M!D-K;T6:UOE1+FAP0U&7I,*GH[9G7Y%-$?0@EW-)7HG+"+_;K:WC7QJFYUR6
M'E13[*ORA(6F1U[4%2(DK76V&]H-CVQD/_OFFLG;%2NK]<B3F QTC6<V'P/)
M%:L_%(,NYZ"H$6(*48<>4.)I>L.WQ5^]MU^]#?IXO!M&5Q >?Y7>RX@<&(U.
MGNE@ 1#[""]72EA&)*?.+8KG)_)<0^[>-*MOOCH5T!R0H%,=;)W1\H/-66YV
M#N[;8&5=9-$1HQ^[A<<B*T\_^,OOK,K4-"Z7].A!P1*Y)7A:].O@ID)A#G#O
MOHZ=#BK(UZ8P3/B"GM)F[&^<G>I\?]?)4PO=.68;26_W99[YM7CG[[.;_?NR
M59BUE8$_3RJYNI5F3L.WRL:^U+TL71M=L<2P<%8=?-;[R.6 [979B@3R$8Y7
M74-$:6]17^T;V^Z+?!XIR@ZW@^XB> &&E;!%Z%6A(=#ZSU("V%?%S9@QSV2O
ME@\WWAHX!SU?RQTFZH6&O-'I&@PB:X=CIXW2#=PL5P!,(?I=CS(VF2=//$4K
M:T7I2!LM%.Z&S8&>K>81YL'J=U!2PN*>\=!=A $;T5SYCGN4,HL?/RU,:S(H
MF##5_B"S%:\#;PI3O.$U6=AS3=NCJ9!U1_9EAAG$433!1.3T](1&3&<J,,GJ
M[>-H$[XKU##?FF^=P=])<Y/D#W5DX#04PHW+0NN<[[>#+2@QRA#K%H"VQ!.8
M!#L7E42J#;O#^J*K+GR)FA/.].,SF#IA_5@GQ2>^)<T@A-EZ;7Z>@>RR!)DL
MCC\84OWS%TFY1F(<#SDT/%ZW$"4;LH)EP::G GA5+>^Q%)V;/PVJJ,U=R@1R
MLX<R3_@W-D118.=[&B2DCH#74C2BV/=$EYVEH(\+^Y]?/9.'VOC\Z?-<MX*"
MJNN.D(&I_Y>U3I^98N1 K)*9C<.<&X^S+P86?: +Q=#'.2+(3KT\R>6QM<;X
M9MVX572/+NS9:IK)=+,:"637%:@^S6ZT<ZKR;2ZT!B4Y/#N;YGK7QD)3C?\+
ML]?MZ(4ICV'+D>D!N0HC^IO'377E:$1?Z:-\_YS2KB#QL#%4! B%Z!5VDX*(
M9<0*.I.9LA<:EK;PS7F06#&=@]L"X/**:$D2U'HH'?07<?0FHT=CY.O'\N+\
MRAX?X"(8O6-H4]RF40U;<>)F:[4.HWKYQA"S96$^:Q9C08L_E212HU%F@+AJ
M]L/+)^>(M!C>H3[54Y8/WY_EM4CYH]ZY.V!0:/=N V<?% .J6E'VX(F;FAC:
MI.[ F^",1OE.73'NU.90:W"S1OB@[D8[_C8Y'?0=^)"&%!7N> %=569.FHV,
M+82QT[OMMLU>YKEO<IH%G6K-K#[J*J@#UW2]YYC0+,!J;0B]/Q+/E6V'OR-N
MPB3CK.%3T!O[^YALK'$IM&J\3"+?Z)/S2HG1UTC#3W.N=WO_ 5UH,4/+#,Q-
M.J>O%/4V'N9^B!1HX\G$C&$#J7H3[ O=!,I>HY"]#'W8$XJJ&%]&K*V"#U1#
M>4K/-)@T,BA8$\%W;NK!$A5+NCB#T4)C\F*'J61$OAZJ:&TH+%;J/R)-@^L'
M#W;':!,-$ D.970BY%/Y]6GR(_I)*/;)IP;<LQC%)-&_IY&LJ)AT.":=J/JS
ML:ESUN+@H&]NM^1<34UB?$75OK%SW._K4P/^2MF6_2Z@2[V;OA<TFG/FHR'V
MB-U/X[X %[8.I/#97V^H1D:-X=8N!N=:MSKO&8AT\(I5$.N$=AQXN_/XCG_8
M*V_+)R^=N8A>Q7GW1>F9!5\%5*U\-V#^-7+M (QK@K0>>H\06)_)^=,I6!\%
M-;&!E<6+P'I>1[T<0>J*R\:=_4,M:YYK )(]T7Y"^-HUCAR/VT(VC/1;1ISO
M:5ABSW)U2 N7ZHO/T0S<IO7H,4O/&8YC732R]TM6L'0&R48A(44QS=.CI[WZ
MYBJIVKJ&B()<.P)J&VZ[H6T.TAS'EP@39F>B;B1(B^&C4*QR)^SAPH+C1YJN
M8=9Y4*XJ7T8SC3[%_<K85-_8(ZBS_0AJ#Q!/--BZ!'K"/G8EO=G/"67,LD,=
ME$59!S%3OD[>XLS $S+0>H.O\Y,#L\7L;/]6OAEU76AS<=7@6$\@[5:,0W&P
MN*0JY4OD/F'\M@"[NP,O]VI?SV!<A AS&*@$=!EALV:FC0+H6,@CCO/L8PL[
M4:;'4KR#B>%/H(+3W;QEQ#=T0I^_ROCG.)?$6>8J6=#8L#&GV9#F*Y1Q,F83
M=O2T,C?,/H8))F7EDF+/:=2:I3M.&C"C.X*E @4708M3'5IZV$@$)1(<FJTL
M$T_GW!Z[,T:LN;N,:$;KC9VDJ51Z>=0G9!2F3I I7$CYHVX8!=BGET7$A?SJ
M5Y>?EQ:]>)]*1"SN8EC3G2GA&@&+WM"H1S^L:M\^/JS5J97I:%A%:_,P83-D
M'2F.SYAST_HDFPM&]66GNK<TUIC<:GKSR\$LU<H@:!P(%ZI1T!UE%4')ONE_
M '*C7K\*GOC<)FKPXUK?8 A7B[X$TAY*O%XV]3I6G>WOITTZDC,/]W&G?">N
M.;NX7/D')P6[;G$CW0]B5L!.FHQXE6\PJO\I?QF1PFT,5XZ[QXI=TJ\KJ*OI
M8:!4%&+87$,WE=*U*^AX,*:OC$4/L&>-<-/R0P5 IH2S?C;D&+G=\C3HG*=H
M=_#NNT)W7M(DZ7.!4"=\ '2Y<><<R)K@* 4#TC.]L,N3\87"@B>TXG/]LSY'
MY,K5>8D7 -8-K#XP+_1_4RD?1J>&KNVD5,(.4=OG6*)"AQ?\%]+>E1-?^W<Z
MF6NQO@_(ZGT]V"C%#*#%BB;J0!E?E/;%%:-QX3=W=&$#?I N^!53E4'C[RX;
M#&W0)L\UD1TN,%I:O[<_JSI1Y@=5 8(#P"0[<U:0COJF"[8N'STY+@M/GR5N
MA&)/ %/%1>\)I8'-E>_&8_.S7,.&[[J_Y14'>3QNCK'ZM=ZL[M[ZXQ<%O "&
MWM.E.WRGP_$/(?4".LF_T!DHR\*'<RU(A8@F$)/IA$= +%_(#2!+T&MY[C9^
M8+)<KRHF 6E(:T6B:):B7$WTPX>O%M'*A VV4E>=]L@\CY?0^44K*$G(V N8
M9L+?<W2Y(]U%2U6\26J+:\C]X2*%?!U4,?<S^%'(,1Z5N=PP].^T.SWM 7RX
MJQ"8D,RFT^TGZ'O+:8E?1 VY15JIM8,8_;%\]QM:W?+-C#WGZ$:0CY*0X:-H
MBI5TE-C?#%-TK*$YU;ZA>ZDZC* V42 ^&:NO0.MZ/2&2%O!SW$RLKU+7\%"/
MO9/%D;;C&0E'W#+;!N./_G7?CB3?C#,DTDP5':)X+AHB"-4&4$T9%'X28I;3
M*D1FA-0[HG;ETF[=\ ,]T;Q^JFW[!U[">=<W*#;EP]CJV^?$+R-^Q?S^<8X
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M)IL5WJ7)&&64\,<#[NUW_W!PJIHMX?VY6N2_Y_#NYSNUO \;IRC9!I^&=30
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M5/!#($^.2TZMG=Q>;>NB7>''0B02]PWH0Q?<HH?+)12/@+/84=UA;W5O _S
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M@BY*%2WUJF ;/V ]SUH++]YE]GK\ JD-]6KFS>= 1E334H#5O=6_F[."24)
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M0<'Z%ZI48L]WAUH_:2C[2%$N?QI>W.-SZ1(NJ(J+@O5$H7:+2QK+H9/>J!2
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M\VYDD3?:%'@WX,W:+F5.GCG([E$3 H@UUV,WE^:L*@4D&NAZ//C9>D/S/IN
M@"!?G/9C5FP:XSU#QM&_!>QYMDNG[GB>T\3Y5QO:'[2G=\UH*UQK=NKX?,YS
M;Z^_:_O%O'2?RLHB&U7L1G3IJ8JLP2)4<()S?G+:CE?78%]\7>GIG[1D@GT.
M6"?;_^&[QY+_Y:DG%Z_=>'K5<-L%K<U+UW^\1/IB5P*=S^ZI02>;!A!.KH\+
M@<1,HJ00Z*\B7%U\]VOM^/I"N'>DP)C4[H@6)WT;:Q:Q*+8C."L$,H?Y,:Q(
MQ/M[B",_-PO21=]49W>M;_Z!XJ-%: ,Q18'O44E"P,:2)@1DW7&SNJOP?R-=
M%(UM6>Q1(6!8LHC^I"_8S 9+> M0%IFJSF;&"P["7K=8:,0WHD[V2I?'8IQ^
M]<CSD66+GOW[EOJ?,WMUZJN";*Q:WTK'[SEEY_[= %9J64+^63%!AG6B<BFW
MU^SX9^N&PB;,SMSE;V)';Q\J-41Q[+1UA@1_I"ULNJ^6IOYPST5@YUVL)@<1
M2Y6G?];,G3KDBDW+?W3Q-SCR46!&Z#VBWA-]E]^ZP>\W\MS-SRD6)+YZD%'*
M>!"1;-UXA^_,W;:6<N-"_H&NBS.LZS6S@^TN!0]9UY;UU2Y>'^;D>]QK>J'Q
M\FAZB,4+SE(ZNF[7:+4;D(IUG(U)/?J!3#PV-3N;:Q7P+YG4$M,RN<G_LGYK
ML]*[\2?X4'OQ/S>QW $TL+?K7[,0^^Y^Q%K6M."J@#(SZH?[,/HOB7SZ7S.C
ME P?YB.$P%&_.#3X= #]<\M_F"B^\E\D)_\I4_^8Y/]LDY2/3WAZ=?I6OXV>
MT>F0S?QA;WQI:,-?WJ:^LF(2Y3?$U+<E?Q754'$0O;XI5TE4!B.."X$OYI\'
MJ\M$W, TVSGG4@'CL89/<)'[^)CGXPN[;YTT[>]0O]^FXS=>'UV\,TX-:)@K
M+EUHE3_W>"+QG.TIQX.*+8#L [QX>DM%-S,%68=J1TOQQ>!+$,H)3+AK[.7&
M+2_@SMNT"/2AWGLYK4@YOBYK_F [VA_VN<0A;W7*Q_<LHY*P"@2IB((9#VS\
M_-*$F3/E3$)'8M9($'LV*,IS28 _PU$O^]*;97G&1F\P?FSO =/!F)CXWW__
MW:KDA\QY>/N:0R#E#>4.<1NLC=U22 .[V[0-X>U<3 Q38>DTZFZST3>&5'*8
MG&J;-WJ0>C1+Q4S#%NZC*@9P:#+./27^;@RIM)I%.3C=,:7=E#<:N57*C8,:
M#^W40"3S#[)Z0EO10+,J/N8T',JB;9NMQ6J2 BT0,C9:S%1J %<(;)K.CHBN
MP8D3?H,SGL-==IF#+:_A!X/MH]D)<0/!9IW:ZF^&JLLT/:(P)P<%Q? B%(^-
M\18?)!PI@F^@U6!:1ZXQJ$_'B.'MURY56\B1NDCR!/LB..A(S1#?83VK1 M!
MKU5@.I7A$[R\5,^^?0T*,HHGSG];S7U6V^ [^E<F^HW;_$8V(G9R)ZS/6D3R
MI1M ^PZ$%.$H2+GG,TQ4"5S5X!N0.>14ZQUP/K8*1K_P9_R]%+E"KY +H"G@
M+-$L1%RSZ;!AL*45(F'.&R4*BRN!H]G*E.?X1A:I$Z4!D\[#0;[%L&>;8!NL
MRB&-T3N8;^KNA><XN;D.4VTXR%A7<^L:3A NY?YTL^&/99P<GGRJ,JLU2Y7A
ME!5KDA-UT&T4E^XXLFMPJ7O]@K@>DB$$.%?RN+NM-TYC-UKN0LWOD4HEX-CK
MM]M4A8#*<A Z+M(OEB_/PB0(@:WEUML]",XQ;"M1 Z\Q-' ?:-Y',.\/*]-J
M5CL_ \$4CZ&Y&NGYL G)*(^%FH3Y,BXBT=POVE"PB:]8"9'2EI&QDV9P)81J
MG32!TU%W=>";N0!4,$4W]&RYF:LS2-W(/4YPXSKY<# )U' V2>[UZS[JH5"I
M:!,GW+F1I12+'B.#TK](OA7D;&R[-#K R:"3*:.W_AS'QW(G;-J]-8:N4@.M
MM[QCH31A*3:)/DL2#XC,:!J#+D3D:J6P1N]:>EMB0O.51VJF(*,GQG(*]'-5
M#0.L ;0/\QYV4RE!N92@ #]EY5 2;Q!V0LPV9DIV5_M3F?:R/'R6.QP#*9Z'
M:=<AQ[;5B(3P?%&*Y"K#9"XJ,8MA'Q-NT#@>[$,7H!+L&B%B1GB>?4G@86V(
MPV3$G*B$I4 *U^T._R#Z'J[9ZAUXVQFV8LV[G+56%4R,"$SEM+ET4X'NJ.Z@
MY6%+DT)_AG51! >I'+A_VKRCD_+B6^3SZ=60ER^CTMIFW^\3 E<12=FC*5P8
M^8RO"#X1 M7Q%([('Y&(9*KN*_Z%X>K%N 94O$ ;MF$S4WVACJSV;ESL*B4Q
M/-BBO<&O@QG?0(PK,*,;HEU2/$=K+(+=KUZE6H46>[DBJT@=W>1X!K8U&'D.
MK(CG6ZS]%H2L$E7DN2RNDQ]FJ*(&K>3%5P+)"6SH-[C1[P5<:T_M(WA=EZQA
M%37VE_$-7DTS;E:\#$QZ'B17.%WG\=4W:ZX*6CD,<03]#$2J0/FSH*]A-,5Z
M9Z"W$3A9>8E[#CYB%F.M@S=C8Z*-A8#4-T9J 1LZ&^$M5R-*(#DB>NM$P$:"
M8PDZN?1C"KO$Z4I;E)*X72]O'/(C5Y.D*-%8B3*"'U>3$BW8 0]"9FW:!V&R
M_IW>.X;4_9P>-_;\"GW"PN,UJ)]JR'<7E3X1S!/HP#[VKC6_5KO^UM[4/!R.
MD _@168^GEJ+:*E@*"#NY>J.[GM65T4^,D)4Y2O":V"A0,WH:HV6#UNJD[EE
MAIR/3BPM1^$R$8H!W@8@*:6L1BQP))/NT  NKBI%R%T/#?]1^WA-DW\)QA3"
M)U98$1TH22=N2F^T]W;X$(3SAM.?P?>7YF^[0_9I5'O(>8JS&!?&W#)+O$DI
M\R=MI49!NBZ#?,57WA?&9CSLDX.-<RAJTS_\#8IGB"_7+/A;WL*^D'W[ W?W
M6=?<C;#GFA7Q(_)-$;UD_9:*E4T'PZ]U#:$&IY^'\'O=YDT526VM?503N:GT
MJU5!S>J0S1&E6I+OVT?B\__V@WLV44_4C>]R>M?$/XM<73/A)@.9"8XA5$B?
MM*>$@.\S<786/U%;\=?.FCI!SZ^=-;*T+X=!ROK=>1HO<*'X/[5?Y[\SQ!7;
ML=^E1"RA(H"V).K)5A38 ,VGX#IH:U)X?2%PNN2$"*GBY$E_:0L!05.A"#H$
M\7DD5JD0^!Y%4Q%=NQ:+LFY79K""R!<"_*SSY#7]@YAUA_?D3FJ8$'BP-V']
MX2&L(/]KT=1&I=-8AM1W';>%%?Y6I,#9A9.UGDA4%P)#,:<KVC36)T6<3UP(
MO'M/.",$*A%T].J?@28_>U,HWT/P^8+6WRBK->\Q?00#(9!^EX[E*2<+@6%O
M?Q).=!$SVX7 '=*W'67G/$G+6X5 "WI)WK4$WJQ)R/I&PAG^+=#_^?IY\MY.
MI=.VP+\?#G]&;B5I !Y[#EC93]G9%_,[-.,ZGN?4V[N>ALE0_@TA<(NT7V!\
M*WQ^=$$AX%LV[DT K=ZTZ[33)&42N_:-E*IS7XWUF_ZG_K"G.0Z\8.Q"DQ
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M^?O_R2\WB/M)+6^^Y*'C^:BC\EJ)3$=5R]>W&@>=PIWCE?MQ7:-UWTBYF3<
MN4MG4F^=5N'2BNQ/2!#^7SR.JSB\UU\=]0@K'??PH-DM,@[\.L)EC.@NA_0>
M-17K@HL?&SSJO+]_4=EN(<#<N$D.%T +&JHMR)&JW]V%>7BF7OG^4Z6/#C<=
M"@IM/O2)P%>;Q8?V^%8%%^8&&Y-=5JRIF65?8C2#BU3&DD_NKOWL4EOM==-U
M^FK1%_(#VA%_4/<4.%%<&]45?RS%\JAX*2+L^OKMTW^KB0A\>)VH@=?K+ZJ0
M(*YZI>TH^VXZ30R7JWE;M^-YU@$N&?G\DGZD_/:'I*GFM?XR!J*=Q.O?\S4'
M;EL;7_LF&Z3\]^AGK:WX27TI$LB^%]4" 2IZ&5*!)[0T> 3PLL#)LU&K4:&S
M>'J,=B_1ZVE)$%#JHET?\/3R]-4W]<MCQ\ %'2_RQJ\JURUX:KL*YBA"?;_\
M5[?*\Q@?X?[?8V%[[[LC-Z>G!>?NK.D^VX,?MJF8JZ[CBFYC'VO2^9'C?;H,
MG:9-H5TE=98\QFLT;%'2EJ\.+C#1R3>"<KY1BG#H]CS?;X>H^C_&.4 "=I.?
MA_,&]HZL/7]LBPR[H71>44@=6I(*DO63[W<*C6!JS4@HU.".-3PX*3:BMDR\
MM:%$"2-8P42;=J.RO$LH[#+MRN2LCIP$\3XZ7H*H.!XM0;Q\:R<(QQ:UPB7@
MW&X4^.?5!*JP\?;[IJ_V1U@UUO]5U$0DGO0]'7F=L: 1 VRE#$^N^3>Q1/XO
M L>,W7-82_:_*J7_T%M#@!WBQK^)I:O_H;=\1$IKFOY3+Y4<'PH#MHQJBA3/
MU/;/#?K769B3O_UND'2F,+%6]E/*SFVV:E&#-3O4;0G:C3A&7VKH4I<28N32
M";]' 9K7;NJ^U]5Z\#+98_CNHQO/\M?8W,0_^B=_-GG4T5Z4B5$A>O1\7P0V
M#PN]\9J$L3:LD@3!]2$P> J4Y@6YH*BY**D@ S;4Q=FLB>%VGAVU9LO.9$4A
M$^D&<,+9C,.]X5CDQ,G7=OLFC'HZ$V:]'Q;VO%=*UK$\PW]X^L;?,R[]G-CX
MLT>:9?,52&$S^$J@;3Z(@[Q#6\-E)&LD,)&);-EJG";1 !P?LZ4D8=2%=O %
M=/*B"UC[@D_>4#]>-9M!</PGV>$^,R_=0IC<G+\G1/'JLN(X[._>[S>(V#<+
M5#-8I:A-XO=THYYYQI4N%1C-1[;A$AA(\0[B[R VU2:$-Z[JGM(^H3\4YN[%
M-;X?5K;67=TT[V"?1_]2B"JARC5DPZQ4$A@1+?G8"D=>$3X%J)YLI\@%L5'"
M *Z3"7>,J"K*(OJ!72T2Q%:B;3DAJ$TCNQ5 C<R*=4!L.DEOEJX 74Y(J\9O
M)MB+MU#6"8_U?"=BBP/I&R&R4-]S(NW-,#Y01ZNFOHH6Z]^&K2"G7!<J@Z7-
MI(WP2@1WBJXM/#^(O:H=X@UAF5@D@>D!L=N-(G@&B?3=,[X[&4YH#_!TRK.I
M"(P1%)'X#9"?LK*KJ;ZM:FYNGEU;>OY2_00T.7>#;@T!J=1RTMZ@J! F)=5S
MA8E6%D;#%P*X(<CW_A"J%2\?;&-9,DS/Y'G@EEGW%O$: 20D6!X+*3K<-6O(
M\V<*]KEB4 /$/=&1+V<BSFNS6,@D0*FZ*XFQGBXGU,YN$J!3Q'NFL4K"RR_A
M/AXZWDR"T("#F)C-,"Z(,^9S5HVXA\M0%V+ZPX.C?2&#5D!V>AEID!(V:V1]
MRBGTCRSMH[R)WO:0'*'AZKE_=@(URH2Z7/+]470+91WQ> ])0?@[' LEXQ,Q
M&E!"*FV7^!"(:L,I$K=6@JIWGW7;A'/2G$_WTESX"])%O:T&"3N&-XQ?GV5.
MJ/71,+AXLW'[<PTJ.JR7XD\,52%>]JY-. ^9)D$,HW3$&C"3[RV6@\83[M&,
M>$XJ+"Z^+62+@Q%&'<YF'CL%QF4G#CF )#)'.=>[TFI] 1'/U=1V^/;3N](+
M7J*3<,.WV4P-]!TCN@+Q N0OC0,E IX;D4)'$AK:,PBA+1,'!TAZ!&?6A"Y>
MBU#B.SAOYNBEC3T%)]O$W*3"?<Q\O=[GY",]9H :X?7$;'/]IX<QEXNGG^D<
M*!1_QJK1@L%9;U$1<0>7@0A _8;1=ES%LOCX-7#L8<B\#,*UU@)*-"1(Y<FV
M.GDQ,6854'X2E[R)G&"EVC:^RU;S5#]1CE?%5[!O&5UJ'"SAO@VWQ7QCS5+2
M*%OIAL-")]@.=.-\%J_M%KI NDQIXX7AI80A'C:.=HP/;"9$M #RBLT:X9UI
MC+A_#G<EY,27E!,26AG;;(P"@FZB4ZY=6VS<.>3=^&C(N<'1^J1-@EA-LT5P
M$6A!<M&)^3O H3E1^6>B*AV.!=VO>FXNIAO18.0S&,WTW1+/8IFP-M=Q.W5;
M<]#,D#4!P+9K*GVN-,@L(>%+RG%IM&$J2GU\PJ,6YB HNUUGMQ03R3'0WP1G
MGO\]TDZB)W8][<AE#F4C7'(*7&AB)^5$W*^>9<3[&G9?ZJ7MSM]YN9^&*H(;
MG 9RSSB%G!R86PQR<O.!7"F7@:!7=PBL>"!P813%=R+'5Z/O>R);J.N%1\"5
M)K*2\ S<B&K%;H89[3H:[Z#)>+H>S.+,,Y@A,D +ED]>.Z-Q.KL,7N#B6QMB
M^<'70[9X3^MHU_YSD#AQIJX^;L;S4@"J=J&-K0G+.(N*;;2Y"VL"*%4KL3;'
M5K%3)'T0F6ACRPMVY+&3KF&,"(X<"2*%&,SSD66I8$Q[I2OE,1P= )4XI#AV
M4\4H^!7-"WM/>$Q),)F@ZMUG;$KQHBRK5H'?$CAIUIRN=J0J<=]@-3)6T-74
MI0Z7";%<0#T(NY6FRG.Z!:C,TK</.+M45U;TDG;5I87CE @,>\@U-UATMVA6
MQP0ZBN.4X9SJ^^9,V\G#)DRK(,HZ&,=3><>EC/ ]AC *\(MV"4*F !3'O;3G
M:8=R?.,X6"1L;F3"RMZ8LY) M"T;)NZ%@Y&M"JBYG)K)I)W@>'^4;Q7W!4\[
MT/$!,@H^PA^/\(4FYV7!A59!813]%5C'NT+128O0SLS+0*Z!5YMU-*"AN&O&
M<8_-P:[PYSZ! @DB/NO;B77C@Y3GTT/9*ZI#*Q86&<15J3@Y6/<(-V+?YE:'
MJLE<F?/C-AKZ=!L+_2&R8]^2MKU+-M,-%_$">V_Q[VKK>6SK0S;AA<= V-7S
M(0K>0/"G8*>TZA"%KTVH(\3M<&0Y',H"JJ7(I^31=J&4Z [G7@@O=&<"(:1:
MN@R(O$>TX" W=%B/[4[7++OEI.@%7:LM/EF^[SFD7TN)^.KCT;7)UWJ5.,U0
MT(7M..1$O*+8?(I2M?P$=.2S6E"IGLA6]+81CYG1C3"Y)7^G>1*WT?$8S2W8
M3[PM3=YCJ#H88Z@<?.SD0'F8%*[&]$J.7;V$$#Z0(.Y=@Z-=AG2P"=@*BE I
MEYM*5X*!-U,8 _@)2,&)[A/W@!DLS-YNW4&C^? 8?*L)S#[238RF=E'U+'Q1
M#7"LY2!ZGYG<V0FGX]9_!G.HTZ:;Z1+$@T76T@IU,F49(RH$+AL9+G=7U?5C
M@Q?DA"$#Q A@U?XJI<HM3BC'4059L1A4 *,:-2]7(/0>%&[E,]1F5%<P>R%6
M6X@Z(?9,;P'XCH*K XLI!81CK<Y>QMDQ,;J!E.XEA/*_G9(.JO^W!$B'9?_M
MC#27]%\R(/VQ!O\ 7TMNHJ1L$_=YRLYK2KW1<J@H'[CF8_ ';.0'DB:Y$2R4
M.AS1(J RK<LLVO(-H'/Y%J ,84AJ+K5O%L/,U=-]QZ#DBH16?(#T[H33?WHV
MF_FA9N<!$XH*78G4H4&=M^0OQ/INEPZU&?$*7,<%8C$;^HQHJF7PYFCE0729
MS64HA&^1O,16]#(N@7ZV"&2$IE!(<K@MX ->:\'!IS97A//>FHVK'N_A@'.G
MU@B6)(BUB[ B;^$.=DVXK4R[ & N; RB6\!E$(I'H\B3MLU$:+"DO!!K/H$=
MU.V?)ZD1#,Z\K:U05?&TLA>5E=GFI95G$7VHA-1I[+4^A>*BZ!6G?WZOLI8/
M!P2!3(Y]8EBCX;)[K8AL8U(N](%82404>"OX]H(W= ZCDJ^ M.\EGH'6%$/H
ME+GJ+@WX;IB''J/75%K@1'6?4772><.;MH,+C*@_UM@I_3^^?MMVV*!;D>6<
M?A/^@00<?CDNIXN>4>F; SR]<U0R+Y0%>98W!!45%1>%FQ45JE2.!+J%CM.R
M*KQ/SRL.MZV]N7/=KLF/ 0=T!@4U]:CG8I=?AJLW'"0(,!L^K26D!&8VZ7$.
M-EM-RM@FR:2OMYV=?FLB$_L1IFYO\ILZIGBO[=N!%TG,_LP3+378U]^48YX6
M.11I)!L3HIQ^N)3L>M'1I6P )$!HTX\'?=?P/@[M;3O7],U=J\#E+\*',T5[
MWP9VH1[_L5R=&64V5?^P*+G\Q?Q5EWNAW[X\?J%Y&KA.3A+RFWT59KL#!6R^
M!+%_[F*&6/,%#Q#)839+-2R]3H+X(( [#C4WV]JKV7R9)/MNOLEZU_0B8M7H
ME]MB%.>T0H 94]VW8_Z;8R%>M)FX\!.;]I47DOCYT^>;E-&%^4LB?5/&M]RY
MA\LA0@O[5@E"L(VH+9WQF!"I65\<$C60=HVQ]BUP -EZIE)EI8*_I^OE-/7A
M/5:D\;9S<5VW+&7TB $-HBSAZ[+ISCQ.,VHJVP9U3#[]Z5+7-"NJ-QL!>L_T
MWG_KM^]KGN?^S-=7 GY\JE%SZ/0WHMZ^-6!8<J7& ;XHC8%=69J*KEHW*7MZ
MF1<#CS#F(O6M"-><W"U4F4FF)0X*Q;T!IJ-.52N3W*ZT>6$X-TVWU7RF0N%X
MRZ?O[EMI;?>\$G4?G5"&LG\47B%';O0VGG]-T$G [Q2S*M^C6_+6Y3U)K+53
MMSQT4@]Q*UKG3[VP=DO6D(LP-_E^  \ZQRG;2'CC=,BP[JISV\4+Z\K&OM[?
MH5D[]K4AN):]\NVWPMGS-\Q>=^0475O_6\W)J^]>NS:=#SJ7<5+OZ>O!5X9Z
M!>_*E H>V2F=<=>^\"\1N=X@D?$%"4@0OGW E)DX&@NZQDH0ZF-0B P6,@9Q
M/("K62UDO*<N[H)4A7<7)(C9T1#1>D:7GWAC[\W5VT3O2:D W!8YS8HO6Q]S
MPT3J_&W\5Y O5H39A)1Y<?F5[#K1_:_8//$J*HTP#2P9(H/Q F96@ 1QZQ?U
M="-&@C#Y"5BV([\=FLYOO;W"JHN:(FIS%I2%=I 9.9:F6-CQ9G;T7L,;AU.N
MGC$%RHHS48V0*]FI=_X6IB=ROUZ5GDH/+L)4Y<<25HZTA=#']T\<8TYLJ?4*
MDC=/$]KQ&H^JIR=P&SQDE"W._EXX/N.V1],X]\581GC$#K?,LFN]O!^HMYA=
MP@NP[>IZV(BD3;3JNP!1VRE;/+WPYMFA5IW1H>%[E1+:L-O,Y -^%V"2- H?
M726I5?PHOS[4D=PR\:F7-^F+Z[:Y"/%LM/^\(+0%5PW)6H3&O+XS'8="D.B@
M;'!)XR\G?QH^N>B,<]/Y&_TSQU1Q:]RVQK?RIMN5#Y@TG=_;5_JGE**NC(Q[
M8XS3[1]=T+G9^G:X+J'C5<T247E7!D$XRCA8<K_E3&JFFT9FP.G";8_S]CH7
M0U9O&&L9YY$(I KAPSSM,A346EOE.;T\>C61D-VFJG_18Q&_P6/\(#J!IG[Y
MT/%!FR-1*7IW4[-[?;WS3(ZEHX==T5KBX8D],!52Y"OT'VPKF-%1_PMDQ+U9
M^P".;O&TF[/J_!!0[U3]).!*J%;(JR#5:X*LTAM)9A_OJ<V7E4D0N@N4=M0V
MH=LKX@GX>=DX@=+NV;&GOO_ZP([TB4\&D4:F9<;M2HY.AL?_^EGLJ&#\87=9
ML/"]]IGBG,C+_QPUO'>\6<E*M7W1;E35"SS>;8V<FR?>B9R4883.-_V2(!2$
M&TN9C#$=74):[CE^B'+5G$EISLU=!RS_^'#!;:0H _RD<>/^05J5PND0N8U_
M1AWRK)ER7C[WBG/#B0ME)[R?!C^J^'NI5:4;L_QN"2+CHTVE]&65.2GW=41[
MSVX13O:T>='>[C@-^$_[[&QD0F!<2'>,[G($N.O/E[J]S_:]_=*.M)7[;%]W
MYMZM0Y-F4[=1"L0#YY6.%'N^\M[2C/CB]_1N?HS)'83V(<P]6:WT=Z+3T8)T
MFO\/[H#@U(VW!.OV-$S(MYNI)0#TWB$&2_EN/>,'9>9F>MMYO)_Y7/QE:8@7
MW%$N;%?20?49W?SJ>?C.TPM^OI.V-[#9=3)*L[/NVT8VMK]0=;6_@Y @R'^O
M^O4#\59Y66+42L+2F_EC8ML,,?T:8['2:C#@UKEZW(I:WI!9]L"!>N/K06C]
MZY,F3R>MO'\^9HS^A5<J0O_Z\ROP\0OIAU [3?;NXGZE-<N&U\C>J5KY#/'S
M:=_*Q"+[@?J(7V2\+Z6K?^BQ4$>J,'2/2A!40\^E1#%'4">^'P3?IC0[A2V?
MJYX6[HTQQ_;5CPZ5YY>.N?;,,,CX8O:=UW>C_*=SPI5<X_\56F11?,HOE26\
MX&>N!'$X4(*PQ,&[L<)\UKRN!.$GQ I2"+<8/506]H?1#&-ITD)\9T!\BP+^
M ?RR)8_:BUDPL*0"?B6)%B,DB$<-EA)$92!57'[P)[@@;>.7K/<2Q%Q!@OCU
M31;KW!D[X +J@\S)[2OMP*E0EN]F6]&A3L"= E[/DFWI2A9)84F>X2&3S^12
M6^:V'3QH+4$LE?ZRLCUN&P,W"6T)*-_(-L !"YX@*\,4KNK<@D4243GZ8AW=
M!([ES8>>2_#J8Y^IB?_^=\#$YKA]+VH;^[ZEJ_31]/UL[@5<N5+_]NWY#K5T
M,^%0V],$[5:B>E+'P<FX]%V1^6>2OK6[$0(WYJLJ)N9Y#9P[@,P?./\<=>E7
MWI#IV895S!K>YY)[,$7^Z>1^5G^+H]R3KU"\5ZS[YU,5:C1]R[,U<A=!QY&7
MW%*'(OO$Y'L.W;F/'%<5CMY.59J)RA#Q%]AEU@8#6!-\VK'E%OC'>LP8!R_4
M7\)/\QY(G5Q\"_Q3@L#2I3JG!>\B07PK9F1A>5MO^HO67D+!$10)P@HWP>!=
M(*B*[Q :)(BMHUC15DIE4_XMYQ(U6Y'HE04"8:"WHK8T#2]J=UW($4IG,)X)
M_[":@%4E"+D8M]E/1.>_EZE'8>=5;^&9 ?$...0(E)JO3&$*F('F0T9%4W6"
MF$63MI+/WAXVSI^#LKN5@@K3]_@%G?7<%?S(<!W+V+IEPJ #//2YI8;XZ-Q^
MM5.GS6E7OY47^1^3.^XR&[WW;$? WDSEW:?/E,P'_'S[X^>N@=5;#&T"VKSS
MX,<29!POROWIT(&FKP3//]\D*]WH:;NBED.PL:@KV[2R=:]ID6_9H4_4OUX_
M*^K<?:AX:*9&^73[Y/QMZ/0&0[VKL^D4\]!TG/:&^=B[;H8_B]^,1A?W+3E1
MNT69IKU!5S)\TW8QUM]+WOWLPO]*S.&-2(/YUJ(LC!J,:L9O 8*"C[6,VM^E
MZ4*X%@'[7@U99;J^MO1"(=&ELJ_FEXWARY'1J\N>]UDNM7T21-WH)\<4#R/=
M]7[;M_W:12^BIF.OH[?!)2V,]8LB7 NJFMV,'[%V ;2G7,F0-;\K@6C) ];Y
MCG06SW99W ^N7E *FM#N\QM:"M@9+T'@&APGZY/'[/MUDT=/?,LZ<0<3W@-P
M"E"@5!IJ"'U 5%(8+@VO8!:2TCXXRPVYL^1.-.&?" ^KAI-X* 7'<&Z9[1<I
M7![8Q>!IRS,/GC1K*=5;-O]Z_7Q2"5M0@-5IA);FA\,F\ZV7L(E A<7\&@C?
MQJXUDK914SPB0521YV,X*R)*.#NI-@);M= 2LGY:14<;.OZ$O[")$%YFX\&C
M*,!D;[)=?5V?V:'K0MN2HD\%8GV-]+=#RW1MC$KO)(2=__J_Q=VDXL$_\+%
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M#GJ+!!%02RDG;R84#P[*1!8'N@I"9HU(.-('E!K&G+7J!<=R6/,[0E=W$L_
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MO.LV'M"+=F"-\ "DV8RMMF_#J9 W3N7;]M$<BX2*HJ=T-3B4STHG1C\GL-W
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M\_/$-WUF;R!_"8&-7&$HOTN!(,\49"<*<:7N4Z.G,X.-QN>71!]=ET$[M>8
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MHAX)C_0-W"!:\K^7B"_A%%?TEOO(91>)_ZLOE'",RB()HO@597H^A#\DO3[
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M%V23_9F0IFC]E#-[CO%\)A$;B!^\TRI$B==M#F2NXTNS,&OXVZ%VKEGM?L)
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M=\[G/E+%RL%G,QC5PS-\Q."['Y%E2U92N-U&F7RI'MC!L\D"S7?'R]!(YF%
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MHC%UDJ=)*ET\L!"WCW..*4]I!C$RWTHX>^_.8-P4*24>Y40K=]=B._'YQ/3
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MI5JMS)#OI7<M=ODX41M=FSE/=Y<XI.P[]?1"KKF5B9UR=#+7WG5!NGA#]?F
ME@O5=S44K;Z3* %+^ 38)!#[T=1+_JKQ-:G]NF=O&E7T$@])5G"^_%S^Y&:C
MCNJUIDK4KLS6J #,, U=I^*?O;%G2]G3\L0=*3)R&U]XZ5IWRZA<VYN*&AM8
M,S>L"N1ELH?\IQ[K^,;*!"^B1$7S3!141)CY*G/CKT2>\FN_\P6VEH^R@V8M
M4<!,7,V^UT\_RDN< 1I.CN::]MTK\M7_4'A OR3UK;Z#5IZ>HG?SBS[:KJVB
M2@8[V4#O6->.6',)MZC<M"]59Z+:_8UU731-H>K.SX5)+0.!>YLXQ9>&0S7/
M*)0?3M$R.+GQE%:L@BI6@E17QTAQJ6W]>%Y@V7;Q;N@WXPZOWY5=3<RI_*:3
M8ZS)'SLY_C)-VD)O^*S@[C^\Z>:GGX:=/T%4K[BSU,Y,7UL5'X6JE.T_5%[:
ME5K4?.T4RG>>-EBW@_P>_8H)'0]B\E\/=#)^7XX/)2G#@A2$*W_R@W,YG7.=
M""^]<07!@%./\Q'F$Q[P5QXFV;=A*IJ_/U$7CYY FQ,!C&%9)81"[3'\W+7_
M?^H[:N[TS\3#<%O=YP>0/.;L'2QX/&@1HW>.8&OS+>(*G24-;WPRF 9_(LLI
MNT:W#$-C\*;OIWJ>G-?3D;6AZ!@IC%27/;^=X"4O?C[*<XN<RL"2(I0$[T=^
M?7[*&+Z.&T$$Q%H_1']/094(AYE9@XR\80"N*A*#4/[J)O+'?5GD<=?C)$-N
M/O_&"?+_4G6.:]$9.8F?3PQ?U'@6M>-*JOQ=K\+8'3>DW%)WI 6V;[-2?RAW
M)N7#6M.2O[IZ=@[>_(EO(T3%J!_X^)"@0O]0 G@V+2T]XWY]K2;SL\3%&[2\
M:4IO_P3'IRL%_:HI1(C::UT[CKSM29CIQ+7?K_^WU=LTP=4_Z;[7*/@+=O3@
M]O\DPO^U;W'5#*NAFT2S(OQ[OGCE9,AIJDS0%^JM.0R04&".2,MY1J<H;REH
M0%#*\,_K/54>#4&SZB&RM[Y[#>8(40WZ[,GUFMG#_0%N9QL\[ BILZ]TWRL(
M43GT_W(94; PBFA2C2O(F)[N<Q1XG1EAKSB+-AU$0GZT0@N.<ZFI!0\3X4;L
MK76(<4:1)],%2N1Z1)U^Z?M;LJUQ*G9^5W_08OM_NGZ8U(2;_:%$B,+M1!3H
MAVS7 / ,D[<[$RY^ULKL1=3GI?W]?Z\P=S,0[95N'A8/UA+33@*?_/CE8(%7
M9X#_XL_;OY_7*<'O./#TMJ+1T&NE_05#+DDE1G^U+%WMCV7IZ,9,G!0BVR8K
M1DEK6V_2OAL$L;+WO;:44J>+B.9IATSAI+&CHBP\7\MP!CX=%/;;*G9&ZE?0
M[A_+6@]O"5$4-("HQT-1?VFJDTP<RXE'$+&'B6( !0.,Q1M/[AQ*\[S96\$(
MSAW$A4_+Z6Q;FCE:;L1V:S^;_=VQYXRTW'?C%ITW.X]KJ\MM#?6_OU[W]$WM
MH(23CGM.L#(.Y=1;GDY0WK-#5#,"5:7RO=40T@&OUS/0-=[+&/CU59\7'/KJ
M-FY)")O>A$[VP#?B4SQV,)X0M:%6#DZ12;!KQLF'1EI/FW5@;9]"E0\)M-9*
MRYW ^>)">OR\G076$Z)$Y!*TW<KMW5R F9E8PD^(O,+53SFRKQ0#GLV64D_!
MRD95QZ:Z;: IP:9%+D.I)?,1X@R:JVDIIWOF"(-OY)]WST6&N-4A3_F5;=V?
M_:M#&G,]?'1I04'X]:)?B@F^/ (T!+RT 5ICB/*^'"85W@YHIEC*$K<!P^6@
M%;R3:""X:4".$Z+D29I\;(W@$:Q&=!XX609B8_B2(5P[,ZHD<1]HD3Z)E;3<
M/IJ-!D2C8-6Q:ET*V]N*KS],O  PHLW%0 P7,R4=:CP9"RZW8->7,S]VVE4#
MY"9JG&8SN>QT]I:G*_DINXC&;.8Z:)JL,$1N> '24@U578@N0#EBTZL)_:U-
M),W^*:E]/V=K%]\A]U!E21V8TLQ4^H->?C @PJ(EAVI'FCEVL1B@6P-]-2&.
MIZI^N%+NJD^F[##]_K"757Y QC7/ )[^ZXK^*^-;*A--XMY,:$"V0%$DN8&D
M36/3&L=JG%@6>RSD7PUOSZS/5D[# 6>I,CN&=30;LAK'2@J@,/O$SUGK)PTB
M[I@=C\W2B-\ZM!\C3>H:P(J2]/E7!;=J9$%U)T"3"J,F>.0RL-] %7\46(@G
M*1$H7%QC!_:5JZ7\>Z+CIH4!);E\.L&N<0"C%"KFC3X:-VNOZ?%>KUR^LK2/
M:+&&QY0D&I1"GN#!PY#; U+OU;A['&PTK"1()?NC%>'.2IJT7C#&L0:HC"-9
M$*B-_639LEI'M][D2M@(($^"?H"T,T!/=0VH^?&!?YUN+_%@;I!KR,32O5[$
M?*X(4:OJ)/*CZ'7*@5@)\ZT<O,AXG>9 3=!C0E"+TKI,1&B= ,,2^(X%A$XO
M4*TP'XH>.%I:TX>O<2S"!7*^G4!_U-4X_MS3'QE"75HS5KQ.%1IQ[#*@*T%B
M]22];KYAX8D@']4>HA,[6*Q)3FG=LUSKKH"L)TE^Q2=\/ ,\,NY)U[C*\R2'
M/KNWO,WH;GILA2*M)9P=1\L0T2"C!9T8ACLOJ.2+/B;57W5K$(_P,:*"08U9
ME.0Z.?A=V+ ,,'/]_HO>[?V[#.A)V,TUCJ!#*V?=C3Q!5D]+=Z":20_1QJ]H
M*,#9*GA)<]G:'G#D"%%3\LO[^"90?B$1"X[4YW:3 R;(4M#!)M-,RCQSE3?Q
M,J"6">0%B^X'\VZ'11K=A'4 RK7YF42?;3V7=0*[/06*]ZM!*<^//@%&F4\C
MNPKXEH#$,XY E"-1@BB?P&P+H"1WFL8F*X];*G7AB3CV2_'#^]B]Y\HP4I\^
MVCT>Y67%&!M+^@P%+%0 GVTNFCK<W/5\W1<,"U-?7"O?HJ;2#RL3S)JOHJDU
M89&@7HN2<7*9^-[F:E<&-X)7*HIC])@?#"HX81MQ!I\W=N6J;\ES0?2 ?:E=
M)%7RQBNLO*6:)W\W1&//4++\IIP*!X-6&L5K+XL1[<&124$A\7!=^4?-. -<
M,FS<I5.W>T4=%"I.PUL)9);:O66+\4$,]6&VHU2 D9H6S:=GOCV"*CEN;*Q
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M,)EA41>"PZ[EX#EYN>W75KJ89Q8Z%X@"]^#[[8J(Q()N*WLG7*#$=+.7R&]
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MLTF&4W D0A$!F^8%4== 2"GK)F%-J-]%D:P%HA=3&X7TQFA#CQ?<U!;JQFJ
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MTO(G/AW(CSM- 5$#9ZV<]13:#Q9,&N^4/[N",2N8F"X:Q9L ,'XE-"@.K8)
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M%LR@= _@4%^VAIQ)NVC13VM6J$!%0($4QVN"3I0:^3<H[$ &K\[E9%HT2O+
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M.]:9Y[7-]^=^D.A1ISDV!DE3#_:GSKJM@C=S06U9&;RF%F#?G,DR5G:4.6L
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M1"M"C-YV&>L'_@E02P$"% ,4    " "8@FI:2XX-\)T0    K   $0
M        @ $     96YS8RTR,#(T,3(S,2YX<V102P$"% ,4    " "8@FI:
M8]G?J3P4  "F[   %0              @ ',$   96YS8RTR,#(T,3(S,5]C
M86PN>&UL4$L! A0#%     @ F()J6I <F"L[-0  VD,# !4
M ( !.R4  &5N<V,M,C R-#$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( )B":EJV
M*?3O5'8  (S&!@ 5              "  :E:  !E;G-C+3(P,C0Q,C,Q7VQA
M8BYX;6Q02P$"% ,4    " "8@FI:SN!((NM3  "*:@4 %0
M@ $PT0  96YS8RTR,#(T,3(S,5]P<F4N>&UL4$L! A0#%     @ F()J6C8K
M@)-@ P  :PX   H              ( !3B4! &5X,C,M,2YH=&U02P$"% ,4
M    " "8@FI::3(Q[$L(  #A2P  "@              @ '6* $ 97@S,2TQ
M+FAT;5!+ 0(4 Q0    ( )B":EH7;:[;1P@  -M+   *              "
M 4DQ 0!E>#,Q+3(N:'1M4$L! A0#%     @ F()J6BD&4]R8!   9!X   H
M             ( !N#D! &5X,S(M,2YH=&U02P$"% ,4    " "8@FI:P#6M
MTY<$  !#'@  "@              @ %X/@$ 97@S,BTR+FAT;5!+ 0(4 Q0
M   ( )B":EHH!(E!47<# +E[(  ,              "  3=# 0!F;W)M,3 M
M:RYH=&U02P$"% ,4    " "8@FI:%\&5DD4" 0#"/ $ $
M@ &RN@0 9F]R;3$P+6M?,# Q+FIP9U!+ 0(4 Q0    ( )B":EH D4L+#10!
M !A/ 0 0              "  26]!0!F;W)M,3 M:U\P,#(N:G!G4$L%!@
0   -  T &0,  &#1!@    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>form10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:ENSC="http://ensysce.com/20241231"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ensc-20241231.xsd" xlink:type="simple"/>
    <context id="From2024-01-01to2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_CommonStock0.0001ParValuePerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENSC:CommonStock0.0001ParValuePerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_WarrantsToPurchaseOneShareOfCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENSC:WarrantsToPurchaseOneShareOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
        </entity>
        <period>
            <instant>2024-06-28</instant>
        </period>
    </context>
    <context id="AsOf2025-03-07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
        </entity>
        <period>
            <instant>2025-03-07</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_EBIRIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ENSC:EBIRIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_EBIRIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ENSC:EBIRIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_KeyPersonnelMember_custom_EBIRIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ENSC:EBIRIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ENSC:KeyPersonnelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_UnrelatedPartyMember_custom_EBIRIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ENSC:EBIRIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ENSC:UnrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2023-03-012023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2024-12-012024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
        </entity>
        <period>
            <startDate>2024-12-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember_custom_CustomerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ENSC:CustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember_custom_CustomerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ENSC:CustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-08-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
        </entity>
        <period>
            <instant>2024-08-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_LiabilityClassifiedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ENSC:LiabilityClassifiedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_LiabilityClassifiedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ENSC:LiabilityClassifiedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_LiabilityClassifiedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ENSC:LiabilityClassifiedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_MPARMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ENSC:MPARMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_MPARMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ENSC:MPARMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TAAPOUDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ENSC:TAAPOUDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_TAAPOUDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ENSC:TAAPOUDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_ConvertibleDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_ConvertibleDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TwoThousandTwentyThreeNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ENSC:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_TwoThousandTwentyThreeNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ENSC:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_FinancedInsuranceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ENSC:FinancedInsuranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_FinancedInsuranceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ENSC:FinancedInsuranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TwoThousandTwentyThreeNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ENSC:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_TwoThousandTwentyThreeNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ENSC:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-222023-10-23_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENSC:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-22</startDate>
            <endDate>2023-10-23</endDate>
        </period>
    </context>
    <context id="From2023-10-222023-10-23_custom_SecuritiesPurchaseAgreementMember_custom_TwoThousandTwentyThreeNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ENSC:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENSC:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-22</startDate>
            <endDate>2023-10-23</endDate>
        </period>
    </context>
    <context id="AsOf2023-10-25_custom_FirstClosingSecuritiesPurchaseAgreementMember_custom_TwoThousandTwentyThreeNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ENSC:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENSC:FirstClosingSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-25</instant>
        </period>
    </context>
    <context id="From2023-10-242023-10-25_custom_FirstClosingSecuritiesPurchaseAgreementMember_custom_TwoThousandTwentyThreeNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ENSC:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENSC:FirstClosingSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-24</startDate>
            <endDate>2023-10-25</endDate>
        </period>
    </context>
    <context id="AsOf2023-11-29_custom_SecondClosingSecuritiesPurchaseAgreementMember_custom_TwoThousandTwentyThreeNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ENSC:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENSC:SecondClosingSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-29</instant>
        </period>
    </context>
    <context id="From2023-11-292023-11-29_custom_SecondClosingSecuritiesPurchaseAgreementMember_custom_TwoThousandTwentyThreeNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ENSC:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENSC:SecondClosingSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-29</startDate>
            <endDate>2023-11-29</endDate>
        </period>
    </context>
    <context id="AsOf2023-10-23_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENSC:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-23</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TwoThousandTwentyThreeNotesMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ENSC:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENSC:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-06-012024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-11-272024-11-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
        </entity>
        <period>
            <startDate>2024-11-27</startDate>
            <endDate>2024-11-27</endDate>
        </period>
    </context>
    <context id="AsOf2024-11-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
        </entity>
        <period>
            <instant>2024-11-27</instant>
        </period>
    </context>
    <context id="From2024-10-182024-10-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
        </entity>
        <period>
            <startDate>2024-10-18</startDate>
            <endDate>2024-10-18</endDate>
        </period>
    </context>
    <context id="From2024-08-012024-08-31_custom_RegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENSC:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-08-31_custom_RegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENSC:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-31</instant>
        </period>
    </context>
    <context id="From2024-08-012024-08-31_custom_PrefundedWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENSC:PrefundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-08-31_custom_PrefundedWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENSC:PrefundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-31</instant>
        </period>
    </context>
    <context id="AsOf2024-02-29_custom_SeriesAandBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENSC:SeriesAandBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="AsOf2023-11-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="From2024-02-012024-02-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="From2024-08-012024-08-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-08-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-31</instant>
        </period>
    </context>
    <context id="AsOf2024-02-29_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="AsOf2024-02-29_custom_SeriesAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENSC:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="AsOf2024-02-29_custom_SeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENSC:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="From2024-02-012024-02-29_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="From2023-05-112023-05-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
        </entity>
        <period>
            <startDate>2023-05-11</startDate>
            <endDate>2023-05-12</endDate>
        </period>
    </context>
    <context id="AsOf2023-05-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
        </entity>
        <period>
            <instant>2023-05-12</instant>
        </period>
    </context>
    <context id="AsOf2023-05-12_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-12</instant>
        </period>
    </context>
    <context id="AsOf2023-05-12_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-12</instant>
        </period>
    </context>
    <context id="AsOf2023-05-12_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-12</instant>
        </period>
    </context>
    <context id="From2023-02-012023-02-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-02</endDate>
        </period>
    </context>
    <context id="AsOf2023-02-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
        </entity>
        <period>
            <instant>2023-02-02</instant>
        </period>
    </context>
    <context id="From2023-02-062023-02-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
        </entity>
        <period>
            <startDate>2023-02-06</startDate>
            <endDate>2023-02-06</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WarrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ENSC:WarrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WarrantOneMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ENSC:WarrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WarrantOneMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ENSC:WarrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_WarrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ENSC:WarrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WarrantTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ENSC:WarrantTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_WarrantTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ENSC:WarrantTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WarrantThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ENSC:WarrantThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WarrantThreeMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ENSC:WarrantThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WarrantThreeMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ENSC:WarrantThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_WarrantThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ENSC:WarrantThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WarrantFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ENSC:WarrantFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WarrantFourMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ENSC:WarrantFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WarrantFourMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ENSC:WarrantFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_WarrantFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ENSC:WarrantFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-08-29_custom_InstitutionalInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENSC:InstitutionalInvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-29</instant>
        </period>
    </context>
    <context id="AsOf2024-08-29_custom_InvestorWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENSC:InvestorWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-29</instant>
        </period>
    </context>
    <context id="AsOf2024-08-29_custom_PlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENSC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-29</instant>
        </period>
    </context>
    <context id="AsOf2024-08-29_custom_PlacementAgentWarrantsMember11635781">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENSC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-29</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_InvestorWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENSC:InvestorWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-02-12_us-gaap_WarrantMember_custom_PlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENSC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-12</instant>
        </period>
    </context>
    <context id="AsOf2024-02-12_custom_SeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENSC:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-12</instant>
        </period>
    </context>
    <context id="AsOf2024-02-12_custom_SeriesAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENSC:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-12</instant>
        </period>
    </context>
    <context id="AsOf2024-02-12_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-12</instant>
        </period>
    </context>
    <context id="AsOf2024-08-31_us-gaap_WarrantMember_custom_PlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENSC:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-31</instant>
        </period>
    </context>
    <context id="AsOf2023-10-25_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-25</instant>
        </period>
    </context>
    <context id="AsOf2023-11-28_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-28</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2024-08-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
        </entity>
        <period>
            <instant>2024-08-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_PublicWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENSC:PublicWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_Notes2021And2022Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENSC:Notes2021And2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-29_custom_Notes2021And2022Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENSC:Notes2021And2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-29</instant>
        </period>
    </context>
    <context id="AsOf2024-02-29_custom_TwoThousandTwentyOneOmnibusIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ENSC:TwoThousandTwentyOneOmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_BoardOfMembersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ENSC:BoardOfMembersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember_custom_StockOptionAvailableForFutureGrantUnder2021OmnibusIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ENSC:StockOptionAvailableForFutureGrantUnder2021OmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WarrantOutstandingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENSC:WarrantOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CaliforniaFranchiseTaxBoardMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2017-12-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="From2017-01-012017-12-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CaliforniaFranchiseTaxBoardMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_DomesticCountryMember_us-gaap_ResearchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_StateAndLocalJurisdictionMember_us-gaap_ResearchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENSC:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-04-252024-04-25_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-25</startDate>
            <endDate>2024-04-25</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-01-31_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-01-31_us-gaap_SubsequentEventMember_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001716947</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Segment">
        <measure>ENSC:Segment</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2024-01-01to2024-12-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2024-01-01to2024-12-31" id="Fact000004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2024-01-01to2024-12-31" id="Fact000005">0001716947</dei:EntityCentralIndexKey>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0148"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0149"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0154"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0155"
      unitRef="USD"
      xsi:nil="true"/>
    <ENSC:LossOnConversionsAndChangeInFairValueOfConvertibleNotes
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0231"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0285"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0286"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0287"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0288"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0289"
      unitRef="USD"
      xsi:nil="true"/>
    <ENSC:StockIssuedDuringPeriodValueCommitmentFee
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0293"
      unitRef="USD"
      xsi:nil="true"/>
    <ENSC:StockIssuedDuringPeriodValueCommitmentFee
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0295"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0303"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0304"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0311"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0312"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0317"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0319"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0320"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0323"
      unitRef="USD"
      xsi:nil="true"/>
    <ENSC:TransactionCostsAssociatedWithPublicOffering
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0329"
      unitRef="USD"
      xsi:nil="true"/>
    <ENSC:TransactionCostsAssociatedWithPublicOffering
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0331"
      unitRef="USD"
      xsi:nil="true"/>
    <ENSC:TransactionCostsAssociatedWithPublicOffering
      contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0332"
      unitRef="USD"
      xsi:nil="true"/>
    <ENSC:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0337"
      unitRef="USD"
      xsi:nil="true"/>
    <ENSC:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0339"
      unitRef="USD"
      xsi:nil="true"/>
    <ENSC:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0343"
      unitRef="USD"
      xsi:nil="true"/>
    <ENSC:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0344"
      unitRef="USD"
      xsi:nil="true"/>
    <ENSC:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0345"
      unitRef="USD"
      xsi:nil="true"/>
    <ENSC:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0346"
      unitRef="USD"
      xsi:nil="true"/>
    <ENSC:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0347"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0351"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1
      contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0354"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0355"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0357"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0358"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0379"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0380"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0381"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0382"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0383"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0389"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0390"
      unitRef="USD"
      xsi:nil="true"/>
    <ENSC:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0405"
      unitRef="USD"
      xsi:nil="true"/>
    <ENSC:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0406"
      unitRef="USD"
      xsi:nil="true"/>
    <ENSC:IssuanceOfCommonStockUponWarrantInducements
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0413"
      unitRef="USD"
      xsi:nil="true"/>
    <ENSC:IssuanceOfCommonStockUponWarrantInducements
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0414"
      unitRef="USD"
      xsi:nil="true"/>
    <ENSC:TransactionCostsAssociatedWithPublicOfferingAndWarrantInducements
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0419"
      unitRef="USD"
      xsi:nil="true"/>
    <ENSC:TransactionCostsAssociatedWithPublicOfferingAndWarrantInducements
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0421"
      unitRef="USD"
      xsi:nil="true"/>
    <ENSC:TransactionCostsAssociatedWithPublicOfferingAndWarrantInducements
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0422"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0425"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0427"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0428"
      unitRef="USD"
      xsi:nil="true"/>
    <ENSC:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0431"
      unitRef="USD"
      xsi:nil="true"/>
    <ENSC:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0432"
      unitRef="USD"
      xsi:nil="true"/>
    <ENSC:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0433"
      unitRef="USD"
      xsi:nil="true"/>
    <ENSC:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0434"
      unitRef="USD"
      xsi:nil="true"/>
    <ENSC:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0435"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0439"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0442"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0443"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0445"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0446"
      unitRef="USD"
      xsi:nil="true"/>
    <ENSC:LossOnConversionsAndChangeInFairValueOfConvertibleNotes
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0482"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProvisionForLoanLeaseAndOtherLosses
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0491"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0516"
      unitRef="USD"
      xsi:nil="true"/>
    <ENSC:ProceedsFromWarrantInducementNetOfIssuanceCosts
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0519"
      unitRef="USD"
      xsi:nil="true"/>
    <ENSC:TransactionCostsFromPublicOfferings
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0521"
      unitRef="USD"
      xsi:nil="true"/>
    <ENSC:TransactionCostAssociatedWithWarrantInducement
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0525"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0527"
      unitRef="USD"
      xsi:nil="true"/>
    <ENSC:IncrementalFairValueOfWarrantInducement1
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0558"
      unitRef="USD"
      xsi:nil="true"/>
    <ENSC:IncrementalFairValueOfWarrantInducement2
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0561"
      unitRef="USD"
      xsi:nil="true"/>
    <ENSC:OriginalDebtDiscountFromConvertibleNotes
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0566"
      unitRef="USD"
      xsi:nil="true"/>
    <ENSC:DebtDiscountFromWarrantsIssuance
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0569"
      unitRef="USD"
      xsi:nil="true"/>
    <ENSC:IssuanceCostFromConvertibleNotes
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0572"
      unitRef="USD"
      xsi:nil="true"/>
    <ENSC:SettlementOfCommitmentFeeInShares
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0578"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl0639"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0640"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl0644"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0645"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl0649"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0650"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl0654"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0655"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="AsOf2024-12-31_custom_FinancedInsuranceMember"
      id="xdx2ixbrl0770"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="AsOf2023-12-31_custom_FinancedInsuranceMember"
      id="xdx2ixbrl0792"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1097"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1099"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1101"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1103"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1105"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1107"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1109"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1111"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1113"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <ENSC:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1115"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1123"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1129"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1137"
      unitRef="USD"
      xsi:nil="true"/>
    <ENSC:IncomeTaxReconciliationExpiringAttributes
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1208"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1219"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1220"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1245"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1246"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1248"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1249"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilities
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1251"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilities
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1252"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1254"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1255"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1289"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2024-01-01to2024-12-31" id="Fact000012">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2024-01-01to2024-12-31" id="Fact000013">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2024-01-01to2024-12-31" id="Fact000014">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2024-01-01to2024-12-31" id="Fact000015">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2024-01-01to2024-12-31" id="Fact000016">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2024-01-01to2024-12-31" id="Fact000017">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2024-01-01to2024-12-31" id="Fact000018">001-38306</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2024-01-01to2024-12-31" id="Fact000019">ENSYSCE BIOSCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2024-01-01to2024-12-31" id="Fact000020">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2024-01-01to2024-12-31" id="Fact000021">82-2755287</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2024-01-01to2024-12-31" id="Fact000022">7946                                             Ivanhoe Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2024-01-01to2024-12-31" id="Fact000023">Suite 201</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2024-01-01to2024-12-31" id="Fact000024">La     Jolla</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2024-01-01to2024-12-31" id="Fact000025">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2024-01-01to2024-12-31" id="Fact000026">92037</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2024-01-01to2024-12-31" id="Fact000027">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2024-01-01to2024-12-31" id="Fact000028">263-4196</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="From2024-01-012024-12-31_custom_CommonStock0.0001ParValuePerShareMember"
      id="Fact000029">Common     Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2024-01-012024-12-31_custom_CommonStock0.0001ParValuePerShareMember"
      id="Fact000030">ENSC</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2024-01-012024-12-31_custom_CommonStock0.0001ParValuePerShareMember"
      id="Fact000031">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="From2024-01-012024-12-31_custom_WarrantsToPurchaseOneShareOfCommonStockMember"
      id="Fact000032">Warrants,     to purchase one share of Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2024-01-012024-12-31_custom_WarrantsToPurchaseOneShareOfCommonStockMember"
      id="Fact000033">ENSCW</dei:TradingSymbol>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2024-01-01to2024-12-31" id="Fact000034">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2024-01-01to2024-12-31" id="Fact000035">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2024-01-01to2024-12-31" id="Fact000036">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2024-01-01to2024-12-31" id="Fact000037">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2024-01-01to2024-12-31" id="Fact000038">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2024-01-01to2024-12-31" id="Fact000039">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2024-01-01to2024-12-31" id="Fact000040">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="From2024-01-01to2024-12-31" id="Fact000041">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2024-01-01to2024-12-31" id="Fact000042">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="From2024-01-01to2024-12-31" id="Fact000043">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="AsOf2024-06-28"
      decimals="-5"
      id="Fact000044"
      unitRef="USD">4000000.0</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2025-03-07"
      decimals="INF"
      id="Fact000045"
      unitRef="Shares">1405134</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000046">None</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000072">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_904_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20240101__20241231_zUKS2abTeTnl"&gt;We
have developed and implemented cybersecurity risk management &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90E_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_zHF0Co8bNU5i"&gt;processes&lt;/span&gt; intended to protect the confidentiality, integrity and availability
of our critical systems and information.&lt;/span&gt;&lt;/span&gt;Our
cybersecurity risk management program includes:&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;physical,
    technological and administrative controls intended to support our cybersecurity and data governance framework, including protections
    designed to protect the confidentiality, integrity and availability of our key information systems;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;risk
    assessments designed to help identify material cybersecurity risks to our critical systems and information;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;designated
    team members are responsible for managing our cybersecurity risk assessment processes, our security controls, and our response to
    cybersecurity incidents; and&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_900_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240101__20241231_zcYWaDPcQxKl"&gt;the
    use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of our security controls.&lt;/span&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_903_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_c20240101__20241231_zVdSnzIvXkNe"&gt;We
have &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90B_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20240101__20241231_zfiiJoTFjLdl"&gt;no&lt;/span&gt;t identified risks from known cybersecurity threats that have materially affected or are reasonably likely to materially affect
us, including our operations, business strategy, results of operations, or financial condition&lt;/span&gt;. See Item 1A. &#x201c;Risk Factors &#x2013;
Cyber-attacks or other failures in our telecommunications or information technology systems, or those of our collaborators, CROs,
third-party logistics providers, distributors or other contractors or consultants, could result in information theft, data corruption
and significant disruption of our business operations.&#x201d;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000073">We
have developed and implemented cybersecurity risk management &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90E_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_zHF0Co8bNU5i"&gt;processes&lt;/span&gt; intended to protect the confidentiality, integrity and availability
of our critical systems and information.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="From2024-01-01to2024-12-31" id="Fact000074">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="From2024-01-01to2024-12-31" id="Fact000075">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000076">We
have &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90B_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20240101__20241231_zfiiJoTFjLdl"&gt;no&lt;/span&gt;t identified risks from known cybersecurity threats that have materially affected or are reasonably likely to materially affect
us, including our operations, business strategy, results of operations, or financial condition</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="From2024-01-01to2024-12-31" id="Fact000077">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000080">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
Board considers cybersecurity risk as part of its risk oversight function. &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_904_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_c20240101__20241231_zoYYvSunh82i"&gt;The &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_905_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_dbT_c20240101__20241231_zqU5TW3cZ1Y8"&gt;Audit Committee&lt;/span&gt; oversees our cybersecurity and other information
technology risks and management&#x2019;s implementation of our cybersecurity risk management program&lt;/span&gt;. &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_907_ecyd--CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_c20240101__20241231_zELxueJrRiN1"&gt;The Audit Committee receives periodic
reports from management on our cybersecurity risks. In addition, &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90E_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_dbT_c20240101__20241231_zGUxsf9VJjVe"&gt;management&lt;/span&gt; updates the Board and the Audit Committee, as necessary,
regarding any material cybersecurity incidents, as well as any incidents with lesser impact potential.&lt;/span&gt;&lt;/span&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90B_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240101__20241231_zdeUgQwC1NF9"&gt;Our
management team, including our Chief Financial Officer, is responsible for assessing and managing our material risks from cybersecurity
threats.&lt;/span&gt; Our Chief Financial Officer has primary responsibility for our overall cybersecurity risk management program. Our Chief Financial
Officer has experience supervising and managing company information technology departments.Our
management team supervises efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means,
which may include briefings from external security personnel; threat intelligence and other information obtained from governmental, public
or private sources; and alerts and reports produced by security tools deployed in the information technology environment.</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000081">The &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_905_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_dbT_c20240101__20241231_zqU5TW3cZ1Y8"&gt;Audit Committee&lt;/span&gt; oversees our cybersecurity and other information
technology risks and management&#x2019;s implementation of our cybersecurity risk management program</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="From2024-01-01to2024-12-31" id="Fact000082">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000083">The Audit Committee receives periodic
reports from management on our cybersecurity risks. In addition, &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90E_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_dbT_c20240101__20241231_zGUxsf9VJjVe"&gt;management&lt;/span&gt; updates the Board and the Audit Committee, as necessary,
regarding any material cybersecurity incidents, as well as any incidents with lesser impact potential.</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="From2024-01-01to2024-12-31" id="Fact000084">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000085">Our
management team, including our Chief Financial Officer, is responsible for assessing and managing our material risks from cybersecurity
threats.</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="From2024-01-01to2024-12-31" id="Fact000086">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="From2024-01-01to2024-12-31" id="Fact000087">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="From2024-01-01to2024-12-31" id="Fact000088">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="From2024-01-01to2024-12-31" id="Fact000089">false</ecd:NonRule10b51ArrTrmntdFlag>
    <dei:AuditorFirmId contextRef="From2024-01-01to2024-12-31" id="Fact000090">659</dei:AuditorFirmId>
    <dei:AuditorName contextRef="From2024-01-01to2024-12-31" id="Fact000091">Moss Adams LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2024-01-01to2024-12-31" id="Fact000092">San Diego, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000100"
      unitRef="USD">3502077</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000101"
      unitRef="USD">1123604</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:UnbilledReceivablesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000103"
      unitRef="USD">124115</us-gaap:UnbilledReceivablesCurrent>
    <us-gaap:UnbilledReceivablesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000104"
      unitRef="USD">97561</us-gaap:UnbilledReceivablesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000106"
      unitRef="USD">1718490</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000107"
      unitRef="USD">1067703</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000109"
      unitRef="USD">5344682</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000110"
      unitRef="USD">2288868</us-gaap:AssetsCurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000112"
      unitRef="USD">252550</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000113"
      unitRef="USD">419217</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000115"
      unitRef="USD">5597232</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000116"
      unitRef="USD">2708085</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000124"
      unitRef="USD">1357079</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000125"
      unitRef="USD">1936007</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000127"
      unitRef="USD">548458</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000128"
      unitRef="USD">542260</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000130"
      unitRef="USD">301660</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000131"
      unitRef="USD">854697</us-gaap:NotesPayableCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000133"
      unitRef="USD">2207197</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000134"
      unitRef="USD">3332964</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000139"
      unitRef="USD">10096</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000140"
      unitRef="USD">26388</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000142"
      unitRef="USD">10096</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000143"
      unitRef="USD">26388</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000145"
      unitRef="USD">2217293</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000146"
      unitRef="USD">3359352</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000157"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000159"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000161"
      unitRef="Shares">1500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000163"
      unitRef="Shares">1500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000165"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000167"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000169"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000171"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000176"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000178"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000180"
      unitRef="Shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000182"
      unitRef="Shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000184"
      unitRef="Shares">1355779</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000186"
      unitRef="Shares">209745</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000188"
      unitRef="Shares">1355773</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000190"
      unitRef="Shares">209739</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000173"
      unitRef="USD">136</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000174"
      unitRef="USD">21</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000192"
      unitRef="USD">133252585</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000193"
      unitRef="USD">121234195</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000195"
      unitRef="USD">-129544299</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000196"
      unitRef="USD">-121557074</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000198"
      unitRef="USD">3708422</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000199"
      unitRef="USD">-322858</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000201"
      unitRef="USD">-328483</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000202"
      unitRef="USD">-328409</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000204"
      unitRef="USD">3379939</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000205"
      unitRef="USD">-651267</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000207"
      unitRef="USD">5597232</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000208"
      unitRef="USD">2708085</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000210"
      unitRef="USD">5210031</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000211"
      unitRef="USD">2230520</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000216"
      unitRef="USD">7219437</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000217"
      unitRef="USD">7587473</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000219"
      unitRef="USD">4720728</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000220"
      unitRef="USD">5361234</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000222"
      unitRef="USD">11940165</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000223"
      unitRef="USD">12948707</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000225"
      unitRef="USD">-6730134</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000226"
      unitRef="USD">-10718187</us-gaap:OperatingIncomeLoss>
    <ENSC:LossOnConversionsAndChangeInFairValueOfConvertibleNotes
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000232"
      unitRef="USD">-146479</ENSC:LossOnConversionsAndChangeInFairValueOfConvertibleNotes>
    <ENSC:ChangeInFairValueOfLiabilityClassifiedWarrants
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000234"
      unitRef="USD">16292</ENSC:ChangeInFairValueOfLiabilityClassifiedWarrants>
    <ENSC:ChangeInFairValueOfLiabilityClassifiedWarrants
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000235"
      unitRef="USD">283958</ENSC:ChangeInFairValueOfLiabilityClassifiedWarrants>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000237"
      unitRef="USD">1290444</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000238"
      unitRef="USD">353945</us-gaap:InterestExpenseNonoperating>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000240"
      unitRef="USD">17277</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000241"
      unitRef="USD">15420</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000243"
      unitRef="USD">-1256875</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000244"
      unitRef="USD">91912</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000246"
      unitRef="USD">-7987009</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000247"
      unitRef="USD">-10626275</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000249"
      unitRef="USD">-74</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000250"
      unitRef="USD">-13201</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000252"
      unitRef="USD">290</us-gaap:WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount>
    <us-gaap:WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000253"
      unitRef="USD">12937</us-gaap:WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000255"
      unitRef="USD">-7987225</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000256"
      unitRef="USD">-10626011</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000261"
      unitRef="USDPShares">-11.45</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000263"
      unitRef="USDPShares">-11.45</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000265"
      unitRef="USDPShares">-70.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000267"
      unitRef="USDPShares">-70.40</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000269"
      unitRef="Shares">697686</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000271"
      unitRef="Shares">697686</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000273"
      unitRef="Shares">150937</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000275"
      unitRef="Shares">150937</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000283"
      unitRef="Shares">35650</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000277"
      unitRef="USD">4</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000278"
      unitRef="USD">107216615</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000279"
      unitRef="USD">-110931063</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000280"
      unitRef="USD">-315208</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000281"
      unitRef="USD">-4029652</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000291"
      unitRef="Shares">4064</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <ENSC:StockIssuedDuringPeriodSharesCommitmentFee
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000299"
      unitRef="Shares">2964</ENSC:StockIssuedDuringPeriodSharesCommitmentFee>
    <ENSC:StockIssuedDuringPeriodValueCommitmentFee
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000294"
      unitRef="USD">400000</ENSC:StockIssuedDuringPeriodValueCommitmentFee>
    <ENSC:StockIssuedDuringPeriodValueCommitmentFee
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000297"
      unitRef="USD">400000</ENSC:StockIssuedDuringPeriodValueCommitmentFee>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000307"
      unitRef="Shares">27240</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000301"
      unitRef="USD">3</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000302"
      unitRef="USD">3056889</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000305"
      unitRef="USD">3056892</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000315"
      unitRef="Shares">92109</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000309"
      unitRef="USD">9</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000310"
      unitRef="USD">9049995</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000313"
      unitRef="USD">9050004</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000318"
      unitRef="USD">879160</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000321"
      unitRef="USD">879160</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000324"
      unitRef="USD">1066483</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000327"
      unitRef="USD">1066483</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <ENSC:TransactionCostsAssociatedWithPublicOffering
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000330"
      unitRef="USD">-447879</ENSC:TransactionCostsAssociatedWithPublicOffering>
    <ENSC:TransactionCostsAssociatedWithPublicOffering
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000333"
      unitRef="USD">-447879</ENSC:TransactionCostsAssociatedWithPublicOffering>
    <ENSC:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000341"
      unitRef="Shares">47792</ENSC:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares>
    <ENSC:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000335"
      unitRef="USD">5</ENSC:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants>
    <ENSC:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000336"
      unitRef="USD">-5</ENSC:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000349"
      unitRef="Shares">80</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000352"
      unitRef="USD">12937</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1>
    <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000353"
      unitRef="USD">-12937</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000359"
      unitRef="USD">-10613074</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000360"
      unitRef="USD">-13201</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000361"
      unitRef="USD">-10626275</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000369"
      unitRef="Shares">209739</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000363"
      unitRef="USD">21</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000364"
      unitRef="USD">121234195</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000365"
      unitRef="USD">-121557074</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000366"
      unitRef="USD">-328409</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000367"
      unitRef="USD">-651267</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000377"
      unitRef="Shares">209739</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000371"
      unitRef="USD">21</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000372"
      unitRef="USD">121234195</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000373"
      unitRef="USD">-121557074</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000374"
      unitRef="USD">-328409</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000375"
      unitRef="USD">-651267</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000385"
      unitRef="Shares">5</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000393"
      unitRef="Shares">49702</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000387"
      unitRef="USD">5</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000388"
      unitRef="USD">1168595</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000391"
      unitRef="USD">1168600</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000401"
      unitRef="Shares">236880</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000395"
      unitRef="USD">24</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000396"
      unitRef="USD">1669977</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000399"
      unitRef="USD">1670001</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <ENSC:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000409"
      unitRef="Shares">139028</ENSC:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares>
    <ENSC:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000403"
      unitRef="USD">14</ENSC:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants>
    <ENSC:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000404"
      unitRef="USD">2433066</ENSC:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants>
    <ENSC:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000407"
      unitRef="USD">2433080</ENSC:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants>
    <ENSC:IssuanceOfCommonStockUponWarrantInducementsShares
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000417"
      unitRef="Shares">720357</ENSC:IssuanceOfCommonStockUponWarrantInducementsShares>
    <ENSC:IssuanceOfCommonStockUponWarrantInducements
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000411"
      unitRef="USD">72</ENSC:IssuanceOfCommonStockUponWarrantInducements>
    <ENSC:IssuanceOfCommonStockUponWarrantInducements
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000412"
      unitRef="USD">8103870</ENSC:IssuanceOfCommonStockUponWarrantInducements>
    <ENSC:IssuanceOfCommonStockUponWarrantInducements
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000415"
      unitRef="USD">8103942</ENSC:IssuanceOfCommonStockUponWarrantInducements>
    <ENSC:TransactionCostsAssociatedWithPublicOfferingAndWarrantInducements
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000420"
      unitRef="USD">-1468131</ENSC:TransactionCostsAssociatedWithPublicOfferingAndWarrantInducements>
    <ENSC:TransactionCostsAssociatedWithPublicOfferingAndWarrantInducements
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000423"
      unitRef="USD">-1468131</ENSC:TransactionCostsAssociatedWithPublicOfferingAndWarrantInducements>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000426"
      unitRef="USD">110723</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000429"
      unitRef="USD">110723</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000437"
      unitRef="Shares">62</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000440"
      unitRef="USD">290</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1>
    <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000441"
      unitRef="USD">-290</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000447"
      unitRef="USD">-7986935</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000448"
      unitRef="USD">-74</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000449"
      unitRef="USD">-7987009</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000457"
      unitRef="Shares">1355773</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000451"
      unitRef="USD">136</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000452"
      unitRef="USD">133252585</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000453"
      unitRef="USD">-129544299</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000454"
      unitRef="USD">-328483</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000455"
      unitRef="USD">3379939</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000465"
      unitRef="Shares">1355773</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000459"
      unitRef="USD">136</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000460"
      unitRef="USD">133252585</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000461"
      unitRef="USD">-129544299</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000462"
      unitRef="USD">-328483</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000463"
      unitRef="USD">3379939</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000470"
      unitRef="USD">-7987009</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000471"
      unitRef="USD">-10626275</us-gaap:ProfitLoss>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000476"
      unitRef="USD">43927</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000477"
      unitRef="USD">18648</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000479"
      unitRef="USD">1197200</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000480"
      unitRef="USD">326151</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <ENSC:LossOnConversionsAndChangeInFairValueOfConvertibleNotes
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000483"
      unitRef="USD">-146479</ENSC:LossOnConversionsAndChangeInFairValueOfConvertibleNotes>
    <ENSC:ChangeInFairValueOfLiabilityClassifiedWarrants
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000485"
      unitRef="USD">16292</ENSC:ChangeInFairValueOfLiabilityClassifiedWarrants>
    <ENSC:ChangeInFairValueOfLiabilityClassifiedWarrants
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000486"
      unitRef="USD">283958</ENSC:ChangeInFairValueOfLiabilityClassifiedWarrants>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000488"
      unitRef="USD">110723</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000489"
      unitRef="USD">879160</us-gaap:ShareBasedCompensation>
    <us-gaap:ProvisionForLoanLeaseAndOtherLosses
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000492"
      unitRef="USD">-150</us-gaap:ProvisionForLoanLeaseAndOtherLosses>
    <ENSC:IncreaseDecreaseInUnbilledReceivable
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000494"
      unitRef="USD">26554</ENSC:IncreaseDecreaseInUnbilledReceivable>
    <ENSC:IncreaseDecreaseInUnbilledReceivable
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000495"
      unitRef="USD">-179260</ENSC:IncreaseDecreaseInUnbilledReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000497"
      unitRef="USD">251965</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000498"
      unitRef="USD">-1392181</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000500"
      unitRef="USD">-578928</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000501"
      unitRef="USD">-1234287</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000503"
      unitRef="USD">6198</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000504"
      unitRef="USD">-1284233</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000506"
      unitRef="USD">-7502700</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000507"
      unitRef="USD">-10779982</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000512"
      unitRef="USD">1670001</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000513"
      unitRef="USD">9050004</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000515"
      unitRef="USD">2433080</us-gaap:ProceedsFromWarrantExercises>
    <ENSC:ProceedsFromWarrantInducementNetOfIssuanceCosts
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000518"
      unitRef="USD">8103942</ENSC:ProceedsFromWarrantInducementNetOfIssuanceCosts>
    <ENSC:TransactionCostsFromPublicOfferings
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000522"
      unitRef="USD">447879</ENSC:TransactionCostsFromPublicOfferings>
    <ENSC:TransactionCostAssociatedWithWarrantInducement
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000524"
      unitRef="USD">1468131</ENSC:TransactionCostAssociatedWithWarrantInducement>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000528"
      unitRef="USD">1605635</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000530"
      unitRef="USD">485190</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000531"
      unitRef="USD">1000208</us-gaap:RepaymentsOfConvertibleDebt>
    <ENSC:RepaymentInsurancePremiums
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000533"
      unitRef="USD">372529</ENSC:RepaymentInsurancePremiums>
    <ENSC:RepaymentInsurancePremiums
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000534"
      unitRef="USD">451668</ENSC:RepaymentInsurancePremiums>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000536"
      unitRef="USD">9881173</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000537"
      unitRef="USD">8755884</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000539"
      unitRef="USD">2378473</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000540"
      unitRef="USD">-2024098</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000542"
      unitRef="USD">1123604</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000543"
      unitRef="USD">3147702</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000545"
      unitRef="USD">3502077</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000546"
      unitRef="USD">1123604</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000551"
      unitRef="USD">3200</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000552"
      unitRef="USD">3200</us-gaap:IncomeTaxesPaidNet>
    <ENSC:IncrementalFairValueOfWarrantInducement1
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000557"
      unitRef="USD">10210616</ENSC:IncrementalFairValueOfWarrantInducement1>
    <ENSC:IncrementalFairValueOfWarrantInducement2
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000560"
      unitRef="USD">5167372</ENSC:IncrementalFairValueOfWarrantInducement2>
    <ENSC:ConversionsOfConvertibleNotesIntoCommonStock
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000563"
      unitRef="USD">1168600</ENSC:ConversionsOfConvertibleNotesIntoCommonStock>
    <ENSC:ConversionsOfConvertibleNotesIntoCommonStock
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000564"
      unitRef="USD">3056892</ENSC:ConversionsOfConvertibleNotesIntoCommonStock>
    <ENSC:OriginalDebtDiscountFromConvertibleNotes
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000567"
      unitRef="USD">136000</ENSC:OriginalDebtDiscountFromConvertibleNotes>
    <ENSC:DebtDiscountFromWarrantsIssuance
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000570"
      unitRef="USD">1066483</ENSC:DebtDiscountFromWarrantsIssuance>
    <ENSC:IssuanceCostFromConvertibleNotes
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000573"
      unitRef="USD">226503</ENSC:IssuanceCostFromConvertibleNotes>
    <ENSC:FinancedInsurancePremiums
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000575"
      unitRef="USD">232155</ENSC:FinancedInsurancePremiums>
    <ENSC:FinancedInsurancePremiums
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000576"
      unitRef="USD">445737</ENSC:FinancedInsurancePremiums>
    <ENSC:SettlementOfCommitmentFeeInShares
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000579"
      unitRef="USD">400000</ENSC:SettlementOfCommitmentFeeInShares>
    <ENSC:DeemedDividendRelatedToWarrantsDownRoundProvision
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000581"
      unitRef="USD">290</ENSC:DeemedDividendRelatedToWarrantsDownRoundProvision>
    <ENSC:DeemedDividendRelatedToWarrantsDownRoundProvision
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000582"
      unitRef="USD">12937</ENSC:DeemedDividendRelatedToWarrantsDownRoundProvision>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000584">&lt;p id="xdx_80D_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zdVDDbnm08oh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
1 &#x2013; &lt;span id="xdx_82A_z1F2juPiW7ai"&gt;ORGANIZATION AND PRINCIPAL ACTIVITIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Ensysce
Biosciences, Inc. (&#x201c;Ensysce&#x201d;), along with its &lt;span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EBIRIncMember_zGfKa5m4dwXc" title="Ownership percentage"&gt;79.2&lt;/span&gt;%-owned subsidiary, EBIR, Inc. (&#x201c;EBIR&#x201d;, formerly known as Covistat,
Inc.) and its wholly-owned subsidiaries EBI Operating, Inc. and EBI OpCo, Inc. (collectively, the &#x201c;Company&#x201d;), is a clinical-stage
biotech company using its proprietary technology platforms to develop safer prescription drugs. The primary focus of the Company is its
program developing abuse and overdose resistant pain technology with a clinical stage program being the abuse resistant, TAAP (Trypsin
Activated Abuse Protection) opioid product candidate, PF614. In addition, the Company is developing its MPAR&#xae; (Multi-Pill Abuse Resistant)
technology for overdose protection which will be applied to the PF614 program. The Company is also applying its TAAP and MPAR&#xae; technology
to a methadone prodrug for use in the treatment of Opioid Use Disorder.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
2020, the Company commenced an initiative to develop a therapeutic for the treatment of certain coronavirus infections through the formation
of a separate entity, EBIR, a Delaware corporation. Pursuant to the articles of incorporation, EBIR was authorized to issue &lt;span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20201231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EBIRIncMember_zHhfUxzBMnxf" title="Common stock, shares authorized"&gt;1,000,000&lt;/span&gt;
shares of common stock, $&lt;span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20201231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EBIRIncMember_z20W3jsIvVhi" title="Common stock, par value"&gt;0.001&lt;/span&gt; par value per share, and &lt;span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20201231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EBIRIncMember_zfEbD7IYdRQ7" title="Preferred stock, shares authorized"&gt;100,000&lt;/span&gt; shares of preferred stock, $&lt;span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pp3d_c20201231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EBIRIncMember_zO5JsYwZgeO6" title="Preferred stock, par value"&gt;0.001&lt;/span&gt; par value per share. Ensysce is a &lt;span id="xdx_901_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EBIRIncMember_zkuWFW9jSI79" title="Ownership percentage"&gt;79.2&lt;/span&gt;%
stockholder in EBIR, with &lt;span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20241231__srt--TitleOfIndividualAxis__custom--KeyPersonnelMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EBIRIncMember_zd9VSnMZrrCj" title="Ownership percentage"&gt;19.8&lt;/span&gt;% and &lt;span id="xdx_901_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20241231__srt--TitleOfIndividualAxis__custom--UnrelatedPartyMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EBIRIncMember_zBPTRgK0rZAg" title="Ownership percentage"&gt;1.0&lt;/span&gt;% of the shares held by certain key personnel of the Company and an unrelated party, respectively.
The non-Ensysce owned shares and the activity are reflected on the financial statements as noncontrolling interests.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;/p&gt;

</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2024-12-31_custom_EBIRIncMember"
      decimals="INF"
      id="Fact000586"
      unitRef="Pure">0.792</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2020-12-31_custom_EBIRIncMember"
      decimals="INF"
      id="Fact000588"
      unitRef="Shares">1000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2020-12-31_custom_EBIRIncMember"
      decimals="INF"
      id="Fact000590"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2020-12-31_custom_EBIRIncMember"
      decimals="INF"
      id="Fact000592"
      unitRef="Shares">100000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2020-12-31_custom_EBIRIncMember"
      decimals="3"
      id="Fact000594"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2024-12-31_custom_EBIRIncMember"
      decimals="INF"
      id="Fact000596"
      unitRef="Pure">0.792</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2024-12-31_custom_KeyPersonnelMember_custom_EBIRIncMember"
      decimals="INF"
      id="Fact000598"
      unitRef="Pure">0.198</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2024-12-31_custom_UnrelatedPartyMember_custom_EBIRIncMember"
      decimals="INF"
      id="Fact000600"
      unitRef="Pure">0.010</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:BasisOfAccounting contextRef="From2024-01-01to2024-12-31" id="Fact000602">&lt;p id="xdx_803_eus-gaap--BasisOfAccounting_zTa9y2uZumCd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2 - &lt;span id="xdx_82F_z2pKzmMjd7Xk"&gt;BASIS OF PRESENTATION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States
of America (&#x201c;GAAP&#x201d;) and pursuant to the rules and regulations of the United States Securities Exchange Commission (&#x201c;SEC&#x201d;).
The consolidated financial statements include the accounts of Ensysce Biosciences, Inc. and its subsidiaries. All intercompany balances
and transactions have been eliminated in the consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Reverse
Stock Split&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
March 2023, the Company completed a &lt;span id="xdx_90F_eus-gaap--StockholdersEquityReverseStockSplit_c20230301__20230331_zTRBRKzcP2F2" title="Reverse stock split"&gt;1-for-12&lt;/span&gt; reverse split of its outstanding common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2024, the Company completed a &lt;span id="xdx_900_eus-gaap--StockholdersEquityReverseStockSplit_c20241201__20241231_zoFw0d9CiXJ4" title="Reverse stock split"&gt;1-for-15&lt;/span&gt; reverse split of its outstanding common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
references in these consolidated financial statements to shares and per share amounts in all periods have been retrospectively restated
to reflect the effects of both reverse splits noted above. The number of authorized shares and the par value of the shares did not change
as a result of the reverse stock splits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Going
Concern&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates,
among other things, the realization of assets and satisfaction of liabilities in the normal course of business.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has not generated any product revenue. There is no assurance that profitable operations will ever be achieved, and, if achieved,
would be sustained on a continuing basis. Product development activities, clinical and pre-clinical testing, and commercialization of
the Company&#x2019;s product candidates are necessary to develop the Company&#x2019;s products and will require significant additional
financing. There can be no assurance the Company will be able to obtain such funds. These matters, among others, raise substantial doubt
about the Company&#x2019;s ability to continue as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;While
the Company believes in the viability of its strategy to ultimately realize revenues and in its ability to raise additional funds, management
cannot be certain that additional funding will be available on acceptable terms, or at all. The Company&#x2019;s ability to continue as
a going concern is dependent upon its ability to obtain adequate financing and achieve profitable operations. As a result, these plans
do not alleviate substantial doubt about the Company&#x2019;s ability to continue as a going concern for a period of 12 months following
the date these consolidated financial statements were issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as
a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2in; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ensysce
Biosciences, Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to the Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccounting>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2023-03-012023-03-31" id="Fact000604">1-for-12</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2024-12-012024-12-31" id="Fact000606">1-for-15</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000608">&lt;p id="xdx_802_eus-gaap--SignificantAccountingPoliciesTextBlock_zJcd5sazGsg9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
3 - &lt;span id="xdx_82C_zF7s4AJ9g82f"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--UseOfEstimates_zveVvBY9DfX5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zxqeiaUXWuV2"&gt;Use
of Estimates and Assumptions&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Preparation
of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the
amounts reported in the consolidated financial statements and disclosed in the accompanying notes. Actual results may differ from those
estimates and such differences may be material to the consolidated financial statements. The more significant estimates and assumptions
by management include, but are not limited to, the expense recognition for certain accrued research and development services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z5Hk2uib2D14" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zygQMHvUosyg"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
purposes of the consolidated balance sheets and consolidated statements of cash flows, the Company considers all highly liquid instruments
with maturity of three months or less at the time of issuance to be cash equivalents.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_zo3lGgLiIgy9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 11pt; text-align: justify; text-indent: -11pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zB4hMW0F5Oqf"&gt;Concentrations
of Credit Risk and Off-Balance Sheet Risk&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
and cash equivalents are financial instruments that are potentially subject to concentrations of credit risk. The Company&#x2019;s cash
and cash equivalents are deposited in accounts at large financial institutions and amounts currently exceed federally insured limits.
The Company has no financial instruments with off-balance sheet risk of loss. Additionally, the Company had a concentration in accounts
payable, as &lt;span id="xdx_909_eus-gaap--ConcentrationRiskBenchmarkDescription_c20240101__20241231_zmw5YXQYZ8Hi" title="Concentration of risk, description"&gt;three and two research and development vendors made up greater than 10% individually, and &lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerMember_zEZI17ZmWnC8" title="Concentration of risk"&gt;74&lt;/span&gt;% and &lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerMember_zs976MComFLb" title="Concentration of risk"&gt;38&lt;/span&gt;% in aggregate&lt;/span&gt;, of the
outstanding accounts payable balance as of December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zwleZMKpskh6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zaBuj1PHHCUh"&gt;Segments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 11pt; text-align: justify; text-indent: -11pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company operates and manages its business as &lt;span id="xdx_901_eus-gaap--NumberOfReportableSegments_dc_uSegment_c20240101__20241231_zYDclMDTWv76" title="Number of reportable segments"&gt;&lt;span id="xdx_904_eus-gaap--NumberOfOperatingSegments_dc_uSegment_c20240101__20241231_zSrs0LpfcAm6" title="Number of operating segments"&gt;one&lt;/span&gt;&lt;/span&gt; reportable and operating segment. Operating segments are defined as components of an
enterprise where separate financial information is evaluated regularly by the chief operating decision maker (CODM) in deciding how to
allocate resources and assess performance. The Company&#x2019;s CODM is the Chief Executive Officer, who reviews consolidated financial
information on a company-wide basis for purposes of allocating resources and assessing financial performance and does not regularly review
expenses or financial results on a more granular level.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zfuggtEVtZz8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zS2zZSGaYFt5"&gt;Property
and Equipment&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are fully depreciated as such there is &lt;span id="xdx_902_eus-gaap--Depreciation_do_c20240101__20241231_zW34HL8zFf9k" title="Depreciation"&gt;&lt;span id="xdx_904_eus-gaap--Depreciation_do_c20230101__20231231_z93sEe2bE0od" title="Depreciation"&gt;no&lt;/span&gt;&lt;/span&gt; depreciation expense recognized in the years ended December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zgdfIF1FSFS" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.15in; text-align: justify; text-indent: -0.15in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_z2J6dQFu7Vl3"&gt;Fair
Value Measurement&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
820, &lt;i&gt;Fair Value Measurements&lt;/i&gt;, (&#x201c;ASC 820&#x201d;) provides guidance on the development and disclosure of fair value measurements.
Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset
or paid to transfer a liability in an orderly transaction between willing market participants at the measurement date. As such, fair
value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset
or a liability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ensysce
Biosciences, Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to the Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Quoted
    prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inputs
    other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unobservable
    inputs which are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies,
    or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at
which to classify them for each reporting period. This determination requires significant judgments to be made by the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024 and 2023, the recorded values of cash and cash equivalents, prepaid expenses, accounts payable, and accrued expenses
and other liabilities approximate their fair values due to the short-term nature of these items.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company issued liability classified warrants in connection with the issuance of the 2021 Notes and 2022 Notes. The warrants were liability
classified due to certain cash settlement features and included in &#x201c;Other long-term liabilities&#x201d; on the consolidated balance
sheets. The Company uses a Black Scholes model to estimate the fair value of the warrants. Changes in the fair value of the warrants
are recognized in other income (expense) for each reporting period. Refer to Note 8 for additional details of the warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zqcg3Cg06c27" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following tables present assets and liabilities measured and recorded at fair value on the Company&#x2019;s consolidated balance sheet
as of December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BE_zTJxTK8lOqqa" style="display: none"&gt;SCHEDULE
OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20241231_zbJyGlmmJLo3" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zoWIcGw7gQAd" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zVPzC8Y445B4" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z19LhJzyVOAf" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pp0p0_zSNe1jUc3jbb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left; padding-bottom: 1pt"&gt;Liability classified warrants&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;10,096&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0639"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0640"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;10,096&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_z8S9YHvRoyU7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;10,096&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0644"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0645"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;10,096&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20231231_zIgq62KQtgkl" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zOVXH1TTIcnf" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zWv1Jl7p1Noe" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zIhTClXTKzl7" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pp0p0_zPGmgVRe3Otf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left; padding-bottom: 1pt"&gt;Liability classified warrants&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;26,388&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0649"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0650"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;26,388&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_z5k42qIGqpu4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;26,388&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0654"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0655"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;26,388&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_z6ZttRgJPGj8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ensysce
Biosciences, Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to the Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zErV5LTICKG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the change in fair value of the Company&#x2019;s Level 3 liabilities for the year ended December 31, 2024 (no
level 3 assets as of the year ended December 31, 2024):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_z5EbIprVn8Ke" style="display: none"&gt;SCHEDULE
OF CHANGE IN FAIR VALUE OF COMPANY&#x2019;S LEVEL 3&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Liability classified warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Fair value, December 31, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pp0p0_c20240101__20241231__us-gaap--FairValueByLiabilityClassAxis__custom--LiabilityClassifiedWarrantsMember_zV4N38CxRu87" style="width: 16%; text-align: right" title="Beginning balance"&gt;26,388&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_pp0p0_c20240101__20241231__us-gaap--FairValueByLiabilityClassAxis__custom--LiabilityClassifiedWarrantsMember_zKkx2wpiMFZb" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"&gt;(16,292&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Fair value, December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pp0p0_c20240101__20241231__us-gaap--FairValueByLiabilityClassAxis__custom--LiabilityClassifiedWarrantsMember_zLQych732CG3" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance"&gt;10,096&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zWYSi7SyxWI1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Federal
Grants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
September 2019, the NIH/NIDA awarded the Company a second research and development grant related to the development of its TAAP/MPAR
abuse deterrent technology for Opioid Use Disorder (the &#x201c;OUD Grant&#x201d;). The total approved budget was approximately $&lt;span id="xdx_90D_eus-gaap--GrantsReceivable_iI_pn5n6_c20190930_zncQAFem5bdf" title="Grants receivable"&gt;5.4&lt;/span&gt; million,
and the grant period ended August 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
September 2018, the National Institutes of Health (&#x201c;NIH&#x201d;) through the National Institute on Drug Abuse (&#x201c;NIDA&#x201d;)
awarded the Company a research and development grant related to the development of its MPAR&lt;sup&gt;&#xae;&lt;/sup&gt; overdose prevention technology
(the &#x201c;MPAR Grant&#x201d;). The initial grant was extended several times and cumulative funding under this grant of approximately
$&lt;span id="xdx_90B_eus-gaap--GrantsReceivable_iI_pn5n6_c20231231_zRI4sbUT3RDh" title="Grants receivable"&gt;10.7&lt;/span&gt; million was completed in December 2023. A new multi-year MPAR Grant was awarded by NIH through NIDA in August 2024, providing total
funding of $&lt;span id="xdx_902_eus-gaap--GrantsReceivable_iI_pn6n6_c20240831_zI3h2GAO9uSi" title="Grants receivable"&gt;14&lt;/span&gt; million through May 2027. As December 31, 2024, the remaining cash funding under the grant is $&lt;span id="xdx_90D_eus-gaap--GrantsReceivable_iI_pn5n6_c20241231_zYzjz6bhtdqk" title="Grants receivable"&gt;1.6&lt;/span&gt; million, covering the
period through May 31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes revenue when costs related to the grants are incurred and assessed as reimbursable. The Company believes this policy
is consistent with the overarching premise in Accounting Standards Codification Topic 606, &lt;i&gt;Revenue from Contracts with &lt;/i&gt;Customers
(&#x201c;ASC 606&#x201d;), applied by analogy, to ensure that it recognizes revenues to reflect the transfer of promised goods or services
to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services,
even though there is no &#x201c;exchange&#x201d; as defined in ASC 606. The Company believes the recognition of revenue as costs are incurred
and reimbursable amounts become due is analogous to the concept of transfer of control of a service over time under ASC 606.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_ecustom--ScheduleOfRevenueRecognitionUnderGrantsTableTextBlock_zvfS50tgNAKh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
revenue recognized under the MPAR Grant and OUD Grant was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zICynLUDum6k" style="display: none"&gt;SCHEDULE
OF REVENUE RECOGNITION UNDER GRANTS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240101__20241231_zQTKndyhkRdl" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20230101__20231231_zOdYbHvG8Kqa" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_hsrt--ProductOrServiceAxis__custom--MPARMember_zflyx04Dq5Cg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;MPAR&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;3,086,464&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;1,293,238&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_hsrt--ProductOrServiceAxis__custom--TAAPOUDMember_zl7OjoxNxWKk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;TAAP/OUD&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,123,567&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;937,282&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_zIJOxmHgytAa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,210,031&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,230,520&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zrt76Hy71T1h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amounts
requested or eligible to be requested through the NIH payment management system, but for which cash has not been received, are presented
as an unbilled receivable on the Company&#x2019;s consolidated balance sheet. As all amounts are expected to be remitted timely, no valuation
allowances are recorded.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ensysce
Biosciences, Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to the Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--ResearchAndDevelopmentExpensePolicy_zPwxZtQDdRsd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span&gt;&lt;span&gt;&lt;span id="xdx_864_zuSnCCjjiYI4"&gt;Research
and Development Costs&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s research and development expenses consist primarily of third-party research and development expenses, consulting expenses,
preclinical and clinical studies, and any allocable direct overhead, including facilities and depreciation costs, as well as salaries,
payroll taxes, and employee benefits for those individuals directly involved in ongoing research and development efforts. Research and
development expenses are charged to expense as incurred. Payments made prior to the receipt of goods or services to be used in research
and development are capitalized until the goods or services are received.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zvJ1IjIA6APg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zcuFmWgXI5g4"&gt;General
and Administrative Expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
and administrative expenses consist primarily of personnel costs associated with the Company&#x2019;s executive, finance, human resources,
compliance, and other administrative personnel, as well as accounting and legal professional services fees.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zucMljGhmxLj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zWpvL49RS8d6"&gt;Stock-based
Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company expenses stock-based compensation over the requisite service period based on the estimated grant-date fair value of the awards
using a graded amortization approach. The Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company estimates the fair value of stock option grants using the Black-Scholes option pricing model. The assumptions used in calculating
the fair value of stock-based awards represent management&#x2019;s best estimates and involve inherent uncertainties and the application
of management&#x2019;s judgment. Stock-based compensation costs are recorded in research and development and general and administrative
expenses in the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
time-to-time equity classified awards may be modified. On the modification date, the Company estimates the fair value of the awards immediately
before and immediately after modification. The incremental increase in fair value is recognized as expense immediately to the extent
the underlying equity awards are vested and on a straight-line basis over the same remaining amortization schedule as the unvested underlying
equity awards.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_z5abU6pNVae4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_z9agJgAiu3sl"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income
taxes are recorded in accordance with ASC 740, &lt;i&gt;Income Taxes&lt;/i&gt; (&#x201c;ASC 740&#x201d;), which provides for deferred taxes using an
asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of
events that have been included in the consolidated financial statements or tax returns. Deferred tax assets and liabilities are determined
based on the difference between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates
in effect for the year in which the differences are expected to reverse. Valuation allowances are provided if, based upon the weight
of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company
recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination
by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical
merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and
penalties accrued related to unrecognized tax benefits as income tax expense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ensysce
Biosciences, Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to the Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zpbniCRCshqg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zA7mwy9Prx82"&gt;Earnings
per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
basic earnings per share is calculated by dividing the Company&#x2019;s net income or loss attributable to common stockholders by the
weighted average number of common shares outstanding during the period. The diluted earnings per share is calculated by dividing the
Company&#x2019;s net earnings attributable to common stockholders by the diluted weighted average number of common shares outstanding
during the period, determined using the treasury stock method and the average stock price during the period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ztFHVlIk9OWh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following weighted average shares have been excluded from the calculations of diluted weighted average common shares outstanding because
they would have been anti-dilutive (the Company has utilized the principal balance outstanding and the end of period conversion price
for the Convertible Notes for the purposes of the weighted average share calculation below):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zZtpZSMxpsv6" style="display: none"&gt;SCHEDULE
OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240101__20241231_zA7NsW5MKaOk" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20230101__20231231_zqx6boqTHPy5" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zfqHftzvbIn6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Stock options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;38,734&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;8,784&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zXL6kro0wmf2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;551,287&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;253,208&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zwgsLK7HnB17" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Convertible Notes&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;9,187&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;78,086&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zqIJ72JozqZj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;599,208&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;340,078&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_ze8nSfeAfvJ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zIzPEraSHQZ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zsxBNeZKd276"&gt;Recently
Issued Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2023, the FASB issued ASU 2023-07, &#x201c;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&#x201d;,
which sets forth improvements to the current segment disclosure requirements in accordance with Topic 280 &#x201c;Segment Reporting,&#x201d;
including clarifying that entities with a single reportable segment are subject to both new and existing segment reporting requirements.
ASU 2023-07 will be effective retrospectively for fiscal years beginning after December 15, 2023, and interim periods beginning after
December 15, 2024. The Company adopted the standard with an effective date of January 1, 2024 and the adoption did not have a significant
impact on the consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the FASB issued ASU No. 2023-09, &#x201c;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&#x201d; ASU 2023-09
requires disaggregated information about a reporting entity&#x2019;s effective tax rate reconciliation as well as information on income
taxes paid. ASU 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted.
The Company is currently evaluating the impact of this guidance on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued ASU 2024-03, Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement Expenses (&#x201c;ASU 2024-03&#x201d;), which requires disclosure about the types
of costs and expenses included in certain expense captions presented on the income statement. The new disclosure requirements are effective
for the Company&#x2019;s annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with
early adoption permitted. The Company is currently evaluating the impact of this pronouncement on our related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued ASU 2024-04, &#x201c;Debt &#x2013; Debt with Conversion and other Options (Subtopic 470-20) &#x201c;, which
set forth to improve the relevance and consistency in the application of induced conversion guidance in Subtopic 470-20, Debt&#x2014;
Debt with Conversion and Other Options such as clarifying the requirements for determining whether certain settlements of convertible
debt instruments should be accounted for as an induced conversion. ASU 2024-04 is effective for all entities after December 15, 2025,
with early adoption permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_85E_zryUSNiPk6R6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ensysce
Biosciences, Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to the Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2024-01-01to2024-12-31" id="Fact000610">&lt;p id="xdx_84C_eus-gaap--UseOfEstimates_zveVvBY9DfX5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zxqeiaUXWuV2"&gt;Use
of Estimates and Assumptions&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Preparation
of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the
amounts reported in the consolidated financial statements and disclosed in the accompanying notes. Actual results may differ from those
estimates and such differences may be material to the consolidated financial statements. The more significant estimates and assumptions
by management include, but are not limited to, the expense recognition for certain accrued research and development services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000612">&lt;p id="xdx_840_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z5Hk2uib2D14" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zygQMHvUosyg"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
purposes of the consolidated balance sheets and consolidated statements of cash flows, the Company considers all highly liquid instruments
with maturity of three months or less at the time of issuance to be cash equivalents.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2024-01-01to2024-12-31" id="Fact000614">&lt;p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_zo3lGgLiIgy9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 11pt; text-align: justify; text-indent: -11pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zB4hMW0F5Oqf"&gt;Concentrations
of Credit Risk and Off-Balance Sheet Risk&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
and cash equivalents are financial instruments that are potentially subject to concentrations of credit risk. The Company&#x2019;s cash
and cash equivalents are deposited in accounts at large financial institutions and amounts currently exceed federally insured limits.
The Company has no financial instruments with off-balance sheet risk of loss. Additionally, the Company had a concentration in accounts
payable, as &lt;span id="xdx_909_eus-gaap--ConcentrationRiskBenchmarkDescription_c20240101__20241231_zmw5YXQYZ8Hi" title="Concentration of risk, description"&gt;three and two research and development vendors made up greater than 10% individually, and &lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerMember_zEZI17ZmWnC8" title="Concentration of risk"&gt;74&lt;/span&gt;% and &lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerMember_zs976MComFLb" title="Concentration of risk"&gt;38&lt;/span&gt;% in aggregate&lt;/span&gt;, of the
outstanding accounts payable balance as of December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskBenchmarkDescription contextRef="From2024-01-01to2024-12-31" id="Fact000616">three and two research and development vendors made up greater than 10% individually, and 74% and 38% in aggregate</us-gaap:ConcentrationRiskBenchmarkDescription>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-01-012024-12-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember_custom_CustomerMember"
      decimals="INF"
      id="Fact000618"
      unitRef="Pure">0.74</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember_custom_CustomerMember"
      decimals="INF"
      id="Fact000620"
      unitRef="Pure">0.38</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000622">&lt;p id="xdx_848_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zwleZMKpskh6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zaBuj1PHHCUh"&gt;Segments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 11pt; text-align: justify; text-indent: -11pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company operates and manages its business as &lt;span id="xdx_901_eus-gaap--NumberOfReportableSegments_dc_uSegment_c20240101__20241231_zYDclMDTWv76" title="Number of reportable segments"&gt;&lt;span id="xdx_904_eus-gaap--NumberOfOperatingSegments_dc_uSegment_c20240101__20241231_zSrs0LpfcAm6" title="Number of operating segments"&gt;one&lt;/span&gt;&lt;/span&gt; reportable and operating segment. Operating segments are defined as components of an
enterprise where separate financial information is evaluated regularly by the chief operating decision maker (CODM) in deciding how to
allocate resources and assess performance. The Company&#x2019;s CODM is the Chief Executive Officer, who reviews consolidated financial
information on a company-wide basis for purposes of allocating resources and assessing financial performance and does not regularly review
expenses or financial results on a more granular level.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000624"
      unitRef="Segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000626"
      unitRef="Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000628">&lt;p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zfuggtEVtZz8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zS2zZSGaYFt5"&gt;Property
and Equipment&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are fully depreciated as such there is &lt;span id="xdx_902_eus-gaap--Depreciation_do_c20240101__20241231_zW34HL8zFf9k" title="Depreciation"&gt;&lt;span id="xdx_904_eus-gaap--Depreciation_do_c20230101__20231231_z93sEe2bE0od" title="Depreciation"&gt;no&lt;/span&gt;&lt;/span&gt; depreciation expense recognized in the years ended December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:Depreciation
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000630"
      unitRef="USD">0</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000632"
      unitRef="USD">0</us-gaap:Depreciation>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000634">&lt;p id="xdx_84C_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zgdfIF1FSFS" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.15in; text-align: justify; text-indent: -0.15in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_z2J6dQFu7Vl3"&gt;Fair
Value Measurement&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
820, &lt;i&gt;Fair Value Measurements&lt;/i&gt;, (&#x201c;ASC 820&#x201d;) provides guidance on the development and disclosure of fair value measurements.
Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset
or paid to transfer a liability in an orderly transaction between willing market participants at the measurement date. As such, fair
value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset
or a liability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ensysce
Biosciences, Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to the Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Quoted
    prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inputs
    other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unobservable
    inputs which are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies,
    or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at
which to classify them for each reporting period. This determination requires significant judgments to be made by the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024 and 2023, the recorded values of cash and cash equivalents, prepaid expenses, accounts payable, and accrued expenses
and other liabilities approximate their fair values due to the short-term nature of these items.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company issued liability classified warrants in connection with the issuance of the 2021 Notes and 2022 Notes. The warrants were liability
classified due to certain cash settlement features and included in &#x201c;Other long-term liabilities&#x201d; on the consolidated balance
sheets. The Company uses a Black Scholes model to estimate the fair value of the warrants. Changes in the fair value of the warrants
are recognized in other income (expense) for each reporting period. Refer to Note 8 for additional details of the warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zqcg3Cg06c27" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following tables present assets and liabilities measured and recorded at fair value on the Company&#x2019;s consolidated balance sheet
as of December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BE_zTJxTK8lOqqa" style="display: none"&gt;SCHEDULE
OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20241231_zbJyGlmmJLo3" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zoWIcGw7gQAd" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zVPzC8Y445B4" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z19LhJzyVOAf" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pp0p0_zSNe1jUc3jbb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left; padding-bottom: 1pt"&gt;Liability classified warrants&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;10,096&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0639"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0640"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;10,096&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_z8S9YHvRoyU7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;10,096&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0644"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0645"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;10,096&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20231231_zIgq62KQtgkl" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zOVXH1TTIcnf" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zWv1Jl7p1Noe" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zIhTClXTKzl7" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pp0p0_zPGmgVRe3Otf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left; padding-bottom: 1pt"&gt;Liability classified warrants&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;26,388&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0649"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0650"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;26,388&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_z5k42qIGqpu4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;26,388&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0654"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0655"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;26,388&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_z6ZttRgJPGj8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ensysce
Biosciences, Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to the Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zErV5LTICKG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the change in fair value of the Company&#x2019;s Level 3 liabilities for the year ended December 31, 2024 (no
level 3 assets as of the year ended December 31, 2024):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_z5EbIprVn8Ke" style="display: none"&gt;SCHEDULE
OF CHANGE IN FAIR VALUE OF COMPANY&#x2019;S LEVEL 3&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Liability classified warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Fair value, December 31, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pp0p0_c20240101__20241231__us-gaap--FairValueByLiabilityClassAxis__custom--LiabilityClassifiedWarrantsMember_zV4N38CxRu87" style="width: 16%; text-align: right" title="Beginning balance"&gt;26,388&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_pp0p0_c20240101__20241231__us-gaap--FairValueByLiabilityClassAxis__custom--LiabilityClassifiedWarrantsMember_zKkx2wpiMFZb" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"&gt;(16,292&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Fair value, December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pp0p0_c20240101__20241231__us-gaap--FairValueByLiabilityClassAxis__custom--LiabilityClassifiedWarrantsMember_zLQych732CG3" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance"&gt;10,096&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zWYSi7SyxWI1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Federal
Grants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
September 2019, the NIH/NIDA awarded the Company a second research and development grant related to the development of its TAAP/MPAR
abuse deterrent technology for Opioid Use Disorder (the &#x201c;OUD Grant&#x201d;). The total approved budget was approximately $&lt;span id="xdx_90D_eus-gaap--GrantsReceivable_iI_pn5n6_c20190930_zncQAFem5bdf" title="Grants receivable"&gt;5.4&lt;/span&gt; million,
and the grant period ended August 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
September 2018, the National Institutes of Health (&#x201c;NIH&#x201d;) through the National Institute on Drug Abuse (&#x201c;NIDA&#x201d;)
awarded the Company a research and development grant related to the development of its MPAR&lt;sup&gt;&#xae;&lt;/sup&gt; overdose prevention technology
(the &#x201c;MPAR Grant&#x201d;). The initial grant was extended several times and cumulative funding under this grant of approximately
$&lt;span id="xdx_90B_eus-gaap--GrantsReceivable_iI_pn5n6_c20231231_zRI4sbUT3RDh" title="Grants receivable"&gt;10.7&lt;/span&gt; million was completed in December 2023. A new multi-year MPAR Grant was awarded by NIH through NIDA in August 2024, providing total
funding of $&lt;span id="xdx_902_eus-gaap--GrantsReceivable_iI_pn6n6_c20240831_zI3h2GAO9uSi" title="Grants receivable"&gt;14&lt;/span&gt; million through May 2027. As December 31, 2024, the remaining cash funding under the grant is $&lt;span id="xdx_90D_eus-gaap--GrantsReceivable_iI_pn5n6_c20241231_zYzjz6bhtdqk" title="Grants receivable"&gt;1.6&lt;/span&gt; million, covering the
period through May 31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes revenue when costs related to the grants are incurred and assessed as reimbursable. The Company believes this policy
is consistent with the overarching premise in Accounting Standards Codification Topic 606, &lt;i&gt;Revenue from Contracts with &lt;/i&gt;Customers
(&#x201c;ASC 606&#x201d;), applied by analogy, to ensure that it recognizes revenues to reflect the transfer of promised goods or services
to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services,
even though there is no &#x201c;exchange&#x201d; as defined in ASC 606. The Company believes the recognition of revenue as costs are incurred
and reimbursable amounts become due is analogous to the concept of transfer of control of a service over time under ASC 606.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_ecustom--ScheduleOfRevenueRecognitionUnderGrantsTableTextBlock_zvfS50tgNAKh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
revenue recognized under the MPAR Grant and OUD Grant was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zICynLUDum6k" style="display: none"&gt;SCHEDULE
OF REVENUE RECOGNITION UNDER GRANTS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240101__20241231_zQTKndyhkRdl" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20230101__20231231_zOdYbHvG8Kqa" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_hsrt--ProductOrServiceAxis__custom--MPARMember_zflyx04Dq5Cg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;MPAR&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;3,086,464&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;1,293,238&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_hsrt--ProductOrServiceAxis__custom--TAAPOUDMember_zl7OjoxNxWKk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;TAAP/OUD&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,123,567&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;937,282&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_zIJOxmHgytAa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,210,031&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,230,520&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zrt76Hy71T1h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amounts
requested or eligible to be requested through the NIH payment management system, but for which cash has not been received, are presented
as an unbilled receivable on the Company&#x2019;s consolidated balance sheet. As all amounts are expected to be remitted timely, no valuation
allowances are recorded.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ensysce
Biosciences, Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to the Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000636">&lt;p id="xdx_897_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zqcg3Cg06c27" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following tables present assets and liabilities measured and recorded at fair value on the Company&#x2019;s consolidated balance sheet
as of December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BE_zTJxTK8lOqqa" style="display: none"&gt;SCHEDULE
OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20241231_zbJyGlmmJLo3" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zoWIcGw7gQAd" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zVPzC8Y445B4" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z19LhJzyVOAf" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pp0p0_zSNe1jUc3jbb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left; padding-bottom: 1pt"&gt;Liability classified warrants&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;10,096&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0639"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0640"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;10,096&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_z8S9YHvRoyU7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;10,096&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0644"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0645"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;10,096&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20231231_zIgq62KQtgkl" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zOVXH1TTIcnf" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zWv1Jl7p1Noe" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zIhTClXTKzl7" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pp0p0_zPGmgVRe3Otf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left; padding-bottom: 1pt"&gt;Liability classified warrants&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;26,388&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0649"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0650"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;26,388&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_z5k42qIGqpu4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;26,388&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0654"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0655"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;26,388&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000638"
      unitRef="USD">10096</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000641"
      unitRef="USD">10096</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000643"
      unitRef="USD">10096</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000646"
      unitRef="USD">10096</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000648"
      unitRef="USD">26388</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000651"
      unitRef="USD">26388</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000653"
      unitRef="USD">26388</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000656"
      unitRef="USD">26388</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000658">&lt;p id="xdx_89A_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zErV5LTICKG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the change in fair value of the Company&#x2019;s Level 3 liabilities for the year ended December 31, 2024 (no
level 3 assets as of the year ended December 31, 2024):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_z5EbIprVn8Ke" style="display: none"&gt;SCHEDULE
OF CHANGE IN FAIR VALUE OF COMPANY&#x2019;S LEVEL 3&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Liability classified warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Fair value, December 31, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pp0p0_c20240101__20241231__us-gaap--FairValueByLiabilityClassAxis__custom--LiabilityClassifiedWarrantsMember_zV4N38CxRu87" style="width: 16%; text-align: right" title="Beginning balance"&gt;26,388&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_pp0p0_c20240101__20241231__us-gaap--FairValueByLiabilityClassAxis__custom--LiabilityClassifiedWarrantsMember_zKkx2wpiMFZb" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"&gt;(16,292&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Fair value, December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pp0p0_c20240101__20241231__us-gaap--FairValueByLiabilityClassAxis__custom--LiabilityClassifiedWarrantsMember_zLQych732CG3" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance"&gt;10,096&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2023-12-31_custom_LiabilityClassifiedWarrantsMember"
      decimals="0"
      id="Fact000660"
      unitRef="USD">26388</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="From2024-01-012024-12-31_custom_LiabilityClassifiedWarrantsMember"
      decimals="0"
      id="Fact000662"
      unitRef="USD">-16292</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2024-12-31_custom_LiabilityClassifiedWarrantsMember"
      decimals="0"
      id="Fact000664"
      unitRef="USD">10096</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:GrantsReceivable
      contextRef="AsOf2019-09-30"
      decimals="-5"
      id="Fact000666"
      unitRef="USD">5400000</us-gaap:GrantsReceivable>
    <us-gaap:GrantsReceivable
      contextRef="AsOf2023-12-31"
      decimals="-5"
      id="Fact000668"
      unitRef="USD">10700000</us-gaap:GrantsReceivable>
    <us-gaap:GrantsReceivable
      contextRef="AsOf2024-08-31"
      decimals="-6"
      id="Fact000670"
      unitRef="USD">14000000</us-gaap:GrantsReceivable>
    <us-gaap:GrantsReceivable
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000672"
      unitRef="USD">1600000</us-gaap:GrantsReceivable>
    <ENSC:ScheduleOfRevenueRecognitionUnderGrantsTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000674">&lt;p id="xdx_898_ecustom--ScheduleOfRevenueRecognitionUnderGrantsTableTextBlock_zvfS50tgNAKh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
revenue recognized under the MPAR Grant and OUD Grant was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zICynLUDum6k" style="display: none"&gt;SCHEDULE
OF REVENUE RECOGNITION UNDER GRANTS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240101__20241231_zQTKndyhkRdl" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20230101__20231231_zOdYbHvG8Kqa" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_hsrt--ProductOrServiceAxis__custom--MPARMember_zflyx04Dq5Cg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;MPAR&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;3,086,464&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;1,293,238&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_hsrt--ProductOrServiceAxis__custom--TAAPOUDMember_zl7OjoxNxWKk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;TAAP/OUD&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,123,567&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;937,282&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_zIJOxmHgytAa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,210,031&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,230,520&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ENSC:ScheduleOfRevenueRecognitionUnderGrantsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2024-01-012024-12-31_custom_MPARMember"
      decimals="0"
      id="Fact000676"
      unitRef="USD">3086464</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2023-01-012023-12-31_custom_MPARMember"
      decimals="0"
      id="Fact000677"
      unitRef="USD">1293238</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2024-01-012024-12-31_custom_TAAPOUDMember"
      decimals="0"
      id="Fact000679"
      unitRef="USD">2123567</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2023-01-012023-12-31_custom_TAAPOUDMember"
      decimals="0"
      id="Fact000680"
      unitRef="USD">937282</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000682"
      unitRef="USD">5210031</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000683"
      unitRef="USD">2230520</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2024-01-01to2024-12-31" id="Fact000685">&lt;p id="xdx_843_eus-gaap--ResearchAndDevelopmentExpensePolicy_zPwxZtQDdRsd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span&gt;&lt;span&gt;&lt;span id="xdx_864_zuSnCCjjiYI4"&gt;Research
and Development Costs&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s research and development expenses consist primarily of third-party research and development expenses, consulting expenses,
preclinical and clinical studies, and any allocable direct overhead, including facilities and depreciation costs, as well as salaries,
payroll taxes, and employee benefits for those individuals directly involved in ongoing research and development efforts. Research and
development expenses are charged to expense as incurred. Payments made prior to the receipt of goods or services to be used in research
and development are capitalized until the goods or services are received.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000687">&lt;p id="xdx_84A_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zvJ1IjIA6APg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zcuFmWgXI5g4"&gt;General
and Administrative Expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
and administrative expenses consist primarily of personnel costs associated with the Company&#x2019;s executive, finance, human resources,
compliance, and other administrative personnel, as well as accounting and legal professional services fees.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2024-01-01to2024-12-31" id="Fact000689">&lt;p id="xdx_848_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zucMljGhmxLj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zWpvL49RS8d6"&gt;Stock-based
Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company expenses stock-based compensation over the requisite service period based on the estimated grant-date fair value of the awards
using a graded amortization approach. The Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company estimates the fair value of stock option grants using the Black-Scholes option pricing model. The assumptions used in calculating
the fair value of stock-based awards represent management&#x2019;s best estimates and involve inherent uncertainties and the application
of management&#x2019;s judgment. Stock-based compensation costs are recorded in research and development and general and administrative
expenses in the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
time-to-time equity classified awards may be modified. On the modification date, the Company estimates the fair value of the awards immediately
before and immediately after modification. The incremental increase in fair value is recognized as expense immediately to the extent
the underlying equity awards are vested and on a straight-line basis over the same remaining amortization schedule as the unvested underlying
equity awards.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000691">&lt;p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_z5abU6pNVae4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_z9agJgAiu3sl"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income
taxes are recorded in accordance with ASC 740, &lt;i&gt;Income Taxes&lt;/i&gt; (&#x201c;ASC 740&#x201d;), which provides for deferred taxes using an
asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of
events that have been included in the consolidated financial statements or tax returns. Deferred tax assets and liabilities are determined
based on the difference between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates
in effect for the year in which the differences are expected to reverse. Valuation allowances are provided if, based upon the weight
of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company
recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination
by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical
merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and
penalties accrued related to unrecognized tax benefits as income tax expense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ensysce
Biosciences, Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to the Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000693">&lt;p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zpbniCRCshqg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zA7mwy9Prx82"&gt;Earnings
per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
basic earnings per share is calculated by dividing the Company&#x2019;s net income or loss attributable to common stockholders by the
weighted average number of common shares outstanding during the period. The diluted earnings per share is calculated by dividing the
Company&#x2019;s net earnings attributable to common stockholders by the diluted weighted average number of common shares outstanding
during the period, determined using the treasury stock method and the average stock price during the period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ztFHVlIk9OWh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following weighted average shares have been excluded from the calculations of diluted weighted average common shares outstanding because
they would have been anti-dilutive (the Company has utilized the principal balance outstanding and the end of period conversion price
for the Convertible Notes for the purposes of the weighted average share calculation below):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zZtpZSMxpsv6" style="display: none"&gt;SCHEDULE
OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240101__20241231_zA7NsW5MKaOk" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20230101__20231231_zqx6boqTHPy5" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zfqHftzvbIn6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Stock options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;38,734&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;8,784&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zXL6kro0wmf2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;551,287&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;253,208&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zwgsLK7HnB17" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Convertible Notes&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;9,187&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;78,086&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zqIJ72JozqZj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;599,208&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;340,078&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_ze8nSfeAfvJ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000695">&lt;p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ztFHVlIk9OWh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following weighted average shares have been excluded from the calculations of diluted weighted average common shares outstanding because
they would have been anti-dilutive (the Company has utilized the principal balance outstanding and the end of period conversion price
for the Convertible Notes for the purposes of the weighted average share calculation below):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zZtpZSMxpsv6" style="display: none"&gt;SCHEDULE
OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240101__20241231_zA7NsW5MKaOk" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20230101__20231231_zqx6boqTHPy5" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zfqHftzvbIn6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Stock options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;38,734&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;8,784&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zXL6kro0wmf2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;551,287&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;253,208&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zwgsLK7HnB17" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Convertible Notes&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;9,187&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;78,086&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zqIJ72JozqZj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;599,208&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;340,078&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000697"
      unitRef="Shares">38734</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000698"
      unitRef="Shares">8784</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000700"
      unitRef="Shares">551287</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000701"
      unitRef="Shares">253208</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_ConvertibleDebtSecuritiesMember"
      decimals="INF"
      id="Fact000703"
      unitRef="Shares">9187</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_ConvertibleDebtSecuritiesMember"
      decimals="INF"
      id="Fact000704"
      unitRef="Shares">78086</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000706"
      unitRef="Shares">599208</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000707"
      unitRef="Shares">340078</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000709">&lt;p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zIzPEraSHQZ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zsxBNeZKd276"&gt;Recently
Issued Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2023, the FASB issued ASU 2023-07, &#x201c;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&#x201d;,
which sets forth improvements to the current segment disclosure requirements in accordance with Topic 280 &#x201c;Segment Reporting,&#x201d;
including clarifying that entities with a single reportable segment are subject to both new and existing segment reporting requirements.
ASU 2023-07 will be effective retrospectively for fiscal years beginning after December 15, 2023, and interim periods beginning after
December 15, 2024. The Company adopted the standard with an effective date of January 1, 2024 and the adoption did not have a significant
impact on the consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the FASB issued ASU No. 2023-09, &#x201c;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&#x201d; ASU 2023-09
requires disaggregated information about a reporting entity&#x2019;s effective tax rate reconciliation as well as information on income
taxes paid. ASU 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted.
The Company is currently evaluating the impact of this guidance on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued ASU 2024-03, Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement Expenses (&#x201c;ASU 2024-03&#x201d;), which requires disclosure about the types
of costs and expenses included in certain expense captions presented on the income statement. The new disclosure requirements are effective
for the Company&#x2019;s annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with
early adoption permitted. The Company is currently evaluating the impact of this pronouncement on our related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued ASU 2024-04, &#x201c;Debt &#x2013; Debt with Conversion and other Options (Subtopic 470-20) &#x201c;, which
set forth to improve the relevance and consistency in the application of induced conversion guidance in Subtopic 470-20, Debt&#x2014;
Debt with Conversion and Other Options such as clarifying the requirements for determining whether certain settlements of convertible
debt instruments should be accounted for as an induced conversion. ASU 2024-04 is effective for all entities after December 15, 2025,
with early adoption permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000711">&lt;p id="xdx_808_eus-gaap--OtherCurrentAssetsTextBlock_ziQn7hWltTf9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
4 &#x2013; &lt;span id="xdx_82E_zeFWHpBN5mVb"&gt;PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zhZWYehENRfl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
expenses and other current assets consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_zTOmKgfzXjV4" style="display: none"&gt;SCHEDULE
OF PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20241231_zsJ6JB7ZzWE8" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20231231_zOg38WjypbNl" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--PrepaidResearchAndDevelopment_iI_pp0p0_maOPECzDNl_zX69uge2qLT5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Prepaid research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;1,342,461&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;535,474&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--PrepaidInsurance_iI_pp0p0_maOPECzDNl_z3i4vqRGFku3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepaid insurance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;315,306&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;441,871&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0p0_maOPECzDNl_zMlmPQ5H6G54" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other prepaid expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;42,723&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72,358&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OtherAssetsCurrent_iI_pp0p0_maOPECzDNl_zEOzzEPap5c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other current assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;18,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;18,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PrepaidExpenseCurrent_iTI_pp0p0_mtOPECzDNl_zJP3hFCAOgRf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total prepaid expenses and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,718,490&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,067,703&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A8_z3lPfhNaewUg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000713">&lt;p id="xdx_890_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zhZWYehENRfl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
expenses and other current assets consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_zTOmKgfzXjV4" style="display: none"&gt;SCHEDULE
OF PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20241231_zsJ6JB7ZzWE8" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20231231_zOg38WjypbNl" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--PrepaidResearchAndDevelopment_iI_pp0p0_maOPECzDNl_zX69uge2qLT5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Prepaid research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;1,342,461&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;535,474&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--PrepaidInsurance_iI_pp0p0_maOPECzDNl_z3i4vqRGFku3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepaid insurance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;315,306&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;441,871&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0p0_maOPECzDNl_zMlmPQ5H6G54" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other prepaid expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;42,723&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72,358&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OtherAssetsCurrent_iI_pp0p0_maOPECzDNl_zEOzzEPap5c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other current assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;18,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;18,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PrepaidExpenseCurrent_iTI_pp0p0_mtOPECzDNl_zJP3hFCAOgRf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total prepaid expenses and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,718,490&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,067,703&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <ENSC:PrepaidResearchAndDevelopment
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000715"
      unitRef="USD">1342461</ENSC:PrepaidResearchAndDevelopment>
    <ENSC:PrepaidResearchAndDevelopment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000716"
      unitRef="USD">535474</ENSC:PrepaidResearchAndDevelopment>
    <us-gaap:PrepaidInsurance
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000718"
      unitRef="USD">315306</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000719"
      unitRef="USD">441871</us-gaap:PrepaidInsurance>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000721"
      unitRef="USD">42723</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000722"
      unitRef="USD">72358</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000724"
      unitRef="USD">18000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000725"
      unitRef="USD">18000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000727"
      unitRef="USD">1718490</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000728"
      unitRef="USD">1067703</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000730">&lt;p id="xdx_803_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zcxvTJ4bKsV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
5 &#x2013; &lt;span id="xdx_82B_zrybOIUkKSZ7"&gt;ACCRUED EXPENSES AND OTHER LIABILITIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zyYzX8ee1iMg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
expenses and other liabilities consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_z2VFAiYHpf8d" style="display: none"&gt;SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20241231_z6UyDzuT5hZk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20231231_znNSDBaLHgx5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--AccruedResearchAndDevelopment_iI_maALAOLzFDV_zzYz7el2CYQ6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Accrued research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;324,521&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;329,228&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AccruedProfessionalFeesCurrentAndNoncurrent_iI_maALAOLzFDV_zKpDrbEp3Pu4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;88,995&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;110,202&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OtherAccruedLiabilitiesCurrentAndNoncurrent_iI_maALAOLzFDV_znsy9GWYpIvc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other accrued liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;134,942&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;102,830&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iTI_mtALAOLzFDV_z799HnM7bElk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total accrued expenses and other liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;548,458&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;542,260&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zRQSHJP66Pq1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8A1_zoP5PQLzdP51" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000732">&lt;p id="xdx_894_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zyYzX8ee1iMg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
expenses and other liabilities consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_z2VFAiYHpf8d" style="display: none"&gt;SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20241231_z6UyDzuT5hZk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20231231_znNSDBaLHgx5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--AccruedResearchAndDevelopment_iI_maALAOLzFDV_zzYz7el2CYQ6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Accrued research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;324,521&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;329,228&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AccruedProfessionalFeesCurrentAndNoncurrent_iI_maALAOLzFDV_zKpDrbEp3Pu4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;88,995&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;110,202&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OtherAccruedLiabilitiesCurrentAndNoncurrent_iI_maALAOLzFDV_znsy9GWYpIvc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other accrued liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;134,942&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;102,830&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iTI_mtALAOLzFDV_z799HnM7bElk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total accrued expenses and other liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;548,458&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;542,260&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <ENSC:AccruedResearchAndDevelopment
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000734"
      unitRef="USD">324521</ENSC:AccruedResearchAndDevelopment>
    <ENSC:AccruedResearchAndDevelopment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000735"
      unitRef="USD">329228</ENSC:AccruedResearchAndDevelopment>
    <us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000737"
      unitRef="USD">88995</us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent>
    <us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000738"
      unitRef="USD">110202</us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000740"
      unitRef="USD">134942</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000741"
      unitRef="USD">102830</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000743"
      unitRef="USD">548458</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000744"
      unitRef="USD">542260</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000746">&lt;p id="xdx_804_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zh3ulZPAYho4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
6 - &lt;span id="xdx_82B_zHeM1V6AEDC3"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Purchase
Commitments&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, the Company&#x2019;s commitments included an estimated $&lt;span id="xdx_903_eus-gaap--ContractualObligation_iI_pn5n6_c20241231_z1LgkISEQIgg" title="Contractual obligation"&gt;12.0&lt;/span&gt; million related to the Company&#x2019;s open purchase
orders and contractual obligations that occurred in the ordinary course of business, including commitments with contract research organizations
for multi-year pre-clinical and clinical research studies. Although open purchase orders are considered enforceable and legally binding,
the terms generally allow the Company the option to cancel, reschedule, and adjust its requirements based on its business needs prior
to the delivery of goods or the performance of services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Litigation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024 and 2023, there were no pending legal proceedings against the Company that are expected to have a material adverse
effect on cash flows, financial condition or results of operations. From time to time, the Company could become involved in disputes
and various litigation matters that arise in the normal course of business. These may include disputes and lawsuits related to intellectual
property, licensing, contract law and employee relations matters. Periodically, the Company reviews the status of significant matters,
if any exist, and assesses its potential financial exposure. If the potential loss from any claim or legal claim is considered probable
and the amount can be estimated, the Company accrues a liability for the estimated loss. Legal proceedings are subject to uncertainties,
and the outcomes are difficult to predict. Because of such uncertainties, accruals are based on the best information available at the
time. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ensysce
Biosciences, Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to the Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Lease&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s current lease agreement (as amended) has a term that extends through October 31, 2025, with no option to renew. As of
December 31, 2024, the future lease payments totaled $&lt;span id="xdx_901_eus-gaap--OperatingLeasePayments_c20240101__20241231_zGXcYyDsqZOc" title="Future lease payments"&gt;29,545&lt;/span&gt;. The Company recognized total rent expense of $&lt;span id="xdx_90E_eus-gaap--PaymentsForRent_c20240101__20241231_zaHvxCpJFsFh" title="Rent expense"&gt;35,217&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--PaymentsForRent_c20230101__20231231_z6crpAeTybtj" title="Rent expense"&gt;33,747&lt;/span&gt; in the
year ended December 31, 2024, and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:ContractualObligation
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000748"
      unitRef="USD">12000000.0</us-gaap:ContractualObligation>
    <us-gaap:OperatingLeasePayments
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000750"
      unitRef="USD">29545</us-gaap:OperatingLeasePayments>
    <us-gaap:PaymentsForRent
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000752"
      unitRef="USD">35217</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000754"
      unitRef="USD">33747</us-gaap:PaymentsForRent>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000756">&lt;p id="xdx_80F_eus-gaap--DebtDisclosureTextBlock_ztHWQcqbfxh3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
7 - &lt;span id="xdx_82B_zg5VubIMHgea"&gt;NOTES PAYABLE&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfDebtTableTextBlock_zRdvCmgkuhr1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table provides a summary of the Company&#x2019;s outstanding debt as of December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B8_zxqkAlQYmA68" style="display: none"&gt;SCHEDULE OF DEBT&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Principal balance&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Accrued interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Net debt balance&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%"&gt;2023 Notes&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zU60fbBhchl5" style="width: 14%; text-align: right" title="Principal balance"&gt;216,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zQwwIJ88fsjb" style="width: 14%; text-align: right" title="Accrued interest"&gt;14,368&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_pp0p0_di_c20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zvNzNBWlPKJd" style="width: 2%" title="Unamortized Debt Discount &amp;amp; Issuance Costs"&gt;&#160;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,197,200&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--NotesPayable_iI_pp0p0_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zYbjz8oyRlw3" style="width: 14%; text-align: right" title="Net debt balance"&gt;230,368&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Financed insurance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20241231__us-gaap--DebtInstrumentAxis__custom--FinancedInsuranceMember_zi1MOHF1prN" style="border-bottom: Black 1pt solid; text-align: right" title="Principal balance"&gt;71,292&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20241231__us-gaap--DebtInstrumentAxis__custom--FinancedInsuranceMember_zX7cjlkEPmle" style="border-bottom: Black 1pt solid; text-align: right" title="Accrued interest"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0770"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--NotesPayable_iI_pp0p0_c20241231__us-gaap--DebtInstrumentAxis__custom--FinancedInsuranceMember_zjfPcpqvL9g2" style="border-bottom: Black 1pt solid; text-align: right" title="Net debt balance"&gt;71,292&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20241231_zN6dblsf1W9" style="border-bottom: Black 2.5pt double; text-align: right" title="Principal balance"&gt;287,292&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20241231_zbT8QYGR1xKj" style="border-bottom: Black 2.5pt double; text-align: right" title="Accrued interest"&gt;14,368&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--NotesPayable_iI_pp0p0_c20241231_zKyk7jAmrqDe" style="border-bottom: Black 2.5pt double; text-align: right" title="Net debt balance"&gt;301,660&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table provides a summary of the Company&#x2019;s outstanding debt as of December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Principal&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;balance&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Accrued&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;interest&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Unamortized Debt&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Discount &amp;amp; Issuance Costs&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Net debt&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;balance&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;2023 Notes&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_z6ApS99mzxnd" style="width: 12%; text-align: right" title="Principal balance"&gt;1,836,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zuQoFuAWg6S2" style="width: 12%; text-align: right" title="Accrued interest"&gt;13,078&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_pp0p0_di_c20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zpsKqhY4hFsa" style="width: 12%; text-align: right" title="Unamortized Debt Discount &amp;amp; Issuance Costs"&gt;(1,197,200&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--NotesPayable_iI_pp0p0_c20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zgo6IaYfBrL5" style="width: 12%; text-align: right" title="Net debt balance"&gt;651,878&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Financed insurance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20231231__us-gaap--DebtInstrumentAxis__custom--FinancedInsuranceMember_zZYBHGxwKeM3" style="border-bottom: Black 1pt solid; text-align: right" title="Principal balance"&gt;197,249&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20231231__us-gaap--DebtInstrumentAxis__custom--FinancedInsuranceMember_zOneN2YGSs8l" style="border-bottom: Black 1pt solid; text-align: right" title="Accrued interest"&gt;5,570&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_pp0p0_di_c20231231__us-gaap--DebtInstrumentAxis__custom--FinancedInsuranceMember_z3EUfu8HSr32" style="border-bottom: Black 1pt solid; text-align: right" title="Unamortized Debt Discount &amp;amp; Issuance Costs"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0792"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--NotesPayable_iI_pp0p0_c20231231__us-gaap--DebtInstrumentAxis__custom--FinancedInsuranceMember_zkf50oewR1ta" style="border-bottom: Black 1pt solid; text-align: right" title="Net debt balance"&gt;202,819&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20231231_z1UV83Pl5Crf" style="border-bottom: Black 2.5pt double; text-align: right" title="Principal balance"&gt;2,033,249&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20231231_zRKee8TWZVyd" style="border-bottom: Black 2.5pt double; text-align: right" title="Accrued interest"&gt;18,648&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_pp0p0_di_c20231231_zdnuLAFZdHMc" style="border-bottom: Black 2.5pt double; text-align: right" title="Unamortized Debt Discount &amp;amp; Issuance Costs"&gt;(1,197,200&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--NotesPayable_iI_pp0p0_c20231231_zXNq56k5z4id" style="border-bottom: Black 2.5pt double; text-align: right" title="Net debt balance"&gt;854,697&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zan8qF5u4ao1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Interest
expense&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
interest expense recognized for financed insurance was $&lt;span id="xdx_902_eus-gaap--InterestExpenseDebt_c20240101__20241231_zdv0ZCGKFl0l" title="Interest expense"&gt;8,848&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--InterestExpenseDebt_c20230101__20231231_zAxb6hqFheed" title="Interest expense"&gt;14,716&lt;/span&gt; for the year ended December 31, 2024 and 2023, respectively.
Interest expense recognized for the 2023 Notes was $&lt;span id="xdx_903_eus-gaap--InterestExpense_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zazvpgU2aZg8" title="Interest expense"&gt;1,281,597&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--InterestExpense_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zETvqSJ1YjP7" title="Interest expense"&gt;339,230&lt;/span&gt; for the year-ended December 31, 2024 and 2023, respectively,
which consists of amortization of the debt discount and debt issuance costs and accrued interest.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ensysce
Biosciences, Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to the Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;2023
Notes&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 23, 2023, the Company entered into a Securities Purchase Agreement (&#x201c;SPA&#x201d;) for an aggregate financing of $&lt;span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfDebt_pn5n6_c20231022__20231023__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zp7p0hxFUQ73" title="Debt financing amount"&gt;1.8&lt;/span&gt; million
with investors, including $&lt;span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfDebt_pn5n6_c20231022__20231023__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zr1xVxeaqvL2" title="Debt financing amount"&gt;0.2&lt;/span&gt; million with a board member. At the first closing under the SPA, which occurred on October 25, 2023, the
Company issued to the investors (i) senior secured convertible promissory notes in the aggregate principal amount of $&lt;span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20231025__us-gaap--TypeOfArrangementAxis__custom--FirstClosingSecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zbbfr8W7tcdl" title="Aggregate principal amount"&gt;612,000&lt;/span&gt; for an
aggregate purchase price of $&lt;span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfDebt_c20231024__20231025__us-gaap--TypeOfArrangementAxis__custom--FirstClosingSecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zVTuPS6WcGU" title="Aggregate purchase price"&gt;566,667&lt;/span&gt; and (ii) warrants to purchase &lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231025__us-gaap--TypeOfArrangementAxis__custom--FirstClosingSecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_z0Hg2M4kvoJ3" title="Warrants to purchase common shares"&gt;83,714&lt;/span&gt; shares of the Company&#x2019;s common stock, par value $&lt;span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231025__us-gaap--TypeOfArrangementAxis__custom--FirstClosingSecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zZNmyPVzSY92" title="Common stock, par value"&gt;0.0001&lt;/span&gt;
per share in the aggregate. At the second closing under the SPA, which occurred on November 29, 2023, the Company issued to the investors
referenced above, (i) additional notes in the aggregate principal amount of $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20231129__us-gaap--TypeOfArrangementAxis__custom--SecondClosingSecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zXh6GJVNDM2e" title="Aggregate principal amount"&gt;1,224,000&lt;/span&gt; for an aggregate purchase price of $&lt;span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfDebt_c20231129__20231129__us-gaap--TypeOfArrangementAxis__custom--SecondClosingSecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_znDCO1BygGmg" title="Aggregate purchase price"&gt;1,133,333&lt;/span&gt;
and (i) additional warrants to purchase &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231129__us-gaap--TypeOfArrangementAxis__custom--SecondClosingSecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zMtyK4wa4mMg" title="Warrants to purchase common shares"&gt;167,427&lt;/span&gt; shares of the common stock in the aggregate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company reflected the outstanding principal amount, the remaining unamortized discount (both original issue discount and the relative
fair value discount associated with the warrants discussed below) and the remaining debt issuance costs as a net amount on the face of
the balance sheet. The amortization of the original debt discount (approximately $&lt;span id="xdx_903_eus-gaap--AmortizationOfDebtDiscountPremium_pn5n6_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zZrOI3gczxp" title="Amortization of debt discount premium"&gt;0.1&lt;/span&gt; million) and issuance costs (approximately $&lt;span id="xdx_901_eus-gaap--AmortizationOfFinancingCosts_pn5n6_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_znoBURwnBXp" title="Amortization of financing costs"&gt;0.3&lt;/span&gt;
million) were recorded as interest expense within the consolidated statements of operations. As of December 31, 2024, the original debt
discount and issuance costs were fully amortized to interest expense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
warrants have an exercise price of $&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231023__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zGQi6NF1g2of" title="Warrant, exercise price"&gt;23.5125&lt;/span&gt;, the same as the conversion price, and are exercisable for five years following the issuance
date. The warrants were equity classified as they are indexed to the Company&#x2019;s stock and only settleable in shares. The warrants
were initially measured at fair value using a Black-Scholes valuation model and were allocated along with the 2023 Notes using the relative
fair value method. The initial fair value of $&lt;span id="xdx_904_eus-gaap--PaymentsOfDebtIssuanceCosts_pn5n6_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkykbIhTvnla" title="Payments of debt issuance costs"&gt;1.1&lt;/span&gt; million allocated to the warrants was considered a debt discount and was amortized
to interest expense over the remaining term of the notes. As of December 31, 2024, the discount associated with the warrants was fully
amortized to interest expense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
2024, the Company converted &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20240101__20241231_z2O30PcjZcU9" title="Conversion of shares"&gt;49,702&lt;/span&gt; shares of common stock with a conversion value of $&lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_pn5n6_c20240101__20241231_zle77cfFJId3" title="Conversion of shares value"&gt;1.2&lt;/span&gt; million related to the 2023 Notes. In addition,
in connection with the SPA, the Company incurred a $&lt;span id="xdx_90D_ecustom--ProceedsFromWarrantInducementNetOfIssuanceCosts_pn5n6_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zXFvSxJxpLnj" title="Transaction cost"&gt;1.0&lt;/span&gt; million waiver fee as a result of the 2024 February Warrant Inducement (see Note
8) to pay down $&lt;span id="xdx_904_ecustom--IssuanceOfCommonStockValueUponWarrantInducementNetOfIssuanceCosts_pn5n6_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zN8scmQ2jArc" title="Warrant inducement cost"&gt;0.5&lt;/span&gt; million of the 2023 Notes and incurred $&lt;span id="xdx_90D_ecustom--TransactionCostsAssociatedWithWarrantInducement_pn5n6_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zZEY9dScflk5" title="Transaction cost"&gt;0.5&lt;/span&gt; million in transaction costs recorded as such in the consolidated statement
of stockholders&#x2019; equity. As of December 31, 2024, the remaining amount of the 2023 Notes relates to senior secured convertible
promissory notes held by a Company board member (see Note 11).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Financed
Insurance Premiums&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2024, the Company renewed and financed its directors&#x2019; and officers&#x2019; liability insurance in the amount of $&lt;span id="xdx_902_ecustom--FinancedInsurancePremiums_pn5n6_c20240601__20240630_zA0fv0x4kAt1" title="Financed insurance premiums"&gt;0.2&lt;/span&gt; million.
Monthly payments are scheduled from July 2024 through March 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000758">&lt;p id="xdx_89D_eus-gaap--ScheduleOfDebtTableTextBlock_zRdvCmgkuhr1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table provides a summary of the Company&#x2019;s outstanding debt as of December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B8_zxqkAlQYmA68" style="display: none"&gt;SCHEDULE OF DEBT&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Principal balance&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Accrued interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Net debt balance&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%"&gt;2023 Notes&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zU60fbBhchl5" style="width: 14%; text-align: right" title="Principal balance"&gt;216,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zQwwIJ88fsjb" style="width: 14%; text-align: right" title="Accrued interest"&gt;14,368&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_pp0p0_di_c20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zvNzNBWlPKJd" style="width: 2%" title="Unamortized Debt Discount &amp;amp; Issuance Costs"&gt;&#160;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,197,200&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--NotesPayable_iI_pp0p0_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zYbjz8oyRlw3" style="width: 14%; text-align: right" title="Net debt balance"&gt;230,368&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Financed insurance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20241231__us-gaap--DebtInstrumentAxis__custom--FinancedInsuranceMember_zi1MOHF1prN" style="border-bottom: Black 1pt solid; text-align: right" title="Principal balance"&gt;71,292&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20241231__us-gaap--DebtInstrumentAxis__custom--FinancedInsuranceMember_zX7cjlkEPmle" style="border-bottom: Black 1pt solid; text-align: right" title="Accrued interest"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0770"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--NotesPayable_iI_pp0p0_c20241231__us-gaap--DebtInstrumentAxis__custom--FinancedInsuranceMember_zjfPcpqvL9g2" style="border-bottom: Black 1pt solid; text-align: right" title="Net debt balance"&gt;71,292&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20241231_zN6dblsf1W9" style="border-bottom: Black 2.5pt double; text-align: right" title="Principal balance"&gt;287,292&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20241231_zbT8QYGR1xKj" style="border-bottom: Black 2.5pt double; text-align: right" title="Accrued interest"&gt;14,368&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--NotesPayable_iI_pp0p0_c20241231_zKyk7jAmrqDe" style="border-bottom: Black 2.5pt double; text-align: right" title="Net debt balance"&gt;301,660&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table provides a summary of the Company&#x2019;s outstanding debt as of December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Principal&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;balance&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Accrued&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;interest&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Unamortized Debt&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Discount &amp;amp; Issuance Costs&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Net debt&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;balance&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;2023 Notes&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_z6ApS99mzxnd" style="width: 12%; text-align: right" title="Principal balance"&gt;1,836,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zuQoFuAWg6S2" style="width: 12%; text-align: right" title="Accrued interest"&gt;13,078&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_pp0p0_di_c20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zpsKqhY4hFsa" style="width: 12%; text-align: right" title="Unamortized Debt Discount &amp;amp; Issuance Costs"&gt;(1,197,200&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--NotesPayable_iI_pp0p0_c20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeNotesMember_zgo6IaYfBrL5" style="width: 12%; text-align: right" title="Net debt balance"&gt;651,878&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Financed insurance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20231231__us-gaap--DebtInstrumentAxis__custom--FinancedInsuranceMember_zZYBHGxwKeM3" style="border-bottom: Black 1pt solid; text-align: right" title="Principal balance"&gt;197,249&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20231231__us-gaap--DebtInstrumentAxis__custom--FinancedInsuranceMember_zOneN2YGSs8l" style="border-bottom: Black 1pt solid; text-align: right" title="Accrued interest"&gt;5,570&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_pp0p0_di_c20231231__us-gaap--DebtInstrumentAxis__custom--FinancedInsuranceMember_z3EUfu8HSr32" style="border-bottom: Black 1pt solid; text-align: right" title="Unamortized Debt Discount &amp;amp; Issuance Costs"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0792"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--NotesPayable_iI_pp0p0_c20231231__us-gaap--DebtInstrumentAxis__custom--FinancedInsuranceMember_zkf50oewR1ta" style="border-bottom: Black 1pt solid; text-align: right" title="Net debt balance"&gt;202,819&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20231231_z1UV83Pl5Crf" style="border-bottom: Black 2.5pt double; text-align: right" title="Principal balance"&gt;2,033,249&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20231231_zRKee8TWZVyd" style="border-bottom: Black 2.5pt double; text-align: right" title="Accrued interest"&gt;18,648&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_pp0p0_di_c20231231_zdnuLAFZdHMc" style="border-bottom: Black 2.5pt double; text-align: right" title="Unamortized Debt Discount &amp;amp; Issuance Costs"&gt;(1,197,200&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--NotesPayable_iI_pp0p0_c20231231_zXNq56k5z4id" style="border-bottom: Black 2.5pt double; text-align: right" title="Net debt balance"&gt;854,697&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreeNotesMember"
      decimals="0"
      id="Fact000760"
      unitRef="USD">216000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreeNotesMember"
      decimals="0"
      id="Fact000762"
      unitRef="USD">14368</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="AsOf2023-12-31_custom_TwoThousandTwentyThreeNotesMember"
      decimals="0"
      id="Fact000764"
      unitRef="USD">1197200</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:NotesPayable
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreeNotesMember"
      decimals="0"
      id="Fact000766"
      unitRef="USD">230368</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-12-31_custom_FinancedInsuranceMember"
      decimals="0"
      id="Fact000768"
      unitRef="USD">71292</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:NotesPayable
      contextRef="AsOf2024-12-31_custom_FinancedInsuranceMember"
      decimals="0"
      id="Fact000772"
      unitRef="USD">71292</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000774"
      unitRef="USD">287292</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000776"
      unitRef="USD">14368</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:NotesPayable
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000778"
      unitRef="USD">301660</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-12-31_custom_TwoThousandTwentyThreeNotesMember"
      decimals="0"
      id="Fact000780"
      unitRef="USD">1836000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="AsOf2023-12-31_custom_TwoThousandTwentyThreeNotesMember"
      decimals="0"
      id="Fact000782"
      unitRef="USD">13078</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="AsOf2023-12-31_custom_TwoThousandTwentyThreeNotesMember"
      decimals="0"
      id="Fact000784"
      unitRef="USD">1197200</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:NotesPayable
      contextRef="AsOf2023-12-31_custom_TwoThousandTwentyThreeNotesMember"
      decimals="0"
      id="Fact000786"
      unitRef="USD">651878</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-12-31_custom_FinancedInsuranceMember"
      decimals="0"
      id="Fact000788"
      unitRef="USD">197249</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="AsOf2023-12-31_custom_FinancedInsuranceMember"
      decimals="0"
      id="Fact000790"
      unitRef="USD">5570</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:NotesPayable
      contextRef="AsOf2023-12-31_custom_FinancedInsuranceMember"
      decimals="0"
      id="Fact000794"
      unitRef="USD">202819</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000796"
      unitRef="USD">2033249</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000798"
      unitRef="USD">18648</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000800"
      unitRef="USD">1197200</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:NotesPayable
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000802"
      unitRef="USD">854697</us-gaap:NotesPayable>
    <us-gaap:InterestExpenseDebt
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000804"
      unitRef="USD">8848</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000806"
      unitRef="USD">14716</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpense
      contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyThreeNotesMember"
      decimals="0"
      id="Fact000808"
      unitRef="USD">1281597</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2023-01-012023-12-31_custom_TwoThousandTwentyThreeNotesMember"
      decimals="0"
      id="Fact000810"
      unitRef="USD">339230</us-gaap:InterestExpense>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2023-10-222023-10-23_custom_SecuritiesPurchaseAgreementMember"
      decimals="-5"
      id="Fact000812"
      unitRef="USD">1800000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2023-10-222023-10-23_custom_SecuritiesPurchaseAgreementMember_custom_TwoThousandTwentyThreeNotesMember"
      decimals="-5"
      id="Fact000814"
      unitRef="USD">200000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-10-25_custom_FirstClosingSecuritiesPurchaseAgreementMember_custom_TwoThousandTwentyThreeNotesMember"
      decimals="0"
      id="Fact000816"
      unitRef="USD">612000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2023-10-242023-10-25_custom_FirstClosingSecuritiesPurchaseAgreementMember_custom_TwoThousandTwentyThreeNotesMember"
      decimals="0"
      id="Fact000818"
      unitRef="USD">566667</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-10-25_custom_FirstClosingSecuritiesPurchaseAgreementMember_custom_TwoThousandTwentyThreeNotesMember"
      decimals="INF"
      id="Fact000820"
      unitRef="Shares">83714</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-10-25_custom_FirstClosingSecuritiesPurchaseAgreementMember_custom_TwoThousandTwentyThreeNotesMember"
      decimals="INF"
      id="Fact000822"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-11-29_custom_SecondClosingSecuritiesPurchaseAgreementMember_custom_TwoThousandTwentyThreeNotesMember"
      decimals="0"
      id="Fact000824"
      unitRef="USD">1224000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2023-11-292023-11-29_custom_SecondClosingSecuritiesPurchaseAgreementMember_custom_TwoThousandTwentyThreeNotesMember"
      decimals="0"
      id="Fact000826"
      unitRef="USD">1133333</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-11-29_custom_SecondClosingSecuritiesPurchaseAgreementMember_custom_TwoThousandTwentyThreeNotesMember"
      decimals="INF"
      id="Fact000828"
      unitRef="Shares">167427</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyThreeNotesMember"
      decimals="-5"
      id="Fact000830"
      unitRef="USD">100000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2023-01-012023-12-31_custom_TwoThousandTwentyThreeNotesMember"
      decimals="-5"
      id="Fact000832"
      unitRef="USD">300000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-10-23_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact000834"
      unitRef="USDPShares">23.5125</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyThreeNotesMember_us-gaap_WarrantMember"
      decimals="-5"
      id="Fact000836"
      unitRef="USD">1100000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000838"
      unitRef="Shares">49702</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-01to2024-12-31"
      decimals="-5"
      id="Fact000840"
      unitRef="USD">1200000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <ENSC:ProceedsFromWarrantInducementNetOfIssuanceCosts
      contextRef="From2024-01-012024-12-31_custom_SecuritiesPurchaseAgreementMember"
      decimals="-5"
      id="Fact000842"
      unitRef="USD">1000000.0</ENSC:ProceedsFromWarrantInducementNetOfIssuanceCosts>
    <ENSC:IssuanceOfCommonStockValueUponWarrantInducementNetOfIssuanceCosts
      contextRef="From2024-01-012024-12-31_custom_SecuritiesPurchaseAgreementMember"
      decimals="-5"
      id="Fact000844"
      unitRef="USD">500000</ENSC:IssuanceOfCommonStockValueUponWarrantInducementNetOfIssuanceCosts>
    <ENSC:TransactionCostsAssociatedWithWarrantInducement
      contextRef="From2024-01-012024-12-31_custom_SecuritiesPurchaseAgreementMember"
      decimals="-5"
      id="Fact000846"
      unitRef="USD">500000</ENSC:TransactionCostsAssociatedWithWarrantInducement>
    <ENSC:FinancedInsurancePremiums
      contextRef="From2024-06-012024-06-30"
      decimals="-5"
      id="Fact000848"
      unitRef="USD">200000</ENSC:FinancedInsurancePremiums>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000850">&lt;p id="xdx_809_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zWTGyPa8IOd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
8 - &lt;span&gt;&lt;span id="xdx_82F_zYuABdEVbHF3"&gt;STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s current Certificate of Incorporation authorizes &lt;span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_c20241231_zrV2WUXLqlIf" title="Common stock, shares authorized"&gt;250,000,000&lt;/span&gt; shares of common stock and &lt;span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_c20241231_zteT8gZgWyJ4" title="Preferred stock, shares authorized"&gt;1,500,000&lt;/span&gt; shares of preferred
stock, both with par value equal to $&lt;span id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20241231_z9tCfdW3PySl" title="Preferred stock, par value"&gt;0.0001&lt;/span&gt;. As of December 31, 2024, and December 31, 2023, there were &lt;span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_do_c20241231_zGmajhTfvq3j" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20241231_z9Zb7qDoIgAa" title="Preferred stock, shares outstanding"&gt;&lt;span id="xdx_904_eus-gaap--PreferredStockSharesIssued_iI_do_c20231231_zIDwjrdIbxD" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20231231_zBCrP6cNUYKd" title="Preferred stock, shares outstanding"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; shares of preferred stock
issued and outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ensysce
Biosciences, Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to the Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Reverse
Stock Split&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 27, 2024, the Company filed an amendment to the Company&#x2019;s Third Amended and Restated Certificate of Incorporation (as
amended to date, the &#x201c;Certificate of Incorporation&#x201d;), with the Secretary of State of the State of Delaware to effect a one-for-fifteen
(&lt;span id="xdx_906_eus-gaap--StockholdersEquityReverseStockSplit_c20241127__20241127_z5RC4Vt5IaK" title="Reverse stock split"&gt;1-for-15&lt;/span&gt;) reverse stock split (the &#x201c;Reverse Stock Split&#x201d;) of our common stock, par value $&lt;span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20241127_zuinUQtztzPh" title="Common stock par value"&gt;0.0001&lt;/span&gt; (the &#x201c;Common Stock&#x201d;).
The Reverse Stock Split was effective as of 12:01 am on December 6, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
described in detail in our definitive proxy statement filed with the SEC on October 18, 2024, the Board authorized a &lt;span id="xdx_90B_eus-gaap--StockholdersEquityReverseStockSplit_c20241018__20241018_z8x7qnNMc7Bg" title="Reverse stock split"&gt;1-for-15&lt;/span&gt; reverse
stock split ratio and directed the implementation of the Reverse Stock Split. As a result of the Reverse Stock Split, at the Effective
Time, every fifteen (15) shares of our pre-Reverse Stock Split Common Stock will be combined and reclassified into one (1) share of our
Common Stock. The post-Reverse Stock Split Common Stock began trading on December 6, 2024, with a new CUSIP number of 293602504. The
Reverse Stock Split does not affect any stockholder&#x2019;s ownership percentage of the Common Stock and does not change our authorized
number of shares, alter the par value of the Common Stock or modify any voting rights or other terms of the Common Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
exercise prices, and the number of shares of Common Stock issuable upon exercise of the Company&#x2019;s warrants automatically adjusted,
in accordance with their terms, in proportion to the Reverse Stock Split ratio, and proportionate adjustments were also made to the per
share exercise price and/or the number of shares issuable upon the exercise or vesting of all stock options and restricted stock unit
awards issued by the Company and outstanding immediately prior to the effective time of the Reverse Stock Split, which resulted in a
proportionate decrease in the number of shares of Common Stock reserved for issuance upon exercise or vesting of such stock options and
restricted stock unit awards, and a proportionate increase in the exercise price of all such stock options and restricted stock unit
awards. Concurrently, the number of shares reserved for issuance under the Company&#x2019;s Amended and Restated 2021 Omnibus Incentive
Plan immediately prior to the effective time of the Reverse Stock Split were reduced proportionately.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;No
fractional shares were issued in connection with the Reverse Stock Split. In lieu of the issuance of fractional shares, the Company
rounded up any fractional shares resulting from the Reverse Stock Split to the nearest whole share. Fractional shares will be rounded
up at the participant (per broker) level, with such rounding adjustment subject to each broker&#x2019;s particular processes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;2024
Registered Direct Offering and 2024 August Warrant Inducement&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
August 2024, the Company entered into a definitive Securities Purchase Agreement with certain institutional investors, pursuant to which
the Company agreed to issue and sell in a registered direct offering, (i) an aggregate of &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240801__20240831__us-gaap--StatementEquityComponentsAxis__custom--RegisteredDirectOfferingMember_zMDPs6ZH6uFk" title="Purchase of shares through securities purchase agreement"&gt;166,054&lt;/span&gt; shares of common stock, par value $&lt;span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240831__us-gaap--StatementEquityComponentsAxis__custom--RegisteredDirectOfferingMember_zHrnkP27SJxk" title="Common stock, par value"&gt;0.0001&lt;/span&gt;
per share at an offering price of $&lt;span id="xdx_90F_eus-gaap--SharePrice_iI_c20240831__us-gaap--StatementEquityComponentsAxis__custom--RegisteredDirectOfferingMember_zHxXYICrGoab" title="Common stock, share price"&gt;7.05&lt;/span&gt; per share, (ii) pre-funded warrants to purchase up to &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240801__20240831__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zyXM4NFckifa" title="Purchase of shares through securities purchase agreement"&gt;70,827&lt;/span&gt; shares of common stock, at a price
per pre-funded warrant equal to $&lt;span id="xdx_90A_eus-gaap--SharePrice_iI_c20240831__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_z0CawEybjKc" title="Common stock , share price"&gt;7.0485&lt;/span&gt;, the price per share less $&lt;span id="xdx_908_ecustom--AgentFeesAndOfferingExpensesPerShare_iI_c20240831__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zjvbuUdhoHZf" title="Agent fees and offering expenses , per share"&gt;0.0015&lt;/span&gt;, for gross proceeds of approximately $&lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn4n6_c20240801__20240831__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zYP4YjzkYVr3" title="Common stock, gross proceeds"&gt;1.67&lt;/span&gt; million before the
deduction of placement agent fees and offering expenses. The pre-funded warrants were subsequently exercised in full and were not outstanding
as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company also entered into the August Inducement Letter with certain warrant holders for the exercise of certain outstanding warrants
to purchase up to an aggregate of &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240229__us-gaap--StatementEquityComponentsAxis__custom--SeriesAandBWarrantsMember_zWgE0XnKYRJg" title="Warrants to purchase shares"&gt;480,234&lt;/span&gt; shares of common stock of the Company originally issued in February 2024, having an exercise
price of $&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240229__us-gaap--StatementEquityComponentsAxis__custom--SeriesAandBWarrantsMember_zlFMkjGmzJ7j" title="Warrant, exercise price"&gt;15.90&lt;/span&gt; per share, at a reduced exercise price of $&lt;span id="xdx_905_eus-gaap--SharePrice_iI_pid_c20240229__us-gaap--StatementEquityComponentsAxis__custom--SeriesAandBWarrantsMember_zP21DxvwHphf" title="Share price"&gt;7.05&lt;/span&gt; per share. The Company also agreed to amend certain existing warrants
to purchase up to an aggregate of &lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231130_zR66BDEGu974" title="Warrants to purchase common shares"&gt;133,334 &lt;/span&gt;shares of common stock that were previously issued in November 2023 and have an exercise price
of $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231130_zzncqRn5F0J" title="Warrant, exercise price"&gt;23.51&lt;/span&gt; per share such that the amended warrants will have a reduced exercise price of $&lt;span id="xdx_900_eus-gaap--SharePrice_iI_pid_c20231130_z5UmzlHe2fW4" title="Share price"&gt;7.05&lt;/span&gt; per share effective upon the closing of
the offering and will be exercisable from the date on which stockholder approval is received with respect to the issuance of the shares
of common stock issuable upon exercise of such warrants. As the existing November 2023 and February 2024 warrants and their related newly
issued warrants upon inducement were equity classified before and after the exchange, and as the exchange is directly attributable to
an equity offering, the Company recognized the effect of the modification of approximately $&lt;span id="xdx_90C_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20240201__20240229_zGgjQRCV2e0l" title="Stock issuance costs"&gt;10.2&lt;/span&gt; million as an equity issuance cost.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
a concurrent private placement, pursuant to the terms of the August Inducement Letter and Securities Purchase Agreement, the Company
utilized an exclusive placement agent for the 2024 Registered Direct Offering and 2024 August Warrant Inducement and incurred approximately
$&lt;span id="xdx_90C_eus-gaap--LegalFees_pn5n6_c20240801__20240831_zd571bwMMWvg" title="Legal fees"&gt;0.6&lt;/span&gt; million in legal fees and other closing costs. Additionally, &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20240801__20240831_zyLPZZZ75MEc" title="Warrants issue, description"&gt;the Company issued to the placement agent as compensation unregistered
warrants to purchase up to &lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20240831_zjVKmcCjhfUk" title="Warrants to purchase common stock"&gt;50,200&lt;/span&gt; shares of Common Stock.&lt;/span&gt; The placement agent warrants expire on &lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_pid_dd_c20240831__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjj8096w4L91" title="Warrant maturity date"&gt;August 28, 2029&lt;/span&gt;, and have an exercise
price of $&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240831__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zj8c3RQbGKf2" title="Warrant exercise price"&gt;8.81&lt;/span&gt; per share of Common Stock. The warrants will become exercisable upon stockholder approval and contain customary anti-dilution
adjustments to the exercise price, including for share splits, share dividends, rights offering and pro rata distributions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ensysce
Biosciences, Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to the Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;2024
February Warrant Inducement&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
February 2024, the Company executed an Inducement Letter with certain holders of existing warrants to purchase up to an aggregate of
&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240229__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZ2nDbej97D4" title="Warrants to purchase shares"&gt;240,120&lt;/span&gt; shares of the Company&#x2019;s common stock issued to the holders in connection with the 2023 May Offering. Pursuant to the Inducement
Letter, the holders agreed to exercise for cash their existing warrants to purchase an aggregate of &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240229__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNcS7ZaG4JA1" title="Warrants to purchase common shares"&gt;240,120&lt;/span&gt; shares of Common Stock at
a reduced exercise price of $&lt;span id="xdx_909_eus-gaap--SharePrice_iI_pid_c20240229__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znmKsujBCeXe" title="Share price"&gt;15.90&lt;/span&gt; per share in consideration of the Company&#x2019;s agreement to issue new unregistered Series A Warrants
(the &#x201c;Series A Warrants&#x201d;) to purchase up to &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240229__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsMember_zfVCqlxIhNC2" title="Warrants to purchase common shares"&gt;240,120&lt;/span&gt; shares of Common Stock and new unregistered Series B Warrants (the &#x201c;Series
B Warrants&#x201d;) to purchase up to&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240229__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zNScdBfwMU24" title="Warrants to purchase common shares"&gt; 240,120&lt;/span&gt; shares of Common Stock (collectively, the &#x201c;New Warrant Shares&#x201d;). The Series
A Warrants have an exercise price of $&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240229__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsMember_z5xM6DN4cmSi" title="Warrant, exercise price"&gt;15.90&lt;/span&gt; per share and have a term equal to eighteen months from the date of issuance. The Series
B Warrants have an exercise price of $&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240229__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_z6FS3gStJm67" title="Warrant, exercise price"&gt;15.90&lt;/span&gt; per share and will expire on &lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20240229__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zDHWRkDV8KVk" title="Warrants expiration date"&gt;May 12, 2028&lt;/span&gt;. The gross proceeds to the Company from the exercise
of the warrants were approximately $&lt;span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20240201__20240229__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWptwzDrXoY3" title="Proceeds from warrants"&gt;4.7&lt;/span&gt; million, prior to deducting placement agent fees and estimated offering expenses. As the existing
warrants and the new warrants were equity classified before and after the exchange, and as the exchange is directly attributable to an
equity offering, the Company recognized the effect of the modification of approximately $&lt;span id="xdx_90A_eus-gaap--EquityClassifiedWrittenCallOptionModificationEquityIssuanceIncreaseDecreaseInEquityAmount_pn5n6_c20240201__20240229__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOGbxXSrtFIl" title="Equity issuance costs"&gt;5.2&lt;/span&gt; million as an equity issuance cost.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the execution of the Inducement Letter, the Company executed a waiver related to the 2023 Notes&#x2019; SPA it had entered
into as of October 23, 2023. The SPA contained restrictions on the Company&#x2019;s ability to undertake certain transactions, which included
the execution of the Inducement Letter. The Waiver permitted the Company to execute the Inducement Letter but required repayment of the
certain investor held notes issued under the SPA with a premium following closing of the transaction contemplated thereby. Refer to Note
7 for the details of the waiver fee and the application of the amounts to the outstanding notes and as a transaction cost of the warrant
inducement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company utilized an exclusive placement agent for the 2024 Warrant Inducement and incurred approximately $&lt;span id="xdx_90C_eus-gaap--LegalFees_pn5n6_c20240201__20240229_zF9uCIklDMN6" title="Legal fees"&gt;0.3&lt;/span&gt; million in legal fees and
other closing costs. Additionally, &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_pid_c20240201__20240229_zkuKtZJCrPBb" title="Warrants issue, description"&gt;the Company issued to the placement agent as compensation unregistered warrants to purchase up to
&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20240229_zw1WmjWwJFs3" title="Warrants to purchase common stock"&gt;16,811&lt;/span&gt; shares of Common Stock, equal to 7.0% of the aggregate number of shares of Common Stock (or warrants) placed in the transaction&lt;/span&gt;.
The placement agent warrants expire on &lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_pid_dd_c20240229__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIAt1ngothKd" title="Warrant maturity date"&gt;May 12, 2028&lt;/span&gt;, and have an exercise price of $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240229__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zN0yS4UPZuLa" title="Warrant exercise price"&gt;24.56&lt;/span&gt; per share of Common Stock (equal to 125% of
the reduced exercise price per Existing Warrant). The closing of the offering occurred on February 14, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;2023
May Offering&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 12, 2023, the Company completed a public offering of an aggregate of &lt;span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230511__20230512_z8VEGjvliRzd" title="Sale of stock number of shares issued in transaction"&gt;120,059 &lt;/span&gt;shares of its common stock at par value $&lt;span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230512_zieH72sCICV7" title="Common stock, par value"&gt;0.0001&lt;/span&gt; per
share (including pre-funded warrants in lieu thereof) at a combined offering price of $&lt;span id="xdx_909_ecustom--CombinedOfferingPricePerShare_iI_c20230512_z37pZwZ8kCLe" title="Combined offering price"&gt;58.305&lt;/span&gt; per share, gross proceeds from this offering
were approximately $&lt;span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_pn5n6_c20230511__20230512_zik9BFAOJlL4"&gt;7.0&lt;/span&gt; million before the deduction of placement agent fees and related costs of $&lt;span id="xdx_903_eus-gaap--OtherExpenses_pn5n6_c20230511__20230512_zNJCPdjLS3n7" title="Related costs"&gt;0.7&lt;/span&gt; million. The warrants issued in
connection with the 2023 May Offering are described further below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the offering, the Company also agreed to amend certain existing warrants to purchase up to an aggregate of &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230512_zXDbBddXDXHe" title="Warrants to purchase common shares"&gt;14,006&lt;/span&gt; shares
of the Company&#x2019;s common stock that were previously issued in September 2021 through December 2022 to purchasers in the offering
at exercise prices ranging from $&lt;span id="xdx_907_eus-gaap--SharePrice_iI_pid_c20230512__srt--RangeAxis__srt--MinimumMember_zdTzae4jkZ96" title="Share price"&gt;252.00&lt;/span&gt; to $&lt;span id="xdx_901_eus-gaap--SharePrice_iI_pid_c20230512__srt--RangeAxis__srt--MaximumMember_zOgxnFntbxSa" title="Share price"&gt;2,808.00&lt;/span&gt; per share, such that effective upon the closing of the offering, the amended warrants
had a reduced exercise price of $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230512_zFd35NDbQAV5" title="Warrant, exercise price"&gt;54.60&lt;/span&gt; per share at an additional offering price of $&lt;span id="xdx_903_ecustom--OfferingPricePerShare_iI_c20230512__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMr1snJEmzC5" title="Combined offering price"&gt;1.875&lt;/span&gt; per amended warrant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;2023
February Offering&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 2, 2023, the Company agreed to issue and sell in a registered direct offering an aggregate of &lt;span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230201__20230202_zGegmGchM5E8" title="Sale of stock number of shares issued in transaction"&gt;19,842&lt;/span&gt; shares of common stock
of the Company, par value $&lt;span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230202_zU2eQ6W6QRv4" title="Common stock, par value"&gt;0.0001&lt;/span&gt; per share, at an offering price of $&lt;span id="xdx_902_ecustom--CombinedOfferingPricePerShare_iI_c20230202_zksNFHUNxmv8" title="Combined offering price"&gt;151.20&lt;/span&gt; per share, for gross proceeds of approximately $&lt;span id="xdx_907_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_pn5n6_c20230206__20230206_zTcbsblTicn7" title="Sale of stock, consideration received per transaction"&gt;3.0&lt;/span&gt; million
before the deduction of placement agent fees and related costs of $&lt;span id="xdx_90B_eus-gaap--OtherExpenses_pn5n6_c20230206__20230206_z2Yg7VM3pJFd" title="Related costs"&gt;0.3&lt;/span&gt; million. The closing occurred on February 6, 2023. The warrants
issued in connection with the 2023 February Offering are described further below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ensysce
Biosciences, Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to the Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zHn5nlaenwRe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table provides a summary of outstanding warrants to purchase shares of common stock as of December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zXazZfoKgjmh" style="display: none"&gt;SCHEDULE
OF OUTSTANDING WARRANT&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Reference&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Shares
    Underlying Outstanding Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise
    Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 20%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantOneMember_fYSk___z5mcVPdfxjK6" title="Outstanding warrant"&gt;1,913,906&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantOneMember__srt--RangeAxis__srt--MinimumMember_fYSk___z1fzs5eKzkL6" title="Exercise price"&gt;7.05&lt;/span&gt;
                                            - $&lt;span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantOneMember__srt--RangeAxis__srt--MaximumMember_fYSk___zYSSfkKFHT16" title="Exercise price"&gt;8.8125&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 24%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_ecustom--WarrantDescription_c20240101__20241231__us-gaap--AwardTypeAxis__custom--WarrantOneMember_fYSk___zBi4QCTIPhtb" title="Warrant description"&gt;August 2024 Warrants&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 20%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Equity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(b)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantTwoMember_fYik___zuqMtLVpfG7d" title="Outstanding warrant"&gt;16,811&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantTwoMember_fYik___zDDK2IHj4vDc" title="Exercise price"&gt;24.56&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_ecustom--WarrantDescription_c20240101__20241231__us-gaap--AwardTypeAxis__custom--WarrantTwoMember_fYik___zILx7s0ngawa" title="Warrant description"&gt;February 2024 Warrants&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Equity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(c)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantThreeMember_fYyk___zseDhakt9JB6" title="Outstanding warrant"&gt;162,881&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantThreeMember__srt--RangeAxis__srt--MinimumMember_fYyk___z0db45Uz6Jfd" title="Exercise price"&gt;7.05&lt;/span&gt;
                                       - $&lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantThreeMember__srt--RangeAxis__srt--MaximumMember_fYSk___z9VbRgENyBca" title="Exercise price"&gt;23.51&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_ecustom--WarrantDescription_c20240101__20241231__us-gaap--AwardTypeAxis__custom--WarrantThreeMember_fYyk___zh7PO0s0NUXl" title="Warrant description"&gt;2023 Notes Warrants&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Equity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(d)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantFourMember_fZCk___zx1bn6tK0Puj" title="Outstanding warrant"&gt;73,474&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantFourMember__srt--RangeAxis__srt--MinimumMember_fYyk___z70BJWkvuapc" title="Exercise price"&gt;54.56&lt;/span&gt;
                                       - $&lt;span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantFourMember__srt--RangeAxis__srt--MaximumMember_fYSk___zECjXJ627D37" title="Exercise price"&gt;41,400&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_ecustom--WarrantDescription_c20240101__20241231__us-gaap--AwardTypeAxis__custom--WarrantFourMember_fZCk___zWCcFWYok1tj" title="Warrant description"&gt;Other Warrants&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Equity &amp;amp; Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJTzDJCL87mj" title="Outstanding warrant"&gt;2,167,072&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F0B_zHttwTJw466l" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1F_zzEUMgyiqUNc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    August 29, 2024, in connection with the 2024 Registered Direct Offering and 2024 August Warrant Inducement&lt;b&gt;&lt;i&gt;,&lt;/i&gt;&lt;/b&gt; the Company
    issued equity classified warrants to purchase &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240829__us-gaap--ClassOfWarrantOrRightAxis__custom--InstitutionalInvestorMember_zNG3PCMr6ec2" title="Warrants issued"&gt;1,964,658&lt;/span&gt; shares to certain institutional investors and the placement agent. The warrants
    were issued in connection with the 2024 Registered Direct Offering and the 2024 August Warrant Inducement. The &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240829__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantsMember_zCcwEySoITL6" title="Warrants issued"&gt;1,914,466&lt;/span&gt; investor
    warrants have an exercise price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240829__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantsMember_zKC9jmetdTd9" title="Warrant exercise price"&gt;7.05 &lt;/span&gt;per share and are exercisable from the date on which stockholder approval is received. One
    half of the warrants will expire eighteen months after they are exercisable, and the other half will expire five years after they
    are exercisable. The &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240829__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zXGowZWvK2tl" title="Warrants issued"&gt;50,200&lt;/span&gt; placement agent warrants have an exercise price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240829__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zxoN3w5rZkN7" title="Warrant exercise price"&gt;8.8125&lt;/span&gt; per share, are exercisable upon stockholder
    approval and expire &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20240829__us-gaap--StatementClassOfStockAxis__custom--PlacementAgentWarrantsMember_zcyag8G0Zdfk" title="Warrant expiration date"&gt;August 28, 2029&lt;/span&gt;. In December 2024, &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantsMember_zuUEfDSwdiP2" title="Investor warrants exercised"&gt;50,760&lt;/span&gt; investor warrants were exercised.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F09_z7hCESe76193" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(b)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_F1E_zn22odATDlzh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
                                            February 12, 2024, the Company issued &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240212__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__custom--PlacementAgentWarrantsMember_zDxa1qEyCZYj" title="Warrants issued"&gt;497,042&lt;/span&gt; equity classified warrants (Series A Warrants,
                                            Series B Warrants and placement agent warrants) in connection with the Inducement Letter
                                            for the 2024 February warrant inducement and related warrant restructuring. The Series A
                                            and Series B Warrants were immediately exercisable with an exercise price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240212__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zR9dfSKJaEJ6" title="Warrants, exercise price"&gt;15.90&lt;/span&gt; per share
                                            and expire on &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20240212__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsMember_zZOTCaPZu5Pi" title="Warrant expiration date"&gt;August 14, 2025&lt;/span&gt; and &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20240212__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zaaTSgBzpBSd" title="Warrant expiration date"&gt;May 12, 2028&lt;/span&gt;, respectively. The placement agent warrants
                                            were immediately exercisable with an exercise price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240212__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCmYK51xOsxl" title="Warrant exercise price"&gt;24.56&lt;/span&gt; per share and expire on &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20240212__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zHgYiFEHje1l" title="Warrant expiration date"&gt;May
                                            12, 2028&lt;/span&gt;. In connection with the 2024 August Warrant Inducement, &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240831__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__custom--PlacementAgentWarrantsMember_zaRXUZi5a449" title="Warrants issued"&gt;480,234&lt;/span&gt; warrants were exercised.
                                            As of December 31, 2024, the placement agents remain outstanding.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F03_zsyzqHHpCIGb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(c)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_F15_zRUWJm7e3Vlj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
                                            October 25, 2023, and November 28, 2023, the Company issued warrants to purchase &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231025__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z10EZER6bSc1" title="Warrants issued"&gt;83,714&lt;/span&gt; shares
                                            and &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231128__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zM5GcBQqU1Vd" title="Warrants issued"&gt;167,427&lt;/span&gt; shares, respectively. The warrants were immediately exercisable with an exercise
                                            price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pp4d_c20231025__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGVJ31xafQXb" title="Warrants, exercise price"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pp4d_c20231128__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLgwkQtyqAdc" title="Warrants, exercise price"&gt;23.51&lt;/span&gt;&lt;/span&gt; per share and expire on &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20231025__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKB6m7xuUk91" title="Warrant expiration date"&gt;October 25, 2028&lt;/span&gt;, and &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20231128__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztlLffHDnze5" title="Warrant expiration date"&gt;November 28, 2028&lt;/span&gt;, respectively.
                                            In January 2024, a holder of the warrants exercised &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240131__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zonkSPUuw3Eb" title="Warrants exercisable"&gt;88,261&lt;/span&gt; warrants at an exercise price
                                            of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240131__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuaKVnF1utl" title="Warrant, exercise price"&gt;23.51&lt;/span&gt; per share. In August 2024, an inducement letter was issued to a holder of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240831_zAsZNrYfFeFc" title="Warrants to purchase common shares"&gt;133,334&lt;/span&gt;
                                            warrants to reduce the exercise price from $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--SharePrice_iI_pid_c20240830_zwEOqsMWCRwj" title="Share price"&gt;23.51&lt;/span&gt; to $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--SharePrice_iI_pid_c20240831_z1RxZeUk6qOa" title="Share price"&gt;7.05&lt;/span&gt; per share.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F08_zrT6I50Hspde" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(d)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F11_zMnLjdxbjTVh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
    various dates from the Closing of the Business Combination through September 30, 2023, the Company assumed or issued a total of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230930_ze0v1hh7LLhh" title="Warrants issued"&gt;73,474&lt;/span&gt;
    warrants to provide holders the right to purchase common stock at exercise prices ranging from $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__srt--RangeAxis__srt--MinimumMember_zVIcsZe1mFXd" title="Warrant exercise price"&gt;54.60&lt;/span&gt; - $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__srt--RangeAxis__srt--MaximumMember_zVdRSVUA0kk" title="Warrant exercise price"&gt;41,400&lt;/span&gt; per share. A total
    of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230930__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantMember_zTdEAKVUFAk2" title="Class of warrant or right, outstanding"&gt;2,778&lt;/span&gt; of the outstanding warrants are public warrants which trade on the OTC Pink Open Market under the ticker symbol ENSCW. A
    total of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230930__us-gaap--StatementEquityComponentsAxis__custom--Notes2021And2022Member_zypGz5J7nhb9" title="Class of warrant or right, outstanding"&gt;2,901&lt;/span&gt; outstanding warrants (issued in connection with the 2021 and 2022 Notes) are liability-classified due to certain cash
    settlement features embedded within the warrant agreements. The remaining warrants are equity classified. The warrants expire beginning
    &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230929__us-gaap--StatementEquityComponentsAxis__custom--Notes2021And2022Member_zscjcC1ZwVac" title="Warrant expiration date"&gt;June 30, 2026&lt;/span&gt;, through &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230930__us-gaap--StatementEquityComponentsAxis__custom--Notes2021And2022Member_zUzYNP45Z9a9" title="Warrant expiration date"&gt;August 7, 2028&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A5_zvPN3HK5znT4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000852"
      unitRef="Shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000854"
      unitRef="Shares">1500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000856"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000858"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000860"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000862"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000864"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2024-11-272024-11-27" id="Fact000866">1-for-15</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-11-27"
      decimals="INF"
      id="Fact000868"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2024-10-182024-10-18" id="Fact000870">1-for-15</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-08-012024-08-31_custom_RegisteredDirectOfferingMember"
      decimals="INF"
      id="Fact000872"
      unitRef="Shares">166054</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-08-31_custom_RegisteredDirectOfferingMember"
      decimals="INF"
      id="Fact000874"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SharePrice
      contextRef="AsOf2024-08-31_custom_RegisteredDirectOfferingMember"
      decimals="INF"
      id="Fact000876"
      unitRef="USDPShares">7.05</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-08-012024-08-31_custom_PrefundedWarrantMember"
      decimals="INF"
      id="Fact000878"
      unitRef="Shares">70827</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2024-08-31_custom_PrefundedWarrantMember"
      decimals="INF"
      id="Fact000880"
      unitRef="USDPShares">7.0485</us-gaap:SharePrice>
    <ENSC:AgentFeesAndOfferingExpensesPerShare
      contextRef="AsOf2024-08-31_custom_PrefundedWarrantMember"
      decimals="INF"
      id="Fact000882"
      unitRef="USDPShares">0.0015</ENSC:AgentFeesAndOfferingExpensesPerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-08-012024-08-31_custom_PrefundedWarrantMember"
      decimals="-4"
      id="Fact000884"
      unitRef="USD">1670000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-02-29_custom_SeriesAandBWarrantsMember"
      decimals="INF"
      id="Fact000886"
      unitRef="Shares">480234</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-02-29_custom_SeriesAandBWarrantsMember"
      decimals="INF"
      id="Fact000888"
      unitRef="USDPShares">15.90</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharePrice
      contextRef="AsOf2024-02-29_custom_SeriesAandBWarrantsMember"
      decimals="INF"
      id="Fact000890"
      unitRef="USDPShares">7.05</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-11-30"
      decimals="INF"
      id="Fact000892"
      unitRef="Shares">133334</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-11-30"
      decimals="INF"
      id="Fact000894"
      unitRef="USDPShares">23.51</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharePrice
      contextRef="AsOf2023-11-30"
      decimals="INF"
      id="Fact000896"
      unitRef="USDPShares">7.05</us-gaap:SharePrice>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2024-02-012024-02-29"
      decimals="-5"
      id="Fact000898"
      unitRef="USD">10200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:LegalFees
      contextRef="From2024-08-012024-08-31"
      decimals="-5"
      id="Fact000900"
      unitRef="USD">600000</us-gaap:LegalFees>
    <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees contextRef="From2024-08-012024-08-31" id="Fact000902">the Company issued to the placement agent as compensation unregistered
warrants to purchase up to 50,200 shares of Common Stock.</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2024-08-31"
      decimals="INF"
      id="Fact000904"
      unitRef="Shares">50200</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-08-31_us-gaap_WarrantMember"
      id="Fact000906">2029-08-28</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-08-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000908"
      unitRef="USDPShares">8.81</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-02-29_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000910"
      unitRef="Shares">240120</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-02-29_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000912"
      unitRef="Shares">240120</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharePrice
      contextRef="AsOf2024-02-29_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000914"
      unitRef="USDPShares">15.90</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-02-29_custom_SeriesAWarrantsMember"
      decimals="INF"
      id="Fact000916"
      unitRef="Shares">240120</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-02-29_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact000918"
      unitRef="Shares">240120</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-02-29_custom_SeriesAWarrantsMember"
      decimals="INF"
      id="Fact000920"
      unitRef="USDPShares">15.90</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-02-29_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact000922"
      unitRef="USDPShares">15.90</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-02-29_custom_SeriesBWarrantsMember"
      id="Fact000924">2028-05-12</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2024-02-012024-02-29_us-gaap_WarrantMember"
      decimals="-5"
      id="Fact000926"
      unitRef="USD">4700000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:EquityClassifiedWrittenCallOptionModificationEquityIssuanceIncreaseDecreaseInEquityAmount
      contextRef="From2024-02-012024-02-29_us-gaap_WarrantMember"
      decimals="-5"
      id="Fact000928"
      unitRef="USD">5200000</us-gaap:EquityClassifiedWrittenCallOptionModificationEquityIssuanceIncreaseDecreaseInEquityAmount>
    <us-gaap:LegalFees
      contextRef="From2024-02-012024-02-29"
      decimals="-5"
      id="Fact000930"
      unitRef="USD">300000</us-gaap:LegalFees>
    <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees contextRef="From2024-02-012024-02-29" id="Fact000932">the Company issued to the placement agent as compensation unregistered warrants to purchase up to
16,811 shares of Common Stock, equal to 7.0% of the aggregate number of shares of Common Stock (or warrants) placed in the transaction</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2024-02-29"
      decimals="INF"
      id="Fact000934"
      unitRef="Shares">16811</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-02-29_us-gaap_WarrantMember"
      id="Fact000936">2028-05-12</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-02-29_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000938"
      unitRef="USDPShares">24.56</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2023-05-112023-05-12"
      decimals="INF"
      id="Fact000940"
      unitRef="Shares">120059</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-05-12"
      decimals="INF"
      id="Fact000942"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <ENSC:CombinedOfferingPricePerShare
      contextRef="AsOf2023-05-12"
      decimals="INF"
      id="Fact000944"
      unitRef="USDPShares">58.305</ENSC:CombinedOfferingPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="From2023-05-112023-05-12"
      decimals="-5"
      id="Fact000945"
      unitRef="USD">7000000.0</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:OtherExpenses
      contextRef="From2023-05-112023-05-12"
      decimals="-5"
      id="Fact000947"
      unitRef="USD">700000</us-gaap:OtherExpenses>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-05-12"
      decimals="INF"
      id="Fact000949"
      unitRef="Shares">14006</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharePrice
      contextRef="AsOf2023-05-12_srt_MinimumMember"
      decimals="INF"
      id="Fact000951"
      unitRef="USDPShares">252.00</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2023-05-12_srt_MaximumMember"
      decimals="INF"
      id="Fact000953"
      unitRef="USDPShares">2808.00</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-05-12"
      decimals="INF"
      id="Fact000955"
      unitRef="USDPShares">54.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ENSC:OfferingPricePerShare
      contextRef="AsOf2023-05-12_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000957"
      unitRef="USDPShares">1.875</ENSC:OfferingPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2023-02-012023-02-02"
      decimals="INF"
      id="Fact000959"
      unitRef="Shares">19842</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-02-02"
      decimals="INF"
      id="Fact000961"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <ENSC:CombinedOfferingPricePerShare
      contextRef="AsOf2023-02-02"
      decimals="INF"
      id="Fact000963"
      unitRef="USDPShares">151.20</ENSC:CombinedOfferingPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="From2023-02-062023-02-06"
      decimals="-5"
      id="Fact000965"
      unitRef="USD">3000000.0</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:OtherExpenses
      contextRef="From2023-02-062023-02-06"
      decimals="-5"
      id="Fact000967"
      unitRef="USD">300000</us-gaap:OtherExpenses>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000969">&lt;p id="xdx_89C_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zHn5nlaenwRe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table provides a summary of outstanding warrants to purchase shares of common stock as of December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zXazZfoKgjmh" style="display: none"&gt;SCHEDULE
OF OUTSTANDING WARRANT&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Reference&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Shares
    Underlying Outstanding Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise
    Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 20%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantOneMember_fYSk___z5mcVPdfxjK6" title="Outstanding warrant"&gt;1,913,906&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantOneMember__srt--RangeAxis__srt--MinimumMember_fYSk___z1fzs5eKzkL6" title="Exercise price"&gt;7.05&lt;/span&gt;
                                            - $&lt;span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantOneMember__srt--RangeAxis__srt--MaximumMember_fYSk___zYSSfkKFHT16" title="Exercise price"&gt;8.8125&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 24%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_ecustom--WarrantDescription_c20240101__20241231__us-gaap--AwardTypeAxis__custom--WarrantOneMember_fYSk___zBi4QCTIPhtb" title="Warrant description"&gt;August 2024 Warrants&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 20%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Equity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(b)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantTwoMember_fYik___zuqMtLVpfG7d" title="Outstanding warrant"&gt;16,811&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantTwoMember_fYik___zDDK2IHj4vDc" title="Exercise price"&gt;24.56&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_ecustom--WarrantDescription_c20240101__20241231__us-gaap--AwardTypeAxis__custom--WarrantTwoMember_fYik___zILx7s0ngawa" title="Warrant description"&gt;February 2024 Warrants&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Equity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(c)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantThreeMember_fYyk___zseDhakt9JB6" title="Outstanding warrant"&gt;162,881&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantThreeMember__srt--RangeAxis__srt--MinimumMember_fYyk___z0db45Uz6Jfd" title="Exercise price"&gt;7.05&lt;/span&gt;
                                       - $&lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantThreeMember__srt--RangeAxis__srt--MaximumMember_fYSk___z9VbRgENyBca" title="Exercise price"&gt;23.51&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_ecustom--WarrantDescription_c20240101__20241231__us-gaap--AwardTypeAxis__custom--WarrantThreeMember_fYyk___zh7PO0s0NUXl" title="Warrant description"&gt;2023 Notes Warrants&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Equity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(d)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantFourMember_fZCk___zx1bn6tK0Puj" title="Outstanding warrant"&gt;73,474&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantFourMember__srt--RangeAxis__srt--MinimumMember_fYyk___z70BJWkvuapc" title="Exercise price"&gt;54.56&lt;/span&gt;
                                       - $&lt;span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice_iI_c20241231__us-gaap--AwardTypeAxis__custom--WarrantFourMember__srt--RangeAxis__srt--MaximumMember_fYSk___zECjXJ627D37" title="Exercise price"&gt;41,400&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_ecustom--WarrantDescription_c20240101__20241231__us-gaap--AwardTypeAxis__custom--WarrantFourMember_fZCk___zWCcFWYok1tj" title="Warrant description"&gt;Other Warrants&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Equity &amp;amp; Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJTzDJCL87mj" title="Outstanding warrant"&gt;2,167,072&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F0B_zHttwTJw466l" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1F_zzEUMgyiqUNc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    August 29, 2024, in connection with the 2024 Registered Direct Offering and 2024 August Warrant Inducement&lt;b&gt;&lt;i&gt;,&lt;/i&gt;&lt;/b&gt; the Company
    issued equity classified warrants to purchase &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240829__us-gaap--ClassOfWarrantOrRightAxis__custom--InstitutionalInvestorMember_zNG3PCMr6ec2" title="Warrants issued"&gt;1,964,658&lt;/span&gt; shares to certain institutional investors and the placement agent. The warrants
    were issued in connection with the 2024 Registered Direct Offering and the 2024 August Warrant Inducement. The &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240829__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantsMember_zCcwEySoITL6" title="Warrants issued"&gt;1,914,466&lt;/span&gt; investor
    warrants have an exercise price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240829__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantsMember_zKC9jmetdTd9" title="Warrant exercise price"&gt;7.05 &lt;/span&gt;per share and are exercisable from the date on which stockholder approval is received. One
    half of the warrants will expire eighteen months after they are exercisable, and the other half will expire five years after they
    are exercisable. The &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240829__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zXGowZWvK2tl" title="Warrants issued"&gt;50,200&lt;/span&gt; placement agent warrants have an exercise price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240829__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zxoN3w5rZkN7" title="Warrant exercise price"&gt;8.8125&lt;/span&gt; per share, are exercisable upon stockholder
    approval and expire &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20240829__us-gaap--StatementClassOfStockAxis__custom--PlacementAgentWarrantsMember_zcyag8G0Zdfk" title="Warrant expiration date"&gt;August 28, 2029&lt;/span&gt;. In December 2024, &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantsMember_zuUEfDSwdiP2" title="Investor warrants exercised"&gt;50,760&lt;/span&gt; investor warrants were exercised.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F09_z7hCESe76193" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(b)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_F1E_zn22odATDlzh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
                                            February 12, 2024, the Company issued &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240212__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__custom--PlacementAgentWarrantsMember_zDxa1qEyCZYj" title="Warrants issued"&gt;497,042&lt;/span&gt; equity classified warrants (Series A Warrants,
                                            Series B Warrants and placement agent warrants) in connection with the Inducement Letter
                                            for the 2024 February warrant inducement and related warrant restructuring. The Series A
                                            and Series B Warrants were immediately exercisable with an exercise price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240212__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zR9dfSKJaEJ6" title="Warrants, exercise price"&gt;15.90&lt;/span&gt; per share
                                            and expire on &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20240212__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsMember_zZOTCaPZu5Pi" title="Warrant expiration date"&gt;August 14, 2025&lt;/span&gt; and &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20240212__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zaaTSgBzpBSd" title="Warrant expiration date"&gt;May 12, 2028&lt;/span&gt;, respectively. The placement agent warrants
                                            were immediately exercisable with an exercise price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240212__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCmYK51xOsxl" title="Warrant exercise price"&gt;24.56&lt;/span&gt; per share and expire on &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20240212__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zHgYiFEHje1l" title="Warrant expiration date"&gt;May
                                            12, 2028&lt;/span&gt;. In connection with the 2024 August Warrant Inducement, &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240831__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__custom--PlacementAgentWarrantsMember_zaRXUZi5a449" title="Warrants issued"&gt;480,234&lt;/span&gt; warrants were exercised.
                                            As of December 31, 2024, the placement agents remain outstanding.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F03_zsyzqHHpCIGb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(c)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_F15_zRUWJm7e3Vlj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
                                            October 25, 2023, and November 28, 2023, the Company issued warrants to purchase &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231025__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z10EZER6bSc1" title="Warrants issued"&gt;83,714&lt;/span&gt; shares
                                            and &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231128__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zM5GcBQqU1Vd" title="Warrants issued"&gt;167,427&lt;/span&gt; shares, respectively. The warrants were immediately exercisable with an exercise
                                            price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pp4d_c20231025__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGVJ31xafQXb" title="Warrants, exercise price"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pp4d_c20231128__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLgwkQtyqAdc" title="Warrants, exercise price"&gt;23.51&lt;/span&gt;&lt;/span&gt; per share and expire on &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20231025__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKB6m7xuUk91" title="Warrant expiration date"&gt;October 25, 2028&lt;/span&gt;, and &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20231128__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztlLffHDnze5" title="Warrant expiration date"&gt;November 28, 2028&lt;/span&gt;, respectively.
                                            In January 2024, a holder of the warrants exercised &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240131__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zonkSPUuw3Eb" title="Warrants exercisable"&gt;88,261&lt;/span&gt; warrants at an exercise price
                                            of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240131__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuaKVnF1utl" title="Warrant, exercise price"&gt;23.51&lt;/span&gt; per share. In August 2024, an inducement letter was issued to a holder of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240831_zAsZNrYfFeFc" title="Warrants to purchase common shares"&gt;133,334&lt;/span&gt;
                                            warrants to reduce the exercise price from $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--SharePrice_iI_pid_c20240830_zwEOqsMWCRwj" title="Share price"&gt;23.51&lt;/span&gt; to $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--SharePrice_iI_pid_c20240831_z1RxZeUk6qOa" title="Share price"&gt;7.05&lt;/span&gt; per share.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F08_zrT6I50Hspde" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(d)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F11_zMnLjdxbjTVh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
    various dates from the Closing of the Business Combination through September 30, 2023, the Company assumed or issued a total of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230930_ze0v1hh7LLhh" title="Warrants issued"&gt;73,474&lt;/span&gt;
    warrants to provide holders the right to purchase common stock at exercise prices ranging from $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__srt--RangeAxis__srt--MinimumMember_zVIcsZe1mFXd" title="Warrant exercise price"&gt;54.60&lt;/span&gt; - $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__srt--RangeAxis__srt--MaximumMember_zVdRSVUA0kk" title="Warrant exercise price"&gt;41,400&lt;/span&gt; per share. A total
    of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230930__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantMember_zTdEAKVUFAk2" title="Class of warrant or right, outstanding"&gt;2,778&lt;/span&gt; of the outstanding warrants are public warrants which trade on the OTC Pink Open Market under the ticker symbol ENSCW. A
    total of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230930__us-gaap--StatementEquityComponentsAxis__custom--Notes2021And2022Member_zypGz5J7nhb9" title="Class of warrant or right, outstanding"&gt;2,901&lt;/span&gt; outstanding warrants (issued in connection with the 2021 and 2022 Notes) are liability-classified due to certain cash
    settlement features embedded within the warrant agreements. The remaining warrants are equity classified. The warrants expire beginning
    &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230929__us-gaap--StatementEquityComponentsAxis__custom--Notes2021And2022Member_zscjcC1ZwVac" title="Warrant expiration date"&gt;June 30, 2026&lt;/span&gt;, through &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230930__us-gaap--StatementEquityComponentsAxis__custom--Notes2021And2022Member_zUzYNP45Z9a9" title="Warrant expiration date"&gt;August 7, 2028&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2024-12-31_custom_WarrantOneMember"
      decimals="INF"
      id="Fact000971"
      unitRef="Shares">1913906</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <ENSC:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice
      contextRef="AsOf2024-12-31_custom_WarrantOneMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000973"
      unitRef="USDPShares">7.05</ENSC:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice>
    <ENSC:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice
      contextRef="AsOf2024-12-31_custom_WarrantOneMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000975"
      unitRef="USDPShares">8.8125</ENSC:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice>
    <ENSC:WarrantDescription
      contextRef="From2024-01-012024-12-31_custom_WarrantOneMember"
      id="Fact000977">August 2024 Warrants</ENSC:WarrantDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2024-12-31_custom_WarrantTwoMember"
      decimals="INF"
      id="Fact000979"
      unitRef="Shares">16811</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <ENSC:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice
      contextRef="AsOf2024-12-31_custom_WarrantTwoMember"
      decimals="INF"
      id="Fact000981"
      unitRef="USDPShares">24.56</ENSC:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice>
    <ENSC:WarrantDescription
      contextRef="From2024-01-012024-12-31_custom_WarrantTwoMember"
      id="Fact000983">February 2024 Warrants</ENSC:WarrantDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2024-12-31_custom_WarrantThreeMember"
      decimals="INF"
      id="Fact000985"
      unitRef="Shares">162881</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <ENSC:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice
      contextRef="AsOf2024-12-31_custom_WarrantThreeMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000987"
      unitRef="USDPShares">7.05</ENSC:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice>
    <ENSC:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice
      contextRef="AsOf2024-12-31_custom_WarrantThreeMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000989"
      unitRef="USDPShares">23.51</ENSC:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice>
    <ENSC:WarrantDescription
      contextRef="From2024-01-012024-12-31_custom_WarrantThreeMember"
      id="Fact000991">2023 Notes Warrants</ENSC:WarrantDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2024-12-31_custom_WarrantFourMember"
      decimals="INF"
      id="Fact000993"
      unitRef="Shares">73474</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <ENSC:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice
      contextRef="AsOf2024-12-31_custom_WarrantFourMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000995"
      unitRef="USDPShares">54.56</ENSC:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice>
    <ENSC:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice
      contextRef="AsOf2024-12-31_custom_WarrantFourMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000997"
      unitRef="USDPShares">41400</ENSC:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityOutstandingExercisePrice>
    <ENSC:WarrantDescription
      contextRef="From2024-01-012024-12-31_custom_WarrantFourMember"
      id="Fact000999">Other Warrants</ENSC:WarrantDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001001"
      unitRef="Shares">2167072</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-08-29_custom_InstitutionalInvestorMember"
      decimals="INF"
      id="Fact001004"
      unitRef="Shares">1964658</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-08-29_custom_InvestorWarrantsMember"
      decimals="INF"
      id="Fact001006"
      unitRef="Shares">1914466</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-08-29_custom_InvestorWarrantsMember"
      decimals="INF"
      id="Fact001008"
      unitRef="USDPShares">7.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-08-29_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001010"
      unitRef="Shares">50200</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-08-29_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001012"
      unitRef="USDPShares">8.8125</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-08-29_custom_PlacementAgentWarrantsMember11635781"
      id="Fact001014">2029-08-28</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_InvestorWarrantsMember"
      decimals="INF"
      id="Fact001016"
      unitRef="Shares">50760</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-02-12_us-gaap_WarrantMember_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001019"
      unitRef="Shares">497042</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-02-12_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact001021"
      unitRef="USDPShares">15.90</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-02-12_custom_SeriesAWarrantsMember"
      id="Fact001023">2025-08-14</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-02-12_custom_SeriesBWarrantsMember"
      id="Fact001025">2028-05-12</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-02-12_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001027"
      unitRef="USDPShares">24.56</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-02-12_custom_SeriesBWarrantsMember"
      id="Fact001029">2028-05-12</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-08-31_us-gaap_WarrantMember_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001031"
      unitRef="Shares">480234</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-10-25_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001034"
      unitRef="Shares">83714</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-11-28_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001036"
      unitRef="Shares">167427</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-10-25_us-gaap_WarrantMember"
      decimals="4"
      id="Fact001038"
      unitRef="USDPShares">23.51</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-11-28_us-gaap_WarrantMember"
      decimals="4"
      id="Fact001040"
      unitRef="USDPShares">23.51</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2023-10-25_us-gaap_WarrantMember"
      id="Fact001042">2028-10-25</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2023-11-28_us-gaap_WarrantMember"
      id="Fact001044">2028-11-28</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-01-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001046"
      unitRef="Shares">88261</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-01-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001048"
      unitRef="USDPShares">23.51</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-08-31"
      decimals="INF"
      id="Fact001050"
      unitRef="Shares">133334</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharePrice
      contextRef="AsOf2024-08-30"
      decimals="INF"
      id="Fact001052"
      unitRef="USDPShares">23.51</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2024-08-31"
      decimals="INF"
      id="Fact001054"
      unitRef="USDPShares">7.05</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-09-30"
      decimals="INF"
      id="Fact001057"
      unitRef="Shares">73474</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-09-30_srt_MinimumMember"
      decimals="INF"
      id="Fact001059"
      unitRef="USDPShares">54.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-09-30_srt_MaximumMember"
      decimals="INF"
      id="Fact001061"
      unitRef="USDPShares">41400</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-09-30_custom_PublicWarrantMember"
      decimals="INF"
      id="Fact001063"
      unitRef="Shares">2778</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-09-30_custom_Notes2021And2022Member"
      decimals="INF"
      id="Fact001065"
      unitRef="Shares">2901</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2023-09-29_custom_Notes2021And2022Member"
      id="Fact001067">2026-06-30</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2023-09-30_custom_Notes2021And2022Member"
      id="Fact001069">2028-08-07</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001071">&lt;p id="xdx_80E_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zvNMD7NB2Dmb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
9 - &lt;span id="xdx_822_zJh5UIxtsbC9"&gt;STOCK-BASED COMPENSATION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the Business Combination, the Company assumed the 2021 Omnibus Incentive Plan. In February 2024, the Company&#x2019;s
Board approved an annual increase of &lt;span id="xdx_902_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20240229__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneOmnibusIncentivePlanMember_ze0sw0iTkTxl" title="Common stock, capital shares reserved for future issuance"&gt;10,487&lt;/span&gt; shares available for future grant under the 2021 Omnibus Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognized within general and administrative expense stock-based compensation expense of $&lt;span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zuVm0gTmtYFi" title="Share based compensation expense"&gt;75,494&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zc2UqTqsQkW" title="Share based compensation expense"&gt;627,406&lt;/span&gt; for the year ended
December 31, 2024 and 2023, respectively. During the year ended December 31, 2024 and 2023, the company recognized within research and
development expense stock-based compensation expense of $&lt;span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zrSly4VU8tt" title="Share based compensation expense"&gt;35,229&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zEbEtzMALUtb" title="Share based compensation expense"&gt;251,754&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ensysce
Biosciences, Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to the Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Option
Activity&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2024, the Company did not grant any stock options. During the year ended December 31, 2023, the Company granted
stock options to purchase an aggregate of &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__srt--TitleOfIndividualAxis__custom--BoardOfMembersMember_zMmuRotliVLb" title="Number of restricted stock granted"&gt;37,000&lt;/span&gt; shares of common stock to employees and members of the board of directors. The options
vested immediately and have an exercise price of between $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20231231__srt--RangeAxis__srt--MinimumMember_zX4whuzhOu2k" title="Weighted average exercise price, vested or expected to vest"&gt;16.95&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20231231__srt--RangeAxis__srt--MaximumMember_zyfJUHchePHj" title="Weighted average exercise price, vested or expected to vest"&gt;17.70&lt;/span&gt; per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zSoo4paadGYi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s stock option activity during the year ended December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_zumGmWQcnou3" style="display: none"&gt;SCHEDULE OF STOCK OPTION ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    average&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise
    price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Remaining
    contractual life&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Intrinsic
    value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231_z3l9JqbA6p3a" style="width: 12%; text-align: right" title="Option outstanding, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;38,785&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231_zezRuMLV5NA6" style="width: 12%; text-align: right" title="Weighted average exercise price. beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;501.65&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zooWRqc7cmp7" title="Weighted average remaining contractual term"&gt;9.57&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240101__20241231_zgzhArCAcr8d" style="width: 12%; text-align: right" title="Aggregate intrinsic value, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1097"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231_zMNI7fHiKiXj" style="text-align: right" title="Option outstanding, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1099"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zoQqZkWNioJh" style="text-align: right" title="Weighted average exercise price, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1101"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_pp0p0_c20240101__20241231_zov7cyppPoQ7" style="text-align: right" title="Aggregate intrinsic value, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1103"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20240101__20241231_z8u3AK8QefA2" style="text-align: right" title="Option outstanding, exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1105"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20241231_zVjKu15zBDKa" style="text-align: right" title="Weighted average exercise price, exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1107"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20240101__20241231_zSDXyiP2r521" style="text-align: right" title="Aggregate intrinsic value, exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1109"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expired / Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20240101__20241231_z2Afjhn6Et57" style="border-bottom: Black 1pt solid; text-align: right" title="Option outstanding, expired or forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1111"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zMqLUqBFLRQb" style="text-align: right" title="Weighted average exercise price, expired or forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1113"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue_pp0p0_c20240101__20241231_z6V4kuznpLqc" style="text-align: right" title="Aggregate intrinsic value, expired or forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1115"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20241231_zgDwmLoCOs0k" style="border-bottom: Black 2.5pt double; text-align: right" title="Option outstanding, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;38,785&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231_zPlDVN10Yp31" style="text-align: right" title="Weighted average exercise price, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;501.65&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_zziDb8xbESG8" title="Weighted average remaining contractual term"&gt;8.58&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20240101__20241231_zQG69ztPbRae" style="text-align: right" title="Aggregate intrinsic value, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1123"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercisable at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20241231_z9qExBSCGcyl" style="text-align: right" title="Option, exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;38,734&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20240101__20241231_zBKI5C4aWqI4" style="text-align: right" title="Weighted average exercise price, exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;493.54&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20240101__20241231_zf9zZYpnXOea" style="text-align: right" title="Aggregate intrinsic value, Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1129"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20241231_zPw9sME9h5L4" style="text-align: right" title="Option vested or expected to vest"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;38,785&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20241231_zEU3q1Ptdym9" style="text-align: right" title="Weighted average exercise price, vested or expected to vest"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;501.65&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_zxz8jWI1HIDf" title="Weighted average remaining contractual term, exercisable"&gt;8.58&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_pp0p0_c20241231_z68lzkM2M505" style="text-align: right" title="Aggregate intrinsic value, vested or expected to vest"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1137"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zC6ulsxu0Td6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Option
Valuation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zYYRmefYhdH8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of each stock option granted has been determined using the Black-Scholes option-pricing model. The material assumptions used
in the Black-Scholes model in estimating the fair value of the options granted for the periods presented were as follows (no stock options
were granted during the year ended December 31, 2024):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B1_z2oPX5VQwyVd" style="display: none"&gt;SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231231__srt--RangeAxis__srt--MinimumMember_zZcUquZc0jL4" title="Exercise price"&gt;16.95&lt;/span&gt;
                                       - &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231231__srt--RangeAxis__srt--MaximumMember_zHEjPXhcWan8" title="Exercise price"&gt;17.70&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20230101__20231231_ziENiitsN581" title="Expected stock price volatility, minimum"&gt;106.77&lt;/span&gt;%
                                            - &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20230101__20231231_zJFMwOgQg5Ae" title="Expected stock price volatility, maximum"&gt;106.82&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zk4OslyzUpj4" title="Expected term (years)"&gt;5.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20230101__20231231_zGpGxcLgkT16" title="Risk-free interest rate, minimum"&gt;4.62&lt;/span&gt;%
                                            - &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20230101__20231231_z9sv64O57Lxc" title="Risk-free interest rate, maximum"&gt;4.89&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231_ztwCi9YKlaLl" title="Expected dividend rate"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zfoTvSLUuMk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
    stock-price volatility. &lt;/i&gt;The expected volatility is derived from the historical volatilities of comparable publicly traded companies
    within the Company&#x2019;s industry that the Company considers comparable to the Company&#x2019;s business over a period approximately
    equal to the expected term. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
    term.&lt;/i&gt; The expected term represents the period that the stock-based awards are expected to be outstanding. The Company&#x2019;s
    historical share option exercise experience does not provide a reasonable basis upon which to estimate an expected term due to a
    lack of sufficient data. Therefore, the Company estimates the expected term for employees by using the simplified method provided
    by the Securities and Exchange Commission. The simplified method calculates the expected term as the average of the time-to-vesting
    and the contractual life of the options. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Risk-free
    interest rate. &lt;/i&gt;The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon
    U.S. Treasury notes with maturities approximately equal to the expected term.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
    dividend yield. &lt;/i&gt;The expected dividend is assumed to be zero as the Company has never paid dividends and has no current plans
    to pay any dividends on the Company&#x2019;s common stock.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ensysce
Biosciences, Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to the Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted-average grant date fair value of options granted during the year ended December 31, 2023 was $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231_zE9zS42j7ZM7" title="Weighted-average fair value per share , grant"&gt;13.98&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, the Company had an aggregate of $&lt;span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20241231_z82Eu9qbx6T8" title="Unrecognized stock based compensation"&gt;27,860&lt;/span&gt; of unrecognized share-based compensation cost, which is expected to be
recognized over the weighted average period of &lt;span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardWeightedAveragePeriodExpectedToBeRecognized_dtY_c20240101__20241231_z1erjG8Kif41" title="Weighted average period"&gt;0.75&lt;/span&gt; years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Shares
Reserved for Future Issuance&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_ecustom--ScheduleOfCommonStockFutureIssuanceTableTextBlock_zuUtL05IOrE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following shares of common stock are reserved for future issuance:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B6_z3b6beliuu5l" style="display: none"&gt;SCHEDULE OF COMMON STOCK FUTURE ISSUANCE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Awards outstanding under the 2021
    Omnibus Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOvxi2CvahC4" style="width: 16%; text-align: right" title="Common Stock, capital shares reserved for future issuance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;38,785&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Awards available for future grant under 2021
    Omnibus Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--StockOptionAvailableForFutureGrantUnder2021OmnibusIncentivePlanMember_zM6typmi2vlf" style="text-align: right" title="Common Stock, capital shares reserved for future issuance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,596&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantOutstandingMember_zVYWMclqlRwj" style="border-bottom: Black 1pt solid; text-align: right" title="Common Stock, capital shares reserved for future issuance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,167,072&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total shares of common
    stock reserved for future issuance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20241231_zjzknOyBbv54" style="border-bottom: Black 2.5pt double; text-align: right" title="Total shares of common stock reserved for future issuance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,216,453&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zRAHVVu5xSPg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2024-02-29_custom_TwoThousandTwentyOneOmnibusIncentivePlanMember"
      decimals="INF"
      id="Fact001073"
      unitRef="Shares">10487</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact001075"
      unitRef="USD">75494</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact001077"
      unitRef="USD">627406</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact001079"
      unitRef="USD">35229</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact001081"
      unitRef="USD">251754</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-012023-12-31_custom_BoardOfMembersMember"
      decimals="INF"
      id="Fact001083"
      unitRef="Shares">37000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_srt_MinimumMember"
      decimals="INF"
      id="Fact001085"
      unitRef="USDPShares">16.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_srt_MaximumMember"
      decimals="INF"
      id="Fact001087"
      unitRef="USDPShares">17.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001089">&lt;p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zSoo4paadGYi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s stock option activity during the year ended December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_zumGmWQcnou3" style="display: none"&gt;SCHEDULE OF STOCK OPTION ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    average&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise
    price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Remaining
    contractual life&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Intrinsic
    value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231_z3l9JqbA6p3a" style="width: 12%; text-align: right" title="Option outstanding, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;38,785&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231_zezRuMLV5NA6" style="width: 12%; text-align: right" title="Weighted average exercise price. beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;501.65&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zooWRqc7cmp7" title="Weighted average remaining contractual term"&gt;9.57&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240101__20241231_zgzhArCAcr8d" style="width: 12%; text-align: right" title="Aggregate intrinsic value, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1097"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231_zMNI7fHiKiXj" style="text-align: right" title="Option outstanding, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1099"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zoQqZkWNioJh" style="text-align: right" title="Weighted average exercise price, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1101"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_pp0p0_c20240101__20241231_zov7cyppPoQ7" style="text-align: right" title="Aggregate intrinsic value, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1103"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20240101__20241231_z8u3AK8QefA2" style="text-align: right" title="Option outstanding, exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1105"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20241231_zVjKu15zBDKa" style="text-align: right" title="Weighted average exercise price, exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1107"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20240101__20241231_zSDXyiP2r521" style="text-align: right" title="Aggregate intrinsic value, exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1109"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expired / Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20240101__20241231_z2Afjhn6Et57" style="border-bottom: Black 1pt solid; text-align: right" title="Option outstanding, expired or forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1111"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zMqLUqBFLRQb" style="text-align: right" title="Weighted average exercise price, expired or forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1113"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue_pp0p0_c20240101__20241231_z6V4kuznpLqc" style="text-align: right" title="Aggregate intrinsic value, expired or forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1115"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20241231_zgDwmLoCOs0k" style="border-bottom: Black 2.5pt double; text-align: right" title="Option outstanding, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;38,785&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231_zPlDVN10Yp31" style="text-align: right" title="Weighted average exercise price, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;501.65&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_zziDb8xbESG8" title="Weighted average remaining contractual term"&gt;8.58&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20240101__20241231_zQG69ztPbRae" style="text-align: right" title="Aggregate intrinsic value, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1123"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercisable at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20241231_z9qExBSCGcyl" style="text-align: right" title="Option, exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;38,734&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20240101__20241231_zBKI5C4aWqI4" style="text-align: right" title="Weighted average exercise price, exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;493.54&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20240101__20241231_zf9zZYpnXOea" style="text-align: right" title="Aggregate intrinsic value, Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1129"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20241231_zPw9sME9h5L4" style="text-align: right" title="Option vested or expected to vest"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;38,785&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20241231_zEU3q1Ptdym9" style="text-align: right" title="Weighted average exercise price, vested or expected to vest"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;501.65&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_zxz8jWI1HIDf" title="Weighted average remaining contractual term, exercisable"&gt;8.58&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_pp0p0_c20241231_z68lzkM2M505" style="text-align: right" title="Aggregate intrinsic value, vested or expected to vest"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1137"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001091"
      unitRef="Shares">38785</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001093"
      unitRef="USDPShares">501.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2023-01-012023-12-31" id="Fact001095">P9Y6M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001117"
      unitRef="Shares">38785</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001119"
      unitRef="USDPShares">501.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2024-01-01to2024-12-31" id="Fact001121">P8Y6M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001125"
      unitRef="Shares">38734</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001127"
      unitRef="USDPShares">493.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001131"
      unitRef="Shares">38785</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001133"
      unitRef="USDPShares">501.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2024-01-01to2024-12-31" id="Fact001135">P8Y6M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001139">&lt;p id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zYYRmefYhdH8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of each stock option granted has been determined using the Black-Scholes option-pricing model. The material assumptions used
in the Black-Scholes model in estimating the fair value of the options granted for the periods presented were as follows (no stock options
were granted during the year ended December 31, 2024):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B1_z2oPX5VQwyVd" style="display: none"&gt;SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231231__srt--RangeAxis__srt--MinimumMember_zZcUquZc0jL4" title="Exercise price"&gt;16.95&lt;/span&gt;
                                       - &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231231__srt--RangeAxis__srt--MaximumMember_zHEjPXhcWan8" title="Exercise price"&gt;17.70&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20230101__20231231_ziENiitsN581" title="Expected stock price volatility, minimum"&gt;106.77&lt;/span&gt;%
                                            - &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20230101__20231231_zJFMwOgQg5Ae" title="Expected stock price volatility, maximum"&gt;106.82&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zk4OslyzUpj4" title="Expected term (years)"&gt;5.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20230101__20231231_zGpGxcLgkT16" title="Risk-free interest rate, minimum"&gt;4.62&lt;/span&gt;%
                                            - &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20230101__20231231_z9sv64O57Lxc" title="Risk-free interest rate, maximum"&gt;4.89&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231_ztwCi9YKlaLl" title="Expected dividend rate"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2023-12-31_srt_MinimumMember"
      decimals="INF"
      id="Fact001141"
      unitRef="USDPShares">16.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2023-12-31_srt_MaximumMember"
      decimals="INF"
      id="Fact001143"
      unitRef="USDPShares">17.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001145"
      unitRef="Pure">1.0677</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001147"
      unitRef="Pure">1.0682</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2023-01-012023-12-31" id="Fact001149">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001151"
      unitRef="Pure">0.0462</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001153"
      unitRef="Pure">0.0489</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001155"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001157"
      unitRef="USDPShares">13.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001159"
      unitRef="USD">27860</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <ENSC:SharebasedCompensationArrangementBySharebasedPaymentAwardWeightedAveragePeriodExpectedToBeRecognized contextRef="From2024-01-01to2024-12-31" id="Fact001161">P0Y9M</ENSC:SharebasedCompensationArrangementBySharebasedPaymentAwardWeightedAveragePeriodExpectedToBeRecognized>
    <ENSC:ScheduleOfCommonStockFutureIssuanceTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001163">&lt;p id="xdx_899_ecustom--ScheduleOfCommonStockFutureIssuanceTableTextBlock_zuUtL05IOrE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following shares of common stock are reserved for future issuance:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B6_z3b6beliuu5l" style="display: none"&gt;SCHEDULE OF COMMON STOCK FUTURE ISSUANCE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Awards outstanding under the 2021
    Omnibus Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOvxi2CvahC4" style="width: 16%; text-align: right" title="Common Stock, capital shares reserved for future issuance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;38,785&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Awards available for future grant under 2021
    Omnibus Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--StockOptionAvailableForFutureGrantUnder2021OmnibusIncentivePlanMember_zM6typmi2vlf" style="text-align: right" title="Common Stock, capital shares reserved for future issuance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,596&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantOutstandingMember_zVYWMclqlRwj" style="border-bottom: Black 1pt solid; text-align: right" title="Common Stock, capital shares reserved for future issuance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,167,072&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total shares of common
    stock reserved for future issuance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20241231_zjzknOyBbv54" style="border-bottom: Black 2.5pt double; text-align: right" title="Total shares of common stock reserved for future issuance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,216,453&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ENSC:ScheduleOfCommonStockFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001165"
      unitRef="Shares">38785</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember_custom_StockOptionAvailableForFutureGrantUnder2021OmnibusIncentivePlanMember"
      decimals="INF"
      id="Fact001167"
      unitRef="Shares">10596</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2024-12-31_custom_WarrantOutstandingMember"
      decimals="INF"
      id="Fact001169"
      unitRef="Shares">2167072</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001171"
      unitRef="Shares">2216453</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001173">&lt;p id="xdx_800_eus-gaap--IncomeTaxDisclosureTextBlock_zv5PBNLwc2L7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
10 - &lt;span id="xdx_825_zNk4j5t7Q4Gg"&gt;INCOME TAXES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zZTnJWwXv5j5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Loss
before provision for income taxes consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zNaBR3oaIq67" style="display: none"&gt;SCHEDULE OF INCOME TAXES BENEFIT&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pp0p0_c20240101__20241231__srt--StatementGeographicalAxis__country--US_z59Nsq1xf00f" style="width: 16%; text-align: right" title="Loss before provision for income taxes"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(7,987,009&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pp0p0_c20230101__20231231__srt--StatementGeographicalAxis__country--US_zNmX9uvzzBW4" style="width: 16%; text-align: right" title="Loss before provision for income taxes"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(10,626,275&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_z932wY5APsOg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_ecustom--ScheduleOfFederalAndStateIncomeTaxProvisionBenefitTableTextBlock_z1fo87DK9eY" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
federal and state income tax provision (benefit), included in general and administrative expenses in the Consolidated Statement of Operations,
is summarized as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BF_zjSbCT2gWjT1" style="display: none"&gt;SCHEDULE OF FEDERAL AND STATE INCOME TAX PROVISION (BENEFIT)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Current state provision&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pp0p0_c20240101__20241231_zBH57HOWOXO6" style="width: 16%; text-align: right" title="Current state provision"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,300&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pp0p0_c20230101__20231231_zN4vWxoXWq42" style="width: 16%; text-align: right" title="Current state provision"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,200&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zGfgfCcNbDnj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ensysce
Biosciences, Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to the Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zWMZoPdyyyf3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
effective tax rate of the Company&#x2019;s provision (benefit) for income taxes differs from the federal statutory rate as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B1_zugETMXcPwmj" style="display: none"&gt;SCHEDULE OF FEDERAL INCOME TAX RATE RECONCILIATION&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240101__20241231_zZ614y3olEhe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20230101__20231231_zDgddKBZFF6k" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzZ0P_zhlP8LGZwU57" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income (benefit) taxes at statutory
    rates&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,677,271&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2,231,518&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzZ0P_z0qboDzTYj1a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;State income tax, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(62,342&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(77,243&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_maITEBzZ0P_zAyOgibPmStc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants and convertible debt&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,421&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(90,392&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_maITEBzZ0P_zp0RWO7SZeX5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Nondeductible executive compensation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;17,325&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,107&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_maITEBzZ0P_z4mBefHk9VP8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock based compensation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;22,633&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;580,823&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_di_msITEBzZ0P_zwGgLNGQpVgh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(428,675&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(629,239&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--IncomeTaxReconciliationExpiringAttributes_maITEBzZ0P_zXztURcte3Jg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expiring attributes&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;183,912&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1208"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationTaxContingencies_maITEBzZ0P_zvXAllxY2oM1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Change in tax rates&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(296&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,848&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzZ0P_zMAGBoN4Jbbl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,282&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;77,162&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzZ0P_zOU4xy55K7f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,936,853&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,372,148&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzZ0P_ziFgkx0EaDB8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1219"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1220"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zyNViFpVYzKl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
income taxes reflect the net tax effects of (a) temporary differences between the carrying amounts of assets and liabilities for financial
reporting purposes and the amounts used for income tax purposes, and (b) operating losses and tax credit carryforwards.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zLqQhhHqop98" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s deferred tax assets were comprised of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_zxXcPdtKig97" style="display: none"&gt;SCHEDULE OF DEFERRED TAX ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20241231_zzn5Gwrmdoj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20231231_z2Obiskxomuh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTAGz96z_zv1N7PxqF0E7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net operating
    loss tax carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;29,728,009&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;28,485,164&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_iI_pp0p0_maDTAGz96z_zaldXCXze6s8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,212,263&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,793,138&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pp0p0_maDTAGz96z_ze4nAv8EZuk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Capitalized research costs&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,655,425&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,368,767&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0_maDTAGz96z_z6tTMzyXUgmb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;729,318&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;746,444&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsOther_iI_pp0p0_maDTAGz96z_zImKrQrVvbN7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;36,630&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;31,279&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsGross_iTI_pp0p0_mtDTAGz96z_maDTANzp9G_zZuSG6xTp9N9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;40,361,645&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;38,424,792&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTANzp9G_zX63HUeRvA79" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(40,361,645&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(38,424,792&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsNet_iTI_pp0p0_mtDTANzp9G_maDTALNzQQ7_z0mX2Ur829ag" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1245"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1246"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxLiabilitiesOther_iNI_pp0p0_di_maDTLzuel_zC1227LKsT65" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1248"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1249"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxLiabilities_iNTI_di_mtDTLzuel_msDTALNzQQ7_zFdEMqEMnLz6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1251"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1252"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pp0p0_mtDTALNzQQ7_zVNxT8wB5ZJ3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1254"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1255"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zWY9G2P2h109" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, the Company had federal and California net operating loss (NOL) carryforwards of $&lt;span id="xdx_90A_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zYEOYpWWdzFa" title="Operating loss carryforwards"&gt;116.4&lt;/span&gt; million and $&lt;span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--CaliforniaFranchiseTaxBoardMember_zitnrZogdw3j" title="Operating loss carryforwards"&gt;75.6&lt;/span&gt; million,
respectively, net of the NOLs that will expire due to Internal Revenue Code (IRC) Section 382 limitations. The federal net operating
losses generated in 2018 and after of $&lt;span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20181231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zWlWjCFeEuvd"&gt;34.9&lt;/span&gt; million will &lt;span id="xdx_90C_eus-gaap--TaxCreditCarryforwardDescription_c20240101__20241231_zAQ3JpnZ9fFa" title="Tax credit carryforward, description"&gt;carryforward indefinitely and be available to offset up to 80% of future taxable
income each year&lt;/span&gt;. The federal net operating losses generated prior to 2018 of $&lt;span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20171231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zwgOvUAcPrm"&gt;81.6&lt;/span&gt; million will begin to &lt;span id="xdx_90A_eus-gaap--OperatingLossCarryforwardsLimitationsOnUse_c20170101__20171231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zHTKICxMvaD9" title="Operating loss carryforwards expiration"&gt;expire in 2025&lt;/span&gt; unless previously
utilized. The California NOL carryforwards will begin to &lt;span id="xdx_901_eus-gaap--OperatingLossCarryforwardsLimitationsOnUse_c20240101__20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--CaliforniaFranchiseTaxBoardMember_z9RjMd9ZKbwe" title="Operating loss carryforwards expiration"&gt;expire in 2028&lt;/span&gt;, unless previously utilized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ensysce
Biosciences, Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to the Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
addition, as of December 31, 2024, the Company had federal and state research and development (R&amp;amp;D) tax credit carryforwards of $&lt;span id="xdx_908_eus-gaap--TaxCreditCarryforwardAmount_iI_pn5n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember__us-gaap--TaxCreditCarryforwardAxis__us-gaap--ResearchMember_zPZVLwhzXUE5" title="Tax credit carryforward amount"&gt;5.6&lt;/span&gt;
million and $&lt;span id="xdx_903_eus-gaap--TaxCreditCarryforwardAmount_iI_pn5n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember__us-gaap--TaxCreditCarryforwardAxis__us-gaap--ResearchMember_zTkauLAjEBck" title="Tax credit carryforward amount"&gt;1.7&lt;/span&gt; million, respectively. The federal tax credit carryforwards will begin to &lt;span id="xdx_904_eus-gaap--TaxCreditCarryforwardLimitationsOnUse_c20240101__20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--CaliforniaFranchiseTaxBoardMember_zzjnF69cve15" title="Tax credit carryforward expiration"&gt;expire in 2025&lt;/span&gt; unless previously utilized.
The California research tax credits do not expire.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to IRC Sections 382 and 383, annual use of the Company&#x2019;s NOL and R&amp;amp;D credit carryforwards may be limited in the event that
a cumulative change in ownership of more than 50% occurs within a three-year period. Although the Company has not completed an IRC Section
382/383 analysis regarding the limitation of NOL and R&amp;amp;D credit carryforwards as of December 31, 2024, the Company estimates that
approximately $&lt;span id="xdx_90E_eus-gaap--TaxCreditCarryforwardAmount_iI_pn5n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zh1ghdYYPs73" title="Tax credit carryforward amount"&gt;1.5&lt;/span&gt; million of tax benefits related to NOL and R&amp;amp;D carryforwards acquired in 2015 will expire unused. Accordingly,
the related NOL and R&amp;amp;D credit carryforwards have been removed from deferred tax assets accompanied by a corresponding reduction
of the valuation allowance. Due to the existence of the valuation allowance, limitations created by current and future ownership changes,
if any, related to the Company&#x2019;s operations in the United States will not impact its effective tax rate. Any additional ownership
changes may further limit the ability to use the NOL and R&amp;amp;D credit carryforwards.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_zsvlQX1CuHtb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the activity related to the Company&#x2019;s unrecognized tax benefits:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_z9jwHXM9uL3c" style="display: none"&gt;SCHEDULE
OF UNRECOGNIZED TAX BENEFITS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240101__20241231_zICGxDjWgihi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20230101__20231231_zoobMijdKGs4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--UnrecognizedTaxBenefits_iS_zg1EEFtUZrae" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,685,360&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,428,261&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_zw3IHfOkSFki" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Increases related to current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;141,023&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;128,404&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_zDwD2MFhav37" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Increases related to prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,054&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;128,695&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_iN_di_zuTR172tJSy3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Decreases related to prior
    year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(444&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1289"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--UnrecognizedTaxBenefits_iE_zb3Ic7R5BVXj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,826,993&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,685,360&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zNWOrtcCdIRb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024 and 2023, the Company had unrecognized tax benefits of $&lt;span id="xdx_907_eus-gaap--UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_iI_pn5n6_c20241231_z0FZD3s4hYqg" title="Unrecognized tax benefits that would impact effective tax rate"&gt;1.8&lt;/span&gt; million and $&lt;span id="xdx_90A_eus-gaap--UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_iI_pn5n6_c20231231_z0muZBS40P7d" title="Unrecognized tax benefits that would impact effective tax rate"&gt;1.7&lt;/span&gt; million, respectively. Due to the existence
of the valuation allowance, none of the unrecognized tax benefits would affect the effective tax rate. The Company&#x2019;s policy is
to recognize interest and penalties from uncertain tax positions in income tax expense. The Company did not record any interest or penalties
for the years ended December 31, 2024 or 2023 and had &lt;span id="xdx_900_eus-gaap--FinancingReceivableAccruedInterestWriteoff_do_c20240101__20241231_zZBDwNWQYMf8" title="Financing receivable accrued interest write off"&gt;&lt;span id="xdx_90A_eus-gaap--FinancingReceivableAccruedInterestWriteoff_do_c20230101__20231231_z0kznfEtMKsh" title="Financing receivable accrued interest write off"&gt;no&lt;/span&gt;&lt;/span&gt; accrued interest on the consolidated balance sheets as of December 31, 2024
or 2023. The Company does not anticipate that the total amount of unrecognized tax benefits will significantly increase or decrease within
twelve months of the reporting date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company and its subsidiaries are subject to U.S. federal income tax as well as income tax in multiple state jurisdictions. With few exceptions,
the Company is no longer subject to United States federal income tax examinations for years before 2021 and state and local income tax
examinations before 2020. However, to the extent allowed by law, the tax authorities may have the right to examine prior periods where
net operating losses were generated and carried forward, and make adjustments up to the amount of the NOL carryforward amount. The Company
is not currently under examination by the Internal Revenue Service or any state or local tax authority.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001175">&lt;p id="xdx_89C_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zZTnJWwXv5j5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Loss
before provision for income taxes consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zNaBR3oaIq67" style="display: none"&gt;SCHEDULE OF INCOME TAXES BENEFIT&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pp0p0_c20240101__20241231__srt--StatementGeographicalAxis__country--US_z59Nsq1xf00f" style="width: 16%; text-align: right" title="Loss before provision for income taxes"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(7,987,009&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pp0p0_c20230101__20231231__srt--StatementGeographicalAxis__country--US_zNmX9uvzzBW4" style="width: 16%; text-align: right" title="Loss before provision for income taxes"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(10,626,275&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-01-012024-12-31_country_US"
      decimals="0"
      id="Fact001177"
      unitRef="USD">-7987009</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-01-012023-12-31_country_US"
      decimals="0"
      id="Fact001179"
      unitRef="USD">-10626275</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <ENSC:ScheduleOfFederalAndStateIncomeTaxProvisionBenefitTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001181">&lt;p id="xdx_899_ecustom--ScheduleOfFederalAndStateIncomeTaxProvisionBenefitTableTextBlock_z1fo87DK9eY" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
federal and state income tax provision (benefit), included in general and administrative expenses in the Consolidated Statement of Operations,
is summarized as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BF_zjSbCT2gWjT1" style="display: none"&gt;SCHEDULE OF FEDERAL AND STATE INCOME TAX PROVISION (BENEFIT)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Current state provision&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pp0p0_c20240101__20241231_zBH57HOWOXO6" style="width: 16%; text-align: right" title="Current state provision"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,300&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pp0p0_c20230101__20231231_zN4vWxoXWq42" style="width: 16%; text-align: right" title="Current state provision"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,200&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ENSC:ScheduleOfFederalAndStateIncomeTaxProvisionBenefitTableTextBlock>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001183"
      unitRef="USD">3300</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001185"
      unitRef="USD">3200</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001187">&lt;p id="xdx_890_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zWMZoPdyyyf3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
effective tax rate of the Company&#x2019;s provision (benefit) for income taxes differs from the federal statutory rate as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B1_zugETMXcPwmj" style="display: none"&gt;SCHEDULE OF FEDERAL INCOME TAX RATE RECONCILIATION&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240101__20241231_zZ614y3olEhe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20230101__20231231_zDgddKBZFF6k" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzZ0P_zhlP8LGZwU57" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income (benefit) taxes at statutory
    rates&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,677,271&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2,231,518&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzZ0P_z0qboDzTYj1a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;State income tax, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(62,342&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(77,243&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_maITEBzZ0P_zAyOgibPmStc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants and convertible debt&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,421&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(90,392&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_maITEBzZ0P_zp0RWO7SZeX5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Nondeductible executive compensation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;17,325&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,107&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_maITEBzZ0P_z4mBefHk9VP8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock based compensation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;22,633&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;580,823&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_di_msITEBzZ0P_zwGgLNGQpVgh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(428,675&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(629,239&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--IncomeTaxReconciliationExpiringAttributes_maITEBzZ0P_zXztURcte3Jg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expiring attributes&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;183,912&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1208"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationTaxContingencies_maITEBzZ0P_zvXAllxY2oM1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Change in tax rates&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(296&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,848&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzZ0P_zMAGBoN4Jbbl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,282&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;77,162&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzZ0P_zOU4xy55K7f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,936,853&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,372,148&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzZ0P_ziFgkx0EaDB8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1219"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1220"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001189"
      unitRef="USD">-1677271</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001190"
      unitRef="USD">-2231518</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001192"
      unitRef="USD">-62342</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001193"
      unitRef="USD">-77243</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001195"
      unitRef="USD">-3421</us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001196"
      unitRef="USD">-90392</us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001198"
      unitRef="USD">17325</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001199"
      unitRef="USD">2107</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001201"
      unitRef="USD">22633</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001202"
      unitRef="USD">580823</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001204"
      unitRef="USD">428675</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001205"
      unitRef="USD">629239</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <ENSC:IncomeTaxReconciliationExpiringAttributes
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001207"
      unitRef="USD">183912</ENSC:IncomeTaxReconciliationExpiringAttributes>
    <us-gaap:IncomeTaxReconciliationTaxContingencies
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001210"
      unitRef="USD">-296</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:IncomeTaxReconciliationTaxContingencies
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001211"
      unitRef="USD">-3848</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001213"
      unitRef="USD">11282</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001214"
      unitRef="USD">77162</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001216"
      unitRef="USD">1936853</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001217"
      unitRef="USD">2372148</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001222">&lt;p id="xdx_899_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zLqQhhHqop98" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s deferred tax assets were comprised of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_zxXcPdtKig97" style="display: none"&gt;SCHEDULE OF DEFERRED TAX ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20241231_zzn5Gwrmdoj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20231231_z2Obiskxomuh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
    of December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTAGz96z_zv1N7PxqF0E7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net operating
    loss tax carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;29,728,009&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;28,485,164&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_iI_pp0p0_maDTAGz96z_zaldXCXze6s8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,212,263&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,793,138&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pp0p0_maDTAGz96z_ze4nAv8EZuk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Capitalized research costs&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,655,425&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,368,767&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0_maDTAGz96z_z6tTMzyXUgmb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;729,318&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;746,444&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsOther_iI_pp0p0_maDTAGz96z_zImKrQrVvbN7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;36,630&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;31,279&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsGross_iTI_pp0p0_mtDTAGz96z_maDTANzp9G_zZuSG6xTp9N9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;40,361,645&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;38,424,792&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTANzp9G_zX63HUeRvA79" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(40,361,645&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(38,424,792&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsNet_iTI_pp0p0_mtDTANzp9G_maDTALNzQQ7_z0mX2Ur829ag" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1245"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1246"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxLiabilitiesOther_iNI_pp0p0_di_maDTLzuel_zC1227LKsT65" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1248"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1249"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxLiabilities_iNTI_di_mtDTLzuel_msDTALNzQQ7_zFdEMqEMnLz6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1251"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1252"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pp0p0_mtDTALNzQQ7_zVNxT8wB5ZJ3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1254"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1255"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001224"
      unitRef="USD">29728009</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001225"
      unitRef="USD">28485164</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001227"
      unitRef="USD">5212263</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001228"
      unitRef="USD">4793138</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001230"
      unitRef="USD">4655425</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001231"
      unitRef="USD">4368767</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001233"
      unitRef="USD">729318</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001234"
      unitRef="USD">746444</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001236"
      unitRef="USD">36630</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001237"
      unitRef="USD">31279</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001239"
      unitRef="USD">40361645</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001240"
      unitRef="USD">38424792</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001242"
      unitRef="USD">40361645</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001243"
      unitRef="USD">38424792</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-12-31_us-gaap_DomesticCountryMember"
      decimals="-5"
      id="Fact001257"
      unitRef="USD">116400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-12-31_us-gaap_CaliforniaFranchiseTaxBoardMember"
      decimals="-5"
      id="Fact001259"
      unitRef="USD">75600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2018-12-31_us-gaap_DomesticCountryMember"
      decimals="-5"
      id="Fact001260"
      unitRef="USD">34900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardDescription contextRef="From2024-01-01to2024-12-31" id="Fact001262">carryforward indefinitely and be available to offset up to 80% of future taxable
income each year</us-gaap:TaxCreditCarryforwardDescription>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2017-12-31_us-gaap_DomesticCountryMember"
      decimals="-5"
      id="Fact001263"
      unitRef="USD">81600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse
      contextRef="From2017-01-012017-12-31_us-gaap_DomesticCountryMember"
      id="Fact001265">expire in 2025</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse
      contextRef="From2024-01-012024-12-31_us-gaap_CaliforniaFranchiseTaxBoardMember"
      id="Fact001267">expire in 2028</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="AsOf2024-12-31_us-gaap_DomesticCountryMember_us-gaap_ResearchMember"
      decimals="-5"
      id="Fact001269"
      unitRef="USD">5600000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="AsOf2024-12-31_us-gaap_StateAndLocalJurisdictionMember_us-gaap_ResearchMember"
      decimals="-5"
      id="Fact001271"
      unitRef="USD">1700000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardLimitationsOnUse
      contextRef="From2024-01-012024-12-31_us-gaap_CaliforniaFranchiseTaxBoardMember"
      id="Fact001273">expire in 2025</us-gaap:TaxCreditCarryforwardLimitationsOnUse>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="AsOf2024-12-31_us-gaap_StateAndLocalJurisdictionMember"
      decimals="-5"
      id="Fact001275"
      unitRef="USD">1500000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001277">&lt;p id="xdx_89B_eus-gaap--ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_zsvlQX1CuHtb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the activity related to the Company&#x2019;s unrecognized tax benefits:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_z9jwHXM9uL3c" style="display: none"&gt;SCHEDULE
OF UNRECOGNIZED TAX BENEFITS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240101__20241231_zICGxDjWgihi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20230101__20231231_zoobMijdKGs4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--UnrecognizedTaxBenefits_iS_zg1EEFtUZrae" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,685,360&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,428,261&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_zw3IHfOkSFki" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Increases related to current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;141,023&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;128,404&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_zDwD2MFhav37" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Increases related to prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,054&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;128,695&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_iN_di_zuTR172tJSy3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Decreases related to prior
    year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(444&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1289"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--UnrecognizedTaxBenefits_iE_zb3Ic7R5BVXj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,826,993&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,685,360&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001279"
      unitRef="USD">1685360</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001280"
      unitRef="USD">1428261</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001282"
      unitRef="USD">141023</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001283"
      unitRef="USD">128404</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001285"
      unitRef="USD">1054</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001286"
      unitRef="USD">128695</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001288"
      unitRef="USD">444</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001291"
      unitRef="USD">1826993</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001292"
      unitRef="USD">1685360</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact001294"
      unitRef="USD">1800000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="AsOf2023-12-31"
      decimals="-5"
      id="Fact001296"
      unitRef="USD">1700000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:FinancingReceivableAccruedInterestWriteoff
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001298"
      unitRef="USD">0</us-gaap:FinancingReceivableAccruedInterestWriteoff>
    <us-gaap:FinancingReceivableAccruedInterestWriteoff
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001300"
      unitRef="USD">0</us-gaap:FinancingReceivableAccruedInterestWriteoff>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001302">&lt;p id="xdx_800_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zhAtmqStucB4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
11 - &lt;span id="xdx_822_zJKL2RHB16ne"&gt;RELATED PARTIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, the Company held a $&lt;span id="xdx_907_eus-gaap--SeniorLongTermNotes_iI_pn5n6_c20241231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zRKMZTt0bWk4" title="Debt financing amount"&gt;0.2&lt;/span&gt; million senior secured convertible promissory note plus accrued interest and &lt;span id="xdx_900_ecustom--WarrantOrRightExercisable_iI_c20241231_zpqr6u3T6tEh" title="Warrants exercisable"&gt;29,547&lt;/span&gt; warrants
exercisable for common stock at $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0UAo5juraDb" title="Warrant, exercise price"&gt;23.51&lt;/span&gt; per share issued to a board member in connection to the issuance of the 2023 Notes. On April
25, 2024, the Company and the board member entered into a forbearance agreement that will expire on &lt;span id="xdx_90A_ecustom--WarrantExpirationDate_dd_c20240425__20240425__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFJTRyszzeWb" title="Warrant, expiration date"&gt;April 25, 2025&lt;/span&gt;. Upon termination
of the forbearance period, the Company will owe the remaining outstanding principal balance together with unpaid interest. The Company
may pay the notes in full at any time prior to the conclusion of the forbearance period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:SeniorLongTermNotes
      contextRef="AsOf2024-12-31_custom_SecuritiesPurchaseAgreementMember"
      decimals="-5"
      id="Fact001304"
      unitRef="USD">200000</us-gaap:SeniorLongTermNotes>
    <ENSC:WarrantOrRightExercisable
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001306"
      unitRef="Shares">29547</ENSC:WarrantOrRightExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001308"
      unitRef="USDPShares">23.51</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ENSC:WarrantExpirationDate
      contextRef="From2024-04-252024-04-25_us-gaap_WarrantMember"
      id="Fact001310">2025-04-25</ENSC:WarrantExpirationDate>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001312">&lt;p id="xdx_80E_eus-gaap--SubsequentEventsTextBlock_z1Uv881EMegi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
12 - &lt;span id="xdx_821_zh0Qi4By6Kul"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
January 2025, the Company issued &lt;span id="xdx_901_ecustom--StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares_c20250101__20250131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkLTLf5p1yXk" title="Number of shares issued upon exercise of warrants"&gt;49,361&lt;/span&gt; shares of common stock for $&lt;span id="xdx_906_ecustom--StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants_pid_c20250101__20250131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zooSEUrAHrR4" title="Value of shares issued upon exercise of warrants"&gt;0.3&lt;/span&gt; million upon exercise of August 2024 warrants issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
January 2025, the Company entered into a product development and supply agreement with Galephar Pharmaceutical Research, Inc., a Puerto
Rico specialty drug manufacturer (&#x201c;Galephar&#x201d;). Galephar will support the development, manufacture, packaging and testing
of the Company&#x2019;s PF614 and PF614-MPAR drug products for use in clinical trials and potential future commercial launch. The Company
will pay Galephar upon achievement of defined milestones at up to 1.2 times Galephar&#x2019;s costs, subject to a cap. Payment will be
in the form of common stock at fifty percent (50%) restricted shares and fifty percent (50%) freely tradeable registered shares, with
the number of shares to be issued by the Company determined by the trailing five-day average closing price of the Company&#x2019;s common
stock upon achievement of each milestone. In addition, the Company will issue up to &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20250101__20250131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zl7iJs0qJYc5" title="Restricted common stock issued"&gt;13,801&lt;/span&gt; shares (&lt;span id="xdx_907_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_dp_uPure_c20250101__20250131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zUWyRFchx0ge" title="Shares outstanding percentage"&gt;1&lt;/span&gt;% of shares outstanding upon signing of agreement)
of restricted common stock to Galephar with vesting in three tranches through completion of defined milestones.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <ENSC:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares
      contextRef="From2025-01-012025-01-31_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001314"
      unitRef="Shares">49361</ENSC:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrantsShares>
    <ENSC:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants
      contextRef="From2025-01-012025-01-31_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001316"
      unitRef="USD">0.3</ENSC:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2025-01-012025-01-31_us-gaap_SubsequentEventMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001318"
      unitRef="Shares">13801</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction
      contextRef="From2025-01-012025-01-31_us-gaap_SubsequentEventMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001320"
      unitRef="Pure">0.01</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact000971"
          xlink:label="Fact000971"
          xlink:type="locator"/>
        <link:footnote id="Footnote001002" xlink:label="Footnote001002" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">On
    August 29, 2024, in connection with the 2024 Registered Direct Offering and 2024 August Warrant Inducement<xhtml:b><xhtml:i>,</xhtml:i></xhtml:b> the Company
    issued equity classified warrants to purchase <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240829__us-gaap--ClassOfWarrantOrRightAxis__custom--InstitutionalInvestorMember_zNG3PCMr6ec2"
  title="Warrants issued">1,964,658</xhtml:span> shares to certain institutional investors and the placement agent. The warrants
    were issued in connection with the 2024 Registered Direct Offering and the 2024 August Warrant Inducement. The <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240829__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantsMember_zCcwEySoITL6"
  title="Warrants issued">1,914,466</xhtml:span> investor
    warrants have an exercise price of $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240829__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantsMember_zKC9jmetdTd9"
  title="Warrant exercise price">7.05 </xhtml:span>per share and are exercisable from the date on which stockholder approval is received. One
    half of the warrants will expire eighteen months after they are exercisable, and the other half will expire five years after they
    are exercisable. The <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240829__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zXGowZWvK2tl"
  title="Warrants issued">50,200</xhtml:span> placement agent warrants have an exercise price of $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240829__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsMember_zxoN3w5rZkN7"
  title="Warrant exercise price">8.8125</xhtml:span> per share, are exercisable upon stockholder
    approval and expire <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20240829__us-gaap--StatementClassOfStockAxis__custom--PlacementAgentWarrantsMember_zcyag8G0Zdfk"
  title="Warrant expiration date">August 28, 2029</xhtml:span>. In December 2024, <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantsMember_zuUEfDSwdiP2"
  title="Investor warrants exercised">50,760</xhtml:span> investor warrants were exercised.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000971"
          xlink:to="Footnote001002"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000973"
          xlink:label="Fact000973"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000973"
          xlink:to="Footnote001002"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000975"
          xlink:label="Fact000975"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000975"
          xlink:to="Footnote001002"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000977"
          xlink:label="Fact000977"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000977"
          xlink:to="Footnote001002"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000989"
          xlink:label="Fact000989"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000989"
          xlink:to="Footnote001002"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000997"
          xlink:label="Fact000997"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000997"
          xlink:to="Footnote001002"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000979"
          xlink:label="Fact000979"
          xlink:type="locator"/>
        <link:footnote id="Footnote001017" xlink:label="Footnote001017" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">On
                                            February 12, 2024, the Company issued <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240212__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__custom--PlacementAgentWarrantsMember_zDxa1qEyCZYj"
  title="Warrants issued">497,042</xhtml:span> equity classified warrants (Series A Warrants,
                                            Series B Warrants and placement agent warrants) in connection with the Inducement Letter
                                            for the 2024 February warrant inducement and related warrant restructuring. The Series A
                                            and Series B Warrants were immediately exercisable with an exercise price of $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240212__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zR9dfSKJaEJ6"
  title="Warrants, exercise price">15.90</xhtml:span> per share
                                            and expire on <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20240212__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsMember_zZOTCaPZu5Pi"
  title="Warrant expiration date">August 14, 2025</xhtml:span> and <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20240212__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zaaTSgBzpBSd"
  title="Warrant expiration date">May 12, 2028</xhtml:span>, respectively. The placement agent warrants
                                            were immediately exercisable with an exercise price of $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240212__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCmYK51xOsxl"
  title="Warrant exercise price">24.56</xhtml:span> per share and expire on <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20240212__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zHgYiFEHje1l"
  title="Warrant expiration date">May
                                            12, 2028</xhtml:span>. In connection with the 2024 August Warrant Inducement, <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240831__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__custom--PlacementAgentWarrantsMember_zaRXUZi5a449"
  title="Warrants issued">480,234</xhtml:span> warrants were exercised.
                                            As of December 31, 2024, the placement agents remain outstanding.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000979"
          xlink:to="Footnote001017"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000981"
          xlink:label="Fact000981"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000981"
          xlink:to="Footnote001017"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000983"
          xlink:label="Fact000983"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000983"
          xlink:to="Footnote001017"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000985"
          xlink:label="Fact000985"
          xlink:type="locator"/>
        <link:footnote id="Footnote001032" xlink:label="Footnote001032" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">On
                                            October 25, 2023, and November 28, 2023, the Company issued warrants to purchase <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231025__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z10EZER6bSc1"
  title="Warrants issued">83,714</xhtml:span> shares
                                            and <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231128__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zM5GcBQqU1Vd"
  title="Warrants issued">167,427</xhtml:span> shares, respectively. The warrants were immediately exercisable with an exercise
                                            price of $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pp4d_c20231025__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGVJ31xafQXb"
  title="Warrants, exercise price"><xhtml:span
      class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
      id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pp4d_c20231128__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLgwkQtyqAdc"
      title="Warrants, exercise price">23.51</xhtml:span></xhtml:span> per share and expire on <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20231025__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKB6m7xuUk91"
  title="Warrant expiration date">October 25, 2028</xhtml:span>, and <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20231128__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztlLffHDnze5"
  title="Warrant expiration date">November 28, 2028</xhtml:span>, respectively.
                                            In January 2024, a holder of the warrants exercised <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240131__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zonkSPUuw3Eb"
  title="Warrants exercisable">88,261</xhtml:span> warrants at an exercise price
                                            of $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240131__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuaKVnF1utl"
  title="Warrant, exercise price">23.51</xhtml:span> per share. In August 2024, an inducement letter was issued to a holder of <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240831_zAsZNrYfFeFc"
  title="Warrants to purchase common shares">133,334</xhtml:span>
                                            warrants to reduce the exercise price from $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_90E_eus-gaap--SharePrice_iI_pid_c20240830_zwEOqsMWCRwj"
  title="Share price">23.51</xhtml:span> to $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_90E_eus-gaap--SharePrice_iI_pid_c20240831_z1RxZeUk6qOa"
  title="Share price">7.05</xhtml:span> per share.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000985"
          xlink:to="Footnote001032"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000987"
          xlink:label="Fact000987"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000987"
          xlink:to="Footnote001032"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000991"
          xlink:label="Fact000991"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000991"
          xlink:to="Footnote001032"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000995"
          xlink:label="Fact000995"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000995"
          xlink:to="Footnote001032"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000993"
          xlink:label="Fact000993"
          xlink:type="locator"/>
        <link:footnote id="Footnote001055" xlink:label="Footnote001055" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">At
    various dates from the Closing of the Business Combination through September 30, 2023, the Company assumed or issued a total of <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230930_ze0v1hh7LLhh"
  title="Warrants issued">73,474</xhtml:span>
    warrants to provide holders the right to purchase common stock at exercise prices ranging from $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__srt--RangeAxis__srt--MinimumMember_zVIcsZe1mFXd"
  title="Warrant exercise price">54.60</xhtml:span> - $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__srt--RangeAxis__srt--MaximumMember_zVdRSVUA0kk"
  title="Warrant exercise price">41,400</xhtml:span> per share. A total
    of <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_901_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230930__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantMember_zTdEAKVUFAk2"
  title="Class of warrant or right, outstanding">2,778</xhtml:span> of the outstanding warrants are public warrants which trade on the OTC Pink Open Market under the ticker symbol ENSCW. A
    total of <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230930__us-gaap--StatementEquityComponentsAxis__custom--Notes2021And2022Member_zypGz5J7nhb9"
  title="Class of warrant or right, outstanding">2,901</xhtml:span> outstanding warrants (issued in connection with the 2021 and 2022 Notes) are liability-classified due to certain cash
    settlement features embedded within the warrant agreements. The remaining warrants are equity classified. The warrants expire beginning
    <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230929__us-gaap--StatementEquityComponentsAxis__custom--Notes2021And2022Member_zscjcC1ZwVac"
  title="Warrant expiration date">June 30, 2026</xhtml:span>, through <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9VVFNUQU5ESU5HIFdBUlJBTlQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230930__us-gaap--StatementEquityComponentsAxis__custom--Notes2021And2022Member_zUzYNP45Z9a9"
  title="Warrant expiration date">August 7, 2028</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000993"
          xlink:to="Footnote001055"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000999"
          xlink:label="Fact000999"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000999"
          xlink:to="Footnote001055"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
